PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rowlings, PA; Williams, SF; Antman, KH; Fields, KK; Fay, JW; Reed, E; Pelz, CJ; Klein, JP; Sobocinski, KA; Kennedy, MJ; Freytes, CO; McCarthy, PL; Herzig, RH; Stadtmauer, EA; Lazarus, HM; Pecora, AL; Bitran, JD; Wolff, SN; Gale, RP; Armitage, JO; Vaughan, WP; Spitzer, G; Horowitz, MM				Rowlings, PA; Williams, SF; Antman, KH; Fields, KK; Fay, JW; Reed, E; Pelz, CJ; Klein, JP; Sobocinski, KA; Kennedy, MJ; Freytes, CO; McCarthy, PL; Herzig, RH; Stadtmauer, EA; Lazarus, HM; Pecora, AL; Bitran, JD; Wolff, SN; Gale, RP; Armitage, JO; Vaughan, WP; Spitzer, G; Horowitz, MM			Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW SUPPORT; LONG-TERM SURVIVAL; COMBINATION CHEMOTHERAPY; AUTOLOGOUS MARROW; PROGNOSTIC FACTORS; FOLLOW-UP; PHASE-II; THIOTEPA; THERAPY; RESCUE	Context Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy. Objective To determine factors associated with disease progression or death after autotransplantation in women with metastatic breast cancer. Design Analysis of data collected retrospectively (January 1989 to 1992) and prospectively (1992 through January 1995) for the Autologous Blood and Marrow Transplant Registry. Setting Sixty-three hospitals in North America, Brazil, and Russia. Participants A total of 1188 consecutive women aged 18 to 70 years receiving autotransplants for metastatic or locally recurrent breast cancer, with a median follow-up of 29 1/2 months. Main Outcome Measure Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation. Results Factors associated with significantly (P<.05) increased risk of treatment failure in a Cox multivariate analysis included age older than 45 years (relative hazard, 1.17; 95% confidence interval [CI], 1.02-1.33), Karnofsky performance score less than 90% (1.27; 95% CI, 1.07-1.51), absence of hormone receptors (1.31; 95% CI, 1.15-1.51), prior use of adjuvant chemotherapy (1.31; 95% CI, 1.10-1.56), initial disease-free survival interval after adjuvant treatment of no more than 18 months (1.99; 95% CI, 1.62-2.43), metastases in the liver (1.47; 95% CI, 1.20-1.80) or central nervous system (1.56; 95% CI, 0.99-2.46 [approaches significance]) vs soft tissue, bone, or lung, 3 or more sites of metastatic disease (1.32; 95% CI, 1.13-1.54), and incomplete response vs complete response to standard-dose chemotherapy (1.65; 95% CI, 1.36-1.99). Receiving tamoxifen posttransplantation was associated with a reduced risk of treatment failure in women with hormone receptor-positive tumors (relative hazard, 0.60; 95% CI, 0.47-0.87). Women with no risk factors (n = 38) had a 3-year probability of progression-free survival of 43% (95% CI, 27%-61%) vs 4% (95% CI, 2%-8%) for women with more than 3 risk factors (n = 343), Conclusion These data indicate that some women are unlikely to benefit from autotransplantation and should receive this treatment only after being provided with prognostic information and in the context of clinical trials attempting to improve outcome.	Med Coll Wisconsin, Hlth Policy Inst, Breast Canc Working Comm Autologous Blood & Marro, Milwaukee, WI 53226 USA; Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA; Columbia Univ, Div Med Oncol, New York, NY USA; Univ S Florida, H Lee Moffitt Canc Ctr, Div Bone Marrow Transplantat, Tampa, FL 33682 USA; Baylor Univ, Sammons Canc Ctr, Dallas, TX USA; Univ Nebraska, Med Ctr, Div Hematol Oncol, Omaha, NE USA; Johns Hopkins Hosp, Ctr Oncol, Baltimore, MD 21287 USA; Univ Texas, Hlth Sci Ctr, Adult Bone Marrow Transplant Program, San Antonio, TX USA; Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; Univ Penn, Bone Marrow Transplant Program, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Hackensack Univ, Med Ctr, Hackensack, NJ USA; Lutheran Gen Hosp, Canc Care Ctr, Div Hematol Oncol, Pk Ridge, IL USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Salick Hlth Care Inc, Div Bone Marrow & Stem Cell Transplantat, Los Angeles, CA USA; Univ Alabama, Bone Marrow Transplant Program, Birmingham, AL USA; Georgetown Univ Hosp, Bone Marrow Transplant Div, Washington, DC 20007 USA	Medical College of Wisconsin; University of Chicago; University of Chicago Medical Center; Columbia University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Baylor University; Baylor University Medical Center; University of Nebraska System; University of Nebraska Medical Center; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health San Antonio; Roswell Park Cancer Institute; University of Louisville; University of Pennsylvania; Case Western Reserve University; Hackensack University Medical Center; Vanderbilt University; University of Alabama System; University of Alabama Birmingham; Georgetown University	Horowitz, MM (corresponding author), Med Coll Wisconsin, Hlth Policy Inst, Breast Canc Working Comm Autologous Blood & Marro, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		McCarthy, Philip/ABA-5329-2020; horowitz, Mary/ABH-2173-2021	/0000-0002-1093-8356	NCI NIH HHS [U24-CA-76518, P01-CA-40053, CP-21161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053, U24CA076518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMANN FR, 1988, J SURG ONCOL, V37, P116, DOI 10.1002/jso.2930370211; [Anonymous], 2018, CANCER, V124, P1197, DOI [10.1002/cncr.31178, DOI 10.1002/CNCR.31178]; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; AYASH LJ, 1995, J CLIN ONCOL, V13, P2043, DOI 10.1200/JCO.1995.13.8.2043; AYASH LJ, 1994, J CLIN ONCOL, V12, P37, DOI 10.1200/JCO.1994.12.1.37; Bensinger WI, 1997, BONE MARROW TRANSPL, V19, P1183, DOI 10.1038/sj.bmt.1700820; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; Commenges D, 1995, Lifetime Data Anal, V1, P145, DOI 10.1007/BF00985764; DUNPHY FR, 1994, CANCER, V73, P2157, DOI 10.1002/1097-0142(19940415)73:8<2157::AID-CNCR2820730821>3.0.CO;2-1; DUNPHY FR, 1990, J CLIN ONCOL, V8, P1207, DOI 10.1200/JCO.1990.8.7.1207; FALKSON G, 1991, J CLIN ONCOL, V9, P2153, DOI 10.1200/JCO.1991.9.12.2153; FALKSON G, 1990, CANCER, V66, P1621, DOI 10.1002/1097-0142(19901001)66:7<1621::AID-CNCR2820660729>3.0.CO;2-G; GarciaCarbonero R, 1997, J CLIN ONCOL, V15, P3178, DOI 10.1200/JCO.1997.15.10.3178; Gradishar WJ, 1996, ANN INTERN MED, V125, P599, DOI 10.7326/0003-4819-125-7-199610010-00010; GRAVES EJ, 1991, VITAL HLTH STAT 13, V108, P1; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; KENNEDY MJ, 1995, J CLIN ONCOL, V13, P2477, DOI 10.1200/JCO.1995.13.10.2477; Klein JP., 2003, SURVIVAL ANAL TECHNI; NASH CH, 1980, CANCER, V46, P2380, DOI 10.1002/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; SWENERTON KD, 1979, CANCER RES, V39, P1552; *US DEP HHS, 1992, NAT HOSP DISCH SURV; *US GEN ACC OFF, 1996, GAOHES9683; VAUGHAN WP, 1994, BONE MARROW TRANSPL, V13, P619; WALLERSTEIN R, 1990, J CLIN ONCOL, V8, P1782, DOI 10.1200/JCO.1990.8.11.1782; Weaver CH, 1997, BONE MARROW TRANSPL, V19, P661, DOI 10.1038/sj.bmt.1700728; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824	34	58	58	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1335	1343		10.1001/jama.282.14.1335	http://dx.doi.org/10.1001/jama.282.14.1335			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527180	Bronze			2022-12-28	WOS:000083000800028
J	Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW				Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW			Prevalence of attempting weight loss and strategies for controlling weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT-CONTENT; ADULTS; OVERWEIGHT; EXERCISE; WOMEN	Context Overweight and obesity are increasing in the United States. Changes in diet and physical activity are important for weight control. Objectives To examine the prevalence of attempting to lose or to maintain weight and to describe weight control strategies among US adults. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting The 49 states (and the District of Columbia) that participated in the survey. Participants Adults aged 18 years and older (N = 107 804). Main Outcome Measures Reported current weights and goal weights, prevalence of weight loss or maintenance attempts, and strategies used to control weight (eating fewer calories, eating less fat, or using physical activity) by population subgroup. Results The prevalence of attempting to lose and maintain weight was 28.8% and 35.1% among men and 43.6% and 34.4% among women, respectively. Among those attempting to lose weight, a common strategy was to consume less fat but not fewer calories (34.9% of men and 40.0% of women); only 21.5% of men and 19.4% of women reported using the recommended combination of eating fewer calories and engaging in at least 150 minutes of leisure-time physical activity per week. Among men trying to lose weight, the median weight was 90.4 kg with a goal weight of 81.4 kg. Among women, the median weight was 70.3 kg with a goal weight of 59.0 kg. Conclusions Weight loss and weight maintenance are common concerns for US men and women. Most persons trying to lose weight are not using the recommended combination of reducing calorie intake and engaging in leisure-time physical activity 150 minutes or more per week.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Serdula, MK (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.		Heath, Gregory Wayne/AAE-2464-2020	Heath, Gregory Wayne/0000-0003-2864-5225				ALLRED JB, 1995, J AM DIET ASSOC, V95, P417, DOI 10.1016/S0002-8223(95)00111-5; [Anonymous], 1998, CLIN GUID ID EV TREA; Bouchard C, 1993, Obes Res, V1, P133; BROWNELL KD, 1995, INT J OBESITY, V19, pS122; CAPUTO FA, 1993, INT J OBESITY, V17, P237; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P199; CLELAND R, 1998, COMMERCIAL WEIGHT LO; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JAKICIC JM, 1995, INT J OBESITY, V19, P893; JEFFERY RW, 1995, OBES RES, V3, pS283, DOI 10.1002/j.1550-8528.1995.tb00475.x; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; NELSON DE, 1998, P SECT SURV METH AM; Pronk N P, 1994, Obes Res, V2, P587; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHULMAN J, 1999, 16 ANN BRFSS C MAY 1; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; Shah BV, 1997, SUDAAN USERS MANUAL; SHIDE DJ, 1995, J AM DIET ASSOC, V95, P993, DOI 10.1016/S0002-8223(95)00273-1; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; [No title captured]	22	351	354	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1353	1358		10.1001/jama.282.14.1353	http://dx.doi.org/10.1001/jama.282.14.1353			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527182	Bronze			2022-12-28	WOS:000083000800030
J	King, M				King, M			The US Department of State is policing the population policy lockstep	BRITISH MEDICAL JOURNAL			English	Article									Univ Leeds, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	King, M (corresponding author), 1 Bis Rue Tir, CH-1204 Geneva, Switzerland.							BROWN LR, 1987, STATE WORLD 1987; CAMPBELL CL, 1988, SCI AM           MAR, P78; Chomsky N., 1994, MANUFACTURING CONSEN; Chomsky Noam, 1987, CHOMSKY READER; Eliot T. S., 1946, 4 QUARTETS; Kennan George, 1948, POLICY PLANNING STUD; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; King M, 1997, BRIT MED J, V315, P1441, DOI 10.1136/bmj.315.7120.1441; KING MH, 1994, OXFORD TXB MED, P35; LEWIS CS, 1945, SCREWTAPE LETT; MCINTOSH CA, 1995, POPUL DEV REV, V21, P223, DOI 10.2307/2137493; MCMICHAEL T, 1999, BMJ, V319; Saunders FrancesStonor., 1999, CULTURAL COLD WAR CI	13	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					998	1001		10.1136/bmj.319.7215.998	http://dx.doi.org/10.1136/bmj.319.7215.998			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514171	Green Published			2022-12-28	WOS:000083111700040
J	Oleske, JM; Czarniecki, L				Oleske, JM; Czarniecki, L			Continuum of palliative care: lessons from caring for children infected with HIV-1	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; PERSPECTIVE; MEDICINE; ISSUES; NEEDS; AIDS		Univ Med & Dent New Jersey, Dept Paediat, Div Pulm Allergy Immunol & Infect Dis, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Oleske, JM (corresponding author), Univ Med & Dent New Jersey, Dept Paediat, Div Pulm Allergy Immunol & Infect Dis, Univ Hts, Newark, NJ 07103 USA.		Oleske, James M/C-1951-2016	Oleske, James M/0000-0003-2305-5605				Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BOLAND M, 1995, SEMINARS PEDIAT INFE, V6, P40; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P315; Corner J, 1996, PALLIATIVE MED, V10, P201, DOI 10.1177/026921639601000304; Czarniecki L. M., 1993, PAACNOTES, V5, P492; ELSADR W, 1994, AHCPR PUBLICATION; FERRIS F, 1995, COMPREHENSIVE GUIDE, V4; FOLEY FJ, 1995, J PALLIATIVE CARE, V11, P19, DOI 10.1177/082585979501100204; Futterman D., 1992, AIDS Clinical Care, V4, P95; GROTHE TM, 1995, J PALLIATIVE CARE, V11, P48, DOI 10.1177/082585979501100212; GRUBMAN S, 1995, PEDIATRICS, V95, P657; James L, 1997, J Pediatr Oncol Nurs, V14, P83, DOI 10.1177/104345429701400207; Levetown M, 1996, J PALLIAT CARE, V12, P35, DOI 10.1177/082585979601200308; LEWIS SY, 1994, J DEV BEHAV PEDIATR, V15, pS12; Liben S, 1996, J PALLIAT CARE, V12, P24, DOI 10.1177/082585979601200306; Martinson I, 1996, J PALLIATIVE CARE, V12, P13, DOI 10.1177/082585979601200303; Martinson I M, 1993, J Pediatr Oncol Nurs, V10, P93, DOI 10.1177/104345429301000304; Martinson I M, 1995, Annu Rev Nurs Res, V13, P195; MARTINSON IM, 1986, RES NURS HEALTH, V9, P11, DOI 10.1002/nur.4770090104; Nielsen K, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.4.e4; OLESKE JM, 1995, PEDIATR AIDS HIV INF, V6, P187; Oleske JM, 1996, J NUTR, V126, pS2616, DOI 10.1093/jn/126.suppl_10.2616S; Oleske JM, 1997, HOSP PRACT, V32, P167, DOI 10.1080/21548331.1997.11443514; OLESKE JM, 1994, HOSP PRACT, V29, P81, DOI 10.1080/21548331.1994.11443078; OLESKE JM, 1995, NIH PUBLICATION; Pellegrino ED, 1998, JAMA-J AM MED ASSOC, V279, P1521, DOI 10.1001/jama.279.19.1521; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; Reiter G S, 1996, AIDS Clin Care, V8, P21; Rothpletz-Puglia P., 1997, Topics in Clinical Nutrition, V12, P69; Tasker M., 1992, CAN I TELL YOU SECRE; Trill MD, 1997, ANN NY ACAD SCI, V809, P197, DOI 10.1111/j.1749-6632.1997.tb48083.x; *UN, 1991, CONV RIGHTS CHILDR; VONGUNTEN CF, 1995, J PALLIATIVE CARE, V11, P5, DOI 10.1177/082585979501100202; Welch K, 1998, AIDS PATIENT CARE ST, V12, P125, DOI 10.1089/apc.1998.12.125; *WHO, 1998, REP GLOB HIV AIDS EP; World Health Organization, 1995, WORLD HLTH REP 1995	36	6	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1287	1291		10.1016/S0140-6736(98)12487-X	http://dx.doi.org/10.1016/S0140-6736(98)12487-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243RE	10520650				2022-12-28	WOS:000083010400045
J	Mayer, T; Cates, RJ				Mayer, T; Cates, RJ			Service excellence in health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY; PHYSICIAN; MEDICINE		Georgetown Univ, Sch Med, Dept Emergency Med, Washington, DC USA; Inova Fairfax Hosp, Dept Emergency Med, Falls Church, VA 22042 USA; Inova Fairfax Hosp, Flight Serv, Falls Church, VA 22042 USA; Fairfax Cty Fire & Rescue & Police Helicopter Uni, Falls Church, VA USA	Georgetown University; Inova Fairfax Hospital; Inova Fairfax Hospital	Mayer, T (corresponding author), Inova Fairfax Hosp, Dept Emergency Med, 3300 Gallows Rd, Falls Church, VA 22042 USA.	mayerth@inova.com						Berry L. L., 1995, GREAT SERVICE FRAMEW; BERRY LL, 1999, DELIVERING SERVICE E; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; Carlzon J., 1987, MOMENTS TRUTH; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Cleary P D, 1993, Qual Manag Health Care, V2, P31; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; DEVINE EC, 1992, PATIENT EDUC COUNS, V19, P129, DOI 10.1016/0738-3991(92)90193-M; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; Gerteis M., 1993, PATIENTS EYES; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HART CWL, 1990, HARVARD BUS REV, V68, P148; JONES TO, 1995, HARVARD BUS REV, V73, P88; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410; Kenagy JW, 1999, JAMA-J AM MED ASSOC, V281, P661, DOI 10.1001/jama.281.7.661; LADHENSUO A, 1996, BRIT MED J, V312, P748; Lane WL, 1999, NEW ENGL J MED, V340, P2007; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Mayer T A, 1992, Emerg Med Clin North Am, V10, P523; Mayer TA, 1998, J HEALTHC MANAG, V43, P427, DOI 10.1097/00115514-199809000-00009; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Pellegrino Edmund D., 1993, VIRTUES MED PRACTICE; *ROP CTR PUBL OP R, 1994, GALLUP CNN US TODAY; SCHLESINGER LA, 1991, HARVARD BUS REV, V69, P71; SCHLESINGER LA, 1991, HARVARD BUS REV, V68, P148; Taylor DH, 1999, NEW ENGL J MED, V340, P293, DOI 10.1056/NEJM199901283400408; 1999, US NEWS WORLD R 0719, P58	33	23	24	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1281	1283		10.1001/jama.282.13.1281	http://dx.doi.org/10.1001/jama.282.13.1281			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517432				2022-12-28	WOS:000082901100037
J	Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC				Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC			Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense	SCIENCE			English	Article							PANETH CELL DEFENSINS; ANTIMICROBIAL PEPTIDES; EPITHELIAL-CELLS; GENE-EXPRESSION; MOUSE; CRYPTDIN; PURIFICATION; VERTEBRATES; DEGRADATION; COMPONENTS	Precursors of alpha-defensin peptides require activation for bactericidal activity. In mouse small intestine, matrilysin colocalized with alpha-defensins (cryptdins) in Paneth cell granules, and in vitro it cleaved the pro segment from cryptdin precursors. Matrilysin-deficient (MAT(-/-)) mice Lacked mature cryptdins and accumulated precursor molecules. Intestinal peptide preparations from MAT(-/-) mice had decreased antimicrobial activity. Orally administered bacteria survived in greater numbers and were more virulent in MAT(-/-) mice than in MAT(+/+) mice Thus, matrilysin functions in intestinal mucosal defense by regulating the activity of defensins, which may be a common role for this metalloproteinase in its numerous epithelial sites of expression.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, St Louis, MO 63110 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Washington University (WUSTL); University of California System; University of California Irvine; University of California System; University of California Irvine; Washington University (WUSTL); Vanderbilt University	Wilson, CL (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA.		Ayabe, Tokiyoshi/F-5264-2011; Parks, William C./AAH-6786-2021	Ayabe, Tokiyoshi/0000-0002-8631-5593; 				AYABE T, UNPUB; BEVINS CL, 1994, CIBA F SYMP, V186, P250; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Gad S.C., 1989, PRINCIPLES METHODS T, P463; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1990, EUR J HAEMATOL, V44, P1; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; LOPEZBOADO YS, UNPUB; MARCOTTE PA, 1992, J BIOL CHEM, V267, P13803; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; Quayle AJ, 1998, AM J PATHOL, V152, P1247; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1988, CELL TISSUE RES, V253, P397; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; WELKOS S, 1994, METHOD ENZYMOL, V235, P29; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	40	871	903	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					113	117		10.1126/science.286.5437.113	http://dx.doi.org/10.1126/science.286.5437.113			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506557				2022-12-28	WOS:000082907400047
J	Cheng, CHC; Chen, LB				Cheng, CHC; Chen, LB			Evolution of an antifreeze glycoprotein	NATURE			English	Article									Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Cheng, CHC (corresponding author), Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA.			, liangbiao/0000-0002-0717-8536				Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; Cheng Chi-Hing C., 1998, P311; CLARKE A, 1996, TRENDS ECOL EVOL, V11, P187; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; Eastman J. T, 1993, ANTARCTIC FISH BIOL; HSIAO KC, 1990, P NATL ACAD SCI USA, V87, P9265, DOI 10.1073/pnas.87.23.9265; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEWIN B, 1994, GENES, V5	9	110	122	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					443	444		10.1038/46721	http://dx.doi.org/10.1038/46721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519545				2022-12-28	WOS:000082981200042
J	Truman, JW; Riddiford, LM				Truman, JW; Riddiford, LM			The origins of insect metamorphosis	NATURE			English	Article							COCKROACH NAUPHOETA-CINEREA; JUVENILE HORMONE-III; MANDUCA-SEXTA; EMBRYONIC-DEVELOPMENT; LOCUSTA-MIGRATORIA; ECDYSTEROID TITER; TOBACCO HORNWORM; PIONEER NEURONS; NERVOUS-SYSTEM; EMBRYOGENESIS	Insect metamorphosis is a fascinating and highly successful biological adaptation, but there is much uncertainty as to how it evolved. Ancestral insect species did not undergo metamorphosis and there are stilt some existing species that lack metamorphosis or undergo only partial metamorphosis. Based on endocrine studies and morphological comparisons of the development of insect species with and without metamorphosis, a novel hypothesis for the evolution of metamorphosis is proposed. changes in the endocrinology of development are central to this hypothesis The three stages of the ancestral insect species-pronymph, nymph and adult-are proposed to be equivalent to the larva, pupa and adult stages of insects with complete metamorphosis. This proposal has general implications far insect developmental biology.	Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Truman, JW (corresponding author), Univ Washington, Dept Zool, Box 351800, Seattle, WA 98195 USA.	jwt@u.washington.edu						Asahina S, 1954, MORPHOLOGICAL STUDY; AZAM KM, 1969, ANN ENTOMOL SOC AM, V62, P549, DOI 10.1093/aesa/62.3.549; BAKER FC, 1987, INSECT BIOCHEM, V17, P989, DOI 10.1016/0020-1790(87)90108-9; BATE CM, 1976, NATURE, V260, P54, DOI 10.1038/260054a0; Bergot B. J., 1981, JUVENILE HORMONE BIO, P33; Berlese A., 1913, Redia Firenze, V9; BERNAYS EA, 1971, Z MORPHOL TIERE, V70, P183; BOLLENBACHER WE, 1981, GEN COMP ENDOCR, V44, P302, DOI 10.1016/0016-6480(81)90005-8; BROADIE KS, 1991, ROUX ARCH DEV BIOL, V199, P327, DOI 10.1007/BF01705925; BRUNING E, 1985, INT J INVER REP DEV, V8, P269; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARPENTER FM, 1992, ARTHROPODA R, V3, P1; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Champlin DT, 1998, DEVELOPMENT, V125, P2009; CORBET PHILIP S., 1955, ENT GAZ, V6, P189; Couso JP, 1998, INT J DEV BIOL, V42, P345; Dewitz, 1878, Z WISS ZOOL, V30, P78; DORN A, 1981, TISSUE CELL, V13, P461, DOI 10.1016/0040-8166(81)90019-7; DORN A, 1983, ENTOMOL GEN, V8, P193; Durston AJ, 1998, CURR TOP DEV BIOL, V40, P111, DOI 10.1016/S0070-2153(08)60366-X; EDWARDS JS, 1979, ROUX ARCH DEV BIOL, V186, P151, DOI 10.1007/BF00848176; FAIN MJ, 1975, BIOL BULL-US, V149, P506, DOI 10.2307/1540383; Grueber WB, 1999, J COMP NEUROL, V404, P127, DOI 10.1002/(SICI)1096-9861(19990201)404:1<127::AID-CNE10>3.0.CO;2-M; Heeley W, 1941, P ZOOL SOC LOND B-SY, V111, P79; Heming BS, 1996, CAN J ZOOL, V74, P1008, DOI 10.1139/z96-114; HINTON H. E., 1955, TRANS ROY ENT SOC LONDON, V106, P455; Hinton H. E., 1948, Transactions of the Royal Entomological Society of London, V99, P395; Hinton H.E., 1981, BIOL INSECT EGGS, VI; IMBODEN H, 1978, GEN COMP ENDOCR, V36, P628, DOI 10.1016/0016-6480(78)90104-1; KARAWAIEW W, 1898, Z WISS ZOOL, V64, P385; KREMEN C, J INSECT PHYSL, V44, P287; KRISHNAN KN, 1975, INDIAN J TECHNOL, V13, P1; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KURUSHIMA M, 1975, J INSECT PHYSIOL, V21, P1705, DOI 10.1016/0022-1910(75)90183-3; KUTSCH W, 1987, DEV BIOL, V123, P517, DOI 10.1016/0012-1606(87)90410-6; LAGUEUX M, 1979, J INSECT PHYSIOL, V25, P709, DOI 10.1016/0022-1910(79)90123-9; LAWRENCE JF, 1982, ANNU REV ECOL SYST, V13, P261, DOI 10.1146/annurev.es.13.110182.001401; Lindsay E., 1940, Proceedings of the Royal Society of Victoria N S, V52, P35; MEIER T, 1991, DEVELOPMENT, V112, P241; MERCER WF, 1900, NEW YORK ENTOMOL SOC, V8, P1; MEYER DR, 1980, J EXP ZOOL, V213, P185, DOI 10.1002/jez.1402130205; MICCIARELLI AS, 1977, ACTA EMBRYOL EXP, P295; Monsma SA, 1996, J COMP NEUROL, V367, P10, DOI 10.1002/(SICI)1096-9861(19960325)367:1<10::AID-CNE2>3.0.CO;2-M; Needham JG, 1935, BIOL MAYFLIES; NEUMANN D, 1991, J INSECT PHYSIOL, V37, P101, DOI 10.1016/0022-1910(91)90095-H; Nijhout H.F., 1994, INSECT HORMONES; NOVAK VJA, 1969, J EMBRYOL EXP MORPH, V21, P1; NOVAK VJA, 1975, INSECT HORMONES; Oberlander H., 1985, COMPREHENSIVE INSECT, V1st, P151; Powell P. B., 1904, J NY ENTOMOL SOC, V12, P237; Powell PB., 1905, J N Y ENTOMOL SOC, V13, P5; Poyarkoff E., 1914, Archives de Zoologie Paris, V54; PRATT HS, 1897, PSYCHE, V8, P15; QUENNEDEY A, 1990, TISSUE CELL, V22, P721, DOI 10.1016/0040-8166(90)90067-J; REDDY G, 1980, EXPERIENTIA, V36, P461, DOI 10.1007/BF01975148; RIDDIFOR.LM, 1967, P NATL ACAD SCI USA, V57, P595, DOI 10.1073/pnas.57.3.595; Riddiford L.M., 1972, P95; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; RIDDIFORD LM, 1978, INSECT BIOCHEM, P307; ROHDENDORF EB, 1973, J INSECT PHYSIOL, V19, P37, DOI 10.1016/0022-1910(73)90220-5; SBRENNA G, 1991, MORPHOGENETIC HORMON, V3, P44; SBRENNAMICCIARE.A, 1972, J INSECT PHYSIOL, V18, P1027; SEHNAL F, 1985, COMPREHENSIVE INSECT, V2, P1; Sehnal Frantisek, 1996, P3, DOI 10.1016/B978-012283245-1/50003-8; SMITH RF, 1975, J INSECT PHYSIOL, V21, P723, DOI 10.1016/0022-1910(75)90004-9; SVACHA P, 1992, DEV BIOL, V154, P101, DOI 10.1016/0012-1606(92)90052-I; TEMIN G, 1986, INT J INVER REP DEV, V9, P105, DOI 10.1080/01688170.1986.10510184; Tiegs O. W., 1922, Transactions and Proceedings Royal Society South Australia, V46, P319; TOWER WL, 1903, ZOOL JB, V17, P515; van der Hammen L., 1989, INTRO COMP ARACHNOLO; VAUGHT GL, 1974, ANN ENTOMOL SOC AM, V67, P167, DOI 10.1093/aesa/67.2.167; WATSON JAL, 1967, BIOL BULL, V132, P277, DOI 10.2307/1539895; WEISMANN A, 1864, Z WISS ZOOL, V14, P101; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; WIESMAN A, 1966, Z WISS ZOOL, V16, P1; Williams C.M., 1980, P369; ZACHARUK RY, 1991, ANNU REV ENTOMOL, V36, P331, DOI 10.1146/annurev.en.36.010191.001555	78	354	369	8	162	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					447	452		10.1038/46737	http://dx.doi.org/10.1038/46737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519548				2022-12-28	WOS:000082981200047
J	Brinkman, K; Smeitink, JA; Romijn, JA; Reiss, P				Brinkman, K; Smeitink, JA; Romijn, JA; Reiss, P			Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy	LANCET			English	Article							MULTIPLE SYMMETRICAL LIPOMATOSIS; PROTEASE INHIBITORS; FAT; MYOPATHY; DNA; MUTATION	Highly active antiretroviral therapy (HAART) can induce a characteristic lipodystrophy syndrome of peripheral fat wasting and central adiposity. HIV-1 protease inhibitors are generally believed to be the causal agents, although the syndrome has also been observed with protease-inhibitor-sparing regimens. Here, we postulate that the mitochondrial toxicity of the nucleoside-analogue reverse-transcriptase inhibitors plays an essential part in the development of this lipodystrophy, similar to the role of mitochondrial defects in the development of multiple symmetrical lipomatosis.	Onze Lieve Vrouwe Gasthuis, Dept Internal Med, NL-1091 HA Amsterdam, Netherlands; Univ Nijmegen Hosp, Dept Pediat, Nijmegen, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RA Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	Brinkman, K (corresponding author), Onze Lieve Vrouwe Gasthuis, Dept Internal Med, 1E Oosterpk Str 279, NL-1091 HA Amsterdam, Netherlands.		Smeitink, Jan/C-1351-2013					ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Arner P, 1998, LANCET, V351, P1301, DOI 10.1016/S0140-6736(05)79052-8; Becker-Wegerich P, 1998, ARCH DERMATOL RES, V290, P652, DOI 10.1007/s004030050368; BERKOVIC SF, 1991, ANN NEUROL, V29, P566, DOI 10.1002/ana.410290519; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Campos Y, 1996, NEUROLOGY, V47, P1012, DOI 10.1212/WNL.47.4.1012; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CARR A, 1999, ANTIVIR THER S, V4, P19; Carroll DS, 1998, PALLIATIVE MED, V12, P51, DOI 10.1191/026921698666041220; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; ENZI G, 1984, MEDICINE, V63, P56, DOI 10.1097/00005792-198401000-00004; ENZI G, 1977, J CLIN INVEST, V60, P1221, DOI 10.1172/JCI108881; GALLI M, 1999, ANTIVIR THER S, V4, P29; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; GISOLF E, 1998, 12 WORLD AIDS C GEN; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; LENHARD J, 1999, 6 C RETR OPP INF CHI; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; MALLAL S, 1999, ANTIVIR THER S, V4, P28; MERCIE P, 1999, ANTIVIRAL THER S2, V4, P27; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; SAINTMARC T, 1999, ANTIVIR THER S, V4, P31; SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200; Teplitsky V, 1999, NEW ENGL J MED, V340, P969; VIARD JP, 1999, ANTIVIR THER S, V4, P32; ZANCANARO C, 1990, LAB INVEST, V63, P253	34	657	666	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1112	1115		10.1016/S0140-6736(99)06102-4	http://dx.doi.org/10.1016/S0140-6736(99)06102-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509516				2022-12-28	WOS:000082777500043
J	Dickey, NW; McMenamin, P				Dickey, NW; McMenamin, P			Putting power into patient choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH		Amer Med Assoc, Washington, DC 20005 USA	American Medical Association	McMenamin, P (corresponding author), Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.							*COUNC MED SERV, 1998, 9A98 CMS AM MED ASS; *CTR STUD HLTH SYS, 1998, DATA B CTR STUD HLTH, V12; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; DAVIS K, 1997, MANAGED CARE CHOICE; FRONSTIN P, 1998, SOURCES HLTH INSURAN; Gabel JR, 1997, HEALTH AFFAIR, V16, P103, DOI 10.1377/hlthaff.16.5.103; Kuttner R, 1999, NEW ENGL J MED, V340, P248, DOI 10.1056/NEJM199901213400324; Sheils J, 1999, HEALTH AFFAIR, V18, P176, DOI 10.1377/hlthaff.18.2.176	8	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1305	1308		10.1056/NEJM199910213411711	http://dx.doi.org/10.1056/NEJM199910213411711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247NF	10528044				2022-12-28	WOS:000083226300011
J	McGrath, J; Emmerson, WB				McGrath, J; Emmerson, WB			Fortnightly review - Treatment of schizophrenia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NEUROLEPTICS		Wolston Pk Hosp, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia; Univ Queensland, Royal Brisbane Hosp, Div Mental Hlth Serv, Herston, Qld 4029, Australia; Dist Hlth Serv, Herston, Qld 4029, Australia	Royal Brisbane & Women's Hospital; University of Queensland	McGrath, J (corresponding author), Wolston Pk Hosp, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia.	jjm@brain.wph.uq.edu.au	Emmerson, William Brett/M-1214-2015; McGrath, John Joseph/G-5493-2010	McGrath, John Joseph/0000-0002-4792-6068				Dixon LB, 1995, SCHIZOPHRENIA BULL, V21, P631, DOI 10.1093/schbul/21.4.631; DUGGAN L, 1999, COCHRANE COLLABORATI; *EXP CONS GUID GRO, 1996, J CLIN PSYCHIAT, V57, P11; Fleischhacker WW, 1999, CURR OPIN PSYCHIATR, V12, P53, DOI 10.1097/00001504-199901000-00017; Green MF, 1997, AM J PSYCHIAT, V154, P799; HAGGER C, 1993, BIOL PSYCHIAT, V34, P702, DOI 10.1016/0006-3223(93)90043-D; Herz MI, 1997, AM J PSYCHIAT, V154, P1; HIRSCH SR, 1994, BRIT J PSYCHIAT, V164, P94, DOI 10.1192/bjp.164.1.94; JOY CB, 1999, COCHRANE COLLABORATI; KANE JM, 1989, J CLIN PSYCHIAT, V50, P322; Kane JM, 1999, CURR OPIN PSYCHIATR, V12, P17, DOI 10.1097/00001504-199901000-00012; KANE JM, 1995, LANCET, V346, P820, DOI 10.1016/S0140-6736(95)91630-X; KENNEDY E, 1998, COCHRANE COLLABORATI; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4; LOEBEL AD, 1992, AM J PSYCHIAT, V149, P1183; MARI JJ, 1998, COCHRANE COLLABORATI; MARSHALL M, 1999, COCHRANE COLLABORATI; McGlashan TH, 1996, SCHIZOPHRENIA BULL, V22, P201, DOI 10.1093/schbul/22.2.201; McGorry PD, 1996, SCHIZOPHRENIA BULL, V22, P305, DOI 10.1093/schbul/22.2.305; NATHAN PE, 1998, GUIDE TREATMENTS WOR; Pearsall R, 1998, PSYCHOPHARMACOL BULL, V34, P349; SRISURAPANONT M, 1998, COCHRANE COLLABORATI; TYRER P, 1999, COCHRANE COLLABORATI; WAHLBECK K, 1998, COCHRANE COLLABORATI; Weiden PJ, 1997, J CLIN PSYCHIAT, V58, P63; WYATT RJ, 1991, SCHIZOPHRENIA BULL, V17, P325, DOI 10.1093/schbul/17.2.325; Wykes T, 1998, OUTCOME AND INNOVATION IN PSYCHOLOGICAL TREATMENT OF SCHIZOPHRENIA, P1	28	22	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1999	319	7216					1045	1048		10.1136/bmj.319.7216.1045	http://dx.doi.org/10.1136/bmj.319.7216.1045			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521199	Green Published			2022-12-28	WOS:000083210100029
J	Reilly, JJ; Dorosty, AR; Emmett, PM				Reilly, JJ; Dorosty, AR; Emmett, PM			Prevalence of overweight and obesity in British children: cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX	Estimates of the prevalence of obesity among children are necessary so that the need for preventive measures can be assessed, secular trends monitored, and high risk population groups identified.(1) The aim of this study was therefore to provide current estimates of the prevalence of obesity among British children.	Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, ALSPAC Study Team, Bristol BS8 1TH, Avon, England	University of Glasgow; University of Bristol	Reilly, JJ (corresponding author), Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland.		Dorosty-Motlagh, Ahmad-Reza/E-1003-2018; Emmett, Pauline/AAL-6815-2021	Dorosty-Motlagh, Ahmad-Reza/0000-0002-6937-7776; Emmett, Pauline/0000-0003-1076-4779	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ALSPAC, 1998, CHILDR 90S; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Reilly JJ, 1999, INT J OBESITY, V23, P217, DOI 10.1038/sj.ijo.0800804	5	127	135	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1039	1039		10.1136/bmj.319.7216.1039	http://dx.doi.org/10.1136/bmj.319.7216.1039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521196	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000083210100027
J	Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES				Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES			Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ALVEOLAR RHABDOMYOSARCOMA; SACCHAROMYCES-CEREVISIAE; BURKITT-LYMPHOMA; SURFACE-ANTIGENS; TRANSLOCATION; CELLS; MICROARRAY; FUSION	Although cancer classification has improved over the past 30 years, there has been no general approach for identifying new cancer classes (class discovery) or for assigning tumors to known classes (class prediction). Here, a generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute Leukemias as a test case. A class discovery procedure automatically discovered the distinction between acute myeloid Leukemia (AML) and acute Lymphoblastic Leukemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine the class of new leukemia cases. The results demonstrate the feasibility of cancer classification based solely on gene expression monitoring and suggest a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Canc & Leukemia Grp B, Columbus, OH 43210 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Massachusetts Institute of Technology (MIT)	Golub, TR (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	golub@genome.wi.mit.edu; lander@genome.wi.mit.edu	Downing, James R./N-8102-2018; Mesirov, Jill/AGF-7626-2022; Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Slonim, Donna/0000-0003-3357-437X; Loh, Mignon/0000-0003-4099-4700				BALABANMALENBAUM G, 1977, SCIENCE, V198, P739, DOI 10.1126/science.71759; BENNETT JM, 1969, BLOOD-J HEMATOL, V33, P341, DOI 10.1182/blood.V33.2.341.341; Bishop JF, 1999, MED J AUSTRALIA, V170, P39, DOI 10.5694/j.1326-5377.1999.tb126866.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUCCHERI V, 1993, BLOOD, V82, P853; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DeRisi J, 1996, NAT GENET, V14, P457; DINNDORF PA, 1992, MED PEDIATR ONCOL, V20, P192, DOI 10.1002/mpo.2950200303; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FORKNER CE, 1938, LEUKEMIA ALLIED DISO; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, UNPUB; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150; Huang SY, 1997, BRIT J HAEMATOL, V96, P682, DOI 10.1046/j.1365-2141.1997.d01-2100.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MASTER PS, 1989, BLUT, V59, P221, DOI 10.1007/BF00320851; McLean TW, 1996, BLOOD, V88, P4252; *MED RES COUNC, 1963, BRIT MED J, V1, P7; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PESANDO JM, 1979, BLOOD, V54, P1240; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; QUAGLINO D, 1959, J PATHOL BACTERIOL, V78, P521, DOI 10.1002/path.1700780219; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROPER M, 1983, BLOOD, V61, P830; ROSS W, 1984, CANCER RES, V44, P5857; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; SALLAN SE, 1980, BLOOD, V55, P395; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STEPHENSON CF, 1992, HUM PATHOL, V23, P1270, DOI 10.1016/0046-8177(92)90295-E; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P47, DOI 10.1016/S0889-8588(18)30257-0; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Triche T J, 1988, Prog Clin Biol Res, V271, P475; TSUKIMOTO I, 1976, NEW ENGL J MED, V294, P245, DOI 10.1056/NEJM197601292940503; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517	52	7959	9684	22	792	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					531	537		10.1126/science.286.5439.531	http://dx.doi.org/10.1126/science.286.5439.531			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521349				2022-12-28	WOS:000083121200061
J	Aronson, J				Aronson, J			When I use a word ... - That's show business	BRITISH MEDICAL JOURNAL			English	Article																		1980, J NAT PROD, V43, P242; 1984, J NAT PROD, V47, P698	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					972	972		10.1136/bmj.319.7215.972	http://dx.doi.org/10.1136/bmj.319.7215.972			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514162	Green Published			2022-12-28	WOS:000083111700029
J	Schultze, J; Johnson, P				Schultze, J; Johnson, P			A stimulating new target for cancer immunotherapy	LANCET			English	Editorial Material							FOLLICULAR LYMPHOMA-CELLS; IN-VITRO; B-CELLS; T-CELLS; CD40; HELP		Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Sci Div,CRC,Dept Med Oncol, Southampton SO16 6YD, Hants, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Southampton	Schultze, J (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.		Schultze, Joachim L./ABA-8176-2020; Schultze, Joachim L/D-7794-2011; Johnson, Peter/L-2403-2018; Johnson, Peter/O-3529-2019	Schultze, Joachim L./0000-0003-2812-9853; Schultze, Joachim L/0000-0003-2812-9853; Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974				Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Fisher DC, 1998, BLOOD, V92, p247A; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hirano A, 1999, BLOOD, V93, P2999; JOHNSON PWM, 1993, BLOOD, V82, P1848, DOI 10.1182/blood.V82.6.1848.bloodjournal8261848; Kato K, 1998, J CLIN INVEST, V101, P1133, DOI 10.1172/JCI1472; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SCHULTZE JL, 1995, P NATL ACAD SCI USA, V92, P8200, DOI 10.1073/pnas.92.18.8200; Schultze JL, 1999, J EXP MED, V189, P1, DOI 10.1084/jem.189.1.1; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Schultze JL, 1997, BLOOD, V89, P3806, DOI 10.1182/blood.V89.10.3806.3806_3806_3816; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503	16	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1225	1227		10.1016/S0140-6736(99)90130-7	http://dx.doi.org/10.1016/S0140-6736(99)90130-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520628				2022-12-28	WOS:000083010400005
J	Stout, RW				Stout, RW			A memorable patient - The need to know	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					1001	1001		10.1136/bmj.319.7215.1001	http://dx.doi.org/10.1136/bmj.319.7215.1001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514172	Green Published			2022-12-28	WOS:000083111700041
J	Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D				Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D			Arsenic poisoning in the Ganges delta	NATURE			English	Article							WEST-BENGAL; 6 DISTRICTS; GROUNDWATER; INDIA; BANGLADESH; CALAMITY; DRINKING; WATER		Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India; Dhaka Community Hosp Trust, Dhaka 1217, Bangladesh	Jadavpur University	Chowdhury, TR (corresponding author), Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India.			Roychowdhury, Tarit/0000-0001-6515-5634				AKAI J, 1998, C P 3 FOR ARS CONT G, P51; CHOWDHURY R, 1999, THESIS JADAVPUR U CA; Das D, 1996, ENVIRON GEOCHEM HLTH, V18, P5, DOI 10.1007/BF01757214; DAS D, 1995, ANALYST, V120, P917, DOI 10.1039/an9952000917; DAS D, 1995, THESIS JADAVPUR U CA; Dhar RK, 1997, CURR SCI INDIA, V73, P48; *M MACD LTD, 1999, BRIT GEOL SURV FIN R; Mandal BK, 1998, SCI TOTAL ENVIRON, V218, P185, DOI 10.1016/S0048-9697(98)00220-4; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; NICKSON R, 1997, THESIS U COLL LONDON; Samanta G, 1999, MICROCHEM J, V62, P174, DOI 10.1006/mchj.1999.1713	11	277	299	5	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					545	546		10.1038/44056	http://dx.doi.org/10.1038/44056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524620				2022-12-28	WOS:000083054900035
J	Thomas, LR; Baden, L; Zaleznik, DF				Thomas, LR; Baden, L; Zaleznik, DF			Chest pain with a surprising course	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CHOLECYSTITIS; EMPHYSEMATOUS CHOLECYSTITIS; MYOCARDIAL-INFARCTION; HEMOLYSIS		Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Zaleznik, DF (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, E Campus,SL-435,330 Brookline Ave, Boston, MA 02215 USA.							Gill KS, 1997, BRIT J RADIOL, V70, P986, DOI 10.1259/bjr.70.838.9404199; HICKMAN MS, 1988, ARCH SURG-CHICAGO, V123, P409; HUBL W, 1993, ANN HEMATOL, V67, P145, DOI 10.1007/BF01701741; PATEL J, 1994, CLIN CARDIOL, V17, P505, DOI 10.1002/clc.4960170910; Pun KC, 1996, CHEST, V110, P1353, DOI 10.1378/chest.110.5.1353; RANSOHOFF DF, 1987, ANN INTERN MED, V106, P829, DOI 10.7326/0003-4819-106-6-829; REISS R, 1993, DIGEST DIS, V11, P55, DOI 10.1159/000171401; RYAN ET, 1992, ANN INTERN MED, V116, P218, DOI 10.7326/0003-4819-116-3-218; SHPITZ B, 1995, AM SURGEON, V61, P964; VINGAN HL, 1990, AM J ROENTGENOL, V155, P1013, DOI 10.2214/ajr.155.5.2120927; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187	11	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1134	1138		10.1056/NEJM199910073411507	http://dx.doi.org/10.1056/NEJM199910073411507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511613				2022-12-28	WOS:000083087200007
J	Yang, GH; Fan, LX; Tan, J; Qi, GM; Zhang, YF; Samet, JM; Taylor, CE; Becker, K; Xu, J				Yang, GH; Fan, LX; Tan, J; Qi, GM; Zhang, YF; Samet, JM; Taylor, CE; Becker, K; Xu, J			Smoking in China - Findings of the 1996 National Prevalence Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGING TOBACCO HAZARDS; CIGARETTE-SMOKING; SCHOOL STUDENTS; MORTALITY; HEALTH; CANCER	Context As the world's largest producer and consumer of tobacco products, China bears a large proportion of the global burden of smoking-related disease and may be experiencing a tobacco epidemic. Objective To develop an evidence-based approach supporting tobacco control initiatives in China. Design and Setting A population-based survey consisting of a 52-item questionnaire that included information on demographics, smoking history, smoking-related knowledge and attitudes, cessation, passive smoke exposure, and health status was administered in 145 disease surveillance points in the 30 provinces of China from March through July 1996. Participants A nationally representative random sample of 128 766 persons aged 15 to 69 years were asked to participate; 120 298 (93.8%) provided data and were included in the final analysis. About two thirds of those sampled were from rural areas and one third were from urban areas. Main Outcome Measures Current smoking patterns and attitudes; changes in smoking patterns and attitudes compared with results of a previous national survey conducted in 1984. Results A total of 41 187 respondents smoked at least 1 cigarette per day, accounting for 34.1% of the total number of respondents, an increase of 3.4 percentage points since 1984. Current smoking continues to be prevalent among more men (63%) than women (3.8%). Age at smoking initiation declined by about 3 years for both men and women (from 28 to 25 years). Only a minority of smokers recognized that lung cancer (36%) and heart disease (4%) can be caused by smoking. Of the nonsmokers, 53.5% were exposed to environmental tobacco smoke at least 15 minutes per day on more than 1 day per week. Respondents were generally supportive of tobacco control measures. Conclusion The high rates of smoking in men found in this study signal an urgent need for smoking prevention and cessation efforts; tobacco control initiatives are needed to maintain or decrease the currently low smoking prevalence in women.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Chinese Acad Prevent Med, Beijing, Peoples R China; Chinese Assoc Smoking & Hlth, Beijing, Peoples R China; Global Inst Tobacco Control, Baltimore, MD USA	Johns Hopkins University; Chinese Center for Disease Control & Prevention	Samet, JM (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.							Chen ZM, 1997, JAMA-J AM MED ASSOC, V278, P1500, DOI 10.1001/jama.278.18.1500; *DEP DIS CONTR MIN, 1997, 1995 ANN REP DIS SUR; Lam TH, 1997, JAMA-J AM MED ASSOC, V278, P1505, DOI 10.1001/jama.278.18.1505; Li XM, 1996, SUBST USE MISUSE, V31, P545, DOI 10.3109/10826089609045826; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; Myhre SL, 1996, CANCER DETECT PREV, V20, P223; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; NIU SR, 1995, J HLTH STUDY, V24, P15; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; PETO R, 1994, MORTALITY SMOKING; PETO R, 1990, 7 WORLD C TOB HLTH P; Samer JM, 1998, BMJ-BRIT MED J, V316, P321, DOI 10.1136/bmj.316.7128.321; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; WANG CF, 1995, J CHIN SCH HLTH, V16, P248; WENG XZ, 1987, CHINESE MED J-PEKING, V100, P886; *WHO INT AG RES CA, 1986, TOB SMOK; World Health Organization, 1997, WHO REP 1997 CONQ SU; World Health Organization, 1983, WHOSMO834; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; Yang G H, 1997, Biomed Environ Sci, V10, P1; YANG GH, 1992, J CHIN EPIDEMIOL, V13, P79; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; ZHANG D, 1993, JAMA-J AM MED ASSOC, V269, P2972; ZHU BP, 1992, INT J EPIDEMIOL, V21, P854, DOI 10.1093/ije/21.5.854; Zhu BP, 1996, AM J PUBLIC HEALTH, V86, P368, DOI 10.2105/AJPH.86.3.368; 1993, MMWR MORB MORTAL WKL, V42, P370	27	479	512	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1247	1253		10.1001/jama.282.13.1247	http://dx.doi.org/10.1001/jama.282.13.1247			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517427	Bronze			2022-12-28	WOS:000082901100032
J	Bacic, J; Skorbonja, A; Polanda-Bacic, G				Bacic, J; Skorbonja, A; Polanda-Bacic, G			Three cases of bone and joint surgery in the 14th century	LANCET			English	Article									Gen Hosp, Dept Urol, Dubrovnik, Croatia		Bacic, J (corresponding author), Gen Hosp, Dept Urol, R Miset 20000, Dubrovnik, Croatia.							BACIC J, 1988, TRACING MED PRACTICE, P10; *CROAT AC SCI, 1987, AC SCI ART SLAV MER, V5, P91; *CROAT AC SCI, 1882, AC SCI ART SLAV MER, V2, P304; GLESINGER L, 1978, HIST MED, P149; GREMOSNIK G, 1931, SEVERAL MED CONTRACT, P43; GRMEK MD, 1954, MEDIEVAL CONTRACTS M, P147; JEREMIC R, 1939, SUPPLEMENTS HIST MED, V2, P8; LUCIC J, 1979, CRAFTS SERVICES DUBR, P131; RIZZI G, 1950, HUMANA STUDIA ROMA, V2, P218; ROLLER D, 1951, CRAFTS DUBROVNIK 15, V2, P4; ZIVKOVIC P, 1985, PARITY DUBROVNIK MON, P31; 1897, ZAGRABIAE, V5, P71	12	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1200	1202		10.1016/S0140-6736(98)11502-7	http://dx.doi.org/10.1016/S0140-6736(98)11502-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513727				2022-12-28	WOS:000082954100045
J	McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR				McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR			Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTEC 12B BOTTLES; INFECTION; BACTEREMIA; DIAGNOSIS; EXTRAPULMONARY; NAIROBI; SYSTEM	Background Nosocomial transmission of Mycobacterium tuberculosis is a global public-health concern. Although early clinical recognition of M tuberculosis in hospital inpatients is critical for effective infection control, such recognition may be difficult in patients with HIV infection. To find out whether M tuberculosis bacteraemia frequently goes unrecognised, we did a prospective blood-culture survey in an infectious-diseases hospital in Thailand and a general hospital in Malawi, Methods Consecutive febrile (greater than or equal to 37.5 degrees C axillary or greater than or equal to 38.0 degrees C orally) hospital inpatients (aged greater than or equal to 18 years) were enrolled; blood was obtained for mycobacterial culture and HIV testing. Simple diagnostic tests, such as chest radiographs and sputum smears, were ordered by clinicians as deemed necessary, and were carried out with existing local resources. Findings Of 344 patients enrolled, 255 (74%) were HIV infected, the median age was 33 years (range 18-87), and 208 (61%) were male. 34 (10%) patients had NI tuberculosis bacteraemia; five of these patients were already on antituberculosis therapy. Only HIV-infected patients had M tuberculosis bacteraemia. Of the 29 patients with M tuberculosis bacteraemia who were not already receiving antituberculosis therapy, 13 (45%) had an abnormal chest radiograph or a positive sputum smear. 16 (55%) patients had no additional diagnostic test results to indicate M tuberculosis infection; 18 (81%) of these had a cough. Interpretation In less developed countries where both M tuberculosis and HIV infections are prevalent, M tuberculosis bacteraemia may frequently go unrecognised among febrile hospital inpatients.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Bamrasnaradura Hosp, Bangkok, Thailand; Lilongwe Cent Hosp, Lilongwe, Malawi; Duke Univ, Med Ctr, Durham, NC USA	Centers for Disease Control & Prevention - USA; Duke University	Archibald, LK (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.			McDonald, L. Clifford/0000-0003-3044-5572				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316; BARNES PF, 1987, J INFECT DIS, V156, P377, DOI 10.1093/infdis/156.2.377; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; DOERN GV, 1994, J CLIN MICROBIOL, V32, P2576, DOI 10.1128/JCM.32.10.2576-2577.1994; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; Fandinho FCO, 1997, B WORLD HEALTH ORGAN, V75, P361; Fox J, 1998, ASM NEWS, V64, P73; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359; Inderlied Clark B., 1995, P1385; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; NUNN P, 1992, TUBERCLE LUNG DIS, V73, P45, DOI 10.1016/0962-8479(92)90079-Y; REIMER LG, 1994, CLIN LAB MED, V14, P99, DOI 10.1016/S0272-2712(18)30397-4; SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; WASILAUSKAS B, 1994, J CLIN MICROBIOL, V32, P654, DOI 10.1128/JCM.32.3.654-657.1994; *WHO, 1998, TUB FACT SHEET	22	75	78	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1159	1163		10.1016/S0140-6736(98)12325-5	http://dx.doi.org/10.1016/S0140-6736(98)12325-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513709				2022-12-28	WOS:000082954100011
J	Putney, JW				Putney, JW			"Kissin' cousins": Intimate plasma membrane-ER interactions underlie capacitative calcium entry	CELL			English	Review							FUSION; MECHANISM; RECEPTORS; PROTEINS; RELEASE		NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087, Z01ES090086, Z01ES080045] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Quick MW, 1997, J NEUROSCI, V17, P2967; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	19	119	121	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					5	8		10.1016/S0092-8674(00)80056-2	http://dx.doi.org/10.1016/S0092-8674(00)80056-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520988	Bronze			2022-12-28	WOS:000082981600002
J	Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R				Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R			Cytochrome P4502C is an EDHF synthase in coronary arteries	NATURE			English	Article							ARACHIDONIC-ACID METABOLITE; HYPERPOLARIZING FACTOR; EPOXYEICOSATRIENOIC ACIDS; K+ CHANNELS; MICROCIRCULATION; ENZYMES	In most arterial beds a significant endothelium-dependent dilation to various stimuli persists even after inhibition of nitric oxide synthase and cyclo-oxygenase. This dilator response is preceded by an endothelium-dependent hyperpolarization of vascular smooth muscle cells, which is sensitive to a combination of the calcium-dependent potassium-channel inhibitors charybdotoxin and apamin, and is assumed to be mediated by an unidentified endothelium-derived hyperpolarizing factor (EDHF)(1,2). Here we show that the induction of cytochrome P450 (CYP) 2C8/34 in native porcine coronary artery endothelial cells by beta-naphthoflavone enhances the formation of 11,12-epoxyeicosatrienoic acid, as well as EDHF-mediated hyperpolarization and relaxation. Transfection of coronary arteries with CYP 2C8/34 antisense oligonucleotides results in decreased levels of CYP 2C and attenuates EDHF-mediated vascular responses. Thus, a CYP-epoxygenase product is an essential component of EDHF-mediated relaxation in the porcine coronary artery, and CYP 2C8/34 fulfils the criteria for the coronary EDHF synthase.	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany; Univ Giessen, Zentrum Inneren Med, D-35392 Giessen, Germany; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Justus Liebig University Giessen; Medical College of Wisconsin	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BAUERSACHS J, 1994, BRIT J PHARMACOL, V113, P1548, DOI 10.1111/j.1476-5381.1994.tb17172.x; Bauersachs J, 1996, CIRCULATION, V94, P3341, DOI 10.1161/01.CIR.94.12.3341; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CHEN G, 1988, BRIT J PHARMACOL, V95, P1165, DOI 10.1111/j.1476-5381.1988.tb11752.x; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; FULTON D, 1995, BRIT J PHARMACOL, V114, P99, DOI 10.1111/j.1476-5381.1995.tb14911.x; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; Kiss L, 1998, ANAL BIOCHEM, V261, P16, DOI 10.1006/abio.1998.2674; KOMORI K, 1990, BLOOD VESSELS, V27, P238; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Miura H, 1998, CIRC RES, V83, P501, DOI 10.1161/01.RES.83.5.501; Oltman CL, 1998, CIRC RES, V83, P932; PINTO A, 1987, J PHARMACOL EXP THER, V240, P856; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; PRITCHARD KA, 1990, AM J PATHOL, V136, P1381; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; ROSOLOWSKY M, 1993, AM J PHYSIOL, V264, pH327, DOI 10.1152/ajpheart.1993.264.2.H327; RUBANYI GM, 1987, CIRC RES, V61	22	772	799	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					493	497		10.1038/46816	http://dx.doi.org/10.1038/46816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519554				2022-12-28	WOS:000082981200060
J	Kinsella, JP; Walsh, WF; Bose, CL; Gerstmann, DR; Labella, JJ; Sardesai, S; Walsh-Sukys, MC; McCaffrey, MJ; Cornfield, DN; Bhutani, VK; Cutter, GR; Baier, M; Abman, SH				Kinsella, JP; Walsh, WF; Bose, CL; Gerstmann, DR; Labella, JJ; Sardesai, S; Walsh-Sukys, MC; McCaffrey, MJ; Cornfield, DN; Bhutani, VK; Cutter, GR; Baier, M; Abman, SH			Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION; HYALINE-MEMBRANE DISEASE; DISTRESS SYNDROME; BRONCHOPULMONARY DYSPLASIA; PRETERM INFANTS; BLEEDING-TIME; NEWBORN; ACTIVATION; INHALATION; HEMORRHAGE	Background Inhaled nitric oxide improves oxygenation and lessens the need for extracorporeal-membrane oxygenation in full-term neonates with hypoxaemic respiratory failure and persistent pulmonary hypertension, but potential adverse effects are intracranial haemorrhage and chronic lung disease. We investigated whether low-dose inhaled nitric oxide would improve survival in premature neonates with unresponsive severe hypoxaemic respiratory failure, and would not increase the frequency or severity of intracranial haemorrhage or chronic lung disease. Methods We did a double-blind, randomised controlled trial in 12 perinatal centres that provide tertiary care. 80 premature neonates (gestational age less than or equal to 34 weeks) with severe hypoxaemic respiratory failure were randomly assigned inhaled nitric oxide (n=48) or no nitric oxide (n=32, controls). Our primary outcome was survival to discharge. Analysis was by intention to treat. We studied also the rate and severity of intracranial haemorrhage, pulmonary haemorrhage, duration of ventilation, and chronic lung disease at 36 weeks' postconceptional age. Findings The two groups did not differ for baseline characteristics or severity of disease. Inhaled nitric oxide improved oxygenation after 60 min (p=0.03). Survival at discharge was 52% in the inhaled-nitric-oxide group and 47% in controls (p=0.65). Causes of death were mainly related to extreme prematurity and were similar in the two groups. The two groups did not differ for adverse events or outcomes (intracranial haemorrhage grade 2-4, 28% inhaled nitric oxide and 33% control; pulmonary haemorrhage 13% and 9%; chronic lung disease 60% and 80%). Interpretation Low-dose inhaled nitric oxide improved oxygenation but did not improve survival in severely hypoxaemic premature neonates. Low-dose nitric oxide in the most critically ill premature neonates does not increase the risk of intracranial haemorrhage, and may decrease risk of chronic lung injury.	Univ Colorado, Sch Med, Childrens Hosp, Div Neonatol, Denver, CO 80218 USA; Vanderbilt Univ, Nashville, TN USA; Univ N Carolina, Chapel Hill, NC USA; Utah Valley Reg Med Ctr, Provo, UT USA; Magee Womens & Childrens Hosp, Pittsburgh, PA USA; Univ So Calif, Los Angeles, CA USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Reg Naval Med Ctr, San Diego, CA USA; Univ Minnesota, Minneapolis, MN USA; Penn Hosp, Philadelphia, PA 19107 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Southern California; Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Pennsylvania Medicine	Kinsella, JP (corresponding author), Univ Colorado, Sch Med, Childrens Hosp, Div Neonatol, Box B-070,1056 E 19th Ave, Denver, CO 80218 USA.		Cutter, Gary/AAY-5392-2021	Cutter, Gary/0000-0002-8455-980X	NCRR NIH HHS [MO1 RR00069] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABMAN SH, 1993, PEDIATRICS, V92, P606; Brus F, 1996, PEDIATR RES, V39, P958, DOI 10.1203/00006450-199606000-00006; Cheung PY, 1998, J PEDIATR-US, V133, P735, DOI 10.1016/S0022-3476(98)70142-8; George TN, 1998, J PEDIATR-US, V132, P731, DOI 10.1016/S0022-3476(98)70370-1; Hardart GE, 1999, J PEDIATR-US, V134, P156, DOI 10.1016/S0022-3476(99)70408-7; HOGMAN M, 1993, LANCET, V341, P1664, DOI 10.1016/0140-6736(93)90802-N; Kanwar S, 1995, New Horiz, V3, P93; KINSELLA JP, 1994, AM J PHYSIOL-HEART C, V267, pH1955, DOI 10.1152/ajpheart.1994.267.5.H1955; Kinsella JP, 1997, PEDIATR RES, V41, P457, DOI 10.1203/00006450-199704000-00002; Kinsella JP, 1997, J PEDIATR-US, V131, P55, DOI 10.1016/S0022-3476(97)70124-0; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; Kinsella JP, 1997, SEMIN PERINATOL, V21, P418, DOI 10.1016/S0146-0005(97)80007-9; KINSELLA JP, 1994, PEDIATR RES, V36, P402, DOI 10.1203/00006450-199409000-00022; MALLOY MH, 1992, PEDIATRICS, V90, P881; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; OGDEN BE, 1983, CHEST, V83, P31; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PARTRIDGE JC, 1983, J PEDIATR-US, V102, P281, DOI 10.1016/S0022-3476(83)80544-7; PELIOWSKI A, 1995, J PEDIATR-US, V126, P450, DOI 10.1016/S0022-3476(95)70467-1; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; Skimming JW, 1997, J PEDIATR-US, V130, P225, DOI 10.1016/S0022-3476(97)70347-0; SPEER CP, 1993, PEDIATRICS, V91, P794; Stork E, 1997, NEW ENGL J MED, V336, P597; SUBHEDAR MV, 1997, ARCH DIS CHILD, V77, pF191; Subhedar NV, 1997, ARCH DIS CHILD-FETAL, V77, pF185, DOI 10.1136/fn.77.3.F185; SUGIURA M, 1994, J APPL PHYSIOL, V77, P1355, DOI 10.1152/jappl.1994.77.3.1355; VanMeurs KP, 1997, PEDIATR PULM, V24, P319; ZIMMERMAN JJ, 1995, CLIN PERINATOL, V22, P429	30	180	188	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1061	1065		10.1016/S0140-6736(99)03558-8	http://dx.doi.org/10.1016/S0140-6736(99)03558-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509496				2022-12-28	WOS:000082777500010
J	Skidmore, SJ				Skidmore, SJ			Factors in spread of hepatitis E	LANCET			English	Editorial Material							E VIRUS; INFECTION		Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England		Skidmore, SJ (corresponding author), Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England.							Balayan MS, 1997, J VIRAL HEPATITIS, V4, P155, DOI 10.1046/j.1365-2893.1997.00145.x; BRADLEY DW, 1995, J HEPATOL, V22, P140; Corwin AL, 1999, T ROY SOC TROP MED H, V93, P255, DOI 10.1016/S0035-9203(99)90014-7; Hau CH, 1999, AM J TROP MED HYG, V60, P277, DOI 10.4269/ajtmh.1999.60.277; Hussaini SH, 1997, J VIRAL HEPATITIS, V4, P51, DOI 10.1046/j.1365-2893.1997.00123.x; Lu FM, 1996, CHINESE MED J-PEKING, V109, P919; SCHARSCHMIDT BF, 1995, LANCET, V346, P519, DOI 10.1016/S0140-6736(95)91376-9; SKIDMORE SJ, 1995, BRIT MED J, V310, P414, DOI 10.1136/bmj.310.6977.414; Zhang YF, 1997, CLIN DIAGN LAB IMMUN, V4, P423, DOI 10.1128/CDLI.4.4.423-428.1997	9	22	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1049	1050		10.1016/S0140-6736(99)00241-X	http://dx.doi.org/10.1016/S0140-6736(99)00241-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509491				2022-12-28	WOS:000082777500005
J	Zhou, YQ; Karplus, M				Zhou, YQ; Karplus, M			Interpreting the folding kinetics of helical proteins	NATURE			English	Article							MOLECULAR-DYNAMICS; SIMULATIONS; SYSTEMS	The detailed mechanism of protein folding is one of the major problems in structural biology(1,2). Its solution is of practical as well as fundamental interest because of its possible role in utilizing the many sequences becoming available from genomic analysis(3). Although the Levinthal paradox(4) (namely, that a polypeptide chain can find its unique native state in spite of the astronomical number of configurations in the denatured state) has been resolved(4-7), the reasons for the differences in the folding behaviour of individual proteins remain to be elucidated. Here a C-alpha-based three-helix-bundle-like protein model with a realistic thermodynamic phase diagram is used to calculate several hundred folding trajectories. By varying a single parameter, the difference between the strength of native and non-native contacts, folding is changed from a diffusion-collision mechanism(8) to one that involves simultaneous collapse and partial secondary-structure formation, followed by reorganization to the native structure. Non-obligatory intermediates are important in the former, whereas there is an obligatory on-pathway intermediate in the latter. Our results provide a basis for understanding the range of folding behaviour that is observed in helical proteins.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Strasbourg, ISIS, Lab Chim Biophys, F-67000 Strasbourg, France	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu	Zhou, Yaoqi/B-3284-2009	Zhou, Yaoqi/0000-0002-9958-5699				Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; Cavagnero S, 1999, J MOL BIOL, V285, P269, DOI 10.1006/jmbi.1998.2273; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FERRENBERG AM, 1989, PHYS REV LETT, V63, P1195, DOI 10.1103/PhysRevLett.63.1195; Fersht A., 1998, ENZYME STRUCTURE MEC; Frauenfelder H, 1998, P NATL ACAD SCI USA, V95, P4795, DOI 10.1073/pnas.95.9.4795; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; LI AJ, 1994, P NATL ACAD SCI USA, V91, P10430, DOI 10.1073/pnas.91.22.10430; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; Schlunegger F, 1997, BASIN RES, V9, P1, DOI 10.1046/j.1365-2117.1997.00029.x; Socci ND, 1998, PROTEINS, V32, P136, DOI 10.1002/(SICI)1097-0134(19980801)32:2<136::AID-PROT2>3.3.CO;2-5; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; Zhou YQ, 1999, J MOL BIOL, V285, P1371, DOI 10.1006/jmbi.1998.2374; Zhou YQ, 1997, P NATL ACAD SCI USA, V94, P14429, DOI 10.1073/pnas.94.26.14429; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	30	244	246	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					400	403		10.1038/43940	http://dx.doi.org/10.1038/43940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517642	Bronze			2022-12-28	WOS:000082822600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Net tip - Lab search engine	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1869						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-28	WOS:000082638300037
J	Bodenheimer, T				Bodenheimer, T			Long-term care for frail elderly people - The On Lok model	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROGRAM											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; Binstock RH, 1997, HEALTH SERV RES, V32, P715; CHATTERJI P, 1998, IMPACT PACE PARTICIP; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Eng C., 1996, CURR CONCEPTS GERIAT, V2, P4; Fisher Ian, 1998, N Y Times Web, P30; GRUENBERG L, 1993, ANAL EXPECTED MED CO; HARRINGTON C, 1991, JAMA-J AM MED ASSOC, V266, P3023, DOI 10.1001/jama.266.21.3023; IRVIN CV, 1999, NEW ENGL J MED, V340, P1283; Kassirer JP, 1998, NEW ENGL J MED, V339, P1925, DOI 10.1056/NEJM199812243392609; KUNZ E, 1996, AM J MANAGE CARE, V2, P301; Levit KR, 1998, HEALTH AFFAIR, V17, P35, DOI 10.1377/hlthaff.17.1.35; MCLEOD D, 1998, AARP B           APR; NEWCOMER R, 1996, ANNU REV GERONTOL, V16, P1; RIMER S, 1998, NY TIMES        0315, P1; Vladeck B.C., 1980, UNLOVING CARE NURSIN; White A.J., 1998, EFFECT PACE COSTS ME; [No title captured]; [No title captured]	19	78	82	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1324	1328		10.1056/NEJM199910213411722	http://dx.doi.org/10.1056/NEJM199910213411722			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247NF	10528046				2022-12-28	WOS:000083226300034
J	Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA				Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA			The epidemiology of chronic pain in the community	LANCET			English	Article							GENERAL-POPULATION; PERSISTENT PAIN; PREVALENCE; HEALTH; CARE	Background Chronic pain is recognised as an important problem in the community but our understanding of the epidemiology of chronic pain remains limited. We undertook a study designed to quantify and describe the prevalence and distribution of chronic pain in the community. Methods A random sample of 5036 patients, aged 25 and over, was drawn from 29 general practices in the Grampian region of the UK and surveyed by a postal self-completion questionnaire. The questionnaire included case-screening questions, a question on the cause of the pain, the chronic pain grade questionnaire, the level of expressed needs questionnaire, and sociodemographic questions. Findings 3605 questionnaires were returned completed. 1817 (50.4%) of patients self reported chronic pain, equivalent to 46.5% of the general population. 576 reported back pain and 570 reported arthritis; these were the most common complaints and accounted for a third of all complaints. Backward stepwise logistic-regression modelling identified age, sex, housing tenure, and employment status as significant predictors of the presence of chronic pain in the community. 703 (48.7%) individuals with chronic pain had the least severe grade of pain, and 228 (15.8%) the most severe grade. Of those who reported chronic pain, 312 (17.2%) reported no expressed need, and 509 (28.0%) reported the highest expressed need. Interpretation Chronic pain is a major problem in the community and certain groups within the population are more likely to have chronic pain. A detailed understanding of the epidemiology of chronic pain is essential for efficient management of chronic pain in primary care.	Univ Aberdeen, Sch Med, Dept Gen Practice, Aberdeen AB9 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB9 2ZD, Scotland; Aberdeen Royal Infirm, Dept Anaesthet, Aberdeen, Scotland; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh, Midlothian, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Edinburgh	Elliott, AM (corresponding author), Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland.		Smith, Blair H/G-2834-2012; G, G/A-3459-2012	Smith, Blair H/0000-0002-5362-9430; 				Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Blaxter M., 1990, HLTH LIFESTYLES; BOWSHER D, 1991, Pain Clinic, V4, P223; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; CROFT P, 1993, J RHEUMATOL, V20, P710; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; Crombie IK, 1998, PAIN, V74, P1; CROOK J, 1989, PAIN, V36, P49, DOI 10.1016/0304-3959(89)90111-5; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Davies Huw T. O., 1992, Pain Clinic, V5, P129; DIAMOND A, 1991, ANAESTHESIA, V46, P83, DOI 10.1111/j.1365-2044.1991.tb09343.x; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; International Association for the Study of Pain: Subcommittee on Taxonomy, 1986, PAIN S, V3, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Latham J, 1994, Disabil Rehabil, V16, P39; Locker David, 1983, DISABILITY DISADVANT; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; Purves AM, 1998, PAIN CLINIC, V10, P139; Rothman K., 1998, MODERN EPIDEMIOLOGY; Smith BH, 1997, PAIN, V71, P141, DOI 10.1016/S0304-3959(97)03347-2; Smith BH, 1996, J ROY SOC MED, V89, P181, DOI 10.1177/014107689608900402; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; Von Korff M, 1990, PAIN, V279, P91, DOI DOI 10.1016/0304-3959(90)91125-3; VONKORFF M, 1991, PSYCHOSOM MED, V53, P61, DOI 10.1097/00006842-199101000-00006; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4	25	813	851	0	49	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1248	1252		10.1016/S0140-6736(99)03057-3	http://dx.doi.org/10.1016/S0140-6736(99)03057-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520633				2022-12-28	WOS:000083010400010
J	Wise, J				Wise, J			CSM takes small step towards openness	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					939	939		10.1136/bmj.319.7215.939	http://dx.doi.org/10.1136/bmj.319.7215.939			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514147	Green Published			2022-12-28	WOS:000083111700011
J	Henney, JE				Henney, JE			New drug for sleeplessness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-28	WOS:000082901100007
J	Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF				Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF			A chain initiation factor common to both modular and aromatic polyketide synthases	NATURE			English	Article							ACYL CARRIER PROTEINS; ENGINEERED BIOSYNTHESIS; IN-VITRO; STREPTOMYCES-GLAUCESCENS; RATIONAL DESIGN; PURIFICATION; SPECIFICITY; EXPRESSION; RECONSTITUTION; COMPONENTS	Antibiotic-producing polyketide synthases (PKSs) are enzymes responsible for the biosynthesis in Streptomyces and related filamentous bacteria of a remarkably broad range of bioactive metabolites, including antitumour aromatic compounds such as mithramycin(1) and macrolide antibiotics such as erythromycin(2). The molecular basis for the selection of the starter unit on aromatic PKSs is unknown(3). Here we show that a component of aromatic PKS, previously named 'chain-length factor'(4), is a factor required for polyketide chain initiation and that this factor has decarboxylase activity towards malonyl-ACP (acyl carrier protein). We have re-examined the mechanism of initiation on modular PKSs and have identified as a specific initiation factor a domain of previously unknown function named KSQ, which operates like chain-length factor. Both KSQ and chain-length factor are similar to the ketosynthase domains that catalyse polyketide chain extension in modular multifunctional PKSs and in aromatic PKSs, respectively, except that the ketosynthase domain active-site cysteine residue is replaced by a highly conserved glutamine in KSQ and in chain-length factor. The glutamine residue is important both for decarboxylase activity and for polyketide synthesis.	Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England	University of Cambridge	Leadlay, PF (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Cox, Russell John/F-9190-2015; Simpson, Thomas J/P-5058-2015	Cox, Russell John/0000-0002-1844-0157; Leadlay, Peter/0000-0002-3247-509X; Cortes, Jesus/0000-0002-2475-6983				Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KIM ES, 1995, J BACTERIOL, V177, P1202, DOI 10.1128/jb.177.5.1202-1207.1995; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; KRESZE GB, 1977, EUR J BIOCHEM, V79, P191, DOI 10.1111/j.1432-1033.1977.tb11797.x; Lombo F, 1997, J BACTERIOL, V179, P3354, DOI 10.1128/jb.179.10.3354-3357.1997; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Matharu AL, 1998, CHEM BIOL, V5, P699, DOI 10.1016/S1074-5521(98)90663-9; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MEURER G, 1995, J BACTERIOL, V177, P477, DOI 10.1128/jb.177.2.477-481.1995; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; Rowe CJ, 1998, GENE, V216, P215, DOI 10.1016/S0378-1119(98)00327-8; SHEN B, 1995, J AM CHEM SOC, V117, P6811, DOI 10.1021/ja00131a002; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; Staunton J, 1998, TOP CURR CHEM, V195, P49; Weissman KJ, 1998, BIOCHEMISTRY-US, V37, P11012, DOI 10.1021/bi9806246; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	27	225	264	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					502	505		10.1038/46829	http://dx.doi.org/10.1038/46829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519556				2022-12-28	WOS:000082981200062
J	Barr, MM; Sternberg, PW				Barr, MM; Sternberg, PW			A polycystic kidney-disease gene homologue required for male mating behaviour in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN; INSIGHTS; NEURON; PKD1	The stereotyped mating behaviour of the Caenorhabditis elegans male is made up of several substeps: response, backing, turning, vulva location, spicule insertion and sperm transfer. The complexity of this behaviour is reflected in the sexually dimorphic anatomy and nervous system(1). Behavioural functions have been assigned to most of the male-specific sensory neurons by means of cell ablations; for example, the hook sensory neurons HOA and HOB are specifically required for vulva location(2). We have investigated how sensory perception of the hermaphrodite by the C. elegans male controls mating behaviours. Here we identify a gene, lov-1 (for location of vulva), that is required for two male sensory behaviours: response and vulva location. lov-1 encodes a putative membrane protein with a mucin-like, serine-threonine-rich amino terminus' followed by two blocks of homology to human polycystins, products of the autosomal dominant polycystic kidney-disease loci PKD1 and PKD2 (ref 4). LOV-1 is the closest C. elegans homologue of PKD1. lov-1 is expressed in adult males in sensory neurons of the rays, hook and head, which mediate response, vulva location, and potentially chemotaxis to hermaphrodites, respectively(2,5). PKD-2, the C. elegans homologue of PKD2, is localized to the same neurons as LOV-1, suggesting that they function in the same pathway.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.			Sternberg, Paul/0000-0002-7699-0173				Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BRENNER S, 1974, GENETICS, V77, P71; CARRAWAY KL, 1995, TRENDS GLYCOSCI GLYC, V7, P31, DOI 10.4052/tigg.7.31; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Collet J, 1998, GENETICS, V148, P187; DRISCOLL M, 1997, NEMATODE C ELEGANS, V2, P645; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; SANFORD R, 1997, HUM MOL GENET, V9, P1483; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618	30	387	435	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					386	389		10.1038/43916	http://dx.doi.org/10.1038/43916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517638				2022-12-28	WOS:000082822600054
J	Altschuler, EL				Altschuler, EL			Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning	LANCET			English	Editorial Material							SYNOVIAL MEMBRANES; PERSISTENCE; ARTHROPATHY; DNA		Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Brain & Percept Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Altschuler, EL (corresponding author), Univ Calif San Diego, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.							ANDERSON S, 1995, VIROLOGY, V206, P626, DOI 10.1016/S0042-6822(95)80079-4; BANSAL GP, 1993, J INFECT DIS, V167, P1034, DOI 10.1093/infdis/167.5.1034; Brown KE, 1997, ANNU REV MED, V48, P59; CHOBRA T, 1989, CLIN DERMATOL, V7, P65; delaMare WK, 1997, NATURE, V389, P57, DOI 10.1038/37956; KERR JR, 1995, BRIT J RHEUMATOL, V34, P809; Kingsley G, 1997, LANCET, V349, P1038, DOI 10.1016/S0140-6736(97)22015-5; REID DM, 1985, LANCET, V1, P422; ROTHSCHILD BM, 1988, SCIENCE, V241, P1498, DOI 10.1126/science.3047874; ROTHSCHILD BM, 1992, SEMIN ARTHRITIS RHEU, V22, P181, DOI 10.1016/0049-0172(92)90018-9; SAAL JG, 1992, RHEUMATOL INT, V12, P147, DOI 10.1007/BF00274934; SHORT CL, 1974, ARTHRITIS RHEUM, V17, P193, DOI 10.1002/art.1780170302; Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6; Takahashi Y, 1998, P NATL ACAD SCI USA, V95, P8227, DOI 10.1073/pnas.95.14.8227; WHITE DG, 1985, LANCET, V1, P419; WILLAN R, 1801, REPORTS DIS LONDON P	16	24	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					1026	1027		10.1016/S0140-6736(98)12312-7	http://dx.doi.org/10.1016/S0140-6736(98)12312-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501383				2022-12-28	WOS:000082596000044
J	van der Werf, TS; van der Graaf, WTA; Tappero, JW; Asiedu, K				van der Werf, TS; van der Graaf, WTA; Tappero, JW; Asiedu, K			Mycobacterium ulcerans infection	LANCET			English	Article							DISEASE; EPIDEMIOLOGY; REGION; TOXIN	After tuberculosis and leprosy, Buruli-ulcer disease (caused by infection with Mycobacterium ulcerans) is the third most common mycobacterial disease in immunocompetent people. Countries in which the disease is endemic have been identified, predominantly in areas of tropical rain forest; the emergence of Buruli-ulcer disease in West African countries over the past decade has been dramatic. Current evidence suggests that the infection is transmitted through abraded skin or mild traumatic injuries after contact with contaminated water, soil, or vegetation; there is one unconfirmed preliminary report on possible transmission by insects. The clinical picture ranges from a painless nodule to large, undermined ulcerative lesions that heal spontaneously but slowly. Most patients are children. The disease is accompanied by remarkably few systemic symptoms, but occasionally secondary infections resulting in sepsis or tetanus cause severe systemic disease and death. Extensive scarring can lead to contractures of the limbs, blindness, and other adverse sequelae, which impose a substantial health and economic burden. Treatment is still primarily surgical, and includes excision, skin grafting, or both. Although BCG has a mild but significant protective effect, new vaccine developments directed at the toxins produced by M ulcerans are warranted. In West Africa, affected populations are underprivileged, and the economic burden imposed by Buruli-ulcer disease is daunting. Combined efforts to improve treatment, prevention, control, and research strategies (overseen by the WHO and funded by international relief agencies) are urgently needed.	Univ Groningen Hosp, Dept Internal Med, Intens & Resp Care Unit, NL-9700 RB Groningen, Netherlands; Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Publ Hlth Serv, US Dept HHS, Atlanta, GA USA; WHO, Global buruli Ulcer Initiat, CH-1211 Geneva, Switzerland	University of Groningen; Centers for Disease Control & Prevention - USA; United States Public Health Service; World Health Organization	van der Werf, TS (corresponding author), Univ Groningen Hosp, Dept Internal Med, Intens & Resp Care Unit, POB 30 001, NL-9700 RB Groningen, Netherlands.	t.s.van.der.werf@int.azg.nl	van der Graaf, Winette T/A-5006-2014	van der Graaf, Winette T/0000-0001-7549-3338; van der Werf, Tjip/0000-0002-4824-1642				Aguiar J, 1997, Med Trop (Mars), V57, P83; [Anonymous], 1969, LANCET, V1, P111; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; Bradley DJ, 1971, T R SOC TROP MED HYG, V65, P763; CLANCEY JK, 1961, LANCET, V2, P951; Corlan E, 1997, RESP MED, V91, P21, DOI 10.1016/S0954-6111(97)90133-5; *DURB IMM TRIAL GR, 1999, LANCET, V359, P116; EXNER K, 1987, Handchirurgie Mikrochirurgie Plastische Chirurgie, V19, P230; George KM, 1998, INFECT IMMUN, V66, P587, DOI 10.1128/IAI.66.2.587-593.1998; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; HAYMAN J, 1991, INT J EPIDEMIOL, V20, P1093, DOI 10.1093/ije/20.4.1093; HAYMAN J, 1984, LANCET, V2, P1015; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; KRIEG RE, 1975, AVIAT SPACE ENVIR MD, V46, P1241; LUNN H F, 1965, East Afr Med J, V42, P275; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219, DOI 10.4269/ajtmh.1995.52.219; MEYERS WM, 1974, AM J TROP MED HYG, V23, P924, DOI 10.4269/ajtmh.1974.23.924; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919, DOI 10.4269/ajtmh.1974.23.919; MITCHELL PJ, 1987, J WILDLIFE DIS, V23, P386, DOI 10.7589/0090-3558-23.3.386; Palomino JC, 1998, J CLIN MICROBIOL, V36, P402, DOI 10.1128/JCM.36.2.402-408.1998; PIMSLER M, 1988, J INFECT DIS, V157, P577, DOI 10.1093/infdis/157.3.577; Portaels F, 1999, LANCET, V353, P986, DOI 10.1016/S0140-6736(98)05177-0; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097, DOI 10.1128/JCM.35.5.1097-1100.1997; Portaels F, 1998, ANTIMICROB AGENTS CH, V42, P2070, DOI 10.1128/AAC.42.8.2070; REVILL WDL, 1973, LANCET, V2, P873; Ross BC, 1997, APPL ENVIRON MICROB, V63, P4135, DOI 10.1128/AEM.63.10.4135-4138.1997; SMITH PG, 1976, T ROY SOC TROP MED H, V70, P449, DOI 10.1016/0035-9203(76)90128-0; van OYE E, 1950, Ann Soc Belg Med Trop (1920), V30, P619; VANDERWERF TS, 1989, T ROY SOC TROP MED H, V83, P410, DOI 10.1016/0035-9203(89)90521-X; 1970, BMJ, V2, P378	31	194	200	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					1013	1018		10.1016/S0140-6736(99)01156-3	http://dx.doi.org/10.1016/S0140-6736(99)01156-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501380				2022-12-28	WOS:000082596000041
J	Krieger, J; Breer, H				Krieger, J; Breer, H			Olfactory reception in invertebrates	SCIENCE			English	Review							ODORANT-BINDING-PROTEIN; NUCLEOTIDE-GATED CHANNEL; CYCLIC NUCLEOTIDE; INSECT ANTENNAE; PHEROMONE-BINDING; C-ELEGANS; DROSOPHILA-MELANOGASTER; CHEMOSENSORY RECEPTORS; PHOSPHOLIPASE-C; SENSORY NEURONS	Recent progress in understanding the principles and mechanisms in olfaction is the result of multidisciplinary research efforts that explored chemosensation by using a variety of model organisms. Studies on invertebrates, notably nematodes, insects, and crustaceans, to which diverse experimental approaches can be applied, have greatly helped elucidate various aspects of olfactory Signaling. From the converging results of genetic, molecular, and physiological studies, a common set of chemosensory mechanisms emerges. Recognition and discrimination of odorants as well as chemo-electrical transduction and processing of olfactory signals appear to be mediated by fundamentally similar mechanisms in phylogenetically diverse animals. The common challenge of organisms to decipher the world of odors was apparently met: by a phylogenetically conserved strategy. Thus, comparative studies should continue to provide important contributions toward an understanding of the sense of smell.	Univ Stuttgart Hohenheim, Inst Physiol, D-70599 Stuttgart, Germany	University Hohenheim	Breer, H (corresponding author), Univ Stuttgart Hohenheim, Inst Physiol, Garbenstr 30, D-70599 Stuttgart, Germany.	breer@uni-hohenheim.de	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				Ache Barry W., 1994, Seminars in Cell Biology, V5, P55, DOI 10.1006/scel.1994.1008; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BIGNETTI E, 1985, EUR J BIOCHEM, V149, P227, DOI 10.1111/j.1432-1033.1985.tb08916.x; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; BOEKHOFF I, 1990, CELL SIGNAL, V2, P49, DOI 10.1016/0898-6568(90)90032-6; BOEKHOFF I, 1990, J COMP PHYSIOL B, V160, P99, DOI 10.1007/BF00258768; BOEKHOFF I, 1993, INSECT BIOCHEM MOLEC, V23, P757, DOI 10.1016/0965-1748(93)90063-X; BREER H, 1994, BBA-MOL CELL RES, V1224, P277, DOI 10.1016/0167-4889(94)90201-1; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BREER H, 1991, SENSORY TRANSDUCTION, P94; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Clyne PJ, 1999, NEURON, V22, P339, DOI 10.1016/S0896-6273(00)81094-6; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Coburn CM, 1998, DEVELOPMENT, V125, P249; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, J NEUROSCI, V17, P8259; DU GH, 1995, BIOCHEMISTRY-US, V34, P8726, DOI 10.1021/bi00027a023; Dubin AE, 1998, J NEUROSCI, V18, P5603; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; Freitag J, 1995, NEURON, V15, P1383, DOI 10.1016/0896-6273(95)90016-0; HANSSON BS, 1995, EXPERIENTIA, V51, P1003, DOI 10.1007/BF01946910; HATT H, 1994, P NATL ACAD SCI USA, V91, P6264, DOI 10.1073/pnas.91.14.6264; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Kaissling K.-E., 1987, RH WRIGHT LECT INSEC, P1; Kim MS, 1998, GENETICS, V150, P711; Krieger J, 1999, INSECT BIOCHEM MOLEC, V29, P255, DOI 10.1016/S0965-1748(98)00134-9; Laue M, 1997, CELL TISSUE RES, V288, P149, DOI 10.1007/s004410050802; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MICHEL WC, 1992, J NEUROSCI, V12, P3979; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; Pilpel Y, 1999, NATURE, V398, P285, DOI 10.1038/18552; Prasad BC, 1999, TRENDS GENET, V15, P150, DOI 10.1016/S0168-9525(99)01695-9; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RIESGOESCOVAR J, 1995, P NATL ACAD SCI USA, V92, P2864, DOI 10.1073/pnas.92.7.2864; SCHNEIDER D, 1992, NATURWISSENSCHAFTEN, V79, P241, DOI 10.1007/BF01175388; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STEINBRECHT RA, 1995, CELL TISSUE RES, V282, P203, DOI 10.1007/BF00319112; Steinbrecht RA, 1998, ANN NY ACAD SCI, V855, P323, DOI 10.1111/j.1749-6632.1998.tb10591.x; STENGL M, 1993, J EXP BIOL, V178, P125; STENGL M, 1994, J COMP PHYSIOL A, V174, P187; TALLURI S, 1995, P NATL ACAD SCI USA, V92, P11475, DOI 10.1073/pnas.92.25.11475; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; VOGT RG, 1990, NATO ASI SERIES H, V39, P33; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wegener JW, 1997, J INSECT PHYSIOL, V43, P595, DOI 10.1016/S0022-1910(97)00008-5; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	55	213	260	2	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					720	723		10.1126/science.286.5440.720	http://dx.doi.org/10.1126/science.286.5440.720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531050				2022-12-28	WOS:000083303200042
J	Mombaerts, P				Mombaerts, P			Seven-transmembrane proteins as odorant and chemosensory receptors	SCIENCE			English	Review							PUTATIVE PHEROMONE RECEPTORS; SENSITIVE ADENYLATE-CYCLASE; C-ELEGANS; OLFACTORY EPITHELIUM; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; SENSORY NEURONS; FUNCTIONAL EXPRESSION; MULTIGENE FAMILY; GENE-EXPRESSION	The olfactory systems of various species solve the challenging problem of general molecular recognition in widely differing ways. Despite this variety, the molecular receptors are invariably G protein-coupled seven-transmembrane proteins, and are encoded by the Largest gene families known to exist in a given animal genome. Receptor gene families have been identified in vertebrates and two invertebrate species, the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster. The complexity of the odorant receptor repertoire is estimated in mouse and rat at 1000 genes, or 1 percent of the genome, surpassing that of the immunoglobulin and T cell receptor genes combined. Two distinct seven-transmembrane gene families may encode in rodents the chemosensory receptors of the vomeronasal organ, which is specialized in the detection of pheromones. Remarkably, these five receptor families have practically no sequence homology among them. Genetic manipulation experiments in mice imply that vertebrate odorant receptors may fulfill a dual role, also serving as address molecules that guide axons of olfactory sensory neurons to their precise target in the brain.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	pm@rockvax.rockefeller.edu	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Barth AL, 1996, NEURON, V16, P23, DOI 10.1016/S0896-6273(00)80020-3; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Berghard A, 1998, J NEUROBIOL, V37, P383, DOI 10.1002/(SICI)1097-4695(19981115)37:3<383::AID-NEU4>3.0.CO;2-D; BOZZA T, UNPUB; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Cao YX, 1998, P NATL ACAD SCI USA, V95, P11987, DOI 10.1073/pnas.95.20.11987; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; Colbert HA, 1997, J NEUROSCI, V17, P8259; Doty R.L, 2015, HDB OLFACTION GUSTAT; Dreyer WJ, 1998, P NATL ACAD SCI USA, V95, P9072, DOI 10.1073/pnas.95.16.9072; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FARBMAN AI, 1992, CELL BIOL OLFACTION; Freitag J, 1999, GENE, V226, P165, DOI 10.1016/S0378-1119(98)00575-7; Freitag J, 1998, J COMP PHYSIOL A, V183, P635, DOI 10.1007/s003590050287; Freitag J, 1995, NEURON, V15, P1383, DOI 10.1016/0896-6273(95)90016-0; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; Gao Q, 1999, GENOMICS, V60, P31, DOI 10.1006/geno.1999.5894; Gierer A, 1998, EUR J NEUROSCI, V10, P388, DOI 10.1046/j.1460-9568.1998.00017.x; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Hatt H, 1999, CELL MOL BIOL, V45, P285; Healy MD, 1997, CHEM SENSES, V22, P321, DOI 10.1093/chemse/22.3.321; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; IsselTarver L, 1996, P NATL ACAD SCI USA, V93, P10897, DOI 10.1073/pnas.93.20.10897; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kubick S, 1997, J NEUROCHEM, V69, P465; Laissue PP, 1999, J COMP NEUROL, V405, P543; LANCET D, 1994, NATURE, V372, P321, DOI 10.1038/372321a0; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; Leibovici M, 1996, DEV BIOL, V175, P118, DOI 10.1006/dbio.1996.0100; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matarazzo V, 1998, NEUROSCI LETT, V249, P87, DOI 10.1016/S0304-3940(98)00375-9; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; Nef S, 1996, MECH DEVELOP, V55, P65, DOI 10.1016/0925-4773(95)00491-2; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Pilpel Y, 1999, PROTEIN SCI, V8, P969, DOI 10.1110/ps.8.5.969; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Qasba P, 1998, J NEUROSCI, V18, P227; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Rouquier S, 1998, NAT GENET, V18, P243, DOI 10.1038/ng0398-243; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; Skoufos E, 1999, NUCLEIC ACIDS RES, V27, P343, DOI 10.1093/nar/27.1.343; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1995, J COMP PHYSIOL A, V177, P659; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STROTMANN J, 1994, CELL TISSUE RES, V276, P429; Strotmann J, 1999, GENE, V236, P281, DOI 10.1016/S0378-1119(99)00275-9; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Trask BJ, 1998, HUM MOL GENET, V7, P2007, DOI 10.1093/hmg/7.13.2007; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Velten F, 1998, TISSUE ANTIGENS, V51, P183, DOI 10.1111/j.1399-0039.1998.tb02963.x; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WAKAYAMA T, IN PRESS P NATL ACAD; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Weth F, 1996, P NATL ACAD SCI USA, V93, P13321, DOI 10.1073/pnas.93.23.13321; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Zhou Q, 1997, BIOL BULL, V193, P248, DOI 10.1086/BBLv193n2p248	101	328	358	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					707	711		10.1126/science.286.5440.707	http://dx.doi.org/10.1126/science.286.5440.707			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531047				2022-12-28	WOS:000083303200039
J	Sakane, T; Takeno, M; Suzuki, N; Inaba, G				Sakane, T; Takeno, M; Suzuki, N; Inaba, G			Current concepts - Behcet's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHOCK PROTEIN-PEPTIDES; INTERFERON-ALPHA; CELL-LINES; T-CELLS; COLCHICINE; MANIFESTATIONS; UVEITIS; EPITOPE; TRIAL; HSP		St Marianna Univ, Sch Med, Dept Immunol, Miyamae Ku, Kanagawa 2168511, Japan; St Marianna Univ, Sch Med, Dept Med, Miyamae Ku, Kanagawa 2168511, Japan; Tokyo Womens Med Coll, Dept Ophthalmol, Uveitis Clin, Tokyo 162, Japan; Daini Hosp, Tokyo, Japan	Saint Marianna University; Saint Marianna University; Tokyo Women's Medical University	Sakane, T (corresponding author), St Marianna Univ, Sch Med, Dept Immunol, Miyamae Ku, 2-16-1 Sugao, Kanagawa 2168511, Japan.	t2sakane@marianna-u.ac.jp						AkmanDemir G, 1996, ARCH NEUROL-CHICAGO, V53, P691, DOI 10.1001/archneur.1996.00550070133022; Bang Dongsik, 1995, Journal of Dermatology (Tokyo), V22, P926; Benamour S, 1998, REV RHUM, V65, P299; DILSEN N, 1993, INT CONGR SER, V1037, P165; Direskeneli H, 1996, SCAND J IMMUNOL, V43, P464, DOI 10.1046/j.1365-3083.1996.d01-53.x; Ehrlich G E, 1997, Int Rev Immunol, V14, P81, DOI 10.3109/08830189709116846; Gul A, 1997, BRIT J RHEUMATOL, V36, P922; HAMURYUDAN V, 1991, ARTHRITIS RHEUM, V34, P1071, DOI 10.1002/art.1780340823; Hamuryudan V, 1997, ARTHRITIS RHEUM, V40, P769, DOI 10.1002/art.1780400425; Hamuryudan V, 1998, ANN INTERN MED, V128, P443, DOI 10.7326/0003-4819-128-6-199803150-00004; HAMURYUDAN V, 1994, BRIT J RHEUMATOL, V33, P48; Hu W, 1998, EUR J IMMUNOL, V28, P2444, DOI 10.1002/(SICI)1521-4141(199808)28:08<2444::AID-IMMU2444>3.0.CO;2-N; Inaba G., 1986, RECENT ADV BEHCETS D, P235; Kaklamani VG, 1998, SEMIN ARTHRITIS RHEU, V27, P197, DOI 10.1016/S0049-0172(98)80001-2; Kaneko S, 1997, CLIN EXP IMMUNOL, V108, P204, DOI 10.1046/j.1365-2249.1997.3611265.x; Kastner DL, 1997, ARTHRITIS ALLIED CON, P1279; KAZOKOGLU H, 1991, ANN OPHTHALMOL, V23, P148; Kotake S, 1999, OPHTHALMOLOGY, V106, P586, DOI 10.1016/S0161-6420(99)90120-3; Kotter I, 1996, GER J OPHTHALMOL, V5, P92; Lee Kyong Sik, 1997, Yonsei Medical Journal, V38, P455; Lehner T, 1997, Int Rev Immunol, V14, P21, DOI 10.3109/08830189709116842; MASUDA K, 1989, LANCET, V1, P1093; MIYACHI Y, 1981, BRIT J DERMATOL, V104, P67, DOI 10.1111/j.1365-2133.1981.tb01713.x; Mizuki N, 1997, Int Rev Immunol, V14, P33, DOI 10.3109/08830189709116843; MOCHIZUKI M, 1994, EUR J IMMUNOL, V24, P1536, DOI 10.1002/eji.1830240712; NAKAE K, 1993, INT CONGR SER, V1037, P145; Nussenblatt R B, 1997, Int Rev Immunol, V14, P67, DOI 10.3109/08830189709116845; O'Duffy JD, 1998, J RHEUMATOL, V25, P1938; ODUFFY JD, 1984, AM J MED, V76, P75, DOI 10.1016/0002-9343(84)90753-8; OHNO S, 1982, ARCH OPHTHALMOL-CHIC, V100, P1455; PERVIN K, 1993, J IMMUNOL, V151, P2273; Sakane T, 1997, Int Rev Immunol, V14, P89, DOI 10.3109/08830189709116847; SAKANE T, 1986, ARTHRITIS RHEUM, V29, P371, DOI 10.1002/art.1780290310; SAKANE T, 1982, ARTHRITIS RHEUM, V25, P1343, DOI 10.1002/art.1780251110; Serdaroglu P, 1998, J NEUROL, V245, P197, DOI 10.1007/s004150050205; SILMAN AJ, 1990, LANCET, V335, P1078; STANFORD MR, 1994, CLIN EXP IMMUNOL, V97, P226; SUZUKI N, 1986, ARTHRITIS RHEUM, V29, P212, DOI 10.1002/art.1780290209; Yamashita N, 1997, CLIN EXP IMMUNOL, V107, P241, DOI 10.1111/j.1365-2249.1997.274-ce1159.x; Yasui K, 1996, ANN INTERN MED, V124, P891, DOI 10.7326/0003-4819-124-10-199605150-00005; Zouboulis CC, 1998, ARCH DERMATOL, V134, P1010, DOI 10.1001/archderm.134.8.1010; ZOUBOULIS CC, 1993, INT CONGR SER, V1037, P175; Zouboulis Christos C., 1997, Yonsei Medical Journal, V38, P411	43	1360	1422	2	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1284	1291		10.1056/NEJM199910213411707	http://dx.doi.org/10.1056/NEJM199910213411707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528040				2022-12-28	WOS:000083226300007
J	Baird, DT; Glasier, AF				Baird, DT; Glasier, AF			Science, medicine, and the future - Contraception	BRITISH MEDICAL JOURNAL			English	Review							MIFEPRISTONE RU-486; ESTROGEN; ANDROGEN		Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland; Edinburgh Primary Care NHS Trust, Edinburgh, Midlothian, Scotland	University of Edinburgh	Baird, DT (corresponding author), Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland.	dtbaird@ed.ac.uk						ALEXANDER NJ, 1995, SCI AM, V273, P136; BAIRD D, 1965, BMJ-BRIT MED J, V2, P1141, DOI 10.1136/bmj.2.5471.1141; BAIRD DT, 1993, CLIN APPL MIFEPRISTO, P148; Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; GEMZELLDANIELSSON K, 1993, HUM REPROD, V8, P870, DOI 10.1093/oxfordjournals.humrep.a138157; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GRIFFIN D, 1990, CONRAD W S, P501; HARRISON PF, 1996, CONTRACEPTIVE RES DE, P125; HERR JC, 1996, CONTRACEPTIVE RES DE, P401; LESSEY BA, 1994, FERTIL STERIL, V61, P812; MARTIN CW, 1997, ACTA OBSTET GYNE S76, V167; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Meriggiola MC, 1997, J ANDROL, V18, P240; NIESCHLAG E, 1996, PHARM BIOL CLIN APPL, P395; NORMAN J, 1995, HUM REPROD, V10, P308; RIMMER C, 1992, HUM REPROD, V7, P608, DOI 10.1093/oxfordjournals.humrep.a137705; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUNDARAM K, 1993, ANN MED, V25, P199, DOI 10.3109/07853899309164168; Swahn ML, 1999, HUM REPROD, V14, P485, DOI 10.1093/humrep/14.2.485; *WHO, 1998, WORLD HLTH REP 1998, P120	20	24	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					969	972		10.1136/bmj.319.7215.969	http://dx.doi.org/10.1136/bmj.319.7215.969			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514161	Green Published			2022-12-28	WOS:000083111700028
J	Chua, KB; Goh, KJ; Wong, KT; Kamarulzaman, A; Tan, PSK; Ksiazek, TG; Zaki, SR; Paul, G; Lam, SK; Tan, CT				Chua, KB; Goh, KJ; Wong, KT; Kamarulzaman, A; Tan, PSK; Ksiazek, TG; Zaki, SR; Paul, G; Lam, SK; Tan, CT			Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia	LANCET			English	Article							MORBILLIVIRUS; HORSES; INFECTION; HUMANS	Background Between February and April, 1999, an outbreak of viral encephalitis occurred among pig-farmers in Malaysia. We report findings for the first three patients who died. Methods Samples of tissue were taken at necropsy. Blood and cerebrospinal-fluid (CSF) samples taken before death were cultured for viruses, and tested for antibodies to viruses. Findings The three pig-farmers presented with fever, headache, and altered level of consciousness. Myoclonus was present in two patients. There were signs of brainstem dysfunction with hypertension and tachycardia. Rapid deterioration led to irreversible hypotension and death. A virus causing syncytial formation of vero cells was cultured from the CSF of two patients after 5 days; the virus stained positively with antibodies against Hendra virus by indirect immunofluorescence, IgM capture ELISA showed that all three patients had IgM antibodies in CSF against Hendra viral antigens. Necropsy showed widespread microinfarction in the central nervous system and other organs resulting from vasculitis-induced thrombosis. There was no clinical evidence of pulmonary involvement. Inclusion bodies likely to be of viral origin were noted in neurons near vasculitic blood vessels. Interpretation The causative agent was a previously undescribed paramyxovirus related to the Hendra virus. Close contact with infected pigs may be the source of the viral transmission. Clinically and epidemiologically the infection is distinct from infection by the Hendra virus. We propose that this Hendra-like virus was the cause of the outbreak of encephalitis in Malaysia.	Univ Malaya, Dept Med, Kuala Lumpur 50603, Malaysia; Univ Malaya, Dept Med Microbiol, Kuala Lumpur 50603, Malaysia; Univ Malaya, Dept Pathol, Kuala Lumpur 50603, Malaysia; Univ Malaya, Dept Anesthesiol & Intens Care, Kuala Lumpur 50603, Malaysia; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA USA	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Centers for Disease Control & Prevention - USA	Goh, KJ (corresponding author), Univ Malaya, Dept Med, Kuala Lumpur 50603, Malaysia.		KAMARULZAMAN, ADEEBA/B-5216-2010; Wong, Kum Thong/B-2788-2010; LAM, SAI KIT/B-5231-2010; Goh, Khean Jin/D-1990-2010	Goh, Khean Jin/0000-0001-5416-9627				MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Rogers RJ, 1996, AUST VET J, V74, P243, DOI 10.1111/j.1751-0813.1996.tb15413.x; SELVEY LA, 1995, MED J AUSTRALIA, V162, P642, DOI 10.5694/j.1326-5377.1995.tb126050.x; THONGCHAROEN P, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P559; 1999, MOR MORTAL WKLY REP, V48, P265	6	483	525	1	50	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1257	1259		10.1016/S0140-6736(99)04299-3	http://dx.doi.org/10.1016/S0140-6736(99)04299-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520635				2022-12-28	WOS:000083010400012
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1975: Renato Dulbecco (b 1914), David Baltimore (b 1938), and Howard Martin Temin (1934-94)	LANCET			English	Article									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Raju, TNK (corresponding author), Univ Chicago, Chicago, IL 60637 USA.								0	3	3	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1308	1308		10.1016/S0140-6736(05)76086-4	http://dx.doi.org/10.1016/S0140-6736(05)76086-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520671				2022-12-28	WOS:000083010400072
J	Raleigh, VS				Raleigh, VS			World population and health in transition	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Ctr Publ Hlth Monitoring, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Raleigh, VS (corresponding author), Univ London London Sch Hyg & Trop Med, Ctr Publ Hlth Monitoring, Keppel St, London WC1E 7HT, England.	v.raleigh@lshtm.ac.uk						ADLER M, 1999, TIMES           0730; [Anonymous], 1992, CONCISE HIST WORLD P; BOSELEY S, 1999, GUARDIAN       0630; Cleland J, 1996, TROP MED INT HEALTH, V1, P15, DOI 10.1046/j.1365-3156.1996.d01-8.x; CLELAND J, 1997, FORUM APPL RES PUBLI, V12, P46; Crook N., 1997, PRINCIPLES POPULATIO; *DEP INT DEV, 1999, INT HLTH MATT REPR S; FREJKA T, 1993, INT POP C MONTR 1993, V1; Lee J, 1999, POPUL DEV REV, V25, P33, DOI 10.1111/j.1728-4457.1999.00033.x; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Lutz W., 1994, FUTURE POPULATION WO; MALTHUS TR, 1965, 1 ESSAY POPULATION; Timaeus IM, 1998, AIDS, V12, pS15; *UN, 1999, REP AD HOC COMM WHOL; *UN, 1998, WORLD POP PROSP 1996; *UNAIDS, 1998, REP GLOB HIV AIDS EP; VANDEWALLE E, 1995, POPUL DEV REV, V21, P261, DOI 10.2307/2137494; *WHO, 1998, WORLD REP 1998 LIFE; *WHO, 1999, WORLD HLTH REP 1998; *WORLD BANK GROUP, 1997, HLTH NUTR POP SECT S	20	22	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1999	319	7215					981	984		10.1136/bmj.319.7215.981	http://dx.doi.org/10.1136/bmj.319.7215.981			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514166	Green Published			2022-12-28	WOS:000083111700033
J	Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B				Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B			14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage	NATURE			English	Article							NUCLEAR EXPORT; G(2) CHECKPOINT; CYCLIN B1; ARREST; P21; LOCALIZATION; KINASE; PHASE; CELLS; CRM1	14-3-3 sigma is a member of a family of proteins that regulate cellular activity by binding and sequestering phosphorylated proteins. It has been suggested that 14-3-3 sigma promotes pre-mitotic cell-cycle arrest following DNA damage, and that its expression can be controlled by the p53 tumour suppressor gene(1). Here we describe an improved approach to the generation of human somatic-cell knockouts, which we have used to generate human colorectal cancer cells in which both 14-3-3 sigma alleles are inactivated. After DNA damage, these cells initially arrested in the G2 phase of the cell cycle, but, unlike Cells containing 14-3-3 sigma, the 14-3-3 sigma(-/-) cells were unable to maintain cell-cycle arrest. The 14-3-3 sigma(-/-) cells died ('mitotic catastrophe') as they entered mitosis. This process was associated with a failure of the 14-3-3 sigma-deficient cells to sequester the proteins (cyclin B1 and cdc2) that initiate mitosis and prevent them from entering the nucleus. These results may indicate a mechanism for maintaining the G2 checkpoint and preventing mitotic death.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.		Chan, Timothy A/ABD-5850-2021					Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busler DE, 1996, BIOTECHNIQUES, V21, P1002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	20	781	814	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					616	620		10.1038/44188	http://dx.doi.org/10.1038/44188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524633				2022-12-28	WOS:000083054900058
J	Schneider, RK; Levenson, JL				Schneider, RK; Levenson, JL			Update in psychiatry	ANNALS OF INTERNAL MEDICINE			English	Article									Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Div Consultat Liaison Psychiat, Richmond, VA 23298 USA	Virginia Commonwealth University	Schneider, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Div Consultat Liaison Psychiat, POB 980268, Richmond, VA 23298 USA.	rkschnei@hsc.vcu.edu						ANDERSEN G, 1994, STROKE, V25, P1099, DOI 10.1161/01.STR.25.6.1099; LIPSEY JR, 1984, LANCET, V1, P297; Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490; PARIKH RM, 1988, INT J PSYCHIAT MED, V18, P45; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685	5	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					514	521		10.7326/0003-4819-131-7-199910050-00007	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243VU	10507961				2022-12-28	WOS:000083018800006
J	Cortes, D; Visfeldt, J; Moller, H; Thorup, J				Cortes, D; Visfeldt, J; Moller, H; Thorup, J			Testicular neoplasia in cryptorchid boys at primary surgery: case series	BRITISH MEDICAL JOURNAL			English	Article							TESTIS; CANCER; COHORT; RISK		Rigshosp, Dept Paediat Surg, DK-2100 Copenhagen O, Denmark; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark	Rigshospitalet; Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Thorup, J (corresponding author), Rigshosp, Dept Paediat Surg, 4072, DK-2100 Copenhagen O, Denmark.			Cortes, Dina/0000-0002-6852-6530; Thorup, Jorgen/0000-0003-3550-1107; Moller, Henrik/0000-0001-8200-5929				CORTES D, 1994, J UROLOGY, V151, P722, DOI 10.1016/S0022-5347(17)35071-1; CORTES D, 1998, SCAND J UROL NE S196, V32, P54; Moller H, 1998, BMJ-BRIT MED J, V317, P729, DOI 10.1136/bmj.317.7160.729; MULLER J, 1985, J PEDIATR-US, V106, P431, DOI 10.1016/S0022-3476(85)80670-3; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507	5	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					888	889		10.1136/bmj.319.7214.888	http://dx.doi.org/10.1136/bmj.319.7214.888			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506044	Green Published, Bronze			2022-12-28	WOS:000082975600024
J	Perlmutter, SJ; Leitman, SF; Garvey, MA; Hamburger, S; Feldman, E; Leonard, HL; Swedo, SE				Perlmutter, SJ; Leitman, SF; Garvey, MA; Hamburger, S; Feldman, E; Leonard, HL; Swedo, SE			Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood	LANCET			English	Article							AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS; TOURETTE-SYNDROME; RHEUMATIC-FEVER; CHILDREN; ANTIBODIES; ADOLESCENTS; RELIABILITY; VALIDITY; CHOREA; SCALE	Background In children, exacerbations of ties and obsessive symptoms may occur after infection with group A P-haemolytic streptococci. If post-streptococcal autoimmunity is the cause of the exacerbations, then children might respond to immunomodulatory treatments such as plasma exchange or intravenous immunoglobulin (IVIG), We studied whether plasma exchange or IVIG would be better than placebo (sham IVIG) in reducing severity of neuropsychiatric symptoms. Methods Children with severe, infection-triggered exacerbations of obsessive-compulsive disorder (OCD) or tic disorders, including Tourette syndrome, were randomly assigned treatment with plasma exchange (five single-volume exchanges over 2 weeks), IVIG (1 g/kg daily on 2 consecutive days), or placebo (saline solution given in the same manner as IVIG), Symptom severity was rated at baseline, and at 1 month and 12 months after treatment by use of standard assessment scales for OCD, ties, anxiety, depression, and global function. Findings 30 children entered the study and 29 completed the trial. Ten received plasma exchange, nine IVIG, and ten placebo. At 1 month, the IVIG and plasma-exchange groups showed striking improvements in obsessive-compulsive symptoms (mean improvement on children's Yale-Brown obsessive compulsive scale score of 12 [45%] and 13 [58%], respectively), anxiety (2.1 [31%] and 3.0 [47%] improvement on National Institute of Mental Health anxiety scale), and overall functioning(2.9 [33%] and 2.8 [35%] improvement on National Institute of Mental Health global scale). Tic symptoms were also significantly improved by plasma exchange (mean change on Tourette syndrome unified rating scale of 49%). Treatment gains were maintained at 1 year, with 14 (82%) of 17 children "much' or "very much" improved over baseline (seven of eight for plasma exchange, seven of nine for IVIG), Interpretation Plasma exchange and IVIG were both effective in lessening of symptom severity for children with infection-triggered OCD and tic disorders. Further studies are needed to determine the active mechanism of these interventions, and to determine which children with OCD and tic disorders will benefit from immunomodulatory therapies.	NIMH, Pediat & Dev Neuropsychiat Branch, Bethesda, MD USA; NIMH, Child Psychiat Branch, Bethesda, MD USA; NIH, Ctr Clin, Dept Transfus Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Swedo, SE (corresponding author), 10 Ctr Dr,MSC 1255, Bethesda, MD 20892 USA.	swedos@irp.nimh.nih.gov						ALLEN AJ, 1995, J AM ACAD CHILD PSY, V34, P307, DOI 10.1097/00004583-199503000-00015; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BARRON KS, 1992, J RHEUMATOL, V19, P94; DEVEAUGHGEISS J, 1992, J AM ACAD CHILD PSY, V31, P45, DOI 10.1097/00004583-199201000-00008; Garvey MA, 1996, NEUROLOGY, V46, P1116; Giedd JN, 1996, J AM ACAD CHILD PSY, V35, P913, DOI 10.1097/00004583-199607000-00017; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; Jonasson G, 1993, Tidsskr Nor Laegeforen, V113, P3162; KIESSLING LS, 1993, PEDIATRICS, V92, P39; KURLAN R, 1993, HDB TOURETTES SYNDRO, P199; Kurlan R., 1988, TOURETTE SYNDROME UN; Leckman J. F., 1988, TOURETTES SYNDROME T, P55; Leckman JF, 1997, PSYCHIAT CLIN N AM, V20, P839, DOI 10.1016/S0193-953X(05)70348-8; LEONARD HL, 1993, ARCH GEN PSYCHIAT, V50, P429; March JS, 1995, ANXIETY DISORDERS CH, P251; MCKHANN, 1985, NEUROLOGY, V35, P1096; MISBAH SA, 1993, DRUG SAFETY, V9, P254, DOI 10.2165/00002018-199309040-00003; Murphy DL, 1982, BEHAVIOR PSYCHIATRIC, P335; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Singer HS, 1998, NEUROLOGY, V50, P1618, DOI 10.1212/WNL.50.6.1618; SWEDO SE, 1994, JAMA-J AM MED ASSOC, V272, P1788, DOI 10.1001/jama.272.22.1788; Swedo SE, 1997, AM J PSYCHIAT, V154, P110; Swedo SE, 1998, AM J PSYCHIAT, V155, P264; Tucker DM, 1996, J AM ACAD CHILD PSY, V35, P1684, DOI 10.1097/00004583-199612000-00022; Walkup JT, 1996, AM J HUM GENET, V59, P684; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077	29	361	375	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1153	1158		10.1016/S0140-6736(98)12297-3	http://dx.doi.org/10.1016/S0140-6736(98)12297-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	242QX	10513708				2022-12-28	WOS:000082954100010
J	[Anonymous]				[Anonymous]			Working lives of doctors must be improved	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	1999	319	7214					925	925						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506070				2022-12-28	WOS:000082975600067
J	Brewer, LR; Corzett, M; Balhorn, R				Brewer, LR; Corzett, M; Balhorn, R			Protamine-induced condensation and decondensation of the same DNA molecule	SCIENCE			English	Article							BACTERIOPHAGE HEADS; BINDING; MICROSCOPY; COMPLEXES; COLLAPSE; PACKING; PROTEIN; POLYMER; SPERM	The DNA sperm and certain viruses is condensed by arginine-rich proteins into toroidal subunits, a form of packaging that inactivates their entire genome. Individual DNA molecules were manipulated with an optical trap to examine the kinetics of torus formation induced by the binding of protamine and a subset of its DNA binding domain, Arg(6). Condensation and decondensation experiments with lambda-phage DNA show that toroid formation and stability are influenced by the number of arginine-rich anchoring domains in protamine. The results explain why protamines contain so much arginine and suggest that these proteins must be actively removed from sperm chromatin after fertilization.	Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Brewer, LR (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA.		Brewer, Laurence/G-4056-2012					ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; CAO TM, 1982, BIOCH BIOPHYS RES CO, V108; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KLIMENKO SM, 1967, J MOL BIOL, V23, P523, DOI 10.1016/S0022-2836(67)80122-0; MAEDA S, 1991, VIROLOGY, V180, P807, DOI 10.1016/0042-6822(91)90096-T; NAKANO M, 1989, J BIOCHEM-TOKYO, V105, P133, DOI 10.1093/oxfordjournals.jbchem.a122607; OSTROVSKY B, 1995, BIOPHYS J, V68, P1694, DOI 10.1016/S0006-3495(95)80347-4; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; PORSCHKE D, 1991, J MOL BIOL, V222, P423, DOI 10.1016/0022-2836(91)90220-Z; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; RuizLara SA, 1996, EUR J BIOCHEM, V240, P186, DOI 10.1111/j.1432-1033.1996.0186h.x; Ueda M, 1996, PHYS REV LETT, V77, P2133, DOI 10.1103/PhysRevLett.77.2133; WATANABE F, 1983, J MOL BIOL, V163, P485, DOI 10.1016/0022-2836(83)90070-0; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7	23	198	203	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					120	123		10.1126/science.286.5437.120	http://dx.doi.org/10.1126/science.286.5437.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506559	Green Submitted			2022-12-28	WOS:000082907400049
J	Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS				Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS			Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMEMBRANE GLYCOPROTEIN; LEUCINE-ZIPPER; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS; ATOMIC-STRUCTURE; PROTEIN; FUSION; SUBDOMAIN; DOMAIN	The HIV-1 gp41 protein promotes viral entry by mediating the fusion of viral and cellular membranes. A prominent pocket on the surface of a central trimeric coiled coil within gp41 was previously identified as a potential target for drugs that inhibit HIV-1 entry. We designed a peptide, IQN17, which properly presents this pocket. Utilizing IQN17 and mirror-image phage display, we identified cyclic, D-peptide inhibitors of HIV-1 infection that share a sequence motif. A1.5 Angstrom cocrystal structure of IQN17 in complex with a D-peptide, and NMR studies, show that conserved residues of these inhibitors make intimate contact with the gp41 pocket. Our studies validate the pocket per se as a target for drug development. IQN17 and these D-peptide inhibitors ave likely to be useful for development and identification of a new class of orally bioavailable anti-HIV drugs.	MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Kim, PS (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA.				NIGMS NIH HHS [P01 GM56552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bovey F. A., 1988, NUCL MAGNETIC RESONA; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CAVANAGH J, 1993, J MAGN RESON SER A, V105, P328; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FIELDS C G, 1991, Peptide Research, V4, P95; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	50	402	446	3	81	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					103	115		10.1016/S0092-8674(00)80066-5	http://dx.doi.org/10.1016/S0092-8674(00)80066-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520998	Bronze			2022-12-28	WOS:000082981600012
J	Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG				Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG			A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry	CELL			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; RECEPTOR-RELATED PROTEIN-1; GLYCOPROTEIN-D; POLIOVIRUS RECEPTOR; PSEUDORABIES VIRUS; MOLECULAR-CLONING; CELLS; BINDING; TYPE-1; INFECTION	Herpes simplex virus type 1 (HSV-1) binds to cells through interactions of viral glycoproteins gB and gC with heparan sulfate chains on cell surface proteoglycans. This binding is not sufficient for viral entry, which requires fusion between the viral envelope and cell membrane. Here, we show that heparan sulfate modified by a subset of the multiple D-glucosaminyl 3-O-sulfotransferase isoforms provides sites for the binding of a third viral glycoprotein, go, and for initiation of HSV-1 entry. We conclude that susceptibility of cells to HSV-1 entry depends on (1) presence of heparan sulfate chains to which virus can bind and (2) 3-O-sulfation of specific glucosamine residues in heparan sulfate to generate gD-binding sites or the expression of other previously identified gD-binding receptors.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	rdrrosen@mit.edu; p-spear@nwu.edu	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Shukla, Deepak/0000-0002-3039-6953	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293, U01AI031494] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 59479] Funding Source: Medline; NIAID NIH HHS [R01 AI 36293, U01 AI 31494] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Brynes AP, 1998, J VIROL, V72, P7349, DOI 10.1128/JVI.72.9.7349-7356.1998; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; DEAN HJ, 1994, VIROLOGY, V199, P67, DOI 10.1006/viro.1994.1098; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; Herold BC, 1996, J VIROL, V70, P3461, DOI 10.1128/JVI.70.6.3461-3469.1996; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; KRUMMENACHER C, 1999, IN PRESS J VIROL; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LIU J, 1999, IN PRESS J BIOL CHEM; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Schmidt J, 1997, J VIROL, V71, P17, DOI 10.1128/JVI.71.1.17-24.1997; Schroder C, 1997, J VIROL, V71, P25; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998	48	809	838	0	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					13	22		10.1016/S0092-8674(00)80058-6	http://dx.doi.org/10.1016/S0092-8674(00)80058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520990	Bronze			2022-12-28	WOS:000082981600004
J	Lowenberg, B; Downing, JR; Burnett, A				Lowenberg, B; Downing, JR; Burnett, A			Medical progress - Acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING-FACTOR; BONE-MARROW TRANSPLANTATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; SOUTHWEST-ONCOLOGY-GROUP; TREATMENT-OF-CANCER; REMISSION-INDUCTION CHEMOTHERAPY; ACUTE NONLYMPHOBLASTIC LEUKEMIA; SEVERE CONGENITAL NEUTROPENIA		Univ Rotterdam Hosp, Dept Hematol, NL-3008 AE Rotterdam, Netherlands; Erasmus Univ, Dept Hematol, NL-3008 AE Rotterdam, Netherlands; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; Cardiff Univ, Dept Hematol, Cardiff CF4 4XN, S Glam, Wales	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; St Jude Children's Research Hospital; Cardiff University	Lowenberg, B (corresponding author), Univ Rotterdam Hosp, Dept Hematol, POB 5201, NL-3008 AE Rotterdam, Netherlands.							APPELBAUM FR, 1984, ANN INTERN MED, V101, P581, DOI 10.7326/0003-4819-101-5-581; ARLIN Z, 1990, LEUKEMIA, V4, P177; ARTHUR DC, 1983, BLOOD, V61, P994; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERMAN E, 1991, BLOOD, V77, P1666; BISHOP JF, 1990, BLOOD, V75, P27; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BLOOMFIELD CD, 1985, ANN INTERN MED, V103, P614, DOI 10.7326/0003-4819-103-4-614; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; Burnett A. K., 1996, British Journal of Haematology, V93, P313; BURNETT AK, 1984, LANCET, V2, P1068; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Cassileth PA, 1998, NEW ENGL J MED, V339, P1649, DOI 10.1056/NEJM199812033392301; CATOVSKY D, 1991, ANN HEMATOL, V62, P16, DOI 10.1007/BF01714978; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMPLIN RE, 1985, ANN INTERN MED, V102, P285, DOI 10.7326/0003-4819-102-3-285; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Costello R, 1997, LEUKEMIA, V11, P644, DOI 10.1038/sj.leu.2400629; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Demirer T, 1996, BONE MARROW TRANSPL, V18, P29; DOMBRET H, 1995, NEW ENGL J MED, V332, P1678, DOI 10.1056/NEJM199506223322504; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Dong F, 1997, LEUKEMIA, V11, P120, DOI 10.1038/sj.leu.2400537; ERICKSON P, 1992, BLOOD, V80, P1825; Filipits M, 1998, BLOOD, V91, P1508, DOI 10.1182/blood.V91.5.1508.1508_1508_1513; Frank R, 1995, ONCOGENE, V11, P2667; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; GORIN NC, 1991, LEUKEMIA, V5, P896; GRATWOHL A, 1988, LANCET, V1, P1379; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 1997, CURR TOP MICROBIOL, V220, P81; Harousseau JL, 1997, BLOOD, V90, P2978; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heil G, 1997, BLOOD, V90, P4710, DOI 10.1182/blood.V90.12.4710.4710_4710_4718; Hermans MHA, 1998, BLOOD, V92, P32, DOI 10.1182/blood.V92.1.32.413k42_32_39; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KEATING MJ, 1988, LEUKEMIA, V2, P403; Keating S, 1998, BRIT J HAEMATOL, V102, P1344, DOI 10.1111/j.1365-2141.1998.896hm3674.x; Kern W, 1998, LEUKEMIA, V12, P1049, DOI 10.1038/sj.leu.2401066; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KOIKE T, 1984, BLOOD, V64, P683; KOSARY CL, 1995, NIH PUBLICATION; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KYLE RA, 1970, NEW ENGL J MED, V283, P1121, DOI 10.1056/NEJM197011192832101; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; Leith CP, 1997, BLOOD, V89, P3323; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652; List AF, 1996, BLOOD, V87, P2464, DOI 10.1182/blood.V87.6.2464.bloodjournal8762464; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lowenberg B, 1996, BAILLIERE CLIN HAEM, V9, P147, DOI 10.1016/S0950-3536(96)80041-2; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; Lowenberg B, 1998, J CLIN ONCOL, V16, P872; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; Lowenberg B, 1997, J CLIN ONCOL, V15, P3496; Lowenberg B, 1997, BLOOD, V90, P2952; LOWENBERG B, 1993, BLOOD, V81, P281; LOWENBERG B, 1984, CANCER, V54, P2840, DOI 10.1002/1097-0142(19841215)54:12<2840::AID-CNCR2820541204>3.0.CO;2-4; Lowenberg Bob, 1998, Current Opinion in Oncology, V10, P31; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MATUTES E, 1988, BRIT J HAEMATOL, V69, P205, DOI 10.1111/j.1365-2141.1988.tb07623.x; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P61, DOI 10.1016/0145-2126(92)90102-D; PETERSEN FB, 1993, J CLIN ONCOL, V11, P1353, DOI 10.1200/JCO.1993.11.7.1353; PLUNKETT W, 1987, CANCER RES, V47, P3005; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; Ravindranath Y, 1996, NEW ENGL J MED, V334, P1428, DOI 10.1056/NEJM199605303342203; ROWE JM, 1995, BLOOD, V86, P457, DOI 10.1182/blood.V86.2.457.bloodjournal862457; ROWLEY JD, 1980, BRIT J HAEMATOL, V44, P339, DOI 10.1111/j.1365-2141.1980.tb05902.x; Rubnitz JE, 1996, LEUKEMIA, V10, P74; RYAN DH, 1992, CLIN CHIM ACTA, V206, P9, DOI 10.1016/0009-8981(92)90004-A; SANZ MA, 1993, J CLIN ONCOL, V11, P1661, DOI 10.1200/JCO.1993.11.9.1661; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schiffer CA, 1996, BLOOD, V88, P3675, DOI 10.1182/blood.V88.10.3675.bloodjournal88103675; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Solary E, 1996, BLOOD, V88, P1198, DOI 10.1182/blood.V88.4.1198.bloodjournal8841198; Sonneveld P, 1996, BAILLIERE CLIN HAEM, V9, P185, DOI 10.1016/S0950-3536(96)80043-6; Stevens RF, 1998, BRIT J HAEMATOL, V101, P130, DOI 10.1046/j.1365-2141.1998.00677.x; STONE RM, 1995, NEW ENGL J MED, V332, P1671, DOI 10.1056/NEJM199506223322503; Terpstra W, 1997, LEUKEMIA, V11, P315, DOI 10.1038/sj.leu.2400561; THOMAS ED, 1979, NEW ENGL J MED, V301, P597, DOI 10.1056/NEJM197909133011109; Van Putten W. L. J., 1997, Blood, V90, p65A; VanLeeuwen FE, 1996, BAILLIERE CLIN HAEM, V9, P57, DOI 10.1016/S0950-3536(96)80037-0; Vellenga E, 1999, BONE MARROW TRANSPL, V23, P1279, DOI 10.1038/sj.bmt.1701799; VOGLER WR, 1992, J CLIN ONCOL, V10, P1103, DOI 10.1200/JCO.1992.10.7.1103; Wang J., 1997, Blood, V90, p245A; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weick JK, 1996, BLOOD, V88, P2841, DOI 10.1182/blood.V88.8.2841.bloodjournal8882841; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wheatley D, 1998, BRIT J HAEMATOL, V103, P100; WHO, 1979, WHO HDB REP RES CANC; WIERNIK PH, 1992, BLOOD, V79, P313; Witz F, 1998, BLOOD, V91, P2722; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V11, P125, DOI 10.1016/0165-4608(84)90106-7; YUNIS JJ, 1984, NEW ENGL J MED, V311, P812, DOI 10.1056/NEJM198409273111302; Zittoun R, 1996, J CLIN ONCOL, V14, P2150, DOI 10.1200/JCO.1996.14.7.2150; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	117	1253	1298	3	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1051	1062		10.1056/NEJM199909303411407	http://dx.doi.org/10.1056/NEJM199909303411407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502596				2022-12-28	WOS:000082880500007
J	Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB				Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB			Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; blood pressure monitoring, ambulatory; hypertrophy, left ventricular; coronary arteriosclerosis; blood pressure	LEFT-VENTRICULAR MASS; WHITE COAT HYPERTENSION; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; HYPERTROPHY; VARIABILITY; MORBIDITY; MORTALITY; THICKNESS; CHILDREN	Background: Ambulatory blood pressure may be higher or lower than clinic blood pressure. Attention has focused on "white coat hypertension" (normal ambulatory blood pressure elevated in the clinic). The converse phenomenon of high ambulatory blood pressure but normal office blood pressure-"white coat normotension"-has not been studied. Objective: To assess whether white coat normotension (awake ambulatory blood pressure > 134/90 mm Hg and clinic blood pressure < 140/90 mm Hg) is associated with target organ damage. Design: Cross-sectional observational study. Setting: University hospital hypertension center and participant work sites. Patients: 295 clinically normotensive adults and 64 patients with sustained hypertension (elevated clinic and ambulatory blood pressure). Measurements: Target organ abnormalities were measured by echocardiography and arterial ultrasonography in 61 patients with white coat normotension, 234 with sustained normotension (normal clinic and ambulatory blood pressure), and 64 with sustained hypertension. Results: Patients with white coat normotension were older; had higher body mass indices, serum creatinine concentrations, and glucose levels; and a higher prevalence of current smokers. Left ventricular mass index and relative wall thickness were higher by 13 g/m(2) (Cl, 8 to18 g/m(2)) and by 0.03 (Cl, 0.01 to 0.04), respectively, in patients with white coat normotension compared with those who had sustained normotension. Patients with white coat normotension and those with sustained hypertension did not differ significantly for left ventricular mass index (4 g/m(2) [Cl, -3 to 10 g/m(2)) or relative wall thickness (0.01 [Cl, -0.01 to 0.03]). The prevalence of discrete atherosclerotic plaques was similar in patients with white coat normotension (17 of 61, or 28% [Cl, 17% to 39%]) and those with sustained hypertension (17 of 64, or 27% [Cl, 16% to 38%]), but the difference lost significance after adjustment for age. Conclusions: White coat normotension is associated with left ventricular mass and carotid wall thickness similar to those in sustained hypertension. The association of white coat normotension with prognostically important target organ damage may partly explain the ability of high normal left ventricular mass and high normal clinic blood pressure to predict subsequent hypertension and cardiovascular events in patients with clinical normotension.	Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, New York, NY 10021 USA; Univ Florence, Div Gerontol & Geriatr, I-50141 Florence, Italy	Cornell University; NewYork-Presbyterian Hospital; University of Florence	Devereux, RB (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, Box 222,525 E 68th St, New York, NY 10021 USA.	rbdevere@mail.med.cornell.edu		Schwartz, Joseph/0000-0002-8944-3566; Pini, Riccardo/0000-0002-7940-7908	NHLBI NIH HHS [HL 47540, P01 HL047540, HL 30606, HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047540, P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; DESIMONE G, 1995, J AM COLL CARDIOL, V25, P1056, DOI 10.1016/0735-1097(94)00540-7; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; Devereux RB, 1997, CIRCULATION, V96, P1416, DOI 10.1161/01.CIR.96.5.1416; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; Devereux RB, 1996, AM J CARDIOL, V78, P61, DOI 10.1016/S0002-9149(96)00228-7; Devereux RB, 1991, BLOOD PRESSURE MEASU, P261; FAGARD R, 1995, AM J HYPERTENS, V8, P533, DOI 10.1016/0895-7061(95)00043-O; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOSSE P, 1986, J HYPERTENS, V4, pS297; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Jones EC, 1997, J AM COLL CARDIOL, V29, P1303, DOI 10.1016/S0735-1097(97)82755-6; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KANNEL WB, 1974, PROG CARDIOVASC DIS, V17, P5, DOI 10.1016/0033-0620(74)90034-6; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LARKIN KT, 1998, BLOOD PRESS MONIT, V3, P247; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PALATINI P, 1985, J HYPERTENS, V3, pS425; Palmieri V, 1998, CIRCULATION, V98, P29; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRISANT LM, 1990, AM J HYPERTENS, V3, P81, DOI 10.1093/ajh/3.2.81; RAVOGLI A, 1990, HYPERTENSION, V16, P491, DOI 10.1161/01.HYP.16.5.491; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROSENMAN RH, 1976, CIRCULATION, V54, P51, DOI 10.1161/01.CIR.54.1.51; ROWLANDS DB, 1982, LANCET, V1, P467; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNALL PL, 1992, HYPERTENSION, V19, P488, DOI 10.1161/01.HYP.19.5.488; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; VERDECCHIA P, 1992, HYPERTENSION, V20, P555, DOI 10.1161/01.HYP.20.4.555; VERDECCHIA P, 1995, J HYPERTENS, V13, P1209, DOI 10.1097/00004872-199510000-00016; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793	42	284	301	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					564	+		10.7326/0003-4819-131-8-199910190-00003	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523216				2022-12-28	WOS:000083196600002
J	Matthay, KK; Villablanca, JG; Seeger, RC; Stram, DO; Harris, RE; Ramsay, NK; Swift, P; Shimada, H; Black, CT; Brodeur, GM; Gerbing, RB; Reynolds, CP				Matthay, KK; Villablanca, JG; Seeger, RC; Stram, DO; Harris, RE; Ramsay, NK; Swift, P; Shimada, H; Black, CT; Brodeur, GM; Gerbing, RB; Reynolds, CP		Childrens Canc Grp	Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDRENS-CANCER-GROUP; TOTAL-BODY IRRADIATION; NEURO-BLASTOMA CELLS; N-MYC; METASTATIC NEUROBLASTOMA; INTERNATIONAL CRITERIA; MYELOABLATIVE THERAPY; PROGNOSTIC VALUE; RETINOIC ACID; DIAGNOSIS	Background Children with high-risk neuroblastoma have a poor outcome. In this study, we assessed whether myeloablative therapy in conjunction with transplantation of autologous bone marrow improved event-free survival as compared with chemotherapy alone, and whether subsequent treatment with 13-cis-retinoic acid (isotretinoin) further improves event-free survival. Methods All patients were treated with the same initial regimen of chemotherapy, and those without disease progression were then randomly assigned to receive continued treatment with myeloablative chemotherapy, total-body irradiation, and transplantation of autologous bone marrow purged of neuroblastoma cells or to receive three cycles of intensive chemotherapy alone. All patients who completed cytotoxic therapy without disease progression were then randomly assigned to receive no further therapy or treatment with 13-cis-retinoic acid for six months. Results The mean (+/-SE) event-free survival rate three years after the first randomization was significantly better among the 189 patients who were assigned to undergo transplantation than among the 190 patients assigned to receive continuation chemotherapy (34+/-4 percent vs. 22+/-4 percent, P = 0.034). The event-free survival rate three years after the second randomization was significantly better among the 130 patients who were assigned to receive 13-cis-retinoic acid than among the 128 patients assigned to receive no further therapy (46+/-6 percent vs. 29+/-5 percent, P = 0.027). Conclusions Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with highrisk neuroblastoma. In addition, treatment with 13-cis-retinoic acid was beneficial for patients without progressive disease when it was administered after chemotherapy or transplantation. (N Engl J Med 1999; 341:1165-73.) (C)1999, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; MD Anderson Hosp & Tumor Inst, Dept Surg, Houston, TX USA; Childrens Canc Grp, Arcadia, CA 91066 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles; Cincinnati Children's Hospital Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania	Matthay, KK (corresponding author), Childrens Canc Grp, POB 60012, Arcadia, CA 91066 USA.			Reynolds, C. Patrick/0000-0002-2827-8536	NCI NIH HHS [CA22794, CA13539, CA02649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022794, U10CA002649, U10CA013539] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEMAYOR E, 1992, LARYNGOSCOPE, V102, P1133, DOI 10.1288/00005537-199210000-00008; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; CHATTEN J, 1988, HUM PATHOL, V19, P1187, DOI 10.1016/S0046-8177(88)80151-5; CHEUNG NKV, 1991, J CLIN ONCOL, V9, P1050, DOI 10.1200/JCO.1991.9.6.1050; DAUBENTON JD, 1987, CANCER, V59, P1586, DOI 10.1002/1097-0142(19870501)59:9<1586::AID-CNCR2820590910>3.0.CO;2-D; DINI G, 1991, J CLIN ONCOL, V9, P962, DOI 10.1200/JCO.1991.9.6.962; DINI G, 1989, BONE MARROW TRANSPL, V4, P42; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Garaventa A, 1996, BONE MARROW TRANSPL, V18, P125; HANN HWL, 1985, CANCER RES, V45, P2843; JUCKETT M, 1991, BONE MARROW TRANSPL, V7, P405; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUSHNER BH, 1991, J CLIN ONCOL, V9, P274, DOI 10.1200/JCO.1991.9.2.274; Ladenstein R, 1998, J CLIN ONCOL, V16, P953, DOI 10.1200/JCO.1998.16.3.953; Matthay K K, 1997, Oncology (Williston Park), V11, P1857; MATTHAY KK, 1994, J CLIN ONCOL, V12, P2382, DOI 10.1200/JCO.1994.12.11.2382; MATTHAY KK, 1993, J CLIN ONCOL, V11, P2226, DOI 10.1200/JCO.1993.11.11.2226; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; OHNUMA N, 1995, MED PEDIATR ONCOL, V24, P181, DOI 10.1002/mpo.2950240308; OURSLER DP, 1993, AM J NEPHROL, V13, P167, DOI 10.1159/000168610; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PHILIP T, 1991, J CLIN ONCOL, V9, P1037, DOI 10.1200/JCO.1991.9.6.1037; PINKERTON CR, 1991, BONE MARROW TRANSPL, V7, P112; Reynolds C P, 1994, Prog Clin Biol Res, V385, P237; REYNOLDS CP, 1986, CANCER RES, V46, P5882; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1991, PEDIATR CLIN N AM, V38, P393; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHIMADA H, 1995, J NATL CANCER I, V87, P1470, DOI 10.1093/jnci/87.19.1470; Shuster JJ, 1996, J CLIN ONCOL, V14, P2413, DOI 10.1200/JCO.1996.14.9.2413; SIDELL N, 1982, J NATL CANCER I, V68, P589; Stram DO, 1996, J CLIN ONCOL, V14, P2417, DOI 10.1200/JCO.1996.14.9.2417; Tarbell N J, 1990, Radiother Oncol, V18 Suppl 1, P139, DOI 10.1016/0167-8140(90)90195-3; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894	40	1410	1463	0	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1165	1173		10.1056/NEJM199910143411601	http://dx.doi.org/10.1056/NEJM199910143411601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519894				2022-12-28	WOS:000083087400001
J	Duke, T				Duke, T			Decline in child health in rural Papua New guinea	LANCET			English	Editorial Material									Goroka Base Hosp, Dept Paediat, Goroka, Eastern Highlan, Papua N Guinea		Duke, T (corresponding author), Goroka Base Hosp, Dept Paediat, POB 392, Goroka, Eastern Highlan, Papua N Guinea.	duke@global.net.pg						Alto William A., 1996, Papua New Guinea Medical Journal, V39, P315; Decosas J, 1999, LANCET, V353, P143, DOI 10.1016/S0140-6736(98)11454-X; *DEP HLTH, 1996, PNG NAT HLTH PLAN, P40; *DEP HLTH PAP NEW, 1997, DHS SURV; PATAKISCHWEIZER KJ, 1983, PAPUA NEW GUINEA MED, V26, P178; REILLY Q, 1990, ACHIEVING HLTH ALL Y, P213; Shann F, 1979, P N G Med J, V22, P170; Summerfield D, 1998, LANCET, V351, P1955, DOI 10.1016/S0140-6736(98)06056-5; *UNICEF, 1999, STAT WORLDS CHILDR 1, P91; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2	10	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1291	1294		10.1016/S0140-6736(99)00335-9	http://dx.doi.org/10.1016/S0140-6736(99)00335-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520651				2022-12-28	WOS:000083010400046
J	Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C				Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C			Low-temperature crystallization of silicate dust in circumstellar disks	NATURE			English	Article							SPECTRUM; GRAINS; COMETS; STARS	Silicate dust in the interstellar medium is observed to be amorphous(1), yet silicate dust in comets(2,3) and interplanetary dust particles(4) is sometimes partially crystalline. The dust in young stars(5,6) also appears to be partially crystalline. These clouds to a planetary system, it must undergo some processing, Here we report observations of highly crystalline silicate dust in the disks surrounding binary red-giant stars. The dust was created in amorphous form in the outer atmospheres of the red giants, and therefore must be processed in the disks to become crystalline. The temperatures in these disks are too low for the grains to anneal; therefore, some low-temperature process must be responsible. As the physical properties of the disks around young stars and red giants are similar, our results suggest that low-temperature crystallization of silicate grains also can occur in protoplanetary systems.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; SRON, Lab Space Res Groningen, NL-9700 AV Groningen, Netherlands; SRON, Space Res Lab, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Astron Inst, NL-3508 TA Utrecht, Netherlands	University of Amsterdam; KU Leuven; Utrecht University	Molster, FJ (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.		Van Winckel, Hans/I-7863-2013	Van Winckel, Hans/0000-0001-5158-9327; van den Ancker, Mario/0000-0001-6992-3100				Bradley J. P., 1999, Solid interstellar matter: the ISO revolution, P297; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; Dorschner J, 1995, ASTRON ASTROPHYS REV, V6, P271, DOI 10.1007/BF00873686; Elliman R. G., 1986, MATER RES SOC S P, V51, P319; Gail HP, 1998, ASTRON ASTROPHYS, V332, P1099; GALVIN GJ, 1982, PHYS REV LETT, V48, P33, DOI 10.1103/PhysRevLett.48.33; Grun J, 1997, PHYS REV LETT, V78, P1584, DOI 10.1103/PhysRevLett.78.1584; Hallenbeck S, 1998, ASTROPHYS SPACE SCI, V255, P427; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; JONES TW, 1976, ASTROPHYS J, V209, P509, DOI 10.1086/154746; JURA M, 1995, ASTROPHYS J, V453, P721, DOI 10.1086/176433; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; MOLSTER PJ, IN PRESS ASTRON ASTR; Shu FH, 1997, SCIENCE, V277, P1475, DOI 10.1126/science.277.5331.1475; THIEL K, 1991, NUCL TRACKS RAD MEAS, V19, P709; TIELENS AGGM, 1994, ASTROPHYS J, V431, P321, DOI 10.1086/174488; Van Winckel H, 1998, ASTRON ASTROPHYS, V336, pL17; VANDENANCKER ME, IN PRESS ASTRON ASTR; Waelkens C, 1998, ASTROPHYS SPACE SCI, V255, P25; WATERS LBF, 1999, IAU S, V191, P209; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WILLIAMS JS, 1985, PHYS REV LETT, V55, P1482, DOI 10.1103/PhysRevLett.55.1482; WOOD JA, 1985, PROTOSTARS PLANETS, V2, P687; YAMAMURA I, 1997, ESA, P313	28	162	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					563	565		10.1038/44085	http://dx.doi.org/10.1038/44085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524623				2022-12-28	WOS:000083054900042
J	Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC				Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC			Fruit and vegetable intake in relation to risk of ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; CARDIOVASCULAR-DISEASE; PLASMA HOMOCYSTEINE; MEN; REPRODUCIBILITY; CONSUMPTION; POTASSIUM; MORTALITY; VALIDITY	Context Few studies have evaluated the relationship between fruit and vegetable intake and cardiovascular disease. Objective To examine the associations between fruit and vegetable intake and ischemic stroke. Design, Setting, and Subjects Prospective cohort studies, including 75 596 women aged 34 to 59 years in the Nurses' Health Study with 14 years of follow-up (1980-1994), and 38 683 men aged 40 to 75 years in the Health Professionals' Follow-up Study with 8 years of follow-up (1986-1994). All individuals were free of cardiovascular disease, cancer, and diabetes at baseline. Main Outcome Measure Incidence of ischemic stroke by quintile of fruit and vegetable intake. Results A total of 366 women and 204 men had an ischemic stroke. After controlling for standard cardiovascular risk factors, persons in the highest quintile of fruit and vegetable intake (median of 5.1 servings per day among men and 5.8 servings per day among women) had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.52-0.92) compared with those in the lowest quintile. An increment of 1 serving per day of fruits or vegetables was associated with a 6% tower risk of ischemic stroke (RR, 0.94; 95% CI, 0.90-0.99; P = .01, test for trend). Cruciferous vegetables (RR, 0.68 for an increment of 1 serving per day; 95% CI, 0.49-0.94), green leafy vegetables (RR, 0.79; 95% CI, 0.62-0.99), citrus fruit including juice (RR, 0.81; 95% CI, 0.68-0.96), and citrus fruit juice (RR, 0.75; 95% CI, 0.61-0.93) contributed most to the apparent protective effect of total fruits and vegetables. Legumes or potatoes were not associated with lower ischemic stroke risk. The multivariate pooled RR for total stroke was 0.96 (95% CI, 0.93-1.00) for each increment of 2 servings per day. Conclusions These data support a protective relationship between consumption of fruit and vegetables-particularly cruciferous and green leafy vegetables and citrus fruit and juice-and ischemic stroke risk.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Joshipura, KJ (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, 188 Longwood Ave, Boston, MA 02115 USA.		Joshipura, Kaumudi J/AAA-3852-2020	Joshipura, Kaumudi/0000-0003-1964-7579	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL35464, HL34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GAZIANO JM, 1995, ANN EPIDEMIOL, V5, P225; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hirayama T, 1986, Prog Clin Biol Res, V206, P299; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KNEKT P, 1994, AM J EPIDEMIOL, V139, P180; LEE CN, 1988, NEW ENGL J MED, V318, P995; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STEINMETZ KA, 1993, CANCER RES, V53, P536; Ward M, 1997, QJM-MON J ASSOC PHYS, V90, P519, DOI 10.1093/qjmed/90.8.519; Weinfeld, 1981, STROKE S1, V12, pI13; *WHO STUD GROUP, 1990, WHO TECHNICAL REPORT, V797; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY	27	731	760	2	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1233	1239		10.1001/jama.282.13.1233	http://dx.doi.org/10.1001/jama.282.13.1233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517425	Bronze			2022-12-28	WOS:000082901100030
J	Davis, CL; Marsh, CL				Davis, CL; Marsh, CL			Reduction of organ-retrieval damage and organ-discard rates	LANCET			English	Editorial Material									Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Davis, CL (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.			Marsh, Christopher/0000-0002-6517-076X					0	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1136	1137		10.1016/S0140-6736(99)90167-8	http://dx.doi.org/10.1016/S0140-6736(99)90167-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513700				2022-12-28	WOS:000082954100002
J	Singer, HS				Singer, HS			PANDAS and immunomodulatory therapy	LANCET			English	Editorial Material							RHEUMATIC-FEVER; ANTIBODIES; CHOREA; DISORDERS		Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Singer, HS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA.							Cardoso F, 1997, MOVEMENT DISORD, V12, P701, DOI 10.1002/mds.870120512; Giuliano JD, 1998, ANN NEUROL, V44, P556; HALLETT JJ, 1996, FASEB J, V10, pA1357; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; KIESSLING L S, 1989, Developmental Medicine and Child Neurology, V31, P48; KIESSLING LS, 1993, PEDIATRICS, V92, P39; Kurlan R, 1998, NEUROLOGY, V50, P1530, DOI 10.1212/WNL.50.6.1530; Laurino JP, 1997, ANN CLIN LAB SCI, V27, P230; Matarazzo E B, 1992, J Child Adolesc Psychopharmacol, V2, P215, DOI 10.1089/cap.1992.2.215; Selling L, 1929, ARCH NEURO PSYCHIATR, V22, P1163, DOI 10.1001/archneurpsyc.1929.02220060060005; Singer HS, 1998, NEUROLOGY, V50, P1618, DOI 10.1212/WNL.50.6.1618; SINGER HS, IN PRESS BIOL PSYCHI; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; Swedo SE, 1998, AM J PSYCHIAT, V155, P264	14	31	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1137	1138		10.1016/S0140-6736(99)00204-4	http://dx.doi.org/10.1016/S0140-6736(99)00204-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513701	hybrid			2022-12-28	WOS:000082954100003
J	Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR				Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR		Kidney Advisory Grp	Kidney damage during organ retrieval: data from UK National Transplant Database	LANCET			English	Article								Background Kidney damage at organ retrieval is believed to be an increasing problem that is under reported. We aimed to identify the true rate of such damage and assess the effects on transplant survival. Methods Data from the UK National Transplant Database were analysed on all cadaveric kidneys donated over a 5-year period in the UK. Records indicated whether kidneys had been retrieved by a liver or renal surgical team and whether damage was noted at the time of retrieval or at the transplant procedure. Multivariate Cox's regression models were fitted to 1-year and 3-year transplant-survival data in those kidneys that were transplanted between 1992 and 1994. Findings Of 9014 kidneys retrieved, 96 could not be transplanted because of damage sustained at retrieval. Damage was reported in 1726 (19%) kidneys although by both donor and recipient centres iri only 270 (3%). 1070 (62%) of the damaged organs were from donors aged 40 years or older. Reported kidney damage was more likely for retrievals of kidney only by a renal team (503 [26%]) than for multiorgan retrieval (454 [21%]), the proportion was lower when a liver team retrieved both liver and kidneys (415 [17%]). 794 (14%) kidneys retrieved and retained locally were reported as damaged, compared with 932 (29%) kidneys which had been exported. Donors' age had a significant effect on both 1-year and 3-year transplant survival (p<0.01 for both) but kidney damage did not (1 year p=0.40; 3 year p=0.81). Interpretation Despite the high rate of damage to kidneys at retrieval, most of the organs can be transplanted with no adverse effect on transplant survival. Kidney damage is least likely to occur with kidneys from young donors, and when liver teams or centres undertaking more than 50 retrievals per year do the retrieval.	Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland; United Kingdom Transplant Support Serv Author, Stoke Gifford, England	Royal Infirmary of Edinburgh; University of Edinburgh	Forsythe, JLR (corresponding author), Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Wigmore, Stephen/AAF-3562-2019	Wigmore, Stephen/0000-0002-3614-8002				Cecka J M, 1988, Clin Transpl, P399; GENTLEMAN D, 1990, BMJ-BRIT MED J, V301, P1203, DOI 10.1136/bmj.301.6762.1203; Grossman MD, 1996, TRANSPLANTATION, V62, P1828, DOI 10.1097/00007890-199612270-00026; Lee CM, 1996, TRANSPLANTATION, V62, P1832, DOI 10.1097/00007890-199612270-00027; Nicholls J, 1996, TRANSPLANT P, V28, P142; NYGAARD CE, 1990, J TRAUMA, V30, P728, DOI 10.1097/00005373-199006000-00013; 1995, UNOS UPDATE, V11, P30	7	39	39	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1143	1146		10.1016/S0140-6736(98)09409-4	http://dx.doi.org/10.1016/S0140-6736(98)09409-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513706				2022-12-28	WOS:000082954100008
J	Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W				Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W			Transmission of tuberculosis in a jail	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 11-15, 1998	DENVER, CO	Infect Dis Soc Amer		disease outbreaks; tuberculosis; prisoners; infection control; tuberculin test	CORRECTIONAL HEALTH-CARE; YORK-STATE PRISON; RESISTANT TUBERCULOSIS; INFECTION; POLYMORPHISM; ASSOCIATION; POPULATION; ADMISSION; OUTBREAK; FACILITY	Background: Outbreaks of tuberculosis are uncommonly recognized in jails. In 1996, an increase in active tuberculosis cases was noted among inmates of a large urban jail. Objectives: To determine the source and extent of a tuberculosis outbreak in an urban jail and to recommend control measures. Design: Retrospective cohort study. Setting: Urban jail. Patients: Inmates and guards with tuberculosis. Intervention: Outbreak evaluation and control. Measurements: Medical records of inmates and guards with tuberculosis were reviewed, and inmates were interviewed. DNA fingerprinting was performed on Mycobacterium tuberculosis isolates. Results: From 1 January 1995 through 31 December 1997, active tuberculosis was diagnosed in 38 inmates and 5 guards from the jail. Nineteen (79%) of the 24 culture-positive inmates had isolates with DNA fingerprints matching those of other inmates. Isolates from both culture-positive guards matched the predominant inmate strain; only 6 (14%) of 43 isolates from infected persons in the community had this pattern. The median length of incarceration of all inmates in the jail was 1 day; the median length of continuous incarceration before diagnosis of tuberculosis in inmates was 138 days. Inmates with tuberculosis had been incarcerated a median of 15 times. Forty-three percent of persons in this city with tuberculosis diagnosed from January 1995 through July 1997 had been incarcerated in the jail at some time before diagnosis. Conclusions: Traditional and molecular epidemiologic investigations suggest that tuberculosis was transmitted among inmates and guards in an urban jail. Aggressive measures to screen for active tuberculosis upon incarceration are important for preventing spread of disease in jails and to the surrounding community.	Tennessee Dept Hlth, CEDS, Nashville, TN 37247 USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA	Tennessee Department Health; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Vanderbilt University; Vanderbilt University	Jones, TF (corresponding author), Tennessee Dept Hlth, CEDS, Cordell Hull Bldg,4th Floor,425 5th Ave N, Nashville, TN 37247 USA.	bhudson@mail.acponline.org						ABELES H, 1970, AM REV RESPIR DIS, V101, P706; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BergmireSweat D, 1996, EPIDEMIOL INFECT, V117, P485, DOI 10.1017/S095026880005915X; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *BUR JUST STAT, 1995, BJS B; *BUR JUST STAT, 1998, PROF JAIL INM; *CAS DEF INF COND, 1997, MMWR-MORBID MORTAL W, V46, P1; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Conklin TJ, 1998, AM J PUBLIC HEALTH, V88, P1249; *CONTR TB CORR FAC, 1995, ATL CDCP; DEAN AD, 1994, ATLANTA CDCP; Fountain F F Jr, 1997, Tenn Med, V90, P138; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; HAMMETT T, 1994, TUBERCULOSIS CORRECT; HUTTON MD, 1993, PUBLIC HEALTH REP, V108, P305; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; Koo DT, 1997, AM J PUBLIC HEALTH, V87, P279, DOI 10.2105/AJPH.87.2.279; Layton MC, 1997, AM J PUBLIC HEALTH, V87, P1335, DOI 10.2105/AJPH.87.8.1335; MacIntyre CR, 1997, CLIN INFECT DIS, V24, P1060, DOI 10.1086/513632; PELLETIER AR, 1993, ARCH INTERN MED, V153, P2692, DOI 10.1001/archinte.153.23.2692; Prevention CfDCa, 1996, MMWR-MORBID MORTAL W, V45, P1; Puisis M, 1996, PUBLIC HEALTH REP, V111, P330; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3175, DOI 10.1001/jama.268.22.3175; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; *TUB TRANSM STAT C, 1992, MMWR-MORBID MORTAL W, V41, P927; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; WILCOCK K, 1996, TUBERCULOSIS CORRECT	31	71	74	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					557	+		10.7326/0003-4819-131-8-199910190-00002	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	246ZR	10523215				2022-12-28	WOS:000083196600001
J	Lorenz, K				Lorenz, K			The sharer	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									W Los Angeles Vet Affairs Med Ctr, Dept Internal Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Lorenz, K (corresponding author), W Los Angeles Vet Affairs Med Ctr, Dept Internal Med, 11303 Wilshire Blvd,Code 111G, Los Angeles, CA 90073 USA.	Klorenz@ucla.edu							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					625	626		10.7326/0003-4819-131-8-199910190-00014	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523226				2022-12-28	WOS:000083196600012
J	Shimoni, Z; Dobrousin, A; Cohen, J; Pitlik, S				Shimoni, Z; Dobrousin, A; Cohen, J; Pitlik, S			Lesson of the week - Tetanus in an immunised patient	BRITISH MEDICAL JOURNAL			English	Article									Tel Aviv Univ, Sackler Sch Med, Dept Internal Med C, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Rabin Med Ctr, Dept Internal Med B, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Rabin Med Ctr, Intens Care Unit, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Rabin Medical Center; Tel Aviv University; Rabin Medical Center; Tel Aviv University	Pitlik, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Internal Med C, Rabin Med Ctr, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							BAND JD, 1983, INFECT DIS, P1107; CRONE NE, 1992, NEUROLOGY, V42, P761, DOI 10.1212/WNL.42.4.761; DOLIN R, 1995, PRINCIPLES PRACTICE, P2173; GERGEN P, 1995, NEW ENGL J MED, V332, P761, DOI 10.1056/NEJM199503233321201; MCCOMB JA, 1964, NEW ENGL J MED, V270, P175, DOI 10.1056/NEJM196401232700404; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; TULCHINSKY TH, 1990, ISRAEL J MED SCI, V26, P438	7	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1049	1049		10.1136/bmj.319.7216.1049	http://dx.doi.org/10.1136/bmj.319.7216.1049			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521202	Green Published			2022-12-28	WOS:000083210100031
J	McKeith, IG; O'Brien, JT; Ballard, C				McKeith, IG; O'Brien, JT; Ballard, C			Diagnosing dementia with Lewy bodies	LANCET			English	Editorial Material							DISEASE		Newcastle Gen Hosp, Inst Hlth Elderly, Dept Old Age Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	McKeith, IG (corresponding author), Newcastle Gen Hosp, Inst Hlth Elderly, Dept Old Age Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.		McKeith, Ian/AAH-3382-2021	Ballard, Clive/0000-0003-0022-5632; McKeith, Ian/0000-0002-9250-0568; O'Brien, John/0000-0002-0837-5080				*COMM SAF MED UPD, 1994, CURR PROBL PHARM, V6, P20; HANSEN L, 1990, NEUROLOGY, V40, P1; Holmes C, 1999, BRIT J PSYCHIAT, V174, P45, DOI 10.1192/bjp.174.1.45; Lennox G. G., 1996, P9, DOI 10.1017/CBO9780511601187.005; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; Luis CA, 1999, INT J GERIATR PSYCH, V14, P526, DOI 10.1002/(SICI)1099-1166(199907)14:7<526::AID-GPS965>3.0.CO;2-0; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKEITH IG, IN PRESS NEUROLOGY; McKetin R, 1998, DRUG ALCOHOL DEPEN, V50, P181, DOI 10.1016/S0376-8716(98)00022-2; MCSHANE RH, 1998, NEUROBIOL AGING, V19, P204; Mega MS, 1996, NEUROLOGY, V47, P1403, DOI 10.1212/WNL.47.6.1403; PAPKA M, 1998, NEUROBIOL AGING, V19, P203; Shea C, 1998, Int Psychogeriatr, V10, P229, DOI 10.1017/S1041610298005341; WALKER MP, IN PRESS J HUMAN PSY	15	49	49	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1227	1228		10.1016/S0140-6736(99)90214-3	http://dx.doi.org/10.1016/S0140-6736(99)90214-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520629				2022-12-28	WOS:000083010400006
J	Hart, RG; Benavente, O; McBride, R; Pearce, LA				Hart, RG; Benavente, O; McBride, R; Pearce, LA			Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article						meta-analysis; cerebrovascular disorders; atrial fibrillation; anticoagulants platelet aggregation inhibitors	FIXED MINIDOSE WARFARIN; THROMBOEMBOLIC COMPLICATIONS; RANDOMIZED TRIAL; CLINICAL-TRIALS; ANTICOAGULATION; ASPIRIN; INDOBUFEN; INTENSITY; EVENTS	Purpose: To characterize the efficacy and safety of anticoagulants and antiplatelet agents for prevention of stroke in patients with atrial fibrillation. Data Sources: Randomized trials identified by using the search strategy developed by the Cochrane Collaboration Stroke Review Group. Study Selection: All published randomized trials testing antithrombotic agents to prevent stroke in patients with atrial fibrillation. Data Extraction: Data on interventions, number of participants, duration of exposure and occurrence of all stroke (ischemic and hemorrhagic), major extracranial bleeding, and death were extracted independently by two investigators. Data Synthesis: Sixteen trials included a total of 9874 participants (mean follow-up, 1.7 years). Adjusted-dose warfarin (six trials, 2900 participants) reduced stroke by 62% (95% CI, 48% to 72%); absolute risk reductions were 2.7% per year for primary prevention and 8.4% per year for secondary prevention. Major extracranial bleeding was increased by warfarin therapy (absolute risk increase, 0.3% per year). Aspirin (six trials, 3119 participants) reduced stroke by 22% (CI, 2% to 38%); absolute risk reductions were 1.5% per year for primary prevention and 2.5% per year for secondary prevention. Adjusted-dose warfarin (five trials, 2837 participants) was more efficacious than aspirin (relative risk reduction, 36% [CI, 14% to 52%]). Other randomized comparisons yielded inconclusive results. Conclusions: Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin. The benefit of antithrombotic therapy was not offset by the occurrence of major hemorrhage among participants in randomized trials. Judicious use of antithrombotic therapy, tailored according to the inherent risk for stroke, importantly reduces stroke in patients with atrial fibrillation.	Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX 78284 USA; Axio Res Corp, Seattle, WA 98105 USA	University of Texas System; University of Texas Health San Antonio	Hart, RG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Neurol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Pearce, Lesly/0000-0002-0838-1739	PHS HHS [R01 24224] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; Benavente O, 1999, STROKE MODULE COCHRA; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diener HC, 1997, J NEUROL SCI, V153, P112; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Feinberg WM, 1999, J GEN INTERN MED, V14, P56, DOI 10.1046/j.1525-1497.1999.00281.x; FORNARO G, 1993, CIRCULATION, V87, P162, DOI 10.1161/01.CIR.87.1.162; Green CJ, 1997, CAN J CARDIOL, V13, P811; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARENBERG J, 1993, SEMIN THROMB HEMOST, V19, P116; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1998, ANN INTERN MED, V128, P408, DOI 10.7326/0003-4819-128-5-199803010-00012; HART RG, 1999, IN PRESS CEREBROVASC; Hellemons BSP, 1997, CEREBROVASC DIS, V7, P11; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL P, 1997, STROKE MODULE COCHRA; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; Pengo V, 1998, AM J CARDIOL, V82, P433, DOI 10.1016/S0002-9149(98)00357-9; PETERSEN P, 1989, LANCET, V1, P175; Posada IS, 1999, AM HEART J, V138, P137, DOI 10.1016/S0002-8703(99)70259-0	30	1228	1288	0	35	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					492	+		10.7326/0003-4819-131-7-199910050-00003	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507957				2022-12-28	WOS:000083018800002
J	Bos, JD				Bos, JD			Reappraisal of dermatoses of pregnancy	LANCET			English	Editorial Material							ATOPIC-DERMATITIS; CRITERIA; SKIN		Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bos, JD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands.							Aractingi S, 1998, LANCET, V352, P1898, DOI 10.1016/S0140-6736(98)05121-6; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; HOLMES RC, 1983, J AM ACAD DERMATOL, V8, P405, DOI 10.1016/S0190-9622(83)70046-0; Jones SAV, 1999, BRIT J DERMATOL, V141, P71; PROVOST TT, 1973, J CLIN INVEST, V52, P1779, DOI 10.1172/JCI107359; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WINSTON G, 1982, J AM ACAD DERMATOL, V6, P977	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1140	1140		10.1016/S0140-6736(99)00244-5	http://dx.doi.org/10.1016/S0140-6736(99)00244-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513703				2022-12-28	WOS:000082954100005
J	Wood, PL; Bevan, T				Wood, PL; Bevan, T			Lesson of the week - Child sexual abuse enquiries and unrecognised vulval lichen sclerosus et atrophicus	BRITISH MEDICAL JOURNAL			English	Review							ET-ATROPHICUS		Kettering Gen Hosp NHS Trust, Paediat & Adolescent Gynaecol Clin, Kettering NN16 8UZ, England		Wood, PL (corresponding author), Kettering Gen Hosp NHS Trust, Paediat & Adolescent Gynaecol Clin, Kettering NN16 8UZ, England.							BAYS J, 1990, AM J DIS CHILD, V144, P1319, DOI 10.1001/archpedi.1990.02150360043017; CLARK JA, 1967, ARCH DERMATOL, V95, P476, DOI 10.1001/archderm.95.5.476; DISILVERIO A, 1975, BRIT J DERMATOL, V93, P215; HANDFIELDJONES SE, 1987, BRIT MED J, V294, P1404, DOI 10.1136/bmj.294.6584.1404; HULL D, 1993, ESSENTIAL PAEDIAT; LEVENE MI, 1991, JOLLYS DIS CHILDREN; Warrington SA, 1996, ARCH DIS CHILD, V75, P512, DOI 10.1136/adc.75.6.512	7	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					899	900		10.1136/bmj.319.7214.899	http://dx.doi.org/10.1136/bmj.319.7214.899			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243AU	10506050	Green Published			2022-12-28	WOS:000082975600029
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine in conventional practice	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									Coates JR, 1998, J ALTERN COMPLEM MED, V4, P209, DOI 10.1089/acm.1998.4.209; Fulder S., 1996, HDB ALTERNATIVE COMP, V3rd; SHARMA U, 1995, COMPLEMENTARY MED TO; STONE J, 1996, COMPLEMENTARY MED LA; 1993, COMPLEMENTARY MED NE	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					901	904		10.1136/bmj.319.7214.901	http://dx.doi.org/10.1136/bmj.319.7214.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506051	Green Published			2022-12-28	WOS:000082975600030
J	Showman, AP; Malhotra, R				Showman, AP; Malhotra, R			The Galilean satellites	SCIENCE			English	Review							DIFFERENTIATED INTERNAL STRUCTURE; INFRARED MAPPING SPECTROMETER; GANYMEDE GROOVED TERRAIN; HUBBLE-SPACE-TELESCOPE; CONAMARA CHAOS REGION; ICY SATELLITES; MAGNETIC-FIELD; HIGH-RESOLUTION; NONSYNCHRONOUS ROTATION; JOVIAN MAGNETOSPHERE	NASA's Galileo mission to Jupiter and improved Earth-based observing capabilities have allowed major advances in our understanding of Jupiter's moons lo, Europa, Ganymede, and Callisto over the past few years, Particularly exciting findings include the evidence for internal Liquid water oceans in Callisto and Europa, detection of a strong intrinsic magnetic field within Ganymede, discovery of high-temperature silicate volcanism on lo, discovery of tenuous oxygen atmospheres at Europa and Ganymede and a tenuous carbon dioxide atmosphere at Callisto, and detection of condensed oxygen on Ganymede, Modeling of Landforms seen at resolutions up to 100 times as high as those of Voyager supports the suggestion that tidal heating has played an important role for lo and Europa.	Univ Louisville, Dept Mech Engn, Louisville, KY 40292 USA; Lunar & Planetary Inst, Houston, TX 77058 USA	University of Louisville	Showman, AP (corresponding author), Univ Louisville, Dept Mech Engn, 215 Sackett Hall, Louisville, KY 40292 USA.	showman@flolab.spd.louisville.edu; renu@lpi.jsc.nasa.gov		Malhotra, Renu/0000-0002-1226-3305				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Anderson JD, 1998, SCIENCE, V280, P1573, DOI 10.1126/science.280.5369.1573; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; Baragiola RA, 1998, J GEOPHYS RES-PLANET, V103, P25865, DOI 10.1029/98JE01634; Baragiola RA, 1999, J GEOPHYS RES-PLANET, V104, P14183, DOI 10.1029/1999JE001023; Barth CA, 1997, GEOPHYS RES LETT, V24, P2147, DOI 10.1029/97GL01927; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Blaney DL, 1997, GEOPHYS RES LETT, V24, P2459, DOI 10.1029/97GL02509; Brown ME, 1996, NATURE, V380, P229, DOI 10.1038/380229a0; BURATTI B, 1988, ICARUS, V75, P437, DOI 10.1016/0019-1035(88)90156-X; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; CALVIN WM, 1993, ICARUS, V104, P69, DOI 10.1006/icar.1993.1083; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Calvin WM, 1997, ICARUS, V130, P505, DOI 10.1006/icar.1997.5842; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; Carlson RW, 1999, SCIENCE, V283, P820, DOI 10.1126/science.283.5403.820; Carlson RW, 1999, SCIENCE, V286, P97, DOI 10.1126/science.286.5437.97; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; CARR MH, 1986, J GEOPHYS RES-SOLID, V91, P3521, DOI 10.1029/JB091iB03p03521; Carr MH, 1998, ICARUS, V135, P146, DOI 10.1006/icar.1998.5979; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CASSEN PM, 1982, SATELLITES JUPITER, P93; Clark BE, 1998, ICARUS, V135, P95, DOI 10.1006/icar.1998.5968; Collins GC, 1998, ICARUS, V135, P345, DOI 10.1006/icar.1998.5978; Collins GC, 1998, GEOPHYS RES LETT, V25, P233, DOI 10.1029/97GL03772; Crary FJ, 1998, J GEOPHYS RES-PLANET, V103, P25757, DOI 10.1029/98JE02497; Crary FJ, 1998, J GEOPHYS RES-SPACE, V103, P29359, DOI 10.1029/1998JA900003; CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; Davies ME, 1998, ICARUS, V135, P372, DOI 10.1006/icar.1998.5982; Delitsky ML, 1998, J GEOPHYS RES-PLANET, V103, P31391, DOI 10.1029/1998JE900020; DOMBARD AJ, UNPUB; Domingue DL, 1998, GEOPHYS RES LETT, V25, P4421, DOI 10.1029/1998GL900209; Domingue DL, 1998, GEOPHYS RES LETT, V25, P3117, DOI 10.1029/98GL02386; FAGENTS SA, UNPUB; Frank LA, 1997, GEOPHYS RES LETT, V24, P2151, DOI 10.1029/97GL01744; Frank LA, 1997, GEOPHYS RES LETT, V24, P2159, DOI 10.1029/97GL01632; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; FRIEDSON AJ, 1983, ICARUS, V56, P1, DOI 10.1016/0019-1035(83)90124-0; Geissler PE, 1998, ICARUS, V135, P107, DOI 10.1006/icar.1998.5980; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; Geissler PE, 1999, SCIENCE, V285, P870, DOI 10.1126/science.285.5429.870; GOLDREICH P, 1966, ICARUS, V5, P375, DOI 10.1016/0019-1035(66)90051-0; GOLOMBEK MP, 1982, J GEOPHYS RES, V87, pA77, DOI 10.1029/JB087iS01p00A77; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; Greenberg R, 1998, ICARUS, V135, P64, DOI 10.1006/icar.1998.5986; GREENBERG R, IN PRESS ICARUS; Greenberg R., 1982, SATELLITES JUPITER, P65; Gurnett DA, 1996, NATURE, V384, P535, DOI 10.1038/384535a0; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Hall DT, 1998, ASTROPHYS J, V499, P475, DOI 10.1086/305604; HEAD J, 1998, LUNAR PLANET SCI C, V29; HEAD JW, 1999, LUNAR PLANET SCI C, V30; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; Hendrix AR, 1999, J GEOPHYS RES-PLANET, V104, P14169, DOI 10.1029/1999JE900001; HERRICK DL, 1990, ICARUS, V85, P191, DOI 10.1016/0019-1035(90)90110-U; HOGENBOOM DL, 1995, ICARUS, V115, P258, DOI 10.1006/icar.1995.1096; HOGENBORN DL, 1999, LUNAR PLANET SCI C, V30; Hoppa G, 1999, ICARUS, V137, P341, DOI 10.1006/icar.1998.6065; IOANNOU PJ, 1993, ASTROPHYS J, V406, P266, DOI 10.1086/172438; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Johnson RE, 1999, J GEOPHYS RES-PLANET, V104, P14179, DOI 10.1029/1998JE900036; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; KARGEL JS, 1992, ICARUS, V100, P556, DOI 10.1016/0019-1035(92)90118-Q; Kerswell RR, 1998, GEOPHYS RES LETT, V25, P603, DOI 10.1029/98GL00237; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; KIRK RL, 1987, ICARUS, V69, P91, DOI 10.1016/0019-1035(87)90009-1; Kivelson MG, 1998, J GEOPHYS RES-PLANET, V103, P19963, DOI 10.1029/98JE00227; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1999, J GEOPHYS RES-SPACE, V104, P4609, DOI 10.1029/1998JA900095; Kivelson MG, 1997, GEOPHYS RES LETT, V24, P2155, DOI 10.1029/97GL02201; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; Kliore AJ, 1997, SCIENCE, V277, P355, DOI 10.1126/science.277.5324.355; KUANG Z, 1996, EOS S, V77, pF437; KUPPERS M, UNPUB; Kurth WS, 1997, GEOPHYS RES LETT, V24, P2167, DOI 10.1029/97GL02249; Lane AL, 1997, GEOPHYS RES LETT, V24, P1143, DOI 10.1029/97GL00884; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; Linker JA, 1998, J GEOPHYS RES-PLANET, V103, P19867, DOI 10.1029/98JE00632; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; LUNINE JI, 1982, ICARUS, V52, P14, DOI 10.1016/0019-1035(82)90166-X; MALIN MC, 1986, SATELLITES, P689; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MCEWEN AS, 1988, ICARUS, V73, P385, DOI 10.1016/0019-1035(88)90053-X; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; McKinnon WB, 1997, ICARUS, V130, P540, DOI 10.1006/icar.1997.5826; McKinnon WB, 1999, GEOPHYS RES LETT, V26, P951, DOI 10.1029/1999GL900125; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; Moore JM, 1996, ICARUS, V122, P63, DOI 10.1006/icar.1996.0109; MOORE JM, IN PRESS ICARUS; MOSES JI, 1991, ICARUS, V89, P277, DOI 10.1016/0019-1035(91)90179-W; MULLER WF, 1995, PLANET SPACE SCI, V43, P469, DOI 10.1016/0032-0633(94)00181-P; NASH DB, 1986, SATELLITES, P629; Neubauer FM, 1998, J GEOPHYS RES-PLANET, V103, P19843, DOI 10.1029/97JE03370; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OCKERT ME, 1987, ICARUS, V70, P499, DOI 10.1016/0019-1035(87)90091-1; OJAKANGAS GW, 1986, ICARUS, V66, P341, DOI 10.1016/0019-1035(86)90163-6; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; PAPPALARDO R, 1999, LUNAR PLANET SCI C, V30; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, ICARUS, V135, P276, DOI 10.1006/icar.1998.5966; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PAPPALARDO RT, IN PRESS J GEOPHYS R; Paranicas C, 1998, J GEOPHYS RES-SPACE, V103, P15001, DOI 10.1029/98JA00961; PARMENTIER EM, 1982, NATURE, V295, P290, DOI 10.1038/295290a0; PATEL J, IN PRESS J GEOPHYS R; PEALE SJ, 1999, ANNU REV ASTRON ASTR, V37, P37; Pearl J.S., 1982, SATELLITES JUPITER, P724; PHILLIPS CB, UNPUB; Prockter LM, 1998, ICARUS, V135, P317, DOI 10.1006/icar.1998.5981; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; Roesler FL, 1999, SCIENCE, V283, P353, DOI 10.1126/science.283.5400.353; Sarson GR, 1999, PHYS EARTH PLANET IN, V111, P47, DOI 10.1016/S0031-9201(98)00145-9; Sarson GR, 1997, SCIENCE, V276, P1106, DOI 10.1126/science.276.5315.1106; Saur J, 1998, J GEOPHYS RES-PLANET, V103, P19947, DOI 10.1029/97JE03556; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SCHENK PM, 1993, J GEOPHYS RES-PLANET, V98, P7475, DOI 10.1029/93JE00176; SCHENK PM, 1995, J GEOPHYS RES-PLANET, V100, P19023, DOI 10.1029/95JE01855; Schenk PM, 1998, SCIENCE, V279, P1514, DOI 10.1126/science.279.5356.1514; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; Schubert G., 1986, SATELLITES, P224; Showman AP, 1997, ICARUS, V127, P93, DOI 10.1006/icar.1996.5669; Showman AP, 1997, ICARUS, V129, P367, DOI 10.1006/icar.1997.5778; Sieger MT, 1998, NATURE, V394, P554, DOI 10.1038/29015; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; Spaun NA, 1998, GEOPHYS RES LETT, V25, P4277, DOI 10.1029/1998GL900176; Spencer JR, 1997, ICARUS, V127, P221, DOI 10.1006/icar.1996.5670; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; SPENCER JR, 1987, ICARUS, V70, P99, DOI 10.1016/0019-1035(87)90077-7; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2451, DOI 10.1029/97GL02591; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STEUDEL R, 1986, J GEOPHYS RES-SOLID, V91, P4971, DOI 10.1029/JB091iB05p04971; Stevenson D.J., 1996, EUR OC C SAN JUAN CA, P69; Stevenson DJ, 1986, SATELLITES, P687; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; SULLIVAN R, 1997, GEOL SOC AM ABSTR, V29, pA312; Thomas PC, 1998, ICARUS, V135, P175, DOI 10.1006/icar.1998.5987; TITTEMORE WC, 1990, SCIENCE, V250, P263, DOI 10.1126/science.250.4978.263; TURTLE EP, 1998, LUNAR PLANET SCI C, V29; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637; Vidal RA, 1997, SCIENCE, V276, P1839, DOI 10.1126/science.276.5320.1839; Williams DJ, 1997, GEOPHYS RES LETT, V24, P2163, DOI 10.1029/97GL01931; Williams DJ, 1998, J GEOPHYS RES-SPACE, V103, P17523, DOI 10.1029/98JA01370; Williams KK, 1998, GEOPHYS RES LETT, V25, P4273, DOI 10.1029/1998GL900144; Woronow A., 1982, SATELLITES JUPITER; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015; [No title captured]; 1992, SCI REV, V60	163	111	118	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					77	84		10.1126/science.286.5437.77	http://dx.doi.org/10.1126/science.286.5437.77			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506564				2022-12-28	WOS:000082907400037
J	Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM				Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM			Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors	CELL			English	Article							GROWTH CONE COLLAPSE; PERIPHERAL-NERVE PROJECTION; NEUROPILIN; FAMILY; PROTEIN; TRANSMEMBRANE; MOLECULES; GUIDANCE; SIGNALS; SYSTEM	Class 1 and 3 semaphorins repulse axons but bind to different cell surface proteins. We find that the two known semaphorin-binding proteins, plexin 1 (Plex 1) and neuropilin-1 (NP-1), form a stable complex. Plex 1 alone does not bind semaphorin-3A (Sema3A), but the NP-1/Plex 1 complex has a higher affinity for Sema3A than does NP-1 alone. While Sema3A binding to NP-1 does not alter nonneuronal cell morphology, Sema3A interaction with NP-1/Plex 1 complexes induces adherent cells to round up. Expression of a dominant-negative Plex 1 in sensory neurons blocks Sema3A-induced growth cone collapse. Sema3A treatment leads to the redistribution of growth cone NP-1 and plexin into clusters. Thus, physiologic Sema3A receptors consist of NP-1/plexin complexes.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Nagoya Univ, Grad Sch Sci, Grp Dev Neurobiol, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Yale University; Yale University; Yale University; Yale University; Nagoya University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Jin Z, 1997, J NEUROSCI, V17, P6256; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Takahashi T, 1997, J NEUROSCI, V17, P9183; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	31	666	694	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					59	69		10.1016/S0092-8674(00)80062-8	http://dx.doi.org/10.1016/S0092-8674(00)80062-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520994	hybrid			2022-12-28	WOS:000082981600008
J	Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM				Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM			Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; CELL-SURFACE MOLECULE; MET RECEPTOR; SIGNAL TRANSDUCTION; IDENTIFICATION; NEUROPILIN; NEURONS; GUIDANCE; COLLAPSE; PROTEINS	In Drosophila, plexin A is a functional receptor for semaphorin-1a. Here we show that the human plexin gene family comprises at least nine members in four subfamilies. Plexin-B1 is a receptor for the transmembrane semaphorin Sema4D (CD100), and plexin-C1 is a receptor for the GPI-anchored semaphorin Sema7A (Sema-K1). Secreted (class 3) semaphorins do not bind directly to plexins, but rather plexins associate with neuropilins, coreceptors for these semaphorins. Plexins are widely expressed: in neurons, the expression of a truncated plexin-A1 protein blocks axon repulsion by Sema3A. The cytoplasmic domain of plexins associates with a tyrosine kinase activity. Plexins may also act as ligands mediating repulsion in epithelial cells in vitro. We conclude that plexins are receptors for multiple (and perhaps all) classes of semaphorins, either alone or in combination with neuropilins, and trigger a novel signal transduction pathway controlling cell repulsion.	Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Hop La Pitie Salpetriere, INSERM U106, F-75013 Paris, France	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Tamagnone, L (corresponding author), Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy.		Chedotal, Alain/F-2750-2017; Tamagnone, Luca/J-8948-2018; Ming, Guo-li/J-7880-2013	Chedotal, Alain/0000-0001-7577-3794; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; Ming, Guo-li/0000-0002-2517-6075	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Christensen CRL, 1998, CANCER RES, V58, P1238; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P524, DOI 10.1006/bbrc.1996.1388; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SHINOURA N, 1995, CANCER LETT, V89, P215, DOI 10.1016/0304-3835(95)03690-X; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	40	898	965	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					71	80		10.1016/S0092-8674(00)80063-X	http://dx.doi.org/10.1016/S0092-8674(00)80063-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520995	Bronze			2022-12-28	WOS:000082981600009
J	Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA				Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA			Protein structure - An enzymatic globin from a marine worm	NATURE			English	Article							PEROXIDASE		Univ S Carolina, Dept Chem, Columbia, SC 29208 USA; Univ S Carolina, Dept Biochem & Biol Sci, Columbia, SC 29208 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Pfizer	Lebioda, L (corresponding author), Univ S Carolina, Dept Chem, Columbia, SC 29208 USA.	lebioda@psc.sc.edu	Woodin, Sarah A/K-8481-2014	Woodin, Sarah A/0000-0001-5615-2212				ATOR MA, 1987, J BIOL CHEM, V262, P1542; Chen YP, 1996, J BIOL CHEM, V271, P4609; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; WOODIN SA, 1993, J CHEM ECOL, V19, P517, DOI 10.1007/BF00994322	6	75	75	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					445	445		10.1038/46728	http://dx.doi.org/10.1038/46728			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519547				2022-12-28	WOS:000082981200044
J	Saugstad, OD				Saugstad, OD			Inhaled nitric oxide for preterm infants - still an experimental therapy	LANCET			English	Editorial Material							PERSISTENT PULMONARY-HYPERTENSION; NEWBORN; PIGLETS		Natl Hosp Norway, Dept Paediat Res, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Saugstad, OD (corresponding author), Natl Hosp Norway, Dept Paediat Res, N-0027 Oslo, Norway.		Saugstad, Ola/AAS-9041-2021	Saugstad, Ola/0000-0002-3166-5254				Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Cheung PY, 1998, J PEDIATR-US, V133, P735, DOI 10.1016/S0022-3476(98)70142-8; FINER NN, 1999, COCHRANE LIB; George TN, 1998, J PEDIATR-US, V132, P731, DOI 10.1016/S0022-3476(98)70370-1; Hallman M, 1996, J APPL PHYSIOL, V80, P2026, DOI 10.1152/jappl.1996.80.6.2026; Issa A, 1999, PEDIATR RES, V45, P247, DOI 10.1203/00006450-199902000-00016; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; Meadow W, 1998, PEDIATR RES, V44, P181, DOI 10.1203/00006450-199808000-00007; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; Subhedar NV, 1997, ARCH DIS CHILD-FETAL, V77, pF185, DOI 10.1136/fn.77.3.F185; Yu XQ, 1997, PEDIATR RES, V42, P151, DOI 10.1203/00006450-199708000-00004	11	12	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1047	1048		10.1016/S0140-6736(99)00249-4	http://dx.doi.org/10.1016/S0140-6736(99)00249-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509489				2022-12-28	WOS:000082777500003
J	Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A				Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A			Behavioral and neuroendocrine characteristics of the night-eating syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBESITY SURGERY PATIENTS; GENERAL-POPULATION; MELATONIN LEVELS; NOCTURNAL RISE; BINGE; DISORDERS; LEPTIN; SLEEP; PROTEIN; DEPRESSION	Context Investigators first described the night-eating syndrome (NES), which consists of morning anorexia, evening hyperphagia, and insomnia, in 1955, but, to our knowledge, this syndrome has never been subjected to careful clinical study. Objective To characterize NES on the basis of behavioral characteristics and neuroendocrine data. Design and Setting A behavioral observational study was conducted between January 1996 and June 1997 in a weight and eating disorders program at the University of Pennsylvania. A neuroendocrine study was conducted from May through August 1997 at the Clinical Research Center of the University Hospital, Tromso, Norway, Subjects The behavioral study included 10 obese subjects who met criteria for NES and 10 matched control subjects. The neuroendocrine study included 12 night eaters and 21 control subjects. Behavioral study subjects were observed for 1 week on an outpatient basis, and neuroendocrine study subjects were observed during a 24-hour period in the hospital. Main Outcome Measures The behavioral study measured timing of energy intake, mood level, and sleep disturbances. The neuroendocrine study measured circadian levels of plasma melatonin, leptin, and cortisol, Results In the behavioral study, compared with control subjects, night eaters had more eating episodes in the 24 hours (mean [SD], 9.3 [0.6] vs 4.2 [0.2]; P<.001) and consumed significantly more of their daily energy intake at night than did control subjects (56% vs 15%; P<.001), They averaged 3.6 (0.9) awakenings per night compared with 0.3 (0.3) by controls (P<.001). In night eaters, 52% of these awakenings were associated with food intake, with a mean intake per ingestion of 1134 (1197) kJ, None of the controls ate during their awakenings. In the neuroendocrine study, compared with control subjects, night eaters had attenuation of the nocturnal rise in plasma melatonin and leptin levels (P<.001 for both) and higher circadian levels of plasma cortisol (P = .001). Conclusion A coherent pattern of behavioral and neuroendocrine characteristics was found in subjects with NES.	Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Tromso, Inst Clin Med, Lab Gastroenterol, Tromso, Norway; Univ Tromso, Inst Med Biochem, Tromso, Norway; Univ Tromso Hosp, Dept Clin Chem, N-9012 Tromso, Norway	University of Pennsylvania; University of Pennsylvania; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway	Birketvedt, GS (corresponding author), Univ Penn, Sch Med, Dept Psychiat, 3600 Market St,Suite 736, Philadelphia, PA 19104 USA.	gsb42nor@aol.com	Bilker, Warren/AAS-3515-2021; Dinges, David/P-7183-2019					American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; BERRY EM, 1991, NEUROLOGY, V41, P1295, DOI 10.1212/WNL.41.8.1295; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Fairburn CG, 1993, BINGE EATING NATURE; GREENO CG, 1995, INT J EAT DISORDER, V18, P343, DOI 10.1002/1098-108X(199512)18:4&lt;343::AID-EAT2260180407&gt;3.0.CO;2-P; GRILO CM, 1994, J CONSULT CLIN PSYCH, V62, P611, DOI 10.1037/0022-006X.62.3.611; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Hajak G, 1995, J PINEAL RES, V19, P116, DOI 10.1111/j.1600-079X.1995.tb00179.x; HANSEN T, 1987, ACTA PSYCHIAT SCAND, V75, P428, DOI 10.1111/j.1600-0447.1987.tb02811.x; Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859; HEINRICHS SC, 1995, STRESS BASIC MECHANI, P93; Kellner M, 1997, NEUROENDOCRINOLOGY, V65, P284, DOI 10.1159/000127186; KENNEDY SH, 1989, ARCH GEN PSYCHIAT, V46, P73; Manni R, 1997, SLEEP, V20, P734, DOI 10.1093/sleep/20.9.734; Matkovic V, 1997, J CLIN ENDOCR METAB, V82, P1368, DOI 10.1210/jc.82.5.1368; RAND CSW, 1993, INT J OBESITY, V17, P657; Rand CSW, 1997, INT J EAT DISORDER, V22, P65, DOI 10.1002/(SICI)1098-108X(199707)22:1&lt;65::AID-EAT8&gt;3.0.CO;2-0; ROSEN JC, 1986, INT J EAT DISORDER, V5, P255, DOI 10.1002/1098-108X(198602)5:2<255::AID-EAT2260050206>3.0.CO;2-D; ROSSITER EM, 1990, INT J EAT DISORDER, V9, P513, DOI 10.1002/1098-108X(199009)9:5&lt;513::AID-EAT2260090506&gt;3.0.CO;2-T; SADEH A, 1989, J AMBULATORY MONITOR, V25, P305; SCHENCK CH, 1993, SLEEP, V16, P457; SCHENCK CH, 1994, INT J EAT DISORDER, V15, P343, DOI 10.1002/eat.2260150405; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; SPAGGIARI MC, 1994, SLEEP, V17, P339, DOI 10.1093/sleep/17.4.339; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; Stunkard A, 1996, INT J OBESITY, V20, P1; STUNKARD AJ, 1955, AM J MED, V19, P78, DOI 10.1016/0002-9343(55)90276-X; STUNKARD AJ, 1959, PSYCHIAT QUART, V33, P284, DOI 10.1007/BF01575455; Turnbull AV, 1997, P SOC EXP BIOL MED, V215, P1; VONEN B, 1992, SCAND J CLIN LAB INV, V52, P107, DOI 10.3109/00365519209088773; WINKELMAN JW, 1993, SLEEP RES, V22, P291; WISBERG J, 1990, J SLEEP RES, V19, P384; YOKOGOSHI H, 1986, METABOLISM, V35, P837, DOI 10.1016/0026-0495(86)90225-8; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhdanova IV, 1996, SLEEP, V19, P423, DOI 10.1093/sleep/19.5.423	37	270	278	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					657	663		10.1001/jama.282.7.657	http://dx.doi.org/10.1001/jama.282.7.657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517719	Bronze			2022-12-28	WOS:000082033700025
J	Llinas, R; Henderson, GV				Llinas, R; Henderson, GV			Tremor as a cause of pseudo-ventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Llinas, R (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.			Llinas, Rafael/0000-0002-9161-2699					0	23	24	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1275	1275		10.1056/NEJM199910213411705	http://dx.doi.org/10.1056/NEJM199910213411705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528038				2022-12-28	WOS:000083226300005
J	Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J				Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J			Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women	ANNALS OF INTERNAL MEDICINE			English	Article						cardiovascular diseases; Chlamydia pneumoniae; Helicobacter pylori; simplexvirus; cytomegalovirus; antibodies, anti-adiotypic	CORONARY HEART-DISEASE; INFECTION; ATHEROSCLEROSIS; SEROPOSITIVITY; MORTALITY; EVENTS	Background: Results of cross-sectional and retrospective studies have suggested that chronic infection may be a risk factor for cardiovascular disease. However, prospective data evaluating the relation between baseline antibody titers against various plausible agents and risk for cardiovascular disease are sparse, particularly among women. Objective: To determine whether previous exposure to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, or cytomegalovirus is associated with increased risk for cardiovascular events. Design: Prospective, nested, case-control study. Setting: Women's Health Study. Participants: Apparently healthy postmenopausal women. Measurements: IgG antibody titers against C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus were measured in baseline blood samples obtained from 122 study participants who subsequently reported a first cardiovascular event (case-patients) and 244 participants matched for age and smoking status who did not report a cardiovascular event (controls) during 3 years of follow-up. Results: Little evidence was found of an association between risk for cardiovascular events and baseline IgG sero-positivity for antibodies against C. pneumoniae (rate ratio, 1.1 [95% CI, 0.7 to 1.8]), H. pylori (rate ratio, 0.90 ICI, 0.6 to 1.4]), herpes simplex virus (rate ratio, 1.2 [CI, 0.6 to 2.1]), and cytomegalovirus (rate ratio, 0.9 [CI, 0.6 to 1.5]). In addition, there was little evidence of an association between a participant's total number of infections and subsequent cardiovascular risk (P > 0.2). Conclusion: In apparently healthy postmenopausal women, little evidence was found that previous infection, as measured by IgG antibody titers to C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus, is associated with subsequent risk for cardiovascular disease.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Abbott Laboratories	Ridker, PM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	bhudson@mail.acponline.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; Libby P, 1997, CIRCULATION, V96, P4095; Miettinen H, 1996, EUR HEART J, V17, P682; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, CIRCULATION, V98, P2796, DOI 10.1161/01.CIR.98.25.2796; Ridker PM, 1999, CIRCULATION, V99, P1161, DOI 10.1161/01.CIR.99.9.1161; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P346; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; Strachan DP, 1999, BMJ-BRIT MED J, V318, P1035, DOI 10.1136/bmj.318.7190.1035; Strachan DP, 1998, CIRCULATION, V98, P1286, DOI 10.1161/01.CIR.98.13.1286; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Wald NJ, 1997, BMJ-BRIT MED J, V315, P1199, DOI 10.1136/bmj.315.7117.1199; WANG SP, 1984, 1983 INT S MED VIR, P87; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568; ZHU J, 1998, CIRCULATION, V98, P1	20	102	103	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					573	+		10.7326/0003-4819-131-8-199910190-00004	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523217				2022-12-28	WOS:000083196600003
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Herbal medicine	BRITISH MEDICAL JOURNAL			English	Article									Res Council Complementary Med, London, England									Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MELCHART D, 1999, COCHRANE COLLABORATI; Mills S., 1993, ESSENTIAL BOOK HERBA; Newall CA., 1996, HERBAL MED GUIDE HLT; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	6	107	112	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1050	1053		10.1136/bmj.319.7216.1050	http://dx.doi.org/10.1136/bmj.319.7216.1050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521203	Green Published			2022-12-28	WOS:000083210100032
J	Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS				Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS			Unintended pregnancy among adult women exposed to abuse or household dysfunction during their childhood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SEXUAL ABUSE; ADOLESCENT PREGNANCY; PREVALENCE; ABORTION; RISK	Context Studies have identified childhood sexual and physical abuse as a risk factor for adolescent pregnancy but the relationship between exposure to childhood abuse and unintended pregnancy in adulthood has, to our knowledge, not been studied. Objective To assess whether unintended pregnancy during adulthood is associated with exposure to psychological, physical, or sexual abuse or household dysfunction during childhood. Design and Setting Analysis of data from the Adverse Childhood Experiences Study, a survey mailed to members of a large health maintenance organization who visited a clinic in San Diego, Calif, between August and November 1995 and January and March 1996, The survey had a 63.4% response rate among the target population for this study. Participants A total of 1193 women aged 20 to 50 years whose first pregnancy occurred at or after age 20 years. Main Outcome Measure Risk of unintended first pregnancy by type of abuse (psychological, physical, or sexual abuse; peer sexual assault) and type of household dysfunction (physical abuse of mother by her partner, substance abuse by a household member, mental illness of a household member). Results More than 45% of the women reported that their first pregnancy was unintended, and 65.8% reported exposure to 2 or more types of childhood abuse or household dysfunction. After adjustment for confounders (marital status at first pregnancy and age at first pregnancy), the strongest associations between childhood experiences and unintended first pregnancy included frequent psychological abuse (risk ratio [RR], 1.4; 95% confidence interval [CI], 1.2-1.6), frequent physical abuse of the mother by her partner (RR, 1.4, 95% CI, 1.1-1.7), and frequent physical abuse (RR, 1.5; 95% CI, 1.2-1.8). Women who experienced 4 or more types of abuse during their childhood were 1.5 times (95% CI, 1.2-1.8) more likely to have an unintended first pregnancy during adulthood than women who did not experience any abuse. Conclusions This study indicates that there may be a dose-response association between exposure to childhood abuse or household dysfunction and unintended first pregnancy in adulthood. Additional research is needed to fully understand the causal pathway of this association.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA 92120 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Spitz, AM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS K-35,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	AMS2@cdc.gov	Santelli, John/AAG-3046-2021		ATSDR CDC HHS [TS-44-10/12] Funding Source: Medline	ATSDR CDC HHS		BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; Evins G, 1996, WOMEN HEALTH ISS, V6, P204, DOI 10.1016/1049-3867(95)00012-7; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Glander SS, 1998, OBSTET GYNECOL, V91, P1002, DOI 10.1016/S0029-7844(98)00089-1; Glei DA, 1999, FAM PLANN PERSPECT, V31, P73, DOI 10.2307/2991642; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KOST K, 1995, FAM PLANN PERSPECT, V27, P11, DOI 10.2307/2135971; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARSIGLIO W, 1988, J MARRIAGE FAM, V50, P1023, DOI 10.2307/352112; NAGY S, 1995, PEDIATRICS, V96, P944; *NAT CTR HLTH STAT, 1991, EXP ALC FAM US 1988, P205; PARKER B, 1994, OBSTET GYNECOL, V84, P323; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P53; STEVENSSIMON C, 1994, CHILD ABUSE NEGLECT, V18, P569, DOI 10.1016/0145-2134(94)90083-3; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; WYATT GE, 1985, CHILD ABUSE NEGLECT, V9, P507, DOI 10.1016/0145-2134(85)90060-2; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	19	199	201	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1359	1364		10.1001/jama.282.14.1359	http://dx.doi.org/10.1001/jama.282.14.1359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243MB	10527183	Bronze			2022-12-28	WOS:000083000800031
J	Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK				Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK			X-ray crystallographic structure of the Norwalk virus capsid	SCIENCE			English	Article							TURNIP CRINKLE VIRUS; 3-DIMENSIONAL STRUCTURE; RESOLUTION; CALICIVIRUS; ORGANIZATION; PROTEINS; SEQUENCE; TU	Norwalk virus, a noncultivatable human calicivirus, is the major cause of epidemic gastroenteritis in humans. The first x-ray structure of a calicivirus capsid, which consists of 180 copies of a single protein, has been determined by phase extension from a Low-resolution electron microscopy structure. The capsid protein has a protruding (P) domain connected by a flexible hinge to a shell (S) domain that has a classical eight-stranded P-sandwich motif. The structure of the P domain is unlike that of any other viral protein with a subdomain exhibiting a fold similar to that of the second domain in the eukaryotic translation elongation factor-Tu. This subdomain, Located at the exterior of the capsid, has the Largest sequence variation among Norwalk-Like human calici-viruses and is Likely to contain the determinants of strain specificity and cell binding.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Purdue Univ, Dept Life Sci, W Lafayette, IN 47907 USA	Baylor College of Medicine; Baylor College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Prasad, BVV (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	vprasad@bcm.tmc.edu	Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Prasad, B.V.Venkataram/0000-0002-1172-2071				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; Estes Mary K., 1995, P1009; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GLASS P, UNPUB; GREENBERG HB, 1981, J VIROL, V37, P994, DOI 10.1128/JVI.37.3.994-999.1981; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HARRISON SC, 1996, VIROLOGY, V1, P59; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; JIANG X, 1990, Science (Washington D C), V250, P1580; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V1, P783; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PRASAD BVV, 1994, J VIROL, V68, P5117, DOI 10.1128/JVI.68.8.5117-5125.1994; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMMANN M G, 1983, Journal of Molecular Biology, V166, P37, DOI 10.1016/S0022-2836(83)80049-7; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; Thouvenin E, 1997, J MOL BIOL, V270, P238, DOI 10.1006/jmbi.1997.1095; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WHITE L, 1997, THESIS BAYLOR COLLEG; White LJ, 1996, J VIROL, V70, P6589, DOI 10.1128/JVI.70.10.6589-6597.1996; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	40	666	716	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					287	290		10.1126/science.286.5438.287	http://dx.doi.org/10.1126/science.286.5438.287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514371				2022-12-28	WOS:000083024400043
J	Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS				Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS			Phytochrome signalling is mediated through nucleoside diphosphate kinase 2	NATURE			English	Article							LIGHT CONTROL; TRANSDUCTION; ARABIDOPSIS; GENE; PURIFICATION; MUTANTS; PROTEIN	Because plants are sessile, they have developed intricate strategies to adapt to changing environmental variables, including light, Their growth and development, from germination to flowering, is critically influenced by Light, particularly at red (660 nm) and far-red (730 mn) wavelengths(1,2). Higher plants perceive red and far-red Light by means of specific light sensors called phytochromes(A-E)(3), However, very little is known about how light signals are transduced to elicit responses in plants. Here we report that nucleoside diphosphate kinase 2 (NDPK2) is an upstream component in the phytochrome signalling pathway in the plant Arabidopsis thaliana. In animal and human cells, NDPK acts as a tumour suppressor(4). We show that recombinant NDPK2 in Arabidopsis preferentially binds to the red-light-activated form of phytochrome in vitro and that this interaction increases the activity of recombinant NDPK2. Furthermore, a mutant lacking NDPK2 showed a partial defect in responses to both red and far-red light, including cotyledon opening and greening. These results indicate that NDPK2 is a positive signalling component of the phytochrome-mediated light-signal-transduction pathway in Arabidopsis.	Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea; Kyung Hee Univ, Dept Genet Engn, Suwon 449701, South Korea; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Kwangju Inst & Technol, Dept Life Sci, Kwangju 500712, South Korea	Kyung Hee University; University of Nebraska System; University of Nebraska Lincoln; Gwangju Institute of Science & Technology (GIST)	Choi, G (corresponding author), Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea.		Choi, Giltsu/C-1601-2011	SOH, MOON-SOO/0000-0002-4430-516X				Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Barnes SA, 1996, PLANT J, V10, P1155, DOI 10.1046/j.1365-313X.1996.10061155.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; DEAROLF CR, 1988, DEV BIOL, V13, P203; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; LAPKO VN, 1995, PHOTOCHEM PHOTOBIOL, V62, P194, DOI 10.1111/j.1751-1097.1995.tb05258.x; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Soh MS, 1998, PLANT J, V16, P411, DOI 10.1046/j.1365-313x.1998.00307.x; SOMMER D, 1994, BBA-MOL CELL RES, V1222, P464, DOI 10.1016/0167-4889(94)90055-8; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zimmermann S, 1999, J BIOL CHEM, V274, P17017, DOI 10.1074/jbc.274.24.17017	29	242	261	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					610	613		10.1038/44176	http://dx.doi.org/10.1038/44176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524631				2022-12-28	WOS:000083054900056
J	Zhou, SB; Kinzler, KW; Vogelstein, B				Zhou, SB; Kinzler, KW; Vogelstein, B			Going mad with Smads	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUTANT MICE		Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Zhou, SB (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.							Datto MB, 1999, MOL CELL BIOL, V19, P2495; Grady WM, 1999, CANCER RES, V59, P320; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Riggins GJ, 1997, CANCER RES, V57, P2578; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; WEINSTEIN IB, 1996, FUNDAMENTALS CANC PR, P76; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	8	27	29	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1144	1146		10.1056/NEJM199910073411510	http://dx.doi.org/10.1056/NEJM199910073411510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511616				2022-12-28	WOS:000083087200010
J	Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H				Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H			Nutritional status and mortality of refugee and resident children in a non-camp setting during conflict: follow up study in Guinea-Bissau	BRITISH MEDICAL JOURNAL			English	Article							MEASLES	Objective To study the effects on children of humanitarian aid agencies restricting help to refugee families (internally displaced people). Design Follow up study of 3 months. Setting Prabis peninsular outside Bissau, the capital of Guinea-Bissau, which has functioned as a refugee area for internally displaced people in the ongoing war, and the study area of the Bandim health project in Bissau. Participants 422 children aged 9-23 months in 30 clusters. Main outcome measures Mid upper arm circumference and survival in relation to residence status. Results During the refugee situation all children deteriorated nutritionally, and mortality was high (3.0% in a 6 week period). Rice consumption was higher in families resident in Prabis than in refugees from Bissau but there was no difference in food expenditure. Nutritional status, measured by mid-upper arm circumference, was not associated with rice consumption levels in the family and the decline in circumference was significantly worse for resident than for refugee children, the mid-upper arm circumference of refugee children increased faster than that of resident children, For resident children, mortality was 4.5 times higher (95% confidence interval 1.1 to 30.0) than for refugee children. Mortality for both resident and refugee children was 7.2 times higher (1.3 to 133.9) during the refugee's stay in Prabis compared with the period after the departure of the refugees. Conclusion In a non-camp setting, residents may be more malnourished and have higher mortality than refugees. Major improvements in nutritional status and a reduction in mortality occurred in resident and refugee children as soon as refugees returned home despite the fact that there was no improvement in food availability.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Bandim Hlth Project, Bissau, Guinea Bissau	Aarhus University; Statens Serum Institut	Aaby, P (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.			Aaby, Peter/0000-0001-8331-1389				Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; AABY P, 1997, PROSPECTIVE COMMUNIT, P276; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; VANDAMME W, 1995, LANCET, V346, P360	6	40	41	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					878	881		10.1136/bmj.319.7214.878	http://dx.doi.org/10.1136/bmj.319.7214.878			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506040	Bronze, Green Published			2022-12-28	WOS:000082975600020
J	Nilsson, K; Lindquist, O; Pahlson, C				Nilsson, K; Lindquist, O; Pahlson, C			Association of Rickettsia helvetica with chronic perimyocarditis in sudden cardiac death	LANCET			English	Article							IXODES-RICINUS TICKS; SPOTTED-FEVER; DIAGNOSIS	Background Richettsia helvetica is the only non-imported rickettsia found in Scandinavia. It was first detected in Ixodes ricinus ticks, but has never been linked to human disease. We studied two young Swedish men who died of sudden cardiac failure during exercise, and who showed signs of perimyocarditis similar to those described in rickettsial disease. Methods Samples from the heart and other organs were analysed by PCR and DNA sequencing. May-Grunwald-Giemsa, Grocott, and acridine-orange stains were used for histopathological examinations. Staining of R helvetica grown on shell-vials in vero cells, and the early descriptions of R rickettsii by H T Ricketts and S B Wohlbach served as controls. Immunohistochemistry was done with Proteus OX-19 rabbit antisera as the primary antibody. The structure of rickettsia-like organisms was investigated by transmission electron microscopy. Serological analyses were carried out by indirect immunofluorescence with R helvetica as the antigen. Findings By use of a semi-nested PCR, with primers specific for the 16S rRNA and 17-kDa outer-membrane-protein genes, and sequence analysis of the amplified products, genetic material from R helvetica was detected in the pericardium and in a lymph node from the pulmonary hilum in case 1, and in a coronary artery and the heart muscle in case 2. A serological response in case 1 revealed an endpoint titre for R helvetica of 1/320 (1/256 with R rickettsii as the antigen). Examination of PCR-positive tissue showed chronic interstitial inflammation and the presence of rickettsia-like organisms predominantly located in the endothelium. These organisms reacted with Proteus OX-19 antisera, and their size and form were consistent with rickettsia, Electron microscopy confirmed that the appearance of the organisms was similar to that described for spotted-fever rickettsia. Interpretation R helvetica, transmitted by I ricinus ticks, may be an important pathogen in the aetiology of perimyocarditis, which can result in sudden unexpected cardiac death in young people.	Malardalens Univ, Dept Biol & Chem Engn, S-63105 Eskilstuna, Sweden; Univ Uppsala Hosp, Dept Med Sci, Infect Dis Sect, Uppsala, Sweden; Univ Uppsala, Dept Surg Sci, Unit Forens Med, Uppsala, Sweden; Falu Hosp, Dept Infect Dis, Falun, Sweden	Malardalen University; Uppsala University; Uppsala University Hospital; Uppsala University; Falun Hospital	Pahlson, C (corresponding author), Malardalens Univ, Dept Biol & Chem Engn, POB 325, S-63105 Eskilstuna, Sweden.							ALLEN AC, 1945, AM J PATHOL, V21, P603; BURGDORFER W, 1979, ACTA TROP, V36, P357; CASTILLO JLM, 1984, REV CLIN ESP, V173, P125; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DiNubile MJ, 1996, CLIN INFECT DIS, V23, P160, DOI 10.1093/clinids/23.1.160; GRAND A, 1975, ARCH MAL COEUR VAISS, V68, P1225; GRAND A, 1972, MAL COEUR VAISS, V65, P637; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; LEVINE HD, 1946, AM HEART J, V31, P314, DOI 10.1016/0002-8703(46)90313-4; MARCON G, 1988, Giornale Italiano di Cardiologia, V18, P72; MARSHALL BJ, 1984, LANCET, V1, P1311; Morichau-Beauchant G, 1967, J Fr Med Chir Thorac, V21, P157; Nilsson K, 1999, J CLIN MICROBIOL, V37, P400, DOI 10.1128/JCM.37.2.400-403.1999; Nilsson K, 1997, J CLIN MICROBIOL, V35, P243, DOI 10.1128/JCM.35.1.243-247.1997; Parola P, 1998, EUR J CLIN MICROBIOL, V17, P95; PETER O, 1981, ANN PARASIT HUM COMP, V56, P1; Pieron R, 1976, Poumon Coeur, V32, P161; PIERON R, 1976, SEM HOP PARIS, V52, P621; Pons B, 1965, Gaz Med Fr, V72, P3445; Raoult D, 1997, CLIN MICROBIOL REV, V10, P694, DOI 10.1128/CMR.10.4.694; RICKETTS HT, 1911, MICROORGANISM APPARE, P368; SALVI A, 1985, INT J CARDIOL, V7, P405, DOI 10.1016/0167-5273(85)90094-4; SMADEL JS, 1963, CECILLOEBS TXB MED, P140; TEYSSEIRE N, 1992, J CLIN MICROBIOL, V30, P455, DOI 10.1128/JCM.30.2.455-460.1992; WAREMBOURG H, 1968, LILLE MED, V13, P166; WOHLBACH BS, 1919, J MED RES, V41, P1; WOHLBACH SB, 1922, ETIOLOGY PATHOLOGY T	28	196	201	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1169	1173		10.1016/S0140-6736(99)04093-3	http://dx.doi.org/10.1016/S0140-6736(99)04093-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513711				2022-12-28	WOS:000082954100013
J	Rothwell, PM; Gutnikov, SA; McKinney, PA; Schober, E; Ionescu-Tirgoviste, C; Neu, A				Rothwell, PM; Gutnikov, SA; McKinney, PA; Schober, E; Ionescu-Tirgoviste, C; Neu, A		European Diabet Study Grp	Seasonality of birth in children with diabetes in Europe: multicentre cohort study	BRITISH MEDICAL JOURNAL			English	Article							IDDM		Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Leeds, Paediat Epidemiol Grp, Leeds LS2 9LN, W Yorkshire, England; Univ Vienna, Dept Paediat, A-1090 Vienna, Austria; Inst Diabet Nutr & Metab Dis, Bucharest 79811 2, Romania; Childrens Univ Hosp, D-72070 Tubingen, Germany	Radcliffe Infirmary; University of Oxford; University of Leeds; University of Vienna; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				HYOTY H, 1995, DIABETES, V44, P652, DOI 10.2337/diabetes.44.6.652; Jongbloet PH, 1998, DIABETES CARE, V21, P190, DOI 10.2337/diacare.21.1.190; LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; Rothwell PM, 1996, BRIT MED J, V312, P1456, DOI 10.1136/bmj.312.7044.1456; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18	5	43	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					887	888		10.1136/bmj.319.7214.887	http://dx.doi.org/10.1136/bmj.319.7214.887			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506043	Bronze, Green Published			2022-12-28	WOS:000082975600023
J	Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J				Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J			The structure of the ligand-binding domain of neurexin I beta: Regulation of LNS domain function by alternative splicing	CELL			English	Article							PROTEIN SECONDARY STRUCTURE; CELL-SURFACE PROTEINS; CRYSTAL-STRUCTURE; ALPHA-LATROTOXIN; A-CHAIN; AGRIN; RECEPTOR; LECTIN; DYSTROGLYCAN; LAMININ	Neurexins are expressed in hundreds of isoforms on the neuronal cell surface, where they may function as cell recognition molecules. Neurexins contain LNS domains, folding units found in many proteins like the G domain of laminin A, agrin, and slit. The crystal structure of neurexin I beta, a single LNS domain, reveals two seven-stranded beta sheets forming a jelly roll fold with unexpected structural similarity Po lectins. The LNS domains of neurexin and agrin undergo alternative splicing that modulates their affinity for protein ligands in a neuron-specific manner. These splice sites are localized within loops at one edge of the jelly roll, suggesting a distinct protein interaction surface in LNS domains that is regulated by alternative splicing.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	johann.deisenhofer@email.swmed.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530				Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 ESFEACBM; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missler M, 1998, J NEUROSCI, V18, P3630; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Petrenko AG, 1996, J NEUROSCI, V16, P4360; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 1998, J PHYSIOLOGY-PARIS, V92, P167, DOI 10.1016/S0928-4257(98)80004-1; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	60	113	116	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					93	101		10.1016/S0092-8674(00)80065-3	http://dx.doi.org/10.1016/S0092-8674(00)80065-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520997	Bronze			2022-12-28	WOS:000082981600011
J	Ogg, MS; Brennan, P; Meade, T; Humphries, SE				Ogg, MS; Brennan, P; Meade, T; Humphries, SE			CYP2C9*3 allelic variant and bleeding complications	LANCET			English	Letter							WARFARIN		UCL, London WC1E 6JJ, England; St Bartholomews Sch Med, Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London, England; Royal London Sch Med, Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London, England	University of London; University College London; University of London; Queen Mary University London; University of London; Queen Mary University London	Humphries, SE (corresponding author), UCL, London WC1E 6JJ, England.		Humphries, Stephen E/C-5075-2008	Humphries, Stephen E/0000-0002-8221-6547				Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; DAY INM, 1995, BIOTECHNIQUES, V19, P830; MEADE TW, 1988, EUR HEART J, V9, P836, DOI 10.1093/oxfordjournals.eurheartj.a062576; Meade TW, 1998, LANCET, V351, P233; Steward DJ, 1997, PHARMACOGENETICS, V7, P361, DOI 10.1097/00008571-199710000-00004	5	63	66	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1124	1124		10.1016/S0140-6736(05)76918-X	http://dx.doi.org/10.1016/S0140-6736(05)76918-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509530				2022-12-28	WOS:000082777500058
J	Haase, SB; Reed, SI				Haase, SB; Reed, SI			Evidence that a free-running oscillator drives G1 events in the budding yeast cell cycle	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; POSITIVE FEEDBACK; KINASE; PHOSPHORYLATION; IDENTIFICATION; TRANSITION; GENES; G(1); DEGRADATION	In yeast and somatic cells, mechanisms ensure cell-cycle events are initiated only when preceding events have been completed(1). In contrast, interruption of specific cell-cycle processes in early embryonic cells of many organisms does not affect the timing of subsequent events(2), indicating that cell-cycle events are triggered by a free-running cell-cycle oscillator. Here we present evidence for an independent cell-cycle oscillator in the budding yeast Saccharomyces cerevisiae. We observed periodic activation of events normally restricted to the G1 phase of the cell cycle, in cells lacking mitotic cyclin-dependent kinase activities that are essential far cell-cycle progression, As in embryonic cells, G1 events cycled on schedule, in the absence of S phase or mitosis, with a period similar to the cell-cycle time of wild-type cells. Oscillations of similar periodicity were observed in cells responding to mating pheromone in the absence of G1 cyclin (Cln)- and mitotic cyclin (Clb)-associated kinase activity, indicating that the oscillator may function independently of cyclin-dependent kinase dynamics. We also show that Clb-associated kinase activity is essential for ensuring dependencies by preventing the initiation of new G1 events when cell-cycle progression is delayed.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 94303 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 94303 USA.	sreed@scripps.edu		Haase, Steve/0000-0001-8127-8992				ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHENEVERT J, 1994, GENETICS, V136, P1287; COLLART MA, 1993, CURRENT PROTOCOLS MO, V2; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Ngo LG, 1997, EUR J BIOCHEM, V245, P182, DOI 10.1111/j.1432-1033.1997.00182.x; NOVAK B, 1986, J CELL SCI, V86, P191; REED S, 1992, COLD SPRING HARB SYM, V56, P61; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WHITAKER M, 1990, DEVELOPMENT, V108, P525; XU HX, 1992, MOL CELL BIOL, V12, P5249, DOI 10.1128/MCB.12.11.5249	30	91	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					394	397		10.1038/43930	http://dx.doi.org/10.1038/43930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517640	Bronze			2022-12-28	WOS:000082822600056
J	Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA				Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA		Study Osteoporotic Fractures Res Grp	High blood pressure and bone-mineral loss In elderly white women: a prospective study	LANCET			English	Article							ESSENTIAL-HYPERTENSION; CALCIUM-METABOLISM; URINARY CALCIUM; HIP FRACTURE; OSTEOPOROTIC FRACTURES; YOUNG-PEOPLE; THIAZIDE; DENSITY; POPULATION; PREVENTION	Background High blood pressure is associated with abnormalities in calcium metabolism. Sustained calcium loss may lead to increased bone-mineral loss in people with high blood pressure. We investigated the prospective association between blood pressure and bone-mineral loss over time in elderly white women. Methods We studied 3676 women who were initially assessed in 1988-90 (mean age 73 years [SD 4, range 66-91 years]; mean bodyweight 65.3 kg [11.5]; blood pressure 137/75 mm Hg [17/9]) who were not on thiazide diuretics. Mean follow-up was 3.5 years. Anthropometry, blood pressure, and bone-mineral density at the femoral neck were measured at baseline and bone densitometry was repeated after 3.5 years by dual-energy X-ray absorptiometry. Findings After adjustment for age, initial hone-mineral density, weight and weight change, smoking, and regular use of hormone-replacement therapy, the rate of bone loss at the femoral neck increased with blood pressure at baseline. In the quartiles of systolic blood pressure, yearly bone losses increased from 2.26 mg/cm(2) (95% CI 1.48-3.04) in the first quartile to 3.79 mg/cm(2) in the fourth quartile (3.13-4.45; test for heterogeneity, p=0.03; test for linear trend, p=0.01), equivalent to yearly changes of 0.34% (0.20-0.46) and 0.59% (0.49-0.69; test for heterogeneity, p=0.02; test for linear trend, p=0.005). There was no significant interaction with age. The exclusion of women on antihypertensive drugs did not alter the results, For diastolic blood pressure, there was an association with bone loss in women younger than 75 years. Interpretation Higher blood pressure in elderly white women is associated with increased bone loss at the femoral neck. This association may reflect greater calcium losses associated with high blood pressure, which may contribute to the risk of hip fractures.	St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Epidemiol Unit, London, England; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA	St Georges University London; University of London; London School of Hygiene & Tropical Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cappuccio, FP (corresponding author), St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England.	f.cappuccio@sghms.ac.uk	Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009; Cauley, Jane A/N-4836-2015	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Cauley, Jane A/0000-0003-0752-4408				BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; Cappuccio FP, 1997, LANCET, V350, P850, DOI 10.1016/S0140-6736(97)02264-2; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; *DEP DRUGS DIV DRU, 1991, DRUG EV ANN 1991, P683; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; GADALLAH M, 1991, AM J HYPERTENS, V4, P404, DOI 10.1093/ajh/4.5.404; Geleijnse JM, 1996, J HYPERTENS, V14, P1491, DOI 10.1097/00004872-199612000-00018; GROBBEE DE, 1988, BRIT MED J, V296, P814, DOI 10.1136/bmj.296.6625.814; HVARFNER A, 1987, J HYPERTENS, V5, P451; IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MATKOVIC V, 1995, AM J CLIN NUTR, V62, P417, DOI 10.1093/ajcn/62.2.417; MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; STEIGER P, 1992, J BONE MINER RES, V7, P625; STRAZZULLO P, 1983, CLIN SCI, V65, P137, DOI 10.1042/cs0650137; STRAZZULLO P, 1987, J HUM HYPERTENS, V1, P155; Strazzullo P., 1991, NUTR METABOLISM CARD, V1, P98; Tsuda K, 1998, J HYPERTENS, V16, pS209; UMEMURA S, 1986, J HYPERTENS, V4, P19, DOI 10.1097/00004872-198602000-00004; VANHOOFT IMS, 1993, HYPERTENSION, V21, P267, DOI 10.1161/01.HYP.21.3.267; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WONDERRECKE P, 1999, AM J MED, V106, P273; YAMAKAWA H, 1992, HYPERTENSION, V19, P528, DOI 10.1161/01.HYP.19.6.528; YOUNG EW, 1992, J LAB CLIN MED, V120, P624	35	267	287	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					971	975		10.1016/S0140-6736(99)01437-3	http://dx.doi.org/10.1016/S0140-6736(99)01437-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501357				2022-12-28	WOS:000082596000008
J	Tyrer, P; Hassiotis, A; Ukoumunne, O; Piachaud, J; Harvey, K				Tyrer, P; Hassiotis, A; Ukoumunne, O; Piachaud, J; Harvey, K		UK 700 Grp	Intensive case management for psychotic patients with borderline intelligence	LANCET			English	Article							MENTALLY-ILL	Patients with recurrent psychotic disorder and borderline learning disability who were randomly assigned intensive case management spent less than half the subsequent time in hospital than those who were assigned standard case management.	Univ London Imperial Coll Sci Technol & Med, Paterson Ctr, Dept Publ Mental Hlth, London, ON W2 1PD, Canada; UCL, Acad Dept Psychiat & Behav Sci, London, England; Harperbury Hosp, Horizon NHS Trust, Watford, England; Univ London St Georges Hosp, Sch Med, Sect Community Psychiat, London SW17 0RE, England	University of London; University College London; St Georges University London	Tyrer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Paterson Ctr, Dept Publ Mental Hlth, 20 S Wharf Rd, London, ON W2 1PD, Canada.	p.tyrer@ic.ac.uk	Hassiotis, Angela/A-8803-2012	Hassiotis, Angela/0000-0002-9800-3909				Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; Hassiotis A, 1999, BRIT J PSYCHIAT, V175, P135, DOI 10.1192/bjp.175.2.135; Holloway F, 1998, BRIT J PSYCHIAT, V172, P19, DOI 10.1192/bjp.172.1.19; HOULT J, 1986, BRIT J PSYCHIAT, V149, P137, DOI 10.1192/bjp.149.2.137; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392	5	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					999	1000						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501366				2022-12-28	WOS:000082596000017
J	Flynn, JJ; Parrish, JM; Rakotosamimanana, B; Simpson, WF; Whatley, RL; Wyss, AR				Flynn, JJ; Parrish, JM; Rakotosamimanana, B; Simpson, WF; Whatley, RL; Wyss, AR			A triassic fauna from Madagascar, including early dinosaurs	SCIENCE			English	Article								The discovery of a Middle to Late Triassic (similar to 225 to 230 million years old) terrestrial vertebrate fauna from Madagascar is reported. This fauna documents a temporal interval not well represented by continental vertebrate assemblages elsewhere in the world. It contains two new prosauropod dinosaurs, representing some of the earliest dinosaur occurrences known globally. This assemblage provides information about the poorly understood transition to the dinosaur-dominated faunas of the Latest Triassic.	Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA; Univ Antananarivo, Dept Paleontol & Anthropol Biol, Antananarivo 101, Madagascar; Univ Calif Santa Barbara, Dept Geol, Santa Barbara, CA 93106 USA	Field Museum of Natural History (Chicago); Northern Illinois University; University Antananarivo; University of California System; University of California Santa Barbara	Flynn, JJ (corresponding author), Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA.	flynn@fmnh.org						Beltan Laurence, 1996, P479; BENTON MJ, 1994, IN THE SHADOW OF THE DINOSAURS, P366; Besairie H., 1972, ANN GEOL MADAGASCAR, V35, P1; Besairle H., 1936, Mem Acad Malgache, V21, P1; Bonaparte J. F., 1962, Publ Mus Cienc nat Mar del Plata, V1, P135; Buffetaut E., 1983, NEUES JB GEOLOGIE PA, V1983, P465; CROMPTON A. W., 1957, ANN S AFRICAN MUS, V44, P1; Crompton A.W., 1972, B BRIT MUS NAT HIST, V21, P29; Flynn J., 1998, Journal of Vertebrate Paleontology, V18, p42A; Flynn JJ, 1999, NATURE, V401, P57, DOI 10.1038/43420; Forster CA, 1996, NATURE, V382, P532, DOI 10.1038/382532a0; Galton PM, 1985, STUTTGARTER BEITRAGE, V118, P1; GAUFFRE FX, 1993, PALAEONTOLOGY, V36, P897; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; HOPSON J A, 1984, Palaeontologia Africana, V25, P181; HOPSON JA, 1994, MAJOR FEATURES VERTE, P190; HOPSON JA, 1985, NEUES JB GEOL PAL, V5, P285; HOURCQ VICTOR, 1950, ANN GEOL SERV MINES [MADAGASCAR], V20, P1; Kemp T.S, 1982, MAMMAL LIKE REPTILES; KERMACK D, 1984, ZOOL J LINN SOC-LOND, V82, P101, DOI 10.1111/j.1096-3642.1984.tb00538.x; Krause DW, 1997, NATURE, V390, P504, DOI 10.1038/37343; KRAUSE DW, 1996, ENV CHANGE MADAGASCA, P3; Lucas SG, 1996, ALBERTIANA, V17, P57; Lydekker R, 1895, Q J GEOL SOC LOND, V51, P329; ROGERS RR, 1993, SCIENCE, V260, P794, DOI 10.1126/science.260.5109.794; ROMER ALFRED SHERWOOD, 1967, BREV MUS COMP ZOOL [HARVARD], V264, P1; ROWE T, 1993, MAMMAL PHYLOGENY, P129; Sampson SD, 1998, SCIENCE, V280, P1048, DOI 10.1126/science.280.5366.1048; SWOFFORD DL, 1993, PAUP 3 1 1; VONHUENE F, 1928, ZENTRALBL MINERAL GE, P250; Whatley R. L., 1999, Journal of Vertebrate Paleontology, V19, p84A	31	62	65	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					763	765		10.1126/science.286.5440.763	http://dx.doi.org/10.1126/science.286.5440.763			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531059				2022-12-28	WOS:000083303200051
J	Saunders, WB; Work, DM; Nikolaeva, SV				Saunders, WB; Work, DM; Nikolaeva, SV			Evolution of complexity in paleozoic ammonoid sutures	SCIENCE			English	Article							COPES RULE; BODY-SIZE; TRENDS; EXTINCTION; PATTERNS; HISTORY; EVENTS; SHELL	The septal sutures of 588 genera of Paleozoic ammonoids showed a 1600 percent increase in mean complexity over 140 million years. Within 475 ancestor/descendant pairs, descendants were more than twice as likely to be more complex than their ancestors. Twelve subclades (373 genera) averaged 34 percent increased complexity. These patterns are compatible with an active or driven system of long-term bias for increased complexity. Mass extinctions acted in opposition to this long-term trend, tending to eliminate more-complex farms and resetting the trend with each extinction event.	Bryn Mawr Coll, Dept Geol, Bryn Mawr, PA 19010 USA; Cincinnati Museum Ctr, Geier Collect & Res Ctr, Cincinnati, OH 45202 USA; Russian Acad Sci, Paleontol Res Inst, Moscow 117647, Russia	Bryn Mawr College; Russian Academy of Sciences	Saunders, WB (corresponding author), Bryn Mawr Coll, Dept Geol, Bryn Mawr, PA 19010 USA.	wsaunder@brynmawr.edu	Nikolaeva, Svetlana/P-2877-2017	Nikolaeva, Svetlana/0000-0002-6506-2793				Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; Becker R.T., 1993, AMMONOIDEA ENV ECOLO, V47, P115; BOYAJIAN G, 1992, GEOLOGY, V20, P983, DOI 10.1130/0091-7613(1992)020<0983:EOBCAI>2.3.CO;2; CARLSON SJ, 1992, PALEOBIOLOGY, V18, P344, DOI 10.1017/S0094837300010885; Daniel TL, 1997, PALEOBIOLOGY, V23, P470, DOI 10.1017/S0094837300019849; Erwin D. H, 1993, GREAT PALEOZOIC CRIS; FISHER DC, 1986, PATTERNS PROCESSES H, P99; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; Gould SJ, 1996, FULL HOUSE; Harland W.B., 1990, GEOLOGIC TIME SCALE; Hewitt R.A., 1986, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V172, P47; Hewitt R.A., 1987, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V174, P135; HOUSE MR, 1985, NATURE, V313, P17, DOI 10.1038/313017a0; House MR, 1996, GEOL SOC SP, P163, DOI 10.1144/GSL.SP.1996.001.01.12; HOUSE MR, 1989, PHILOS T ROY SOC B, V325, P307, DOI 10.1098/rstb.1989.0091; Jablonski D, 1997, NATURE, V385, P250, DOI 10.1038/385250a0; Jablonski David, 1996, P256; Jacobs DK, 1996, PALAIOS, V11, P610, DOI 10.2307/3515195; JONES PJ, 1988, NEWSLETTER CARBONIFE, V6, P26; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; LUTZ TM, 1995, PALEOBIOLOGY, V21, P329, DOI 10.1017/S0094837300013336; MACFADDEN BJ, 1986, PALEOBIOLOGY, V12, P355, DOI 10.1017/S0094837300003109; McGhee G.R., 1996, LATE DEVONIAN MASS E; MCSHEA DW, 1991, BIOL PHILOS, V6, P303, DOI 10.1007/BF00132234; MCSHEA DW, 1994, EVOLUTION, V48, P1747, DOI 10.1111/j.1558-5646.1994.tb02211.x; MCSHEA DW, 1993, EVOLUTION, V47, P730, DOI 10.1111/j.1558-5646.1993.tb01229.x; MENNING M, 1992, PERMOPHILES, V20, P2; NORRIS RD, 1991, PALEOBIOLOGY, V17, P388, DOI 10.1017/S0094837300010721; RAUP DM, 1988, PALEOBIOLOGY, V14, P109, DOI 10.1017/S0094837300011866; Roberts J., 1991, NEWSLETTER CARBONIFE, V9, P15; SAUNDERS WB, 1995, PALEOBIOLOGY, V21, P343, DOI 10.1017/S0094837300013348; Saunders WB, 1996, PALEOBIOLOGY, V22, P189, DOI 10.1017/S0094837300016171; SEILACHER A, 1995, PALAIOS, V10, P268; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; Tozer E.T., 1981, AMMONOIDEA, V18, P65; Wagner PJ, 1996, EVOLUTION, V50, P990, DOI 10.1111/j.1558-5646.1996.tb02341.x; ZHAO J, 1978, PALAEONTOL SIN, V154; ZHOU Z., 1996, PERMOPHILES, V29, P52	38	83	85	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					760	763		10.1126/science.286.5440.760	http://dx.doi.org/10.1126/science.286.5440.760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531058				2022-12-28	WOS:000083303200050
J	Silverberg, SJ; Shane, E; Jacobs, TP; Siris, E; Bilezikian, JP				Silverberg, SJ; Shane, E; Jacobs, TP; Siris, E; Bilezikian, JP			A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BONE-MINERAL CONTENT; HYPER-PARATHYROIDISM; TRABECULAR BONE; DENSITY; MILD; DISEASE; ASSAY	Background In the United States, most patients with primary hyperparathyroidism have few or no symptoms. The need for parathyroidectomy to treat all patients with this disorder has therefore been questioned. Methods We studied the clinical course and development of complications for periods of up to 10 years in 121 patients with primary hyperparathyroidism, 101 (83 percent) of whom were asymptomatic. There were 30 men and 91 women (age range, 20 to 79 years). During the study, 61 patients (50 percent) underwent parathyroidectomy, and 60 patients were followed without surgery. Results Parathyroidectomy in patients with or without symptoms led to normalization of serum calcium concentrations and a mean (+/-SE) increase in lumbar-spine bone mineral density of 8+/-2 percent after 1 year (P=0.005) and 12+/-3 percent after 10 years (P=0.03). Bone mineral density of the femoral neck increased 6+/-1 percent after 1 year (P=0.002) and 14+/-4 percent after 10 years (P=0.002). Bone mineral density of the radius did not change significantly. The 52 asymptomatic patients who did not undergo surgery had no change in serum calcium concentration, urinary calcium excretion, or bone mineral density. However, 14 of these 52 patients (27 percent) had progression of disease, defined as the development of at least one new indication for parathyroidectomy. All 20 patients with symptoms had kidney stones. None of the 12 who underwent parathyroidectomy had recurrent kidney stones, whereas 6 of the 8 patients who did not undergo surgery did have a recurrence. Conclusions In patients with primary hyperparathyroidism, parathyroidectomy results in the normalization of biochemical values and increased bone mineral density. Most asymptomatic patients who did not undergo surgery did not have progression of disease, but approximately one quarter of them did have some progression. (N Engl J Med 1999;341:1249-55.) (C)1999, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University	Silverberg, SJ (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NCRR NIH HHS [RR 00645] Funding Source: Medline; NIDDK NIH HHS [R01 DK032333, NIDDK 32333] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032333] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelhadi M, 1998, J CLIN ENDOCR METAB, V83, P3845, DOI 10.1210/jc.83.11.3845; Albright F., 1948, PARATHYROID GLANDS M; Bilezikian John P., 1994, P457; BILEZIKIAN JP, 1985, ANN INTERN MED, V102, P402, DOI 10.7326/0003-4819-102-3-402; CHRISTIANSEN P, 1990, BONE, V11, P75, DOI 10.1016/8756-3282(90)90053-2; COE FL, 1980, NEW ENGL J MED, V302, P224, DOI 10.1056/NEJM198001243020408; COPE O, 1966, NEW ENGL J MED, V274, P1174, DOI 10.1056/NEJM196605262742105; DALEN N, 1974, ACTA ENDOCRINOL-COP, V75, P297, DOI 10.1530/acta.0.0750297; GUNDBERG CM, 1985, CLIN CHEM, V31, P1720; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HODGSON SF, 1981, MAYO CLIN PROC, V56, P521; JIMENEZ LE, 1984, CALCIFIED TISSUE INT, V36, P14, DOI 10.1007/BF02405288; LEPPLA DC, 1982, INVEST RADIOL, V17, P604, DOI 10.1097/00004424-198211000-00013; MARTIN P, 1990, ARCH INTERN MED, V150, P1495, DOI 10.1001/archinte.150.7.1495; MAUTALEN C, 1986, ACTA ENDOCRINOL-COP, V111, P494, DOI 10.1530/acta.0.1110494; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARFITT AM, 1990, J BONE MINER RES, V5, P537; Parfitt AM, 1986, CURRENT CONCEPTS BON, P279; Parfitt MA, 1991, J BONE MINER RES S2, P97; PARISIEN M, 1992, J BONE MINER RES, V7, P913; PARISIEN M, 1995, J BONE MINER RES, V10, P1393; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; SCHOLZ DA, 1981, MAYO CLIN PROC, V56, P473; SEIBEL MJ, 1992, J CLIN ENDOCR METAB, V74, P481, DOI 10.1210/jc.74.3.481; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; TURKEN SA, 1989, AM J MED, V87, P553; VICALE CT, 1949, T AM NEUROL ASSOC, P143	34	615	639	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1249	1255		10.1056/NEJM199910213411701	http://dx.doi.org/10.1056/NEJM199910213411701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528034				2022-12-28	WOS:000083226300001
J	Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG				Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG			Neurogenesis in the neocortex of adult primates	SCIENCE			English	Article							HUMAN CEREBRAL-CORTEX; DENTATE GYRUS; PREFRONTAL CORTEX; HIPPOCAMPAL-NEURONS; RHESUS-MONKEY; CELL-CYCLE; YOUNG NEURONS; BRAIN; RAT; REPLACEMENT	In primates, prefrontal, inferior temporal, and posterior parietal cortex are important for cognitive function. It is shown that in adult macaques, new neurons are added to these three neocortical association areas, but not to a primary sensory area (striate cortex). The new neurons appeared to originate in the subventricular zone and to migrate through the white matter to the neocortex, where they extended axons, These new neurons, which are continually added in adulthood, may play a role in the functions of association neocortex.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Gould, E (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.				NATIONAL EYE INSTITUTE [R01EY011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH052423] Funding Source: NIH RePORTER; NEI NIH HHS [EY11347-29] Funding Source: Medline; NIMH NIH HHS [MH52423-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1967, NEUROSCIENCES STUDY, P723; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; ALVAREZBUYLLA A, 1992, J NEUROBIOL, V23, P396, DOI 10.1002/neu.480230406; ANDERSEN RA, 1985, J COMP NEUROL, V232, P443, DOI 10.1002/cne.902320403; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Barnea A, 1996, P NATL ACAD SCI USA, V93, P714, DOI 10.1073/pnas.93.2.714; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BOURGEOIS JP, 1994, CEREB CORTEX, V4, P78, DOI 10.1093/cercor/4.1.78; Cajal SRY., 1995, HISTOLOGY NERVOUS SY, V1; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; COLOMBEL M, 1992, CANCER RES, V52, P4313; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feinendegen LE, 1967, TRITIUM LABELED MOL; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; GOULD E, UNPUB; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; Honig LS, 1996, CEREB CORTEX, V6, P794, DOI 10.1093/cercor/6.6.794; KAPLAN MS, 1981, J COMP NEUROL, V195, P323, DOI 10.1002/cne.901950211; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; LOPEZGARCIA C, 1988, BRAIN RES, V471, P167; Magiakou MA, 1996, CLIN ENDOCRINOL, V44, P419, DOI 10.1046/j.1365-2265.1996.683505.x; Martin RF, 1996, NEUROIMAGE, V4, P119, DOI 10.1006/nimg.1996.0036; Melchitzky DS, 1998, J COMP NEUROL, V390, P211, DOI 10.1002/(SICI)1096-9861(19980112)390:2<211::AID-CNE4>3.0.CO;2-4; Miller EK, 1996, J NEUROSCI, V16, P5154; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; Nauta WJ, 1970, NEUROSCIENCES, P7; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; NOTTEBOHM F, 1989, NEURAL CONTROL REPRO, P583; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; Pincus D W, 1997, Clin Neurosurg, V44, P17; RAKIC P, 1985, ANN NY ACAD SCI, V457, P193, DOI 10.1111/j.1749-6632.1985.tb20806.x; Rakic P, 1998, NAT NEUROSCI, V1, P645, DOI 10.1038/3643; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1978, POSTGRAD MED J, V54, P25; Rosselli-Austin L, 1979, J Dev Physiol, V1, P295; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHWARTZ ML, 1984, J COMP NEUROL, V226, P403, DOI 10.1002/cne.902260309; Shankle WR, 1998, J THEOR BIOL, V191, P115, DOI 10.1006/jtbi.1997.0570; Sugita N, 1918, J COMP NEUROL, V29, P61, DOI 10.1002/cne.900290202; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	60	933	1011	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					548	552		10.1126/science.286.5439.548	http://dx.doi.org/10.1126/science.286.5439.548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521353				2022-12-28	WOS:000083121200065
J	Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK				Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK			Structural changes in bacteriorhodopsin during ion transport at 2 Angstrom resolution	SCIENCE			English	Article							ORIENTED PURPLE MEMBRANES; LIPIDIC CUBIC PHASES; RETINAL SCHIFF-BASE; LOCAL-ACCESS MODEL; X-RAY-DIFFRACTION; REPROTONATION SWITCH; PROTON-TRANSFER; N-INTERMEDIATE; CHROMOPHORE ISOMERIZATION; DIFFERENCE SPECTROSCOPY	Crystal structures of the Asp(96) to Asn mutant of the light-driven proton pump bacteriorhodopsin and its M photointermediate produced by illumination at ambient temperature have been determined to 1.8 and 2.0 angstroms resolution, respectively. The trapped photoproduct corresponds to the Late M state in the transport cycle-that is, after proton transfer to Asp(85) and release of a proton to the extracellular membrane surface, but before reprotonation of the deprotonated retinal Schiff base. Its density map describes displacements of side chains near the retinal induced by its photoisomerization to 13-cis, 15-anti and an extensive rearrangement of the three-dimensional network of hydrogen-bonded residues and bound water that accounts for the changed pK(a) values (where K-a is the acid constant) of the Schiff base and Asp(85). The structural changes detected suggest the means for conserving energy at the active site and for ensuring the directionality of proton translocation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, UCI Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Cartailler, Jean-Philippe/D-2543-2010; Lanyi, Janos/C-3808-2011; Luecke, Hartmut/F-4712-2012	Cartailler, Jean-Philippe/0000-0002-0312-2391; Luecke, Hartmut/0000-0002-4938-0775	NIGMS NIH HHS [R01-GM59970, R01-GM29498, R01-GM56445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056445, R01GM029498, R01GM059970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Borucki B, 1998, J PHYS CHEM B, V102, P3821, DOI 10.1021/jp980433c; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; Brown LS, 1998, BIOPHYS J, V75, P1455, DOI 10.1016/S0006-3495(98)74064-0; Brown LS, 1998, BIOCHEMISTRY-US, V37, P3982, DOI 10.1021/bi9728396; Brown LS, 1995, BIOPHYS J, V69, P2103, DOI 10.1016/S0006-3495(95)80081-0; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; Dickopf S, 1997, BIOPHYS J, V73, P3171, DOI 10.1016/S0006-3495(97)78343-7; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P9889, DOI 10.1021/bi980934o; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; GERWERT K, 1986, EMBO J, V5, P805, DOI 10.1002/j.1460-2075.1986.tb04285.x; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; Kandori H, 1997, BIOCHEMISTRY-US, V36, P5134, DOI 10.1021/bi9629788; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 1995, ISR J CHEM, V35, P365; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Moltke S, 1998, BIOCHEMISTRY-US, V37, P11821, DOI 10.1021/bi980676v; Nagel G, 1998, BIOPHYS J, V74, P403, DOI 10.1016/S0006-3495(98)77797-5; OESTERHELT D, 1986, EUR BIOPHYS J BIOPHY, V14, P123, DOI 10.1007/BF00263069; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; Rodig C, 1999, FEBS LETT, V445, P14, DOI 10.1016/S0014-5793(99)00088-5; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SASAKI J, 1992, J BIOL CHEM, V267, P20782; Sass HJ, 1997, EMBO J, V16, P1484, DOI 10.1093/emboj/16.7.1484; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; VARO G, 1991, BIOPHYS J, V59, P313, DOI 10.1016/S0006-3495(91)82225-1; VARO G, 1991, BIOCHEMISTRY-US, V30, P5016, DOI 10.1021/bi00234a025; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; WELDLICH O, 1996, BIOCHEMISTRY-US, V35, P10807; ZIMANYI L, 1992, BIOCHEMISTRY-US, V31, P8535, DOI 10.1021/bi00151a022	50	491	540	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					255	260		10.1126/science.286.5438.255	http://dx.doi.org/10.1126/science.286.5438.255			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514362				2022-12-28	WOS:000083024400034
J	Preclik, G; Grune, G; Leser, HG; Lebherz, J; Heldwein, W; Machka, K; Holstege, A; Kern, WV				Preclik, G; Grune, G; Leser, HG; Lebherz, J; Heldwein, W; Machka, K; Holstege, A; Kern, WV			Prospective, randomised, double blind trial of prophylaxis with single dose of co-amoxiclav before percutaneous endoscopic gastrostomy	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTIC-PROPHYLAXIS; COMPLICATIONS; PEG; EXPERIENCE	Objective To determine the efficacy of antibacterial prophylaxis in preventing infectious complications after percutaneous endoscopic gastrostomy. Design Prospective, randomised, placebo controlled, double blind, multicentre study. Setting Departments of internal medicine at six German hospitals. Subjects Of 106 randomised adult patients with dysphagia, 97 received study medication, and 84 completed the study. The median age of the patients was 65 years. Most had dysphagia due to malignant disease (65%), and many (76%) had serious comorbidity. Interventions A single intravenous 2.2 g dose of co-amoxiclav or identical appearing saline was given 30 min before percutaneous endoscopic gastrostomy performed by the thread pull method. Main outcome measures Occurrence of peristomal wound infections and other infections within one week after percutaneous endoscopic gastrostomy. Results The incidence of peristomal and other infections within one week after percutaneous endoscopic gastrostomy was significantly reduced in the antibiotic group (8/41 (20%) v 28/43 (65%), P < 0.001), Similar results were obtained in an intention to treat analysis. Several peristomal wound infections were of minor clinical significance. After wound infections that required no or only local treatment were excluded from the analysis, antibiotic prophylaxis remained highly effective in reducing clinically important wound infections (1/41 (2%) v 11/43 (26%), P < 0.01) and non-wound infections (2 (5%) v 9 (21%), P < 0.05). Conclusions Antibiotic prophylaxis with a single dose of co-amoxiclav significantly reduces the risk of infectious complications after percutaneous endoscopic gastrostomy and should be recommended.	Univ Ulm, Med Klin & Poliklin, D-89070 Ulm, Germany; Klinikum Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Kreiskrankenhaus Boblingen, D-71032 Boblingen, Germany; Univ Munich, D-80366 Munich, Germany; SmithKline Beecham Pharma, D-80804 Munich, Germany	Ulm University; University of Regensburg; University of Munich; GlaxoSmithKline	Kern, WV (corresponding author), Univ Ulm, Med Klin & Poliklin, D-89070 Ulm, Germany.		Holstege, Axel/J-5244-2019					AKKERSDIJK WL, 1995, ENDOSCOPY, V27, P313, DOI 10.1055/s-2007-1005699; Amann W, 1997, SURG ENDOSC-ULTRAS, V11, P741, DOI 10.1007/s004649900440; Ball P, 1997, J CHEMOTHERAPY, V9, P167, DOI 10.1179/joc.1997.9.3.167; BEASLEY SW, 1995, J PEDIATR SURG, V30, P671, DOI 10.1016/0022-3468(95)90687-8; BourdelMarchasson I, 1997, INT J QUAL HEALTH C, V9, P297, DOI 10.1093/intqhc/9.4.297; Chowdhury MA, 1996, J GASTROEN HEPATOL, V11, P835, DOI 10.1111/j.1440-1746.1996.tb00089.x; CHUNG RS, 1990, AM SURGEON, V56, P134; Fox VL, 1997, GASTROINTEST ENDOSC, V45, P64, DOI 10.1016/S0016-5107(97)70304-3; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; GUTT CN, 1996, WORLD J SURG, V20, P1066; JAIN NK, 1987, ANN INTERN MED, V107, P824, DOI 10.7326/0003-4819-107-6-824; JONAS SK, 1985, AM J GASTROENTEROL, V80, P438; KOHLI H, 1995, AM SURGEON, V61, P191; LIGHT VL, 1995, GASTROINTEST ENDOSC, V42, P330, DOI 10.1016/S0016-5107(95)70132-X; PONSKY JL, 1983, ARCH SURG-CHICAGO, V118, P913; RAHA SK, 1994, AGE AGEING, V23, P162, DOI 10.1093/ageing/23.2.162; Schapiro G D, 1996, Gastrointest Endosc Clin N Am, V6, P409; Sturgis TM, 1996, AM J GASTROENTEROL, V91, P2301	18	91	94	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					881	884		10.1136/bmj.319.7214.881	http://dx.doi.org/10.1136/bmj.319.7214.881			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506041	Green Published, Bronze			2022-12-28	WOS:000082975600021
J	Hertel, P; Fagerquist, MV; Svensson, TH				Hertel, P; Fagerquist, MV; Svensson, TH			Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha(2) adrenoceptor blockade	SCIENCE			English	Article							INCREASES EXTRACELLULAR DOPAMINE; MEDIAL PREFRONTAL CORTEX; D-1 RECEPTOR AGONIST; IN-VIVO; ALPHA(2)-ADRENOCEPTOR ANTAGONISM; NUCLEUS-ACCUMBENS; FRONTAL-CORTEX; HIGH-AFFINITY; RAT-BRAIN; SCHIZOPHRENIA	Clozapine exerts superior clinical efficacy and markedly enhances cortical dopamine output compared with classical antipsychotic drugs, Here the alpha(2) adrenoceptor antagonist idazoxan was administered to rats alone or in combination with the D-2/3 dopamine receptor antagonist raclopride. Dopamine efflux in the medial prefrontal cortex and conditioned avoidance responding were analyzed. Idazoxan selectively potentiated the cortical output of dopamine and augmented the suppression of conditioned avoidance responding induced by raclopride. These results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet	Svensson, TH (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden.							Abi-Dargham A, 1997, J NEUROPSYCH CLIN N, V9, P1; AHLENIUS S, 1986, PHARMACOL BIOCHEM BE, V24, P1409, DOI 10.1016/0091-3057(86)90203-0; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; ARNT J, 1982, ACTA PHARMACOL TOX, V51, P321; Ashby CR, 1996, SYNAPSE, V24, P349, DOI 10.1002/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D; BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; BROWNING JL, 1998, SOC NEUR ABSTR, V28, P1741; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CARBONI E, 1990, J NEUROCHEM, V55, P1067, DOI 10.1111/j.1471-4159.1990.tb04599.x; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Coull JT, 1996, PSYCHOPHARMACOLOGY, V123, P239, DOI 10.1007/BF02246578; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; DOXEY JC, 1983, BRIT J PHARMACOL, V78, P489, DOI 10.1111/j.1476-5381.1983.tb08809.x; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; GARRATT JC, 1991, EUR J PHARMACOL, V193, P87, DOI 10.1016/0014-2999(91)90204-4; Green MF, 1996, AM J PSYCHIAT, V153, P321; GRESCH PJ, 1995, J NEUROCHEM, V65, P111; Harvey PD, 1998, AM J PSYCHIAT, V155, P1080, DOI 10.1176/ajp.155.8.1080; HERNANDEZ L, 1995, PHARMACOL BIOCHEM BE, V52, P581, DOI 10.1016/0091-3057(95)00144-L; Hertel P, 1997, NEUROPSYCHOPHARMACOL, V17, P44; Hertel P, 1996, PSYCHOPHARMACOLOGY, V124, P74, DOI 10.1007/BF02245607; JANSSEN PAJ, 1965, J PHARMACOL EXP THER, V244, P684; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; KURIBARA H, 1981, PHARMACOL BIOCHEM BE, V14, P181; Kuroki T, 1999, J PHARMACOL EXP THER, V288, P774; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; Litman RE, 1996, BRIT J PSYCHIAT, V168, P571, DOI 10.1192/bjp.168.5.571; MOGHADDAM B, 1990, J NEUROCHEM, V54, P1755, DOI 10.1111/j.1471-4159.1990.tb01230.x; NOMIKOS GG, 1994, PSYCHOPHARMACOLOGY, V115, P147, DOI 10.1007/BF02244765; NUTT DJ, 1994, J PSYCHOPHARMACOL, V8, P193, DOI 10.1177/026988119400800401; POZZI L, 1994, J NEUROCHEM, V63, P195; Prinssen EPM, 1996, PSYCHOPHARMACOLOGY, V128, P191, DOI 10.1007/s002130050124; Salmi P, 1996, EUR J PHARMACOL, V307, P27, DOI 10.1016/0014-2999(96)00181-1; SANBERG PR, 1988, BEHAV NEUROSCI, V102, P748, DOI 10.1037/0735-7044.102.5.748; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; SCHNEIDER JS, 1994, BRAIN RES, V663, P140, DOI 10.1016/0006-8993(94)90471-5; SVARTENGREN J, 1994, EUR J PHARMACOL, V254, P73, DOI 10.1016/0014-2999(94)90372-7; Tanda G, 1996, PSYCHOPHARMACOLOGY, V123, P127, DOI 10.1007/BF02246169; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; Volonte M, 1997, J NEUROCHEM, V69, P182; WADENBERG ML, 1990, BIOL PSYCHIAT, V28, P297, DOI 10.1016/0006-3223(90)90657-N; WADENBERG ML, 1991, J NEURAL TRANSM-GEN, V83, P43, DOI 10.1007/BF01244451; Wadenberg ML, 1996, EUR NEUROPSYCHOPHARM, V6, P305, DOI 10.1016/S0924-977X(96)00035-1; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; Yamamoto BK, 1998, J NEUROCHEM, V71, P274; Youngren KD, 1999, NEUROPSYCHOPHARMACOL, V20, P403, DOI 10.1016/S0893-133X(98)00082-7	49	165	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					105	107		10.1126/science.286.5437.105	http://dx.doi.org/10.1126/science.286.5437.105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506554				2022-12-28	WOS:000082907400044
J	Emmel, ND; D'Souza, L				Emmel, ND; D'Souza, L			Health effects of forced evictions in the slums of Mumbai	LANCET			English	Editorial Material									Univ Leeds, Nuffield Inst Hlth, Int Div, Leeds LS1 9PL, W Yorkshire, England; CEHAT, Mumbai, India; Nivara Hakk Suraksha Samiti, Mumbai, India	University of Leeds	Emmel, ND (corresponding author), Univ Leeds, Nuffield Inst Hlth, Int Div, 71-75 Clarendon Rd, Leeds LS1 9PL, W Yorkshire, England.							EMMEL ND, 1998, REPEATED EVICTION HO; SURESH H, 1991, FORCED EVICTIONS; *UN COMM, 1997, EC SOC CULT RIGHTS	3	6	6	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1118	1118		10.1016/S0140-6736(05)76907-5	http://dx.doi.org/10.1016/S0140-6736(05)76907-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509519				2022-12-28	WOS:000082777500046
J	Iacopino, V; Ozkalipci, O; Schlar, C				Iacopino, V; Ozkalipci, O; Schlar, C			The Istanbul Protocol: international standards for the effective investigation and documentation of torture and ill treatment	LANCET			English	Editorial Material									Phys Human Rights, Boston, MA 02116 USA; Human Rights Fdn Turkey, Istanbul, Turkey; Act Torture Survivors, Geneva, Switzerland	Human Rights Foundation of Turkey	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.							BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; EURADA, 1999, REP 1999; Iacopino V, 1996, JAMA-J AM MED ASSOC, V276, P396, DOI 10.1001/jama.276.5.396; IACOPINO V, 1998, J AMBUL CARE MANAGE, V21, P5; IACOPINO V, 1995, MED HLTH CARE 21 CEN, P376; Mann Jonathan M, 1994, Health Hum Rights, V1, P6	6	17	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1117	1117						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509518				2022-12-28	WOS:000082777500045
J	Morris, AAM; Carr, A				Morris, AAM; Carr, A			HIV nucleoside analogues: new adverse effects on mitochondria?	LANCET			English	Editorial Material							LIPOMATOSIS; DEPLETION; DNA		Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; St Vincents Hosp, Ctr Immunol, Sydney, NSW, Australia; St Vincents Hosp, HIV Med Unit, Sydney, NSW, Australia	Newcastle University - UK; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Morris, AAM (corresponding author), Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CARR A, 1999, 1 INT WORKSH LIP ADV; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; ENZI G, 1984, MEDICINE, V63, P56, DOI 10.1097/00005792-198401000-00004; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862; LENHARD J, 1999, 6 C RETR OPP INF CHI; MORAES CT, 1991, AM J HUM GENET, V48, P492; SABA J, 1999, 6 C RETR OPP INF CHI; SMITH M, 1999, 2 C GLOB STRAT PREV	12	51	51	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1046	1047		10.1016/S0140-6736(99)00301-3	http://dx.doi.org/10.1016/S0140-6736(99)00301-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509488				2022-12-28	WOS:000082777500002
J	Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J				Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J			Polycystin-L is a calcium-regulated cation channel permeable to calcium ions	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; KIDNEY-DISEASE; GENE; PROTEINS; CHLORIDE; CELLS; PKD1; INHIBIT; ENCODES; ENTRY	Polycystic kidney diseases are genetic disorders in which the renal parenchyma is progressively replaced by fluid-filled cysts(1). Two members of the polycystin family (polycystin-1 and -2) are mutated in autosomal dominant polycystic kidney disease (ADPKD)(2-5), and polycystin-L is deleted in mice with renal and retinal defects(6), Polycystins are membrane proteins that share significant sequence homology(6,7), especially polycystin-2 and -L (50% identity and 71% similarity). The functions of the polycystins remain unknown. Here we show that polycystin-L is a calcium-modulated nonselective cation channel that is permeable to sodium, potassium and calcium ions. Patch-clamp experiments revealed single-channel activity with a unitary conductance of 137 pS. Channel activity was substantially increased when either the extracellular or intracellular calcium-ion concentration was raised, indicating that polycystin-L may act as a transducer of calcium-mediated signalling in vivo. Its large single-channel conductance and regulation by calcium ions distinguish it from other structurally related cation channels.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zhou, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P105; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Jorgensen AJ, 1997, PFLUG ARCH EUR J PHY, V434, P261; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kunze DL, 1997, AM J PHYSIOL-CELL PH, V272, pC27, DOI 10.1152/ajpcell.1997.272.1.C27; LANE JW, 1993, BRIT J PHARMACOL, V108, P116, DOI 10.1111/j.1476-5381.1993.tb13449.x; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Saadi I, 1998, KIDNEY INT, V54, P48, DOI 10.1046/j.1523-1755.1998.00956.x; Sullivan LP, 1998, J AM SOC NEPHROL, V9, P903; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	30	191	203	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					383	386		10.1038/43907	http://dx.doi.org/10.1038/43907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517637				2022-12-28	WOS:000082822600053
J	Muhlbauer, RC; Li, F				Muhlbauer, RC; Li, F			Nutrition - Effect of vegetables on bone metabolism	NATURE			English	Article							OVARIECTOMIZED RATS; DIURNAL RHYTHM; RESORPTION		Univ Bern, Dept Clin Res, Bone Biol Grp, CH-3010 Bern, Switzerland	University of Bern	Muhlbauer, RC (corresponding author), Univ Bern, Dept Clin Res, Bone Biol Grp, Murtenstr 35, CH-3010 Bern, Switzerland.							Anderson JJB, 1997, NUTR RES, V17, P1617, DOI 10.1016/S0271-5317(97)00156-5; Antic VN, 1996, CALCIFIED TISSUE INT, V58, P443, DOI 10.1007/s002239900073; Cecchini MG, 1997, CALCIFIED TISSUE INT, V61, pS9, DOI 10.1007/s002239900377; Kanis JA, 1999, BONE, V24, P279, DOI 10.1016/S8756-3282(99)00010-1; Li F, 1999, J BONE MINER RES, V14, P1457, DOI 10.1359/jbmr.1999.14.8.1457; MUHLBAUER RC, 1990, AM J PHYSIOL, V259, pR679, DOI 10.1152/ajpregu.1990.259.4.R679; MUHLBAUER RC, 1995, J CLIN INVEST, V95, P1933, DOI 10.1172/JCI117875; SILVERMAN SL, 1998, BONE, V23, P1108; White P, 1998, OSTEOPOROSIS CLIN CO; WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756-3282(86)90683-6	10	93	96	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					343	344		10.1038/43824	http://dx.doi.org/10.1038/43824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517630				2022-12-28	WOS:000082822600040
J	Thomson, M				Thomson, M			Helicobacter pylori - the story so far	BRITISH MEDICAL JOURNAL			English	Editorial Material							CAMPYLOBACTER-PYLORI; INFECTION; DISEASE		Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England	University of London; University College London	Thomson, M (corresponding author), Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England.							COGHLAN JG, 1987, LANCET, V2, P109; FORMAN D, 1993, GUT, V34, P1672, DOI 10.1136/gut.34.12.1672; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; MACARTHUR C, 1995, JAMA-J AM MED ASSOC, V273, P729, DOI 10.1001/jama.273.9.729; Malfertheiner P, 1997, EUR J GASTROEN HEPAT, V9, P1; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; OCONNOR HJ, 1987, LANCET, V2, P633; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; TATSUTA M, 1990, GUT, V31, P973, DOI 10.1136/gut.31.9.973; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					541	541						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10523085				2022-12-28	WOS:000082347200018
J	Jacobson, TA; Thomas, DM; Morton, FJ; Offutt, G; Shevlin, J; Ray, S				Jacobson, TA; Thomas, DM; Morton, FJ; Offutt, G; Shevlin, J; Ray, S			Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Pneumococcal immunization rates for elderly and high-risk patients are only one third to one half the target rate of 60% established by the US Public Health Service. Limited or marginal literacy, which affects nearly 100 million Americans, especially the elderly, may contribute to these low rates of immunization. Objective To determine whether the use of a simple, low-literacy educational tool enhances patient-physician dialogue about pneumococcal vaccination and increases rates of immunization. Design A randomized controlled trial conducted between May and June of 1998. Setting Ambulatory care clinic of a 900-bed public reaching hospital serving a predominantly indigent, low-literate, African American, inner-city population. Participants Of 433 patients who presented for routine primary care, had vaccine indications (age greater than or equal to 65 years or chronic disease), and had not been previously vaccinated, 221 were randomly assigned to the intervention group and 212 to the control group. Of the total patient population (mean age, 63 years), 280 (64.7%) had less than a high school education, 401 (92.6%) were African American, and 300 (69.3%) were female. Intervention One-page, low-literacy (below fifth-grade level) educational handout encouraging patients to "ask your doctor about the pneumonia shot" vs a control group (1-page, low-literacy educational handout conveying information about nutrition). Main Outcome Measures Vaccination rates (documented by chart audit) of patients who received pneumococcal vaccination and rates of patients who self-reported having discussed vaccination with their physicians. Results Patients in the intervention group were 4 times more likely to have discussed the pneumococcal vaccine with their physicians than patients in the control group (87/ 221 [39.4%] vs 21/212 [9.9%]; relative risk [RR], 3.97 [95% confidence interval {CI}, 2.71-5.83]), and were more than 5 times as likely to have received the pneumococcal vaccine than the control group (44/221 [19.9%] vs 8/212 [3.8%]; RR, 5.28 [95% CI, 2.80-9.93]). In a multivariate analysis controlling for race, sex, education, insurance status, age, level of physician training, health status, and vaccine indication, only assignment to the intervention group was statistically significantly related to the probability of being immunized or discussing the issue with their physicians (P<.001 for both trends). Conclusions A simple, low-literacy educational tool increased pneumococcal vaccination rates and patient-physician discussions about the vaccine in an elderly, low-literate, indigent, minority population.	Emory Univ, Sch Med, Dept Med, Atlanta, GA 30303 USA; Grady Hlth Syst, Off Hlth Promot & Dis Prevent, Atlanta, GA USA; Atlantic Vet Affairs Med Ctr, Atlanta, GA USA; Georgia Emerging Infect Program, Atlanta, GA USA	Emory University	Jacobson, TA (corresponding author), Emory Univ, Sch Med, Dept Med, Thomas Glenn Bldg,69 Butler St SE, Atlanta, GA 30303 USA.		Jacobson, Terry/AAK-4757-2020	Jacobson, Terry/0000-0002-9926-2179; Ray, Susan/0000-0002-6327-088X				[Anonymous], MMWR; ATKINSON W, 1999, EPIDEMIOLOGY PREVENT; BELCHER DW, 1990, ARCH INTERN MED, V150, P2533, DOI 10.1001/archinte.150.12.2533; *CDC, 1984, MMWR-MORBID MORTAL W, V33, P273; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Davis T., 1994, Journal of General Internal Medicine, V9, P103; Davis TC, 1998, PATIENT EDUC COUNS, V33, P25, DOI 10.1016/S0738-3991(97)00053-0; Davis TC, 1998, J GEN INTERN MED, V13, P230, DOI 10.1046/j.1525-1497.1998.00072.x; Doern GV, 1998, CLIN INFECT DIS, V27, P764, DOI 10.1086/514953; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Kirsch I, 1993, ADULT LITERACY AM 1; Mayeaux EJ, 1996, AM FAM PHYSICIAN, V53, P205; *US PHS, 1991, HLTH PEOPL 2000 NAT; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616	15	116	116	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					646	650		10.1001/jama.282.7.646	http://dx.doi.org/10.1001/jama.282.7.646			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517717	Bronze			2022-12-28	WOS:000082033700023
J	Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R				Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R			Sequencing complex polysaccharides	SCIENCE			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ENZYMATIC DEGRADATION; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; BINDING	Although rapid sequencing of polynucleotides and polypeptides has become commonplace, it has not been possible to rapidly sequence femto- to picomole amounts of tissue-derived complex polysaccharides. Heparin-like glycosaminoglycans (HLGAGs) were readily sequenced by a combination of matrix-assisted Laser desorption ionization mass spectrometry and a notation system for representation of polysaccharide sequences. This will enable identification of sequences that are critical to HLGAG biological activities in anticoagulation, cell growth, and differentiation.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.				NIGMS NIH HHS [GM 57073] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Conrad H. E., 1998, HEPARIN BINDING PROT; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jacquet A, 1998, VIRUS RES, V53, P197, DOI 10.1016/S0168-1702(97)00149-4; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DL, 1989, HEPARIN CHEM BIOL PR; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1995, THROMB RES, V75, P1; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; TURNBULL JH, 1999, P NATL ACAD SCI USA, V96, P2703; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	29	210	249	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					537	542		10.1126/science.286.5439.537	http://dx.doi.org/10.1126/science.286.5439.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521350				2022-12-28	WOS:000083121200062
J	Coats, TJ; Walter, DP				Coats, TJ; Walter, DP			Effect of station design on death in the London Underground: observational study	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE		Royal London Hosp, St Bartholomews & Royal London Sch Med, London E1 1BB, England; Royal London Hosp, London Helicopter Emergency Med Serv, London, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Coats, TJ (corresponding author), Royal London Hosp, St Bartholomews & Royal London Sch Med, London E1 1BB, England.		Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784; Walter, Darren/0000-0002-0819-3287				CLARKE RV, 1994, SOC SCI MED, V38, P443, DOI 10.1016/0277-9536(94)90445-6; COCKS RA, 1987, BMJ-BRIT MED J, V295, P1527, DOI 10.1136/bmj.295.6612.1527; JOHNSTON DWC, 1984, J TRAUMA, V24, P619, DOI 10.1097/00005373-198407000-00012; MYERS C, 1963, T ASS INDEPENDENT ME, V13, P93; ODONNELL I, 1994, SOC SCI MED, V38, P409, DOI 10.1016/0277-9536(94)90440-5	5	18	18	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					957	957		10.1136/bmj.319.7215.957	http://dx.doi.org/10.1136/bmj.319.7215.957			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514158	Green Published, Bronze			2022-12-28	WOS:000083111700025
J	Dyson, T				Dyson, T			Prospects for feeding the world	BRITISH MEDICAL JOURNAL			English	Article									London Sch Econ, Dept Social Policy, London WC2A 2AE, England	University of London; London School Economics & Political Science	Dyson, T (corresponding author), London Sch Econ, Dept Social Policy, London WC2A 2AE, England.							Alexandratos N, 1999, P NATL ACAD SCI USA, V96, P5908, DOI 10.1073/pnas.96.11.5908; ALEXANDRATOS N., 1995, WORLD AGR 2010; Bongaarts J, 1996, POPUL DEV REV, V22, P483, DOI 10.2307/2137717; Brown L.R., 1995, WHO WILL FEED CHINA; CROSSON P, 1996, PERSPECTIVES LONG TE; DYSON I, 1996, POPULATION FOOD; Dyson T, 1999, P NATL ACAD SCI USA, V96, P5929, DOI 10.1073/pnas.96.11.5929; *FAO, 1952, PROD YB; *FAO, 1992, 192 FAO ESS; *INT FOOD POL RES, 1995, 2020 VIS FOOD AGR EN; MITCHELL DO, 1997, WORLD FOOD OUTLOOK; REEVES G, 1996, FOOD SECURITY FUTURE; ROSENZWEIG C, 1994, NATURE, V367, P133, DOI 10.1038/367133a0; WAGGONER PE, 1995, PHYS TODAY, V48, P74, DOI 10.1063/1.2808148	14	9	10	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					988	990		10.1136/bmj.319.7215.988	http://dx.doi.org/10.1136/bmj.319.7215.988			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514168	Green Published			2022-12-28	WOS:000083111700036
J	Napoli, C; Glass, CK; Witztum, JL; Deutsch, R; D'Armiento, FP; Palinski, W				Napoli, C; Glass, CK; Witztum, JL; Deutsch, R; D'Armiento, FP; Palinski, W			Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; CHOLESTEROL HOMEOSTASIS; OXIDATIVE MODIFICATION; VITAMIN-E; FETAL; ASSOCIATION; PRAVASTATIN; SUSCEPTIBILITY	Background Children generally have low cholesterol and no clinical manifestations of atherosclerosis, but fatty-streak formation begins in fetuses and is greatly increased by maternal hypercholesterolaemia during pregnancy. In the FELIC study we assessed the evolution of such lesions during childhood. Methods Computer-assisted imaging was used to measure the area of the largest individual lesion and the cumulative lesion area per section in serial cross-sections through the entire aortic arch and abdominal aorta of 156 normocholesterolaemic children aged 1-13 years, who died of trauma and other causes. Children were classified by whether their mother had been normocholesterolaemic (n=97) or hypercholesterolaemic (n=59) during pregnancy. Atherosclerosis was correlated with 13 established or potential risk factors. Findings The largest fatty streaks in the aortic arch of children younger than 3 years of hypercholesterolaemic mothers were 64% smaller than those previously found in corresponding fetuses (p<0.0001), which suggests that fetal fatty streaks may regress after birth. In the two groups, lesion size in the aortic arch and abdominal aorta increased linearly with age (r=0.87-0.98). However, lesions progressed strikingly faster in children of hypercholesterolaemic mothers than in those of normocholesterolaemic mothers (p<0.0001). Conventional risk factors for atherosclerosis in children or mothers correlated with lesion size, but did not account for the faster progression of atherogenesis in normocholesterolaemic children of hypercholesterolaemic mothers. Interpretation Our results suggest that maternal hypercholesterolaemia during pregnancy induces changes in the fetal aorta that determine the long-term susceptibility of children to fatty-streak formation and subsequent atherosclerosis. If so, cholesterol-lowering interventions in hypercholesterolaemic mothers during pregnancy may decrease atherogenesis in children.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy; Univ Naples Federico II, Dept Human Pathol, Naples, Italy; Univ Calif San Diego, Gen Clin Res Ctr, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of Naples Federico II; University of Naples Federico II; University of California System; University of California San Diego	Napoli, C (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cnapoli@ucsd.edu; wpalinski@ucsd.edu	Palinski, Wulf/AAW-8032-2021; Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Napoli, Claudio/0000-0002-5455-555X; D'ARMIENTO, Francesco Paolo/0000-0002-1391-6451; Palinski, Wulf/0000-0002-5113-0169	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00827] Funding Source: Medline; NHLBI NIH HHS [HL56989] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARKER DJP, 1989, LANCET, V2, P577; BELKNAP WM, 1988, J CLIN INVEST, V82, P2077, DOI 10.1172/JCI113829; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Berge LN, 1996, ACTA OBSTET GYN SCAN, V75, P439, DOI 10.3109/00016349609033350; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brunner E, 1997, AM J PUBLIC HEALTH, V87, P1415, DOI 10.2105/AJPH.87.9.1415; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; *CONS C, 1985, JAMA-J AM MED ASSOC, V153, P2080; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GOWN AM, 1986, AM J PATHOL, V125, P191; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Kilby MD, 1998, J CLIN ENDOCR METAB, V83, P1736, DOI 10.1210/jc.83.5.1736; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; Martyn CN, 1998, LANCET, V352, P173, DOI 10.1016/S0140-6736(97)10404-4; MCMURRY MP, 1981, METABOLISM, V30, P869, DOI 10.1016/0026-0495(81)90065-2; MONTES A, 1984, ARTERIOSCLEROSIS, V4, P407, DOI 10.1161/01.ATV.4.4.407; Napoli C, 1997, AM HEART J, V133, P585, DOI 10.1016/S0002-8703(97)70155-8; Napoli C, 1999, CIRCULATION, V99, P2003, DOI 10.1161/01.CIR.99.15.2003; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Napoli C, 1998, CORONARY ARTERY DIS, V9, P257, DOI 10.1097/00019501-199809050-00003; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PAIGEN B, 1989, GENETICS, V122, P163; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PALINSKI W, 2000, IN PRESS J INTERN ME; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; Reaven PD, 1999, EXP GERONTOL, V34, P527, DOI 10.1016/S0531-5565(99)00037-6; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; Steinberg D., 1999, MOL BASIS CARDIOVASC, P458; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	47	463	473	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1234	1241		10.1016/S0140-6736(99)02131-5	http://dx.doi.org/10.1016/S0140-6736(99)02131-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520631	Green Submitted			2022-12-28	WOS:000083010400008
J	Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS				Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS			Congenital nephrotic syndrome in mice lacking CD2-associated protein	SCIENCE			English	Article							PODOCYTES; CONTACTS; GENES	CD2-associated protein (CD2AP) is an 80-kilodalton protein that is critical for stabilizing contacts between T cells and antigen-presenting cells. In CD2AP-deficient mice, immune function was compromised, but the mice died at 6 to 7 weeks of age from renal failure. In the kidney, CD2AP was expressed primarily in glomerular epithelial cells. Knockout mice exhibited defects in epithelial tell foot processes, accompanied by mesangial cell hyperplasia and extracellular matrix deposition. Supporting a role for CD2AP in the specialized cell junction known as the slit diaphragm, CD2AP associated with nephrin, the primary component of the slit diaphragm.	Washington Univ, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Dept Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Shih, NY (corresponding author), Washington Univ, Ctr Immunol, St Louis, MO 63110 USA.		Shih, Neng-Yao/D-2086-2010; Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; GAUEN LT, 1992, MOL CELL BIOL, V38, P5438; KATO M, 1988, J CELL BIOL, V106, P2203, DOI 10.1083/jcb.106.6.2203; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SHIH N, UNPUB	14	628	683	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					312	315		10.1126/science.286.5438.312	http://dx.doi.org/10.1126/science.286.5438.312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514378				2022-12-28	WOS:000083024400050
J	Ackerman, MJ; Tester, DJ; Porter, CJ; Edwards, WD				Ackerman, MJ; Tester, DJ; Porter, CJ; Edwards, WD			Molecular diagnosis of the inherited long-QT syndrome in a woman who died after near-drowning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KVLQT1		Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Mayo Eugenio Litta Childrens Hosp, Pediat Cardiol Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Ackerman, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Mayo Eugenio Litta Childrens Hosp, Pediat Cardiol Sect, 200 1st St SW, Rochester, MN 55905 USA.							Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Ackerman MJ, 1998, PEDIATR RES, V44, P148, DOI 10.1203/00006450-199808000-00002; Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; GARSON A, 1993, CIRCULATION, V87, P1866, DOI 10.1161/01.CIR.87.6.1866; Kallas Harry J., 1993, Current Opinion in Pediatrics, V5, P295; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; Mizuta Ryuzo, 1993, Acta Paediatrica Japonica, V35, P186; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; OFlaherty JE, 1997, PEDIATRICS, V99, P169, DOI 10.1542/peds.99.2.169; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	14	89	92	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1121	1125		10.1056/NEJM199910073411504	http://dx.doi.org/10.1056/NEJM199910073411504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511610				2022-12-28	WOS:000083087200004
J	Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF				Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF			Reconstitution of actin-based motility of Listeria and Shigella using pure proteins	NATURE			English	Article							FILAMENT TURNOVER; CELL MOTILITY; MONOCYTOGENES; SURFACE; DYNAMICS; FLEXNERI; POLYMERIZATION; SUFFICIENT; NUCLEATION; COMPLEX	Actin polymerization is essential for cell locomotion and is thought to generate the force responsible for cellular protrusions. The Arp2/3 complex is required to stimulate actin assembly at the leading edge in response to signalling(1-6). The bacteria Listeria and Shigella bypass the signalling pathway and harness the Arp2/3 complex to induce actin assembly and to propel themselves in living cells(7-10). However, the Arp2/3 complex alone is insufficient to promote movement. Here we have used pure components of the actin cytoskeleton to reconstitute sustained movement in Listeria and Shigella in vitro. Actin-based propulsion is driven by the free energy released by ATP hydrolysis linked to actin polymerization, and does not require myosin. In addition to actin and activated Arp2/3 complex, actin depolymerizing factor (ADF, or cofilin) and capping protein are also required for motility as they maintain a high steady-state level of G-actin, which controls the rate of unidirectional growth of actin filaments at the surface of the bacterium. The movement is more effective when profilin, alpha-actinin and VASP (for Listeria) are also included. These results have implications for our understanding of the mechanism of actin-based motility in cells.	CNRS, LEBS, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, LEBS, Gif Sur Yvette, France.	carlier@lebs.caps-gif.fr		Boujemaa-Paterski, Rajaa/0000-0001-9645-387X				Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; Goldberg MB, 1997, CELL MOTIL CYTOSKEL, V37, P44, DOI 10.1002/(SICI)1097-0169(1997)37:1<44::AID-CM5>3.3.CO;2-S; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NANAVATI D, 1994, CELL MOTIL CYTOSKEL, V28, P346, DOI 10.1002/cm.970280408; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Sun J P, 1995, J Am Soc Echocardiogr, V8, P29, DOI 10.1016/S0894-7317(05)80355-4; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	31	787	800	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					613	616		10.1038/44183	http://dx.doi.org/10.1038/44183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524632				2022-12-28	WOS:000083054900057
J	Millstone, E; Brunner, E; Mayer, S				Millstone, E; Brunner, E; Mayer, S			Beyond 'substantial equivalence'	NATURE			English	Editorial Material									Univ Sussex, Sci Policy Res Unit, Brighton BN1 9RF, E Sussex, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; GeneWatch UK, Buxton SK17 8NY, Derby, England	University of Sussex; University of London; University College London	Millstone, E (corresponding author), Univ Sussex, Sci Policy Res Unit, Mantell Bldg, Brighton BN1 9RF, E Sussex, England.	e.p.millstone@sussex.ac.uk	Kesim, Haydar K/B-4662-2010; Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474				Bowers J, 1999, SCIENCE, V285, P1562, DOI 10.1126/science.285.5433.1562; *EUR COMM, 1980, FOOD ADD CONS, P41; KUIPER H, 1998, FOOD SAFETY EVALUATI; LYDON J, 1989, PESTIC SCI, V25, P361, DOI 10.1002/ps.2780250406; Masood E, 1999, NATURE, V398, P98, DOI 10.1038/18086; *OECD, 1993, SAF EV FOODS DER MOD; Padgette SR, 1996, J NUTR, V126, P702, DOI 10.1093/jn/126.3.702; WHO, 1991, STRAT ASS SAF FOODS	8	200	226	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					525	526		10.1038/44006	http://dx.doi.org/10.1038/44006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524614				2022-12-28	WOS:000083054900020
J	Dammers, JWHH; Veering, MM; Vermeulen, M				Dammers, JWHH; Veering, MM; Vermeulen, M			Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial	BRITISH MEDICAL JOURNAL			English	Article							EFFICACY	Objective To assess the effect of a 40 mg methylprednisolone injection proximal to the carpal tunnel in patients with the carpal tunnel syndrome. Design Randomised double blind placebo controlled trial. Setting Outpatient neurology clinic in a district general hospital. Participants Patients with symptoms of the carpal tunnel syndrome for more than 3 months, confirmed by electrophysiological tests and aged over 18 years. Intervention Injection with 10 mg lignocaine (lidocaine) or 10 mg lignocaine and 10 mg methylprednisolone. Non-responders who had received lignocaine received 40 mg methylprednisolone and 10 mg lignocaine and were followed in an open study. Main outcome measures Participants were scored as having improved or not improved. Improved was defined as no symptoms or minor symptoms requiring no further treatment. Results At 1 month 6 (20%) of 30 patients in the control group had improved compared with 23 (77%) of 30 patients the intervention group (difference 57% (95% confidence interval 36% to 77%)). After 1 year, 2 of 6 improved patients in the control group did not need a second treatment, compared with 15 of 23 improved patients in the intervention group (difference 43% (23% to 63%), Of the 28 non-responders in the control group, 24 (86%) improved after methylprednisolone. Of these 24 patients, 12 needed surgical treatment within one year. Conclusion A single injection with steroids close to the carpal tunnel may result in long term improvement and should be considered before surgical decompression.	Med Ctr Alkmaar, Dept Neurol, NL-1800 AM Alkmaar, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands	Medical Center Of Alkmaar; University of Amsterdam; Academic Medical Center Amsterdam	Dammers, JWHH (corresponding author), Med Ctr Alkmaar, Dept Neurol, POB 501, NL-1800 AM Alkmaar, Netherlands.							ALTROCCHI PH, 1993, NEUROLOGY, V43, P2406; BURTON RI, 1994, ARCH NEUROL-CHICAGO, V51, P641; Ebenbichler GR, 1998, BRIT MED J, V316, P731, DOI 10.1136/bmj.316.7133.731; GIRLANDA P, 1993, J NEUROL, V240, P187, DOI 10.1007/BF00857526; GREEN DP, 1984, J HAND SURG-AM, V9A, P850, DOI 10.1016/S0363-5023(84)80065-9; Irwin LR, 1996, J HAND SURG-BRIT EUR, V21B, P355, DOI 10.1016/S0266-7681(05)80202-5; OZDOGAN H, 1984, BRIT J RHEUMATOL, V23, P272; PHALEN GS, 1972, CLIN ORTHOP RELAT R, P29; WOOD MR, 1980, HAND, V12, P62, DOI 10.1016/S0072-968X(80)80031-3	9	131	134	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					884	886		10.1136/bmj.319.7214.884	http://dx.doi.org/10.1136/bmj.319.7214.884			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506042	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000082975600022
J	Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC				Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC			Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; CEREBRAL BLOOD-FLOW; TOTAL HEPATECTOMY; BODY-TEMPERATURE; CONTROLLED TRIAL; BRAIN EDEMA; GLUTAMINE; RAT; METABOLISM; AMMONIA	Background Increased intracranial pressure as a complication of acute liver failure has a mortality of about 90% in patients who do not respond to treatment with mannitol and ultrafiltration. We investigated the safety and efficacy of moderate hypothermia for uncontrolled increase in intracranial pressure in patients with acute liver failure. Methods We studied seven consecutive patients aged 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver failure who fulfilled criteria for poor-prognosis liver failure and had increased intracranial pressure that was unresponsive to two treatments with mannitol and ultrafiltration. We used cooling blankets to lower the patients' core temperature to 32-33 degrees C. Patients who were not suitable candidates for OLT (patients 1-3) were cooled for 8 h and then gradually rewarmed over 1 h to 8 baseline temperature of 37 degrees C. Patients who were suitable candidates for OLT (patients 4-7) were cooled before and during the OLT procedure; We measured cerebral blood flow and metabolic indices before and after cooling. Findings The four patients who were candidates for OLT were successfully maintained until transplantation with 13 (range 10-14) h of hypothermia. The three patients who were unsuitable candidates for OLT died after rewarming. Intracranial pressure before cooling was 45 (25-49) mm Hg and was reduced in all patients to 16 (13-17) mm Hg (p<0.05). Cerebral blood flow decreased from 103 (25-134) mt 100 g(-1) min(-1) before cooling to 44 (24-75) mt 100 g(-1) min(-1) after cooling (p<005). The corresponding changes for cerebral perfusion pressure was an increase from 45 (37-56) mm Hg to 70 (60-78) mm Hg (p<0.05) and for cardiac index a decrease from 9.8 (7-13) to 5.1 (4.3-6.1) L per min per m(2) of body surface area. During hypothermia there was no significant relapse of increased intracranial pressure. Arterial ammonia and cerebral uptake of ammonia were significantly reduced with cooling. No adverse effects of hypothermia were observed. Interpretation Moderate hypothermia is useful in the treatment of uncontrolled increase in intracranial pressure in patients with acute liver failure and may serve as a bridge to OLT.	Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Scottish Liver Transplantat Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Dept Anaesthet, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Intens Care Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Maastricht Univ, Dept Surg, Maastricht, Netherlands	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Maastricht University	Jalan, R (corresponding author), Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Deutz, Nicolaas E/J-5200-2012; Damink, Steven WM Olde/U-7919-2019	Damink, Steven WM Olde/0000-0002-5202-9345; Deutz, Nicolaas/0000-0001-5845-6447	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGARWAL S, 1994, HEPATOLOGY, V19, P80, DOI 10.1002/hep.1840190114; ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEJONG CHC, 1993, J CLIN INVEST, V92, P2834, DOI 10.1172/JCI116903; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; Eguchi S, 1996, HEPATOLOGY, V24, P1452; EJLERSEN E, 1994, TRANSPLANT P, V26, P1794; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; JACOBSEN M, 1989, J CEREB BLOOD FLOW M, V9, P717; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Larsen FS, 1996, SEMIN LIVER DIS, V16, P281, DOI 10.1055/s-2007-1007241; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCONNELL JR, 1995, HEPATOLOGY, V22, P69, DOI 10.1016/0270-9139(95)90354-2; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OLAFSSON S, 1995, GASTROENTEROLOGY, V108, P1097, DOI 10.1016/0016-5085(95)90208-2; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; Philips BJ, 1998, HEPATOLOGY, V27, P369, DOI 10.1002/hep.510270209; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; TAKAHASHI H, 1991, AM J PHYSIOL, V261, P825; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trey C, 1970, Prog Liver Dis, V3, P282; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9	30	255	265	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1164	1168		10.1016/S0140-6736(98)12440-6	http://dx.doi.org/10.1016/S0140-6736(98)12440-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513710				2022-12-28	WOS:000082954100012
J	Micchelli, CA; Blair, SS				Micchelli, CA; Blair, SS			Dorsoventral lineage restriction in wing imaginal discs requires Notch	NATURE			English	Article							DORSAL-VENTRAL BOUNDARY; GENE-EXPRESSION; VESTIGIAL GENE; DROSOPHILA; SERRATE; FRINGE; ACTIVATION; CELLS; COMPARTMENT; SIGNAL	The formation of boundaries that prevent the intermixing of cells is an important developmental patterning mechanism. The compartmental lineage restrictions that appear in the developing imaginal discs of Drosophila are striking examples of such boundaries(1). However, little is known about the cellular mechanism underlying compartmental lineage restrictions. The dorsoventral (D/V) lineage restriction that arises late in the developing wing imaginal disc requires the dorsal expression of the transcription factor Apterous and it has been hypothesized that apterous (ap) maintains compartmentalization by directly regulating the expression of molecules that modify cell adhesion or affinity(2). However, ap expression also regulates signalling between dorsal and ventral compartments, resulting in high levels of Notch signalling at the D/V boundary(3-17). Here we show that the formation of Notch-dependent boundary cells ig required for the D/V lineage restriction.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Blair, SS (corresponding author), Univ Wisconsin, Dept Zool, 250 N Mills St, Madison, WI 53706 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; Blair SS, 1997, CURR BIOL, V7, pR686, DOI 10.1016/S0960-9822(06)00356-3; BLAIR SS, 1999, DEV GENETICS EPIGENE, P347; Brennan K, 1997, GENETICS, V147, P177; BROWER DL, 1985, DEV BIOL, V108, P120, DOI 10.1016/0012-1606(85)90014-4; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gho M, 1996, DEVELOPMENT, V122, P1673; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Klein T, 1998, DEVELOPMENT, V125, P2951; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9	30	87	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					473	476		10.1038/46779	http://dx.doi.org/10.1038/46779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519549				2022-12-28	WOS:000082981200055
J	Evans, RL; Tarits, P; Chave, AD; White, A; Heinson, G; Filloux, JH; Toh, H; Seama, N; Utada, H; Booker, JR; Unsworth, MJ				Evans, RL; Tarits, P; Chave, AD; White, A; Heinson, G; Filloux, JH; Toh, H; Seama, N; Utada, H; Booker, JR; Unsworth, MJ			Asymmetric electrical structure in the mantle beneath the East Pacific rise at 17 degrees S	SCIENCE			English	Article							MID-OCEAN RIDGES; GALVANIC DISTORTION; MELT EXTRACTION; WATER; CONDUCTIVITY; INVERSION; MAGMA; WAVE; HYDROGEN; GARNET	The magnetotelluric component of the Mantle Electromagnetic and Tomography (MELT) Experiment measured the electrical resistivity structure of the mantle beneath the fast-spreading southern East Pacific Rise (EPR). The data reveal an asymmetric resistivity structure, with lower resistivity to the west of the ridge. The uppermost 100 kilometers of mantle immediately to the east of the ridge is consistent with a dry olivine resistivity structure indicating a mantle depleted of melt and volatiles. Mantle resistivities to the west of the ridge are consistent with a Low-melt fraction (about 1 to 2 percent interconnected melt) distributed over a broad region and extending to depths of about 150 kilometers, The asymmetry in resistivity structure may be the result of asymmetric spreading rates and a westward migration of the ridge axis and suggests distinct styles of melt formation and delivery in the mantle beneath the two plates.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Flinders Univ S Australia, Adelaide, SA 5042, Australia; Univ Bretagne Occidentale, CNRS, UMR 6538, Brest, France; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Toyama Univ, Toyama 9308555, Japan; Chiba Univ, Chiba, Japan; Univ Tokyo, Earthquake Res Inst, Tokyo 113, Japan; Univ Washington, Geophys Program AK50, Seattle, WA 98195 USA	Woods Hole Oceanographic Institution; Flinders University South Australia; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Bretagne Occidentale; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Toyama; Chiba University; University of Tokyo; University of Washington; University of Washington Seattle	Evans, RL (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	revans@whoi.edu	evans, rob/C-6887-2011; Unsworth, Martyn J/A-6395-2012; Utada, Hisashi/S-8093-2016	Unsworth, Martyn J/0000-0001-8282-4174; Utada, Hisashi/0000-0001-5885-5675; Evans, Robert/0000-0001-5585-0684; Heinson, Graham/0000-0001-7106-0789				BAI Q, 1992, NATURE, V357, P672, DOI 10.1038/357672a0; BEATTIE P, 1993, NATURE, V363, P63, DOI 10.1038/363063a0; BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; BRAUN MG, 1997, EOS, V78, P693; BUCK WR, 1989, GEOPHYS RES LETT, V16, P641, DOI 10.1029/GL016i007p00641; Canales JP, 1998, SCIENCE, V280, P1218, DOI 10.1126/science.280.5367.1218; CHAVE AD, 1994, J GEOPHYS RES-SOL EA, V99, P4669, DOI 10.1029/93JB03368; CHAVE AD, 1989, J GEOPHYS RES-SOLID, V94, P14215, DOI 10.1029/JB094iB10p14215; CHAVE AD, IN PRESS; CONSTABLE SC, 1991, J GEOPHYS RES, V97, P3397; EVANS RL, 1992, GEOPH MONOG SERIES, V71, P353; Filloux J. H., 1987, GEOMAGN AERONOMY+, V1, P143; FILLOUX JH, 1979, REV GEOPHYS, V17, P282, DOI 10.1029/RG017i002p00282; FISCHER G, 1981, GEOPHYS J ROY ASTR S, V67, P257, DOI 10.1111/j.1365-246X.1981.tb02749.x; Forsyth D.W., 1994, EOS T AM GEOPHYS UN, V75, P537, DOI [10.1029/94eo02023, DOI 10.1029/94EO02023]; Forsyth DW, 1998, SCIENCE, V280, P1235, DOI 10.1126/science.280.5367.1235; Forsyth DW, 1998, SCIENCE, V280, P1215, DOI 10.1126/science.280.5367.1235; GALER SJG, 1986, CHEM GEOL, V56, P45, DOI 10.1016/0009-2541(86)90109-9; GROOM RW, 1989, J GEOPHYS RES-SOLID, V94, P1913, DOI 10.1029/JB094iB02p01913; HESS PC, 1992, GEOPH MONOG SERIES, V71, P67; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; KARATO S, 1990, NATURE, V347, P272, DOI 10.1038/347272a0; LIZARRALDE D, 1995, J GEOPHYS RES-SOL EA, V100, P17837, DOI 10.1029/95JB01244; MACKWELL SJ, 1990, J GEOPHYS RES-SOLID, V95, P5079, DOI 10.1029/JB095iB04p05079; MCKENZIE D, 1985, EARTH PLANET SC LETT, V74, P81, DOI 10.1016/0012-821X(85)90168-2; MCKENZIE DP, 1985, J PETROL, V25, P713; MENVIELLE M, 1982, PHYS EARTH PLANET IN, V28, P118, DOI 10.1016/0031-9201(82)90077-2; Nolasco R, 1998, J GEOPHYS RES-SOL EA, V103, P30287, DOI 10.1029/98JB02129; PERROT K, 1998, THESIS U BRETAGNE OC; Roberts JJ, 1999, J GEOPHYS RES-SOL EA, V104, P7055, DOI 10.1029/1998JB900111; SALTERS VJM, 1989, NATURE, V342, P420, DOI 10.1038/342420a0; Scheirer DS, 1998, SCIENCE, V280, P1221, DOI 10.1126/science.280.5367.1221; SCOTT DR, 1992, GEOPH MONOG SERIES, V71, P327; SCOTT DR, 1989, J GEOPHYS RES-SOLID, V94, P2973, DOI 10.1029/JB094iB03p02973; SHANKLAND TJ, 1977, J GEOPHYS RES, V82, P5409, DOI 10.1029/JB082i033p05409; Shen Y, 1998, SCIENCE, V280, P1232, DOI 10.1126/science.280.5367.1232; SMITH JT, 1991, J GEOPHYS RES-SOLID, V96, P3905, DOI 10.1029/90JB02416; SPIEGELMAN M, 1987, EARTH PLANET SC LETT, V83, P137, DOI 10.1016/0012-821X(87)90057-4; TARITS P, 1983, CAN J EARTH SCI, V20, P537, DOI 10.1139/e83-051; TERRA A, 1993, THESIS U PARIS 7; Thomson D. J, 1991, ADV SPECTRUM ANAL AR, VI, P58; Toomey DR, 1998, SCIENCE, V280, P1224, DOI 10.1126/science.280.5367.1224; VASSEUR G, 1977, GEOPHYS J ROY ASTR S, V51, P669, DOI 10.1111/j.1365-246X.1977.tb04213.x; Webb SC, 1998, SCIENCE, V280, P1227, DOI 10.1126/science.280.5367.1227; White SN, 1997, J GEOMAGN GEOELECTR, V49, P1373, DOI 10.5636/jgg.49.1373; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230; WYLLIE PJ, 1971, J GEOPHYS RES, V76, P1328, DOI 10.1029/JB076i005p01328	47	107	119	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					752	756		10.1126/science.286.5440.752	http://dx.doi.org/10.1126/science.286.5440.752			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531056				2022-12-28	WOS:000083303200048
J	Michikawa, Y; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G				Michikawa, Y; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G			Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; HUMAN BRAIN; SEQUENCE; HETEROPLASMY; GENOME; ORIGIN; LOOP; TRANSCRIPTION; HETEROGENEITY; VARIABILITY	Progressive damage to mitochondrial DNA (mtDNA) during Life is thought to contribute to aging processes. However, this idea has been difficult to reconcile with the small fraction of mtDNA so far found to be altered. Here, examination of mtDNA revealed high copy point mutations at specific positions in the control region for replication of human fibroblast mtDNA from normal old, but not young, individuals. Furthermore, in longitudinal studies, one or more mutations appeared in an individual only at an advanced age. Some mutations appeared in more than one individual. Most strikingly, a T414G transversion was found, in a generally high proportion (up to 50 percent) of mtDNA molecules, in 8 of 14 individuals above 65 years of age (57 percent) but was absent in 13 younger individuals.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Milan, Inst Clin Neurol, Dino Ferrari Ctr, IRCCS, I-20122 Milan, Italy; Osped Maggiore Milano Policlin, IRCCS, I-20122 Milan, Italy	California Institute of Technology; University of Milan	Attardi, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Bresolin, Nereo/0000-0001-6694-3595	NATIONAL INSTITUTE ON AGING [R01AG012117] Funding Source: NIH RePORTER; NIA NIH HHS [AG-12117-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GREENBERG BD, 1983, GENE, V21, P33, DOI 10.1016/0378-1119(83)90145-2; HARMAN D, 1983, AGE, V6, P86, DOI 10.1007/BF02432509; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HAUSWIRTH WW, 1985, NUCLEIC ACIDS RES, V13, P8093, DOI 10.1093/nar/13.22.8093; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894; Jazin EE, 1996, P NATL ACAD SCI USA, V93, P12382, DOI 10.1073/pnas.93.22.12382; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; Marchington DR, 1997, AM J HUM GENET, V60, P408; Michikawa Y, 1997, NUCLEIC ACIDS RES, V25, P2455, DOI 10.1093/nar/25.12.2455; MICHIKAWA Y, UNPUB; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; Pallotti F, 1996, AM J HUM GENET, V59, P591; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOONG NW, 1992, NAT GENET, V2, P318; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	28	558	586	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					774	779		10.1126/science.286.5440.774	http://dx.doi.org/10.1126/science.286.5440.774			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531063				2022-12-28	WOS:000083303200055
J	Sestan, N; Artavanis-Tsakonas, S; Rakic, P				Sestan, N; Artavanis-Tsakonas, S; Rakic, P			Contact-dependent inhibition of cortical neurite growth mediated by notch signaling	SCIENCE			English	Article							MAMMALIAN NUMB; IN-VITRO; NEUROGENESIS; DIFFERENTIATION; SYNAPTOGENESIS; TRANSCRIPTION; LOCALIZATION; ACTIVATION; DISEASE; PATHWAY	The exuberant growth of neurites during development becomes markedly reduced as cortical neurons mature. In vitro studies of neurons from mouse cerebral cortex revealed that contact-mediated Notch signaling regulates the capacity of neurons to extend and elaborate neurites, Up-regulation of Notch activity was concomitant with an increase in the number of interneuronal contacts and cessation of neurite growth. In neurons with low Notch activity, which readily extend neurites, up-regulation of Notch activity either inhibited extension or caused retraction of neurites. Conversely, in more mature neurons that had ceased their growth after establishing numerous connections and displayed high Notch activity,inhibition of Notch signaling promoted neurite extension. Thus, the formation of neuronal contacts results in activation of Notch receptors, Leading to restriction of neuronal growth and a subsequent arrest in maturity.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Yale University; Harvard University; Massachusetts General Hospital	Rakic, P (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.	pasko.rakic@yale.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS014841, R01NS026084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14841, NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUNN GA, 1971, J COMP NEUROL, V143, P491, DOI 10.1002/cne.901430406; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Horch HW, 1999, NEURON, V23, P353; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Olson EC, 1998, MOL CELL NEUROSCI, V12, P281, DOI 10.1006/mcne.1998.0712; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RAKIC P, 1982, DEV MODIFIABILITY CE; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SESTAN N, 1999, THESIS YALE U; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vamum-Finney B, 1998, BLOOD, V91, P4084; Van den Pol AN, 1998, J COMP NEUROL, V399, P541; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	50	476	498	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					741	746		10.1126/science.286.5440.741	http://dx.doi.org/10.1126/science.286.5440.741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531053				2022-12-28	WOS:000083303200045
J	Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M				Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M			beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE	SCIENCE			English	Article							TRANSGENIC MICE; DISEASE; PEPTIDE; CELLS; MUTATION; RELEASE; PURIFICATION; GENERATION; INHIBITION; RECEPTOR	Cerebral deposition of amyloid beta peptide (A beta) is an early and critical feature of Alzheimer's disease. A beta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular Localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.	Amgen Inc, Thousand Oaks, CA 91320 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Amgen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Citron, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.							Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 1996, AMYLOID, V3, P150, DOI 10.3109/13506129609045514; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CURRAN EJ, 1995, J COMP NEUROL, V361, P57, DOI 10.1002/cne.903610106; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gouras GK, 1998, J NEUROCHEM, V71, P1920; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	32	3154	3423	11	465	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					735	741		10.1126/science.286.5440.735	http://dx.doi.org/10.1126/science.286.5440.735			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531052	Green Published			2022-12-28	WOS:000083303200044
J	Hunter, JJ; Chien, KR				Hunter, JJ; Chien, KR			Mechanisms of disease - Signaling pathways for cardiac hypertrophy and failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MUSCLE CELL HYPERTROPHY; TRANSGENIC MICE; DILATED CARDIOMYOPATHY; GENE-EXPRESSION; HEART-FAILURE; VENTRICULAR MYOCYTES; DEPENDENT PATHWAYS; RECEPTOR; GROWTH; OVEREXPRESSION		Univ Calif San Diego, Salk Inst, Program Mol Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Chien, KR (corresponding author), Univ Calif San Diego, Salk Inst, Program Mol Med, Dept Med, 0613-C,9500 Gilman Dr, La Jolla, CA 92093 USA.	kchien@ucsd.edu						Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; Chen J, 1998, DEVELOPMENT, V125, P1943; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CHIEN KR, 1997, HEART DIS TXB CARDIO, V2, P1626; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; CURRAN ME, 1999, MOL BASIS CARDIOVASC, P302; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; HUNTER JJ, 1993, HYPERTENSION, V22, P608, DOI 10.1161/01.HYP.22.4.608; HUNTER JJ, 1999, MOL BASIS CARDIOVASC, P211; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kai H, 1998, CIRC RES, V83, P594, DOI 10.1161/01.RES.83.6.594; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LIN MC, 1995, NAT MED, V1, P749, DOI 10.1038/nm0895-749; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINAMISAWA S, IN PRESS CELL; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P9907; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SEIDMAN CE, 1999, MOL BASIS CARDIOVASC, P251; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; THORBURN A, 1993, J BIOL CHEM, V268, P16082; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao RP, 1999, CIRC RES, V84, P43; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Young SG, 1999, MOL BASIS CARDIOVASC	55	676	713	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1276	1283		10.1056/NEJM199910213411706	http://dx.doi.org/10.1056/NEJM199910213411706			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528039				2022-12-28	WOS:000083226300006
J	Karnik, AM				Karnik, AM			Update in pulmonary diseases	ANNALS OF INTERNAL MEDICINE			English	Article							D-DIMER; EMBOLISM; WORKERS		Nassau Cty Med Ctr, E Meadow, NY 11554 USA		Karnik, AM (corresponding author), Nassau Cty Med Ctr, 2201 Hempstead Turnpike, E Meadow, NY 11554 USA.							Cormier Y, 1998, AM J RESP CRIT CARE, V158, P412, DOI 10.1164/ajrccm.158.2.9712095; Davidoff F, 1998, ANN INTERN MED, V129, P327, DOI 10.7326/0003-4819-129-4-199808150-00011; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; Oger E, 1998, AM J RESP CRIT CARE, V158, P65, DOI 10.1164/ajrccm.158.1.9710058; Shuchman M, 1998, ANN INTERN MED, V129, P341, DOI 10.7326/0003-4819-129-4-199808150-00032	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					596	604		10.7326/0003-4819-131-8-199910190-00009	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523221				2022-12-28	WOS:000083196600007
J	MacLennan, A				MacLennan, A		Int Cerebral Palsy Task Force	A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AUSTRALIAN CASE-CONTROL; NORMAL BIRTH-WEIGHT; NEONATAL ENCEPHALOPATHY; PERINATAL ASPHYXIA; RISK-FACTORS; NEWBORN ENCEPHALOPATHY; EXPERT WITNESS; TERM INFANTS; PLACENTAL INSUFFICIENCY; INTRAUTERINE GROWTH		Univ Adelaide, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Adelaide, SA 5006, Australia	University of Adelaide; Womens & Childrens Hospital Australia	MacLennan, A (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Adelaide, SA 5006, Australia.	amaclennan@medicine.aelaid.edu.au	Ferro-Flores, Guillermina/Q-8630-2019; Melendez-Alafort, Laura/B-8918-2013; Rosato, Antonio/E-8626-2010; Uzunov, Nikolay/H-1890-2018	Ferro-Flores, Guillermina/0000-0003-0296-7605; Melendez-Alafort, Laura/0000-0003-0701-3616; Rosato, Antonio/0000-0002-5263-8386; Uzunov, Nikolay/0000-0002-0777-9702				ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; *AM COLL OBST GYN, 1998, INAPPR US TERMS FET; Badawi N, 1998, DEV MED CHILD NEUROL, V40, P520; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Barkovich AJ, 1997, AM J NEURORADIOL, V18, P1816; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; BAX M, 1993, DEV MED CHILD NEUROL, V35, P1022; Belai YI, 1998, AM J OBSTET GYNECOL, V178, P13, DOI 10.1016/S0002-9378(98)70619-2; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; Burke CJ, 1997, DEV MED CHILD NEUROL, V39, P726; Danielian P, 1996, EUR J OBSTET GYN R B, V67, P121; EVRARD P, 1996, ACUTE PERINATAL ASPH, P43; FISHER CW, 1995, AM J OBSTET GYNECOL, V172, P1792, DOI 10.1016/0002-9378(95)91413-7; FREEMAN JM, 1988, PEDIATRICS, V82, P240; GOLDABER GK, OBSTET GYNECOL, V78, P1103; GOVAERT P, 1997, ATLAS NEONATAL BRAIN, P141; GRAFE MR, 1994, J NEUROPATH EXP NEUR, V53, P407, DOI 10.1097/00005072-199407000-00013; GRANT A, 1989, LANCET, V2, P1233; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; Kraus FT, 1997, HUM PATHOL, V28, P246, DOI 10.1016/S0046-8177(97)90114-3; LEVITON A, 1992, PEDIATR NEUROL, V8, P85, DOI 10.1016/0887-8994(92)90026-U; Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2; Low JA, 1997, AM J OBSTET GYNECOL, V176, P957, DOI 10.1016/S0002-9378(97)70385-5; MACLENNAN AH, 1995, MED J AUSTRALIA, V162, P85, DOI 10.5694/j.1326-5377.1995.tb138442.x; Mallard EC, 1998, PEDIATR RES, V43, P262, DOI 10.1203/00006450-199802000-00018; Manning FA, 1998, AM J OBSTET GYNECOL, V178, P696, DOI 10.1016/S0002-9378(98)70479-X; MARTINANCEL A, 1995, J PEDIATR-US, V127, P786, DOI 10.1016/S0022-3476(95)70174-5; MESCHIA G, 1994, MATERNAL FETAL MED P, P288; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1987, AM J DIS CHILD, V141, P1333, DOI 10.1001/archpedi.1987.04460120099045; NELSON KB, 1981, PEDIATRICS, V68, P36; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; Nelson KB, 1996, NEW ENGL J MED, V334, P613, DOI 10.1056/NEJM199603073341001; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; NELSON KB, 1993, CLIN PERINATOL, V20, P327, DOI 10.1016/S0095-5108(18)30396-8; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1989, CLIN PERINATOL, V16, P995, DOI 10.1016/S0095-5108(18)30617-1; Oh W, 1996, PEDIATRICS, V98, P141; Parer JT, 1997, AM J OBSTET GYNECOL, V177, P1385; Perlman JM, 1997, PEDIATRICS, V99, P851, DOI 10.1542/peds.99.6.851; PERLMAN JM, 1989, AM J DIS CHILD, V143, P617, DOI 10.1001/archpedi.1989.02150170119037; Phelan JP, 1998, J MATERN-FETAL INVES, V8, P1; Rees S, 1998, COMP BIOCHEM PHYS A, V119, P653, DOI 10.1016/S1095-6433(98)01001-0; ROBERTSON CMT, 1993, CLIN PERINATOL, V20, P483, DOI 10.1016/S0095-5108(18)30405-6; ROSENBLOOM L, 1994, DEV MED CHILD NEUROL, V36, P285; RUTH VJ, 1988, BRIT MED J, V297, P24, DOI 10.1136/bmj.297.6640.24; Samuels G, 1998, MED J AUSTRALIA, V168, P84, DOI 10.5694/j.1326-5377.1998.tb126721.x; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Sehdev HM, 1997, AM J OBSTET GYNECOL, V177, P1030, DOI 10.1016/S0002-9378(97)70008-5; *SOC OBST GYN CAN, 1997, J SOC OBSTET GYNAECO, V19, P296; *SOC OBST GYN CAN, 1996, J SOC OBSTET GYNAECO, V18, P1267; SOOTHILL PW, 1987, BRIT MED J, V294, P1051, DOI 10.1136/bmj.294.6579.1051; Spencer JAD, 1997, BRIT J OBSTET GYNAEC, V104, P25, DOI 10.1111/j.1471-0528.1997.tb10643.x; STANLEY F, 1999, IN PRESS CLIN DEV ME; STANLEY F, 1984, EPIDEMIOLOGY CEREBRA; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; Topp M, 1997, ACTA OBSTET GYN SCAN, V76, P843, DOI 10.3109/00016349709024363; UMSTAD MP, 1994, AUST NZ J OBSTET GYN, V34, P20, DOI 10.1111/j.1479-828X.1994.tb01032.x; van de Riet JE, 1999, AM J OBSTET GYNECOL, V180, P1024, DOI 10.1016/S0002-9378(99)70676-9; Volpe J, 1995, NEUROL NEWBORN, P467; WESTGATE J, 1994, BRIT J OBSTET GYNAEC, V101, P1054, DOI 10.1111/j.1471-0528.1994.tb13581.x; Willis F, 1997, ARCH DIS CHILD-FETAL, V77, pF57, DOI 10.1136/fn.77.1.F57; YUDKIN PL, 1995, PAEDIATR PERINAT EP, V9, P156, DOI 10.1111/j.1365-3016.1995.tb00131.x; Zain HA, 1998, J REPROD MED, V43, P367	70	464	476	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1999	319	7216					1054	1059		10.1136/bmj.319.7216.1054	http://dx.doi.org/10.1136/bmj.319.7216.1054			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521205	Green Submitted, Green Published			2022-12-28	WOS:000083210100034
J	Posnett, J				Posnett, J			The hospital of the future - Is bigger better? Concentration in the provision of secondary care	BRITISH MEDICAL JOURNAL			English	Editorial Material							VOLUME		Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England	University of York - UK	Posnett, J (corresponding author), Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ALETRAS V, 1997, CONCENTRATION CHOICE, P23; Bentham G, 1995, Soc Sci Med, V40, P131, DOI 10.1016/0277-9536(94)E0048-W; Carr-Hill R, 1997, CONCENTRATION CHOICE, P37; *EFF HLTH CAR B, 1996, HOSP VOL HLTH CAR OU; GODDARD M, 1997, HLTH EC SERIES; HOWLAND G, 1997, IHSM HLTH SOCIAL SER; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; SOWDEN A, 1997, CONCENTRATION CHOICE, P9; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151	9	55	57	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1063	1065		10.1136/bmj.319.7216.1063	http://dx.doi.org/10.1136/bmj.319.7216.1063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521207	Green Published			2022-12-28	WOS:000083210100037
J	Boguski, MS				Boguski, MS			Biosequence exegesis	SCIENCE			English	Editorial Material							SEQUENCE	Annotation of Large-scale gene sequence data will benefit from comprehensive and consistent application of well-documented, standard analysis methods and from progressive and vigilant efforts to ensure quality and utility and to keep the annotation up to date. However, it is imperative to Learn how to apply information derived from functional genomics and proteomics technologies to conceptualize and explain the behaviors of biological systems. Quantitative and dynamical models of systems behaviors will supersede the Limited and static forms of single-gene annotation that are now the norm. Molecular biological epistemology will increasingly encompass both teleological and causal explanations.	NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Boguski, MS (corresponding author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, 8600 Rockville Pike, Bethesda, MD 20894 USA.							BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Doolittle RF, 1997, J MOL MED-JMM, V75, P239; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Hayles K., 1999, WE BECAME POSTHUMAN, DOI 10.7208/chicago/9780226321394.001.0001; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; INSLOW RL, 1999, CIRC RES, V84, P571; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Judson H. F., 1996, 8 DAY CREATION; SANGER F, 1988, ANNU REV BIOCHEM, V57, P1, DOI 10.1146/annurev.bi.57.070188.000245; SHAW S, 1998, BRIT SOC IMM ANN M H; Sober E, 1993, PHILOS BIOL; Weiner J., 1999, TIME LOVE MEMORY GRE; Wheelan SJ, 1998, GENOME RES, V8, P168, DOI 10.1101/gr.8.3.168	14	44	48	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					453	455		10.1126/science.286.5439.453	http://dx.doi.org/10.1126/science.286.5439.453			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521334				2022-12-28	WOS:000083121200045
J	Bach, PB; Cramer, LD; Warren, JL; Begg, CB				Bach, PB; Cramer, LD; Warren, JL; Begg, CB			Racial differences in the treatment of early-stage lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOCIAL-FACTORS; THERAPY; VALIDATION; MORTALITY; MORBIDITY; SURVIVAL	Background If discovered at an early stage, non-small-cell lung cancer is potentially curable by surgical resection. However, two disparities have been noted between black patients and white patients with this disease. Blacks are less likely to receive surgical treatment than whites, and they are likely to die sooner than whites. We undertook a population-based study to estimate the disparity in the rates of surgical treatment and to evaluate the extent to which this disparity is associated with differences in overall survival. Methods We studied all black patients and white patients 65 years of age or older who were given a diagnosis of resectable non-small-cell lung cancer (stage I or II) between 1985 and 1993 and who resided in 1 of the 10 study areas of the Surveillance, Epidemiology, and End Results (SEER) program (10,984 patients). Data on the diagnosis, stage of disease, treatment, and demographic characteristics of the patients were obtained from the SEER data base. Information on coexisting illnesses, type of Medicare coverage, and survival was obtained from linked Medicare inpatient-discharge records. Results The rate of surgery was 12.7 percentage points lower for black patients than for white patients (64.0 percent vs. 76.7 percent, P<0.001), and the five-year survival rate was also lower for blacks (26.4 percent vs. 34.1 percent, P<0.001). However, among the patients undergoing surgery, survival was similar for the two racial groups, as it was among those who did not undergo surgery. Furthermore, analyses in which adjustments were made for factors that are predictive of either candidacy for surgery or survival did not alter the influence of race on these outcomes. Conclusions Our analyses suggest that the lower survival rate among black patients with early-stage, non-small-cell lung cancer, as compared with white patients, is largely explained by the lower rate of surgical treatment among blacks. Efforts to increase the rate of surgical treatment for black patients appear to be a promising way of improving survival in this group. (N Engl J Med 1999;341:1198-205.) (C)1999, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Pulm Serv, New York, NY 10021 USA; NCI, Appl Res Branch, Bethesda, MD USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bach, PB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave,Box 221, New York, NY 10021 USA.							ADAY LA, 1975, MED CARE, V13, P447, DOI 10.1097/00005650-197506000-00001; BallardBarbash R, 1996, JNCI-J NATL CANCER I, V88, P716, DOI 10.1093/jnci/88.11.716; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collett D, 1994, MODELLING SURVIVAL D; Culler SD, 1998, MED CARE, V36, P804, DOI 10.1097/00005650-199806000-00004; Dale W, 1996, PROSTATE, V29, P271, DOI 10.1002/(SICI)1097-0045(199611)29:5<271::AID-PROS1>3.0.CO;2-D; ETTINGER DS, 1996, ONCOLOGY S, V10, pS81; GILLUM RF, 1990, J NATL MED ASSOC, V82, P417; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; HAMMOND JR, 1976, AM J PUBLIC HEALTH, V66, P788, DOI 10.2105/AJPH.66.8.788; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lam W K, 1998, Respirology, V3, P51, DOI 10.1046/j.1440-1843.1998.d01-8.x; LIN AY, 1992, JAMA-J AM MED ASSOC, V267, P1661, DOI 10.1001/jama.267.12.1661; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; National Center for Health and Statistic, 1997, US DEC LIF TABL 1989, V1; Percy C., 1990, INT CLASSIFICATION D; POTOSKY AL, 1993, MED CARE, V31, P732; RIES LAG, 1997, NIH PUBLICATION; Riley GF, 1999, JAMA-J AM MED ASSOC, V281, P720, DOI 10.1001/jama.281.8.720; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SHIELDS TW, 1993, CLIN CHEST MED, V14, P121; Smith TJ, 1995, LUNG CANCER-J IASLC, V13, P235, DOI 10.1016/0169-5002(95)00496-3; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675	30	785	789	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1198	1205		10.1056/NEJM199910143411606	http://dx.doi.org/10.1056/NEJM199910143411606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245BY	10519898				2022-12-28	WOS:000083087400006
J	Baud, O; Foix-L'Helias, L; Kaminski, M; Audibert, F; Jarreau, PH; Papiernik, E; Huon, C; Lepercq, J; Dehan, M; Lacaze-Masmonteil, T				Baud, O; Foix-L'Helias, L; Kaminski, M; Audibert, F; Jarreau, PH; Papiernik, E; Huon, C; Lepercq, J; Dehan, M; Lacaze-Masmonteil, T			Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL HEART-RATE; RISK-FACTORS; CORTICOSTEROID-THERAPY; CEREBRAL-PALSY; BETAMETHASONE; DEXAMETHASONE; PEROXYNITRITE	Background Antenatal glucocorticoid therapy decreases the incidence of several complications among very premature infants. However, its effect on the occurrence of cystic periventricular leukomalacia, a major cause of cerebral palsy, remains unknown. Methods We retrospectively analyzed a cohort of 883 live-born infants, with gestational ages ranging from 24 to 31 weeks, who were born between January 1993 and December 1996 at three perinatal centers in the Paris area. The mothers of 361 infants had received betamethasone before delivery, the mothers of 165 infants had received dexamethasone before delivery, and the mothers of 357 infants did not receive glucocorticoids. We compared the rates of cystic periventricular leukomalacia among the three groups of infants in bivariate and multivariate analyses after adjustment for confounding factors. Results The rate of cystic periventricular leukomalacia was 4.4 percent among the infants whose mothers had received betamethasone, 11.0 percent among the infants whose mothers had received dexamethasone, and 8.4 percent among the infants whose mothers had not received a glucocorticoid. After adjustment for gestational age, the mode of delivery, and the presence or absence of chorioamnionitis, prolonged interval between the rupture of membranes and delivery (>24 hours), preeclampsia, and the use of tocolytic drugs, antenatal exposure to betamethasone was associated with a lower risk of cystic periventricular leukomalacia than was either the absence of glucocorticoid therapy (adjusted odds ratio, 0.5; 95 percent confidence interval, 0.2 to 0.9) or exposure to dexamethasone (adjusted odds ratio, 0.3; 95 percent confidence interval, 0.1 to 0.7). The adjusted odds ratio for the group of infants whose mothers had received dexamethasone as compared with the group of infants whose mothers had not received a glucocorticoid was 1.5 (95 percent confidence interval, 0.8 to 2.9). Conclusions Antenatal exposure to betamethasone but not dexamethasone is associated with a decreased risk of cystic periventricular leukomalacia among very premature infants. (N Engl J Med 1999;341:1190-6.) (C)1999, Massachusetts Medical Society.	Univ Hosp Antoine Beclere, Serv Reanimat Neonatale, Clamart, France; Univ Hosp Antoine Beclere, Serv Gynecol Obstet, Clamart, France; INSERM, U149, Unite Rech Epidemiol Sante Femmes & Enfants, Villejuif, France; Univ Hosp Cochin Port Royal, Serv Reanimat Neonatale, Paris, France; Univ Hosp Cochin Port Royal, Serv Gynecol Obstet, Paris, France; Univ Hosp St Vincent de Paul, Serv Reanimat Neonatale, Paris, France; Univ Hosp St Vincent de Paul, Serv Gynecol Obstet, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP	Lacaze-Masmonteil, T (corresponding author), Assistance Publ Hop Paris, Hop Antoine Beclere, 157 Rue Porte de Trivaux, F-92141 Clamart, France.		Foix-L'Hélias, Laurence/AAH-4933-2019; Audibert, François/AAL-1265-2020; Foix-L'Helias, Laurence/AAB-4375-2020	Foix-L'Hélias, Laurence/0000-0002-5699-4839; Audibert, Francois/0000-0002-2697-3826				BALLARD PL, 1995, AM J OBSTET GYNECOL, V173, P254, DOI 10.1016/0002-9378(95)90210-4; Baud O, 1998, J PEDIATR-US, V132, P813, DOI 10.1016/S0022-3476(98)70309-9; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; deVries LS, 1996, ACTA PAEDIATR, V85, P765, DOI 10.1111/j.1651-2227.1996.tb14149.x; GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; Hosmer DWJ., 1989, APPL LOGISTIC REGRES, P307; KLIEGMAN RM, 1984, NEW ENGL J MED, V310, P1093, DOI 10.1056/NEJM198404263101707; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Leroy B, 1971, Rev Fr Gynecol Obstet, V66, P391; Magee LA, 1997, BRIT J OBSTET GYNAEC, V104, P1233, DOI 10.1111/j.1471-0528.1997.tb10968.x; Mulder EJH, 1997, BRIT J OBSTET GYNAEC, V104, P1239, DOI 10.1111/j.1471-0528.1997.tb10969.x; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Rayburn WF, 1997, AM J OBSTET GYNECOL, V176, P842, DOI 10.1016/S0002-9378(97)70609-4; Reist M, 1998, J NEUROCHEM, V71, P2431; Senat MV, 1998, BRIT J OBSTET GYNAEC, V105, P749, DOI 10.1111/j.1471-0528.1998.tb10206.x; Spinillo A, 1998, BRIT J OBSTET GYNAEC, V105, P865, DOI 10.1111/j.1471-0528.1998.tb10231.x; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	20	268	277	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1190	1196		10.1056/NEJM199910143411604	http://dx.doi.org/10.1056/NEJM199910143411604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519896				2022-12-28	WOS:000083087400004
J	Paton, NI; Leo, YS; Zaki, SR; Auchus, AP; Lee, KE; Ling, AE; Chew, SK; Ang, B; Rollin, PE; Umapathi, T; Sng, I; Lee, CC; Lim, E; Ksiazek, TG				Paton, NI; Leo, YS; Zaki, SR; Auchus, AP; Lee, KE; Ling, AE; Chew, SK; Ang, B; Rollin, PE; Umapathi, T; Sng, I; Lee, CC; Lim, E; Ksiazek, TG			Outbreak of Nipah-virus infection among abattoir workers in Singapore	LANCET			English	Article							ENCEPHALITIS; DISEASE; HORSES	Background In March 1999, an outbreak of encephalitis and pneumonia occurred in workers at an abattoir in Singapore. We describe the clinical presentation and the results of investigations in these patients. Methods Clinical and laboratory data were collected by systemic review of the case records. Serum and cerebrospinal fluid (CSF) samples were tested for IgM antibodies to Nipah virus with an IgM capture ELISA, Reverse-transcriptase PCR was done on the CSF and tissue samples from one patient who died. Findings Eleven patients were confirmed to have acute Nipah-virus infection based on raised IgM in serum. Nipah virus was identified by reverse-transcriptase PCR in the CSF and tissue of the patient who died. The patients were all men, with a median age of 44 years. The commonest presenting symptoms were fever, headache, and drowsiness. Eight patients presented with signs of encephalitis (decreased level of consciousness or focal neurological signs). Three patients presented with atypical pneumonia, but one later developed hallucinations and had evidence of encephalitis on CSF examination. Abnormal laboratory findings included a low lymphocyte count (nine patients), low platelet count, low serum sodium, and high aspartate aminostransferase concentration (each observed in five patients). The CSF protein was high in eight patients and white-blood-cell count was high in seven. Chest radiography showed mild interstitial shadowing in eight patients. Magnetic resonance imaging (MRI) showed focal areas of increased signal intensity in the cortical white marker in all eight patients who were scanned. The nine patients with encephalitis received empirical treatment with intravenous aciclovir and eight survived. Interpretation Infection with Nipah virus caused an encephalitis illness with characteristic focal areas of increased intensity seen on MRI, Lung involvement was also common, acid the disease may present as an atypical pneumonia.	Tan Tock Seng Hosp, Communicable Dis Ctr, Dept Infect Dis, Singapore 308433, Singapore; Ctr Dis Control & Prevent, Atlanta, GA USA; Singapore Gen Hosp, Dept Neurol, Singapore 0316, Singapore; Natl Inst Neurosci, Singapore, Singapore; Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; Minist Hlth, Singapore, Singapore	Tan Tock Seng Hospital; Centers for Disease Control & Prevention - USA; Singapore General Hospital; National Neuroscience Institute (NNI); Singapore General Hospital; Ministry of Health-Singapore	Paton, NI (corresponding author), Tan Tock Seng Hosp, Communicable Dis Ctr, Dept Infect Dis, Moulmein Rd, Singapore 308433, Singapore.			Rollin, Pierre/0000-0002-4608-2641				CDC, 1999, MMWR-MORBID MORTAL W, V48, P265; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P335; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; Kumar S, 1997, NEURORADIOLOGY, V39, P180, DOI 10.1007/s002340050388; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Paterson DL, 1998, CLIN INFECT DIS, V27, P112, DOI 10.1086/514614; SELVEY LA, 1995, MED J AUSTRALIA, V162, P45	8	277	293	1	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1253	1256		10.1016/S0140-6736(99)04379-2	http://dx.doi.org/10.1016/S0140-6736(99)04379-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520634				2022-12-28	WOS:000083010400011
J	Joughin, I; Gray, L; Bindschadler, R; Price, S; Morse, D; Hulbe, C; Mattar, K; Werner, C				Joughin, I; Gray, L; Bindschadler, R; Price, S; Morse, D; Hulbe, C; Mattar, K; Werner, C			Tributaries of West Antarctic Ice streams revealed by RADARSAT interferometry	SCIENCE			English	Article							SUBGLACIAL GEOLOGY; SATELLITE IMAGERY; SHEET; STAGNATION; GLACIER; ONSET; FLOW	lnterferometric RADARSAT data are used to map ice motion in the source areas of four West Antarctic ice streams. The data reveal that tributaries, coincident with subglacial valleys, provide a spatially extensive transition between slow inland flow and rapid ice stream flow and that adjacent ice streams draw from shared source regions. Two tributaries flow into the stagnant ice stream C, creating an extensive region that is thickening at an average rate of 0.49 meters per year. This is one of the Largest rates of thickening ever reported in Antarctica.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Canada Ctr Remote Sensing, Applicat Div, Ottawa, ON K1A 0Y7, Canada; NASA, Oceans & Ice Branch, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; SAIC Gen Sci Corp, Beltsville, MD 20705 USA; Univ Texas, Inst Geophys, Austin, TX 78759 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Natural Resources Canada; Strategic Policy & Results Sector - Natural Resources Canada; Canada Centre for Mapping & Earth Observation (CCMEO); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Science Applications International Corporation (SAIC); University of Texas System; University of Texas Austin	Joughin, I (corresponding author), CALTECH, Jet Prop Lab, M-S 300-235,4800 Oak Grove Dr, Pasadena, CA 91109 USA.	ian@radar-sci.jpl.nasa.gov	Joughin, Ian R/A-2998-2008; Price, Stephen F/E-1568-2013; Joughin, Ian/AAR-7778-2021	Joughin, Ian R/0000-0001-6229-679X; Price, Stephen F/0000-0001-6878-2553; Joughin, Ian/0000-0001-6229-679X; Hulbe, Christina/0000-0003-4765-7037				ALLEY RB, 1994, ANN GLACIOL, V20, P187, DOI 10.3189/172756494794587032; ALLEY RB, 1991, SCIENCE, V254, P959, DOI 10.1126/science.254.5034.959; Anandakrishnan S, 1998, NATURE, V394, P62, DOI 10.1038/27889; [Anonymous], COMMUNICATION; Bamber JL, 1997, ANN GLACIOL, V25, P439, DOI 10.3189/S0260305500014427; Bell RE, 1998, NATURE, V394, P58, DOI 10.1038/27883; BENTLEY CR, 1987, J GEOPHYS RES-SOLID, V92, P8843, DOI 10.1029/JB092iB09p08843; Bindschadler R, 1997, ANN GLACIOL, V24, P409, DOI 10.3189/S0260305500012520; Bindschadler R, 1998, SCIENCE, V282, P428, DOI 10.1126/science.282.5388.428; Bindschadler R, 1998, SCIENCE, V279, P689, DOI 10.1126/science.279.5351.689; BINDSCHADLER R, 1990, EOS T AM GEOPHYS UN, V17, P741; BINDSCHADLER RA, 1991, SCIENCE, V252, P242, DOI 10.1126/science.252.5003.242; BLANKENSHIP D, UNPUB; CHEN X, 1998, SURV LAND INF SYST, V58, P247; GOLDSTEIN RM, 1993, SCIENCE, V262, P1525, DOI 10.1126/science.262.5139.1525; GRAY AL, 1998, IGARSS 98 SEATTL WA; Hodge SM, 1996, J GEOPHYS RES-OCEANS, V101, P6669, DOI 10.1029/95JC02961; JEZEK KC, 1998, INT GEOSC REM SENS S; Joughin IR, 1998, IEEE T GEOSCI REMOTE, V36, P25, DOI 10.1109/36.655315; MICHEL R, 1997, THESIS U PARIS 11; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661; Payne AJ, 1998, GEOPHYS RES LETT, V25, P3173, DOI 10.1029/98GL52327; PRICE S, UNPUB; RETZLAFF R, 1993, J GLACIOL, V39, P553, DOI 10.3189/S0022143000016440; RETZLAFF R, 1993, J GLACIOL, V39, P495, DOI 10.3189/S0022143000016397; Rignot EJ, 1998, SCIENCE, V281, P549, DOI 10.1126/science.281.5376.549; Rose K. E., 1979, J GLACIOL, V24, P63; SCAMBOS TA, 1992, REMOTE SENS ENVIRON, V42, P177, DOI 10.1016/0034-4257(92)90101-O; SCAMBOS TA, 1991, ANTARCT J US, V26, P312; SHABTAIE S, 1987, J GEOPHYS RES-SOLID, V92, P1311, DOI 10.1029/JB092iB02p01311; STEPHENSON SN, 1990, ANN GLACIOL, V14, P273, DOI DOI 10.3189/S0260305500008740.; THIEL KH, 1996, WORKSH GLAC APPL SAT; Venteris ER, 1998, ANN GLACIOL, V27, P227; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]; WHILLANS IM, 1988, ANN GLACIOL, V0011, P00187; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456; 1993, CAN J REMOTE SENSING, V19	37	157	159	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					283	286		10.1126/science.286.5438.283	http://dx.doi.org/10.1126/science.286.5438.283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514370				2022-12-28	WOS:000083024400042
J	Lockless, SW; Ranganathan, R				Lockless, SW; Ranganathan, R			Evolutionarily conserved pathways of energetic connectivity in protein families	SCIENCE			English	Article							HORMONE RECEPTOR COMPLEX; K+ CHANNEL; PDZ-DOMAIN; CRYSTAL-STRUCTURE; SIGNALING COMPLEXES; POTASSIUM CHANNEL; MUTANT CYCLES; LONG-RANGE; BINDING; RECOGNITION	For mapping energetic interactions in proteins, a technique was developed that uses evolutionary data for a protein family to measure statistical interactions between amino acid positions, For the PDZ domain family, this analysis predicted a set of energetically coupled positions for a binding site residue that includes unexpected Long-range interactions. Mutational studies confirm these predictions, demonstrating that the statistical energy function is a good indicator of thermodynamic coupling in proteins. Sets of intracting residues form connected pathways through the protein fold that may be the basis for efficient energy conduction within proteins.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ranganathan, R (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rama@chop.swmed.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brenman JE, 1998, J NEUROSCI, V18, P8805; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doolittle R., 1996, METHOD ENZYMOL, V266, P1; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ESSER L, UNPUB; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Hedstrom L, 1996, BIOL CHEM, V377, P465; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEHER E, 1994, P NATL ACAD SCI USA, V91, P98, DOI 10.1073/pnas.91.1.98; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERRY KM, 1989, BIOCHEMISTRY-US, V28, P7961, DOI 10.1021/bi00445a061; PETTIGREW DW, 1982, P NATL ACAD SCI-BIOL, V79, P1849, DOI 10.1073/pnas.79.6.1849; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1993, NEURON, V11, P67; SOCOLICH M, UNPUB; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tolman RC, 1938, PRINCIPLES STAT MECH; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	49	1013	1029	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					295	299		10.1126/science.286.5438.295	http://dx.doi.org/10.1126/science.286.5438.295			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514373				2022-12-28	WOS:000083024400045
J	Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP				Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP			A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats	SCIENCE			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; IN-VIVO; PEROXYNITRITE; INFLAMMATION; INJURY; COMPLEXES; EDEMA; MICE	Many human diseases are associated with the overproduction of oxygen free radicals that inflict cell damage. A manganese(II) complex with a bis(cyclohexylpyridine)-substituted macrocyclic Ligand (M40403) was designed to be a functional mimic of the superoxide dismutase (SOD) enzymes that normally remove these radicals. M40403 had high catalytic SOD activity and was chemically and biologically stable in vivo. injection of M40403 into rat models of inflammation and ischemia-reperfusion injury protected the animals against tissue damage, Such mimics may result in better clinical therapies for diseases mediated by superoxide radicals.	MetaPhore Pharmaceut, St Louis, MO 63114 USA; Monsanto Co, GD Searle & Co, Discovery Pharmacol, St Louis, MO 63167 USA; Johns Hopkins Univ, Sch Med, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; Monsanto Co, GD Searle & Co, Discovery Med Chem, St Louis, MO 63198 USA	Monsanto; Johns Hopkins University; Saint Louis University; University of Messina; Monsanto	Salvemini, D (corresponding author), MetaPhore Pharmaceut, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com	Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011	Misko, Thomas/0000-0001-7917-422X				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BITTERMAN H, 1988, P SOC EXP BIOL MED, V188, P265; CABELLI DE, IN PRESS BIOMIMETIC; Deshmukh DR, 1997, AM J PHYSIOL-CELL PH, V273, pC1130, DOI 10.1152/ajpcell.1997.273.4.C1130; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HIRSCHELMANN R, 1981, EXPERIENTIA, V37, P1313, DOI 10.1007/BF01948381; Horie Y, 1998, CIRC RES, V83, P691, DOI 10.1161/01.RES.83.7.691; IANARO A, 1994, IMMUNOLOGY, V82, P370; JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PETKAU A, 1986, CANCER TREAT REV, V13, P17, DOI 10.1016/0305-7372(86)90012-5; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Riley DP, 1997, J AM CHEM SOC, V119, P6522, DOI 10.1021/ja964271e; Riley DP, 1996, INORG CHEM, V35, P5213, DOI 10.1021/ic960262v; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; Riley DP, 1999, INORG CHEM, V38, P1908, DOI 10.1021/ic981319b; RILEY DP, 1997, CATTECH, V1, P41; ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042-7158.1971.tb08661.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SCHRAUFSTATTER IU, 1987, INT J TISSUE REACT, V9, P317; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SQUADRITO F, 1995, BRIT J PHARMACOL, V115, P395, DOI 10.1111/j.1476-5381.1995.tb16346.x; WARREN JS, 1990, FREE RADICAL BIO MED, V8, P163, DOI 10.1016/0891-5849(90)90089-2; Weiss RH, 1996, J BIOL CHEM, V271, P26149, DOI 10.1074/jbc.271.42.26149; WEISS RH, 1993, J BIOL CHEM, V268, P23049	29	448	494	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					304	306		10.1126/science.286.5438.304	http://dx.doi.org/10.1126/science.286.5438.304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514375				2022-12-28	WOS:000083024400047
J	Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M				Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M			Commitment to the B-lymphoid lineage depends on the transcription factor Pax5	NATURE			English	Article							MOUSE BONE-MARROW; MURINE FETAL LIVER; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; STEM-CELLS; DENDRITIC CELLS; FACTOR BSAP; C-FOS; PRO-B; MACROPHAGES	The Pax5 gene encoding the B-cell-specific activator protein (BSAP) is expressed within the haematopoietic system exclusively in the B-lymphoid lineage, where it is required in vivo for progression beyond the pro-B-cell stage. However, Pax5 is not essential for in vitro propagation of pro-B cells in the presence of interleukin-ir and stromal cells. Here we show that pro-B cells lacking Pax5 are also incapable of in vitro B-cell differentiation unless Pax5 expression is restored by retroviral transduction, Pax5(-/-) pro-B cells ape not restricted in their lineage fate, as stimulation with appropriate cytokines induces them to differentiate into functional macrophages, osteoclasts, dendritic cells, granulocytes and natural killer cells. As expected far a clonogenic haematopoietic progenitor with lymphomyeloid developmental potential, the Pax5(-/-) pro-B cell expresses genes of different lineage-affiliated programmes, and restoration of Pax5 activity represses this lineage-promiscuous transcription. Pax5 therefore plays an essential role in B-lineage commitment by suppressing alternative lineage choices.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Basel Inst Immunol, CH-4005 Basel, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Busslinger, M (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	busslinger@nt.imp.univie.ac.at	Nutt, Stephen L/C-9256-2013; Busslinger, Meinrad J./J-1249-2016	Nutt, Stephen L/0000-0002-0020-6637; Busslinger, Meinrad J./0000-0002-9111-9351				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Aiba Y, 1997, BLOOD, V90, P3923, DOI 10.1182/blood.V90.10.3923; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; Akerblad P, 1999, MOL CELL BIOL, V19, P392; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Borrello MA, 1996, IMMUNOL TODAY, V17, P471, DOI 10.1016/0167-5699(96)20031-B; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; Busslinger Meinrad, 1998, P83; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; Raulet DH, 1999, CURR OPIN IMMUNOL, V11, P129, DOI 10.1016/S0952-7915(99)80023-5; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Thevenin C, 1998, J EXP MED, V188, P735, DOI 10.1084/jem.188.4.735; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	50	867	890	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					556	562		10.1038/44076	http://dx.doi.org/10.1038/44076			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524622				2022-12-28	WOS:000083054900041
J	Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K				Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K			Involvement of visual cortex in tactile discrimination of orientation	NATURE			English	Article							MAGNETIC BRAIN-STIMULATION; COIL SUPPRESSION; BLIND HUMANS; PERCEPTION; ACTIVATION; TOUCH; SITE; EYE; LIP	The primary sense modalities (vision, touch and so on) are generally thought of as distinct. However, visual imagery is implicated in the normal tactile perception of some object properties, such as orientation(1), shape and size(2). Furthermore, certain tactile tasks, such as discrimination of grating orientation(1) and object recognition: are associated with activity in areas of visual cortex. Here we show that disrupting function of the occipital cortex using focal transcranial magnetic stimulation (TMS) interferes with the tactile discrimination of grating orientation. The specificity of this effect is illustrated by its time course and spatial restriction over the scalp, and by the failure of occipital TMS to affect either detection of an electrical stimulus applied to the fingerpad or tactile discrimination of grating texture. In contrast, TMS over the somatosensory cortex blocked discrimination of grating texture as well as orientation. We also report that, during tactile discrimination of grating orientation, an evoked potential is recorded over posterior scalp regions with a latency corresponding to the peak of the TMS interference effect (about 180 ms). The findings indicate that visual cortex is closely involved in tactile discrimination of orientation. To our knowledge, this is the first demonstration that visual cortical processing is necessary for normal tactile perception.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University	Sathian, K (corresponding author), Emory Univ, Sch Med, Dept Neurol, WMRB-6000,PO Drawer 5,1639 Pierce Dr, Atlanta, GA 30322 USA.			Sathian, Krish/0000-0001-9495-2499				Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Deibert E, 1999, NEUROLOGY, V52, P1413, DOI 10.1212/WNL.52.7.1413; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; EPSTEIN CM, 1990, NEUROLOGY, V40, P666, DOI 10.1212/WNL.40.4.666; Epstein CM, 1996, NEUROLOGY, V47, P1590, DOI 10.1212/WNL.47.6.1590; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; GALLETTI C, 1991, EUR J NEUROSCI, V3, P452, DOI 10.1111/j.1460-9568.1991.tb00832.x; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; JOHNSON KO, 1992, ANNU REV NEUROSCI, V15, P227, DOI 10.1146/annurev.ne.15.030192.001303; KLATZKY RL, 1987, J EXP PSYCHOL GEN, V116, P356; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Mellet E, 1996, J NEUROSCI, V16, P6504; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Sadato N, 1998, BRAIN, V121, P1213, DOI 10.1093/brain/121.7.1213; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Sathian K, 1996, NEUROLOGY, V46, P1464, DOI 10.1212/WNL.46.5.1464; Sathian K, 1997, NEUROREPORT, V8, P3877, DOI 10.1097/00001756-199712220-00008; Sathian K, 1997, PERCEPT PSYCHOPHYS, V59, P119, DOI 10.3758/BF03206854; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; VANBOVEN RW, 1994, NEUROLOGY, V44, P2361, DOI 10.1212/WNL.44.12.2361; VEGABERMUDEZ F, 1991, J NEUROPHYSIOL, V65, P531, DOI 10.1152/jn.1991.65.3.531; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	24	325	330	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					587	590		10.1038/44139	http://dx.doi.org/10.1038/44139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524625				2022-12-28	WOS:000083054900050
J	Hurst, JW				Hurst, JW			Quotations on the wall	ANNALS OF INTERNAL MEDICINE			English	Article									Emory Univ, Sch Med, Atlanta, GA 30322 USA	Emory University	Hurst, JW (corresponding author), 1462 Clifton Rd NE,Suite 301, Atlanta, GA 30322 USA.							CHURCHILL W, 1930, MY EARLY LIFE ROVING, P9; CIORAN EM, 1988, ANATHEMAS ADMIRATION, P9; Emerson Ralph Waldo, 1876, LETT SOCIAL AIMS	3	2	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					551	554		10.7326/0003-4819-131-7-199910050-00036	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507984				2022-12-28	WOS:000083018800033
J	Waterlow, J				Waterlow, J			Treatment of children with malnutrition and diarrhoea	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Waterlow, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.							Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SMITH R, 1963, LANCET, V1, P771; WATERLOW JC, 1978, NUTRITION CLIN MANAG, P49; Waterlow JC, 1992, PROTEIN ENERGY MALNU; WATERLOW JC, 1992, NUTR CLIN MANAGEMENT; World Health Organization, 1999, MAN SEV MALN MAN PHY	7	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1142	1142		10.1016/S0140-6736(99)00329-3	http://dx.doi.org/10.1016/S0140-6736(99)00329-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513705				2022-12-28	WOS:000082954100007
J	Evans, SK; Lundblad, V				Evans, SK; Lundblad, V			Est1 and Cdc13 as comediators of telomerase access	SCIENCE			English	Article							DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; IN-VITRO; YEAST; SENESCENCE; LENGTH; MAINTENANCE; MUTANTS; DEFECT	Cdc13 and Est1 are single-strand telomeric DNA binding proteins that contribute to telomere replication in the yeast Saccharomyces cerevisiae. Here it is shown that fusion of Cdc13 to the telomerase-associated Est1 protein results in greatly elongated telomeres. Fusion proteins consisting of mutant versions of Cdc13 or Est1 confer similar telomere elongation, indicating that close physical proximity can bypass telomerase-defective mutations in either protein. Fusing Cdc13 directly to the catalytic core of telomerase allows stable telomere maintenance in the absence of Est1, consistent with a role for Est1 in mediating telomerase access. Telomere length homeostasis therefore is maintained in part by restricting access of telomerase to chromosome termini, but this limiting situation can be overcome by directly tethering telomerase to the telomere.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lundblad, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055867] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM55867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANDRA A, UNPUB; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; EVANS S, UNPUB; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; HUGHES TJ, UNPUB; Lendvay TS, 1996, GENETICS, V144, P1399; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; NUGENT CI, UNPUB; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094	21	363	376	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					117	120		10.1126/science.286.5437.117	http://dx.doi.org/10.1126/science.286.5437.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506558				2022-12-28	WOS:000082907400048
J	Gil, D; Graves, J; Hazon, N; Wells, A				Gil, D; Graves, J; Hazon, N; Wells, A			Male attractiveness and differential testosterone investment in zebra finch eggs	SCIENCE			English	Article							EXTRA-PAIR PATERNITY; GENETIC QUALITY; MATERNAL TESTOSTERONE; ULTRAVIOLET VISION; BODY-MASS; IMMUNOCOMPETENCE; INDICATOR; ORNAMENTATION; POPULATIONS; VIABILITY	Good-genes hypotheses of sexual selection predict that offspring fathered by preferred males should have increased viability resulting from superior genetic quality. Several studies of birds have reported findings consistent with this prediction, but maternal effects are an important confounding variable. Those studies that have attempted to control for maternal effects have only considered differential maternal investment after egg laying. However, female birds differentially deposit testosterone in the eggs, and this influences the development of the chick. This study shows that female birds deposit higher amounts of testosterone and 5 alpha-dihydrotestosterone in their eggs when mated to more attractive males.	Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TS, Fife, Scotland	University of St Andrews	Gil, D (corresponding author), Univ Paris 10, Lab Psychophysiol & Ethol, UPRESA CNRS 7025, F-92001 Nanterre, France.	Diego.Gil@u-paris10.fr	Gil, Diego/L-1666-2014	Gil, Diego/0000-0003-3179-1987				Al-Afaleq AI, 1998, IMMUNOPHARM IMMUNOT, V20, P315, DOI 10.3109/08923979809038547; Andersson Malte, 1994; Bennett ATD, 1996, NATURE, V380, P433, DOI 10.1038/380433a0; BURLEY N, 1986, EVOLUTION, V40, P1191, DOI 10.1111/j.1558-5646.1986.tb05744.x; BURLEY N, 1988, AM NAT, V132, P611, DOI 10.1086/284877; Cuthill IC, 1997, P ROY SOC B-BIOL SCI, V264, P1093, DOI 10.1098/rspb.1997.0151; DELOPE F, 1993, EVOLUTION, V47, P1152, DOI 10.1111/j.1558-5646.1993.tb02142.x; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; GAUSE WC, 1986, CLIN IMMUNOL IMMUNOP, V39, P464, DOI 10.1016/0090-1229(86)90174-1; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; Hasselquist D, 1999, BEHAV ECOL SOCIOBIOL, V45, P167, DOI 10.1007/s002650050550; HEGNER RE, 1986, HORM BEHAV, V20, P313, DOI 10.1016/0018-506X(86)90040-1; Hillgarth Nigella, 1997, P78; Hoikkala A, 1998, P ROY SOC B-BIOL SCI, V265, P503, DOI 10.1098/rspb.1998.0323; Hunt S, 1997, ANIM BEHAV, V54, P1383, DOI 10.1006/anbe.1997.0540; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Lipar JL, 1999, AUK, V116, P231, DOI 10.2307/4089471; Mock D. W., 1997, EVOLUTION SIBLING RI; MOLLER AP, 1994, P NATL ACAD SCI USA, V91, P6929, DOI 10.1073/pnas.91.15.6929; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; Ros AFH, 1997, AM NAT, V150, P201, DOI 10.1086/286063; Saino N, 1995, BEHAV ECOL, V6, P397, DOI 10.1093/beheco/6.4.397; SCHUURS AHWM, 1992, INT ARCH ALLERGY IMM, V97, P337, DOI 10.1159/000236142; Schwabl H, 1997, NATURE, V386, P231, DOI 10.1038/386231a0; Schwabl H, 1996, J EXP ZOOL, V276, P157, DOI 10.1002/(SICI)1097-010X(19961001)276:2<157::AID-JEZ9>3.3.CO;2-Y; SCHWABL H, 1993, P NATL ACAD SCI USA, V90, P11446, DOI 10.1073/pnas.90.24.11446; Schwabl H, 1996, COMP BIOCHEM PHYS A, V114, P271, DOI 10.1016/0300-9629(96)00009-6; SEARCY WA, 1988, ECOLOGY, V69, P85, DOI 10.2307/1943163; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; Staub NL, 1997, GEN COMP ENDOCR, V108, P1, DOI 10.1006/gcen.1997.6962; Verhulst S, 1999, P NATL ACAD SCI USA, V96, P4478, DOI 10.1073/pnas.96.8.4478; Welch AM, 1998, SCIENCE, V280, P1928, DOI 10.1126/science.280.5371.1928; Wilkinson GS, 1998, NATURE, V391, P276, DOI 10.1038/34640; ZANN RA, 1966, ZEBRA FINCH	35	424	427	0	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					126	128		10.1126/science.286.5437.126	http://dx.doi.org/10.1126/science.286.5437.126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506561				2022-12-28	WOS:000082907400051
J	Solomon, SC; Bullock, MA; Grinspoon, DH				Solomon, SC; Bullock, MA; Grinspoon, DH			Climate change as a regulator of tectonics on Venus	SCIENCE			English	Article							ATMOSPHERE; HISTORY	Tectonics, volcanism, and climate on Venus may be strongly coupled. Large excursions in surface temperature predicted to follow a global or near-global volcanic event diffuse into the interior and introduce thermal stresses of a magnitude sufficient to influence widespread tectonic deformation. This sequence of events accounts for the timing and many of the characteristics of deformation in the ridged plains of Venus, the most widely preserved volcanic terrain on the planet.	Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA	Carnegie Institution for Science	Solomon, SC (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.							Basilevsky AT, 1996, GEOPHYS RES LETT, V23, P1497, DOI 10.1029/96GL00975; Basilevsky AT, 1998, J GEOPHYS RES-PLANET, V103, P8531, DOI 10.1029/98JE00487; Bilotti F, 1999, ICARUS, V139, P137, DOI 10.1006/icar.1999.6092; BIRCH F, 1948, AM J SCI, V246, P729; BULLOCK MA, 1994, ICARUS, V107, P142, DOI 10.1006/icar.1994.1012; Bullock MA, 1996, J GEOPHYS RES-PLANET, V101, P7521, DOI 10.1029/95JE03862; BULLOCK MA, 1993, GEOPHYS RES LETT, V20, P2147, DOI 10.1029/93GL02505; BULLOCK MA, UNPUB; COFFIN MF, 1994, REV GEOPHYS, V32, P1, DOI 10.1029/93RG02508; COLLINS GC, 1997, LUNAR PLANET SCI, V28, P243; FEGLEY B, 1989, NATURE, V337, P55, DOI 10.1038/337055a0; GRINSPOON DH, 1993, NATURE, V363, P428, DOI 10.1038/363428a0; Guest JE, 1999, ICARUS, V139, P55, DOI 10.1006/icar.1999.6091; Hansen VL, 1996, ICARUS, V123, P296, DOI 10.1006/icar.1996.0159; HASHIMOTO GL, 1999, LUNAR PLANET SCI, V30, P1867; Head JW, 1998, GEOLOGY, V26, P35, DOI 10.1130/0091-7613(1998)026<0035:SOTDIT>2.3.CO;2; Ivanov MA, 1996, J GEOPHYS RES-PLANET, V101, P14861, DOI 10.1029/96JE01245; IVANOV MA, 1998, LUNAR PLANET SCI, V29, P1653; KRASNOPOLSKY VA, 1994, ICARUS, V109, P58, DOI 10.1006/icar.1994.1077; Kreslavsky MA, 1998, J GEOPHYS RES-PLANET, V103, P11103, DOI 10.1029/98JE00360; KRESLAVSKY MA, 1999, LUNAR PLANET SCI, V30, P1192; MCGILL GE, 1993, GEOPHYS RES LETT, V20, P2047; McKinnon W. B., 1997, VENUS, P969; Phillips RJ, 1998, SCIENCE, V279, P1492, DOI 10.1126/science.279.5356.1492; PHILLIPS RJ, 1992, J GEOPHYS RES, V97, P15921; Sandwell DT, 1997, ICARUS, V129, P232, DOI 10.1006/icar.1997.5721; SCHABER GG, 1992, J GEOPHYS RES-PLANET, V97, P13257, DOI 10.1029/92JE01246; SCHULTZ RA, 1993, J GEOPHYS RES-PLANET, V98, P10883, DOI 10.1029/93JE00691; SOLOMON SC, 1992, J GEOPHYS RES-PLANET, V97, P13199, DOI 10.1029/92JE01418; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; Timoshenko S., 1970, THEORY ELASTICITY, P433; TURCOTTE DL, 1982, GEODYNAMICS, P158; TURCOTTE DL, 1983, J GEOPHYS RES S, V88, pA585, DOI DOI 10.1029/JB088IS02P0A585	33	61	62	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					87	90		10.1126/science.286.5437.87	http://dx.doi.org/10.1126/science.286.5437.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506565				2022-12-28	WOS:000082907400038
J	Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL				Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL			Myosin VI is an actin-based motor that moves backwards	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; UNCONVENTIONAL MYOSIN; CRYOELECTRON MICROSCOPY; MOLECULAR MOTOR; IMAGE-ANALYSIS; ADP RELEASE; GENE; NCD; DIRECTION; DEAFNESS	Myosins and kinesins are molecular motors that hydrolyse ATP to track along actin filaments and microtubules, respectively. Although the kinesin family includes motors that move towards either the plus or minus ends of microtubules(1), all characterized myosin motors move towards the barbed (+) end of actin filaments(2). Crystal structures of myosin II (refs 3-6) have shown that small movements within the myosin motor core are transmitted through the 'converter domain' to a 'lever arm' consisting of a light-chain-binding helix and associated light chains(5,6), The lever arm further amplifies the motions of the converter domain into large directed movements(3,5-7). Here we report that myosin VI, an unconventional myosin(8-12), moves towards the pointed (-) end of actin. We visualized the myosin VI construct bound to actin using cryo-electron microscopy and image analysis, and found that an ADP-mediated conformational change in the domain distal to the motor, a structure likely to be the effective lever arm, is in the opposite direction to that observed for other myosins, Thus, it appears that myosin VI achieves reverse-direction movement by rotating its lever arm in the opposite direction to conventional myosin lever arm movement.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Pennsylvania; Scripps Research Institute; University of California System; University of California San Diego; University of Illinois System; University of Illinois Urbana-Champaign	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.	Lsweeney@mail.med.upenn.edu	Sweeney, H Lee/F-1862-2010	Carragher, Bridget/0000-0002-0624-5020; HASSON, TAMA/0000-0002-5405-662X				Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; POLLARD TD, 1982, METHOD ENZYMOL, V85, P123; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	30	532	543	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					505	508		10.1038/46835	http://dx.doi.org/10.1038/46835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519557				2022-12-28	WOS:000082981200063
J	Tulloch, J				Tulloch, J			Integrated approach to child health in developing countries	LANCET			English	Article							COTRIMOXAZOLE; ILLNESS; MALARIA		WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland	University of Geneva; World Health Organization	Tulloch, J (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.							[Anonymous], 1999, WORLD HLTH REPORT 19; [Anonymous], 1996, GLOBAL BURDEN DIS CO; BLACK RE, 1993, PEDIATR INFECT DIS J, V12, P751, DOI 10.1097/00006454-199309000-00010; BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; DARAMOLA OO, 1991, T ROY SOC TROP MED H, V85, P345, DOI 10.1016/0035-9203(91)90285-7; Kolstad PR, 1998, TROP MED INT HEALTH, V3, P691, DOI 10.1046/j.1365-3156.1998.00290.x; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; *WHO, 1998, REP DIV CHILD HLTH D; *WHO, 1997, B WHO S, V75; WHO UNICEF, 1997, INT MAN CHILDH ILLN	10	57	57	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP	1999	354			2			S16	S20						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239QH	10507254				2022-12-28	WOS:000082780700004
J	Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL				Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL			CFPR chloride channel regulation by an interdomain interaction	SCIENCE			English	Article							CYSTIC-FIBROSIS; CFTR; SYNTAXIN; DOMAIN	The cystic fibrosis gene encodes a chloride channel, CFTR (cystic fibrosis transmembrane conductance regulator), that regulates salt and water transport across epithelial tissues. Phosphorylation of the cytoplasmic regulatory (R) domain by protein kinase A activates CFTR by an unknown mechanism. The amino-terminal cytoplasmic tail of CFTR was found to control protein kinase A-dependent channel gating through a physical interaction with the R domain. This regulatory activity mapped to a cluster of acidic residues in the NH2-terminal tail; mutating these residues proportionately inhibited R domain binding and CFTR channel function. CFTR activity appears to be governed by an interdomain interaction involving the amino-terminal tail, which is a potential target for physiologic and pharmacologic modulators of this ion channel.	Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Naren, AP (corresponding author), Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA.	kirk@phybio.bhs.uab.edu	Cormet-Boyaka, Estelle/H-5624-2011	Blalock, J. Edwin/0000-0001-5303-8123	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010509, R01DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline; NIDDK NIH HHS [DK51868, DK50830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1989, CELL, V66, P1066; FU J, UNPUB; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NAREN AP, UNPUB; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; QUICK MW, UNPUB; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	17	108	108	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					544	548		10.1126/science.286.5439.544	http://dx.doi.org/10.1126/science.286.5439.544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521352				2022-12-28	WOS:000083121200064
J	Beecham, L				Beecham, L			Cooperation could provide better hospital case	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					940	940						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514149				2022-12-28	WOS:000083111700015
J	Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H				Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H			Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses	SCIENCE			English	Article							NF-KAPPA-B; GERMINAL CENTER FORMATION; NECROSIS-FACTOR RECEPTOR; ACUTE INFECTIOUS-MONONUCLEOSIS; CELLS IN-VIVO; AFFINITY MATURATION; DEFICIENT MICE; CD40-DEFICIENT MICE; CYTOPLASMIC DOMAIN; IMMUNE-RESPONSES	The effect of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on the activation and differentiation of normal B cells was investigated. B cells of transgenic mice expressing LMP1 under the control of immunoglobulin promoter/enhancer displayed enhanced expression of activation antigens and spontaneously proliferated and produced antibody. Humoral immune responses of LMP1 transgenic mice in CD40-deficient or normal backgrounds revealed that LMP1 mimics CD40 signals to induce extrafollicular 13 cell differentiation but, unlike CD40, blocks germinal center formation. Thus, these specific properties of LMP1 may determine the site of primary B cell infection and the state of infection in the natural course of EBV infection, whereas subsequent loss of LMP1 expression may affect the site of persistent latent infection.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Osaka 5650871, Japan; Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Osaka University; University of North Carolina; University of North Carolina Chapel Hill	Uchida, J (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, 3-1 Yamada Oka, Osaka 5650871, Japan.	kikutani@ragtime.biken.osaka-u.ac.jp	Kikutani, Hitoshi/C-9525-2009	Muraoka, Masaaki/0000-0002-2926-5374	NCI NIH HHS [CA19014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; ANAGNOSTOPOULOS I, 1995, BLOOD, V85, P744, DOI 10.1182/blood.V85.3.744.bloodjournal853744; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CATTORETTI G, 1997, BLOOD, V90, P175; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GAUCHAT JF, 1992, J IMMUNOL, V148, P2291; GRAY D, 1988, IMMUNOLOGY, V65, P73; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLEY EA, 1988, J EXP MED, V168, P2059, DOI 10.1084/jem.168.6.2059; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; IZURNI KM, 1997, P NATL ACAD SCI USA, V94, P12592; JABARA HH, 1990, J IMMUNOL, V145, P3468; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kato J, 1998, J IMMUNOL, V160, P4788; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MACLENNAN ICM, 1988, CURR TOP MICROBIOL, V141, P138; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDOBITEK G, 1992, BLOOD, V79, P2520; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROBINSON JE, 1981, J EXP MED, V153, P235, DOI 10.1084/jem.153.2.235; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; UCHIDA J, UNPUB; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	52	299	312	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					300	303		10.1126/science.286.5438.300	http://dx.doi.org/10.1126/science.286.5438.300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514374				2022-12-28	WOS:000083024400046
J	Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S				Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S			Cell division - A histone-H3-like protein in C-elegans	NATURE			English	Article							CENP-A; CAENORHABDITIS-ELEGANS; CENTROMERE; HISTONE		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buchwitz, BJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Riddle D. L, 1997, C ELEGANS, P47; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	11	203	209	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					547	548		10.1038/44062	http://dx.doi.org/10.1038/44062			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524621				2022-12-28	WOS:000083054900038
J	Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R				Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R			Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds	NATURE			English	Article							APICAL ECTODERMAL RIDGE; DEVELOPING CHICK LIMB; SONIC HEDGEHOG; DEFORMITY GENE; PATTERN-FORMATION; PROTEINS; GROWTH; FGF-4; EXPRESSION; INDUCTION	Outgrowth and patterning of the vertebrate limb are controlled by reciprocal interactions between the posterior mesenchyme (polarizing region) and a specialized ectodermal structure, the apical ectodermal ridge (AER)(1). Sonic hedgehog (SHH) signalling by the polarizing region modulates fibroblast growth factor (FGF)4 signalling by the posterior AER, which in turn maintains the polarizing region (SHH/FGF4 feedback loop)(2,3). Here we report that the secreted bone-morphogenetic-protein (BMP) antagonist Gremlin(4) relays the SHH signal from the polarizing region to the AER. Mesenchymal Gremlin expression is lost in limb buds of mouse embryos homozygous for the limb deformity (Id) mutation, which disrupts establishment of the SHH/FGF4 feedback loop(5-7). Grafting Gremlin-expressing cells into Id mutant limb buds rescues Fgf4 expression and restores the SHH/FGF4 feedback loop. Analysis of Shh-null mutant embryos(8,9) reveals that SHH signalling is required for maintenance of Gremlin and Formin (the gene disrupted by the ld mutations)(10,11). In contrast, Formin, Gremlin and Fgf4 activation are independent of SHH signalling. This study uncovers the cascade by which the SHH signal is relayed from the posterior mesenchyme to the AER and establishes that Formin-dependent activation of the BMP antagonist Gremlin is sufficient to induce Fgf4 and establish the SHH/FGF4 feedback loop.	Univ Utrecht, Fac Biol, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Cambridge, MA 02138 USA	Utrecht University; European Molecular Biology Laboratory (EMBL); Harvard University	Zeller, R (corresponding author), Univ Utrecht, Fac Biol, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	R.Zeller@bio.uu.nl	Zuniga, Aimée/AAG-7335-2020; Zeller, Rolf/C-2610-2013; Zuniga, Aimée/Q-2692-2018; McMahon, Andrew P/ABE-7520-2020	Zuniga, Aimée/0000-0002-9953-3637; Zeller, Rolf/0000-0002-3186-7403; Zuniga, Aimée/0000-0002-9953-3637; 				Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho KWY, 1998, CURR OPIN GENET DEV, V8, P443, DOI 10.1016/S0959-437X(98)80116-0; Duprez D, 1998, DEVELOPMENT, V125, P495; Duprez DM, 1996, DEVELOPMENT, V122, P1821; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Haramis AG, 1995, DEVELOPMENT, V121, P4237; Hofmann C, 1996, DEV GENET, V19, P43, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;43::AID-DVG5&gt;3.0.CO;2-0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kuhlman J, 1997, DEVELOPMENT, V124, P133; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUSSIER M, 1993, INT J DEV BIOL, V37, P555; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Pizette S, 1999, DEVELOPMENT, V126, P883; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; Zuniga A, 1999, DEVELOPMENT, V126, P13	30	364	368	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					598	602		10.1038/44157	http://dx.doi.org/10.1038/44157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524628				2022-12-28	WOS:000083054900053
J	Dale, JJ; Ruckley, CV; Harper, DR; Gibson, B; Nelson, EA; Prescott, RJ				Dale, JJ; Ruckley, CV; Harper, DR; Gibson, B; Nelson, EA; Prescott, RJ			Randomised, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers	BRITISH MEDICAL JOURNAL			English	Article							ULCERATION	Objective To determine whether pentoxifylline 400 mg (Trental 400) taken orally three times daily, in addition to ambulatory compression bandages and dressings, improves the healing rate of pure venous ulcers. Design Randomised, double blind placebo controlled trial, parallel group study of factorial design, permitting the simultaneous evaluation of alternative pharmaceutical, bandaging, and dressings materials. Setting Leg ulcer clinics of a teaching and a district general hospital in southern Scotland. Participants 200 patients with confirmed venous ulcers and in whom other major causal factors were excluded. Interventions Pentoxifylline 400 mg three times daily or placebo. Main outcome measure Complete healing (full epithelialisation) of all ulcers on the 11 trial leg. Results Complete healing occurred in 65 of the 101 (64%) patients receiving pentoxifylline and 52 of the 99 (53%) patients receiving placebo. Conclusions The difference in the healing rates between patients taking pentoxifylline and those taking placebo did not reach statistical significance.	Royal Infirm Edinburgh, Dept Vasc Surg, Edinburgh EH3 9YW, Midlothian, Scotland; Falkirk & Dist Royal Infirm, Dept Surg, Falkirk FK1 5QE, Scotland; Univ York, Dept Hlth Sci & Clin Evaluat, York YK1 5DD, N Yorkshire, England; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh EH8 9AG, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of York - UK; University of Edinburgh	Ruckley, CV (corresponding author), Royal Infirm Edinburgh, Dept Vasc Surg, Edinburgh EH3 9YW, Midlothian, Scotland.		Nelson, Andrea/K-2733-2012	Nelson, Andrea/0000-0001-6741-3078				BOSANQUET N, 1992, PHLEBOLOGY S, V1, P44; *BRIT MED ASS PHAR, 1998, BRIT NAT FORM; BURNAND K, 1976, LANCET, V1, P936; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CALLAM MJ, 1987, BRIT MED J, V294, P1389, DOI 10.1136/bmj.294.6584.1389; CALLAM MJ, 1992, PHLEBOLOGY, V7, P136, DOI 10.1177/026835559200700402; COLERIDGESMITH PD, 1988, BRIT MED J, V296, P1920; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; PEMLER K, 1979, FORTSCHR MED, V21, P1019; Prescott RJ, 1998, PHLEBOLOGY, V13, P107, DOI 10.1177/026835559801300305; Ramani A KG, 1996, ANGIOLOGY, V44, P623; SMITH JM, 1992, PHLEBOLOGY, V7, P108, DOI 10.1177/026835559200700307; Weitgasser H., 1983, PHARMATHERAPEUTICA, V3, P143	14	53	58	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					875	878		10.1136/bmj.319.7214.875	http://dx.doi.org/10.1136/bmj.319.7214.875			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506039	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000082975600019
J	Horton, R; Smith, R				Horton, R; Smith, R			Time to register randomised trials	LANCET			English	Editorial Material							PUBLICATION BIAS		Lancet, London WC1B 3SL, England; BMJ, London WC1H 9JR, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.			Smith, Richard/0000-0001-9634-2918				Chalmers I, 1999, LANCET, V353, P490, DOI 10.1016/S0140-6736(98)07618-1; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; DICKERSIN K, 1993, DOINT MORE GOOD HARM; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; Marshall E, 1999, SCIENCE, V285, P1466; McNamee D, 1997, LANCET, V350, P6, DOI 10.1016/S0140-6736(05)66237-X; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; Roberts I, 1998, BRIT MED J, V317, P763, DOI 10.1136/bmj.317.7161.763; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088	12	28	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1138	1139		10.1016/S0140-6736(99)00328-1	http://dx.doi.org/10.1016/S0140-6736(99)00328-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513702				2022-12-28	WOS:000082954100004
J	Young, LS				Young, LS			Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health	LANCET			English	Editorial Material							EBV PERSISTENCE; TUMORS		Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				ALLDAY MJ, 1988, LANCET, V1, P855; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Faulkner GC, 1999, J VIROL, V73, P1555, DOI 10.1128/JVI.73.2.1555-1564.1999; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Sugawara Y, 1999, VIROLOGY, V256, P196, DOI 10.1006/viro.1999.9619	9	8	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1141	1142		10.1016/S0140-6736(99)00237-8	http://dx.doi.org/10.1016/S0140-6736(99)00237-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513704				2022-12-28	WOS:000082954100006
J	Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M				Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M			CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs	CELL			English	Article							DENDRITIC CELL MATURATION; CHEMOKINE RECEPTOR; T-CELLS; MOLECULAR-CLONING; TISSUE CHEMOKINE; B-CELLS; LYMPHOCYTES; EXPRESSION; MEMORY; LIGAND	The proper function of immune surveillance requires well-coordinated mechanisms in order to guide the patrolling immune cells through peripheral tissues and into secondary lymphoid organs. Analyzing gene-targeted mice, we identified the chemokine receptor CCR7 as an important organizer of the primary immune response. CCR7-deficient mice show severely delayed kinetics regarding the antibody response and lack contact sensitivity and delayed type hypersensitivity reactions. Due to the impaired migration of lymphocytes, these animals reveal profound morphological alterations in all secondary lymphoid organs. Upon activation, mature skin dendritic cells fail to migrate into the draining lymph nodes. Thus, in order to bring together lymphocytes and dendritic cells to form the characteristic microarchitecture of secondary lymphoid organs, CCR7 is required to rapidly initiate an adoptive immune response.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; GSF, Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany; Univ Munich, Inst Mol Anim Breeding, Gene Ctr, D-81377 Munich, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Forster, R (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Forster, Reinhold/0000-0001-6190-7923; Lipp, Martin/0000-0002-0087-2672; Wolf, Eckhard/0000-0002-0430-9510				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HILL S, 1990, IMMUNOLOGY, V71, P277; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Liu YJ, 1997, J EXP MED, V186, P625, DOI 10.1084/jem.186.5.625; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; Sozzani S, 1998, J IMMUNOL, V161, P1083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Tanabe S, 1997, J IMMUNOL, V159, P5671; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	34	1806	1878	3	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					23	33		10.1016/S0092-8674(00)80059-8	http://dx.doi.org/10.1016/S0092-8674(00)80059-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520991	Bronze			2022-12-28	WOS:000082981600005
J	Takahashi, JS				Takahashi, JS			Perspectives: Neurobiology - Narcolepsy genes wake up the sleep field	SCIENCE			English	Editorial Material							DEPRIVATION; NEURONS		Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Northwestern University	Takahashi, JS (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, 2153 N Campus Dr, Evanston, IL 60208 USA.	J-takahashi@nwu.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; DEMENT WC, 1994, PRINCIPLES PRACTICES, P309; KUSHIDA CA, 1989, SLEEP, V12, P22, DOI 10.1093/sleep/12.1.22; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; Peyron C, 1998, J NEUROSCI, V18, P9996; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Siegel JM, 1999, CELL, V98, P409, DOI 10.1016/S0092-8674(00)81969-8; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171	18	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2076	2077		10.1126/science.285.5436.2076	http://dx.doi.org/10.1126/science.285.5436.2076			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523205				2022-12-28	WOS:000082734300028
J	DerSimonian, R; Levine, RJ				DerSimonian, R; Levine, RJ			Resolving discrepancies between a meta-analysis and a subsequent large controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PREGNANCY-INDUCED HYPERTENSION; ACUTE MYOCARDIAL-INFARCTION; CALCIUM SUPPLEMENTATION; CLINICAL-TRIALS; METAANALYSIS; PREECLAMPSIA; PREVENTION; RISK; DESIGN	Context A recent mete-analysis found calcium supplementation to be highly effective in preventing preeclampsia but a large National Institutes of Health trial (Calcium for Preeclampsia Prevention [CPEP]) found no risk reduction due to calcium in healthy nulliparous women. Objectives To resolve discrepancies between the results of the meta-analysis and the CPEP trial and to assess the role of effect heterogeneity in the discrepancies. Data Sources Literature search of English-language articles published prior to July 10, 1997, the date of publication of the CPEP trial, using MEDLINE and by a manual search of bibliographies of published articles. Study Selection Trials were included if they reported data on preeclampsia and calcium supplementation. Fourteen trials were systematically evaluated for differences in study design and patient populations. One trial was excluded because its results were reported after publication of the major CPEP results. Data Extraction The sample size and number of subjects who developed preeclampsia in the calcium supplementation group vs a control group were recorded and analyzed on an intent-to-treat basis. Each author independently extracted the data. Data Synthesis Substantial heterogeneity existed across trials (P = .001). After stratifying studies by the presence of a placebo-controlled group and by high-risk and low-risk populations, the conclusions of the meta-analysis of placebo-controlled trials enrolling a low-risk population (relative risk, 0.79; 99% confidence interval, 0.44-1.42; P = .30) were compatible with the conclusions of the CPEP trial that calcium supplementation does not prevent preeclampsia in healthy nulliparous women. In contrast, the data implied a strong beneficial calcium effect (relative risk, 0.19; 99% confidence interval, 0.08-0.46; P = .001) in healthy high-risk subject populations. However, only 225 women were analyzed and because of inconsistent data, these results remain equivocal. Conclusions Further studies are needed to establish the efficacy of calcium for preeclampsia prevention in healthy high-risk populations. A single summary measure does not adequately describe the findings of a meta-analysis when the observed effects in individual studies differ substantially. In such settings the primary focus should be to identify and incorporate pertinent covariates that reduce heterogeneity and allow for optimum treatment strategies.	NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	DerSimonian, R (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, 6100 Execut Blvd,MSC 7510, Bethesda, MD 20892 USA.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ATALLAH AN, 1999, CALCIUM SUPPLEMENTAT; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Bailar JC, 1998, NEW ENGL J MED, V338, P62; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHAUDHURI SK, 1969, J OBSTET GYN INDIA, V19, P313; Cong K J, 1993, Zhonghua Fu Chan Ke Za Zhi, V28, P657; CONG KJ, 1995, CHINESE MED J-PEKING, V108, P57; Cong KJ., 1992, BEIJING MED J, V5, P268; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N; DerSimonian R, 1990, Hepatology, V11, P1083, DOI 10.1002/hep.1840110627; DERSIMONIAN R, 1993, J CLIN EPIDEMIOL, V46, P163, DOI 10.1016/0895-4356(93)90054-5; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; HASSELBLAD V, 1995, MED CARE, V33, P202; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P1089, DOI 10.1001/jama.279.14.1089; ITO M, 1994, INT J GYNECOL OBSTET, V47, P115, DOI 10.1016/0020-7292(94)90350-6; LAIRD N, 1992, ANN INTERN MED, V116, P78; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Levine RJ, 1996, CONTROL CLIN TRIALS, V17, P442, DOI 10.1016/S0197-2456(96)00106-7; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; LOPEZJARAMILLO P, 1989, BRIT J OBSTET GYNAEC, V96, P648, DOI 10.1111/j.1471-0528.1989.tb03278.x; LopezJaramillo P, 1997, OBSTET GYNECOL, V90, P162, DOI 10.1016/S0029-7844(97)00254-8; LOPEZJARAMILLO P, 1990, LANCET, V335, P293, DOI 10.1016/0140-6736(90)90112-I; MARYA RK, 1987, GYNECOL OBSTET INVES, V24, P38, DOI 10.1159/000298772; MONTANARO D, 1986, MINER METAB RES ITAL, V7, P121; MONTANARO D, 1987, 10 INT C NEPHR MIL I; MONTANARO D, 1990, 7 WORLD C HYP PREG P; MOSTELLER F, 1992, STAT SCI, V7, P227; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; *PEOPL LEAG HLTH, 1902, LANCET, V2, P10; SANCHEZRAMOS L, 1994, OBSTET GYNECOL, V84, P349; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; SUZUKI Y, 1996, INT SOC STUD HYP PRE; THEOBALD GW, 1937, LANCET, V2, P1397; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; VILLAR J, 1987, OBSTET GYNECOL, V70, P317; VILLAR J, 1990, AM J OBSTET GYNECOL, V163, P1124, DOI 10.1016/0002-9378(90)90669-X; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9	47	58	61	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					664	670		10.1001/jama.282.7.664	http://dx.doi.org/10.1001/jama.282.7.664			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517720				2022-12-28	WOS:000082033700026
J	Dienstag, JL; Schiff, ER; Wright, TL; Perrillo, RP; Hann, HWL; Goodman, Z; Crowther, L; Condreay, LD; Woessner, M; Rubin, M; Brown, NA				Dienstag, JL; Schiff, ER; Wright, TL; Perrillo, RP; Hann, HWL; Goodman, Z; Crowther, L; Condreay, LD; Woessner, M; Rubin, M; Brown, NA		US Lamivudine Invest Grp	Lamivudine as initial treatment for chronic hepatitis B in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Gastroenterological-Association / Digestive Disease Week	MAY 16-22, 1998	NEW ORLEANS, LOUISIANA	Amer Gastroenterol Assoc			TERM FOLLOW-UP; VIRUS-INFECTION; INTERFERON-ALFA; THERAPY; TRIAL; POLYMERASE; REPLICATION; RESISTANCE; MUTATIONS	Background Although the nucleoside analogue lamivudine has shown promise in patients with chronic hepatitis B, long-term data on patients from the United States are lacking. Methods We randomly assigned previously untreated patients with chronic hepatitis B to receive either 100 mg of oral lamivudine or placebo daily for 52 weeks. We then followed them for an additional 16 weeks to evaluate post-treatment safety and the durability of responses. The primary end point with respect to efficacy was a reduction of at least 2 points in the score on the Histologic Activity Index. On this scale, scores can range from 0 (normal) to 22 (most severe abnormalities). Results Of the 143 randomized patients, 137 were included in the efficacy analysis: 66 in the lamivudine group and 71 in the placebo group. The other six patients were excluded at the base-line visit because of the absence of a documented history of hepatitis B surface antigen for at least six months. After 52 weeks of treatment, lamivudine recipients were more likely than placebo recipients to have a histologic response (52 percent vs. 23 percent, P<0.001), loss of hepatitis B e antigen (HBeAg) in serum (32 percent vs. 11 percent, P=0.003), sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable levels (44 percent vs. 16 percent, P<0.001), and sustained normalization of serum alanine aminotransferase levels (41 percent vs. 7 percent, P<0.001), and they were less likely to have increased hepatic fibrosis (5 percent vs. 20 percent, P=0.01). Lamivudine recipients were also more likely to undergo HBeAg seroconversion, defined as the loss of HBeAg, undetectable levels of serum HBV DNA, and the appearance of antibodies against HBeAg (17 percent vs. 6 percent, P=0.04). HBeAg responses persisted in most patients for 16 weeks after the discontinuation of treatment. Lamivudine was well tolerated. Self-limited post-treatment elevations in serum alanine aminotransferase were more common in lamivudine recipients: 25 percent had serum alanine aminotransferase levels that were at least three times base-line levels, as compared with 8 percent of placebo recipients (P=0.01). The clinical condition of all patients remained stable during the study. Conclusions In U.S. patients with previously untreated chronic hepatitis B, one year of lamivudine therapy had favorable effects on histologic, virologic, and biochemical features of the disease and was well tolerated. HBeAg responses were usually sustained after treatment. (N Engl J Med 1999;341:1256-63.) (C)1999, Massachusetts Medical Society.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Liver Biliary Pancreas Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Univ Miami, Med Ctr, Ctr Liver Dis, Miami, FL 33152 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA; Vet Affairs Med Ctr, Div Gastroenterol, San Francisco, CA 94121 USA; Alton Ochsner Med Fdn & Ochsner Clin, Div Gastroenterol, New Orleans, LA 70121 USA; Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA; Armed Forces Inst Pathol, Washington, DC 20306 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Ochsner Health System; Jefferson University; United States Department of Defense; GlaxoSmithKline	Dienstag, JL (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.		ting, huang/V-6326-2017	Dienstag, Jules/0000-0001-7024-0980	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR01066] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; Chayama K, 1998, HEPATOLOGY, V27, P1711, DOI 10.1002/hep.510270634; Dienstag J. L., 1996, Hepatology, V24, p188A; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DIENSTAG JL, 1998, HARRISONS PRINCIPLES, V2, P1677; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; Heathcote J., 1998, Journal of Hepatology, V28, P43, DOI 10.1016/S0168-8278(98)80380-2; Honkoop P, 1998, J VIRAL HEPATITIS, V5, P307, DOI 10.1046/j.1365-2893.1998.00121.x; HONKOOP P, 1995, LANCET, V346, P1156, DOI 10.1016/S0140-6736(95)91829-9; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; PEACE K, 1988, BIOPHARMACEUTICAL ST; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1990, HEPATOLOGY, V12, P1433, DOI 10.1002/hep.1840120626; Schiff E, 1998, HEPATOLOGY, V28, p163A; Schiff E, 1998, HEPATOLOGY, V28, p388A; SEEFF LB, 1987, NEW ENGL J MED, V316, P965, DOI 10.1056/NEJM198704163161601; SEEFF LB, 1986, SEMIN LIVER DIS, V6, P11, DOI 10.1055/s-2008-1040788; TASSOPOULOS NC, 1987, GASTROENTEROLOGY, V92, P1844, DOI 10.1016/0016-5085(87)90614-7; Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1053/jhep.1996.v24.pm0008781348; TYRRELL DLJ, 1993, HEPATOLOGY, V18, pA112, DOI 10.1016/0270-9139(93)91978-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	35	1076	1146	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1256	1263		10.1056/NEJM199910213411702	http://dx.doi.org/10.1056/NEJM199910213411702			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528035				2022-12-28	WOS:000083226300002
J	Jaakkimainen, RL; Boyle, E; Tudiver, F				Jaakkimainen, RL; Boyle, E; Tudiver, F			Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; NONULCER DYSPEPSIA; CAMPYLOBACTER-PYLORI; FUNCTIONAL DYSPEPSIA; PEPTIC-ULCER; GASTROINTESTINAL SYMPTOMS; DUODENAL-ULCER; INFECTION; GASTRITIS; METAANALYSIS	Objectives To examine the association between Helicobacter pylori infection and non-ulcer dyspepsia, and to assess the effect of eradicating H pylori on dyspeptic symptoms in patients with non-ulcer dyspepsia Design Systematic review and meta-analysis of (a) observational studies examining the association between Helicobacter pylori infection and non-ulcer dyspepsia (association studies), and (b) therapeutic trials examining the association between eradication of H pylori and dyspeptic symptoms in patients with non-ulcer dyspepsia (eradication trials). Data sources Randomised controlled trials and observational studies conducted worldwide and published between January 1983 and March 1999. Main outcome measures Summary odds ratios and summary symptom scores. Results 23 association studies and 5 eradication trials met the inclusion criteria. In the association studies the summary odds ratio for H pylori infection in patients with non-ulcer dyspepsia was 1.6 (95% confidence interval 1.4 to 1.8). In the eradication trials the summary odds ratio for improvement in dyspeptic symptoms in patients with non-ulcer dyspepsia in whom H pylori was eradicated was 1.9 (1.3 to 2.6). Conclusions Some evidence shows an association between H pylori infection and dyspeptic symptoms in patients referred to gastroenterologists. An improvement in dyspeptic symptoms occurred among patients with non-ulcer dyspepsia in whom H pylori was eradicated.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Family & Community Med, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; SUNY Hlth Sci Ctr, Dept Family Med, Ctr Evidence Based Practice, Syracuse, NY 13210 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Jaakkimainen, RL (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Family & Community Med, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.	liisa.jaakkimainen@ices.on.ca	Boyle, Eleanor/G-4567-2016; Jaakkimainen, Liisa/GPP-4256-2022	Boyle, Eleanor/0000-0002-9012-9128; 				AGREUS L, 1995, SCAND J GASTROENTERO, V30, P752, DOI 10.3109/00365529509096323; Alarcon T, 1999, INT J ANTIMICROB AG, V12, P19, DOI 10.1016/S0924-8579(99)00051-5; [Anonymous], 1994, NIH Consens Statement, V12, P1; Armstrong D, 1996, SCAND J GASTROENTERO, V31, P38, DOI 10.3109/00365529609094532; BERNERSEN B, 1992, BRIT MED J, V304, P1276, DOI 10.1136/bmj.304.6837.1276; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; *BORL INT, 1996, AN SOFTW STAT WIND; CHAMBERS TC, 1981, CONTROLLED CLIN TRIA, V2, P31; Chiba N, 1998, CAN J GASTROENTEROL, V12, P83, DOI 10.1155/1998/175926; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; *COCHR COLL, 1999, REV MAN VERS 4 0 WIN; COLLINS JSA, 1989, J PATHOL, V158, P303, DOI 10.1002/path.1711580407; CZINN SJ, 1991, SCAND J GASTROENTERO, V26, P33, DOI 10.3109/00365529109093205; Davis S, 1996, Aust Fam Physician, V25, P56; Ducons JA, 1999, ALIMENT PHARM THERAP, V13, P775, DOI 10.1046/j.1365-2036.1999.00549.x; Ebell MH, 1997, J FAM PRACTICE, V44, P545; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Fendrick AM, 1997, AM J GASTROENTEROL, V92, P2017; Fleiss JL, 1981, STAT METHODS RATES P, P218; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; Gill H H, 1993, Indian J Gastroenterol, V12, P9; GLUPCZYNSKI Y, 1988, AM J GASTROENTEROL, V83, P365; Goves J, 1998, ALIMENT PHARM THERAP, V12, P147; Gurakan F, 1996, TURKISH J PEDIATR, V38, P329; HEATLEY RV, 1987, LANCET, V2, P779; Hedges L. V., 1985, STAT METHODS METAANA, P107; Hobbs FDR, 1996, FAM PRACT, V13, P225, DOI 10.1093/fampra/13.3.225; Hoffman PS, 1999, CAN J GASTROENTEROL, V13, P243, DOI 10.1155/1999/838072; HOLCOMBE C, 1991, T ROY SOC TROP MED H, V85, P553, DOI 10.1016/0035-9203(91)90258-Z; HOLTMANN G, 1994, DIGEST DIS SCI, V39, P1090, DOI 10.1007/BF02087563; Holtmann G, 1996, DIGEST DIS SCI, V41, P1285, DOI 10.1007/BF02088548; KATELARIS PH, 1992, GUT, V33, P1462, DOI 10.1136/gut.33.11.1462; Malaty HM, 1996, AM J EPIDEMIOL, V143, P257, DOI 10.1093/oxfordjournals.aje.a008736; MANSI C, 1993, AM J GASTROENTEROL, V88, P1011; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCDOWELL I, 1987, MEASURING HLTH GUIDE, P20; MCNULTY CAM, 1986, BRIT MED J, V293, P645, DOI 10.1136/bmj.293.6548.645; Mukhopadhyay D K, 1992, Indian J Gastroenterol, V11, P76; O'Connor HJ, 1999, ALIMENT PHARM THER, V13, P117; OBrien B, 1997, CAN J GASTROENTEROL, V11, P323, DOI 10.1155/1997/290183; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; OMORAIN C, 1993, SCAND J GASTROENTERO, V28, P30, DOI 10.3109/00365529309098340; PATEL P, 1995, LANCET, V346, P1315, DOI 10.1016/S0140-6736(95)92340-3; Petitti D.B., 1994, METHODS QUANTITATIVE, V24, P119; PETTROSS CW, 1988, DIGEST DIS SCI, V33, P649, DOI 10.1007/BF01540425; Phull PS, 1996, BRIT MED J, V312, P349, DOI 10.1136/bmj.312.7027.349; PRASAD S, 1994, J GASTROEN HEPATOL, V9, P501, DOI 10.1111/j.1440-1746.1994.tb01281.x; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; ROKKAS T, 1987, AM J GASTROENTEROL, V82, P1149; Rosenstock S, 1997, GUT, V41, P169, DOI 10.1136/gut.41.2.169; SCHLEMPER RJ, 1995, J GASTROEN HEPATOL, V10, P633, DOI 10.1111/j.1440-1746.1995.tb01362.x; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; Sonnenberg A, 1996, AM J GASTROENTEROL, V91, P1773; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; Su Yu-Chung, 1995, Kaohsiung Journal of Medical Sciences, V11, P8; Talley N, 1991, GASTROENTEROL INT, V4, P145; Talley N J, 1996, Aust Fam Physician, V25, P47; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; Talley NJ, 1997, GASTROENTEROLOGY, V113, pS67, DOI 10.1016/S0016-5085(97)80016-9; THOMPSON WG, 1995, CAN MED ASSOC J, V153, P293; Tsega E, 1996, ETHIOPIAN MED J, V34, P65; TUCCI A, 1992, GASTROENTEROLOGY, V103, P768, DOI 10.1016/0016-5085(92)90004-I; UYUB AM, 1994, SCAND J GASTROENTERO, V29, P209, DOI 10.3109/00365529409090465; VAIRA D, 1992, ITAL J GASTROENTEROL, V24, P400; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P177; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P189; VANZANTEN SJOV, 1993, SCAND J GASTROENTERO, V28, P40, DOI 10.3109/00365529309098356; WARNDORFF DK, 1989, J ROY COLL GEN PRACT, V39, P499; WILHELMSEN I, 1994, SCAND J GASTROENTERO, V29, P522, DOI 10.3109/00365529409092466; Wu JCY, 1999, AM J GASTROENTEROL, V94, P1790, DOI 10.1111/j.1572-0241.1999.01207.x; Zar S, 1998, BRIT MED BULL, V54, P217	76	122	127	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1999	319	7216					1040	1044B		10.1136/bmj.319.7216.1040	http://dx.doi.org/10.1136/bmj.319.7216.1040			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521198	Green Published, Bronze			2022-12-28	WOS:000083210100028
J	De Teresa, JM; Barthelemy, A; Fert, A; Contour, JP; Montaigne, F; Seneor, P				De Teresa, JM; Barthelemy, A; Fert, A; Contour, JP; Montaigne, F; Seneor, P			Role of metal-oxide interface in determining the spin polarization of magnetic tunnel junctions	SCIENCE			English	Article							ROOM-TEMPERATURE; MAGNETORESISTANCE; ELECTRONS	The role of the metal-oxide interface in determining the spin polarization of electrons tunneling from or into ferromagnetic transition metals in magnetic tunnel junctions is reported. The spin polarization of cobalt in tunnel junctions with an alumina barrier is positive, but it is negative when the barrier is strontium titanate or cerium lanthanite. The results are ascribed to bonding effects at the transition metal-barrier interface. The influence of the electronic structure of metal-oxide interfaces on the spin polarization raises interesting fundamental problems and opens new ways to optimize the magnetoresistance of tunnel junctions.	Thomson CSF, Cent Rech Lab, CNRS, Unite Mixte Phys, F-91404 Orsay, France; Univ Paris Sud, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Thales Group; UDICE-French Research Universities; Universite Paris Saclay	Fert, A (corresponding author), Thomson CSF, Cent Rech Lab, CNRS, Unite Mixte Phys, Domaine Corbeville, F-91404 Orsay, France.	fert@lcr.thomson-csf.com	BARTHELEMY, Agnès/ABB-5522-2020; Montaigne, François/A-1037-2010; Montaigne, François/P-2353-2019; DE TERESA, JOSE M/E-2430-2011	Montaigne, François/0000-0003-4010-9935; DE TERESA, JOSE M/0000-0001-9566-0738				De Boeck J, 1998, SCIENCE, V281, P357; De Teresa JM, 1999, PHYS REV LETT, V82, P4288, DOI 10.1103/PhysRevLett.82.4288; HERTZ JA, 1973, PHYS REV B, V8, P3252, DOI 10.1103/PhysRevB.8.3252; Kobayashi KL, 1998, NATURE, V395, P677, DOI 10.1038/27167; MacLaren JM, 1999, PHYS REV B, V59, P5470, DOI 10.1103/PhysRevB.59.5470; MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; MOODERA JS, 1998, APPL PHYS LETT, V81, P1953; Nassar J, 1998, APPL PHYS LETT, V73, P698, DOI 10.1063/1.121952; Nguyen-Manh D, 1998, MATER RES SOC SYMP P, V492, P319, DOI 10.1557/PROC-492-319; Park JH, 1998, NATURE, V392, P794, DOI 10.1038/33883; Sharma M, 1999, PHYS REV LETT, V82, P616, DOI 10.1103/PhysRevLett.82.616; STEARNS MB, 1997, J MAGN MAGN MATER, V5, P187; TEDROW PM, 1973, PHYS REV B, V7, P318, DOI 10.1103/PhysRevB.7.318; WANG K, 1999, THESIS NEW YORK U; Zhang S, 1997, PHYS REV LETT, V79, P3744, DOI 10.1103/PhysRevLett.79.3744	16	523	523	7	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					507	509		10.1126/science.286.5439.507	http://dx.doi.org/10.1126/science.286.5439.507			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521341				2022-12-28	WOS:000083121200053
J	Mallon, PWG; Evans, M; Hall, M; Bailey, R				Mallon, PWG; Evans, M; Hall, M; Bailey, R			"Something moving in my head"	LANCET			English	Article							COCHLIOMYIA-HOMINIVORAX; MYIASIS		Hosp Trop Dis, London WC1E 6AU, England; Nat Hist Museum, Dept Entomol, London SW7 5BD, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; Natural History Museum London	Bailey, R (corresponding author), Hosp Trop Dis, Mortimer Market,Capper St,Tottenham Court Rd, London WC1E 6AU, England.		Hall, Martin/AAF-8135-2020	Hall, Martin/0000-0002-8917-9646				DEKAMINSKY RG, 1993, T ROY SOC TROP MED H, V87, P199, DOI 10.1016/0035-9203(93)90492-9; ELAZAZY OME, 1990, T ROY SOC TROP MED H, V84, P747, DOI 10.1016/0035-9203(90)90175-E; KONKOL KA, 1992, CLIN INFECT DIS, V14, P366, DOI 10.1093/clinids/14.1.366; KRON MA, 1992, J AM ACAD DERMATOL, V27, P264, DOI 10.1016/S0190-9622(08)80737-2; PILCHARD EI, 1989, FOREIGN ANIMAL DIS R, V174, P1	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1260	1260		10.1016/S0140-6736(99)06246-7	http://dx.doi.org/10.1016/S0140-6736(99)06246-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520636				2022-12-28	WOS:000083010400013
J	Herwaldt, BL				Herwaldt, BL			Leishmaniasis	LANCET			English	Article							INDIAN VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; MUCOCUTANEOUS LEISHMANIASIS; CYTOKINE RESPONSES; NATURAL-HISTORY; KALA-AZAR; DIAGNOSIS; CELL; DNA; GUATEMALA	In 1903, Leishman and Donovan separately described the protozoan now called Leishmania donovani in splenic tissue from patients in India with the life-threatening disease now called visceral leishmaniasis. Almost a century later, many features of leishmaniasis and its major syndromes (ie, visceral, cutaneous, and mucosal) have remained the same; but also much has changed. As before, epidemics of this sandfly-borne disease occur periodically in India and elsewhere; but leishmaniasis has also emerged in new regions and settings, for example, as an AIDS-associated opportunistic infection. Diagnosis still typically relies on classic microbiological methods, but molecular-based approaches are being tested. Pentavalent antimony compounds have been the mainstay of antileishmanial therapy for half a century, but lipid formulations of amphotericin B (though expensive and administered parenterally) represent a major advance for treating visceral leishmaniasis. A pressing need is for the technological advances in the understanding of the immune response to leishmania and the pathogenesis of leishmaniasis to be translated into field-applicable and affordable methods for diagnosis, treatment, and prevention of this disease.	Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Herwaldt, BL (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Highway NE,Mailstop F22, Atlanta, GA 30341 USA.							AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Alcais A, 1997, AM J HUM GENET, V61, P968, DOI 10.1086/514882; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; Arias JR, 1996, EMERG INFECT DIS, V2, P145, DOI 10.3201/eid0202.960213; Ashford RW, 1996, CLIN DERMATOL, V14, P523, DOI 10.1016/0738-081X(96)00041-7; Ashford RW, 1997, ANN TROP MED PARASIT, V91, P693, DOI 10.1080/00034989760428; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Berman JD, 1999, CLIN INFECT DIS, V28, P49, DOI 10.1086/515086; Bernier R, 1998, J IMMUNOL, V160, P2881; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; Davidson RN, 1997, GENITOURIN MED, V73, P237; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; DESJEUX P, 1998, LEISHMANIA HIV GRIDL; Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; Hewitt S, 1998, T ROY SOC TROP MED H, V92, P273, DOI 10.1016/S0035-9203(98)91007-0; HO JL, 1994, BIOTHERAPY, V7, P223, DOI 10.1007/BF01878488; KALTER DC, 1994, DERMATOL CLIN, V12, P37, DOI 10.1016/S0733-8635(18)30200-6; Kenney RT, 1998, J INFECT DIS, V177, P815, DOI 10.1086/517817; Laguna F, 1999, AIDS, V13, P1063, DOI 10.1097/00002030-199906180-00009; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; Modabber F, 1995, ANN TROP MED PARASIT, V89, P83, DOI 10.1080/00034983.1995.11813017; NAVIN TR, 1990, AM J TROP MED HYG, V42, P36, DOI 10.4269/ajtmh.1990.42.36; REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O; Reed SG, 1996, CLIN DERMATOL, V14, P471, DOI 10.1016/0738-081X(96)00038-7; RODRIGUEZ N, 1994, J CLIN MICROBIOL, V32, P2246; SCHARTONKERSTEN T, 1995, J IMMUNOL, V154, P5320; Seaman J, 1996, ANN INTERN MED, V124, P664, DOI 10.7326/0003-4819-124-7-199604010-00007; SHAW JJ, 1994, MEM I OSWALDO CRUZ, V89, P471, DOI 10.1590/S0074-02761994000300033; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Sundar S, 1997, AM J TROP MED HYG, V56, P522, DOI 10.4269/ajtmh.1997.56.522; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; Sundar S, 1998, ANN TROP MED PARASIT, V92, P755, DOI 10.1080/00034989858998; Weigle K, 1996, CLIN DERMATOL, V14, P433, DOI 10.1016/0738-081X(96)00036-3; WEIGLE KA, 1987, AM J TROP MED HYG, V36, P489, DOI 10.4269/ajtmh.1987.36.489; *WHO, 1990, WHO TECH REP SER, V793; Wilson SM, 1995, ANN TROP MED PARASIT, V89, P95, DOI 10.1080/00034983.1995.11813019; World Health Organization, 1994, REP CONS M LEISHM HI	41	1179	1229	2	142	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1191	1199		10.1016/S0140-6736(98)10178-2	http://dx.doi.org/10.1016/S0140-6736(98)10178-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513726	Green Submitted			2022-12-28	WOS:000082954100044
J	Newberry, D; Sharma, V; Reiff, D; De Lorenzo, F				Newberry, D; Sharma, V; Reiff, D; De Lorenzo, F			A "little cough" for 40 years	LANCET			English	Article							ESOPHAGEAL FISTULA; ADULT		Thrombosis Res Inst, London SW3 6LR, England; Ashford & St Peters Hosp, Ashford, Middx, England	Thrombosis Research Institute	De Lorenzo, F (corresponding author), Thrombosis Res Inst, London SW3 6LR, England.			Sharma, Vivek/0000-0003-1419-5833				AZOULAY D, 1992, J THORAC CARDIOV SUR, V104, P381; DEPAEPE A, 1993, ARCH DIS CHILD, V68, P743, DOI 10.1136/adc.68.6.743; ENOKSEN A, 1979, SCAND J THORAC CARD, V13, P173, DOI 10.3109/14017437909100988; STPEHENS RW, 1976, ANN OTO RHINOL LARYN, V85, P613; VASQUEZ RE, 1988, RADIOLOGY, V167, P93, DOI 10.1148/radiology.167.1.3347754	5	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1174	1174		10.1016/S0140-6736(99)10014-X	http://dx.doi.org/10.1016/S0140-6736(99)10014-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513712				2022-12-28	WOS:000082954100014
J	Lee, JT; Lu, NF				Lee, JT; Lu, NF			Targeted mutagenesis of Tsix leads to nonrandom X inactivation	CELL			English	Article							CHROMOSOME INACTIVATION; XIST GENE; MOUSE EMBRYOS; INSITU HYBRIDIZATION; LINKED GENES; RNA; DIFFERENTIATION; STABILIZATION; EXPRESSION; INTERPHASE	During X inactivation, mammalian female cells make the selection of one active and one inactive X chromosome. X chromosome choice occurs randomly and results in Xist upregulation on the inactive X. We have hypothesized that the antisense gene, Tsix, controls Xist expression. Here, we create a targeted deletion of Tsix in female and male mouse cells. Despite a deficiency of Tsix RNA, X chromosome counting remains intact: female cells still inactivate one X, while male cells block X inactivation. However, heterozygous female cells show skewed Xist expression and primary nonrandom inactivation of the mutant X. The ability of the mutant X to block Xist accumulation is compromised. We conclude that Tsix regulates Xist in cis and determines X chromosome choice without affecting silencing. Therefore, counting, choice, and silencing are genetically separable. Contrasting effects in XX and XY cells argue that negative and positive factors are involved in choosing active and inactive Xs.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058839] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58839A01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 1998, GENET RES, V72, P217, DOI 10.1017/S0016672398003516; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Cattanach BM, 1994, MOUSE GENOME, V92, P114; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COOPER DW, 1971, NATURE-NEW BIOL, V230, P155, DOI 10.1038/newbio230155a0; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EICHER EM, 1970, ADV GENET, V15, P175, DOI 10.1016/S0065-2660(08)60074-7; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1971, NATURE-NEW BIOL, V232, P229, DOI 10.1038/newbio232229a0; LYON MF, 1972, BIOL REV, V47, P1; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; OHNO S, 1969, ANNU REV GENET, V3, P495, DOI 10.1146/annurev.ge.03.120169.002431; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Papaioannou V., 1993, Gene targeting: a practical approach., P107; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Torres RM, 1997, LAB PROTOCOLS CONDIT; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Wurst W., 1993, Gene targeting: a practical approach., P33	47	400	419	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					47	57		10.1016/S0092-8674(00)80061-6	http://dx.doi.org/10.1016/S0092-8674(00)80061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520993	Bronze			2022-12-28	WOS:000082981600007
J	Pal-Bhadra, M; Bhadra, U; Birchler, JA				Pal-Bhadra, M; Bhadra, U; Birchler, JA			Cosuppression of nonhomologous transgenes in Drosophila involves mutually related endogenous sequences	CELL			English	Article							POLYCOMB RESPONSE ELEMENT; ADH PROMOTER SWITCH; GENE-EXPRESSION; ALCOHOL-DEHYDROGENASE; DNA-METHYLATION; VIRUS-RESISTANCE; BITHORAX COMPLEX; MELANOGASTER; PLANTS; WHITE	Cosuppression refers to the phenomenon in which silencing among dispersed homologous genes occurs. Here we demonstrate that two nonhomologous reciprocal fusion genes, white-Alcohol dehydrogenase (w-Adh) and Adh-w, exhibit cosuppression using the endogenous Adh sequence as an intermediary. Deletion of the endogenous Adh gene eliminates the interaction, while reintroduction of an 8.6 kb Adh fragment restores the silencing. Using truncated Adh constructs, a nontranscribed segment in the Adh regulatory region was found to be one of the sequences required for homology recognition. The silencing interaction is initiated during early development. The silenced transgenes are associated with the Polycomb group complex of chromatin proteins.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Birchler, JA (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	birchlerj@missouri.edu						Bahramian MB, 1999, MOL CELL BIOL, V19, P274; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIRCHLER JA, 1990, GENETICS, V124, P677; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gubb D, 1997, GENETICS, V146, P919; Hagstrom K, 1997, GENETICS, V146, P1365; HIEBERT JC, 1994, GENETICS, V136, P913; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KASSIS JA, 1991, GENETICS, V128, P751; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LAURIEAHLBERG CC, 1987, GENETICS, V115, P129; Mallin DR, 1998, GENETICS, V148, P331; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; Mihaly J, 1998, MOL CELL, V1, P1065, DOI 10.1016/S1097-2765(00)80107-0; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Paro R., 1996, EPIGENETIC MECH GENE, P507; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROBERTSON HM, 1988, GENETICS, V118, P461; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sigrist CJA, 1997, GENETICS, V147, P209; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; ZACHAR Z, 1982, CELL, V30, P529, DOI 10.1016/0092-8674(82)90250-1	55	67	75	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					35	46		10.1016/S0092-8674(00)80060-4	http://dx.doi.org/10.1016/S0092-8674(00)80060-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520992	Bronze			2022-12-28	WOS:000082981600006
J	Smil, V				Smil, V			Mow many billions to go?	NATURE			English	Editorial Material									Univ Manitoba, Dept Geophys, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Smil, V (corresponding author), Univ Manitoba, Dept Geophys, Winnipeg, MB R3T 2N2, Canada.								0	7	7	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					429	429		10.1038/46689	http://dx.doi.org/10.1038/46689			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519538				2022-12-28	WOS:000082981200029
J	Morrin, MM; Farrell, RJ; Kruskal, JB; LaMont, JT				Morrin, MM; Farrell, RJ; Kruskal, JB; LaMont, JT			Virtual colonoscopy: a kinder, gentler colorectal cancer screening test?	LANCET			English	Editorial Material									Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morrin, MM (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02115 USA.							*AM CANC SOC, 1998, PUBL AM CANC SOC; [Anonymous], 1997, JAMA-J AM MED ASSOC, V281, P1581; Hara A, 1996, RADIOLOGY S, V201, P252; Hara AK, 1997, RADIOLOGY, V205, P59, DOI 10.1148/radiology.205.1.9314963; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; Sonnenberg A, 1999, AM J GASTROENTEROL, V94, P2268; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Vining DJ., 1994, AM J ROENTGENOL, V162, pS104; Weishaupt D, 1999, LANCET, V354, P835; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	10	22	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1048	1049		10.1016/S0140-6736(99)00302-5	http://dx.doi.org/10.1016/S0140-6736(99)00302-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509490				2022-12-28	WOS:000082777500004
J	Fairley, CK; Sinclair, MI; Rizak, S				Fairley, CK; Sinclair, MI; Rizak, S			Monitoring not the answer to cryptosporidium in water	LANCET			English	Editorial Material									Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Fairley, CK (corresponding author), Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia.			Sinclair, Martha/0000-0002-5900-487X; Christopher, Fairley/0000-0001-9081-1664				*AUSTR DRINK WAT G, 1996, AGR RES MAN COUNC AU; BOUCHIER I, 1998, CRYPTOSPOIRIDIUM WAT; CHAPPELL CH, 1998, CRYPTOSPORIDIUM WATE, P11; *DEP ENV TRANSP RE, 1998, PUBL HLTH DRINK WAT; EPA, 1998, FED REGISTER, V2040, P69389; *FED PROV SUBC DRI, 1997, PROT DRINK WAT DOC P; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MCCLELLAN P, 1998, SYDNEY WATER INQUIRY; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; *PUBL HLTH LAB SER, 1999, FACTS FIG CRYPT; Sinclair MI, 1998, MED J AUSTRALIA, V169, P296, DOI 10.5694/j.1326-5377.1998.tb140278.x; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VESEY G, 1997, INT S WAT CRYPT MARC; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; 1999, WATER SUPPLY WATER Q	15	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					967	969		10.1016/S0140-6736(99)90065-X	http://dx.doi.org/10.1016/S0140-6736(99)90065-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501354				2022-12-28	WOS:000082596000005
J	Islam, F				Islam, F			This time it was not a drill	BRITISH MEDICAL JOURNAL			English	Editorial Material									St Marys Hosp, London, England	Imperial College London	Islam, F (corresponding author), St Marys Hosp, London, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1079	1079		10.1136/bmj.319.7216.1079	http://dx.doi.org/10.1136/bmj.319.7216.1079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521227	Green Published			2022-12-28	WOS:000083210100079
J	Hong, SH; Zhu, J; Mirkin, CA				Hong, SH; Zhu, J; Mirkin, CA			Multiple ink nanolithography: Toward a multiple-pen nano-plotter	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; SCANNING PROBE MICROSCOPY; ATOMIC-FORCE MICROSCOPE; NANOMETER-SCALE; PATTERN TRANSFER; THIN-FILMS; FABRICATION; SI; RESISTS; NANOSTRUCTURE	The formation of intricate nanostructures will require the ability to maintain surface registry during several patterning steps. A scanning probe method, dip-pen nanolithography (DPN), can be used to pattern monolayers of different organic molecules down to a 5-nanometer separation. An "overwriting" capability of DPN allows one nanostructure to be generated and the areas surrounding that nanostructure to be filled in with a second type of "ink."	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Ctr Nanofabricat & Mol Self Assembly, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		Mirkin, Chad A/E-3911-2010; Hong, Seunghun/B-2545-2012	Mirkin, Chad/0000-0002-6634-7627				Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; BERGGREN KK, 1995, SCIENCE, V269, P1255, DOI 10.1126/science.7652572; Bottomley LA, 1998, ANAL CHEM, V70, p425R; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Carr DW, 1997, J VAC SCI TECHNOL A, V15, P1446, DOI 10.1116/1.580559; Chen CS, 1998, BIOTECHNOL PROGR, V14, P356, DOI 10.1021/bp980031m; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; Feldheim DL, 1998, CHEM SOC REV, V27, P1; JACKMAN RJ, 1995, SCIENCE, V269, P664, DOI 10.1126/science.7624795; JASCHKE M, 1995, LANGMUIR, V11, P1061, DOI 10.1021/la00004a004; KIM Y, 1992, SCIENCE, V257, P375, DOI 10.1126/science.257.5068.375; Komeda T, 1998, J VAC SCI TECHNOL A, V16, P1680, DOI 10.1116/1.581142; KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/ja00049a061; Muller HU, 1995, J VAC SCI TECHNOL B, V13, P2846, DOI 10.1116/1.588302; Nyffenegger RM, 1997, CHEM REV, V97, P1195, DOI 10.1021/cr960069i; Perkins FK, 1996, APPL PHYS LETT, V68, P550, DOI 10.1063/1.116396; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Piner RD, 1997, LANGMUIR, V13, P6864, DOI 10.1021/la970921w; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Rosa JC, 1998, APPL PHYS LETT, V73, P2684, DOI 10.1063/1.122553; Schoer JK, 1997, LANGMUIR, V13, P2323, DOI 10.1021/la960369v; SONDAGHUETHORST JAM, 1994, APPL PHYS LETT, V64, P285, DOI 10.1063/1.111182; Sugimura H, 1996, J VAC SCI TECHNOL A, V14, P1223, DOI 10.1116/1.580271; Wang DW, 1997, APPL PHYS LETT, V70, P1593, DOI 10.1063/1.118625; Whelan CS, 1996, APPL PHYS LETT, V69, P4245, DOI 10.1063/1.116959; WILBUR JL, 1995, LANGMUIR, V11, P825, DOI 10.1021/la00003a025; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q; Xu S, 1997, LANGMUIR, V13, P127, DOI 10.1021/la962029f; Younkin R, 1997, APPL PHYS LETT, V71, P1261, DOI 10.1063/1.119867	30	470	496	1	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					523	525		10.1126/science.286.5439.523	http://dx.doi.org/10.1126/science.286.5439.523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521346				2022-12-28	WOS:000083121200058
J	McPherson, A				McPherson, A			The problem with medical advice columns	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					928	928		10.1136/bmj.319.7214.928	http://dx.doi.org/10.1136/bmj.319.7214.928			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506074	Green Published			2022-12-28	WOS:000082975600072
J	Guillot, T				Guillot, T			Interiors of giant planets inside end outside the solar system	SCIENCE			English	Review							VOYAGER TRACKING DATA; LOW-MASS STARS; HELIUM ABUNDANCE; GRAVITY-FIELD; BROWN DWARFS; MODELS; JUPITER; HYDROGEN; NEPTUNE; SATURN	An understanding of the structure and composition of the giant planets is rapidly evolving because of (i) high-pressure experiments with the ability to study metallic hydrogen and define the properties of its equation of state and (ii) spectroscopic and in situ measurements made by telescopes and satellites that allow an accurate determination of the chemical composition of the deep atmospheres of the giant planets. However, the total amount of heavy elements that Jupiter, Saturn, Uranus, and Neptune contain remains poorly constrained. The discovery of extrasolar giant planets with masses ranging from that of Saturn to a few times the mass of Jupiter opens up new possibilities for understanding planet composition and formation. Evolutionary models predict that gaseous extrasolar giant planets should have a variety of atmospheric temperatures and chemical compositions, but the radii are estimated to be close to that of Jupiter (between 0.9 and 1.7 Jupiter radii). provided that they contain mostly hydrogen and helium.	Observ Cote Azur, Dept Cassini, CNRS, UMR 6529, F-06304 Nice 04, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur	Guillot, T (corresponding author), Observ Cote Azur, Dept Cassini, CNRS, UMR 6529, Boite Postale 4229, F-06304 Nice 04, France.	guillot@obs-nice.fr		Guillot, Tristan/0000-0002-7188-8428				ALEXANDER DR, 1994, ASTROPHYS J, V437, P879, DOI 10.1086/175039; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ATREYA SK, IN PRESS PLANET SPAC; Bahcall JN, 1995, REV MOD PHYS, V67, P781, DOI 10.1103/RevModPhys.67.781; BODENHEIMER P, IN PRESS ICARUS; BORUCKI WJ, 1984, ICARUS, V58, P121, DOI 10.1016/0019-1035(84)90102-7; Boss AP, 1998, ASTROPHYS J, V503, P923, DOI 10.1086/306036; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; Burrows A, 1999, ASTROPHYS J, V512, P843, DOI 10.1086/306811; CAMPBELL JK, 1989, ASTRON J, V97, P1485, DOI 10.1086/115088; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; Chabrier G, 1997, ASTRON ASTROPHYS, V327, P1039; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; Collins GW, 1998, SCIENCE, V281, P1178, DOI 10.1126/science.281.5380.1178; COLLINS GW, UNPUB; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; CONRATH BJ, UNPUB; Fegley B, 1996, ASTROPHYS J, V472, pL37, DOI 10.1086/310356; Folkner WM, 1998, J GEOPHYS RES-PLANET, V103, P22847, DOI 10.1029/98JE01635; FRENCH RG, 1988, ICARUS, V73, P349, DOI 10.1016/0019-1035(88)90104-2; GAUTIER D, 1981, J GEOPHYS RES-SPACE, V86, P8713, DOI 10.1029/JA086iA10p08713; Gautier D, 1995, SPACE SCI S, P547; GOUKENLEUQUE C, UNPUB; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; Guillot T, 1997, ICARUS, V130, P534, DOI 10.1006/icar.1997.5812; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; GUILLOT T, 1997, ASTRONOMICAL BIOCH O, P343; GUILLOT T, UNPUB; GUILLOT T, 1996, ASTROPHYS J LETT, V460, P993; GUILLOT T, IN PRESS PLANET SPAC; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Hubbard WB, 1997, PHYS PLASMAS, V4, P2011, DOI 10.1063/1.872570; Hubbard WB, 1999, ICARUS, V137, P357, DOI 10.1006/icar.1998.6064; Hubbard WB, 1995, SPACE SCI S, P109; HUBBARD WB, 1989, ICARUS, V78, P102, DOI 10.1016/0019-1035(89)90072-9; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; HUBBARD WB, IN PRESS PLANET SPAC; KARKOSCHKA E, 1992, ICARUS, V97, P161, DOI 10.1016/0019-1035(92)90125-Q; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; Magro WR, 1996, PHYS REV LETT, V76, P1240, DOI 10.1103/PhysRevLett.76.1240; Marcy GW, 1998, ANNU REV ASTRON ASTR, V36, P57, DOI 10.1146/annurev.astro.36.1.57; Marley MS, 1999, ASTROPHYS J, V513, P879, DOI 10.1086/306881; Marley MS, 1996, SCIENCE, V272, P1919, DOI 10.1126/science.272.5270.1919; MARLEY MS, 1995, J GEOPHYS RES-PLANET, V100, P23349, DOI 10.1029/95JE02362; Nellis WJ, 1999, PHYS REV B, V59, P3434, DOI 10.1103/PhysRevB.59.3434; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; OWEN WM, 1991, ASTRON J, V101, P1511, DOI 10.1086/115783; Podolak M, 1995, PLANET SPACE SCI, V43, P1517, DOI 10.1016/0032-0633(95)00061-5; PODOLAK M, UNPUB; Podolak M., 1991, URANUS, P29; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; POLLACK JB, 1986, ICARUS, V67, P409, DOI 10.1016/0019-1035(86)90123-5; Roos-Serote M, 1998, J GEOPHYS RES-PLANET, V103, P23023, DOI 10.1029/98JE01049; ROUSTLON MS, 1995, EOS, V76, P343; SALPETER EE, 1973, ASTROPHYS J, V181, pL83, DOI 10.1086/181190; SAUMON D, 1995, ASTROPHYS J SUPPL S, V99, P713, DOI 10.1086/192204; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; SAUMON D, IN PRESS HIGH PRESSU; SCHMITT RW, 1994, ANNU REV FLUID MECH, V26, P255, DOI 10.1146/annurev.fl.26.010194.001351; Schneider J, 1999, CR ACAD SCI II B, V327, P621, DOI 10.1016/S1287-4620(99)80093-3; Seager S, 1998, ASTROPHYS J, V502, pL157, DOI 10.1086/311498; Showman AP, 1998, ICARUS, V132, P205, DOI 10.1006/icar.1998.5898; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; Trilling DE, 1998, ASTROPHYS J, V500, P428, DOI 10.1086/305711; von Zahn U, 1998, J GEOPHYS RES-PLANET, V103, P22815, DOI 10.1029/98JE00695; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; WUCHTERL G, IN PRESS PROTOSTARS, V4; Young RE, 1998, J GEOPHYS RES-PLANET, V103, P22775, DOI 10.1029/98JE01051; Zhang KK, 1996, SCIENCE, V273, P941, DOI 10.1126/science.273.5277.941; ZHARKOV VN, 1991, ANN GEOPHYS, V9, P357; ZHARKOV VN, 1978, PHYSICS PLANETARY IN; [No title captured]	77	417	420	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					72	77		10.1126/science.286.5437.72	http://dx.doi.org/10.1126/science.286.5437.72			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506563				2022-12-28	WOS:000082907400036
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Raju, TNK (corresponding author), Univ Chicago, Chicago, IL 60637 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1130	1130		10.1016/S0140-6736(05)76931-2	http://dx.doi.org/10.1016/S0140-6736(05)76931-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509540				2022-12-28	WOS:000082777500071
J	Anderson, BL				Anderson, BL			Psychophysics - Putting plaids in perspective	NATURE			English	Article							COMPONENTS; STEREOPSIS		MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Anderson, BL (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.			Anderson, Barton/0000-0003-0313-4285				Anderson BL, 1997, PERCEPTION, V26, P419, DOI 10.1068/p260419; Farell B, 1998, NATURE, V395, P689, DOI 10.1038/27192; GILLAM B, 1988, PERCEPTION, V17, P603, DOI 10.1068/p170603; Gillam B, 1999, VISION RES, V39, P493, DOI 10.1016/S0042-6989(98)00131-X; Hibbard PB, 1998, VISION RES, V38, P1073, DOI 10.1016/S0042-6989(97)00275-7; LAWSON RB, 1974, J EXP PSYCHOL, V103, P1142, DOI 10.1037/h0037366; Morgan MJ, 1997, VISION RES, V37, P2737, DOI 10.1016/S0042-6989(97)00074-6; NAKAYAMA K, 1990, VISION RES, V30, P811	8	5	5	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					342	342		10.1038/43819	http://dx.doi.org/10.1038/43819			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	240JJ	10517629	Bronze			2022-12-28	WOS:000082822600038
J	Horton, B				Horton, B			Keeping in touch with research	NATURE			English	Article																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					410	410						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517643				2022-12-28	WOS:000082822600062
J	Dorfer, L; Moser, M; Bahr, F; Spindler, K; Egarter-Vigl, E; Giullen, S; Dohr, G; Kenner, T				Dorfer, L; Moser, M; Bahr, F; Spindler, K; Egarter-Vigl, E; Giullen, S; Dohr, G; Kenner, T			A medical report from the stone age?	LANCET			English	Article									Graz Univ, Inst Physiol, A-8010 Graz, Austria; Austrian Soc Controlled Acupuncture, Graz, Austria; Joanneum Res Inst Noninvas Diag, Weiz, Austria; German Acad Acupuncture & Auriculomed, Munich, Germany; Univ Innsbruck, Inst Pre & Protohist, A-6020 Innsbruck, Austria; Ctr Mallqui, Ilo, Peru; Inst Pathol, Bozen Bolzano, Italy; Graz Univ, Inst Histol & Embryol, A-8010 Graz, Austria	University of Graz; University of Innsbruck; University of Graz	Moser, M (corresponding author), Graz Univ, Inst Physiol, Harrachgasse 21, A-8010 Graz, Austria.		Dohr, Gottfried/E-8070-2010; Moser, Maximilian/J-6105-2014	Moser, Maximilian/0000-0001-9292-5091				Allison MJ, 1996, MAN IN ICE, V3, P125; Aspock H, 1996, PARASITOL TODAY, V12, P255, DOI 10.1016/0169-4758(96)30008-2; BAHR F, 1996, EINFUHRUNG WISSENSCH; BAHR F, 1998, EXPERT OPINIONS CORR; Beijing Shanghai a NCoTCM, 1980, ESSENTIALS CHINESE A; BERNHARD W, 1992, MANN EIS, V1, P163; CAPASSO L, 1998, LANCET, V352, P9143; Capasso L., 1993, J PALEOPATHOLOGY, V5, P173; Dorfer L, 1998, SCIENCE, V282, P242; HASENOHRL N, 1998, MED TRIBUNE, V47, P10; HOPFEL F, 1992, MANN EIS, V1; Maciocia G, 1989, FDN CHINESE MED COMP; Moser M., 1999, DISCOVERING ARCHAEOL, V1, P16; O'Connor J, 1996, ACUPUNCTURE COMPREHE; OEGGEL K, 1998, OPENING LECT MUSEUM; ROLLE R, 1992, MANN EIS, V1, P334; Rudenko S. I, 1970, FROZEN TOMBS SIBERIA; SEIDLER H, 1992, SCIENCE, V258, P455, DOI 10.1126/science.1411539; Sjovold T., 1995, MANN EIS, V2, P279; SPINDLER K, 1994, MAN ICE PRESEVED BOD; Spindler K., 1992, MANN EIS, P131; VANDERVELDEN E, 1995, MAN ICE, V2, P275; WERTSCH G, 1996, AKUPUNKTURATLAS	23	73	76	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					1023	1025		10.1016/S0140-6736(98)12242-0	http://dx.doi.org/10.1016/S0140-6736(98)12242-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501382				2022-12-28	WOS:000082596000043
J	Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC				Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC		WHO Global Surveillance Monitoring Project	Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTION; TRANSMISSION; SURVIVAL; ISSUES	Objective To estimate the risk and prevalence of Mycobacterium tuberculosis (MTB) infection and tuberculosis (TB) incidence, prevalence, and mortality, including disease attributable to human immunodeficiency virus (HIV), for 212 countries in 1997. Participants A panel of 86 TB experts and epidemiologists from more than 40 countries was chosen by the World Health Organization (WHO), with final agreement being reached between country experts and WHO staff. Evidence Incidence of TB and mortality in each country was determined by (1) case notification to the WHO, (2) annual risk of infection data from tuberculin surveys, and (3) data on prevalence of smear-positive pulmonary disease from prevalence surveys, Estimates derived from relatively poor data were strongly influenced by panel member opinion. Objective estimates were derived from high-quality data collected recently by approved procedures, Consensus Process Agreement was reached by (1) participants reviewing methods and data and making provisional estimates in dosed workshops held at WHO's 6 regional offices, (2) principal authors refining estimates using standard methods and all available data, and (3) country experts reviewing and adjusting these estimates and reaching final agreement with WHO staff. Conclusions In 1997, new cases of TB totaled an estimated 7.96 million (range, 6.3 million-11.1 million), including 3.52 million (2.8 million-4.9 million) cases (44%) of infectious pulmonary disease (smear-positive), and there were 16.2 million (12.1 million-22.5 million) existing cases of disease. An estimated 1.87 million (1.4 million-2.8 million) people died of TB and the global case fatality rate was 23% but exceeded 50% in some African countries with high HIV rates, Global prevalence of MTB infection was 32% (1.86 billion people). Eighty percent of all incident TB cases were found in 22 countries, with more than half the cases occurring in 5 Southeast Asian countries, Nine of 10 countries with the highest incidence rates per capita were in Africa. Prevalence of MTB/HIV coinfection worldwide was 0.18% and 640 000 incident TB cases (8%) had HIV infection. The global burden of tuberculosis remains enormous, mainly because of poor control in Southeast Asia, sub-Saharan Africa, and eastern Europe, and because of high rates of M tuberculosis and HIV coinfection in some African countries.	WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland	World Health Organization	Dye, C (corresponding author), WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland.		Dye, Christopher/AIC-4659-2022	RAVIGLIONE, Mario/0000-0002-9331-2067; Dye, Christopher/0000-0002-2957-1793				BARNETT G D, 1977, Bulletin of the International Union Against Tuberculosis, V52, P5; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CAUTHEN G, 1988, WHO PUBL; Cauthen GM, 1996, AM J EPIDEMIOL, V144, P69, DOI 10.1093/oxfordjournals.aje.a008856; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DeCock KM, 1996, JAMA-J AM MED ASSOC, V276, P1502, DOI 10.1001/jama.276.18.1502; *DEP HLTH TUB CONT, 1997, NAT TUB PREV SURV 19; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Hilleboe HE, 1941, PUBLIC HEALTH REP, V56, P895, DOI 10.2307/4583713; KREBS W, 1930, AARGAULSCHEN HEILSTA, P345; MURRAY C, 1993, DIS CONTROL PRIORITI; MURRAY CJL, 1996, GLOBAL HLTH STAT, V2; OHMORI M, 1995, STAGNATION DECLINE T; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; STYBLO K, 1978, Bulletin of the International Union Against Tuberculosis, V53, P141; Styblo K., 1985, B INT UNION TUBERC, V60, P117; STYBLO K, 1997, EXPECTED DECREASE TU; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP; *US BUR BENS, 1997, HIV AIDS SURV DAT JA; van den Broek J, 1998, INT J TUBERC LUNG D, V2, P547; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; *WHO, 1999, GLOB TUB CONR WHO RE; *WHO, 1998, 1996 WHO STAT ANN; *WHO, 1994, WHO PUBL; *WHO, 1996, DEM DAT HLTH SIT ASS; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1998, GLOB TUB CONTR WHO R	37	2361	2523	6	193	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					677	686		10.1001/jama.282.7.677	http://dx.doi.org/10.1001/jama.282.7.677			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517722				2022-12-28	WOS:000082033700028
J	Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ				Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ			beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6	SCIENCE			English	Article							CHEMOKINE RECEPTOR; CYSTIC-FIBROSIS; PROTEIN; PEPTIDE; HIV-1; IDENTIFICATION; INTERACTS; MIGRATION; RANTES; PLASMA	Defensins contribute to host defense by disrupting the cytoplasmic membrane of microorganisms. This report shows that human beta-defensins are also chemotactic for immature dendritic cells and memory T cells. Human beta-defensin was selectively chemotactic for cells stably transfected to express human CCR6, a chemokine receptor preferentially expressed by immature dendritic cells and memory T cells. The beta-defensin-induced chemotaxis was sensitive to pertussis toxin and inhibited by antibodies to CCR6. The binding of iodinated LARC, the chemokine Ligand for CCR6, to CCR6-transfected cells was competitively displaced by beta-defensin. Thus, beta-defensins may promote adaptive immune responses by recruiting dendritic and T cells to the site of microbial invasion through interaction with CCR6.	NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Allegheny Univ Hlth Sci, Pittsburgh, PA 15212 USA; Magainin Res Inst, Plymouth Meeting, PA 19642 USA; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Kiel	Oppenheim, JJ (corresponding author), NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.	oppenhei@mail.ncifcrf.gov	Howard, O M Zack/B-6117-2012; Schroeder, Jens M/B-3994-2009	Howard, O M Zack/0000-0002-0505-7052; Chertov, Oleg/0000-0002-0426-2521	NATIONAL CANCER INSTITUTE [Z01BC009369] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; Prohaszka Z, 1997, MOL IMMUNOL, V34, P809, DOI 10.1016/S0161-5890(97)00097-7; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; Yang D., UNPUB	26	1418	1553	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					525	528		10.1126/science.286.5439.525	http://dx.doi.org/10.1126/science.286.5439.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521347				2022-12-28	WOS:000083121200059
J	Markert, ML; Boeck, A; Hale, LP; Kloster, AL; McLaughlin, TM; Batchvarova, MN; Douek, DC; Koup, RA; Kostyu, DD; Ward, FE; Rice, HE; Mahaffey, SM				Markert, ML; Boeck, A; Hale, LP; Kloster, AL; McLaughlin, TM; Batchvarova, MN; Douek, DC; Koup, RA; Kostyu, DD; Ward, FE; Rice, HE; Mahaffey, SM			Transplantation of thymus tissue in complete DiGeorge syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; T-CELL DEFICIENCY; NUDE-MICE; VELOCARDIOFACIAL SYNDROMES; COMBINED IMMUNODEFICIENCY; CHARGE ASSOCIATION; COMPLETE FORMS; ORGAN-CULTURE; LYMPHOCYTES-T; FETAL THYMUS	Background The DiGeorge syndrome is a congenital disorder that affects the heart, parathyroid glands, and thymus. In complete DiGeorge syndrome, patients have severely reduced T-cell function. Methods We treated five infants (age, one to four months) with complete DiGeorge syndrome by transplantation of cultured postnatal thymus tissue. Follow-up evaluations included immune phenotyping and proliferative studies of peripheral-blood mononuclear cells plus biopsy of the thymus allograft. Thymic production of new T cells was assessed in peripheral blood by tests for T-cell-receptor recombination excision circles, which are formed from excised DNA during the rearrangement of T-cell-receptor genes. Results After the transplantation of thymus tissue, T-cell proliferative responses to mitogens developed in four of the five patients. Two of the patients survived with restoration of immune function; three patients died from infection or abnormalities unrelated to transplantation. Biopsies of grafted thymus in the surviving patients showed normal morphologic features and active T-cell production. In three patients, donor T cells could be detected about four weeks after transplantation, although there was no evidence of graft-versus-host disease on biopsy or at autopsy. In one patient, the T-cell development within the graft was demonstrated to accompany the appearance of recently developed T cells in the periphery and coincided with the onset of normal T-cell function. In one patient, there was evidence of thymus function and CD45RA+CD62L+ T cells more than five years after transplantation. Conclusions In some infants with profound immunodeficiency and complete DiGeorge syndrome, the transplantation of thymus tissue can restore normal immune function. Early thymus transplantation - before the development of infectious complications - may promote successful immune reconstitution. (N Engl J Med 1999;341:1180-9.) (C)1999, Massachusetts Medical Society.	Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC 27710 USA; Univ Vienna, Dept Pediat, Vienna, Austria; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA	Duke University; Duke University; Duke University; Duke University; Duke University; University of Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Markert, ML (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Box 3068, Durham, NC 27710 USA.	marke001@mc.duke.edu			NCI NIH HHS [R01-CA28936] Funding Source: Medline; NCRR NIH HHS [MO1-RR30] Funding Source: Medline; NIAID NIH HHS [U19-AI38550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUST CS, 1970, LANCET, V1, P1080; BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BORZY MS, 1979, NEW ENGL J MED, V301, P565, DOI 10.1056/NEJM197909133011101; BORZY MS, 1989, J CLIN IMMUNOL, V9, P386, DOI 10.1007/BF00917103; Bowers DC, 1998, LANCET, V352, P1983, DOI 10.1016/S0140-6736(98)00094-4; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; CLEVELAND WW, 1968, LANCET, V2, P1211; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; DAVENPORT SLH, 1986, CLIN GENET, V29, P298; Davis CM, 1997, J CLIN IMMUNOL, V17, P167, DOI 10.1023/A:1027382600143; Daw SCM, 1996, NAT GENET, V13, P458, DOI 10.1038/ng0896-458; DELACHAPELLE A, 1981, HUM GENET, V57, P253, DOI 10.1007/BF00278938; DICTOR M, 1984, AM J CLIN PATHOL, V82, P487, DOI 10.1093/ajcp/82.4.487; DiGeorge A. M., 1968, BIRTH DEFECTS OAS, V4, P116; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DRISCOLL DA, 1993, J MED GENET, V30, P813, DOI 10.1136/jmg.30.10.813; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; GOLDSOBEL AB, 1987, J PEDIATR-US, V111, P40, DOI 10.1016/S0022-3476(87)80339-6; HONG R, 1979, J EXP MED, V149, P398, DOI 10.1084/jem.149.2.398; Hong R, 1998, SEMIN HEMATOL, V35, P282; HONG R, 1986, CLIN IMMUNOL IMMUNOP, V40, P136, DOI 10.1016/0090-1229(86)90077-2; Hong R, 1996, TRANSPLANTATION, V61, P444, DOI 10.1097/00007890-199602150-00023; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JOSE DG, 1974, AUST NZ J MED, V4, P267, DOI 10.1111/j.1445-5994.1974.tb03187.x; KAST WM, 1984, J EXP MED, V160, P1752, DOI 10.1084/jem.160.6.1752; KERNAN NA, 1986, BLOOD, V68, P770; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; KOSTYU DD, 1993, HUM IMMUNOL, V38, P148, DOI 10.1016/0198-8859(93)90532-6; KRUISBEEK AM, 1981, J IMMUNOL, V127, P2168; LAKE JP, 1980, J EXP MED, V152, P1805, DOI 10.1084/jem.152.6.1805; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; Markert ML, 1997, CLIN IMMUNOL IMMUNOP, V82, P26, DOI 10.1006/clin.1996.4266; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Markert ML, 1997, PEDIATR PULM, V24, P364; Markert ML, 1997, J IMMUNOL, V158, P998; MAYUMI M, 1989, EUR J PEDIATR, V148, P518, DOI 10.1007/BF00441546; METLAY LA, 1987, AM J MED GENET, V26, P577, DOI 10.1002/ajmg.1320260311; MULLER W, 1989, EUR J PEDIATR, V149, P96, DOI 10.1007/BF01995856; MULLER W, 1988, EUR J PEDIATR, V147, P496; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; PAGON RA, 1981, J PEDIATR-US, V99, P223, DOI 10.1016/S0022-3476(81)80454-4; REECE ER, 1981, CANCER RES, V41, P4243; Thomas R A, 1987, Am J Med Genet Suppl, V3, P43; WELLS TR, 1986, BRIT J RADIOL, V59, P1065, DOI 10.1259/0007-1285-59-707-1065; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; Zhao Y, 1997, J IMMUNOL, V158, P1641; ZINKERNAGEL RM, 1980, J EXP MED, V151, P376, DOI 10.1084/jem.151.2.376	48	173	176	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1180	1189		10.1056/NEJM199910143411603	http://dx.doi.org/10.1056/NEJM199910143411603			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10523153				2022-12-28	WOS:000083087400003
J	Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ				Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ			Crystal structure of invasin: A bacterial integrin-binding protein	SCIENCE			English	Article							CELL-ADHESION MOLECULE-1; YERSINIA-PSEUDOTUBERCULOSIS; MAMMALIAN-CELLS; LIGAND INTERACTION; RECEPTOR; IDENTIFICATION; DOMAINS; INTERNALIZATION; FIBRONECTIN; LOOP	The Yersinia pseudotuberculosis invasin protein promotes bacterial entry by binding to host cell integrins with higher affinity than natural substrates such as fibronectin, The 2.3 angstrom crystal structure of the invasin extracellular region reveals five domains that form a 180 angstrom rod with structural similarities to tandem fibronectin type III domains. The integrin-binding surfaces of invasin and fibronectin include similarly Located key residues, but in the context of different folds and surface shapes. The structures of invasin and fibronectin provide an example of convergent evolution, in which invasin presents an optimized surface for integrin binding, in comparison with host substrates.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Tufts University	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abagyan RA, 1997, J MOL BIOL, V273, P355, DOI 10.1006/jmbi.1997.1287; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dersch P, 1999, EMBO J, V18, P1199, DOI 10.1093/emboj/18.5.1199; Diederichs K, 1998, PROTEIN SCI, V7, P2413, DOI 10.1002/pro.5560071119; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1993, J BIOL CHEM, V268, P15840; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; Liu H, 1999, INFECT IMMUN, V67, P2045; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Marra A, 1997, INFECT IMMUN, V65, P3412, DOI 10.1128/IAI.65.8.3412-3421.1997; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEPE JC, 1993, INFECT AGENT DIS, V2, P236; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Saltman LH, 1996, J BIOL CHEM, V271, P23438, DOI 10.1074/jbc.271.38.23438; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Worley MJ, 1998, MOL MICROBIOL, V29, P1471, DOI 10.1046/j.1365-2958.1998.01030.x; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x	62	224	230	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					291	295		10.1126/science.286.5438.291	http://dx.doi.org/10.1126/science.286.5438.291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514372				2022-12-28	WOS:000083024400044
J	Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G				Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G			Coordinated polar localization of auxin efflux carrier PIN1 by GNOM ARF GEF	SCIENCE			English	Article							ARABIDOPSIS GENE MONOPTEROS; PATTERN-FORMATION; BREFELDIN-A; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; NUCLEOTIDE EXCHANGE; PROTEIN; EMBRYO; CELLS; REDISTRIBUTION	The plant hormone auxin is transported in a polar manner along the shoot-root axis, which requires efflux carriers such as PIN1. Asymmetric localization-of PIN1 develops from a random distribution in Arabidopsis early embryogenesis. Coordinated polar localization of PIN1 is defective in gnom embryos. GNOM is a membrane-associated guanine-nucleotide exchange factor on ADP-ribosylation factor G protein (ARF GEF). Thus, GNOM-dependent vesicle trafficking may establish cell polarity, resulting in polar auxin transport.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany	Eberhard Karls University of Tubingen; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Max Planck Society	Jurgens, G (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 1, D-72076 Tubingen, Germany.		Palme, Klaus/A-9524-2013; Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019; Geldner, Niko/Y-2481-2019	Palme, Klaus/0000-0002-2728-3835; Jackson, Catherine/0000-0002-0843-145X; Geldner, Niko/0000-0002-2300-9644; Grebe, Markus/0000-0001-7571-0670				BERLETH T, 1993, DEVELOPMENT, V118, P575; Busch M, 1996, MOL GEN GENET, V250, P681, DOI 10.1007/BF02172979; Delbarre A, 1998, PLANT PHYSIOL, V116, P833, DOI 10.1104/pp.116.2.833; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAYER U, 1993, DEVELOPMENT, V117, P149; Morris DA, 1998, PLANTA, V205, P606, DOI 10.1007/s004250050363; Park JM, 1997, PLANT PHYSIOL, V115, P763, DOI 10.1104/pp.115.2.763; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; SACHS T, 1991, DEVELOPMENT S, V1, P83; SATIATJEUNEMAITRE B, 1992, J CELL SCI, V103, P1153; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Vroemen CW, 1996, PLANT CELL, V8, P783, DOI 10.1105/tpc.8.5.783; WENT FW, 1929, REC TRAV BOT NEERL, V25, P1	22	565	598	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					316	318		10.1126/science.286.5438.316	http://dx.doi.org/10.1126/science.286.5438.316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514379				2022-12-28	WOS:000083024400051
J	Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN				Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN			Long-term sequelae of spontaneous axillary-subclavian venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; UPPER-EXTREMITY; PAIN	Background: The frequency and severity of post-thrombotic sequelae after spontaneous axillary-subclavian venous thrombosis remain poorly known. Objective: To determine the late sequelae of conventionally treated spontaneous axillary-subclavian venous thrombosis. Design: Cross-sectional study. Setting: University department of vascular medicine. Patients: 54 patients seen during an 18-year period (mean follow-up, 5 years). Measurements: Scores for the severity of post-thrombotic symptoms were graded on a numerical rating scale ranging from 0 to 10 and on a 6-point verbal rating scale. Ultrasonographic sequelae were classified as grade 0, normal flow; grade 1, moderate obstruction; or grade 2, severe obstruction or occlusion. Results: Verbal scores were "nil/negligible" in 47% of patients and "severe/intolerable" in 13%; numerical scores were 0 to 3 in 78% of patients and 7 to 10 in 9%. Grade 2 ultrasonographic sequelae were found in 22% of cases. No relation was seen between ultrasonographic sequelae and symptom severity scores. Conclusion: The overall clinical outcome of spontaneous axillary-subclavian venous thrombosis is good, and there is no relation between the severity of late symptoms and ultrasonographic sequelae.	Hop Broussais, Serv Med Vasc, F-75674 Paris 14, France; Hop Broussais, Ctr Blaude Bernard Rech Malad Vasc Peripher, F-75674 Paris 14, France; Hop St Joseph, Serv Chirurg Vasc, F-75674 Paris 14, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite	Fiessinger, JN (corresponding author), Hop Broussais, Serv Med Vasc, 96 Rue Didot, F-75674 Paris 14, France.							ADAMS JT, 1965, ARCH SURG-CHICAGO, V91, P29; AMELI FM, 1987, CAN J SURG, V30, P167; BECKER DM, 1991, ARCH INTERN MED, V151, P1934, DOI 10.1001/archinte.151.10.1934; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Elliott G, 1997, LANCET, V349, P1188, DOI 10.1016/S0140-6736(05)62408-7; GLOVICZKI P, 1986, J VASC SURG, V4, P333, DOI 10.1067/mva.1986.avs0040333; GRASSI CJ, 1990, RADIOLOGY, V175, P651, DOI 10.1148/radiology.175.3.2188295; HAIRE WD, 1995, CLIN CHEST MED, V16, P341; HOUDE RW, 1982, ACTA ANAESTH SCAND, V26, P25, DOI 10.1111/j.1399-6576.1982.tb01840.x; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Lindblad B, 1988, Eur J Vasc Surg, V2, P161, DOI 10.1016/S0950-821X(88)80069-0; MACHLEDER HI, 1993, J VASC SURG, V17, P305, DOI 10.1016/0741-5214(93)90416-J; Meier GH, 1996, J VASC SURG, V24, P974, DOI 10.1016/S0741-5214(96)70043-5; MOLINA JE, 1995, J AM COLL SURGEONS, V181, P414; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; RICHARD HM, 1992, RADIOGRAPHICS, V12, P527, DOI 10.1148/radiographics.12.3.1609143; TILNEY NL, 1970, ARCH SURG-CHICAGO, V101, P792	18	49	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					510	513		10.7326/0003-4819-131-7-199910050-00006	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507960				2022-12-28	WOS:000083018800005
J	Dinniss, S				Dinniss, S			Personal view - The machismo of medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					929	929		10.1136/bmj.319.7214.929	http://dx.doi.org/10.1136/bmj.319.7214.929			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506076	Green Published			2022-12-28	WOS:000082975600073
J	Furberg, CD; Herrington, DM; Psaty, BM				Furberg, CD; Herrington, DM; Psaty, BM			Are drugs within a class interchangeable?	LANCET			English	Editorial Material							CHRONIC HEART-FAILURE; BETA-BLOCKERS; SURVIVAL; STATINS		Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA USA	Wake Forest University; Wake Forest University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Furberg, CD (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA.							CUSHMAN DW, 1989, BR J CLIN PHARM, V28, P115; *DIV DRUG MARK ADV, 1999, FDA WARN LETT NOV PH; Furberg CD, 1999, CIRCULATION, V99, P185, DOI 10.1161/01.CIR.99.2.185; Packer M, 1998, EUR HEART J, V19, pB40; PITT B, 1994, CIRCULATION, V90, P1550, DOI 10.1161/01.CIR.90.3.1550; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Soriano JB, 1997, PROG CARDIOVASC DIS, V39, P445, DOI 10.1016/S0033-0620(97)80039-4; Thomas M, 1998, LANCET, V352, P1830, DOI 10.1016/S0140-6736(05)79893-7; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; VENNING GR, 1983, BRIT MED J, V286, P289, DOI 10.1136/bmj.286.6361.289; WOLFE SM, 1995, DIFFERENCES NUMBER D; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1980, FED REG, V45, P76356	13	90	92	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1202	1204		10.1016/S0140-6736(99)03190-6	http://dx.doi.org/10.1016/S0140-6736(99)03190-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513728				2022-12-28	WOS:000082954100046
J	Maurer, D; Lewis, TL; Brent, HP; Levin, AV				Maurer, D; Lewis, TL; Brent, HP; Levin, AV			Rapid improvement in the acuity of infants after visual input	SCIENCE			English	Article							CARD PROCEDURE; MONOCULAR DEPRIVATION; PRETERM INFANTS; GRATING ACUITY; FOS PROTEIN; FULL-TERM; CORTEX; PATTERN; EXPRESSION; CHILDREN	Visual acuity was assessed in 28 human infants who had been deprived of all patterned visual input by cataracts in one or both eyes until they were treated at 1 week to 9 months of age. Immediately after treatment, acuity was no better than that of normal newborns. Acuity improved significantly over the next month, with some improvement apparent after as little as 1 hour of visual input. Unlike findings at older ages, the pattern of results was the same for eyes treated for monocular and for binocular deprivation. The results indicate that patterned visual input is necessary for the postnatal improvement of human visual acuity and that the onset of such input initiates rapid functional development.	McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada; Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada	McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Maurer, D (corresponding author), McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada.	maurer@mcmaster.ca						ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BEAVER CJ, 1993, J COMP NEUROL, V333, P469, DOI 10.1002/cne.903330402; BROWN AM, 1986, AM J OPHTHALMOL, V102, P245, DOI 10.1016/0002-9394(86)90153-4; COURAGE ML, 1990, OPTOMETRY VISION SCI, V67, P713, DOI 10.1097/00006324-199009000-00011; DOBSON V, 1987, DEV MED CHILD NEUROL, V29, P199; LEWIS TL, 1995, INVEST OPHTH VIS SCI, V36, P2080; LEWIS TL, 1993, CLIN VISION SCI, V8, P591; MASH C, 1995, VISION RES, V35, P303, DOI 10.1016/0042-6989(94)00113-Z; MAYER DL, 1982, VISION RES, V22, P1141, DOI 10.1016/0042-6989(82)90079-7; MAYER DL, 1995, INVEST OPHTH VIS SCI, V36, P671; MIRANDA SB, 1970, J EXP CHILD PSYCHOL, V10, P189, DOI 10.1016/0022-0965(70)90071-8; Mitchell DE, 1998, CURR BIOL, V8, pR897; Mitchell DE, 1998, CURR BIOL, V8, P1179, DOI 10.1016/S0960-9822(07)00489-7; MITCHELL DE, 1994, INVEST OPHTH VIS SCI, V35, P1773; MOWER GD, 1994, MOL BRAIN RES, V21, P47, DOI 10.1016/0169-328X(94)90376-X; ROSEN KM, 1992, P NATL ACAD SCI USA, V89, P5437, DOI 10.1073/pnas.89.12.5437; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; TELLER DY, 1986, DEV MED CHILD NEUROL, V28, P779; VANHOFVANDUIN J, 1986, VISION RES, V26, P909, DOI 10.1016/0042-6989(86)90149-5	19	107	109	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					108	110		10.1126/science.286.5437.108	http://dx.doi.org/10.1126/science.286.5437.108			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506555				2022-12-28	WOS:000082907400045
J	Kuttner, R				Kuttner, R			Managed care and medical education	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*ASS AM MED COLL, 1997, AC MED I PROGR ISS, P5; BRIGGSSTYLE C, 1997, COST TEACHING HPHC; *COMM FUND, 1997, LEV PLAYING FIELD FI; Flexner A., 1910, FLEXNER REPORT; Iglehart JK, 1999, NEW ENGL J MED, V341, P299, DOI 10.1056/NEJM199907223410424; LUDMERER KM, 1999, TIME HEAL AM MED ED, P283; LUDMERER KM, 1999, TIME HEAL AM MED ED, pR22; Moore G T, 1986, Health Aff (Millwood), V5, P147, DOI 10.1377/hlthaff.5.1.147; MOORE JD, 1999, MODERN HEALTHCA 0607, P34; *PEW HLTH PROF COM, 1995, REF GRAD MED ED REP; REUTER JA, 1999, PATTERNS SPECIALTY C; REUTER JA, 1997, FINANCING ACAD HLTH, P22; SHOREY JM, 1998, DESCRIPTION HARVARD; Starr P, 1982, SOCIAL TRANSFORMATIO	14	39	39	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1092	1096		10.1056/NEJM199909303411421	http://dx.doi.org/10.1056/NEJM199909303411421			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502601				2022-12-28	WOS:000082880500026
J	Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A				Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A			Congenital heart disease in mice deficient for the DiGeorge syndrome region	NATURE			English	Article							22Q11 DELETIONS; MOUSE; GENE; PAX3	The heterozygous chromosome deletion within the band 22q11 (del22q11) is an important cause of congenital cardiovascular defects(1), It is the genetic basis of DiGeorge syndrome and causes the most common deletion syndrome in humans(2). Because the deleted region is largely conserved in the mouse, we were able to engineer a chromosome deletion (Df1) spanning a segment of the murine region homologous to the human deleted region. Here we describe heterozygously deleted (Df1/+) mice with cardiovascular abnormalities of the same type as those associated with del22q11; we have traced the embryological origin of these abnormalities to defective development of the fourth pharyngeal arch arteries. Genetic complementation of the deletion using a chromosome duplicated for the Df1 DNA segment corrects the heart defects, indicating that they are caused by reduced dosage of genes located within Df1. The Df1/+ mouse model reveals the pathogenic basis of the most clinically severe aspect of DiGeorge syndrome and uncovers a new mechanism leading to aortic arch abnormalities. These mutants represent a mouse model of a human deletion syndrome generated by chromosome engineering.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Baldini, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		genes, anthony/F-2541-2012; botta, annalisa/AAB-8680-2019; BOTTA, ANNALISA/AAD-1581-2022; Baldini, Antonio/M-2355-2015	BOTTA, ANNALISA/0000-0003-4031-5624; Baldini, Antonio/0000-0002-5330-0256; Bradley, Allan/0000-0002-2349-8839				BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; Botta A, 1997, MAMM GENOME, V8, P890, DOI 10.1007/s003359900606; Conway SJ, 1997, DEVELOPMENT, V124, P505; Farrell MJ, 1999, CIRC RES, V84, P127, DOI 10.1161/01.RES.84.2.127; Galili N, 1997, GENOME RES, V7, P17, DOI 10.1101/gr.7.1.17; Iida K, 1997, DEVELOPMENT, V124, P4627; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kidd PG, 1997, MANUAL CLIN LAB IMMU, V5th, P229; Kirby M. L., 1999, HEART DEV, P179; KRUISBECK AM, 1991, CURRENT PROTOCOLS IM; KRUISBECK AM, 1993, CURRENT PROTOCOLS IM; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lindsay EA, 1998, HUM MOL GENET, V7, P629, DOI 10.1093/hmg/7.4.629; Lindsay EA, 1998, MOL MED TODAY, V4, P350, DOI 10.1016/S1357-4310(98)01302-1; Liu PT, 1998, GENETICS, V150, P1155; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Pizzuti A, 1997, HUM MOL GENET, V6, P259, DOI 10.1093/hmg/6.2.259; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sutherland HF, 1998, GENOMICS, V52, P37, DOI 10.1006/geno.1998.5414; WILSON DI, 1994, AM J HUM GENET S, V55, pA975; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698	26	309	313	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					379	383		10.1038/43900	http://dx.doi.org/10.1038/43900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517636				2022-12-28	WOS:000082822600052
J	Gerstein, M; Chothia, C				Gerstein, M; Chothia, C			Signal transduction - Proteins in motion	SCIENCE			English	Editorial Material							MEMBRANE-PROTEINS; RECEPTOR; DOMAIN		Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Yale University; MRC Laboratory Molecular Biology	Gerstein, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.							Arkin IT, 1997, PROTEINS, V28, P465, DOI 10.1002/(SICI)1097-0134(199708)28:4<465::AID-PROT1>3.0.CO;2-9; Boyd D, 1998, PROTEIN SCI, V7, P201, DOI 10.1002/pro.5560070121; CHOTHIA C, 1983, NATURE, V302, P500, DOI 10.1038/302500a0; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; Gerstein M, 1998, PROTEINS, V33, P518, DOI 10.1002/(SICI)1097-0134(19981201)33:4<518::AID-PROT5>3.0.CO;2-J; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; TSAI, 1999, J MOL BIOL, V290, P253; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420	19	19	19	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1682	1683		10.1126/science.285.5434.1682	http://dx.doi.org/10.1126/science.285.5434.1682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523185				2022-12-28	WOS:000082472600021
J	Gmachl, C; Tredicucci, A; Sivco, DL; Hutchinson, AL; Capasso, F; Cho, AY				Gmachl, C; Tredicucci, A; Sivco, DL; Hutchinson, AL; Capasso, F; Cho, AY			Bidirectional semiconductor laser	SCIENCE			English	Article							QUANTUM CASCADE LASERS; ROOM-TEMPERATURE	A semiconductor laser capable of operating under both positive and negative bias voltage is reported. Its active region behaves functionally as two different laser materials, emitting different wavelengths. depending on the design, when biased with opposite polarities. This concept was used for the generation of two wavelengths (6.3 and 6.5 micrometers) in the midinfrared region of the spectrum from a single quantum cascade laser structure. The two wavelengths are excited independently of each other and separated in time. This may have considerable impact on various semiconductor laser applications including trace gas analysis in remote sensing applications with differential absorption spectroscopy.	AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs	Gmachl, C (corresponding author), AT&T Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Tredicucci, Alessandro/M-6166-2015	Tredicucci, Alessandro/0000-0003-3619-3011				BERRYMAN KW, 1999, IEEE OSA CLEO 99 C, P52; Capasso F, 1999, PHYS WORLD, V12, P27; CAPASSO F, 1987, SCIENCE, V235, P172, DOI 10.1126/science.235.4785.172; Cho AY, 1994, MOL BEAM EPITAXY; Faist J, 1997, NATURE, V387, P777, DOI 10.1038/42872; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Faist J, 1998, IEEE J QUANTUM ELECT, V34, P336, DOI 10.1109/3.658728; Faist J, 1996, APPL PHYS LETT, V68, P3680, DOI 10.1063/1.115741; Gmachl C, 1999, IEEE J SEL TOP QUANT, V5, P808, DOI 10.1109/2944.788454; GMACHL C, IN PRESS IEEE PHOTON; Hsu CF, 1997, P SOC PHOTO-OPT INS, V3001, P271, DOI 10.1117/12.273796; Louderback DA, 1999, IEEE PHOTONIC TECH L, V11, P304, DOI 10.1109/68.748216; Olafsen LJ, 1998, APPL PHYS LETT, V72, P2370, DOI 10.1063/1.121359; SIGRIST MW, 1994, AIR MONITORING SPECT, pCH3; Tredicucci A, 1998, APPL PHYS LETT, V72, P2388, DOI 10.1063/1.121365; Tredicucci A, 1998, NATURE, V396, P350, DOI 10.1038/24585; Yang BH, 1998, APPL PHYS LETT, V72, P2220, DOI 10.1063/1.121265	17	55	56	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					749	752		10.1126/science.286.5440.749	http://dx.doi.org/10.1126/science.286.5440.749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531055				2022-12-28	WOS:000083303200047
J	Keverne, EB				Keverne, EB			The vomeronasal organ	SCIENCE			English	Review							PUTATIVE PHEROMONE RECEPTORS; ACCESSORY OLFACTORY-BULB; CHEMOSIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; MULTIGENE FAMILY; URINARY PROTEINS; GARTER SNAKES; MOUSE; MAMMALS; NEURONS	The vomeronasal organ (VNO) is a chemoreceptor organ enclosed in a cartilaginous capsule and separated from the main olfactory epithelium. The vomeronasal neurons have two distinct types of receptor that differ from each other and from the large family of odorant receptors, The VNO receptors are seven-transmembrane receptors coupled to CTP-binding protein, but appear to activate inositol 1,4,5-trisphosphate signaling as opposed to cyclic adenosine monophosphate. The nature of stimulus access suggests that the VNO responds to nonvolatile cues, leading to activation of the hypothalamus by way of the accessory olfactory bulb and amygdala. The areas of hypothalamus innervated regulate reproductive, defensive, and ingestive behavior as well as neuroendocrine secretion.	Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England	University of Cambridge	Keverne, EB (corresponding author), Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England.	ebk10@cus.cam.ac.uk	Mucignat, Carla/N-6299-2017; Oka, Yoshitaka/C-9670-2010	Mucignat, Carla/0000-0001-5307-0414; Oka, Yoshitaka/0000-0002-3482-3051				BASKYS A, 1992, TRENDS NEUROSCI, V15, P92, DOI 10.1016/0166-2236(92)90018-4; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berliner DL, 1996, J STEROID BIOCHEM, V58, P1, DOI 10.1016/0960-0760(96)00011-8; Berliner DL, 1996, J STEROID BIOCHEM, V58, P259, DOI 10.1016/0960-0760(96)00062-3; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; BRENNAN PA, 1992, NEUROSCIENCE, V49, P277, DOI 10.1016/0306-4522(92)90095-J; Brennan PA, 1999, NEUROSCIENCE, V90, P1463, DOI 10.1016/S0306-4522(98)00556-9; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Doving KB, 1998, J EXP BIOL, V201, P2913; Dulac C, 1997, SEMIN CELL DEV BIOL, V8, P197, DOI 10.1006/scdb.1997.0140; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; ELOIT C, 1998, 13 C EUR CHEM RES OR; GUILLAMON A, 1993, NATO ADV SCI INST SE, V73, P363; GWENDOLYN D, 1994, J NEUROSCI, V14, P3643; Halem HA, 1999, J NEUROBIOL, V39, P249, DOI 10.1002/(SICI)1097-4695(199905)39:2<249::AID-NEU9>3.3.CO;2-I; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194; Jia CP, 1997, NEUROREPORT, V8, P1887, DOI 10.1097/00001756-199705260-00019; Kawai F, 1999, NAT NEUROSCI, V2, P133, DOI 10.1038/5686; Keverne E.B., 1983, P79; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; Keverne EB, 1996, P ROY SOC B-BIOL SCI, V263, P689, DOI 10.1098/rspb.1996.0103; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; Kroner C, 1996, NEUROREPORT, V7, P2989, DOI 10.1097/00001756-199611250-00038; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liman ER, 1996, J NEUROSCI, V16, P4625; Liman ER, 1996, CURR OPIN NEUROBIOL, V6, P487, DOI 10.1016/S0959-4388(96)80054-7; Liu WM, 1998, ARCH BIOCHEM BIOPHYS, V358, P204, DOI 10.1006/S0003-9861(98)90000-5; Matsuda H, 1996, BRAIN RES, V712, P35; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Meisami E, 1998, ANN NY ACAD SCI, V855, P708, DOI 10.1111/j.1749-6632.1998.tb10649.x; MEREDITH M, 1994, PHYSIOL BEHAV, V56, P345, DOI 10.1016/0031-9384(94)90205-4; Mimmack ML, 1997, MOL BRAIN RES, V47, P345, DOI 10.1016/S0169-328X(97)00104-6; Monti-Bloch L, 1998, J STEROID BIOCHEM, V65, P237, DOI 10.1016/S0960-0760(98)00025-9; Moss RL, 1998, CHEM SENSES, V23, P483, DOI 10.1093/chemse/23.4.483; Moss RL, 1997, J NEUROPHYSIOL, V77, P2856, DOI 10.1152/jn.1997.77.5.2856; MUCIGNATCARETTA C, 1995, J PHYSIOL-LONDON, V486, P517, DOI 10.1113/jphysiol.1995.sp020830; MULLERSCHWARZE D, 1979, CHEM ECOLOGY ODOUR C; Paredes RG, 1998, HORM BEHAV, V33, P48, DOI 10.1006/hbeh.1998.1435; Risold PY, 1997, BRAIN RES REV, V24, P197, DOI 10.1016/S0165-0173(97)00007-6; Robertson DHL, 1996, BIOCHEM J, V316, P265, DOI 10.1042/bj3160265; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Rouquier S, 1998, NAT GENET, V18, P243, DOI 10.1038/ng0398-243; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Saito H, 1998, DEV BRAIN RES, V110, P69, DOI 10.1016/S0165-3806(98)00096-0; Sasaki K, 1999, BRAIN RES, V823, P161, DOI 10.1016/S0006-8993(99)01164-6; Smith TD, 1997, ANAT REC, V248, P447; Stern K, 1998, NATURE, V392, P177, DOI 10.1038/32408; Stoddart MD, 1980, ECOLOGY VERTEBRATE O; Sugai T, 1997, NEUROSCIENCE, V79, P871, DOI 10.1016/S0306-4522(96)00690-2; TANIGUCHI K, 1993, NEUROSCI LETT, V158, P185, DOI 10.1016/0304-3940(93)90260-R; TAYLOR JG, 1991, BIOL CYBERN, V64, P301, DOI 10.1007/BF00199593; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Trotier D, 1998, CHEM SENSES, V23, P49, DOI 10.1093/chemse/23.1.49; vonCampenhausen H, 1997, NEUROREPORT, V8, P2607, DOI 10.1097/00001756-199707280-00037; Wang D, 1997, ARCH BIOCHEM BIOPHYS, V348, P96, DOI 10.1006/abbi.1997.0366; Wekesa KS, 1997, ENDOCRINOLOGY, V138, P3497, DOI 10.1210/en.138.8.3497; Wray S, 1996, DEV BIOL, V180, P631, DOI 10.1006/dbio.1996.0334; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; Zancanaro C, 1997, CHEM SENSES, V22, P439, DOI 10.1093/chemse/22.4.439	65	321	340	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					716	720		10.1126/science.286.5440.716	http://dx.doi.org/10.1126/science.286.5440.716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531049				2022-12-28	WOS:000083303200041
J	Mori, K; Nagao, H; Yoshihara, Y				Mori, K; Nagao, H; Yoshihara, Y			The olfactory bulb: Coding and processing of odor molecule information	SCIENCE			English	Review							RECEPTOR GENE-EXPRESSION; MITRAL TUFTED CELLS; RABBIT; RAT; EPITHELIUM; ORGANIZATION; PROJECTIONS; SYSTEM; RECOGNITION; MECHANISMS	Olfactory sensory neurons detect a large variety of odor molecules and send information through their axons to the olfactory bulb, the first site for the processing of olfactory information in the brain. The axonal connection is precisely organized so that signals from 1000 different types of odorant receptors are sorted out in 1800 glomeruli in the mouse olfactory bulb. Individual glomerular modules presumably represent a single type of receptor and are thus tuned to specific molecular features of odorants. Local neuronal circuits in the bulb mediate Lateral inhibition among glomerular modules to sharpen the tuning specificity of output neurons. They also mediate synchronized oscillatory discharges among specific combinations of output neurons and may contribute to the integration of signals from distinct odorant receptors in the olfactory cortex.	RIKEN, Lab Neuronal Recognit Mol, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neurobiol Synapse, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; RIKEN; University of Tokyo	Mori, K (corresponding author), RIKEN, Lab Neuronal Recognit Mol, Wako, Saitama 3510198, Japan.	moriken@postman.riken.go.jp	Oka, Yoshitaka/C-9670-2010; Yoshihara, Yoshihiro/N-6481-2015	Oka, Yoshitaka/0000-0002-3482-3051; Yoshihara, Yoshihiro/0000-0002-0319-7166; Mori, Kensaku/0000-0001-7853-9370				ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Bozza TC, 1998, J NEUROSCI, V18, P4560; Brennan PA, 1997, PROG NEUROBIOL, V51, P457, DOI 10.1016/S0301-0082(96)00069-X; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUONVISO N, 1990, J NEUROPHYSIOL, V63, P447, DOI 10.1152/jn.1990.63.3.447; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; FUJITA SC, 1985, BRAIN RES, V326, P192, DOI 10.1016/0006-8993(85)91403-9; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; GUTHRIE KM, 1995, CHEM SENSES, V20, P271, DOI 10.1093/chemse/20.2.271; Haberly LB, 1998, SYNAPTIC ORG BRAIN, P377; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; Johnson BA, 1999, J COMP NEUROL, V409, P529; Johnson BA, 1998, J COMP NEUROL, V393, P457, DOI 10.1002/(SICI)1096-9861(19980420)393:4<457::AID-CNE5>3.0.CO;2-#; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KABA H, 1995, REV NEUROSCIENCE, V6, P125; Kashiwadani H, 1999, J NEUROPHYSIOL, V82, P1786, DOI 10.1152/jn.1999.82.4.1786; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; Landsteiner K, 1936, J EXP MED, V63, P325, DOI 10.1084/jem.63.3.325; Laurent G, 1996, TRENDS NEUROSCI, V19, P489, DOI 10.1016/S0166-2236(96)10054-0; LEON M, 1987, TRENDS NEUROSCI, V10, P434, DOI 10.1016/0166-2236(87)90016-6; LEVETEAU J, 1966, SCIENCE, V153, P175, DOI 10.1126/science.153.3732.175; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MEREDITH M, 1986, J NEUROPHYSIOL, V56, P572, DOI 10.1152/jn.1986.56.3.572; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; MORI K, 1985, J COMP NEUROL, V242, P214, DOI 10.1002/cne.902420205; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MORI K, 1977, FOOD INTAKE CHEM SEN, P33; Mori Kensaku, 1994, Seminars in Cell Biology, V5, P65, DOI 10.1006/scel.1994.1009; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; ONODA N, 1992, NEUROSCI LETT, V137, P157, DOI 10.1016/0304-3940(92)90393-L; PINCHING AJ, 1971, J CELL SCI, V9, P347; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Royet JP, 1998, BRAIN RES, V788, P35, DOI 10.1016/S0006-8993(97)01504-7; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; SALLAZ M, 1993, NEUROREPORT, V4, P55, DOI 10.1097/00001756-199301000-00014; SATO Y, 1995, J NEUROPHYSIOL, V73, P298, DOI 10.1152/jn.1995.73.1.298; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; Shepherd G.M., 1998, SYNAPTIC ORG BRAIN, P159; SHEPHERD GM, 1987, ANN NY ACAD SCI, V510, P98; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; Shipley MT, 1996, J NEUROBIOL, V30, P123; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; SULLIVAN SL, 1995, CURR OPIN GENET DEV, V5, P516, DOI 10.1016/0959-437X(95)90057-N; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Yang XJ, 1998, P NATL ACAD SCI USA, V95, P7715, DOI 10.1073/pnas.95.13.7715; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5	71	633	649	5	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					711	715		10.1126/science.286.5440.711	http://dx.doi.org/10.1126/science.286.5440.711			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531048				2022-12-28	WOS:000083303200040
J	Gerbert, B; Caspers, N; Bronstone, A; Moe, J; Abercrombie, P				Gerbert, B; Caspers, N; Bronstone, A; Moe, J; Abercrombie, P			A qualitative analysis of how physicians with expertise in domestic violence approach the identification of victims	ANNALS OF INTERNAL MEDICINE			English	Article						domestic violence; mass screening; confidentiality; research methods; physician's role	TREATING WIFE ABUSE; BATTERED WOMEN; PANDORA BOX; CARE; EXPERIENCES; EMERGENCY; PREVALENCE; CLINICIAN	Background: Physicians have been called upon to identify victims of domestic violence, but few studies provide insight into how physicians can navigate around the barriers to identification. Objective: To describe how physicians who are committed to helping battered patients identify victims of domestic violence in health care encounters. Design: Six focus groups were conducted. Setting: Focus group research facilities. Participants: 45 emergency department, obstetrician/ gynecologist, and primary care physicians in the San Francisco Bay Area who identify and intervene with victims of domestic violence. Measurements: Through constant comparison, a template of open codes was constructed to identify themes that emerged from the data. Data were analyzed according to the conventions of qualitative research. Results: The data revealed five major themes: 1) how physicians framed screening questions to reduce patient discomfort; 2) patient signs that "switched on a light bulb" for physicians to suspect abuse; 3) direct and indirect approaches to identification, with an emphasis on facilitating patient trust and disclosure over time; 4) the rarity of direct patient disclosure; and 5) how physicians redefined successful outcomes of universal screening. Physicians also described two new barriers to screening: mandatory reporting and "burnout" due to lack of direct disclosure. Conclusions: Identifying domestic abuse is difficult even for physicians committed to helping victims. Physician reports illustrate the need to frame questions and develop indirect approaches that foster patient trust. Given the many barriers to screening and the rarity of direct patient disclosure, it may be more productive to redefine the goals of universal screening so that compassionate asking in and of itself constitutes the first step in helping battered patients.	Univ Calif San Francisco, Div Behav Sci, San Francisco, CA 94111 USA	University of California System; University of California San Francisco	Gerbert, B (corresponding author), Univ Calif San Francisco, Div Behav Sci, 601 Montgomery St,Suite 810, San Francisco, CA 94111 USA.	gerbert@itsa.ucsf.edu			NIMH NIH HHS [1 R01 MH51580] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051580] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; ASHUR MLC, 1993, JAMA-J AM MED ASSOC, V269, P2367, DOI 10.1001/jama.269.18.2367; BROWN JB, 1993, J FAM PRACTICE, V36, P185; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Chescheir N, 1996, ANN EMERG MED, V27, P766, DOI 10.1016/S0196-0644(96)70199-3; El-Bayoumi G, 1998, MED CLIN N AM, V82, P391, DOI 10.1016/S0025-7125(05)70612-X; Ferris L E, 1992, Fam Med, V24, P276; FERRIS LE, 1994, MED CARE, V32, P1163, DOI 10.1097/00005650-199412000-00001; Ferris LE, 1997, JAMA-J AM MED ASSOC, V278, P851, DOI 10.1001/jama.278.10.851; Freund KM, 1996, J GEN INTERN MED, V11, P44, DOI 10.1007/BF02603485; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; Gerbert B, 1999, WOMEN HEALTH, V29, P115, DOI 10.1300/J013v29n03_08; Gerbert B, 1996, WOMEN HEALTH, V24, P1; Hamberger L K, 1992, Fam Med, V24, P283; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; Johnson M, 1997, J FAM PRACTICE, V44, P391; KURZ D, 1987, SOC PROBL, V34, P69, DOI 10.1525/sp.1987.34.1.03a00050; Kurz D, 1990, Violence Vict, V5, P243; KUZEL AJ, 1992, RES METH PR, V3, P31; LEE D, 1993, SAN FRANCISCO FAMILY; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Martins R., 1992, J WOMENS HEALTH, V1, P77; Mazza D, 1996, MED J AUSTRALIA, V164, P14, DOI 10.5694/j.1326-5377.1996.tb94101.x; McCauley J, 1998, J GEN INTERN MED, V13, P549, DOI 10.1046/j.1525-1497.1998.00166.x; McGrath ME, 1997, ACAD EMERG MED, V4, P297, DOI 10.1111/j.1553-2712.1997.tb03552.x; MORGAN DL, 1988, FOCUS GROUPS QUALTAT; Muelleman RL, 1998, AM J EMERG MED, V16, P128, DOI 10.1016/S0735-6757(98)90028-6; PARSONS LH, 1995, AM J OBSTET GYNECOL, V173, P381, DOI 10.1016/0002-9378(95)90256-2; Patton M. Q., 1990, QUALITATIVE EVALUATI; Rodriguez MA, 1998, WESTERN J MED, V169, P337; Rodriguez MA, 1996, ARCH FAM MED, V5, P153, DOI 10.1001/archfami.5.3.153; SALBER P, 1997, ACTION NOTES PHYSICI, V23, P2; SANDELOWSKI M, 1986, ADV NURS SCI, V8, P27, DOI 10.1097/00012272-198604000-00005; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; STILLMAN FA, 1992, HLTH BEHAV RES MINOR, P168; STRAUSS AL, BASICS QUALTATIVE RE; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; Titus K, 1996, JAMA-J AM MED ASSOC, V275, P1863, DOI 10.1001/jama.275.24.1863	38	116	119	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					578	+		10.7326/0003-4819-131-8-199910190-00005	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246ZR	10523218				2022-12-28	WOS:000083196600004
J	Beecham, L				Beecham, L			Patients' complaints: GMC could do better	BRITISH MEDICAL JOURNAL			English	News Item																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1022	1022		10.1136/bmj.319.7216.1022	http://dx.doi.org/10.1136/bmj.319.7216.1022			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521178	Green Published			2022-12-28	WOS:000083210100008
J	Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW				Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW			Body-mass index and mortality in a prospective cohort of US adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; ISCHEMIC-HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; NATIONAL-HEALTH; RELATIVE WEIGHT; OLDER PERSONS; EVANS COUNTY; 26-YEAR RISK; WHITE WOMEN	Background Body-mass index (the weight in kilograms divided by the square of the height in meters) is known to be associated with overall mortality. We investigated the effects of age, race, sex, smoking status, and history of disease on the relation between body-mass index and mortality. Methods In a prospective study of more than 1 million adults in the United States (457,785 men and 588,369 women), 201,622 deaths occurred during 14 years of follow-up. We examined the relation between body-mass index and the risk of death from all causes in four subgroups categorized according to smoking status and history of disease. In healthy people who had never smoked, we further examined whether the relation varied according to race, cause of death, or age. The relative risk was used to assess the relation between mortality and body-mass index. Results The association between body-mass index and the risk of death was substantially modified by smoking status and the presence of disease. In healthy people who had never smoked, the nadir of the curve for body-mass index and mortality was found at a body-mass index of 23.5 to 24.9 in men and 22.0 to 23.4 in women. Among subjects with the highest body-mass indexes, white men and women had a relative risk of death of 2.58 and 2.00, respectively, as compared with those with a body-mass index of 23.5 to 24.9. Black men and women with the highest body-mass indexes had much lower risks of death (1.35 and 1.21), which did not differ significantly from 1.00. A high body-mass index was most predictive of death from cardiovascular disease, especially in men (relative risk, 2.90; 95 percent confidence interval, 2.37 to 3.56). Heavier men and women in all age groups had an increased risk of death. Conclusions The risk of death from all causes, cardiovascular disease, cancer, or other diseases increases throughout the range of moderate and severe overweight for both men and women in all age groups. The risk associated with a high body-mass index is greater for whites than for blacks. (N Engl J Med 1999;341:1097-105.) (C)1999, Massachusetts Medical Society.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Calle, EE (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.							Allison DB, 1997, INT J OBESITY, V21, P424, DOI 10.1038/sj.ijo.0800423; BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR, 1995, HOM GARD B, V232; *DEP AGR, 1990, HOM GARD B, V232; Diehr P, 1998, AM J PUBLIC HEALTH, V88, P623, DOI 10.2105/AJPH.88.4.623; Dunn SE, 1997, CANCER RES, V57, P4667; DurazoArvizu R, 1997, ANN EPIDEMIOL, V7, P383, DOI 10.1016/S1047-2797(97)00044-6; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P1254; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; GARFINKEL L, 1986, CANCER-AM CANCER SOC, V58, P1826, DOI 10.1002/1097-0142(19861015)58:8+<1826::AID-CNCR2820581407>3.0.CO;2-6; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; LOSONCZY KG, 1995, AM J EPIDEMIOL, V141, P312, DOI 10.1093/aje/141.4.312; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rothman K, 1986, MODERN EPIDEMIOLOGY; Singh PN, 1998, EPIDEMIOLOGY, V9, P246, DOI 10.1097/00001648-199805000-00007; STEVENS J, 1993, J GERONTOL, V48, pM249, DOI 10.1093/geronj/48.6.M249; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; Troiano RP, 1996, INT J OBESITY, V20, P63; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WHO, 1977, MAN INT STAT CLASS D, V1; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; World Health Organization, 1995, WHO TECH REP SER, V854, P1	40	2678	2768	3	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1097	1105		10.1056/NEJM199910073411501	http://dx.doi.org/10.1056/NEJM199910073411501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511607				2022-12-28	WOS:000083087200001
J	Danse, EM; Laterre, PF				Danse, EM; Laterre, PF			Emphysematous cholecystitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Luc Univ Hosp, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Danse, EM (corresponding author), St Luc Univ Hosp, B-1200 Brussels, Belgium.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1126	1126		10.1056/NEJM199910073411505	http://dx.doi.org/10.1056/NEJM199910073411505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511611				2022-12-28	WOS:000083087200005
J	McColl, G; Kohsaka, H; Szer, J; Wicks, I				McColl, G; Kohsaka, H; Szer, J; Wicks, I			High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; AUTOIMMUNE-DISEASES; REPERTOIRE; IRRADIATION; REMISSION; BLOOD		Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Rheid Rheumatol Lab, Rheumatol Unit, Melbourne, Vic 3050, Australia; Royal Melbourne Hosp, Ctr Rheumat Dis, Melbourne, Vic 3050, Australia; Tokyo Med & Dent Univ, Sch Med, Dept Internal Med, Tokyo 1138519, Japan; Royal Melbourne Hosp, Dept Clin Haematol & Med Oncol, Bone Marrow Transplant Serv, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Tokyo Medical & Dental University (TMDU); Royal Melbourne Hospital	Wicks, I (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Rheid Rheumatol Lab, Rheumatol Unit, Melbourne, Vic 3050, Australia.		McColl, Geoffrey J/C-5358-2015	McColl, Geoffrey J/0000-0003-2741-5233; Szer, Jeff/0000-0001-6783-2301				Burt RK, 1998, BLOOD, V92, P3505, DOI 10.1182/blood.V92.10.3505.422k48_3505_3514; Burt RK, 1997, NEW ENGL J MED, V337, P1777, DOI 10.1056/NEJM199712113372416; Cooley HM, 1997, ARTHRITIS RHEUM, V40, P1712, DOI 10.1002/art.1780400923; Durez P, 1998, LANCET, V352, P881, DOI 10.1016/S0140-6736(05)60008-6; Euler HH, 1996, BLOOD, V88, P3621, DOI 10.1182/blood.V88.9.3621.bloodjournal8893621; Joske DJL, 1997, LANCET, V350, P337, DOI 10.1016/S0140-6736(05)63388-0; KAMIYA M, 1993, J RHEUMATOL, V20, P225; KNAANSHANZER S, 1991, BONE MARROW TRANSPL, V8, P333; Kohsaka H, 1998, ARTHRITIS RHEUM, V41, P1911; KOHSAKA H, 1993, EUR J IMMUNOL, V23, P1895, DOI 10.1002/eji.1830230825; MARMONT AM, 1994, STEM CELLS, V12, P125, DOI 10.1002/stem.5530120119; Mizushima N, 1997, CLIN EXP IMMUNOL, V110, P428, DOI 10.1046/j.1365-2249.1997.4331451.x; Snowden JA, 1997, BRIT J HAEMATOL, V99, P9, DOI 10.1046/j.1365-2141.1997.3273144.x; Snowden JA, 1996, LANCET, V348, P1112, DOI 10.1016/S0140-6736(05)65267-1; Tamm M, 1996, ANN RHEUM DIS, V55, P779, DOI 10.1136/ard.55.10.779; Tyndall A, 1997, BONE MARROW TRANSPL, V19, P643, DOI 10.1038/sj.bmt.1700727; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wicks I, 1997, ARTHRITIS RHEUM, V40, P1005, DOI 10.1002/art.1780400603	18	36	38	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					507	509		10.7326/0003-4819-131-7-199910050-00005	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507959				2022-12-28	WOS:000083018800004
J	Jonkers, IJAM; de Man, FHAF; Onkenhout, W; van der Laarse, A; Smelt, AHM				Jonkers, IJAM; de Man, FHAF; Onkenhout, W; van der Laarse, A; Smelt, AHM			Implication of fibrate therapy for homocysteine	LANCET			English	Letter									Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Paediat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jonkers, IJAM (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, POB 9600, NL-2300 RC Leiden, Netherlands.	IJAMJonkers@aig.azl.nl						Auwerx J, 1996, ATHEROSCLEROSIS, V124, pS29, DOI 10.1016/0021-9150(96)05854-6; de Lorgeril M, 1999, LANCET, V353, P209, DOI 10.1016/S0140-6736(05)77220-2; Dennis VW, 1996, KIDNEY INT, V50, pS11; Dierkes J, 1999, LANCET, V354, P219, DOI 10.1016/S0140-6736(99)02153-4; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007	5	33	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1208	1208		10.1016/S0140-6736(05)75415-5	http://dx.doi.org/10.1016/S0140-6736(05)75415-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513736				2022-12-28	WOS:000082954100055
J	Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W				Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W			Precisely localized LTD in the neocortex revealed by infrared-guided laser stimulation	SCIENCE			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC ACTIVATION; DENDRITIC SPINES; RAT HIPPOCAMPUS; AMPA RECEPTORS; VISUAL-CORTEX; DEPRESSION; NMDA; PHOTOSTIMULATION; ENHANCEMENT	In a direct approach to elucidate the origin of long-term depression (LTD), glutamate was applied onto dendrites of neurons in rat neocortical slices. An infrared-guided laser stimulation was used to release glutamate from caged glutamate in the focal spot df an ultraviolet laser. A burst of light flashes caused an LTD-like depression of glutamate receptor responses, which was highly confined to the region of "tetanic" stimulation (<10 micrometers). A similar depression of glutamate receptor responses was observed during LTD of synaptic transmission. A spatially highly specific postsynaptic mechanism tan account for the LTD induced by glutamate release.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Dodt, HU (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2, D-80804 Munich, Germany.			Eder, Matthias/0000-0002-2579-2628				ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1996, CORTICAL PLASTICITY, P61; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Dodt HU, 1998, EUR J NEUROSCI, V10, P3351, DOI 10.1046/j.1460-9568.1998.00338.x; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; KUNG G, 1972, Z MIKROSK ANAT FORSC, V3, P396; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LYNCH GS, 1976, NATURE, V263, P151, DOI 10.1038/263151a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; PETIT DL, 1997, NEURON, V19, P465; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; SWARTZWELDER HS, 1989, NEUROPHARMACOLOGY, V28, P441, DOI 10.1016/0028-3908(89)90076-2; TSIEN RW, 1990, COLD SH Q B, V55, P147; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	68	90	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					110	113		10.1126/science.286.5437.110	http://dx.doi.org/10.1126/science.286.5437.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506556				2022-12-28	WOS:000082907400046
J	Allen, KB; Dowling, RD; Fudge, TL; Schoettle, GP; Selinger, SL; Gangahar, DM; Angell, WW; Petracek, MR; Shaar, CJ; O'Neill, WW				Allen, KB; Dowling, RD; Fudge, TL; Schoettle, GP; Selinger, SL; Gangahar, DM; Angell, WW; Petracek, MR; Shaar, CJ; O'Neill, WW			Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	71st Scientific Session of the American-Heart-Association	NOV 08-12, 1998	DALLAS, TX	Amer Heart Assoc			MYOCARDIAL REVASCULARIZATION; LASER	Background Transmyocardial revascularization involves the creation of channels in the myocardium with a laser to relieve angina. We compared the safety and efficacy of transmyocardial revascularization performed with a holmium laser with those of medical therapy in patients with refractory class IV angina (according to the criteria of the Canadian Cardiovascular Society). Methods In a prospective study conducted between March 1996 and July 1998 at 18 centers, 275 patients with medically refractory class IV angina and coronary disease that could not be treated with percutaneous or surgical revascularization were randomly assigned to receive transmyocardial revascularization followed by continued medical therapy (132 patients) or medical therapy alone (143 patients). Results After one year of follow-up, 76 percent of the patients who had undergone transmyocardial revascularization had improvement in angina (a reduction of two or more classes), as compared with 32 percent of the patients who received medical therapy alone (P<0.001). Kaplan-Meier survival estimates at one year (based on an intention-to-treat analysis) were similar for the patients assigned to undergo transmyocardial revascularization and those assigned to receive medical therapy alone (84 percent and 89 percent, respectively; P = 0.23). At one year, the patients in the transmyocardial-revascularization group had a significantly higher rate of survival free of cardiac events (54 percent, vs. 31 percent in the medical-therapy group; P<0.001), a significantly higher rate of freedom from treatment failure (73 percent vs. 47 percent, P<0.001), and a significantly higher rate of freedom from cardiac-related rehospitalization (61 percent vs. 33 percent, P<0.001). Exercise tolerance and quality-of-life scores were also significantly higher in the transmyocardial-revascularization group than in the medical-therapy group (exercise tolerance, 5.0 MET [metabolic equivalent] vs. 3.9 MET; P = 0.05; quality-of-life score, 21 vs. 12; P = 0.003). However, there were no differences in myocardial perfusion between the two groups, as assessed by thallium scanning. Conclusions Patients with refractory angina who underwent transmyocardial revascularization and received continued medical therapy, as compared with similar patients who received medical therapy alone, had a significantly better outcome with respect to improvement in angina, survival free of cardiac events, freedom from treatment failure, and freedom from cardiac-related rehospitalization. (N Engl J Med 1999;341:1029-36.) (C)1999, Massachusetts Medical Society.	St Vincent Hosp & Indiana Heart Inst, Dept Cardiothorac Surg, Indianapolis, IN USA; Univ Louisville & Jewish Heart & Lung Inst, Dept Cardiothorac Surg, Louisville, KY USA; Terrebonne Hosp, Dept Cardiothorac Surg, Houma, LA USA; Methodist Hosp, Dept Cardiothorac Surg, Memphis, TN USA; Sacred Heart Med Ctr, Dept Cardiothorac Surg, Spokane, WA USA; Bryan Mem Hosp, Dept Cardiothorac Surg, Lincoln, NE USA; Tampa Gen Hosp, Dept Cardiothorac Surg, Tampa, FL 33606 USA; St Thomas Heart Inst, Nashville, TN USA; William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA	University of Louisville; Tampa General Hospital; Beaumont Health	Allen, KB (corresponding author), 8333 Naab Rd,Suite 300, Indianapolis, IN 46260 USA.	cvsurgeon@iquest.net						Al-Sheikh T, 1999, CIRCULATION, V100, P135, DOI 10.1161/01.CIR.100.2.135; Allen KB, 1998, CIRCULATION, V98, P476; Allen KB, 1998, EUR J CARDIO-THORAC, V14, pS100; Beck CS, 1935, ANN SURG, V102, P801, DOI 10.1097/00000658-193511000-00001; Burkhoff D, 1996, ANN THORAC SURG, V61, P1532, DOI 10.1016/0003-4975(96)00090-2; Cooley DA, 1996, J THORAC CARDIOV SUR, V111, P791, DOI 10.1016/S0022-5223(96)70339-2; COOLEY DA, 1994, TEX HEART I J, V21, P220; Dowling RD, 1998, CIRCULATION, V98, pII73; *FOOD DRUG ADM, 1997, CIRC SYST DEV PAN M, P15; *FOOD DRUG ADM, 1998, CIRC SYST DEV PAN M, P30; FRAZIER OH, 1995, CIRCULATION, V92, P58, DOI 10.1161/01.CIR.92.9.58; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Horvath KA, 1997, J THORAC CARDIOV SUR, V113, P645, DOI 10.1016/S0022-5223(97)70221-6; Horvath KA, 1996, J THORAC CARDIOV SUR, V111, P1047, DOI 10.1016/S0022-5223(96)70381-1; Horvath KA, 1998, CIRCULATION, V98, P217; KOHMOTO T, 1996, CIRCULATION S1, V94, P294; Kwong KF, 1997, J THORAC CARDIOV SUR, V114, P883, DOI 10.1016/S0022-5223(97)70001-1; KWONG KF, 1997, CIRCULATION S1, V96, P565; MARCH RJ, 1997, 77 ANN M AM ASS THOR, P94; MIRHOSEINI M, 1986, LASER SURG MED, V6, P459, DOI 10.1002/lsm.1900060507; MIRHOSEINI M, 1982, Lasers in Surgery and Medicine, V2, P187, DOI 10.1002/lsm.1900020209; Schofield PM, 1999, LANCET, V353, P519, DOI 10.1016/S0140-6736(98)11478-2; SEN PK, 1965, J THORAC CARDIOV SUR, V50, P181, DOI 10.1016/S0022-5223(19)33205-2; Spanier T, 1997, J Clin Laser Med Surg, V15, P269; VINBERG A, 1954, J INT COLL SURG, V22, P503; Vincent JG, 1997, EUR J CARDIO-THORAC, V11, P888, DOI 10.1016/S1010-7940(97)01203-7; Wearn JT, 1933, AM HEART J, V9, P143, DOI 10.1016/S0002-8703(33)90711-5	27	278	292	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1029	1036		10.1056/NEJM199909303411403	http://dx.doi.org/10.1056/NEJM199909303411403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	241JX	10502592				2022-12-28	WOS:000082880500003
J	Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C				Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C			Silencing of TGF-beta signalling by the pseudoreceptor BAMBI	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; XENOPUS-EMBRYOS; RECEPTOR; GENE; ORGANIZER; IDENTIFICATION; TRANSDUCTION; EXPRESSION; ACTIVATION	Members of the transforming growth factor-beta (TGF-beta) superfamily, including TGF-beta, bone morphogenetic proteins (BMPs), activins and nodals, are vital for regulating growth and differentiation(1). These growth factors transduce their signals through pairs of transmembrane type I and type II receptor kinases(2-4). Here, we have cloned a transmembrane protein, BAMBI, which is related to TGP-beta-family type I receptors but lacks an intracellular kinase domain. We show that BAMBI is co-expressed with the ventralizing morphogen BMP4 (refs 5, 6) during Xenopus embryogenesis and that it requires BMP signalling for its expression. The protein stably associates with TGF-beta-family receptors and inhibits BMP and activin as well as TGF-beta signalling. Finally, we provide evidence that BAMBI's inhibitory effects are mediated by its intracellular domain, which resembles the homodimerization interface of a type I receptor and prevents the formation of receptor complexes. The results indicate that BAMBI negatively regulates TGF-beta-family signalling by a regulatory mechanism involving the interaction of signalling receptors with a pseudoreceptor.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumor Virol, D-69120 Heidelberg, Germany; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Onichtchouk, Daria/E-1741-2012; Dosch, Roland/H-9633-2019	Onichtchouk, Daria/0000-0001-6497-1445; Dosch, Roland/0000-0001-9247-8586; Massague, Joan/0000-0001-9324-8408				CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; DALE L, 1992, DEVELOPMENT, V115, P573; Degen WGJ, 1996, INT J CANCER, V65, P460, DOI 10.1002/(SICI)1097-0215(19960208)65:4<460::AID-IJC12>3.3.CO;2-B; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JONES CM, 1992, DEVELOPMENT, V115, P639; KAUFMANN E, 1996, EMBO J, V15, P6379; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	30	548	585	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					480	485		10.1038/46794	http://dx.doi.org/10.1038/46794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519551				2022-12-28	WOS:000082981200057
J	van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N				van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N			Tom22 is a multifunctional organizer of the mitochondrial preprotein translocase	NATURE			English	Article							OUTER-MEMBRANE PROTEIN; GENERAL IMPORT PORE; RECEPTOR COMPLEX; YEAST MITOCHONDRIA; NEUROSPORA-CRASSA; CELL VIABILITY; CHANNEL; COMPONENT; DOMAINS; MOM22	Mitochondrial preproteins are imported by a multisubunit translocase of the outer membrane (TOM), including receptor proteins and a general import pore(1-5). The central receptor Tom22 binds preproteins through both its cytosolic domain and its intermembrane space domain(6-10) and is stably associated with the channel protein Tom40 (refs 11-13). Here we report the unexpected observation that a yeast strain can survive without Tom22, although it is strongly reduced in growth and the import of mitochondrial proteins. Tom22 is a multifunctional protein that is required for the higher-level organization of the TOM machinery. In the absence of Tom22, the translocase dissociates into core complexes, representing the basic import units, but lacks a tight control of channel gating. The single membrane anchor of Tom22 is required for a stable interaction between the core complexes, whereas its cytosolic domain, serves as docking point for the peripheral receptors Tom20 and Tom70. Thus a preprotein translocase can combine receptor functions with distinct organizing roles in a multidomain protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Biocentrum Amsterdam, Inst Mol Cell Biol, NL-1098 SM Amsterdam, Netherlands; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Amsterdam; University Osnabruck; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Ryan, Michael/X-2152-2019; Meisinger, Chris/J-1110-2014; Ryan, Michael T/C-6673-2011; Pfanner, Nikolaus/AAV-7878-2021	Ryan, Michael/0000-0003-2586-8829; Meisinger, Chris/0000-0002-8326-3548; Ryan, Michael T/0000-0003-2586-8829; Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Guthrie C, 1991, METHOD ENZYMOL, P194; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, EMBO J, V14, P4205; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	26	232	237	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					485	489		10.1038/46802	http://dx.doi.org/10.1038/46802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519552				2022-12-28	WOS:000082981200058
J	Balen, A				Balen, A			Pathogenesis of polycystic ovary syndrome - the enigma unravels?	LANCET			English	Editorial Material							INSULIN-RESISTANCE; PREGNANCY; MECHANISM		Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England	Leeds General Infirmary	Balen, A (corresponding author), Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England.							BALEN AH, 1993, BRIT J OBSTET GYNAEC, V100, P1082, DOI 10.1111/j.1471-0528.1993.tb15170.x; Balen AH, 1995, HUM REPROD, V10, P2705; CLARK AM, 1995, HUM REPROD, V10, P2705, DOI 10.1093/oxfordjournals.humrep.a135772; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641; Homburg R, 1996, HUM REPROD, V11, P29; Jacobs HS, 1999, HUM REPROD UPDATE, V5, P166, DOI 10.1093/humupd/5.2.166; Lockwood GM, 1998, J CLIN ENDOCR METAB, V83, P1730, DOI 10.1210/jc.83.5.1730; MICHELMORE KF, IN PRESS CLIN ENDOCR; Nestler JE, 1999, NEW ENGL J MED, V340, P1314, DOI 10.1056/NEJM199904293401703; Ong KKL, 1999, NAT GENET, V21, P262, DOI 10.1038/6775; POLSON DW, 1988, LANCET, V1, P870; Tapanainen JS, 1999, J CLIN ENDOCR METAB, V84, P1711, DOI 10.1210/jc.84.5.1711; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; Waterworth DM, 1997, LANCET, V349, P986, DOI 10.1016/S0140-6736(96)08368-7	15	77	78	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					966	967		10.1016/S0140-6736(99)00218-4	http://dx.doi.org/10.1016/S0140-6736(99)00218-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501353				2022-12-28	WOS:000082596000004
J	Wairagkar, NS; Gandhi, BV; Katrak, SM; Shaikh, NJ; Parikh, PR; Wadia, NH; Gadkari, DA				Wairagkar, NS; Gandhi, BV; Katrak, SM; Shaikh, NJ; Parikh, PR; Wadia, NH; Gadkari, DA			Acute renal failure with neurological involvement in adults associated with measles virus isolation	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; INFECTION; DISEASE; PUNE	Background Three people with clinical manifestations of acute renal failure with neurological involvement of unknown cause were admitted to a hospital in Mumbai, India. We describe clinical presentations and investigations of the cause. Methods We analysed case reports and laboratory findings for the patients (age 37-43 years, two men, one woman) that were provided by the clinicians in charge. Serum and cerebrospinal fluid were tested for viral cause by IgM ELISA to Japanese encephalitis, West Nile fever, dengue, and measles. Samples were inoculated in vero-cell culture for virus isolation. The virus isolates were confirmed with indirect immunofluoresence with antimeasles immune sera and mouse monoclonal antibodies to measles HA and F proteins and with neutralisation tests using antimeasles immune sera. Findings Clinical features were fever, vomiting, oliguria or anuria, bilateral facial weakness, impaired hearing, blindness, proximal and distal areflexic limb paralysis, and respiratory paralysis. No patient had a macropapular rash. Blood urea nitrogen (4.64-27.8 mmol/L) and creatinine (601.1-1105.0 mu mol/L) were high, and cerebrospinal fluid contained high concentrations of proteins and pleocytosis. Kidney biopsy samples in two patients showed severe interstitial nephritis, IgM antibodies to measles were found in blood and cerebrospinal fluid. Vero-cell cultures from serum and cerebrospinal fluid of one patient and cerebrospinal fluid of two patients, showed cytopathic effects characteristic of measles. Interpretation Unusual manifestations of acute renal failure with neurological involvement associated with measles virus in adults presenting without rash was confirmed. Our findings may affect the development of measles-elimination programmes.	Natl Inst Virol, Poona 411001, Maharashtra, India; Jaslok Hosp & Res Ctr, Mumbai, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Virology (NIV)	Wairagkar, NS (corresponding author), Natl Inst Virol, 20-A Dr Ambedkar Rd,Post Box 11, Poona 411001, Maharashtra, India.							AARLI JA, 1974, EUR NEUROL, V12, P79, DOI 10.1159/000114607; AKHTAR M, 1973, ARCH PATHOL, V96, P145; DETELS R, 1973, LANCET, V2, P11; FORTHAL DN, 1992, J INFECT DIS, V166, P421, DOI 10.1093/infdis/166.2.421; Frustaci A, 1990, Cardiologia, V35, P347; GRESSER I, 1960, NEW ENGL J MED, V275, P516; GUR I, 1984, ISRAEL J MED SCI, V20, P441; HANNINEN P, 1980, J CLIN MICROBIOL, V11, P610; KHATIB R, 1993, INFECTION, V21, P112, DOI 10.1007/BF01710744; KIPPS A, 1983, LANCET, V2, P1406; KOBUNE F, 1990, J VIROL, V64, P700, DOI 10.1128/JVI.64.2.700-705.1990; KOFFLER D, 1964, ARCH PATHOL, V78, P267; LIN CY, 1983, PEDIATRICS, V71, P398; MILLER DL, 1964, BRIT MED J, V2, P75, DOI 10.1136/bmj.2.5401.75; PRASAD SR, 1995, INDIAN J MED RES, V101, P1; PURDHAM DR, 1974, J CLIN PATHOL, V27, P994, DOI 10.1136/jcp.27.12.994; ROTA PA, 1995, J CLIN MICROBIOL, V33, P2485, DOI 10.1128/JCM.33.9.2485-2488.1995; SHAIKH NJ, 1997, IND J VIROL, V1312, P91; SIEGEL C, 1990, AM J CLIN PATHOL, V94, P464, DOI 10.1093/ajcp/94.4.464; TAKANO Y, 1990, VIRCHOWS ARCH A, V416, P271, DOI 10.1007/BF01678987; TERMEULEN V, 1972, LANCET, V2, P1172; VALMARI P, 1987, PEDIATR INFECT DIS J, V6, P59, DOI 10.1097/00006454-198701000-00015; Wairagkar NS, 1998, LANCET, V351, P495, DOI 10.1016/S0140-6736(05)78682-7; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WONG RD, 1993, AM J MED, V95, P377, DOI 10.1016/0002-9343(93)90306-A	25	13	13	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					992	995		10.1016/S0140-6736(98)10101-0	http://dx.doi.org/10.1016/S0140-6736(98)10101-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501362				2022-12-28	WOS:000082596000013
J	Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP				Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP			Ecological analysis of ethnic differences in relation between tuberculosis and poverty	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC DEPRIVATION; IMMIGRATION; ENGLAND	Objective To examine the effect of ethnicity on the relation between tuberculosis and deprivation. Design Retrospective ecological study comparing incidence of tuberculosis in white and south Asian residents of the 39 electoral wards in Birmingham with ethnic specific indices of deprivation. Setting Birmingham, 1989-93. Subjects 1516 notified cases of tuberculosis. Main outcome measures Rates of tuberculosis and measures of deprivation. Results Univariate analysis showed significant associations of tuberculosis rates for the whole population with several indices of deprivation (P < 0.01) and with the proportion of the population of south Asian origin (P < 0.01). All deprivation covariates were positively associated with each other but on multiple regression, higher level of overcrowding was independently associated with tuberculosis rates. For the white population, overcrowding was associated with tuberculosis rates independently of ether variables (P = 0.0036). No relation with deprivation was found for the south Asian population in either single or multivariable analyses. Conclusions Poverty is significantly associated with tuberculosis in the white population, but no such relation exists far those of Asian ethnicity. These findings suggest that causal factors, and therefore potential interventions, will also differ by ethnic group.	Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Birmingham B9 5SS, W Midlands, England; Birmingham Hlth Author, Birmingham B16 9RG, W Midlands, England; Open Univ, Dept Stat, Milton Keynes MK7 6AA, Bucks, England	Heart of England NHS Foundation Trust; University of Birmingham; Open University - UK	Hawker, JI (corresponding author), Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.			Farrington, Conor Patrick/0000-0002-7148-2612				Bakhshi S S, 1997, Ethn Health, V2, P147; BAKHSHI SS, 1995, J PUBLIC HEALTH MED, V17, P343; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; Borgdorff MW, 1998, AM J EPIDEMIOL, V147, P187; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; *BRIT TUB ASS, 1966, TUBERCLE, V47, P145; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DOHERTY MJ, 1995, BRIT MED J, V311, P187, DOI 10.1136/bmj.311.6998.187b; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; KEARNEY MT, 1993, BRIT MED J, V307, P1143, DOI 10.1136/bmj.307.6912.1143; MANGTANI P, 1995, BRIT MED J, V310, P963, DOI 10.1136/bmj.310.6985.963; MCCARTHY OR, 1984, BRIT J DIS CHEST, V78, P248, DOI 10.1016/S0007-0971(84)80118-7; MEREDITH SK, 1992, THORAX, V47, P770; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; Springett V H, 1991, CDR (Lond Engl Rev), V1, pR149; *STAT SCI, 1997, S PLUS WIND US MAN V; Tocque K, 1998, INT J TUBERC LUNG D, V2, P213; Townsend PP., 1988, HLTH DEPRIVATION INE; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; WEBER HW, 1899, TUBERCULOSIS, V1, P101; *WHO, 1995, STOP TB SOURC REP TU	23	52	56	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1031	1034		10.1136/bmj.319.7216.1031	http://dx.doi.org/10.1136/bmj.319.7216.1031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521193	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000083210100024
J	Owens, K; King, MC				Owens, K; King, MC			Genomic views of human history	SCIENCE			English	Editorial Material							Y-CHROMOSOME; ASHKENAZI JEWS; HAPLOTYPES; DIVERSITY; ORIGINS		Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Owens, K (corresponding author), Univ Washington, Dept Genet, Box 357720, Seattle, WA 98195 USA.			King, Mary-Claire/0000-0001-9426-1743				Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Comas D, 1998, AM J HUM GENET, V63, P1824, DOI 10.1086/302133; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; EXCOFFIER L, 1992, GENETICS, V131, P479; GREELY H, 1997, HOUSTON LAW REV, V33, P1431; Greely HT, 1998, ANNU REV ANTHROPOL, V27, P473, DOI 10.1146/annurev.anthro.27.1.473; Jin L, 1999, P NATL ACAD SCI USA, V96, P3796, DOI 10.1073/pnas.96.7.3796; Jorde LB, 1997, P NATL ACAD SCI USA, V94, P3100, DOI 10.1073/pnas.94.7.3100; Kaessmann H, 1999, NAT GENET, V22, P78, DOI 10.1038/8785; Krings M, 1999, AM J HUM GENET, V64, P1166, DOI 10.1086/302314; MartinezLaso J, 1996, TISSUE ANTIGENS, V47, P63, DOI 10.1111/j.1399-0039.1996.tb02515.x; MOTULSKY AG, 1995, NAT GENET, V9, P99, DOI 10.1038/ng0295-99; Perez-Lezaun A, 1999, AM J HUM GENET, V65, P208, DOI 10.1086/302451; PIAZZA A, 1995, P NATL ACAD SCI USA, V92, P5836, DOI 10.1073/pnas.92.13.5836; Poloni ES, 1997, AM J HUM GENET, V61, P1015, DOI 10.1086/301602; Rana BK, 1999, GENETICS, V151, P1547; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; Skorecki K, 1997, NATURE, V385, P32, DOI 10.1038/385032a0; Snow C., 1959, 2 CULTURES SCI REVOL; Spurdle AB, 1996, AM J HUM GENET, V59, P1126; *TEL AV U NAT FDN, 1999, 2 INT S MEM RM GOODM; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; WILSON AC, 1992, SCI AM, V266, P68	26	50	51	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					451	453		10.1126/science.286.5439.451	http://dx.doi.org/10.1126/science.286.5439.451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521333				2022-12-28	WOS:000083121200044
J	Pop, VJ; van Baar, AL; Vulsma, T				Pop, VJ; van Baar, AL; Vulsma, T			Should all pregnant women be screened for hypothyroidism?	LANCET			English	Editorial Material									Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands; Emmas Children Hosp, Dept Neonatal, Amsterdam, Netherlands; Emmas Children Hosp, Dept Paediat Endocrinol, Amsterdam, Netherlands	Tilburg University; Emma Children's Hospital; Emma Children's Hospital	Pop, VJ (corresponding author), Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands.		van Baar, Anneloes/L-8236-2013	van Baar, Anneloes/0000-0002-3498-9019				BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; De Santiago J., 1999, J ENDOCRINOL INVES S, V22, P68; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P2577, DOI 10.1210/jc.84.7.2577; Lazarus JH, 1999, THYROID, V9, P659, DOI 10.1089/thy.1999.9.659; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; Rovet J, 1996, J CHILD PSYCHOL PSYC, V37, P579, DOI 10.1111/j.1469-7610.1996.tb01444.x; Utiger RD, 1999, NEW ENGL J MED, V341, P601, DOI 10.1056/NEJM199908193410809	9	16	16	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1224	1225						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520627				2022-12-28	WOS:000083010400004
J	Rozov, A; Burnashev, N				Rozov, A; Burnashev, N			Polyamine-dependent facilitation of postsynaptic AMPA receptors counteracts paired-pulse depression	NATURE			English	Article							TERM SYNAPTIC PLASTICITY; RAT HIPPOCAMPAL SLICES; CALCIUM-PERMEABLE AMPA; GLUTAMATE RECEPTORS; KAINATE RECEPTORS; RECTIFICATION; INTERNEURONS; NEURONS; BLOCK; BRAIN	At many glutamatergic synapses in the brain, calcium-permeable alpha - amino - 3 - hydro - 5 - methyl - 4 - isoxazolepropionate receptor (AMPAR) channels mediate fast excitatory transmission(1-6). These channels are blocked by endogenous intracellular polyamines(7-9), which are found in virtually every type of cell(10,11). In excised patches, use-dependent relief of polyamine block enhances glutamate-evoked currents through recombinant and native calcium-permeable, polyamine-sensitive AMPAR channels(12). The contribution of polyamine unblock to synaptic currents during high-frequency stimulation may be to facilitate currents and maintain current amplitudes in the face of a slow recovery from desensitization or presynaptic depression(12,13). Here we show, on pairs and triples of synaptically connected neurons in slices, that this mechanism contributes to short-term plasticity in local circuits formed by presynaptic pyramidal neurons and postsynaptic multipolar interneurons in layer 2/3 of rat neocortex, Activity-dependent relief from polyamine block of postsynaptic calcium-permeable AMPARs in the interneurons either reduces the rate of paired-pulse depression in a frequency-dependent manner or, at a given stimulation frequency, induces facilitation of a synaptic response that would otherwise depress. This mechanism for the enhancement of synaptic gain appears to be entirely postsynaptic.	Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society	Burnashev, N (corresponding author), Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.		Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013					BarnesDavies M, 1996, J PHYSIOL-LONDON, V495P, pP44; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; Isa T, 1996, J PHYSIOL-LONDON, V491, P719, DOI 10.1113/jphysiol.1996.sp021252; JONES HC, 1988, J PHYSIOL-LONDON, V402, P579, DOI 10.1113/jphysiol.1988.sp017223; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McBain CJ, 1998, J PHYSIOL-LONDON, V511, P331, DOI 10.1111/j.1469-7793.1998.331bh.x; OTIS TS, 1995, J PHYSIOL-LONDON, V482, P309, DOI 10.1113/jphysiol.1995.sp020519; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; SHAW GG, 1979, BIOCHEM PHARMACOL, V28, P1, DOI 10.1016/0006-2952(79)90261-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Thomson AM, 1997, J PHYSIOL-LONDON, V502, P131, DOI 10.1111/j.1469-7793.1997.131bl.x; WATANABE S, 1991, J BIOL CHEM, V266, P20803; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1994, NETH J ZOOL, V44, P495	23	151	153	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					594	598		10.1038/44151	http://dx.doi.org/10.1038/44151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524627				2022-12-28	WOS:000083054900052
J	Epstein, N				Epstein, N			To dream	ANNALS OF INTERNAL MEDICINE			English	Article											Epstein, N (corresponding author), 2820 E 4th St, Tucson, AZ 85716 USA.	Nempe@aol.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					540	541		10.7326/0003-4819-131-7-199910050-00013	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507966				2022-12-28	WOS:000083018800010
J	Chelala, C; Beyrer, C				Chelala, C; Beyrer, C			Drug use and HIV/AIDS in Burma	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Chelala, C (corresponding author), 390 W Broadway, New York, NY 10012 USA.							United Nations Children's Fund World Health Organization World Bank Group, 2021, LEVELS TRENDS CHILD	1	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1119	1119		10.1016/S0140-6736(05)76908-7	http://dx.doi.org/10.1016/S0140-6736(05)76908-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509520				2022-12-28	WOS:000082777500047
J	Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA				Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA			Familial dementia caused by polymlerization of mutant neurosergin	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; INHIBITOR; MUTATION; DISEASE; LOOP; POLYMERIZATION; SERPINS; LIVER	Aberrant protein processing with tissue deposition is associated with many common neurodegenerative disorders(1,2); however, the complex interplay of genetic and environmental factors has made it difficult to decipher the sequence of events linking protein aggregation with clinical disease(3). Substantial progress has been made toward understanding the pathophysiology of prototypical conformational diseases and protein polymerization in the super-family of serine proteinase inhibitors (serpins)(4,5). Here we describe a new disease, familial encephalopathy with neuroserpin inclusion bodies, characterized clinically as an autosomal dominantly inherited dementia, histologically by unique neuronal inclusion bodies and biochemically by polymers of the neuron-specific serpin, neuroserpin(6,7). We report the cosegregation of point mutations in the neuroserpin gene (PI12) with the disease in two families. The significance of one mutation, S49P, is evident from its homology to a previously described serpin mutation(8), whereas that of the other, S52R, is predicted by modelling of the serpin template. Our findings provide a molecular mechanism for a familial dementia and imply that inhibitors of protein polymerization may be effective therapies for this disorder and perhaps for other more common neurodegenerative diseases.	SUNY Hlth Sci Ctr, Dept Clin Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Radiol, Syracuse, NY 13210 USA; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Holland Labs, Rockville, MD 20855 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Publ Hlth, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Obstet Gynecol, Portland, OR 97210 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; MRC Ctr, Mol Biol Lab, Cambridge CB2 2XY, England	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Zurich; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); American Red Cross; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Cambridge; University of Cambridge; MRC Laboratory Molecular Biology	Shrimpton, AE (corresponding author), SUNY Hlth Sci Ctr, Dept Clin Pathol, 750 E Adams St, Syracuse, NY 13210 USA.		Kinter, Jochen/C-4515-2008	Gooptu, Bibek/0000-0002-5223-1121; Muenke, Maximilian/0000-0002-7719-6545; Lawrence, Daniel/0000-0003-3126-1935	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULAK KS, 1993, J BIOL CHEM, V268, P18088; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; CERVOSNAVARRO, 1995, METABOLIC DEGENERATI; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 1998, THORAX, V53, P1022, DOI 10.1136/thx.53.12.1022; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28, P1; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Shrimpton AE, 1997, HUM MUTAT, V10, P436, DOI 10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; WALLACE AJ, 1993, J MED GENET, V30, P346; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; YERBY MS, 1986, NEUROLOGY, V36, P68, DOI 10.1212/WNL.36.1.68	26	286	299	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					376	379		10.1038/43897	http://dx.doi.org/10.1038/43897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517635	Bronze			2022-12-28	WOS:000082822600051
J	Calverley, PMA				Calverley, PMA			Blood pressure, breathing, and the carotid body	LANCET			English	Editorial Material							OBSTRUCTIVE SLEEP-APNEA; SYMPATHETIC ACTIVITY; HYPERTENSION		Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England		Calverley, PMA (corresponding author), Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England.							Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; Engleman HM, 1996, SLEEP, V19, P378, DOI 10.1093/sleep/19.5.378; HEDNER J, 1995, EUR RESPIR J, V8, P222, DOI 10.1183/09031936.95.08020222; LEUENBERGER U, 1995, J APPL PHYSIOL, V79, P581, DOI 10.1152/jappl.1995.79.2.581; Narkiewicz K, 1999, CIRCULATION, V99, P1183, DOI 10.1161/01.CIR.99.9.1183; Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772; Narkiewicz K, 1997, J HYPERTENS, V15, P1613, DOI 10.1097/00004872-199715120-00062; Narkiewicz K, 1998, CIRCULATION, V97, P943; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Osanai S, 1999, EUR RESPIR J, V13, P418, DOI 10.1183/09031936.99.13241899; REES K, 1995, AM J RESP CRIT CARE, V152, P1016, DOI 10.1164/ajrccm.152.3.7663777; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	16	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					969	970		10.1016/S0140-6736(99)90135-6	http://dx.doi.org/10.1016/S0140-6736(99)90135-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501355				2022-12-28	WOS:000082596000006
J	Heppenstall, B; Tan, V				Heppenstall, B; Tan, V			Well-leg compartment syndrome	LANCET			English	Editorial Material							LITHOTOMY POSITION		Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Tan, V (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.							Adler LM., 1997, TECH ORTHOP, V12, P133, DOI [10.1097/00013611-199706010-00007, DOI 10.1097/00013611-199706010-00007]; Halliwill JR, 1998, ANESTHESIOLOGY, V89, P1373, DOI 10.1097/00000542-199812000-00014; MATSEN FA, 1983, PRACTICAL APPROACH C, P88; MOSES TA, 1994, UROLOGY, V43, P746, DOI 10.1016/0090-4295(94)90204-6; Mulhall J P, 1993, Conn Med, V57, P129; SLATER RR, 1994, ORTHOPEDICS, V17, P954; TAN V, 1998, ORTH TRAUM ASS 14 AN; TAN V, IN PRESS J ORTHOPAED; Wiger P, 1998, J ORTHOP TRAUMA, V12, P343, DOI 10.1097/00005131-199806000-00008	9	37	37	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					970	970		10.1016/S0140-6736(98)00409-7	http://dx.doi.org/10.1016/S0140-6736(98)00409-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501356	hybrid			2022-12-28	WOS:000082596000007
J	Glossop, NRJ; Lyons, LC; Hardin, PE				Glossop, NRJ; Lyons, LC; Hardin, PE			Interlocked feedback loops within the Drosophila circadian oscillator	SCIENCE			English	Article							PERIOD PROTEIN; CLOCK GENE; BEHAVIORAL RHYTHMS; DOUBLE-TIME; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION; HOMOLOG; SYSTEM; BRAIN	Drosophila Clock (dClk) is rhythmically expressed, with peaks in mRNA and protein (dCLK) abundance early in the morning. dClk mRNA cycling is shown here to be regulated by PERIOD-TIMELESS (PER-TIM)-mediated release of dCLK- and CYCLE (CYC)-dependent repression. Lack of both PER-TIM derepression and dCLK-CYC repression results in high levels of dClk mRNA, which implies that a separate dClk activator is present. These results demonstrate that the Drosophila circadian feedback loop is composed of two interlocked negative feedback Loops: a per-tim loop, which is activated by dCLK-CYC and repressed by PER-TIM, and a dClk Loop, which is repressed by dCLK-CYC and derepressed by PER-TIM.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Hardin, PE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.			Hardin, Paul/0000-0002-3370-9011	NINDS NIH HHS [NS-31214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031214, R29NS031214] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 1999, MOL CELL BIOL, V19, P5316; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; MEESE DA, 1994, 941 CRREL REPORT; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SO VW, 1997, EMBO J, V16, P7146; ZERR DM, 1990, J NEUROSCI, V10, P2749	25	302	311	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					766	768		10.1126/science.286.5440.766	http://dx.doi.org/10.1126/science.286.5440.766			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531060				2022-12-28	WOS:000083303200052
J	McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL				McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL		Evidence-Based Med Working Grp	Users' Guides to the Medical Literature - XIX. Applying clinical trial results - B. Guidelines for determining whether a drug is exerting (more than) a class effect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVERAGE CHOLESTEROL LEVELS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; RANDOMIZED TRIALS; DOUBLE-BLIND; RISK; PRAVASTATIN; HYPERCHOLESTEROLEMIA; TECHNOLOGY		John Radcliffe Hosp, Natl Hlth Serv Res & Dev Ctr Evidence Based Med, Oxford OX3 9DU, England; Ottawa Hosp, Div Gen Internal Med, Ottawa, ON, Canada; Loeb Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada	University of Oxford; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	McAlister, FA (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Wells, George A/M-4549-2017; McAlister, Finlay/C-4151-2013	Wells, George A/0000-0002-2289-9139; McAlister, Finlay/0000-0001-7435-3341				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK RJ, 1995, PLANT PHYSIOL, V108, P4; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Fager G, 1997, ARTERIOSCL THROM VAS, V17, P3527, DOI 10.1161/01.ATV.17.12.3527; Furberg CD, 1996, AM J HYPERTENS, V9, P122, DOI 10.1016/0895-7061(96)00014-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; Gotto AM, 1997, CIRCULATION, V96, P4424; Grover SA, 1998, ARCH INTERN MED, V158, P655, DOI 10.1001/archinte.158.6.655; Grover SA, 1998, ARCH INTERN MED, V158, P1228; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HUNT D, 1992, LANCET, V339, P753; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Korttila K, 1997, ACTA ANAESTH SCAND, V41, P914, DOI 10.1111/j.1399-6576.1997.tb04809.x; Lacour A, 1998, CAN J CARDIOL, V14, P355; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Marshall WJS, 1998, CAN MED ASSOC J, V158, P489; McAlister FA, 1997, DRUGS, V54, P235, DOI 10.2165/00003495-199754020-00003; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SACKETT DL, 1980, MONITORING DRUG SAFE, P427; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V280, P683, DOI 10.1001/jama.280.8.683; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, BRIT MED J, V306, P1648; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tu JV, 1998, CAN J CARDIOL, V14, P349; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	53	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1371	1377		10.1001/jama.282.14.1371	http://dx.doi.org/10.1001/jama.282.14.1371			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527185				2022-12-28	WOS:000083000800033
J	Caldwell, J				Caldwell, J			Paths to lower fertility	BRITISH MEDICAL JOURNAL			English	Article									Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 2601, Australia	Australian National University	Caldwell, J (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, GPO Box 4, Canberra, ACT 2601, Australia.							BANKS JA, 1955, POPULATION STUDIES, V8, P22; Caldwell J. C., 1982, THEORY FERTILITY DEC; Caldwell JC, 1999, POPUL DEV REV, V25, P67, DOI 10.1111/j.1728-4457.1999.00067.x; Caldwell JC, 1998, POPUL DEV REV, V24, P675, DOI 10.2307/2808021; CALDWELL JC, 1988, STUD FAMILY PLANN, V19, P19, DOI 10.2307/1966736; CALDWELL JC, 1999, FERTILITY DEV COUNTR; CALDWELL JC, IN PRESS POP DEV REV; CALDWELL JC, 1988, CAUSES DEMOGRAHIC CH; Caldwell P., 1986, LIMITING POPULATION; Coale Ansley., 1986, DECLINE FERTILITY EU; GOLDSTONE JA, 1986, POP STUD-J DEMOG, V40, P5, DOI 10.1080/0032472031000141816; Hajnal J., 1965, POPULATION HIST ESSA; KHUDA B, IN PRESS COMP PERSPE; Kirk D, 1944, AM SOCIOL REV, V9, P28, DOI 10.2307/2086020; *UN SECR POP DIV, 1998, WORLD POP PROSP 1998, V1; Wrigley EA, 1981, POPULATION HIST ENGL	16	6	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					985	987		10.1136/bmj.319.7215.985	http://dx.doi.org/10.1136/bmj.319.7215.985			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10514167	Green Published			2022-12-28	WOS:000083111700035
J	Hellemons, BSP; Langenberg, M; Lodder, J; Vermeer, F; Schouten, HJA; van Ree, JW; Knottnerus, JA				Hellemons, BSP; Langenberg, M; Lodder, J; Vermeer, F; Schouten, HJA; van Ree, JW; Knottnerus, JA			Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; GENERAL-PRACTICE; WARFARIN; STROKE; ANTICOAGULATION; PREVALENCE; THROMBOSIS; THERAPY; CANCER; RISK	Objective To investigate the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice. Design Randomised controlled trial. Participants 729 patients aged greater than or equal to 60 pars with atrial fibrillation, recruited in general practice, who had no established indication for coumarin. Mean age was 75 years and mean follow up 2.7 years. Setting Primary care in the Netherlands. Interventions Patients eligible for standard intensity coumarin (international normalised ratio 2.5-3.5) were randomly assigned to standard anticoagulation, very low intensity coumarin (international normalised ratio 1.1-1.6), or aspirin (150 mg/day) (stratum 1). Patients ineligible for standard anticoagulation were randomly assigned to low anticoagulation or aspirin (stratum 2). Main outcome measures Strike, systemic embolism, major haemorrhage, and vascular death. Results 108 primary events occurred (annual event rate 5.5%), including 13 major haemorrhages (0.7% a year), The hazard ratio was 0.91 (0.61 to 1.36) for low anticoagulation versus aspirin and 0.78 (0.34 to 1.81) for standard anticoagulation versus aspirin. Non-vascular death it as less common in die low anticoagulation Ir;roup than in die aspirin group (0.41, 0.20 to 0.82). There nas no significant difference between the treatment groups in bleeding incidence, High systolic and lo iv diastolic blood pressure and age were independent prognostic Factors. Conclusion In a general practice population (without established indications for coumarin) neither low nor standard intensity anticoagulation is better than aspirin in preventing primary outcome events. Aspirin may therefore be the first choice in patients with atrial fibrillation in general practice.	Univ Maastricht, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Neurol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Methodol & Stat, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Cardiol, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University	Hellemons, BSP (corresponding author), Univ Maastricht, Dept Gen Practice, POB 616, NL-6200 MD Maastricht, Netherlands.	Bep.Hellemons@HAG.Unimans.NL	Knottnerus, Johannes A/A-3829-2009; Knottnerus, Andre/F-4866-2013					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Blackshear JL, 1996, LANCET, V348, P633; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Fuster V, 1997, LANCET, V350, P389; Hart RG, 1996, STROKE, V27, P585, DOI 10.1161/01.STR.27.4.585; Hellemons BSP, 1999, CONTROL CLIN TRIALS, V20, P386, DOI 10.1016/S0197-2456(99)00010-0; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KNOTTNERUS JA, 1991, FAM PRACT, V8, P305, DOI 10.1093/fampra/8.4.305; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANDEFELD CS, 1989, AM J MED, V87, P144; Langenberg M, 1996, BRIT MED J, V313, P1534, DOI 10.1136/bmj.313.7071.1534; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; Lip GYH, 1999, LANCET, V353, P4, DOI 10.1016/S0140-6736(05)74877-7; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; RICKLES FR, 1983, BLOOD, V62, P14; Schouten HJA, 1995, BIOMETRICS, V51, P1529, DOI 10.2307/2533283; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; SNAPINN SM, 1992, STAT MED, V11, P659, DOI 10.1002/sim.4780110510; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; Zwietering P, 1996, SCAND J PRIM HEALTH, V14, P244, DOI 10.3109/02813439608997092	34	171	174	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1999	319	7215					958	964		10.1136/bmj.319.7215.958	http://dx.doi.org/10.1136/bmj.319.7215.958			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514159	Green Published, Bronze			2022-12-28	WOS:000083111700026
J	Talley, NJ; Vakil, N; Ballard, ED; Fennerty, MB				Talley, NJ; Vakil, N; Ballard, ED; Fennerty, MB			Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUNCTIONAL DYSPEPSIA; CONSENSUS-CONFERENCE; MANAGEMENT; INFECTION; DISEASE; TRIALS	Background The relation between Helicobacter pylori infection and nonulcer dyspepsia is uncertain. We tested the hypothesis that curing the infection will relieve symptoms of dyspepsia. Methods We randomly assigned 170 H. pylori-infected patients with nonulcer dyspepsia to receive twice-daily treatment with 20 mg of omeprazole, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 14 days and 167 such patients to receive identical-appearing placebos; all patients were then followed through regular visits for 12 months. Symptoms were scored on diary cards for seven days before each visit. A carbon-13 urea breath test was performed at base line and repeated at 1 and 12 months, and endoscopic biopsy was performed at 12 months to determine H. pylori status. Treatment was considered successful if the patient had only mild pain or discomfort or none at all. Results The rate of eradication of H. pylori infection was 90 percent in the active-treatment group and 2 percent in the placebo group at four to six weeks (P<0.001). At 12 months, there was no significant difference between groups in the rate of successful treatment (46 percent in the active-treatment group and 50 percent in the placebo group; relative likelihood of success with active treatment, 0.93; 95 percent confidence interval, 0.73 to 1.18; P = 0.56). There was also no significant difference in the rate of successful treatment at 12 months between patients who were H. pylori-negative and those who were H. pylori-positive (48 percent vs. 49 percent). The rates of successful treatment were also similar when patients were analyzed according to the type of dyspepsia (ulcer-like, reflux-like, or dysmotility-like) and changes in the quality of life. There was no significant association between treatment success and histologic improvement in chronic gastritis at 12 months (P = 0.68). Conclusions We found no evidence that curing H. pylori infection in patients with nonulcer dyspepsia leads to relief of symptoms. (N Engl J Med 1999; 341:1106-11.) (C)1999, Massachusetts Medical Society.	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia; Univ Wisconsin, Sch Med, Milwaukee, WI 53201 USA; Bethesda Hosp, Dept Family Med, Cincinnati, OH USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Nepean Hospital; University of Sydney; University of Wisconsin System; University of Wisconsin Milwaukee; Oregon Health & Science University	Talley, NJ (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Clin Sci Bldg, Penrith, NSW 2751, Australia.	talley@pnc.com.au	Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM GASTR ASS, 1998, GASTROENTEROLOGY, V114, P579; Armstrong D, 1996, SCAND J GASTROENTERO, V31, P38, DOI 10.3109/00365529609094532; BERNERSEN B, 1992, BRIT MED J, V304, P1276, DOI 10.1136/bmj.304.6837.1276; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; HEIKKINEN M, 1995, SCAND J GASTROENTERO, V30, P519, DOI 10.3109/00365529509089783; Hunt R, 1998, CAN J GASTROENTEROL, V12, P31, DOI 10.1155/1998/170180; KLAUSER AG, 1993, DIGEST DIS SCI, V38, P147, DOI 10.1007/BF01296788; Lam SJ, 1998, J GASTROEN HEPATOL, V13, P1, DOI 10.1111/j.1440-1746.1998.tb00537.x; Leidy N K, 1999, Value Health, V2, P113, DOI 10.1046/j.1524-4733.1999.02210.x; Malaty H M, 1996, Helicobacter, V1, P165, DOI 10.1111/j.1523-5378.1996.tb00032.x; Malfertheiner P, 1997, EUR J GASTROEN HEPAT, V9, P1; Mant JWF, 1998, QUAL LIFE RES, V7, P221, DOI 10.1023/A:1008873930267; MCCARTHY C, 1995, DIGEST DIS SCI, V40, P114, DOI 10.1007/BF02063953; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; RICHTER JE, 1991, SCAND J GASTROENTERO, V26, P11, DOI 10.3109/00365529109109531; Searle S.R., 1971, LINEAR MODELS; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; Talley NJ, 1998, ALIMENT PHARM THER, V12, P1055; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; Ware JE, 1993, SF36 HLTH SURVEY MAN; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	26	264	269	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1106	1111		10.1056/NEJM199910073411502	http://dx.doi.org/10.1056/NEJM199910073411502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511608				2022-12-28	WOS:000083087200002
J	Cassell, EJ				Cassell, EJ			Diagnosing suffering: A perspective	ANNALS OF INTERNAL MEDICINE			English	Article									Cornell Univ, Weill Med Coll, New York, NY USA	Cornell University	Cassell, EJ (corresponding author), 28 Old Fulton St, Brooklyn, NY 11201 USA.		COZZA, DEBORA/AAH-2572-2021; De Carlo, Esterina/Q-1309-2016	COZZA, DEBORA/0000-0002-1730-089X; De Carlo, Esterina/0000-0001-7883-1283				CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1991, NATURE SUFFERING GOA, P30; CASSELL EJ, 1997, DOCTORING NATURE PRI, P121; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P141; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; HUNTER KM, 1991, DOCTORS STORIES NARR, P121; LAUER Q, 1978, TRIUMPH SUBJECTIVITY, P70; LOCKE J, 1995, ESSAY HUMAN UNDERSTA, P433; Lynn J, 1997, J AM GERIATR SOC, V45, P526; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	14	184	186	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					531	534		10.7326/0003-4819-131-7-199910050-00009	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507963				2022-12-28	WOS:000083018800007
J	Torgerson, DJ; Raftery, J				Torgerson, DJ; Raftery, J			Economics notes - Discounting	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Dept Hlth Studies, York YO1 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ Birmingham, Birmingham B15 2RT, W Midlands, England	University of York - UK; University of York - UK; University of Birmingham	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Studies, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				CAIRNS JA, 1994, HEALTH ECON, V3, P221, DOI 10.1002/hec.4730030404; *DEP HLTH, 1995, POL APPR HLTH; Drummond M., 1994, EC ANAL ALONGSIDE CO; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P250; *TASK FORC PRINC E, 1995, ANN INTERN MED, V122, P61; TORGERSON DJ, 1995, QJM-MON J ASSOC PHYS, V88, P135; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189	9	62	65	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					914	915		10.1136/bmj.319.7214.914	http://dx.doi.org/10.1136/bmj.319.7214.914			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243AU	10506056	Green Published			2022-12-28	WOS:000082975600035
J	Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R				Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R			Dissociation of CH4 at high pressures and temperatures: Diamond formation in giant planet interiors?	SCIENCE			English	Article							CHEMICAL-VAPOR-DEPOSITION; X-RAY-DIFFRACTION; METHANE; URANUS; HYDROCARBONS; NEPTUNE; FILMS; MBAR; GPA	Experiments using Laser-heated diamond anvil cells show that methane (CH4) breaks down to form diamond at pressures between 10 and 50 gigapascals and temperatures of about 2000 to 3000 kelvin. Infrared absorption and Raman spectroscopy, along with x-ray diffraction, indicate the presence of polymeric hydrocarbons in addition to the diamond, which is in agreement with theoretical predictions, Dissociation of CH4 at high pressures and temperatures can influence the energy budgets of planets containing substantial amounts of CH4, water, and ammonia, such as Uranus and Neptune.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Miller Inst Basic Res Sci, Berkeley, CA 94720 USA; Univ Calif Lawrence Livermore Natl Lab, Phys Directorate, Div H, Livermore, CA 94551 USA; Univ Missouri, Dept Phys, Kansas City, MO 64110 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Missouri System; University of Missouri Kansas City	Benedetti, LR (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.							Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ANGUS JC, 1993, PHILOS T ROY SOC A, V342, P195, DOI 10.1098/rsta.1993.0014; ATOU T, 1995, J SOLID STATE CHEM, V118, P299, DOI 10.1006/jssc.1995.1348; BADDING JV, 1991, SCIENCE, V253, P412; BENEDETTI LR, UNPUB; Bini R, 1997, PHYS REV B, V55, P14800, DOI 10.1103/PhysRevB.55.14800; BLOCK S, 1970, SCIENCE, V169, P586, DOI 10.1126/science.169.3945.586; Bloss FD., 1961, INTRO METHODS OPTICA, V116, P485, DOI 10.1524/zkri.1961.116.3-6.485; BUTLER RN, UNPUB; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; Jeanloz R, 1996, PHILOS T R SOC A, V354, P1279, DOI 10.1098/rsta.1996.0049; Kavner A, 1998, J APPL PHYS, V83, P7553, DOI 10.1063/1.367520; KLAGES CP, 1993, APPL PHYS A-MATER, V56, P513, DOI 10.1007/BF00331401; Liebert J, 1999, NATURE, V400, P316, DOI 10.1038/22430; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; MAO HK, 1979, REV SCI INSTRUM, V50, P1002, DOI 10.1063/1.1135966; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; Michler J, 1998, J APPL PHYS, V83, P187, DOI 10.1063/1.366672; NELLIS WJ, 1981, J CHEM PHYS, V75, P3055, DOI 10.1063/1.442401; NGUYEN JH, 1993, REV SCI INSTRUM, V64, P3456, DOI 10.1063/1.1144267; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; RADOUSKY HB, 1990, J CHEM PHYS, V93, P8235, DOI 10.1063/1.459302; REE FH, 1979, J CHEM PHYS, V70, P974, DOI 10.1063/1.437487; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0; WENTORF RH, 1965, J PHYS CHEM-US, V69, P3063, DOI 10.1021/j100893a041; WU YH, 1995, J RAMAN SPECTROSC, V26, P963, DOI 10.1002/jrs.1250261007; Yoshimoto M, 1999, NATURE, V399, P340, DOI 10.1038/20653	27	143	147	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					100	102		10.1126/science.286.5437.100	http://dx.doi.org/10.1126/science.286.5437.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506552				2022-12-28	WOS:000082907400042
J	Sugarman, J				Sugarman, J			Policy forum: Human genetics - Ethical considerations in leaping from bench to bedside	SCIENCE			English	Editorial Material							THERAPY		Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Sugarman, J (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.			Sugarman, Jeremy/0000-0001-7022-8332				[Anonymous], 1979, BELM REP; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Fletcher JC, 1996, HUM GENE THER, V7, P1605, DOI 10.1089/hum.1996.7.13-1605; *JONSEN A, 1998, SOURCE BOOK BIOETHIC, P29; JUENGST ET, 1990, HUM GENE THER, V1, P425, DOI 10.1089/hum.1990.1.4-425; Kahn J. P., 1998, CONSENT SEEKING JUST; King NMP, 1999, HUM GENE THER, V10, P133, DOI 10.1089/10430349950019264; Lederer S., 1995, SUBJECTED SCI; SUGARMAN J, 1999, GEN THER POL C REP P; Sugarman Jeremy, 1998, IRB, V20, P1, DOI 10.2307/3564262; World Medical Association, 1996, DECL HELS; Zanjani ED, 1999, SCIENCE, V285, P2084, DOI 10.1126/science.285.5436.2084; 1946, TRIALS WAR CRIMINALS, P181	15	13	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2071	2072		10.1126/science.285.5436.2071	http://dx.doi.org/10.1126/science.285.5436.2071			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523204				2022-12-28	WOS:000082734300025
J	Zanjani, ED; Anderson, WF				Zanjani, ED; Anderson, WF			Review: Medicine - Prospects for in utero human gene therapy	SCIENCE			English	Review							HEMATOPOIETIC STEM-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW CELLS; INUTERO TRANSPLANTATION; RECOMBINANT ADENOVIRUS; MEDIATED TRANSFER; PERIPHERAL-BLOOD; T-CELL; FETAL; SHEEP	Gene therapy for the treatment of disease in children and adults is being actively pursued at many medical centers. However, a number of genetic disorders result in irreversible damage to the fetus before birth. In these cases, as well as for those with genetic diseases who may benefit from therapy before symptoms are manifested, in utero gene therapy (IUGT) could be beneficial. Although some successes with in utero gene transfer have been reported in animals, significant questions remain to be answered before IUGT clinical trials would be acceptable. This review analyzes the state of the art and delineates the studies that still need to be performed before it would be appropriate to consider human IUGT.	Univ Nevada, Vet Adm Med Ctr, Reno, NV 89520 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Southern California	Zanjani, ED (corresponding author), Univ Nevada, Vet Adm Med Ctr, Reno, NV 89520 USA.							ADAMS TE, 1990, MOL BIOL MED, V7, P341; Anderson WF, 1998, NATURE, V392, P25; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; Billings PR, 1999, NAT MED, V5, P255, DOI 10.1038/6457; BINNS RM, 1967, NATURE, V214, P179, DOI 10.1038/214179a0; BLAZAR BR, 1995, BLOOD, V86, P4353, DOI 10.1182/blood.V86.11.4353.bloodjournal86114353; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; BOWMAN J, 1994, MATERNAL FETAL MED P, P730; BUI T, 1995, AIDS RES HUM RETROV, V11, P955, DOI 10.1089/aid.1995.11.955; CHOI H, 1981, J COMP NEUROL, V10, P683; CLAPP DW, 1991, BLOOD, V78, P1132, DOI 10.1182/blood.V78.4.1132.bloodjournal7841132; CLAPP DW, 1995, BLOOD, V86, P2113, DOI 10.1182/blood.V86.6.2113.bloodjournal8662113; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; COUTELLE C, 1995, NAT MED, V1, P864, DOI 10.1038/nm0995-864; DEMATTEO RP, 1995, ANN SURG, V222, P229, DOI 10.1097/00000658-199509000-00002; Dunbar C, 1996, HUM GENE THER, V7, P231, DOI 10.1089/hum.1996.7.2-231; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; EKHTERAE D, 1990, BLOOD, V75, P365; FLAKE AW, 1991, EXP HEMATOL, V19, P1061; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; Flake AW, 1997, JAMA-J AM MED ASSOC, V278, P932, DOI 10.1001/jama.278.11.932; FLEISCHMAN RA, 1979, P NATL ACAD SCI USA, V76, P5736, DOI 10.1073/pnas.76.11.5736; FLETCHER JC, 1992, FETAL DIAGN THER, V7, P158, DOI 10.1159/000263664; Fletcher JC, 1996, HUM GENE THER, V7, P1605, DOI 10.1089/hum.1996.7.13-1605; Frey BM, 1998, BLOOD, V91, P2781, DOI 10.1182/blood.V91.8.2781.2781_2781_2792; Hanania EG, 1996, P NATL ACAD SCI USA, V93, P15346, DOI 10.1073/pnas.93.26.15346; HARRISON MR, 1989, LANCET, V2, P1425; HAYAASHI SI, 1996, GENE THER, V78, P878; HOLZINGER A, 1995, PEDIATR RES, V38, P844, DOI 10.1203/00006450-199512000-00004; Iwamoto HS, 1999, GENE THER, V6, P98, DOI 10.1038/sj.gt.3300804; JOLLY RD, 1976, PEDIATR RES, V10, P219, DOI 10.1203/00006450-197604000-00003; Kagami H, 1998, HUM GENE THER, V9, P305, DOI 10.1089/hum.1998.9.3-305; KANTOFF PW, 1989, BLOOD, V73, P1066; KOCH KS, 1991, J CELL SCI, V99, P121; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Liu JM, 1997, HUM GENE THER, V8, P1715, DOI 10.1089/hum.1997.8.14-1715; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MCGANN KA, 1994, J INFECT DIS, V169, P746, DOI 10.1093/infdis/169.4.746; Mychaliska GB, 1997, J PEDIATR SURG, V32, P976, DOI 10.1016/S0022-3468(97)90381-X; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PICUS J, 1985, TRANSPLANTATION, V39, P297, DOI 10.1097/00007890-198503000-00018; Porada CD, 1998, HUM GENE THER, V9, P1571, DOI 10.1089/hum.1998.9.11-1571; Rezaie P, 1999, MICROSC RES TECHNIQ, V45, P359, DOI 10.1002/(SICI)1097-0029(19990615)45:6<359::AID-JEMT4>3.3.CO;2-4; Schneider H, 1999, NAT MED, V5, P256, DOI 10.1038/6458; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SEKHON HS, 1995, NAT MED, V1, P1201, DOI 10.1038/nm1195-1201; Senut MC, 1998, J CLIN INVEST, V101, P1565, DOI 10.1172/JCI1959; TOURAINE JL, 1989, LANCET, V1, P1382; TRAN N, IN PRESS EXP HEMATOL; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; UENO H, 1983, VIRCHOWS ARCH A, V400, P31, DOI 10.1007/BF00627006; vanDijk BA, 1996, AM J MED GENET, V61, P264, DOI 10.1002/(SICI)1096-8628(19960122)61:3<264::AID-AJMG11>3.0.CO;2-R; Wengler GS, 1996, LANCET, V348, P1484, DOI 10.1016/S0140-6736(96)09392-0; Westgren M, 1996, TRANSPLANTATION, V61, P1176, DOI 10.1097/00007890-199604270-00010; Winkler A, 1999, HUM GENE THER, V10, P667, DOI 10.1089/10430349950018742; Woo YJ, 1997, CIRCULATION, V96, P3561; Yang EY, 1999, J PEDIATR SURG, V34, P235, DOI 10.1016/S0022-3468(99)90181-1; Ye XH, 1998, HUM GENE THER, V9, P2135, DOI 10.1089/hum.1998.9.14-2135; ZANJANI ED, 1991, BLOOD CELLS, V17, P349; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; ZANJANI ED, 1993, BLOOD, V81, P339	63	101	105	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2084	2088		10.1126/science.285.5436.2084	http://dx.doi.org/10.1126/science.285.5436.2084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523208				2022-12-28	WOS:000082734300033
J	Hughes, CM; Lapane, KL; Mor, V				Hughes, CM; Lapane, KL; Mor, V			Impact of legislation on nursing home care in the United States: lessons for the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							ANTIPSYCHOTIC DRUG-USE; RESIDENT ASSESSMENT INSTRUMENT; OBRA REGULATIONS; PSYCHOACTIVE MEDICATION; PRESCRIBING PRACTICES; PSYCHOTROPICS; FACILITIES; EDUCATION; POLICY; HEALTH		Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA	Brown University	Hughes, CM (corresponding author), Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland.							AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; AVORN J, 1990, HEALTH AFFAIR, V9, P6, DOI 10.1377/hlthaff.9.3.6; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; Butler RN, 1997, BRIT MED J, V315, P1082, DOI 10.1136/bmj.315.7115.1082; CHALLIS DJ, 1996, ASSESSMENT CONTINUIN; DEITCH R, 1985, LANCET, V1, P1113; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; Greengross S, 1997, BRIT MED J, V315, P1029, DOI 10.1136/bmj.315.7115.1029; Hawes C, 1997, AGE AGEING, V26, P19, DOI 10.1093/ageing/26.suppl_2.19; *HLTH CAR FIN ADM, 1995, STAT OP MAN; Institute of Medicine, 1986, IMPR QUAL CAR NURS H; IRWIN WG, 1986, BRIT MED J, V293, P857, DOI 10.1136/bmj.293.6551.857; KANE RL, 1994, JAMA-J AM MED ASSOC, V271, P393, DOI 10.1001/jama.271.5.393; Llorente MD, 1998, J AM GERIATR SOC, V46, P198, DOI 10.1111/j.1532-5415.1998.tb02539.x; McGrath AM, 1996, BRIT MED J, V312, P611; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; OBORNE CA, 1998, PHARM J, V261, pR59; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; Richards T, 1998, BRIT MED J, V317, P896; ROVNER BW, 1992, AM J PSYCHIAT, V149, P1390; Royal College of Physicians, 1997, MED OLD PEOPL; SEMLA TP, 1994, J AM GERIATR SOC, V42, P648, DOI 10.1111/j.1532-5415.1994.tb06865.x; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; SMITH DA, 1990, GERIATRICS, V45, P44; Stoudemire A, 1996, GEN HOSP PSYCHIAT, V18, P77, DOI 10.1016/0163-8343(95)00130-1; STREIM JE, 1995, PSYCHIAT ANN, V25, P413, DOI 10.3928/0048-5713-19950701-10; TESSIER EG, 1993, GERIATRIC DRUG HDB L, P165; Turrell AR, 1998, BRIT MED J, V317, P942	31	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1060	1062		10.1136/bmj.319.7216.1060	http://dx.doi.org/10.1136/bmj.319.7216.1060			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521206	Green Published			2022-12-28	WOS:000083210100035
J	Tyrer, P				Tyrer, P			The national service framework: a scaffold for mental health - Implementation is key to determining whether it's a support or a gallows	BRITISH MEDICAL JOURNAL			English	Editorial Material									Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W2 1PD, England	Imperial College London	Tyrer, P (corresponding author), Imperial Coll Sch Med, Div Neurosci & Psychol Med, St Marys Campus,Paterson Ctr, London W2 1PD, England.							Adams J., 1995, RISK, V1st ed.; Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Department of Health, 1999, NAT SERV FRAM MENT H; Evans MO, 1999, BRIT J PSYCHIAT, V175, P23, DOI 10.1192/bjp.175.1.23; Gilbody S, 1999, BRIT J PSYCHIAT, V175, P303, DOI 10.1192/bjp.175.4.303; Henderson C, 1999, ACTA PSYCHIAT SCAND, V99, P188, DOI 10.1111/j.1600-0447.1999.tb00975.x; JENKINS R, 1990, BRIT J PSYCHIAT, V157, P500, DOI 10.1192/bjp.157.4.500; MARI JJ, 1996, COCHRANE COLLABORATI; Marshall D.S., 1997, DEV RECOMMENDED PRAC, DOI [10.2118/38154-MS, DOI 10.2118/38154-MS]; OYEBODE F, 1999, PSYCHOL BULL, V23, P7; ROSENFIELD S, 1992, J HEALTH SOC BEHAV, V33, P299, DOI 10.2307/2137310	12	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1017	1018		10.1136/bmj.319.7216.1017	http://dx.doi.org/10.1136/bmj.319.7216.1017			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521173	Green Published			2022-12-28	WOS:000083210100003
J	Evans, WE; Relling, MV				Evans, WE; Relling, MV			Pharmacogenomics: Translating functional genomics into rational therapeutics	SCIENCE			English	Review							CONVERTING ENZYME GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMORPHIC DRUG-METABOLISM; RECEPTOR GENE; THIOPURINE METHYLTRANSFERASE; TARDIVE-DYSKINESIA; P-GLYCOPROTEIN; DIHYDROPYRIMIDINE DEHYDROGENASE; ESSENTIAL-HYPERTENSION; POOR METABOLIZERS	Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications. Pharmacogenomic studies are rapidly elucidating the inherited nature of these differences in drug disposition and effects, thereby enhancing drug discovery and providing a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Coll Pharm, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018	Evans, William E./0000-0002-9333-5322; 	NATIONAL CANCER INSTITUTE [R37CA036401, R01CA051001, R01CA078224] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51001, R01 CA78224, R37 CA36401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; Benetos A, 1996, HYPERTENSION, V28, P1081, DOI 10.1161/01.HYP.28.6.1081; Black AJ, 1998, ANN INTERN MED, V129, P716, DOI 10.7326/0003-4819-129-9-199811010-00007; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BROSEN K, 1989, EUR J CLIN PHARMACOL, V36, P537, DOI 10.1007/BF00637732; Caraco Y, 1996, J PHARMACOL EXP THER, V278, P1165; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; Chen CH, 1997, BIOL PSYCHIAT, V41, P827, DOI 10.1016/S0006-3223(96)00543-4; Cohen J, 1997, SCIENCE, V275, P776, DOI 10.1126/science.275.5301.776; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; DESMEULES J, 1991, EUR J CLIN PHARMACOL, V41, P23, DOI 10.1007/BF00280101; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; ESSEN GGV, 1996, LANCET, V347, P94; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GONZALEZ FJ, 1995, TRENDS PHARMACOL SCI, V16, P325, DOI 10.1016/S0165-6147(00)89065-3; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Haas M, 1998, KIDNEY BLOOD PRESS R, V21, P66, DOI 10.1159/000025845; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Henrion D, 1998, J VASC RES, V35, P356, DOI 10.1159/000025605; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Kapitany T, 1998, SCHIZOPHR RES, V32, P101, DOI 10.1016/S0920-9964(98)00038-3; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; LEE JT, 1990, NEW ENGL J MED, V322, P1764, DOI 10.1056/NEJM199006213222502; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; Lennard L, 1998, THER DRUG MONIT, V20, P527, DOI 10.1097/00007691-199810000-00014; LENNARD MS, 1983, CLIN PHARMACOL THER, V34, P732, DOI 10.1038/clpt.1983.242; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Lipworth BJ, 1999, CHEST, V115, P324, DOI 10.1378/chest.115.2.324; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; Marshall A, 1997, NAT BIOTECHNOL, V15, P954, DOI 10.1038/nbt1097-954; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756; Mizuiri S, 1997, NEPHRON, V75, P310, DOI 10.1159/000189554; NAKAMURA H, 1995, J PHARMACOL EXP THER, V274, P1099; Nakano Y, 1997, AM J HYPERTENS, V10, P1064, DOI 10.1016/S0895-7061(97)00279-3; Nebert DW, 1997, AM J HUM GENET, V60, P265; O'Toole L, 1998, J CARDIOVASC PHARM, V32, P988, DOI 10.1097/00005344-199812000-00017; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Poulsen L, 1996, EUR J CLIN PHARMACOL, V51, P289, DOI 10.1007/s002280050200; Priori SG, 1999, CIRCULATION, V99, P674, DOI 10.1161/01.CIR.99.5.674; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Ratain MJ, 1996, PHARMACOGENETICS, V6, P93, DOI 10.1097/00008571-199602000-00008; Rebbeck TR, 1998, J NATL CANCER I, V90, P1225, DOI 10.1093/jnci/90.16.1225; Relling MV, 1999, BLOOD, V93, P2817; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; Sasaki M, 1996, J HYPERTENS, V14, P1403, DOI 10.1097/00004872-199612000-00003; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Schuetz EG, 1999, J BIOCHEM MOL TOXIC, V13, P219; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SINDRUP SH, 1993, PAIN, V53, P335, DOI 10.1016/0304-3959(93)90229-I; Spielberg SP, 1996, J PHARMACOKINET BIOP, V24, P509, DOI 10.1007/BF02353477; Steen VM, 1997, MOL PSYCHIATR, V2, P139, DOI 10.1038/sj.mp.4000249; Steward DJ, 1997, PHARMACOGENETICS, V7, P361, DOI 10.1097/00008571-199710000-00004; Tyndale RF, 1997, PHARMACOGENETICS, V7, P375, DOI 10.1097/00008571-199710000-00006; vanderKleij FGH, 1997, NEPHROL DIAL TRANSPL, V12, P42; vanderKleij FGH, 1997, KIDNEY INT, pS23; WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270; ZHOU HH, 1989, NEW ENGL J MED, V320, P565, DOI 10.1056/NEJM198903023200905	71	1759	1921	4	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					487	491		10.1126/science.286.5439.487	http://dx.doi.org/10.1126/science.286.5439.487			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521338				2022-12-28	WOS:000083121200050
J	Molnar, P; Anderson, HJ; Audoine, E; Eberhart-Phillips, D; Gledhill, KR; Klosko, ER; McEvilly, TV; Okaya, D; Savage, MK; Stern, T; Wu, FT				Molnar, P; Anderson, HJ; Audoine, E; Eberhart-Phillips, D; Gledhill, KR; Klosko, ER; McEvilly, TV; Okaya, D; Savage, MK; Stern, T; Wu, FT			Continous deformation versus faulting through the continental lithosphere of New Zealand	SCIENCE			English	Article							AUSTRALIA-PACIFIC BOUNDARY; SOUTH ISLAND; STRIKE-SLIP; PLATE BOUNDARY; FINITE STRAIN; ANISOTROPY; OBLIQUE; CONSTRAINTS; KINEMATICS; TECTONICS	Seismic anisotropy and P-wave delays in New Zealand imply widespread deformation in the underlying mantle, not slip on a narrow fault zone, which is characteristic of plate boundaries in oceanic regions. Large magnitudes of shear-wave splitting and orientations of fast polarization parallel to the Alpine fault show that pervasive simple shear of the mantle lithosphere has accommodated the cumulative strike-slip plate motion. Variations in P-wave residuals across the Southern Alps rule out underthrusting of one slab of mantle Lithosphere beneath another but permit continuous deformation of Lithosphere shortened by about 100 kilometers since 6 to 7 million years ago.	Univ Washington, Quaternary Res Ctr, Seattle, WA 98195 USA; Univ Washington, Geophys Program, Seattle, WA 98195 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Minist Res Sci & Technol, Wellington, New Zealand; Inst Geol & Nucl Sci, Dunedin, New Zealand; Victoria Univ Wellington, Sch Earth Sci, Inst Geophys, Wellington, New Zealand; Univ Otago, Dunedin, New Zealand; Gracefield Res Ctr, Inst Geol & Nucl Sci, Lower Hutt, New Zealand; SUNY Binghamton, Dept Geol Sci, Binghamton, NY 13902 USA; Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Massachusetts Institute of Technology (MIT); GNS Science - New Zealand; Victoria University Wellington; University of Otago; GNS Science - New Zealand; State University of New York (SUNY) System; State University of New York (SUNY) Binghamton; Northwestern University; University of California System; University of California Berkeley; University of Southern California	Molnar, P (corresponding author), Univ Washington, Quaternary Res Ctr, Seattle, WA 98195 USA.	molnar@chandler.mit.edu	Savage, Martha K/F-1857-2011; Eberhart-Phillips, Donna/H-3233-2018	Savage, Martha K/0000-0002-2080-0676; Eberhart-Phillips, Donna/0000-0003-0392-8659; Stern, Tim/0000-0002-2986-3278				ALLIS RG, 1981, GEOLOGY, V9, P303, DOI 10.1130/0091-7613(1981)9<303:CUBTSA>2.0.CO;2; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; Beaumont C, 1996, J GEOPHYS RES-SOL EA, V101, P3333, DOI 10.1029/95JB02401; BEAVAN J, IN PRESS J GEOPHYS R; Ben Ismail W, 1998, TECTONOPHYSICS, V296, P145; Bourne SJ, 1998, NATURE, V391, P655, DOI 10.1038/35556; BRACE WF, 1980, J GEOPHYS RES, V85, P6248, DOI 10.1029/JB085iB11p06248; BRAUN J, 1995, J GEOPHYS RES-SOL EA, V100, P18059, DOI 10.1029/95JB01683; BUROV EB, 1995, J GEOPHYS RES-SOL EA, V100, P3905, DOI 10.1029/94JB02770; CARTER RM, 1976, EARTH PLANET SC LETT, V31, P85, DOI 10.1016/0012-821X(76)90099-6; ENGLAND P, 1986, J GEOPHYS RES-SOLID, V91, P3664, DOI 10.1029/JB091iB03p03664; GOETZE C, 1977, HIGH PRESSURE RES AP, P3; HATHERTON T, 1967, NEW ZEAL J GEOL GEOP, V10, P1330, DOI 10.1080/00288306.1967.10423219; HATHERTON T, 1969, GEOL SOC AM BULL, V80, P213, DOI 10.1130/0016-7606(1969)80[213:GAOTEA]2.0.CO;2; HOLBROOK WS, 1998, EOS T AGU S, V79, pF901; HOLT WE, 1991, EARTH PLANET SC LETT, V107, P523, DOI 10.1016/0012-821X(91)90098-3; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Klosko ER, 1999, GEOPHYS RES LETT, V26, P1497, DOI 10.1029/1999GL900273; Little TA, 1998, TECTONICS, V17, P285, DOI 10.1029/97TC03148; MAINPRICE D, 1993, PHYS EARTH PLANET IN, V78, P257, DOI 10.1016/0031-9201(93)90160-B; Marson-Pidgeon K, 1999, J GEOPHYS RES-SOL EA, V104, P20277, DOI 10.1029/1999JB900212; Marson-Pidgeon K, 1997, GEOPHYS RES LETT, V24, P3297, DOI 10.1029/97GL03274; Mattauer M, 1986, GEOL SOC SPEC PUBL, V19, P37, DOI 10.1144/GSL.SP.1986.019.01.02; Matte P, 1996, EARTH PLANET SC LETT, V142, P311, DOI 10.1016/0012-821X(96)00086-6; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; Molnar P., 1992, INT GEOPHYS ACAD PRE, V51, P435; MUMME TC, 1985, 204 GEOPH DIV DEP SC; Nicolas A., 1987, FORMATION ANISOTROPY, DOI DOI 10.1029/GD016P0111; NORRIS RJ, 1990, J STRUCT GEOL, V12, P715, DOI 10.1016/0191-8141(90)90084-C; NORRIS RJ, 1979, ROYAL SOC NZ B, V18, P21; RIBE NM, 1992, J GEOPHYS RES-SOL EA, V97, P8737, DOI 10.1029/92JB00551; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; SCHERWATH M, 1998, EOS S, V79, pF901; SHEARER PM, 1986, GEOPHYS J ROY ASTR S, V87, P967, DOI 10.1111/j.1365-246X.1986.tb01979.x; Sibson R.H., 1999, B ROYAL SOC NZ, V18, P55; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; STERN T, UNPUB; STERN TA, 1997, EOS T AM GEOPHYS UN, V78, P329; Sutherland R, 1999, NEW ZEAL J GEOL GEOP, V42, P295, DOI 10.1080/00288306.1999.9514846; Sutherland R, 1995, NEW ZEAL J GEOL GEOP, V38, P419, DOI 10.1080/00288306.1995.9514669; Sutherland R, 1996, NEW ZEAL J GEOL GEOP, V39, P251, DOI 10.1080/00288306.1996.9514709; SUTHERLAND R, 1995, TECTONICS, V14, P819, DOI 10.1029/95TC00930; Sutherland R, 1999, TECTONOPHYSICS, V308, P341, DOI 10.1016/S0040-1951(99)00108-0; TIPPETT JM, 1993, J GEOPHYS RES-SOL EA, V98, P16119, DOI 10.1029/92JB02115; WALCOTT RI, 1984, GEOPHYS J ROY ASTR S, V79, P613, DOI 10.1111/j.1365-246X.1984.tb02244.x; Walcott RI, 1998, REV GEOPHYS, V36, P1, DOI 10.1029/97RG03084; Wellman H.W., 1979, R SOC N Z B, V18, P13; WOODWARD DJ, 1979, B R SOC NZ, V18, P95; YU Y, 1994, J GEOPHYS RES-SOL EA, V99, P15399, DOI 10.1029/94JB00936; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	50	122	122	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					516	519		10.1126/science.286.5439.516	http://dx.doi.org/10.1126/science.286.5439.516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521344				2022-12-28	WOS:000083121200056
J	Aveyard, P; Cheng, KK; Almond, J; Sherratt, E; Lancashire, R; Lawrence, T; Griffin, C; Evans, O				Aveyard, P; Cheng, KK; Almond, J; Sherratt, E; Lancashire, R; Lawrence, T; Griffin, C; Evans, O			Cluster randomised controlled trial of expert system based on the transtheoretical ("stages of change") model for smoking prevention and cessation in schools	BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENT SMOKING; METAANALYSIS; PEOPLE	Objectives To examine whether a year long programme based on the transtheoretical model of behaviour change, incorporating three sessions using an expert system computer program and three class lessons, could reduce the prevalence of teenage smoking. Design Cluster randomised trial comparing the intervention to a control group exposed only to health education as part of the English national curriculum. Setting 52 schools in the West Midlands region. Participants 8352 students in year 9 (age 13-14 years) at those schools. Main outcome measures Prevalence of teenage smoking 12 months after the start of the intervention. Results Of the 8352 students recruited, 7444 (89.1%) were followed up at 12 months. The intention to treat odds ratio for smoking in the intervention group relative to control was 1.08 (95% confidence interval 0.89 to 1.33). Sensitivity analysis for loss to follow up and adjustment for potential confounders did not alter these findings. Conclusions The smoking prevention and cessation intervention based on the transtheoretical model, as delivered in this trial, is ineffective in schoolchildren aged 13-14.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Aveyard, P (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.		Clarke, Joanne/AAY-3849-2020; Cheng, Kar/AAL-8899-2021	Clarke, Joanne/0000-0003-2563-5451; Cheng, Kar/0000-0002-1516-1857; Aveyard, Paul/0000-0002-1802-4217				*BIRM HLTH ED DEP, 1994, DRAG BREATH; BOSELEY S, 1999, GUARDIAN        0323, P4; BRUVOLD WH, 1993, AM J PUBLIC HEALTH, V83, P872, DOI 10.2105/AJPH.83.6.872; CHARLTON A, 1989, BRIT MED J, V298, P90, DOI 10.1136/bmj.298.6666.90; DAVIDSON R, 1992, BRIT J ADDICT, V87, P821; DOOLING M, 1993, DRUGS USE ABUSE; ELDERS MJ, 1994, AM J PUBLIC HEALTH, V84, P543, DOI 10.2105/AJPH.84.4.543; Goldstein H., 1998, USERS GUIDE MLWIN; Jarvis L., 1997, SMOKING SECONDARY SC; MICHELL L, 1994, SMOKING PREVENTION P; Pallonen UE, 1998, ADDICT BEHAV, V23, P303, DOI 10.1016/S0306-4603(97)00074-9; Pallonen UE, 1998, SUBST USE MISUSE, V33, P935, DOI 10.3109/10826089809056250; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PROCHASKA JO, 1988, J CONSULT CLIN PSYCH, V56, P520, DOI 10.1037/0022-006X.56.4.520; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; REDDING CA, IN PRESS COG BEHAV P; *SECR STAT HLTH SE, 1998, SMOK KILLS WHIT PAP; SHERRATT E, 1999, WORKING TOGETHER BET, P215; SHERRATT E, 1997, W MIDLANDS YOUNG PEO; Stead M, 1996, HLTH ED J, V55, P31, DOI [10.1177/001789699605500105, DOI 10.1177/001789699605500105]; VELICER WF, 1993, ADDICT BEHAV, V18, P269, DOI 10.1016/0306-4603(93)90029-9; VELICER WF, 1990, ADDICT BEHAV, V15, P271, DOI 10.1016/0306-4603(90)90070-E; Velicer WF, 1999, HEALTH PSYCHOL, V18, P21; Velicer WF, 1999, ADDICT BEHAV, V24, P455, DOI 10.1016/S0306-4603(98)00100-2; Velicer WF, 1996, ADDICT BEHAV, V21, P555, DOI 10.1016/0306-4603(95)00083-6	26	117	118	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					948	953		10.1136/bmj.319.7215.948	http://dx.doi.org/10.1136/bmj.319.7215.948			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10514156	Green Published, Bronze			2022-12-28	WOS:000083111700021
J	Steptoe, A; Doherty, S; Rink, E; Kerry, S; Kendrick, T; Hilton, S				Steptoe, A; Doherty, S; Rink, E; Kerry, S; Kendrick, T; Hilton, S			Behavioural counselling in general practice for the promotion of healthy behaviour among adults at increased risk of coronary heart disease: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							DIETARY INTERVENTION; PHYSICAL-ACTIVITY; EDUCATION; SMOKING; CARE	Objective To measure the effect of behaviourally oriented counselling in general practice on healthy behaviour and biological risk factors in patients at increased risk of coronary heart disease. Design Cluster randomised controlled trial. Participants 883 men and women selected for die presence of one or more modifiable risk factors: regular cigarette smoking, high serum cholesterol concentration (6.5-9.0 mmol/l), and high body mass index (25-35) combined with low physical activity Intervention Brief behavioural counselling, on the basis of the stage of change model, carried out by practice nurses to reduce smoking and dietary fat intake and to increase regular: physical activity Main outcome measures Questionnaire measures of diet exercise, and smoking habits, and blood pressure, serum total cholesterol concentration, weight, body mass index, and smoking cessation (with biochemical validation) at 4 and 12 months. Results Favourable differences were recorded in the intervention group for dietary fat intake, regular-exercise, and cigarettes smoked per day at 4 and 12 months. Systolic blood pressure was reduced to a greater extent in the intervention group at 4 but not at 12 months. No differences were found between groups in changes in total serum cholesterol concentration, weight, body mass index, diastolic pressure, or smoking cessation. Conclusions Brief behavioural counselling by practice nurses led to improvements in healthy behaviour. More extended counselling to help patients sustain and build on behaviour changes may be required before differences in biological risk factors emerge.	St George Hosp, Sch Med, Dept Psychol, London SW17 0RE, England; St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England	St Georges University London; St Georges University London	Steptoe, A (corresponding author), St George Hosp, Sch Med, Dept Psychol, London SW17 0RE, England.		Steptoe, Andrew/Y-2440-2019; Kendrick, Tony/H-8558-2014	Kendrick, Tony/0000-0003-1618-9381; Steptoe, Andrew/0000-0001-7808-4943				Ashworth P., 1997, HLTH ED J, V56, P166; Bland JM, 1998, BRIT MED J, V316, P129; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; COULTER A, 1995, BRIT MED J, V310, P1099; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Doherty S C, 1998, J Cardiovasc Risk, V5, P147, DOI 10.1097/00043798-199806000-00002; Fairhurst K, 1998, BMJ-BRIT MED J, V317, P1130; HILLSDON M, 1995, J EPIDEMIOL COMMUN H, V49, P448, DOI 10.1136/jech.49.5.448; HILTON S, 1999, HLTH ED J, V58, P3; *HLTH ED AUTH, 1994, HELP PEOPL CHANG HLT; Howard-Pitney B, 1997, AM J PUBLIC HEALTH, V87, P1971, DOI 10.2105/AJPH.87.12.1971; HUNT P, 1996, EATING EXERCISE BEHA; Jackson C, 1997, HEALTH EDUC RES, V12, P143, DOI 10.1093/her/12.1.143; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Johanson M, 1998, SOC SCI MED, V47, P103, DOI 10.1016/S0277-9536(98)00031-8; Kok G, 1997, PATIENT EDUC COUNS, V30, P19, DOI 10.1016/S0738-3991(96)00953-6; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; McCann T J, 1997, J Cardiovasc Risk, V4, P41; Pierce JP, 1998, ADDICTION, V93, P277, DOI 10.1046/j.1360-0443.1998.93227711.x; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; SILAGE C, 1998, COCHRANE LIB; *SPORTS COUNC HLTH, 1992, ALL DUNB NAT FITN SU; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; Treasure T, 1998, BRIT MED J, V317, P362; WEST RJ, 1984, BRIT J ADDICT, V79, P215; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; Wood D, 1998, J HYPERTENS, V16, P1407, DOI 10.1097/00004872-199816100-00003; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313	29	171	173	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					943	947		10.1136/bmj.319.7215.943	http://dx.doi.org/10.1136/bmj.319.7215.943			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10514155	Green Published, Bronze			2022-12-28	WOS:000083111700019
J	Ritz, E; Orth, SR				Ritz, E; Orth, SR			Nephropathy in patients with type 2 diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONVERTING-ENZYME-INHIBITION; CALCIUM-CHANNEL BLOCKERS; BLOOD-PRESSURE; RENAL-DISEASE; NIDDM PATIENTS; KIDNEY-FUNCTION; PIMA-INDIANS; PROGRESSION; PROTEINURIA; MICROALBUMINURIA		Heidelberg Univ, Dept Internal Med, Renal Unit, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Ritz, E (corresponding author), Heidelberg Univ, Dept Internal Med, Renal Unit, Bergheimer Str 56A, D-69115 Heidelberg, Germany.							Bakris GL, 1998, KIDNEY INT, V54, P1283, DOI 10.1046/j.1523-1755.1998.00083.x; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; BIESENBACH G, 1994, NEPHROL DIAL TRANSPL, V9, P1097, DOI 10.1093/ndt/9.8.1097; Bluthner M, 1999, KIDNEY INT, V55, P1247, DOI 10.1046/j.1523-1755.1999.00399.x; Bowden DW, 1997, DIABETES, V46, P882, DOI 10.2337/diabetes.46.5.882; Chantrel F, 1999, NEPHROL DIAL TRANSPL, V14, P129, DOI 10.1093/ndt/14.1.129; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Christensen PK, 1997, KIDNEY INT, V52, P1369, DOI 10.1038/ki.1997.463; Cooper ME, 1998, LANCET, V352, P213, DOI 10.1016/S0140-6736(98)01346-4; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Erley CM, 1999, NEPHROL DIAL TRANSPL, V14, P1064, DOI 10.1093/ndt/14.5.1064; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90; Ferrannini E, 1997, HYPERTENSION, V30, P1144, DOI 10.1161/01.HYP.30.5.1144; Fioretto P, 1996, DIABETOLOGIA, V39, P1569, DOI 10.1007/s001250050616; Fisher NDL, 1999, KIDNEY INT, V56, P635, DOI 10.1046/j.1523-1755.1999.00579.x; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Guasch A, 1997, J AM SOC NEPHROL, V8, P793; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HASSLACHER C, 1989, NEPHROL DIAL TRANSPL, V4, P859, DOI 10.1093/ndt/4.10.859; HIRSCHL MM, 1995, NEPHROL DIAL TRANSPL, V10, P1515; Imperatore G, 1998, DIABETES, V47, P821, DOI 10.2337/diabetes.47.5.821; Ismail N, 1999, KIDNEY INT, V55, P1, DOI 10.1046/j.1523-1755.1999.00232.x; JACOBSON HR, 1995, AM J KIDNEY DIS, V25, P103, DOI 10.1016/0272-6386(95)90635-5; Jeffers BW, 1997, KIDNEY INT, V52, P473, DOI 10.1038/ki.1997.355; KAWAZU S, 1994, J DIABETES COMPLICAT, V8, P13, DOI 10.1016/1056-8727(94)90005-1; Keller CK, 1996, J AM SOC NEPHROL, V7, P2627; Kloke HJ, 1998, KIDNEY INT, V53, P1559, DOI 10.1046/j.1523-1755.1998.00912.x; Koren W, 1997, DIABETOLOGIA, V40, P302, DOI 10.1007/s001250050678; Krolewski AS, 1999, KIDNEY INT, V55, P1582, DOI 10.1046/j.1523-1755.1999.00371.x; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Mogensen CE, 1999, DIABETOLOGIA, V42, P263, DOI 10.1007/s001250051151; Mogensen CE, 1998, BRIT MED J, V317, P693, DOI 10.1136/bmj.317.7160.693; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Nakano S, 1998, DIABETES, V47, P1501, DOI 10.2337/diabetes.47.9.1501; *NAT I DIAB DIG KI, 1998, NIH PUBL; Nielsen FS, 1997, DIABETES, V46, P1182, DOI 10.2337/diabetes.46.7.1182; OLIVARIUS ND, 1993, DIABETOLOGIA, V36, P1007, DOI 10.1007/BF02374492; Orth SR, 1997, KIDNEY INT, V51, P1669, DOI 10.1038/ki.1997.232; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; PETTITT DJ, 1990, DIABETOLOGIA, V33, P438, DOI 10.1007/BF00404096; Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; RITZ E, IN PRESS AM J KIDNEY; Ruggenenti P, 1997, LANCET, V349, P1857; Ruilope LM, 1997, J HYPERTENS, V15, pS63, DOI 10.1097/00004872-199715022-00005; SAWICKI PT, 1994, DIABETES CARE, V17, P126, DOI 10.2337/diacare.17.2.126; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Strojek K, 1997, KIDNEY INT, V51, P1602, DOI 10.1038/ki.1997.220; Tarnow L, 1998, NEPHROL DIAL TRANSPL, V13, P1125, DOI 10.1093/ndt/13.5.1125; Toeller M, 1997, DIABETOLOGIA, V40, P1219, DOI 10.1007/s001250050810; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospect Diabet Study Grp, 1999, BMJ-BRIT MED J, V318, P29; Velussi M, 1996, DIABETES, V45, P216, DOI 10.2337/diabetes.45.2.216; Wagner J, 1999, J AM SOC NEPHROL, V10, P545; WEIDMANN P, 1993, NEPHROL DIAL TRANSPL, V8, P582; Yokoyama H, 1997, DIABETOLOGIA, V40, P405, DOI 10.1007/s001250050694; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	66	542	571	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1127	1133		10.1056/NEJM199910073411506	http://dx.doi.org/10.1056/NEJM199910073411506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511612				2022-12-28	WOS:000083087200006
J	Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP				Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP			Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; questionnaires; hypertension; obesity; snoring	PREVALENCE; POPULATION; ADULTS; PREDICTION; COMMUNITY; ACCIDENTS; HEALTH; SAMPLE; MEN	Background: Although sleep apnea is common, it often goes undiagnosed in primary care encounters. Objective: To test the Berlin Questionnaire as a means of identifying patients with sleep apnea. Design: Survey followed by portable, unattended sleep studies in a subset of patients. Setting: Five primary care sites in Cleveland, Ohio. Patients: 744 adults (of 1008 surveyed [74%]), of whom 100 underwent sleep studies. Measurements: Survey items addressed the presence and frequency of snoring behavior, waketime sleepiness or fatigue, and history of obesity or hypertension. Patients with persistent and frequent symptoms in any two of these three domains were considered to be at high risk for sleep apnea. Portable sleep monitoring was conducted to measure the number of respiratory events per hour in bed (respiratory disturbance index [RDI]). Results: Questions about symptoms demonstrated internal consistency (Cronbach correlations, 0.86 to 0.92). Of the 744 respondents, 279 (37.5%) were in a high-risk group that was defined a priori. For the 100 patients who underwent sleep studies, risk grouping was useful in prediction of the RDI. For example, being in the high-risk group predicted an RDI greater than 5 with a sensitivity of 0.86, a specificity of 0.77, a positive predictive value of 0.89, and a likelihood ratio of 3.79. Conclusion: The Berlin Questionnaire provides a means of identifying patients who are likely to have sleep apnea.	Case Western Reserve Univ, Ctr Sleep Educ & Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sleep Disorders Res Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Strohl, KP (corresponding author), Case Western Reserve Univ, Ctr Sleep Educ & Res, 10701 E Blvd, Cleveland, OH 44106 USA.			Netzer, Nikolaus/0000-0001-7534-3575	NHLBI NIH HHS [HL-03650, HL-42215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042215, K07HL003650] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball EM, 1997, ARCH INTERN MED, V157, P419, DOI 10.1001/archinte.157.4.419; Bradley TD, 1998, AM J RESP CRIT CARE, V157, P335; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; CIRIGNOTTA F, 1989, ACTA NEUROL SCAND, V79, P366, DOI 10.1111/j.1600-0404.1989.tb03802.x; Flemons WW, 1996, SLEEP, V19, pS243; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; Haponik EF, 1996, J GEN INTERN MED, V11, P759, DOI 10.1007/BF02598994; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; LOGUE E, 1995, J FAM PRACTICE, V41, P357; Lyznicki JM, 1998, JAMA-J AM MED ASSOC, V279, P1908, DOI 10.1001/jama.279.23.1908; MAISLIN G, 1995, SLEEP, V18, P158, DOI 10.1093/sleep/18.3.158; Marin JM, 1997, INT J EPIDEMIOL, V26, P381, DOI 10.1093/ije/26.2.381; Ohayon MM, 1997, BRIT MED J, V314, P860; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P711, DOI 10.1164/ajrccm.152.2.7633731; Redline S, 1998, CLIN CHEST MED, V19, P1, DOI 10.1016/S0272-5231(05)70428-7; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Stoohs R A, 1997, Sleep Breath, V2, P11; Wu H, 1996, NEUROLOGY, V46, P1254, DOI 10.1212/WNL.46.5.1254; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705	24	1829	1901	0	56	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					485	+		10.7326/0003-4819-131-7-199910050-00002	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507956				2022-12-28	WOS:000083018800001
J	Douglas, A				Douglas, A			A lesson learnt - An inspirational teacher	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					889	889		10.1136/bmj.319.7214.889	http://dx.doi.org/10.1136/bmj.319.7214.889			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506046	Green Published			2022-12-28	WOS:000082975600025
J	Carlson, RW; Johnson, RE; Anderson, MS				Carlson, RW; Johnson, RE; Anderson, MS			Sulfuric acid on Europa and the radiolytic sulfur cycle	SCIENCE			English	Article							MAGNETOSPHERIC ION-BOMBARDMENT; ICY GALILEAN SATELLITES; IRRADIATION EXPERIMENTS; REFLECTANCE SPECTRA; SURFACE-COMPOSITION; SPECTROSCOPY; OXYGEN; SYSTEM	A comparison of laboratory spectra with Galileo data indicates that hydrated sulfuric acid is present and is a major component of Europa's surface. In addition, this moon's visually dark surface material, which spatially correlates with the sulfuric acid concentration, is identified as radiolytically altered sulfur polymers. Radiolysis of the surface: by magnetospheric plasma bombardment continuously cycles sulfur between three forms: sulfuric acid, sulfur dioxide, and sulfur polymers, with sulfuric acid being about 50 times as abundant as the other forms. Enhanced sulfuric acid concentrations are found in Europa's geologically young terrains, suggesting that low-temperature, liquid sulfuric acid may influence geological processes.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Virginia, Sch Engn & Appl Sci, Charlottesville, VA 22903 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Virginia	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	rcarlson@lively.jpl.nasa.gov						Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; CARLSON RW, 1998, HIGHLIGHTS ASTRONO B, V11, P1078; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; COOPER JR, UNPUB; DONALDSON GW, 1968, J PHYS CHEM-US, V72, P3552, DOI 10.1021/j100856a033; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; HOCHANADEL CJ, 1955, J AM CHEM SOC, V77, P3215, DOI 10.1021/ja01617a017; HOGENBOOM DL, 1995, ICARUS, V115, P258, DOI 10.1006/icar.1995.1096; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jayne JT, 1997, J PHYS CHEM A, V101, P10000, DOI 10.1021/jp972549z; JOHNSON ER, 1952, J AM CHEM SOC, V74, P4147, DOI 10.1021/ja01136a056; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; JOHNSON RE, 1988, ICARUS, V75, P423, DOI 10.1016/0019-1035(88)90155-8; JOHNSON TV, 1983, J GEOPHYS RES, V88, P5789, DOI 10.1029/JB088iB07p05789; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEBOFSKY LA, 1976, ICARUS, V28, P379, DOI 10.1016/0019-1035(76)90151-2; Martin ST, 1997, J PHYS CHEM B, V101, P5307, DOI 10.1021/jp970607a; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; Moore M., COMMUNICATION; MOORE MH, 1984, ICARUS, V59, P114, DOI 10.1016/0019-1035(84)90059-9; MOOTZ D, 1987, Z NATURFORSCH B, V42, P1231, DOI 10.1515/znb-1987-1004; NANOBASHVILI EM, 1957, P 1 ALL UN C RAD CHE, P69; NANOBASHVILI EM, 1964, P 2 ALL UN C RAD CHE, P159; NASH DB, 1977, ICARUS, V31, P40, DOI 10.1016/0019-1035(77)90070-7; NELSON ML, 1986, ICARUS, V65, P129, DOI 10.1016/0019-1035(86)90068-0; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OSHAUGHNESSY DJ, 1988, NATURE, V333, P240, DOI 10.1038/333240a0; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SASAKI T, 1978, J CHEM PHYS, V68, P2718, DOI 10.1063/1.436109; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; STRAZZULLA G, 1993, ADV SPACE RES, V13, P189; THOMPSON BA, 1963, J GEOPHYS RES, V68, P6431, DOI 10.1029/JZ068i024p06431; YAROSLAVTSEV AB, 1983, ZH NEORG KHIM+, V28, P2746; ZELEZNIK FJ, 1991, J PHYS CHEM REF DATA, V20, P1157, DOI 10.1063/1.555899	42	258	260	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					97	99		10.1126/science.286.5437.97	http://dx.doi.org/10.1126/science.286.5437.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506568				2022-12-28	WOS:000082907400041
J	Perrotta, AT; Shih, IH; Been, MD				Perrotta, AT; Shih, IH; Been, MD			Imidazole rescue of a cytosine mutation in a self-cleaving ribozyme	SCIENCE			English	Article							HEPATITIS-DELTA-VIRUS; RNA; CLEAVAGE; CATALYSIS; SEQUENCES; MUTANT; BASES; CORE	Ribozymes use a number of the same catalytic strategies as protein enzymes. However, general base catalysis by a ribozyme has not been demonstrated. In the hepatitis delta virus antigenomic ribozyme, imidazole buffer rescued activity of a mutant with a cytosine-76 (C76) to uracil substitution. In addition, a C76 to adenine substitution reduced the apparent pK(a) (where K-a is the acid constant) of the self-cleavage reaction by an amount consistent with differences in the pK(a) values of these two side chains. These results suggest that, in the wild-type ribozyme, C76 acts as a general base. This finding has implications for potential catalytic functions of conserved cytosines and adenines in other ribozymes and in ribonuclear proteins with enzymatic activity.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Been, MD (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.				NIGMS NIH HHS [GM47322] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; Bravo C, 1996, NUCLEIC ACIDS RES, V24, P1351, DOI 10.1093/nar/24.7.1351; Cech TR, 1999, RNA WORLD, P321; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LEGAULT P, 1994, J AM CHEM SOC, V116, P8390, DOI 10.1021/ja00097a066; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1998, RNA, V4, P1332, DOI 10.1017/S1355838298980979; Perrin D. D., 2012, BUFFERS PH METAL ION; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Perrotta AT, 1998, J MOL BIOL, V279, P361, DOI 10.1006/jmbi.1998.1798; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; Saenger W., 1984, SPRINGER ADV TEXTS C; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; Wadkins TS, 1999, RNA, V5, P720, DOI 10.1017/S1355838299990209; WADKINS TS, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	28	249	256	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					123	126		10.1126/science.286.5437.123	http://dx.doi.org/10.1126/science.286.5437.123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506560				2022-12-28	WOS:000082907400050
J	De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C				De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C			Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1	NATURE			English	Article							TRANSCRIPTION FACTOR GATA-1; TNF RECEPTORS; APOPTOSIS; ANEMIA; GENE; DIFFERENTIATION; HEMATOPOIESIS; EXPRESSION; PROTEASE; DISEASE	The production of red blood cells follows the sequential formation of proerythroblasts and basophilic, polychromatophilic and orthochromatic erythroblasts, and is promoted by the hormone erythropoietin (Epo) in response to tissue hypoxia(1). However, little is known about the negative regulation of this process(2). Death receptors are a family of surface molecules that trigger caspase activation and apoptosis in a variety of cell types(3-5). Here we show that immature erythroid cells express several death receptors whose ligands are produced by mature erythroblasts. Exposure of erythroid progenitors to mature erythroblasts or death-receptor ligands resulted in caspase-mediated degradation of the transcription factor GATA-1, which is associated with impaired erythroblast development. Expression of a caspase-resistant GATA-1 mutant, but not of the wild-type gene, completely restored erythroid expansion and differentiation following the triggering of death receptors, indicating that there is regulatory feedback between mature and immature erythroblasts through caspase-mediated cleavage of GATA-1. Similarly, erythropoiesis blockade following Epo deprivation was largely prevented by the expression of caspase-inhibitory proteins or caspase-resistant GATA-1 in erythroid progenitors. Caspase-mediated cleavage of GATA-1 may therefore represent an important negative control mechanism in erythropoiesis.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Catania, Ist Patol Gen, I-95124 Catania, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06122 Perugia, Italy	Jefferson University; University of Catania; Istituto Superiore di Sanita (ISS); University of Perugia	De Maria, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	rdemaria@lac.jci.tju.edu	De Maria, Ruggero/S-6385-2019; Zeuner, Ann/K-8607-2016; Testa, Ugo/J-6472-2016; Grignani, Francesco/AAC-2565-2022; Bonci, Desiree/K-6488-2016; Alnemri, Emad S/B-4526-2010; Eramo, Adriana/K-6694-2016; Zeuner, Ann/A-8529-2010	De Maria, Ruggero/0000-0003-2255-0583; Testa, Ugo/0000-0001-7900-8942; Bonci, Desiree/0000-0002-2472-5140; Eramo, Adriana/0000-0002-0814-6683; Zeuner, Ann/0000-0002-8295-3715				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis D, 1997, BRIT J RHEUMATOL, V36, P950; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grignani F, 1998, CANCER RES, V58, P14; Gupta P, 1999, LEUKEMIA, V13, P44, DOI 10.1038/sj.leu.2401233; Hasegawa D, 1998, BLOOD, V91, P2793, DOI 10.1182/blood.V91.8.2793.2793_2793_2799; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Krammer P H, 1999, Adv Immunol, V71, P163; KRANTZ SB, 1991, BLOOD, V77, P419; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUSTEN LS, 1995, BLOOD, V85, P989, DOI 10.1182/blood.V85.4.989.bloodjournal854989; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vyas P, 1999, BLOOD, V93, P2867; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	324	332	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					489	493		10.1038/46809	http://dx.doi.org/10.1038/46809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519553				2022-12-28	WOS:000082981200059
J	Schuler, J; Dissmann, M				Schuler, J; Dissmann, M			Heart in the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Krankenhaus Reinickendorf, D-13500 Berlin, Germany		Schuler, J (corresponding author), Krankenhaus Reinickendorf, D-13500 Berlin, Germany.		Schuler, Jochen/J-7892-2012						0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1045	1045		10.1056/NEJM199909303411405	http://dx.doi.org/10.1056/NEJM199909303411405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502594				2022-12-28	WOS:000082880500005
J	Blot, F; Nitenberg, G; Chachaty, E; Raynard, B; Germann, N; Antoun, S; Laplanche, A; Brun-Buisson, C; Tancrede, C				Blot, F; Nitenberg, G; Chachaty, E; Raynard, B; Germann, N; Antoun, S; Laplanche, A; Brun-Buisson, C; Tancrede, C			Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures	LANCET			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; TIP CULTURE; SEPSIS; BACTEREMIA; COMPLICATIONS; MANAGEMENT; INFECTIONS	Background A method of diagnosing catheter-related infection (CRI) without removing the catheter would be useful. An earlier positivity of central compared with peripheral venous-blood cultures may be associated with catheter-related bacteraemia. We evaluated prospectively the differential time to positivity (DTP) of paired blood cultures drawn simultaneously via the catheter hub and from a peripheral venous site. Methods Over a 14-month period in an intensive-care unit of a cancer referral centre, simultaneous hub-blood and peripheral-blood cultures (a mean of two per patient) were obtained from patients with a suspected CRI. According to clinical criteria and quantitative culture of the catheter tip, cases were classified as CRI or sepsis of other origin. At least one pair of hub-blood and peripheral-blood cultures was obtained within 48 h before catheter removal, and we recorded the DTP between hub-blood and peripheral-blood cultures with an automatic device for detection of blood culture positivity. Findings We analysed 93 catheters removed because of suspicion of CRI, in 28 episodes, the same micro-organisms were found in both hub-blood and peripheral-blood cultures. A diagnosis of definite bacteraemic CRI was made in 16 of the 17 patients in whom a positive hub-blood culture was detected at least 2 hours earlier than peripheral-blood culture. About half (9/17) of these episodes occurred in long-term (>30 days) devices. CRI was excluded in ten of the 11 patients with a DTP lower than 2 h. The DTP of paired blood cultures was significantly greater in patients with CRI than in others (p<10(-4)). A cut-off DTP value of 120 min had 91% specificity and 94% sensitivity for the diagnosis of CRI. Three of 17 episodes with only hub-blood culture positive were associated with CRI. Interpretation This prospective study suggests that measurement of the differential time to positivity between hub-blood and peripheral-blood cultures is a simple and reliable tool for in-situ diagnosis of catheter-related sepsis in cancer patients. Further studies are needed to confirm these data for short-term catheters.	Inst Gustave Roussy, Serv Reanimat Polyvalente, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Microbiol Med, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France; Hop Henri Mondor, Serv Reanimat Med, F-94010 Creteil, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Blot, F (corresponding author), Inst Gustave Roussy, Serv Reanimat Polyvalente, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.							ANDREMONT A, 1988, J CLIN MICROBIOL, V26, P2297, DOI 10.1128/JCM.26.11.2297-2299.1988; Archer GL, 1985, INFECT CONTROL, V6, P12; Blot F, 1998, J CLIN MICROBIOL, V36, P105, DOI 10.1128/JCM.36.1.105-109.1998; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CAPDEVILA JA, 1992, EUR J CLIN MICROBIOL, V11, P403, DOI 10.1007/BF01961854; DOUARD MC, 1994, NUTRITION, V10, P397; FLYNN PM, 1987, PEDIATR INFECT DIS J, V6, P729, DOI 10.1097/00006454-198708000-00007; Gransden WR, 1998, CURR OPIN INFECT DIS, V11, P461, DOI 10.1097/00001432-199808000-00012; KHATIB R, 1995, J CLIN MICROBIOL, V33, P816, DOI 10.1128/JCM.33.4.816-820.1995; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MACCABE WR, 1962, ARCH INTERN MED, V110, P847; MERMEL LA, 1998, 38 INT C ANT AG CHEM, pK5; MOYER MA, 1983, ARCH INTERN MED, V143, P66, DOI 10.1001/archinte.143.1.66; Quilici N, 1997, CLIN INFECT DIS, V25, P1066, DOI 10.1086/516090; RAAD II, 1992, DIAGN MICR INFEC DIS, V15, P13, DOI 10.1016/0732-8893(92)90052-U; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RAAD II, 1995, CLIN INFECT DIS, V20, P593, DOI 10.1093/clinids/20.3.593; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHUMAN ES, 1985, AM J SURG, V149, P627, DOI 10.1016/S0002-9610(85)80142-2; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; SiegmanIgra Y, 1997, J CLIN MICROBIOL, V35, P928, DOI 10.1128/JCM.35.4.928-936.1997; Souvenir D, 1998, J CLIN MICROBIOL, V36, P1923, DOI 10.1128/JCM.36.7.1923-1926.1998; WIDMER AF, 1992, ARCH INTERN MED, V152, P1299, DOI 10.1001/archinte.152.6.1299; WING EJ, 1979, ARCH INTERN MED, V139, P482, DOI 10.1001/archinte.139.4.482	25	265	282	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1071	1077		10.1016/S0140-6736(98)11134-0	http://dx.doi.org/10.1016/S0140-6736(98)11134-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509498				2022-12-28	WOS:000082777500012
J	Fekety, R; Byrne, P; Silva, J; Joseph, R; Miller, JM				Fekety, R; Byrne, P; Silva, J; Joseph, R; Miller, JM			The hunt for Clostridium difficile: 21-year follow-up of a stool specimen sent for culture	LANCET			English	Article									Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA; Dept Vet Affairs Med Ctr, Detroit, MI USA; Univ Calif Davis, Sch Med, Deans Off, Sacramento, CA 95817 USA; Ctr Dis Control & Prevent, Anaerobe Lab, Atlanta, GA USA	University of Michigan System; University of Michigan; University of California System; University of California Davis; Centers for Disease Control & Prevention - USA	Fekety, R (corresponding author), 812 Berkshire Rd, Ann Arbor, MI 48104 USA.							RIFKIN GD, 1977, LANCET, V2, P1103; TANG YJ, 1994, MOL CELL PROBE, V8, P463, DOI 10.1006/mcpr.1994.1066	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1115	1116		10.1016/S0140-6736(99)06064-X	http://dx.doi.org/10.1016/S0140-6736(99)06064-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509517				2022-12-28	WOS:000082777500044
J	Goulis, J; Leandro, G; Burroughs, AK				Goulis, J; Leandro, G; Burroughs, AK			Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis	LANCET			English	Article; Proceedings Paper	34th Annual Meeting of the European-Association-for-the-Study-of-the-Liver	APR 08-12, 1999	NAPLES, ITALY	European Assoc Study Liver			PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SHORT-TERM; MULTICENTER TRIAL; CLINICAL-TRIALS; FOLLOW-UP; SURVIVAL; MODEL	Background Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease progression and survival is uncertain. The aim of this study was to clarify the efficacy of UDCA in primary biliary cirrhosis. Methods A systematic review, including the use of metaanalysis, was done for the randomised and switch-over phases of trials comparing UDCA with placebo, obtained from Medline and Embase databases, and from manual searches derived from review articles and abstracts of major international meetings. All trials had more than a mean of 6 months' follow-up and only included patients with primary biliary cirrhosis (PBC) according to established diagnostic criteria. Findings 17 relevant articles were identified: 11 randomised controlled trials, including 1272 patients, and six reports of the switch-over phases. UCDA had a favourable effect on liver biochemistry in most of the studies but not on symptoms or the progression of histological stage; two studies did not assess survival, liver transplantation, or complications of liver disease. Meta-analysis showed no difference between UDCA and placebo in the incidence of death (odds ratio 1.21, 95% CI 0.71-2.04), liver related death (0.72, 0.22-2.32), liver transplantation (1.27, 0.78-2.07), death or liver transplantation (1.26, 0.87-1.82), and in the development of complications of liver disease (1.11, 0.64-1.92). With the primary end point defined by the authors (a combined end point in three studies, and death or liver transplantation in the others) an odds ratio of 1.53 (0.97-2.42) was obtained. Assessment of the switch-over phases, during which there was a longer follow-up, did not change the results of the metaanalysis. Interpretation Published randomised controlled trials of UDCA do not show evidence of therapeutic benefit in PBC and its use as standard therapy needs to be re-examined.	Royal Free Hosp, London NW3 2QG, England; Osped Gastroenterol S De Bellis, IRCCS, Castellana Grotte, Italy	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; IRCCS Saverio de Bellis	Burroughs, AK (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.		Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X; Leandro, Gioacchino/0000-0001-6624-4532				Angulo P, 1999, HEPATOLOGY, V29, P644, DOI 10.1002/hep.510290301; BATTEZZATI PM, 1993, J HEPATOL, V17, P332, DOI 10.1016/S0168-8278(05)80214-4; Beuers U, 1998, HEPATOLOGY, V28, P1449, DOI 10.1002/hep.510280601; Bonnand AM, 1999, HEPATOLOGY, V29, P39, DOI 10.1002/hep.510290140; CARITHERS JR, 1996, GASTROENTEROLOGY, V110, pA1163; COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5; Degott C, 1999, HEPATOLOGY, V29, P1007, DOI 10.1002/hep.510290444; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; DiMario F, 1996, DIGEST DIS SCI, V41, P1108; Eriksson LS, 1997, SCAND J GASTROENTERO, V32, P179, DOI 10.3109/00365529709000190; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Garrido MC, 1996, J CLIN PATHOL, V49, P556, DOI 10.1136/jcp.49.7.556; GLUUD C, 1999, J HEPATOL, V30, pA83; HADZIYANNIS SJ, 1989, HEPATOLOGY, V10, P580; HEATHCOTE EJ, 1994, HEPATOLOGY, V19, P1149, DOI 10.1002/hep.1840190512; HUGHES MD, 1992, STAT MED, V11, P1731, DOI 10.1002/sim.4780111307; HWANG SJ, 1993, J GASTROEN HEPATOL, V8, P217, DOI 10.1111/j.1440-1746.1993.tb01189.x; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; Kilmurry MR, 1996, HEPATOLOGY, V23, P1148; Kim WR, 1998, HEPATOLOGY, V28, P33, DOI 10.1002/hep.510280106; LEUSCHNER U, 1989, GASTROENTEROLOGY, V97, P1268, DOI 10.1016/0016-5085(89)91698-3; Lindor KD, 1997, ANN INTERN MED, V126, P733, DOI 10.7326/0003-4819-126-9-199705010-00010; Lindor KD, 1997, MAYO CLIN PROC, V72, P1137, DOI 10.4065/72.12.1137; Lindor KD, 1996, GASTROENTEROLOGY, V110, P1515, DOI 10.1053/gast.1996.v110.pm8613058; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LINDOR KD, 1997, HEPATOLOGY, V26, pA439; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; PARES A, IN PRESS J HEPATOL; POUPON R, 1987, LANCET, V1, P834; Poupon RE, 1997, GASTROENTEROLOGY, V113, P884, DOI 10.1016/S0016-5085(97)70183-5; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; POUPON RE, 1994, NEW ENGL J MED, V330, P1242; ROBBINS J, 1986, BIOMETRICS, V42, P311; SHAPIRO JM, 1979, GUT, V20, P137, DOI 10.1136/gut.20.2.137; SIMKO V, 1994, AM J GASTROENTEROL, V89, P392; TURNER IB, 1994, J GASTROEN HEPATOL, V9, P162, DOI 10.1111/j.1440-1746.1994.tb01237.x; VUORISTO M, 1995, GASTROENTEROLOGY, V108, P1470, DOI 10.1016/0016-5085(95)90696-7; 1999, DRUG THER B, V37, P30	39	236	247	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1053	1060		10.1016/S0140-6736(98)11293-X	http://dx.doi.org/10.1016/S0140-6736(98)11293-X			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509495				2022-12-28	WOS:000082777500009
J	Bradshaw, DY				Bradshaw, DY			A visit to the doctor	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Bradshaw, DY (corresponding author), 750 E Adams St, Syracuse, NY 13210 USA.	bradshad@mailbox.hscsyr.edu		Bradshaw, Deborah/0000-0002-6047-6129					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					627	628		10.7326/0003-4819-131-8-199910190-00015	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523227				2022-12-28	WOS:000083196600013
J	Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW				Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW			Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT DIAPHRAGM; POSTSYNAPTIC CHANGES; PROLONGED PARALYSIS; ALPHA-BUNGAROTOXIN; VERTEBRATE MUSCLE; TURNOVER RATE; DEGRADATION; SYNAPSE; STABILIZATION	Quantitative fluorescence imaging was used to study the regulation of acetylcholine receptor (AChR) number and density at neuromuscular junctions in Living adult mice. At fully functional synapses, AChRs have a half-life of about 14 days. However, 2 hours after neurotransmission was blocked, the half-life of the AChRs was now Less than a day; the rate was 25 times faster than before. Most of the Lost receptors were not quickly replaced. Direct muscle stimulation or restoration of synaptic transmission inhibited this process. AChRs that were removed from nonfunctional synapses resided for hours in the perijunctional membrane before being Locally internalized. Dispersed AChRs could also reaggregate at the junction once neurotransmission was restored. The rapid and reversible alterations in AChR density at the neuromuscular junction in vivo parallel changes thought to occur in the central nervous system at synapses undergoing potentiation and depression.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Akaaboune, M (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.		Culican, Susan/F-4279-2019	Culican, Susan/0000-0002-0273-4310				ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BRETT RS, 1982, BRAIN RES, V233, P133, DOI 10.1016/0006-8993(82)90935-0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CULICAN SM, UNPUB; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DENNIS MJ, 1974, J PHYSIOL-LONDON, V237, P431, DOI 10.1113/jphysiol.1974.sp010490; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FU DX, 1994, J BIOL CHEM, V269, P26152; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; HARTZELL HC, 1972, J GEN PHYSIOL, V60, P248, DOI 10.1085/jgp.60.3.248; Kurt TL, 1996, J TOXICOL-CLIN TOXIC, V34, P253, DOI 10.3109/15563659609013783; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; Lissin DV, 1999, J NEUROSCI, V19, P1263; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MCMANAMAN JL, 1981, J NEUROSCI, V1, P771, DOI 10.1523/JNEUROSCI.01-07-00771.1981; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; RAMSAY DA, 1992, BRAIN RES, V581, P198, DOI 10.1016/0006-8993(92)90709-I; RAVDIN P, 1977, ANAL BIOCHEM, V80, P585, DOI 10.1016/0003-2697(77)90682-0; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHYNG SL, 1989, J CELL BIOL, V108, P647, DOI 10.1083/jcb.108.2.647; STANLEY EF, 1983, SCIENCE, V222, P67, DOI 10.1126/science.6623057; STYA M, 1984, J NEUROSCI, V4, P70; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2	35	189	189	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					503	507		10.1126/science.286.5439.503	http://dx.doi.org/10.1126/science.286.5439.503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521340				2022-12-28	WOS:000083121200052
J	Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S				Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S			A new primate from the Middle Eocene of Myanmar and the Asian early origin of anthropoids	SCIENCE			English	Article							THAILAND; CHINA	A new genus and species of anthropoid primate, Bahinia pondaungensis gen. et sp. nov., is described from the Yashe Kyitchaung Locality in the Late Middle Eocene Pondaung Formation (Myanmar). it is related to Eosimias, but it is represented by more complete remains. including upper dentition with associated lower jaw fragment. it is interpreted as a new representative of the family Eosimiidae, which corresponds to the sister group of the Amphipithecidae and of all other anthropoids. Eosimiidae are now recorded from three distinct Middle Eocene Localities in Asia, giving support to the hypothesis of an Asian origin of anthropoids.	Univ Montpellier 2, Inst Sci Evolut, F-34095 Montpellier 5, France; Univ Pathein, Dept Geol, Pathein, Myanmar; Dept Mineral Resources, Geol Survey Div, Paleontol Sect, Bangkok 10400, Thailand; Univ Yangon, Dept Geol, Yangon, Myanmar; Minist Def, Off Strateg Studies, Yangon, Myanmar	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Department of Mineral Resources - Thailand; University of Yangon	Ducrocq, S (corresponding author), Univ Montpellier 2, Inst Sci Evolut, Case 064, F-34095 Montpellier 5, France.			chaimanee, yaowalak/0000-0002-8432-3880				Beard K. Christopher, 1998, Bulletin of Carnegie Museum of Natural History, V34, P260; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Chaimanee Y, 1997, NATURE, V385, P429, DOI 10.1038/385429a0; CHOW M, 1961, VERTEBRAT PALASIATIC, V1, P1; DUCROCQ S, 1995, J HUM EVOL, V28, P477, DOI 10.1006/jhev.1995.1035; GINGERICH PD, 1980, AM J PHYS ANTHROPOL, V52, P231; Gingerich Philip D., 1994, P163; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; JAEGER JA, UNPUB; Jaeger JJ, 1998, CR ACAD SCI III-VIE, V321, P953, DOI 10.1016/S0764-4469(99)80010-9; Kay Richard F., 1994, P361; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Rose Kenneth D., 1994, P1; Rossow KD, 1998, VET PATHOL, V35, P1, DOI 10.1177/030098589803500101; RUSSELL DE, 1980, CR ACAD SCI D NAT, V291, P621; RUSSELL DE, 1987, CR ACAD SCI II, V304, P209; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; Simons Elwyn L., 1994, P179; Szalay F.S., 1979, EVOLUTIONARY HIST PR; TONG YS, 1997, PALEONTOLOGICA SIN C, V26, P189	25	104	111	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					528	530		10.1126/science.286.5439.528	http://dx.doi.org/10.1126/science.286.5439.528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521348				2022-12-28	WOS:000083121200060
J	Vance, ML; Mauras, N				Vance, ML; Mauras, N			Growth hormone therapy in adults and children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NATIONAL COOPERATIVE GROWTH; IDIOPATHIC SHORT STATURE; BONE-MINERAL DENSITY; GH-DEFICIENT ADULTS; BODY-COMPOSITION; REPLACEMENT THERAPY; FINAL HEIGHT; HYPOPITUITARY ADULTS; PITUITARY-TUMORS; DOUBLE-BLIND		Univ Virginia, Med Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Nemours Childrens Clin, Jacksonville, FL USA	University of Virginia	Vance, ML (corresponding author), Univ Virginia, Med Ctr, Dept Internal Med, Box 601, Charlottesville, VA 22908 USA.							ALBERTSSONWIKLAND K, 1989, ACTA PAEDIATR SCAND, P35; AlShoumer KAS, 1996, EUR J ENDOCRINOL, V135, P559, DOI 10.1530/eje.0.1350559; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; ATTIE KM, 1995, J PEDIATR-US, V127, P244, DOI 10.1016/S0022-3476(95)70302-0; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; Baumann G, 1997, ACTA PAEDIATR, V86, P33; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bernasconi S, 1997, CLIN ENDOCRINOL, V47, P261, DOI 10.1046/j.1365-2265.1997.2751082.x; BESHYAH SA, 1995, J CLIN ENDOCR METAB, V80, P356, DOI 10.1210/jc.80.2.356; BINGYOU RG, 1993, CALCIFIED TISSUE INT, V52, P183, DOI 10.1007/BF00298715; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; Blethen SL, 1997, DRUG SAFETY, V17, P303, DOI 10.2165/00002018-199717050-00003; Blethen SL, 1997, J CLIN ENDOCR METAB, V82, P418, DOI 10.1210/jc.82.2.418; Blethen SL, 1996, J CLIN ENDOCR METAB, V81, P1704, DOI 10.1210/jc.81.5.1704; BRIDGES NA, 1994, HORM RES, V42, P231, DOI 10.1159/000184198; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; CELNIKER AC, 1989, J CLIN ENDOCR METAB, V68, P469, DOI 10.1210/jcem-68-2-469; CLAYTON PE, 1991, J PEDIATR-US, V118, P226, DOI 10.1016/S0022-3476(05)80487-1; COGAN JD, 1994, J CLIN ENDOCR METAB, V79, P1261, DOI 10.1210/jc.79.5.1261; Cuneo RC, 1998, J CLIN ENDOCR METAB, V83, P107, DOI 10.1210/jc.83.1.107; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; CUNEO RC, 1993, METABOLISM, V42, P1519, DOI 10.1016/0026-0495(93)90145-E; CUNEO RC, 1990, HORM RES, V33, P55, DOI 10.1159/000181585; Cuttler L, 1996, JAMA-J AM MED ASSOC, V276, P531, DOI 10.1001/jama.276.7.531; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; deZegher F, 1996, J CLIN ENDOCR METAB, V81, P1887, DOI 10.1210/jc.81.5.1887; FINE RN, 1995, PEDIATR NEPHROL, V9, P451, DOI 10.1007/BF00866726; FINE RN, 1994, J PEDIATR-US, V124, P374, DOI 10.1016/S0022-3476(94)70358-2; Fine RN, 1996, KIDNEY INT, V49, pS115; FRADKIN JE, 1993, JAMA-J AM MED ASSOC, V270, P2829, DOI 10.1001/jama.270.23.2829; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; GODDARD AD, 1995, NEW ENGL J MED, V333, P1093, DOI 10.1056/NEJM199510263331701; HADDAD SF, 1991, NEUROSURGERY, V29, P509, DOI 10.1227/00006123-199110000-00004; Hansen TB, 1995, CLIN ENDOCRINOL, V43, P689, DOI 10.1111/j.1365-2265.1995.tb00536.x; Hardin DS, 1997, J PEDIATR-US, V131, pS65, DOI 10.1016/S0022-3476(97)70015-5; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; HINTZ RL, 1995, J CLIN ENDOCR METAB, V80, P2298, DOI 10.1210/jc.80.8.2298; Hintz RL, 1999, NEW ENGL J MED, V340, P502, DOI 10.1056/NEJM199902183400702; HOFFMAN DM, 1994, LANCET, V344, P206; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; HokkenKoelega ACS, 1996, KIDNEY INT, V49, pS128; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; JORGENSEN JOL, 1991, ACTA ENDOCRINOL-COP, V125, P449; JORGENSEN JOL, 1989, LANCET, V1, P1221; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; Laursen T, 1997, ENDOCRINOL METAB, V4, P281; LEHMANN ED, 1993, LANCET, V341, P309, DOI 10.1016/0140-6736(93)92664-F; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Lindgren AC, 1997, ACTA PAEDIATR, V86, P60; LIPPE B, 1993, INT CONGR SER, V1014, P77; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; Longobardi S, 1998, CLIN ENDOCRINOL, V48, P137, DOI 10.1046/j.1365-2265.1998.00281.x; LYON AJ, 1985, ARCH DIS CHILD, V60, P932, DOI 10.1136/adc.60.10.932; MacGillivray MH, 1996, J CLIN ENDOCR METAB, V81, P1806, DOI 10.1210/jc.81.5.1806; MAES M, 1994, 11 KAB INT GROWTH ST, P15; MARDH G, 1994, ENDOCRINOLOGY MET SA, V1, P43; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; MARTHA PM, 1992, J CLIN ENDOCR METAB, V74, P336, DOI 10.1210/jc.74.2.336; MAURAS N, 1987, J CLIN ENDOCR METAB, V64, P596, DOI 10.1210/jcem-64-3-596; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; Merimee T., 1996, MODERN ENDOCRINOLOGY, V4; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; MOORE WV, 1992, J PEDIATR-US, V120, P702, DOI 10.1016/S0022-3476(05)80231-8; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; NISHI Y, 1990, ACTA ENDOCRINOL-COP, V122, P267, DOI 10.1530/acta.0.1220267; OHALLORAN DJ, 1993, J CLIN ENDOCR METAB, V76, P1344, DOI 10.1210/jc.76.5.1344; OHTA K, 1992, BIOCHEM BIOPH RES CO, V189, P851, DOI 10.1016/0006-291X(92)92281-2; PARKS JS, 1993, TRENDS ENDOCRIN MET, V4, P81, DOI 10.1016/1043-2760(93)90083-Q; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; PHILLIPS JA, 1987, GROWTH HORMONE BASIC, P11; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; Romano AA, 1996, J PEDIATR-US, V128, pS18, DOI 10.1016/S0022-3476(96)70005-7; ROSE SR, 1988, NEW ENGL J MED, V319, P201, DOI 10.1056/NEJM198807283190403; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSEN T, 1994, ENDOCRINOL METAB, V1, P55; Rosenfeld RG, 1998, J PEDIATR-US, V132, P319, DOI 10.1016/S0022-3476(98)70452-4; ROTENSTEIN D, 1989, J PEDIATR-US, V115, P417, DOI 10.1016/S0022-3476(89)80844-3; RUTHERFORD OM, 1989, ACTA PAEDIATR SCAND, P61; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Seikaly MG, 1997, PEDIATRICS, V100, P879, DOI 10.1542/peds.100.5.879; SMITH WJ, 1993, J CLIN ENDOCR METAB, V77, P1294, DOI 10.1210/jc.77.5.1294; SNEL YEM, 1995, EUR J ENDOCRINOL, V133, P445, DOI 10.1530/eje.0.1330445; STANHOPE R, 1989, ACTA PAEDIATR SCAND, P47; STANHOPE R, 1991, ACTA PAEDIATR SCAND, P47; STANHOPE R, 1991, ARCH DIS CHILD, V66, P1180, DOI 10.1136/adc.66.10.1180; Takahashi Y, 1996, NEW ENGL J MED, V334, P1207; Takahashi Y, 1996, NEW ENGL J MED, V334, P432, DOI 10.1056/NEJM199602153340704; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; Tonshoff B, 1991, Acta Paediatr Scand Suppl, V379, P33; TORRADO C, 1991, J PEDIATR-US, V119, P478, DOI 10.1016/S0022-3476(05)82068-2; TUFFLI GA, 1995, J CLIN ENDOCR METAB, V80, P1416, DOI 10.1210/jc.80.4.1416; Van Es A, 1991, Acta Paediatr Scand Suppl, V379, P42; Veldhuis JD, 1996, J PEDIATR ENDOCR MET, V9, P237; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147	101	180	189	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1206	1216		10.1056/NEJM199910143411607	http://dx.doi.org/10.1056/NEJM199910143411607			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519899				2022-12-28	WOS:000083087400007
J	[Anonymous]				[Anonymous]			Doctors need 5% pay rise just to stand still	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1999	319	7215					1010	1010						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514184				2022-12-28	WOS:000083111700065
J	O'Hanlan, KA				O'Hanlan, KA			Domestic partnership benefits at medical universities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Med Ctr, Palo Alto, CA 94305 USA	Stanford University	O'Hanlan, KA (corresponding author), Stanford Med Ctr, Palo Alto, CA 94305 USA.		O'Hanlan, Katherine/A-4073-2017	O'Hanlan, Katherine/0000-0002-7577-4188				*AM MED WOM ASS, 1993, J AM MED WOMEN ASSOC, V49, P86; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P538; BERSOFF DN, 1991, AM PSYCHOL, V46, P950, DOI 10.1037/0003-066X.46.9.950; BUSH CN, 1991, STANFORD U CAMPUS RE, P1; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; FRIED B, 1992, REPORT SUBCOMMITTEE, P37; KOHN S, 1999, DOMESTIC PARTNER ORG, P120; OHANLAN KA, 1991, FAC SEN STANF U OCT; 1992, TOT COMP NEWS    DEC, P1	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1289	+		10.1001/jama.282.13.1289	http://dx.doi.org/10.1001/jama.282.13.1289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517436	hybrid			2022-12-28	WOS:000082901100041
J	Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y				Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y			The age of the carbonates in martian meteorite ALH84001	SCIENCE			English	Article							PETROLOGIC EVIDENCE; SM-ND; MARS; ORIGIN; DIFFERENTIATION; TEMPERATURE; CHRONOLOGY; RB; SR	The age of secondary carbonate mineralization in the martian meteorite ALH84001 was determined to be 3.90 +/- 0.04 billion years by rubidium-strontium (Rb-Sr) dating and 4.04 +/- 0.10 billion years by Lead-Lead (Pb-Pb) dating. The Rb-Sr and Pb-Pb isochrons are defined by Leachates of a mixture of high-graded carbonate (visually estimated as similar to 5 percent). whitlockite (trace), and orthopyroxene (similar to 95 percent). The carbonate formation age is contemporaneous with a period in martian history when the surface is thought to have had flowing water, but also was undergoing heavy bombardment by meteorites. Therefore, this age does not distinguish between aqueous and impact origins for the carbonates.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Univ Texas, Dept Geol Sci, Austin, TX 78713 USA; Lockheed Engn & Sci Co, Houston, TX 77258 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Texas System; University of Texas Austin; Lockheed Martin	Borg, LE (corresponding author), Univ New Mexico, Inst Meteorit, Albuquerque, NM 87131 USA.		Connelly, James/O-7996-2015					BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Bogard DD, 1999, METEORIT PLANET SCI, V34, P451, DOI 10.1111/j.1945-5100.1999.tb01353.x; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; CARR MH, 1996, WATER MARS, V20, P229; FANNALE FP, 1992, MARS, P1135; Gilmour JD, 1997, METEORIT PLANET SCI, V32, pA48; Gleason JD, 1997, GEOCHIM COSMOCHIM AC, V61, P3503, DOI 10.1016/S0016-7037(97)00173-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; Hartmann W.K., 1981, BASALTIC VOLCANISM T, P1049; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; JAGOUTZ E, 1994, METEORITICS, V29, P478; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; Scott ERD, 1998, METEORIT PLANET SCI, V33, P709, DOI 10.1111/j.1945-5100.1998.tb01677.x; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; TATSUMOTO M, 1973, SCIENCE, V180, P1279, DOI 10.1126/science.180.4092.1279; TRIEMAN AH, 1995, METEORITICS, V30, P294; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Wadhwa M, 1998, METEORIT PLANET SCI, V33, P685, DOI 10.1111/j.1945-5100.1998.tb01674.x; Wadhwa M., 1996, METEORIT PLANET SCI, V31, pA145; Warren PH, 1998, J GEOPHYS RES-PLANET, V103, P16759, DOI 10.1029/98JE01544; YORK D, 1966, CAN J PHYS, V44, P1079, DOI 10.1139/p66-090; [No title captured]; [No title captured]	32	130	134	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					90	94		10.1126/science.286.5437.90	http://dx.doi.org/10.1126/science.286.5437.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506566	Green Submitted			2022-12-28	WOS:000082907400039
J	Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S				Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S			Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEX-III DEFICIENCY; C-OXIDASE DEFICIENCY; SKELETAL-MUSCLE; POINT MUTATION; MYOPATHY; MTDNA; PATIENT; DISEASE; GENOME	Background The mitochondrial myopathies typically affect many organ systems and are associated with mutations in mitochondrial DNA (mtDNA) that are maternally inherited. However, there is also a sporadic form of mitochondrial myopathy in which exercise intolerance is the predominant symptom. We studied the biochemical and molecular characteristics of this sporadic myopathy. Methods We sequenced the mtDNA cytochrome b gene in blood and muscle specimens from five patients with severe exercise intolerance, lactic acidosis in the resting state (in four patients), and biochemical evidence of complex III deficiency. We compared the clinical and molecular features of these patients with those previously described in four other patients with mutations in the cytochrome b gene. Results We found a total of three different nonsense mutations (G15084A, G15168A, and G15723A), one missense mutation (G14846A), and a 24-bp deletion (nucleotides 15498 to 15521) in the cytochrome b gene in the five patients. Each of these mutations impairs the enzymatic function of the cytochrome b protein. In these patients and those previously described, the clinical manifestations included progressive exercise intolerance, proximal limb weakness, and in some cases, attacks of myoglobinuria. There was no maternal inheritance and there were no mutations in tissues other than muscle. The absence of these findings suggests that the disorder is due to somatic mutations in myogenic stem cells after germ-layer differentiation. All the point mutations involved the substitution of adenine for guanine, but all were in different locations. Conclusions The sporadic form of mitochondrial myopathy is associated with somatic mutations in the cytochrome b gene of mtDNA. This myopathy is one cause of the common and often elusive syndrome of exercise intolerance. (N Engl J Med 1999; 341:1037-44.) (C)1999, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, H Houston Merritt Clin Res Ctr Muscular Dystrophy, Dept Neurol, New York, NY 10032 USA; Hosp Valle De Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Spain; UCL, Inst Neurol, London, England; Tech Univ Dresden, Klinikum Carl Gustav Carus, Neurol Klin, D-8027 Dresden, Germany; Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Genoa, Italy; NINDS, NIH, Bethesda, MD 20892 USA; Uppsala Univ, Dept Biochem, Uppsala, Sweden; Ottawa Hosp, Dept Lab Med, Ottawa, ON, Canada	Columbia University; Hospital Universitari Vall d'Hebron; University of London; University College London; Technische Universitat Dresden; University of Genoa; IRCCS Istituto Giannina Gaslini; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Uppsala University; University of Ottawa; Ottawa Hospital Research Institute	DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	sd12@columbia.edu	Hanna, Michael G/B-1995-2009; Bruno, Claudio/A-3148-2015	Bruno, Claudio/0000-0002-3426-2901; ANDREU, antonio luis/0000-0002-3936-3234; Hanna, Michael/0000-0003-0825-4075; Pallotti, Francesco/0000-0001-9946-8516	NICHD NIH HHS [P01HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, P01NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andreu AL, 1999, MOL GENET METAB, V67, P49, DOI 10.1006/mgme.1999.2843; Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444; Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DiMauro S, 1997, MOL GENETIC BASIS NE, P201; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kennaway N. G., 1998, MOL GENET METAB, V63, P49; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; MIRANDA AF, 1986, METHOD ENZYMOL, V119, P619; Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617; REICHMANN H, 1986, ARCH NEUROL-CHICAGO, V43, P957, DOI 10.1001/archneur.1986.00520090081024; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; SCIACCO M, 1994, HUM MOL GENET, V3, P687; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Weber K, 1997, AM J HUM GENET, V60, P373	28	313	321	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1037	1044		10.1056/NEJM199909303411404	http://dx.doi.org/10.1056/NEJM199909303411404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502593				2022-12-28	WOS:000082880500004
J	Fauci, AS				Fauci, AS			The AIDS epidemic - Considerations for the 21st century	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTION; UNITED-STATES; TRANSMISSION; RESERVOIR; MORTALITY		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1999, WORLD HLTH REPORT 19; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Coates TJ, 1998, SCI AM, V279, P96, DOI 10.1038/scientificamerican0798-96; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper DA, 1999, NAT MED, V5, P611, DOI 10.1038/9454; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dore GJ, 1998, AIDS, V12, P2354; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Elias CJ, 1996, AIDS, V10, pS43; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Folkers GK, 1998, NAT MED, V4, P491, DOI 10.1038/nm0598supp-491; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Kilbourne E.D., 1987, INFLUENZA, P3; Kramer Larry, 1994, REPORTS HOLOCAUST ST; Krause RM, 1998, BIOMED RES REP, P1; Mann JM, 1997, HASTINGS CENT REP, V27, P6, DOI 10.2307/3528660; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 1999, LANCET, V353, P766, DOI 10.1016/S0140-6736(99)90028-4; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Quinn TC, 1998, BIOMED RES REP, P327; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SABA J, 1999, RESULTS PETRA INTERV; SWEENEY PA, 1997, INT C ANT AG CHEM TO; *UN, 1999, DEM IMP HIV AIDS; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Weiss RA, 1999, NATURE, V397, P385, DOI 10.1038/17008; *WHO, 1998, AIDS EP UPD DEC 1998; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; World Health Organization, 1999, REM OBST HLTH DEV; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 1998, MMWR MORB MORTAL WKL, P47	48	188	195	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1046	1050		10.1056/NEJM199909303411406	http://dx.doi.org/10.1056/NEJM199909303411406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502595				2022-12-28	WOS:000082880500006
J	Rauskolb, C; Correla, T; Irvine, KD				Rauskolb, C; Correla, T; Irvine, KD			Fringe-dependent separation of dorsal and ventral cells in the Drosophila wing	NATURE			English	Article							IMAGINAL DISC; NOTCH; LIMB; COMPARTMENTALIZATION; EXPRESSION; ACTIVATION; BOUNDARY; RECEPTOR; PROTEIN; SERRATE	The separation of cells into populations that do not intermix, termed compartments, is a fundamental organizing principle during development(1-5). Dorsal-ventral compartmentalization of the Drosophila wing is regulated downstream of the apterous (np) gene, which encodes a transcription factor that specifies dorsal wing fate(6-8). fringe (fng) is normally expressed by dorsal cells downstream of ap(9); here we show that fng plays a key role in dorsal-ventral compartmentalization. Loss of fng function causes dorsal cells to violate the compartment boundary, and ectopic expression of the Fng protein causes ventral cells to violate the compartment boundary. Fng modulates signalling through the Notch receptor(10,11). Notch and its ligands are essential for formation of the dorsal-ventral compartment border, and repositioning the stripe of Notch activation that is normally established there appears to reposition the compartment border. However, activation of Notch does not itself confer either dorsal or ventral cell location, and fng can influence compartmentalization even within regions of ubiquitous Notch activation. Our results indicate that the primary mechanism by which fng establishes a compartment border is by positioning a stripe of Notch activation, but also that fng may exert additional influences on compartmentalization.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu						Altabef M, 1997, DEVELOPMENT, V124, P4547; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Ito K, 1997, DEVELOPMENT, V124, P761; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1999, DEVELOPMENT, V126, P2441; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Michaud JL, 1997, DEVELOPMENT, V124, P1453; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; XU T, 1993, DEVELOPMENT, V117, P1223	29	90	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					476	480		10.1038/46786	http://dx.doi.org/10.1038/46786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519550				2022-12-28	WOS:000082981200056
J	Mercier, JC; Thebaud, B; Onody, P; Storme, L; van Overmeire, B; Breart, G; Dehan, M; Gold, F; Doyon, F; Pons, G; Dinh-Xuan, AT; Nafa, S; de Clety, SC; Paris-Llado, J; Dreyfuss, JF; Truffert, P; Storme, L; Lequien, P; Lacaze, T; Zupan, V; Magny, JF; Kassis, M; Voyer, M; Danan, C; Dassieu, G; Devaux, AM; Blanc, T; Ensel, P; Wroblewski, I; Marey, C; Andrini, P; Pinquier, D; Farnoux, C; Beaufils, F; Pauchard, JY; Guillermet-Fromentin, C; Menget, A; Desfreres, L; Jarreau, PH; Moriette, G; Lanchier-Quiennec, C; Le Pommelet, C; Durand, P; Matis, J; Simeoni, U; Francoise, M; Germain, JF; Gouyon, JB; Debillon, T; Roze, JC; Morville, P; Bloom, MC; Lelong-Tissier, MC; Fries, F; Laloum, D; Guillois, B; Hamon, I; Cortey, A; Hascoet, JM; Rayet, I; Teyssier, G; Cantagrel, S; Chamboux-Cheliakine, C; Laugier, J; Mansir, T; Galperine, I; Demarquez, JL; Jouvet, P; Jugie, M; Hubert, P; Soupre, D; Sizun, J; Huon, C; Oriot, D; Picaud, JC; Claris, O; Bourgeois, J; Putet, G; van Overmeire, B; de Groote, K; van Reempts, P; Lecoutere, D; Clerckx, A; Blum, D; de Clety, SC; Lombet, J; Rigo, J; Vanhaesebrouck, P; Mouraux, T; Haumont, D; Grossman, D				Mercier, JC; Thebaud, B; Onody, P; Storme, L; van Overmeire, B; Breart, G; Dehan, M; Gold, F; Doyon, F; Pons, G; Dinh-Xuan, AT; Nafa, S; de Clety, SC; Paris-Llado, J; Dreyfuss, JF; Truffert, P; Storme, L; Lequien, P; Lacaze, T; Zupan, V; Magny, JF; Kassis, M; Voyer, M; Danan, C; Dassieu, G; Devaux, AM; Blanc, T; Ensel, P; Wroblewski, I; Marey, C; Andrini, P; Pinquier, D; Farnoux, C; Beaufils, F; Pauchard, JY; Guillermet-Fromentin, C; Menget, A; Desfreres, L; Jarreau, PH; Moriette, G; Lanchier-Quiennec, C; Le Pommelet, C; Durand, P; Matis, J; Simeoni, U; Francoise, M; Germain, JF; Gouyon, JB; Debillon, T; Roze, JC; Morville, P; Bloom, MC; Lelong-Tissier, MC; Fries, F; Laloum, D; Guillois, B; Hamon, I; Cortey, A; Hascoet, JM; Rayet, I; Teyssier, G; Cantagrel, S; Chamboux-Cheliakine, C; Laugier, J; Mansir, T; Galperine, I; Demarquez, JL; Jouvet, P; Jugie, M; Hubert, P; Soupre, D; Sizun, J; Huon, C; Oriot, D; Picaud, JC; Claris, O; Bourgeois, J; Putet, G; van Overmeire, B; de Groote, K; van Reempts, P; Lecoutere, D; Clerckx, A; Blum, D; de Clety, SC; Lombet, J; Rigo, J; Vanhaesebrouck, P; Mouraux, T; Haumont, D; Grossman, D		Franco-Belgium Collaborative NO Tria	Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION; DISTRESS SYNDROME; PRETERM INFANTS; DOSE-RESPONSE; NEWBORN; OXYGENATION; MULTICENTER; DISEASE	Background Inhaled nitric oxide improves oxygenation in severely hypoxaemic term neonates, which lessens the need for extracorporeal-membrane oxygenation. Improvement in other relevant outcomes remains unknown, and safety of inhaled nitric oxide is uncertain In preterm neonates. We did a randomised controlled trial to assess use of inhaled nitric oxide in preterm and near-term neonates. Methods We randomly assigned 204 preterm (<33 weeks) and near-term (greater than or equal to 33 weeks) neonates with oxygenation indices from 12.5 to 30.0 and 15 to 40, respectively, 10 parts per million (ppm) inhaled nitric oxide (n=105) or control ventilation therapy without nitric oxide (n=99). The primary endpoint was the oxygenation index at 2 h. Analysis was done by intention to treat. Findings 12 neonates were excluded, leaving 97 (45 preterm) in the nitric-oxide group and 95 (40 preterm) in the control group. The decline in oxygenation index at 2 h was greater in the nitric-oxide group than in the control group (IQR 6.2 [median 8.4] vs -2.9 [12.4], p=0.005), but was significant only in near-term neonates (p=0.03). Survivors assigned nitric oxide spent fewer days on mechanical ventilation and in the neonatal intensive-care unit, but this was also significant only in near-term neonates (6 [3] vs 7 [3] days, p=0.05, and 9 [6] vs 12 [9] days, p=0.02, respectively). Interpretation Low-dose inhaled nitric oxide early in the course of neonatal respiratory failure improves oxygenation and shortens duration of mechanical ventilation and the length of stay in intensive care. Inhaled nitric oxide was not, however, significantly beneficial in preterm neonates.	Hop Robert Debre, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Mercier, JC (corresponding author), Hop Robert Debre, 48 Blvd Serurier, F-75019 Paris, France.		SIMEONI, Umberto/AAQ-1870-2021; Simeoni, Umberto/GRO-6971-2022; Rozé, Jean-Christophe/AAS-1314-2021; DINH-XUAN, Anh Tuan/A-9691-2008; Debillon, Thierry/M-6929-2014; Jouvet, Philippe A/H-3293-2018	SIMEONI, Umberto/0000-0003-0730-9337; Simeoni, Umberto/0000-0003-0730-9337; DINH-XUAN, Anh Tuan/0000-0001-8651-5176; Jouvet, Philippe A/0000-0001-5684-3398				BARRINGTON KJ, 1999, COCHRANE LIB; Cheung PY, 1998, J PEDIATR-US, V133, P735, DOI 10.1016/S0022-3476(98)70142-8; Christou H, 1998, PEDIATRICS, V102, P1390, DOI 10.1542/peds.102.6.1390; Davidson D, 1998, PEDIATRICS, V101, P325, DOI 10.1542/peds.101.3.325; Day RW, 1996, PEDIATRICS, V98, P698; FINER NN, 1994, J PEDIATR-US, V124, P302, DOI 10.1016/S0022-3476(94)70324-8; FINER NN, 1999, COCHRANE LIB; Goldman AP, 1996, PEDIATRICS, V98, P706; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Kinsella JP, 1997, PEDIATR RES, V41, P457, DOI 10.1203/00006450-199704000-00002; Kinsella JP, 1997, J PEDIATR-US, V131, P55, DOI 10.1016/S0022-3476(97)70124-0; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; KINSELLA JP, 1995, J PEDIATR-US, V126, P853, DOI 10.1016/S0022-3476(95)70197-4; Mercier JC, 1998, EUR J PEDIATR, V157, P747, DOI 10.1007/s004310050928; PALMER RMJ, 1987, NATURE, V327, P523; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; Skimming JW, 1997, J PEDIATR-US, V130, P225, DOI 10.1016/S0022-3476(97)70347-0; Steinhorn RH, 1997, J PEDIATR-US, V130, P417, DOI 10.1016/S0022-3476(97)70203-8; Stork E, 1997, NEW ENGL J MED, V336, P597; Subhedar NV, 1997, ARCH DIS CHILD-FETAL, V77, pF185, DOI 10.1136/fn.77.3.F185; Subhedar NV, 1997, ARCH DIS CHILD-FETAL, V77, pF191, DOI 10.1136/fn.77.3.F191; VanMeurs KP, 1997, PEDIATR PULM, V24, P319; WALTHER FJ, 1992, PEDIATRICS, V90, P899; Wessel DL, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e7	27	110	114	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1066	1071						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509497				2022-12-28	WOS:000082777500011
J	Leevers, SJ				Leevers, SJ			Perspectives: Cell biology - All creatures great and small	SCIENCE			English	Editorial Material							GROWTH; DIVISION; KINASE		Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London	Leevers, SJ (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1P 8BT, England.	sallyl@ludwig.ucLac.uk						Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Galloni M, 1999, DEVELOPMENT, V126, P2365; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Stocker H., COMMUNICATION; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Verdu J., COMMUNICATION; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3	13	17	18	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2082	2083		10.1126/science.285.5436.2082	http://dx.doi.org/10.1126/science.285.5436.2082			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523207				2022-12-28	WOS:000082734300032
J	Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC				Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC			Dystrophin expression in the mdx mouse restored by stem cell transplantation	NATURE			English	Article							GENE-THERAPY; ENDOTHELIAL-CELLS; NUCLEAR DOMAINS; SKELETAL-MUSCLE; FULL-LENGTH; MICE; MARROW; BONE; INJECTION; MYOBLASTS	The development of cell or gene therapies for diseases involving cells that are widely distributed throughout the body has been severely hampered by the inability to achieve the disseminated delivery of cells or genes to the affected tissues or organ(1). Here we report the results of bone marrow transplantation studies in the mdx mouse, an animal model of Duchenne's muscular dystrophy(2), which indicate that the intravenous injection of either normal haematopoietic stem cells or a novel population of muscle-derived stem cells into irradiated animals results in the reconstitution of the haematopoietic compartment of the transplanted recipients, the incorporation of donor-derived nuclei into muscle, and the partial restoration of dystrophin expression in the affected muscle. These results suggest that the transplantation of different stem cell populations, using the procedures of bone marrow transplantation, might provide an unanticipated avenue for treating muscular dystrophy as well as other diseases where the systemic delivery of therapeutic cells to sites throughout the body is critical. Our studies also suggest that the inherent developmental potential of stem cells isolated from diverse tissues or organs may be more similar than previously anticipated.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mulligan, RC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.	kunkel@rascal.med.harvard.edu; mulligan@rascal.med.harvard.edu	Ahmad Khan, Mohammad Kalim/AAA-2751-2022; Gussoni, Emanuela/AAL-6150-2021	Ahmad Khan, Mohammad Kalim/0000-0002-8004-1448; Gussoni, Emanuela/0000-0002-9915-3677				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baroffio A, 1995, DIFFERENTIATION, V59, P259, DOI 10.1046/j.1432-0436.1995.5940259.x; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; Gussoni E, 1997, NAT MED, V3, P970, DOI 10.1038/nm0997-970; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Saito T, 1995, Tissue Eng, V1, P327, DOI 10.1089/ten.1995.1.327; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404	29	1441	1638	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					390	394		10.1038/43919	http://dx.doi.org/10.1038/43919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517639				2022-12-28	WOS:000082822600055
J	Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC				Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC			Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak	LANCET			English	Article							NEUROGENIC PULMONARY-EDEMA; POLYMERASE CHAIN-REACTION; JAPANESE ENCEPHALITIS; ENZYME-IMMUNOASSAY; RAPID DIAGNOSIS; MYOCARDITIS; VIRUS; ENCEPHALOMYELITIS; IDENTIFICATION; SAMPLES	Background In mid-1997, several children died in Sarawak, Malaysia,during an epidemic of enterovirus-71 (EV71) hand, foot, and mouth disease. The children who died had a febrile illness that rapidly progressed to cardiopulmonary failure and the cause was not satisfactorily resolved. We describe the isolation and identification of a subgenus B adenovirus from the children who died. Methods We studied two groups of children presenting to Sibu Hospital from April 14 to Sept 30, 1997. For children who died, the inclusion criterion was death after febrile illness, and for those who did not die it was acute flaccid paralysis (AFP). Serum and cerebrospinal fluid samples were tested for IgM antibodies to Japanese encephalitis and dengue viruses. Viruses isolated were identified by immunofluorescence, reverse-transcriptase PCR, or PCR and DNA sequencing. Findings Enterovirus was isolated in three (19%) of 16 children who died and in none of the eight surviving children with AFP. However, an agent that was initially difficult to identify was found in ten (63%) children who died and five (63%) surviving children who had AFP. The agents isolated from ten (66.7%) of these 15 children were eventually identified as adenoviruses and were isolated mainly from clinically important sterile sites or tissues. All the enterovirus positive children who died had this second agent. Interpretation Our data raises doubts that EV71 was the only aetiological agent in these deaths.	Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia; Sibu Hosp, Sibu, Sarawak, Malaysia	University of Malaysia Sarawak	Cardosa, MJ (corresponding author), Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia.	jcardosa@mailhost.unimas.my	Cardosa, Mary Jane/A-3611-2009					ALLARD A, 1990, J CLIN MICROBIOL, V28, P2659, DOI 10.1128/JCM.28.12.2659-2667.1990; [Anonymous], 1997, Wkly Epidemiol Rec, V72, P211; BOWLES NE, 1986, LANCET, V1, P1120; BRANDON F. B., 1962, ADVANCES VIRUS RES, V9, P157; CARDOSA MJ, 1995, CLIN DIAGN VIROL, V3, P343, DOI 10.1016/0928-0197(94)00049-Z; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; Kidd AH, 1996, J CLIN MICROBIOL, V34, P622, DOI 10.1128/JCM.34.3.622-627.1996; Libby P, 1997, CIRCULATION, V95, P551, DOI 10.1161/01.CIR.95.3.551; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; Romero Jose R., 1993, P401; Solomon T, 1998, J CLIN MICROBIOL, V36, P2030, DOI 10.1128/JCM.36.7.2030-2034.1998; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P184; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	18	106	116	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					987	991		10.1016/S0140-6736(98)11032-2	http://dx.doi.org/10.1016/S0140-6736(98)11032-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501361	Green Accepted			2022-12-28	WOS:000082596000012
J	Brand, DA; Kliger, AS				Brand, DA; Kliger, AS			Planning for a kidney transplant - Is my doctor listening?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL DECISION-ANALYSIS; EXPECTED UTILITY-THEORY; UNRELATED DONORS; HEALTH OUTCOMES; PRIMER; EXPERIENCE; PREFERENCES		New York Med Coll, Ctr Primary Care Educ & Res, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	New York Medical College; New York Medical College; Yale University	Brand, DA (corresponding author), New York Med Coll, Ctr Primary Care Educ & Res, 600 Munger Pavil, Valhalla, NY 10595 USA.		Kliger, Alan/AAN-6653-2021					Baron J, 1996, MED DECIS MAKING, V16, P7, DOI 10.1177/0272989X9601600103; Brand DA, 1998, MED DECIS MAKING, V18, P249, DOI 10.1177/0272989X9801800301; BRETT AS, 1981, NEW ENGL J MED, V305, P1150, DOI 10.1056/NEJM198111053051911; Buckingham JK, 1996, MED DECIS MAKING, V16, P335; Choukroun G, 1995, J AM SOC NEPHROL, V6, P1634; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cohen BJ, 1996, MED DECIS MAKING, V16, P1, DOI 10.1177/0272989X9601600101; D'Alessandro AM, 1998, SURGERY, V124, P604, DOI 10.1067/msy.1998.91482; DALESSANDRO AM, 1995, ANN SURG, V222, P353, DOI 10.1097/00000658-199509000-00012; David I, 1998, MED DECIS MAKING, V18, P347, DOI 10.1177/0272989X9801800313; Detsky AS, 1997, MED DECIS MAKING, V17, P126, DOI 10.1177/0272989X9701700202; Detsky AS, 1997, MED DECIS MAKING, V17, P123, DOI 10.1177/0272989X9701700201; Douard J, 1996, MED DECIS MAKING, V16, P10, DOI 10.1177/0272989X9601600105; Eeckhoudt L, 1996, MED DECIS MAKING, V16, P12, DOI 10.1177/0272989X9601600106; FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Hornberger J, 1996, MED CARE, V34, pDS23; HORNBERGER JC, 1992, J CLIN EPIDEMIOL, V45, P505, DOI 10.1016/0895-4356(92)90099-9; Krahn MD, 1997, MED DECIS MAKING, V17, P142, DOI 10.1177/0272989X9701700204; Lenert LA, 1998, MED DECIS MAKING, V18, P76, DOI 10.1177/0272989X9801800115; Lowell JA, 1996, SURGERY, V119, P538, DOI 10.1016/S0039-6060(96)80264-9; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; Naimark D, 1997, MED DECIS MAKING, V17, P152, DOI 10.1177/0272989X9701700205; Nease RF, 1996, MED DECIS MAKING, V16, P399, DOI 10.1177/0272989X9601600410; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; RANSOHOFF DF, 1976, YALE J BIOL MED, V49, P165; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; SCHWARTZ WB, 1979, NEW ENGL J MED, V300, P556, DOI 10.1056/NEJM197903083001011; Shaffer D, 1998, ARCH SURG-CHICAGO, V133, P426, DOI 10.1001/archsurg.133.4.426; Sox HC, 1988, MED DECISION MAKING; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; *TREEAG SOFTW INC, 1996, DEC AN TREEAG COMP S; *UN ORG SHAR, 1997, TRANSPL FACTS STAT; Weinstein MC, 1980, CLIN DECISION ANAL; Wu G, 1996, MED DECIS MAKING, V16, P9, DOI 10.1177/0272989X9601600104	36	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					691	694		10.1001/jama.282.7.691	http://dx.doi.org/10.1001/jama.282.7.691			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517725	Bronze			2022-12-28	WOS:000082033700031
J	Leshner, AI				Leshner, AI			Science-based views of drug addiction and its treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-MEDICATION HYPOTHESIS; ABUSE TREATMENT; FOLLOW-UP; DEPENDENCE; DISORDERS; HEALTH		NIDA, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Leshner, AI (corresponding author), 6001 Execut Blvd,Room 5274,MSC9581, Bethesda, MD 20892 USA.	leshner@nih.gov						Adger H, 1999, PEDIATRICS, V103, P1083; Alterman AI, 1998, PSYCHOL ADDICT BEHAV, V12, P233; *AM FAM PHYS, 1994, MON AM FAM PHYS; American Psychiatric Association, 1995, PRACT GUID TREATM PA; [Anonymous], 1998, JAMA, V280, P1936; Ball J.C., 2012, EFFECTIVENESS METHAD; Drake RE, 1998, SCHIZOPHRENIA BULL, V24, P589, DOI 10.1093/oxfordjournals.schbul.a033351; FLEMING MF, 1992, TXB PRIMARY CARE MED, P25; Friedmann PD, 1998, JAMA-J AM MED ASSOC, V279, P1227, DOI 10.1001/jama.279.15.1227; Goldstein A., 1994, ADDICTION BIOL DRUG; Hubbard RL, 1997, PSYCHOL ADDICT BEHAV, V11, P261, DOI 10.1037/0893-164X.11.4.261; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Kleber HD, 1996, PRIM PSYCHIAT, V1, P42; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; Metzger DS, 1999, PUBLIC HEALTH, V113, P97; National Institute on Drug Abuse, 1999, NIH PUBL; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OBRIEN CP, 1997, HOSP PRACTICE SPECIA; Salomon N, 1999, J SUBST ABUSE TREAT, V16, P229, DOI 10.1016/S0740-5472(98)00033-6; Simpson DD, 1997, PSYCHOL ADDICT BEHAV, V11, P294, DOI 10.1037/0893-164X.11.4.294; SIMPSON DD, 1997, TREATING DRUG ABUSER, P41; Weisner C, 1995, HEALTH SERV RES, V30, P707	26	111	111	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1314	1316		10.1001/jama.282.14.1314	http://dx.doi.org/10.1001/jama.282.14.1314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243MB	10527162				2022-12-28	WOS:000083000800001
J	Hay, EM; Paterson, SM; Lewis, M; Hosie, G; Croft, P				Hay, EM; Paterson, SM; Lewis, M; Hosie, G; Croft, P			Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care	BRITISH MEDICAL JOURNAL			English	Article							HUMERAL EPICONDYLITIS; GENERAL-PRACTICE; EFFICACY	Objective To compare the clinical effectiveness of local corticosteroid injection, standard non-steroidal anti-inflammatory drugs, and simple analgesics for the early treatment of lateral epicondylitis in primary care, Design Multicentre pragmatic randomised controlled trial. Setting 23 general practices in North Staffordshire and South Cheshire. Participants 164 patients aged 18-70 years presenting with a new episode of lateral epicondylitis. Interventions Local injection of 20 mg methylprednisolone plus lignocaine, naproxen 500 mg twice daily Ibr two weeks, or placebo tablets. All participants received a standard advice sheer and co-codamol as required. Main outcome measures Participants' global assessment of improvement (five point scale) at four weeks. Pain,function, and "main complaint" measured on 10 point Likert scales at 4 weeks, 6 months, and 12 months Results Over 2 years,53 subjects cz ere randomised to injection, 53 to naproxen, and 58 to placebo. Prognostic variables were similar between groups at baseline. At 4 weeks, 48 patients (92%) in the injection group were completely better or improved compared with 30 (57%) in the naproxen group (P < 0.001) and 28 (50%) in the placebo group (P < 0.001). At 12 months, 43 patients (84%) in the injection group had pain scores less than or equal to 3 compared with 45 (85%) in the naproxen group and 44 (82%) in the placebo group (P > 0.05), Conclusions Early local corticosteroid. injection is effective for lateral epicondylitis. Outcome at one year was good in all groups, and effective early treatment does not seem to influence this.	Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England; Keele Univ, Postgrad Med Sch, Primary Care Sci Res Ctr, Stoke On Trent ST4 7QB, Staffs, England	Keele University	Hay, EM (corresponding author), Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England.							Assendelft WJJ, 1996, BRIT J GEN PRACT, V46, P209; BEURSKENS AJ, 1995, LANCET, V346, P1596, DOI 10.1016/S0140-6736(95)91930-9; CHARD MD, 1989, BRIT J RHEUMATOL, V28, P186; Foy R, 1998, BRIT MED J, V317, P1168, DOI 10.1136/bmj.317.7167.1168; Halle J S, 1986, J Orthop Sports Phys Ther, V8, P62; HAMILTON PG, 1986, J ROY COLL GEN PRACT, V36, P464; KIVI P, 1983, SCAND J REHABIL MED, V15, P37; LABELLE H, 1992, J BONE JOINT SURG BR, V74, P646, DOI 10.1302/0301-620X.74B5.1388172; Labelle H, 1997, ARCH FAM MED, V6, P257, DOI 10.1001/archfami.6.3.257; LANYON P, 1995, ANN RHEUM DIS, V54, P735, DOI 10.1136/ard.54.9.735; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MITCHELL RI, 1990, SPINE, V15, P514, DOI 10.1097/00007632-199006000-00016; STRATFORD P, 1987, Physiotherapy Canada, V39, P250; STULL PA, 1986, CLIN THER, V9, P62	14	182	187	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					964	968		10.1136/bmj.319.7215.964	http://dx.doi.org/10.1136/bmj.319.7215.964			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514160	Bronze, Green Published			2022-12-28	WOS:000083111700027
J	Prut, Y; Fetz, EE				Prut, Y; Fetz, EE			Primate spinal interneurons show pre-movement instructed delay activity	NATURE			English	Article							PREMOTOR CORTEX; MOTOR CORTEX; CORTICOSPINAL PROJECTIONS; INTENDED DIRECTION; WRIST MOVEMENTS; REACHING TASK; FRONTAL-LOBE; MONKEY; AREAS; FOREPERIOD	Preparatory changes in neural activity before the execution of a movement have been documented in tasks that involve an instructed delay period (an interval between a transient instruction cue and a subsequently triggered movement). Such preparatory activity occurs in many motor centres in the brain, including the primary motor cortex(1-6), premotor cortex(7-9), supplementary motor area(6,10,11) and basal ganglia(6,12,13). Activity during the instructed delay period reflects movement planning, as it correlates with parameters of the cue and the subsequent movement (such as direction and extent(5,6,9)), although it occurs well before muscle activity. How such delay-period activity shapes the ensuring motor action remains unknown. Here we show that spinal interneurons also exhibit early pre-movement delay activity that often differs from their responses during the subsequent muscle activity. This delay activity resembles the set-related activity found in various supraspinal areas, indicating that movement preparation may occur simultaneously over widely distributed regions, including spinal levels. Our results also suggest that two processes occur in the spinal circuitry during this delay period: the motor network is primed with rate changes in the same direction as subsequent movement-related activity; and a superimposed global inhibition suppresses the expression of this activity in muscles.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Prut, Y (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357330, Seattle, WA 98195 USA.							ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1987, EXP BRAIN RES, V67, P623; Baumgartner C, 1996, NEUROLOGY, V46, P753, DOI 10.1212/WNL.46.3.753; BONNET M, 1991, ELECTROEN CLIN NEURO, V81, P135, DOI 10.1016/0168-5597(91)90007-K; BRUNIA CHM, 1982, PSYCHOPHYSIOLOGY, V19, P63, DOI 10.1111/j.1469-8986.1982.tb02600.x; BURKE D, 1980, J PHYSIOL-LONDON, V306, P337, DOI 10.1113/jphysiol.1980.sp013400; DUM RP, 1991, J NEUROSCI, V11, P667; GEORGOPOULOS AP, 1989, EXP BRAIN RES, V75, P183; GERILOVSKY L, 1983, ELECTROEN CLIN NEURO, V56, P487, DOI 10.1016/0013-4694(83)90233-X; HE SQ, 1993, J NEUROSCI, V13, P952; JAEGER D, 1993, EXP BRAIN RES, V95, P51; KOMIYAMA T, 1990, EXP BRAIN RES, V79, P357, DOI 10.1007/BF00608245; KUBOTA K, 1979, BRAIN RES, V168, P435, DOI 10.1016/0006-8993(79)90189-6; KURATA K, 1993, J NEUROPHYSIOL, V69, P187, DOI 10.1152/jn.1993.69.1.187; KURATA K, 1988, EXP BRAIN RES, V69, P327; KUYPERS HGJ, 1970, BRAIN RES, V24, P29, DOI 10.1016/0006-8993(70)90272-6; MOLL L, 1977, SCIENCE, V198, P317, DOI 10.1126/science.410103; MURRAY EA, 1981, J COMP NEUROL, V195, P339, DOI 10.1002/cne.901950212; Perlmutter SI, 1998, J NEUROPHYSIOL, V80, P2475, DOI 10.1152/jn.1998.80.5.2475; REQUIN J, 1977, ATTENTION PERFORM, V6, P139; RIEHLE A, 1995, BEHAV BRAIN RES, V70, P1, DOI 10.1016/0166-4328(94)00180-N; Sawaguchi T, 1996, J NEUROPHYSIOL, V75, P2150, DOI 10.1152/jn.1996.75.5.2150; TANJI J, 1976, J NEUROPHYSIOL, V39, P1062, DOI 10.1152/jn.1976.39.5.1062; TANJI J, 1980, J NEUROPHYSIOL, V43, P60, DOI 10.1152/jn.1980.43.1.60; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; TOYOSHIMA K, 1982, J HIRNFORSCH, V23, P257; WEINRICH M, 1982, J NEUROSCI, V2, P1329; WISE SP, 1986, PROG BRAIN RES, V64, P117	29	169	171	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					590	594		10.1038/44145	http://dx.doi.org/10.1038/44145			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524626				2022-12-28	WOS:000083054900051
J	Schneider, JS; Levin, S				Schneider, JS; Levin, S			Uneasy partners: The lesbian and gay health care community and the AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NYU, Sch Med, New York, NY 10012 USA; Access Consulting Int Inc, Washington, DC USA	New York University	Schneider, JS (corresponding author), NYU, Sch Med, New York, NY 10012 USA.							*ACCR COUNC GRAD M, 1999, I REV REQ; *AM AC FAM PHYS, 1999, COMP AAFP POS SEL HL; *AM MED ASS, 1982, P AM MED ASS HOUS DE, V2, P579; *AM MED ASS, 1992, P AM MED ASS HOUS DE, V1, P151; *AM MED ASS, 1999, CULT COMP COMP; *AM MED ASS, 1989, DEL HDB; *AM MED ASS, 1999, POL COMP; *AM MED ASS, 1990, P AM MED ASS HOUS DE, V1, P276; *AM MED ASS, 1998, POLICY COMPENDIUM; *AM MED ASS, 1998, POL COMP; BEACH RK, 1993, PEDIATRICS, V92, P631; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; JONES RJ, 1982, JAMA-J AM MED ASSOC, V248, P736; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; MCCORMICK B, 1998, AM MED NEWS     1019, P24; Wallick M M, 1997, N C Med J, V58, P123; WALLICK MM, 1995, ACAD MED, V70, P2, DOI 10.1097/00001888-199501000-00003	18	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1287	1288		10.1001/jama.282.13.1287	http://dx.doi.org/10.1001/jama.282.13.1287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517435	hybrid			2022-12-28	WOS:000082901100040
J	Hewson, B				Hewson, B			The law on managing patients who deliberately harm themselves and refuse treatment	BRITISH MEDICAL JOURNAL			English	Article								A recent BMJ paper on managing patients who harm themselves and refuse treatment produced many responses on our website questioning the legality of the advice. Some of these letters are published on p916. We commissioned Barbara Hewson, a barrister with a specialist interest in the subject, to clarify these issues.	Littman Chambers, London WC1R 5JP, England		Hewson, B (corresponding author), Littman Chambers, 12 Grays Inn, London WC1R 5JP, England.							Hassan TB, 1999, BRIT MED J, V319, P107, DOI 10.1136/bmj.319.7202.107; KENNEDY I, 1998, PRINCIPLES MED LAW, P117; Law Commission, 1993, 129 LAW COMM; Law Commission, 1993, MENT INC AD DEC MAK; Law Commission, 1995, MENT INC	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					905	907		10.1136/bmj.319.7214.905	http://dx.doi.org/10.1136/bmj.319.7214.905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506053	Green Published			2022-12-28	WOS:000082975600031
J	Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H				Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H			MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover	CELL			English	Article							TYPE-1 MATRIX METALLOPROTEINASE; PRO-GELATINASE-A; EXTRACELLULAR-MATRIX; OSTEOBLAST DIFFERENTIATION; HYPERTROPHIC CHONDROCYTES; INTERSTITIAL COLLAGENASE; RHEUMATOID-ARTHRITIS; MOUSE EMBRYOGENESIS; BONE-RESORPTION; IN-VIVO	MT1-MMP is a membrane-bound matrix metalloproteinase (MT-MMP) capable of mediating pericellular proteolysis of extracellular matrix components. MT1-MMP is therefore thought to be an important molecular tool for cellular remodeling of the surrounding matrix. To establish the biological role of this membrane proteinase we generated MT1-MMP-deficient mice by gene targeting. MT1-MMP deficiency causes craniofacial dysmorphism, arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due to ablation of a collagenolytic activity that is essential for modeling of skeletal and extraskeletal connective tissues. Our findings demonstrate the pivotal function of MT1-MMP in connective tissue metabolism, and illustrate that modeling of the soft connective tissue matrix by resident cells is essential for the development and maintenance of the hard tissues of the skeleton.	Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA; Univ Roma La Sapienza, I-00161 Rome, Italy; Univ Aquila, I-67100 Laquila, Italy; McGill Univ, Shriners Hosp Children, Canadian Unit, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; NCI, Vet & Tumor Pathol Sect, Anim Sci Branch, Div Basic Sci, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Sapienza University Rome; University of L'Aquila; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birkedal-Hansen, H (corresponding author), Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA.	hbhansen@dir.nidcr.nih.gov	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Holmbeck, Kenn/0000-0002-4472-3257	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676, ZIADE000380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, Z01DE000380] Funding Source: NIH RePORTER; Telethon [E.1029] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Telethon(Fondazione Telethon)		Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; BIANCO P, 1984, BASIC APPL HISTOCHEM, V28, P265; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Chen HX, 1998, DEV GENET, V22, P314, DOI 10.1002/(SICI)1520-6408(1998)22:4<314::AID-DVG2>3.0.CO;2-9; Chin JR, 1997, DEVELOPMENT, V124, P1519; COLE AA, 1985, AM J ANAT, V174, P119, DOI 10.1002/aja.1001740203; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMERO P, 1998, J BIOL CHEM, V273, P32347; Gravallese EM, 1998, AM J PATHOL, V152, P943; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kaufmann MH, 1998, ATLAS MOUSE DEV; KIDWELL JF, 1961, J HERED, V52, P145, DOI 10.1093/oxfordjournals.jhered.a107050; Kinoh H, 1996, J CELL SCI, V109, P953; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; Kuznetsov S, 1996, CALCIFIED TISSUE INT, V59, P265, DOI 10.1007/s002239900121; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUFTI AM, 1970, J ANAT, V106, P135; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATTOT V, 1995, J CELL SCI, V108, P529; MELCHER AH, 1981, J ULTRA MOL STRUCT R, V77, P1, DOI 10.1016/S0022-5320(81)80064-0; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Nagase H, 1998, Cell Res, V8, P179; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; StahleBackdahl M, 1997, LAB INVEST, V76, P717; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki Y, 1998, J RHEUMATOL, V25, P1154; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1996, KIDNEY INT, V49, pS68; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	53	1041	1074	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					81	92		10.1016/S0092-8674(00)80064-1	http://dx.doi.org/10.1016/S0092-8674(00)80064-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520996	Bronze			2022-12-28	WOS:000082981600010
J	Orr-Weaver, TL				Orr-Weaver, TL			The ties that bind: Localization of the sister-chromatid cohesin complex on yeast chromosomes	CELL			English	Review							MEIOSIS		MIT, Dept Biol, Cambridge, MA 02142 USA; Whitehead Inst, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Orr-Weaver, TL (corresponding author), Whitehead Inst, Cambridge, MA 02142 USA.							Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Krawchuk MD, 1999, GENETICS, V153, P57; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Parisi S, 1999, MOL CELL BIOL, V19, P3515; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774	19	32	32	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					1	4		10.1016/S0092-8674(00)80055-0	http://dx.doi.org/10.1016/S0092-8674(00)80055-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520987	Bronze			2022-12-28	WOS:000082981600001
J	Dawes, PT				Dawes, PT			MRI abnormalities in rheumatoid arthritis	LANCET			English	Editorial Material									N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Dawes, PT (corresponding author), N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England.							DAWES P T, 1988, British Journal of Rheumatology, V27, P21; Gaffney K, 1998, ANN RHEUM DIS, V57, P152, DOI 10.1136/ard.57.3.152; HASSELL AB, 1993, Q J MED, V86, P601; Klarlund M, 1999, RHEUMATOLOGY, V38, P66, DOI 10.1093/rheumatology/38.1.66; Mc Gonagle D, 1999, RHEUMATOLOGY, V38, P329, DOI 10.1093/rheumatology/38.4.329; McQueen FM, 1999, ANN RHEUM DIS, V58, P156, DOI 10.1136/ard.58.3.156; Molenaar ETH, 1999, J RHEUMATOL, V26, P749; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; WOLFE F, 1993, J RHEUMATOL, V20, P2005	9	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1051	1052		10.1016/S0140-6736(99)90121-6	http://dx.doi.org/10.1016/S0140-6736(99)90121-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509493				2022-12-28	WOS:000082777500007
J	Stewart, S; Marley, JE; Horowitz, JD				Stewart, S; Marley, JE; Horowitz, JD			Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study	LANCET			English	Article							ELDERLY PATIENTS; HOSPITALIZATION; MORBIDITY; OUTCOMES; CARE	Background Hospital admissions among patients with congestive heart failure (CHF) are a major contributor to health-care costs. Previous investigations suggest that the therapeutic efficacy of pharmacotherapy in CHF may be improved by strategies incorporating home visits to identify and address factors precipitating deterioration and resultant readmission. Methods Chronic CHF patients discharged home after acute hospital admission were randomly assigned usual care (n=100) or a multidisciplinary, home-based intervention (n=100), consisting of a home visit by a cardiac nurse 7-14 days after discharge. The primary endpoint of the study was frequency of unplanned readmission plus out-of-hospital death within 6 months. Findings During 6 months' follow-up there were 129 primary endpoint events in the usual-care group and 77 in the intervention group (p=0.02). More intervention-group than usual-care patients remained event-free (38 vs 51; p=0.04). Overall, there were fewer unplanned readmissions (68 vs 118; p=0.03) and associated days in hospital (460 vs 1173; p=0.02) among intervention-group patients. Hospital-based costs were Australian $490 300 for the intervention group and A$922 600 for the usual-care group (p=0.16); the mean cost of the intervention was A$350 per patient, and other community-based costs were similar for both groups. Interpretation A home-based intervention has the potential to decrease the rate of unplanned readmissions and associated health-care costs, prolong event-free and total survival, and improve quality of life among patients with chronic CHF.	Univ Adelaide, Dept Gen Practice, Adelaide, SA 5005, Australia; Univ Adelaide, Queen Elizabeth Hosp, Dept Cardiol, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Horowitz, JD (corresponding author), Queen Elizabeth Hosp, Dept Cardiol, 28 Woodville Rd, Woodville, SA 5011, Australia.		Stewart, Simon/M-3316-2016; Marley, John/F-1239-2010	Stewart, Simon/0000-0001-9032-8998; Horowitz, John/0000-0001-6883-0703				Burns RB, 1997, J AM GERIATR SOC, V45, P276, DOI 10.1111/j.1532-5415.1997.tb00940.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Jaagosild P, 1998, ARCH INTERN MED, V158, P1081, DOI 10.1001/archinte.158.10.1081; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Luzier AB, 1998, AM J CARDIOL, V82, P465, DOI 10.1016/S0002-9149(98)00361-0; MCMURRAY J, 1993, BR J MED EC, V6, P99; Michalsen A, 1998, HEART, V80, P437, DOI 10.1136/hrt.80.5.437; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 1996, AM J MED, V101, P270, DOI 10.1016/S0002-9343(96)00172-6; Stewart S, 1999, AUST NZ J MED, V29, P220, DOI 10.1111/j.1445-5994.1999.tb00687.x; Stewart S, 1999, ARCH INTERN MED, V159, P257, DOI 10.1001/archinte.159.3.257; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WILLIAMS JF, 1995, J AM COLL CARDIOL, V26, P1376	26	430	452	0	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1077	1083		10.1016/S0140-6736(99)03428-5	http://dx.doi.org/10.1016/S0140-6736(99)03428-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	239PA	10509499				2022-12-28	WOS:000082777500013
J	Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N				Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N			Discovery of tetraploidy in a mammal	NATURE			English	Article									Univ Austral Chile, Inst Ecol & Evoluc, Valdivia, Chile; Texas A&M Univ, Dept Wildlife & Fisheries Sci, College Stn, TX 77843 USA; Inst Argentino Invest Zonas Aridas, Cricyt, RA-5500 Mendoza, Argentina	Universidad Austral de Chile; Texas A&M University System; Texas A&M University College Station; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Gallardo, MH (corresponding author), Univ Austral Chile, Inst Ecol & Evoluc, Casilla 567, Valdivia, Chile.			Ojeda, Ricardo/0000-0001-5246-0496				CONTRERAS LC, 1990, EXPERIENTIA, V46, P506, DOI 10.1007/BF01954248; Ferrari MR, 1998, ANDROLOGIA, V30, P85; Gallardo MH, 1997, CHROMOSOM T, V12, P347; Muller HJ, 1925, AM NAT, V59, P346, DOI 10.1086/280047; NIEBUHR E, 1974, HUMANGENETIK, V21, P103, DOI 10.1007/BF00281030; OHNO S., 1963, CYTO GENETICS [BASEL], V2, P42, DOI 10.1159/000129764; Ojeda RA, 1999, J ARID ENVIRON, V41, P443, DOI 10.1006/jare.1999.0496; ORR HA, 1990, AM NAT, V136, P759, DOI 10.1086/285130; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q	10	127	134	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					341	341		10.1038/43815	http://dx.doi.org/10.1038/43815			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517628	Bronze			2022-12-28	WOS:000082822600037
J	Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV				Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV			Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA	LANCET			English	Article							STEROID 5-ALPHA-REDUCTASE; SUSCEPTIBILITY LOCUS; RISK; POLYMORPHISM; CHROMOSOME	Background Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease, Methods We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5 alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells, Findings The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro V-max than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)). Interpretation The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5 alpha-reductase enzyme may be the cause of the increased risk.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System	Reichardt, JKV (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, 2250 Alcazar St,IGM 240, Los Angeles, CA 90033 USA.	reichard@hsc.usc.edu		Reichardt, Juergen/0000-0001-6458-2773	NATIONAL CANCER INSTITUTE [R01CA054281, R01CA063464, R01CA068581, U01CA063464, R37CA054281] Funding Source: NIH RePORTER; NCI NIH HHS [CA63464, CA68581, CA54281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIOLE GL, 1991, ANNU REV MED, V42, P9, DOI 10.1146/annurev.med.42.1.9; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; DAVIS DL, 1993, HUM MOL GENET, V2, P820, DOI 10.1093/hmg/2.6.820; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huggins C, 1941, CANCER RES, V1, P293; Kantoff PW, 1997, CANCER EPIDEM BIOMAR, V6, P189; KOLONEL LN, IN PRESS AM J EPIDEM; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Makridakis N, 1997, CANCER RES, V57, P1020; McIndoe RA, 1997, AM J HUM GENET, V61, P347, DOI 10.1086/514853; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MONTIE JE, 1992, SEMIN UROL, V11, P10; MONTIE JE, 1996, COMPREHENSIVE TXB GE, P712; Moore DD, 1995, GLOB MOB SURV; REICHARDT JKV, 1995, CANCER RES, V55, P3973; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; Ross RK, 1998, CANCER RES, V58, P4497; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477	24	224	235	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					975	978		10.1016/S0140-6736(98)11282-5	http://dx.doi.org/10.1016/S0140-6736(98)11282-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501358				2022-12-28	WOS:000082596000009
J	Reading, PJ; Hudgson, P; Johnson, MA; Jenkins, A				Reading, PJ; Hudgson, P; Johnson, MA; Jenkins, A			A sartorial challenge	LANCET			English	Article							POLYARTERITIS-NODOSA		Newcastle Gen Hosp, Reg Neurosci Ctr, Dept Neurol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Reg Neurosci Ctr, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Neurol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle General Hospital; Newcastle General Hospital; Newcastle University - UK	Reading, PJ (corresponding author), Newcastle Gen Hosp, Reg Neurosci Ctr, Dept Neurol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.							FERREIRO JE, 1986, AM J MED, V80, P312, DOI 10.1016/0002-9343(86)90031-8; FORT JG, 1994, J RHEUMATOL, V21, P945; GARCIA F, 1992, J RHEUMATOL, V19, P303; HOFMAN DM, 1992, CLIN RHEUMATOL, V11, P402, DOI 10.1007/BF02207202; MAXEINER SR, 1952, SURG CLIN N AM, V32, P1225	5	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					996	996		10.1016/S0140-6736(99)05342-8	http://dx.doi.org/10.1016/S0140-6736(99)05342-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501363				2022-12-28	WOS:000082596000014
J	Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX				Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX			Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein	SCIENCE			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR SMAD4; DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; CDNA CLONES; N-COR; PROMOTER; SKI	Smad proteins mediate transforming growth factor-beta (TGF-beta) signaling to regulate cell growth and differentiation. The SnoN oncoprotein was found to interact with Smad2 and Smad4 and to repress their abilities to activate transcription through recruitment of the transcriptional corepressor N-CoR, Immediately after TGF-beta stimulation, SnoN is rapidly degraded by the nuclear accumulation of Smad3, allowing the activation of TGF-beta target genes. By 2 hours, TGF-beta induces a marked increase in SnoN expression, resulting in termination of Smad-mediated transactivation. Thus, SnoN maintains the repressed state of TGF-beta-responsive genes in the absence of ligand and participates in negative feedback regulation of TGF-beta signaling.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Luo, KX (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 229 Stanley Hall,Mail Code 3206, Berkeley, CA 94720 USA.							Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYER PL, 1993, ONCOGENE, V8, P457; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	49	423	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					771	774		10.1126/science.286.5440.771	http://dx.doi.org/10.1126/science.286.5440.771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531062	Green Submitted			2022-12-28	WOS:000083303200054
J	Barabasi, AL; Albert, R				Barabasi, AL; Albert, R			Emergence of scaling in random networks	SCIENCE			English	Article							WORLD-WIDE-WEB; COMPLEXITY; INTERNET; DYNAMICS	Systems as diverse as genetic networks or the World Wide Web are best described as networks with complex topology. A common property of many Large networks is that the vertex connectivities follow a scale-free power-law distribution. This feature was found to be a consequence of two generic mechanisms: (i) networks expand continuously by the addition of new vertices, and (ii) new vertices attach preferentially to sites that are already well connected. A model based on these two ingredients reproduces the observed stationary scale-free distributions, which indicates that the development of Large networks is governed by robust self-organizing phenomena that go beyond the particulars of the individual systems.	Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA	University of Notre Dame	Barabasi, AL (corresponding author), Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA.	alb@nd.edu	Xie, Jianjun/D-9838-2012; Barabasi, Albert-Laszlo/S-6474-2017; Albert, Reka/E-2195-2011	Albert, Reka/0000-0002-9485-0828; Barabasi, Albert/0000-0002-4028-3522				Albert R, 1999, NATURE, V401, P130, DOI 10.1038/43601; [Anonymous], 1990, 6 DEGREES SEPARATION; Arthur WB, 1999, SCIENCE, V284, P107, DOI 10.1126/science.284.5411.107; Banavar JR, 1999, NATURE, V399, P130, DOI 10.1038/20144; Barabasi AL, 1999, PHYSICA A, V272, P173, DOI 10.1016/S0378-4371(99)00291-5; BARTHELEMY M, 1999, PHYS REV LETT, V82, P1580; BOLLOBA B, 1985, RANDOM GRAPHS; ERDOS P, 1960, B INT STATIST INST, V38, P343; Gallagher R, 1999, SCIENCE, V284, P79, DOI 10.1126/science.284.5411.79; Huberman BA, 1998, SCIENCE, V280, P95, DOI 10.1126/science.280.5360.95; Huberman BA, 1999, NATURE, V401, P131, DOI 10.1038/43604; Koch C, 1999, SCIENCE, V284, P96, DOI 10.1126/science.284.5411.96; Kochen Manfred, 1989, SMALL WORLD; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; Redner S, 1998, EUR PHYS J B, V4, P131, DOI 10.1007/s100510050359; SEVICE RF, 1999, SCIENCE, V284, P80; TU YO, COMMUNICATION; Wasserman S., 1994, STRUCTURAL ANAL SOCI, DOI 10.1017/CBO9780511815478; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; 1999, SCI AM, V280, P54	22	22208	23973	148	2517	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					509	512		10.1126/science.286.5439.509	http://dx.doi.org/10.1126/science.286.5439.509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521342	Green Submitted			2022-12-28	WOS:000083121200054
J	Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS				Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS			The mammalian gene collection	SCIENCE			English	Editorial Material							HUMAN-GENOME-PROJECT; EXPRESSION; SEQUENCE; CDNA	The Mammalian Cone Collection (MGC) project is a new effort by the NIH to generate full-length complementary DNA (cDNA) resources. This project will provide publicly accessible resources to the full research community. The MGC project entails the production of libraries, sequencing, and database and repository development, as well as the support of Library construction, sequencing, and analytic technologies dedicated to the goal of obtaining a full set of human and other mammalian full-length (open reading frame) sequences and clones of expressed genes.	NCI, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], COMMUNICATION; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Carninci P, 1997, DNA Res, V4, P61, DOI 10.1093/dnares/4.1.61; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; *COMM MAPP SEQ HUM, 1988, REP COMM MAPP SEQ HU; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; EDERY I, 1995, MOL CELL BIOL, V15, P3363; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Rubin GM, 1998, TRENDS GENET, V14, P340, DOI 10.1016/S0168-9525(98)01568-6; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; SOARES MA, UNPUB; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Williamson AR, 1999, DRUG DISCOV TODAY, V4, P115, DOI 10.1016/S1359-6446(99)01303-3	16	210	229	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					455	457		10.1126/science.286.5439.455	http://dx.doi.org/10.1126/science.286.5439.455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521335				2022-12-28	WOS:000083121200046
J	Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR				Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR			Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion	ANNALS OF INTERNAL MEDICINE			English	Article						epidemiology, molecular; drug resistance, microbial; human immunodeficiency virus; human immunodeficiency virus infections; anti-HIV agents	TYPE-1 SUBTYPE; UNITED-STATES; VIRUS; SENSITIVITY; PREVALENCE; INFECTION; DIVERSITY; COMMUNITY; THERAPY; PLASMA	Background: Regular testing of military personnel identifies early HIV infection; this identification provides a sentinel cohort in which to describe the evolving molecular epidemiology of HIV-1 transmission. Objective: To describe the prevalence and epidemiologic correlates associated with the acquisition of non-subtype B and drug-resistant HIV infections. Design: Cross-sectional study. Setting: Military referral hospital. Patients: 95 military personnel with HIV-1 seroconversion. Measurements: Self-reported questionnaire, CD4 cell counts, plasma HIV-1 RNA levels, and nucleic acid sequence analysis for drug-resistant mutations and HIV-1 genetic subtype. Results: 95 patients were enrolled between February 1997 and February 1998. The likely geographic location of HIV-1 acquisition was overseas in 8% of patients, the United States in 68%, and either overseas or the United States in 24%. Seven patients (7.4%) had subtype E infection; the remainder had subtype B infection. Eight of 31 (26%) treatment-naive patients had mutations in the reverse transcriptase or protease gene associated with drug resistance. Conclusions: The percentage of HIV-1 non-subtype B infection and antiretroviral drug-resistant mutations was relatively high in U.S. military personnel with recently acquired HIV-1 infection.	San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, San Diego, CA 92182 USA; Naval Hlth Res Ctr, Div Clin Epidemiol, San Diego, CA 92186 USA; Naval Hlth Res Ctr, San Diego, CA 92152 USA; Naval Med Ctr, San Diego, CA 92134 USA; Henry M Jackson Fdn Advancement Mil Med, Rockville, MD USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	California State University System; San Diego State University; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Center San Diego; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of California System; University of California San Diego	Brodine, SK (corresponding author), San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, 5500 Campanile Dr, San Diego, CA 92182 USA.		Mascola, John/AAI-7193-2021		NIAID NIH HHS [AI 38858, AI 27670, AI 36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, P30AI036214, U01AI038858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH JD, 1998, CURRENT OPINION INFE, P3; Brodine SK, 1997, INFECT MED, V14, P739; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Debyser Z, 1998, AIDS RES HUM RETROV, V14, P453, DOI 10.1089/aid.1998.14.453; Gaywee J, 1996, J ACQ IMMUN DEF SYND, V13, P392, DOI 10.1097/00042560-199612010-00014; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hawkes S, 1998, INFECT DIS CLIN N AM, V12, P413, DOI 10.1016/S0891-5520(05)70011-8; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; Irwin KL, 1997, J INFECT DIS, V176, P1629, DOI 10.1086/517343; LEVIN LI, 1995, AM J PUBLIC HEALTH, V85, P1500, DOI 10.2105/AJPH.85.11.1500; Mayers DL, 1998, JAMA-J AM MED ASSOC, V279, P2000, DOI 10.1001/jama.279.24.2000; Nolte FS, 1998, J CLIN MICROBIOL, V36, P716, DOI 10.1128/JCM.36.3.716-720.1998; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Pinkerton SD, 1998, AM J PUBLIC HEALTH, V88, P1239, DOI 10.2105/AJPH.88.8.1239; Rayfield MA, 1996, EMERG INFECT DIS, V2, P209, DOI 10.3201/eid0203.960307; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	20	95	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					502	+		10.7326/0003-4819-131-7-199910050-00004	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507958				2022-12-28	WOS:000083018800003
J	Bevan, G				Bevan, G			The medical service increment for teaching (SIFT): a 400m pound anachronism for the English NHS?	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Econ & Polit Sci, Dept Operat Res, London WC2A 2AE, England	University of London; London School Economics & Political Science	Bevan, G (corresponding author), Univ London London Sch Econ & Polit Sci, Dept Operat Res, Houghton St, London WC2A 2AE, England.							BEVAN G, 1987, FINANCIAL ACCOUNTABI, V3, P147; CULYER AJ, 1987, SOC ECON ADMIN, V12, P20; *DEP HLTH SOC SEC, 1980, REP ADV GROUP RES AL; Department of Health and Social Security, 1976, SHAR RES HLTH ENGL R; Department of Health and Social Security, 1988, REV RES ALL WORK PAR; FOOTE G, 1988, TECHNICAL PAPER SERV; General Medical Council, 1993, TOM DOCT; *HLTH DEP GREAT BR, 1989, GEN PRACT NAT HLTH S; *LOND EC, 1991, ALL MED SIFTR CAMB D; MURRAY E, 1995, MED EDUC, V29, P66, DOI 10.1111/j.1365-2923.1995.tb02804.x; *NHS EX, 1995, REV ARR FUND SERV IN; *NHS EX, 1995, SIFT FUT; *NHS EX, 1998, SIFT ACC REP; PERRIN J, 1987, FINANCIAL ACCOUNTABI, V3, P209; Seiford LM, 1997, ANN OPER RES, V73, P393, DOI 10.1023/A:1018949800069; SHELDON TA, 1992, BRIT MED J, V305, P310, DOI 10.1136/bmj.305.6848.310-b; SHERMAN HD, 1984, MED CARE, V22, P922, DOI 10.1097/00005650-198410000-00005; SNIJDERS EHM, 1987, FINANCIAL ACCOUNTABI, V3, P193; STEVENS SS, 1946, SCIENCE, V103, P677, DOI 10.1126/science.103.2684.677; *U LOND, 1991, U STRAT SERV INCR TE; 1997, CM3807	21	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					908	911		10.1136/bmj.319.7214.908	http://dx.doi.org/10.1136/bmj.319.7214.908			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506054	Green Published			2022-12-28	WOS:000082975600033
J	Zar, HJ; Brown, G; Donson, H; Brathwaite, N; Mann, MD; Weinberg, EG				Zar, HJ; Brown, G; Donson, H; Brathwaite, N; Mann, MD; Weinberg, EG			Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial	LANCET			English	Article							METERED-DOSE INHALER; DRUG DELIVERY; SALBUTAMOL; EFFICACY; NEBULIZERS; DEVICES	Background A metered-dose inhale, (MDI) with spacer is the best way to deliver bronchodilator therapy for treatment of acute asthma, In developing countries, commercially produced spacers are generally unavailable or too costly. We tested the efficacy of home-made spacers (500 mL plastic bottle, polystyrene cup) compared with a conventional spacer for delivery of a beta(2) agonist via MDI for children with acute asthma. Methods We studied children aged 5 to 13 years with acute asthma, stratified into those with mild airways obstruction (peak expiratory flow [PEF] 60-79% of predicted value) or moderate to severe airways obstruction (PEF 20-59% of predicted value). A beta(2) agonist (fenoterol hydrobromide) was given via MDI and one of four randomly assigned spacers (conventional spacer, sealed 500 mL plastic bottle, unsealed 500 mt bottle, 200 mt polystyrene cup). Clinical score, pulmonary function tests, and oximetry were recorded at baseline and 15 min after treatment. If a second bronchodilator treatment was needed, nebulised fenoterol was given and the assessment repeated 15 min later. Primary outcome measures were changes in clinical score and pulmonary function, and need for and response to nebulisation. Findings 88 children were eligible for study, In 44 children with moderate to severe airways obstruction, a cup gave significantly less bronchodilation (median increase in: forced expiratory volume in 1 s [FEV1] 0%; PEF 12%) compared with the conventional spacer (37%; 59%), sealed bottle (33%; 36%), or unsealed bottle (18%; 21%, p<0.05 for difference between groups). Nebulisation was required by ten of 11 who had used a cup, nine of 11 who had used an unsealed bottle, eight of 11 who had used a sealed bottle, and only four of 11 who had used a conventional spacer. After nebulisation, improvement in FEV1 (15.5%) and PEF (26%) was more marked in children who had used a cup than in those who had used a conventional spacer (5.5% FEV1; 4% PEF), seared bottle (3%; 0%), or unsealed bottle (7%; 9%), For 44 children with mild airways obstruction, response to bronchodilator was similar for all spacers and need for nebulisation was not associated with use of a particular spacer. Interpretation A conventional spacer and sealed 500 mL plastic bottle produced similar bronchodilation, an unsealed bottle gave intermediate improvement in lung function, and a polystyrene cup was least effective as a spacer for children with moderate to severe airways obstruction. Use of bottle spacers should be incorporated into guidelines for asthma management in developing countries.	Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa; Red Cross War Mem Childrens Hosp, Cape Town, South Africa	University of Cape Town	Zar, HJ (corresponding author), Child Hlth Unit, 46 Sawkins Rd, ZA-7700 Rondebosch, South Africa.	heather@rmh.uct.ac.za	Zar, Heather/GZL-5350-2022	Zar, Heather/0000-0002-9046-759X				Amirav I, 1997, ARCH PEDIAT ADOL MED, V151, P876, DOI 10.1001/archpedi.1997.02170460014003; CATES CJ, 1997, AIRWAYS MODULE COCHR; CHOU KJ, 1995, ARCH PEDIAT ADOL MED, V149, P201, DOI 10.1001/archpedi.1995.02170140083015; CLARK DJ, 1996, THORAX, V51, P853; COGSWELL JJ, 1975, BRIT J DIS CHEST, V69, P177, DOI 10.1016/0007-0971(75)90077-7; CORR D, 1982, J AEROSOL SCI, V13, P1, DOI 10.1016/0021-8502(82)90002-7; EVERARD ML, 1992, ARCH DIS CHILD, V67, P580, DOI 10.1136/adc.67.5.580; FOLK TF, 1997, PEDIAT PULMONOL, V24, P204; FUGISANG G, 1986, EUR J RESPIR DIS, V69, P109; *GLOB IN ASTHM, 1995, NHLBI WHO WORKSH, P23; HENRY RL, 1983, BRIT MED J, V286, P2021, DOI 10.1136/bmj.286.6383.2021; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; LEE N, 1991, Journal of Allergy and Clinical Immunology, V87, P307, DOI 10.1016/0091-6749(91)91954-R; Lipworth BJ, 1997, THORAX, V52, P1036, DOI 10.1136/thx.52.12.1036; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; Tal A, 1996, J PEDIATR-US, V128, P479, DOI 10.1016/S0022-3476(96)70357-8; TEO J, 1988, PEDIATR PULM, V5, P244, DOI 10.1002/ppul.1950050411; *WHO PROGR CONTR A, 1993, BRONCH OTH MED TREAT, P14; Wildhaber JH, 1996, EUR RESPIR J, V9, P1943, DOI 10.1183/09031936.96.09091943; ZAPLETAL A, 1977, Zeitschrift fuer Erkrankungen der Atmungsorgane, V149, P343; Zar HJ, 1999, S AFR MED J, V89, P40; Zar HJ, 1998, ANN TROP PAEDIATR, V18, P75, DOI 10.1080/02724936.1998.11747931	22	55	61	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					979	982		10.1016/S0140-6736(98)12445-5	http://dx.doi.org/10.1016/S0140-6736(98)12445-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501359				2022-12-28	WOS:000082596000010
J	Silberberg, SD; Magleby, KL				Silberberg, SD; Magleby, KL			Biomedicine - Beating the odds with big K	SCIENCE			English	Editorial Material							ACTIVATED POTASSIUM CHANNELS; HIGH-CONDUCTANCE; MUSCLE; CA		Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA	Ben Gurion University; Ben Gurion University; University of Miami	Silberberg, SD (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.		Silberberg, Shai/ABA-2778-2020					ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Cook NS., 1990, POTASSIUM CHANNELS S; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Nimigean CM, 1999, J GEN PHYSIOL, V113, P425, DOI 10.1085/jgp.113.3.425; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Stefani E, 1997, P NATL ACAD SCI USA, V94, P5427, DOI 10.1073/pnas.94.10.5427; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929	17	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1859	1860		10.1126/science.285.5435.1859	http://dx.doi.org/10.1126/science.285.5435.1859			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515790				2022-12-28	WOS:000082638300031
J	Berger, A				Berger, A			What is allodynia?	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BERDE C, 1995, PAIN, V62, P1, DOI 10.1016/0304-3959(95)00035-Q; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Gardmark M, 1998, J PHARM SCI, V87, P813, DOI 10.1021/js980056f; 1998, CURRENT OPINION ANAE, V11, P436	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					629	629						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10523091				2022-12-28	WOS:000082460300030
J	Fahnestock, DT				Fahnestock, DT			Partnership for good dying	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					615	616		10.1001/jama.282.7.615	http://dx.doi.org/10.1001/jama.282.7.615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517702				2022-12-28	WOS:000082033700001
J	Griffin, EA; Staknis, D; Weitz, CJ				Griffin, EA; Staknis, D; Weitz, CJ			Light-independent role of CRY1 and CRY2 in the mammalian circadian clock	SCIENCE			English	Article							DROSOPHILA PERIOD GENE; TRANSCRIPTION; PHOTORECEPTOR; CRYPTOCHROME; EXPRESSION; TIMELESS; ORTHOLOG; HOMOLOGS; PROTEIN; MPER1	Cryptochrome (CRY), a photoreceptor for the circadian clock in Drosophila, binds to the clock component TIM in a light-dependent fashion and blocks its function. In mammals, genetic evidence suggests a role for CRYs within the clock, distinct from hypothetical photoreceptor functions. Mammalian CRY1 and CRY2 are here shown to act as light-independent inhibitors of CLOCK-BMAL1, the activator driving Per1 transcription. CRY1 or CRY2 (or both) showed Light-independent interactions with CLOCK and BMAL1, as well as with PER1, PER2, and TIM. Thus, mammalian CRYs act as light-independent components of the circadian clock and probably regulate Per1 transcriptional cycling by contacting both the activator and its feedback inhibitors.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	cweitz@hms.harvard.edu		Griffin, Edmund/0000-0001-7291-6091	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059943] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-59943] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GRIFFIN EA, UNPUB; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lucas RJ, 1999, CURR BIOL, V9, pR214, DOI 10.1016/S0960-9822(99)80132-8; Lucas RJ, 1999, J BIOL RHYTHM, V14, P4, DOI 10.1177/074873099129000380; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, IN PRESS P NATL ACAD; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	27	493	506	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					768	771		10.1126/science.286.5440.768	http://dx.doi.org/10.1126/science.286.5440.768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531061				2022-12-28	WOS:000083303200053
J	Beecham, L				Beecham, L			Alan Milburn returns to UK health department	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1021	1021		10.1136/bmj.319.7216.1021	http://dx.doi.org/10.1136/bmj.319.7216.1021			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521176	Green Published			2022-12-28	WOS:000083210100006
J	Keigwin, LD; Pickart, RS				Keigwin, LD; Pickart, RS			Slope water current over the Laurentian Fan on interannual to millennial time scales	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; HOLOCENE; CIRCULATION; SEDIMENTS; MARGIN	The strength and position of surface and deep currents in the slope water south of Newfoundland are thought to vary as a coupled system in relation to the dipole in atmospheric sea Level pressure known as the North Atlantic oscillation (NAO). Paleoceanographic data from the Laurentian Fan, used as a proxy for sea surface temperature. reveal that surface slope waters north of the Gulf Stream experienced warming during the Little Ice Age of the 16th to 19th centuries and support the notion of an NAO-driven coupled system. The NAO may be a useful model for millennial-scale ocean variability during interglacial climate states.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Keigwin, LD (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.							Appenzeller C, 1998, SCIENCE, V282, P446, DOI 10.1126/science.282.5388.446; Bacon S, 1998, NATURE, V394, P871, DOI 10.1038/29736; Balsam WL, 1987, PALEOCEANOGRAPHY, V2, P531, DOI 10.1029/PA002i005p00531; Bianchi GG, 1999, NATURE, V397, P515, DOI 10.1038/17362; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; CIE Colorimetry, 1986, CIE COL; CSANADY GT, 1988, CONT SHELF RES, V8, P565, DOI 10.1016/0278-4343(88)90068-4; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; Fuglister F.C, 1963, PROGRESS OCEANOGRAPH, V1, P265, DOI DOI 10.1016/0079-6611(63)90007-7; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; KEIGWIN LD, 1994, J GEOPHYS RES-OCEANS, V99, P12397, DOI 10.1029/94JC00525; KEIGWIN LD, 1995, PALEOCEANOGRAPHY, V10, P973, DOI 10.1029/95PA02643; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; KEIGWIN LD, 1989, DEEP-SEA RES, V36, P845, DOI 10.1016/0198-0149(89)90032-0; Kohfeld KE, 1996, PALEOCEANOGRAPHY, V11, P679, DOI 10.1029/96PA02617; LAINE EP, 1981, MAR GEOL, V39, P277, DOI 10.1016/0025-3227(81)90076-1; Pickart RS, 1999, J PHYS OCEANOGR, V29, P2541, DOI 10.1175/1520-0485(1999)029<2541:MSAIVO>2.0.CO;2; Pickart RS, 1998, DEEP-SEA RES PT I, V45, P1053, DOI 10.1016/S0967-0637(97)00084-8; Piper DJW, 1998, PALEOCEANOGRAPHY, V13, P205, DOI 10.1029/97PA03641; SAUTTER LR, 1989, J FORAMIN RES, V19, P253, DOI 10.2113/gsjfr.19.4.253; Skene K. I., 1998, THESIS DALHOUSIE U; STOW DAV, 1981, AAPG BULL, V65, P375; SUMAN DO, 1989, DEEP-SEA RES, V36, P869, DOI 10.1016/0198-0149(89)90033-2	23	120	122	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					520	523		10.1126/science.286.5439.520	http://dx.doi.org/10.1126/science.286.5439.520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521345				2022-12-28	WOS:000083121200057
J	Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME				Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME			A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins	SCIENCE			English	Article							INHIBITORY MACROCYCLIC PEPTIDES; HUMAN BETA-DEFENSIN-1; ANTIBIOTIC AS-48; AIRWAY EPITHELIA; CYSTIC-FIBROSIS; BETA-DEFENSINS; HOST-DEFENSE; CIRCULIN-A; PURIFICATION; LUNG	Analysis of rhesus macaque leukocytes disclosed the presence of an 18-residue macrocyclic, tridisulfide antibiotic peptide in granules of neutrophils and monocytes. The peptide, termed rhesus theta defensin-1 (RTD-1), is microbicidal for bacteria and fungi at Low micromolar concentrations. Antibacterial activity of the cyclic peptide was threefold greater than that of an open-chain analog, and the cyclic conformation was required for antimicrobial activity in the presence of 150 millimolar sodium chloride. Biosynthesis of RTD-1 involves the head-to-tail ligation of two alpha-defensin-related nonapeptides, requiring the formation of two new peptide bonds. Thus, host defense cells possess mechanisms for synthesis and granular packaging of macrocyclic antibiotic peptides that are components of the phagocyte antimicrobial armamentarium.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Davis, Sch Vet Med, Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	University of California System; University of California Irvine; University of California System; University of California Davis; University of California System; University of California Davis	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.		Abrams, William R/A-5782-2008		NIAID NIH HHS [AI22931] Funding Source: Medline; NIDDK NIH HHS [DK44632, DK33506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022931, R37AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Blond A, 1999, EUR J BIOCHEM, V259, P747, DOI 10.1046/j.1432-1327.1999.00085.x; Boman HG, 1998, IMMUNOLOGIST, V6, P234; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GALVEZ A, 1989, ANTIMICROB AGENTS CH, V33, P437, DOI 10.1128/AAC.33.4.437; Ganz T, 1997, Curr Opin Hematol, V4, P53; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; MARTINEZBUENO M, 1994, J BACTERIOL, V176, P6334, DOI 10.1128/jb.176.20.6334-6339.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TANG YQ, IN PRESS INFECT IMMU; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; YOUNT NY, 1995, J IMMUNOL, V155, P4476; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1995, FEBS LETT, V368, P197, DOI 10.1016/0014-5793(95)00633-K	34	593	659	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					498	502		10.1126/science.286.5439.498	http://dx.doi.org/10.1126/science.286.5439.498			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521339	Green Submitted			2022-12-28	WOS:000083121200051
J	Bull, C				Bull, C		British Paediat Cardiac Assoc	Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK	LANCET			English	Article							PRENATAL-DIAGNOSIS; ECHOCARDIOGRAPHY; FETUS	Background Assessment of the effect of fetal diagnosis on the prevalence of congenital heart disease at term requires national ascertainment because referral patterns are not rigorously structured. Methods Between 1993 and 1995, all 17 paediatric cardiac centres in the UK submitted to a database lists of all fetuses diagnosed, and all infants needing surgery or interventional catheterisation or dying in the first year of life because of structural heart disease: details included the postal area of residence. Findings There were 4799 affected pregnancies, 4165 babies born alive, 1124 fetal diagnoses, and 567 terminations of pregnancy because the fetus had structural heart disease. Thus, a fetal diagnosis was made in 23.4% of affected pregnancies (11.7% of all affected livebirths) with geographical variability in diagnostic rates. babies born alive. Interpretation Fetal cardiac screening has an effect on the prevalence and types of congenital heart disease seen at term because many affected pregnancies are terminated. If detection rates of affected fetuses rose nationally to those seen in the 15 postal areas where detection rates were significantly higher than the national average in 1993-95, we would expect about 218 fewer affected individuals to be born annually.	Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Bull, C (corresponding author), Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, Great Ormond St, London WC1N 3JH, England.							ABUHARB M, 1995, BRIT HEART J, V74, P192; ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; ALLAN LD, 1980, BRIT HEART J, V44, P444; BONNETT D, 1988, FETAL DIAGN THER S1, V13, P148; Breslow NE., 1987, STAT METHODS CANC RE, P81; *CENTR STAT OFF, 1996, SOC TRENDS, V26, P62; CHANG AC, 1991, J THORAC CARDIOV SUR, V102, P841, DOI 10.1016/S0022-5223(19)33933-9; Copel JA, 1997, ULTRASOUND OBST GYN, V10, P237, DOI 10.1046/j.1469-0705.1997.10040237.x; CULLEN S, 1992, ARCH DIS CHILD-FETAL, V67, P775, DOI 10.1136/adc.67.7_Spec_No.775; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Hyett J, 1999, BRIT MED J, V318, P81, DOI 10.1136/bmj.318.7176.81; LANGE LW, 1980, CIRCULATION, V62, P799, DOI 10.1161/01.CIR.62.4.799; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; Marteau TM, 1995, PRENATAL DIAG, V15, P1215, DOI 10.1002/pd.1970151304; *OFF NAT STAT, 1995, AB STAT, V22, P13; *OFF NAT STAT, 1997, REG TRENDS, V32, P37; SADIQ M, 1995, BRIT HEART J, V73, P173; SHARLAND GK, 1992, BRIT J OBSTET GYNAEC, V99, P220, DOI 10.1111/j.1471-0528.1992.tb14503.x; Stumpflen I, 1996, LANCET, V348, P854, DOI 10.1016/S0140-6736(96)04069-X; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; WYLLIE J, 1994, BRIT HEART J, V71, P20	23	255	261	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1242	1247		10.1016/S0140-6736(99)01167-8	http://dx.doi.org/10.1016/S0140-6736(99)01167-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520632				2022-12-28	WOS:000083010400009
J	Cassen, R; Visaria, P				Cassen, R; Visaria, P			India: looking ahead to one and a half billion people	BRITISH MEDICAL JOURNAL			English	Article									London Sch Econ, Dept Social Policy, London WC2A 2AE, England; Univ Delhi, Inst Econ Growth, Delhi 110007, India	University of London; London School Economics & Political Science; University of Delhi	Cassen, R (corresponding author), London Sch Econ, Dept Social Policy, London WC2A 2AE, England.							ANDERSON D, 1994, OXFORD ECON PAP, P46; BHATIA B, 1992, 100 WORLD I DEV EC R; BLOOM DE, 1998, POPULATION DYNAMICS; CASSEN R, 1978, INDIA POPULATION EC; *CENTR STAT OFF, 1996, NAT SAMPL SURV 55 RO; CHAPMAN GP, 1992, WATER QUEST SUSTAINA; DE A, 1999, PROBE REPORT PUBLIC; *DEP EC SOC AFF, 1998, WORLD POP PROSP 1998; Dinar A., 1998, World Bank Technical Paper; Dyson T, 1996, POPULATION FOOD GLOB; EASTWOOD R, 1998, S POP CHANG EC DEV B; GODWIN P, 1998, LOOMING EPIDEMIC IMP; *GOV IND, 1991, 1991 CENS GEN TABL; *GOV IND, 1998, VIT RAT IND 1971 199; *GOV IND, 1997, WHIT PAP POLL DELH; Haq M. U., 1997, HUMAN DEV S ASIA; International Institute for Population Sciences, 1995, IND NAT FAM HLTH SUR; Jain AK, 1988, INFANT MORTALITY IND; KOENIG MA, 1999, IMPROVING QUALITY CA; Lloyd C.B., 1994, INVESTING NEXT GENER; RAO CHH, 1994, AGR GROWTH POVERTY E; Saleth R.M., 1997, 395 WORLD BANK; SHAH T, 1992, GROUNDWATER MARKETS; *TAT EN RES I, 1998, 2047 TERI; The World Bank, 1997, PRIM ED IND; *UN DEV PROGR, 1997, HUM DEV REP 1997, P175; World Health Organization, 1999, WORLD HLTH REP MAK D	27	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					995	997		10.1136/bmj.319.7215.995	http://dx.doi.org/10.1136/bmj.319.7215.995			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514170	Green Submitted, Green Published			2022-12-28	WOS:000083111700039
J	Henney, JE				Henney, JE			Quick test for pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-28	WOS:000082901100008
J	Barabino, SML; Keller, W				Barabino, SML; Keller, W			Last but not least: Regulated poly(A) tail formation	CELL			English	Review							PRE-MESSENGER-RNA; POLYADENYLATION FACTOR; IN-VITRO; POLYMERASE; PHOSPHORYLATION; PROTEIN; SUBUNIT		Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Basel	Barabino, SML (corresponding author), Univ Basel, Biozentrum, Dept Cell Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Ashe MP, 1997, EMBO J, V16, P5752, DOI 10.1093/emboj/16.18.5752; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X	18	82	85	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					9	11		10.1016/S0092-8674(00)80057-4	http://dx.doi.org/10.1016/S0092-8674(00)80057-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520989	Bronze			2022-12-28	WOS:000082981600003
J	McNamara, JM; Gasson, CE; Houston, AI				McNamara, JM; Gasson, CE; Houston, AI			Incorporating rules for responding into evolutionary games	NATURE			English	Article							VIGILANCE; PREDATION; RISK	Evolutionary game theory(1,2) is concerned with the evolutionarily stable outcomes of the process of natural selection. The theory is especially relevant when the fitness of an organism depends on the behaviour of other members of its population. Here we focus on the interaction between two organisms that have a conflict of interest. The standard approach to such two-player games is to assume that each player chooses a single action and that the evolutionarily stable action of each player is the best given the action of its opponent. We argue that, instead, most two-player games should be modelled as involving a series of interactions in which opponents negotiate the final outcome, Thus we should be concerned with evolutionarily stable negotiation rules rather than evolutionarily stable actions. The evolutionarily stable negotiation rule of each player is the best rule given the rule of its opponent. As we show, the action chosen as a result of the negotiation is not the best action given the action of the opponent. This conclusion necessitates a fundamental change in the way that evolutionary games are modelled.	Univ Bristol, Sch Math, Bristol BS8 1TW, Avon, England; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bristol; University of Bristol	McNamara, JM (corresponding author), Univ Bristol, Sch Math, Univ Walk, Bristol BS8 1TW, Avon, England.	john.mcnamara@bristol.ac.uk						Clutton-Brock T., 1991, P234; Dugatkin L.A., 1997, COOPERATION ANIMALS; GODFRAY HCJ, 1991, NATURE, V352, P328, DOI 10.1038/352328a0; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HATCHWELL BJ, 1990, BEHAV ECOL SOCIOBIOL, V27, P199; Houston A.I., 1985, P471; JOHNSTONE RA, 1994, P ROY SOC B-BIOL SCI, V256, P169, DOI 10.1098/rspb.1994.0066; LIMA SL, 1987, J THEOR BIOL, V124, P303, DOI 10.1016/S0022-5193(87)80118-2; MARKMAN S, 1995, ANIM BEHAV, V50, P655, DOI 10.1016/0003-3472(95)80127-8; Maynard Smith J., 1982, pi; MCNAMARA JM, 1992, ANIM BEHAV, V43, P641, DOI 10.1016/0003-3472(92)90086-O; Mock D. W., 1997, EVOLUTION SIBLING RI; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Parker GA, 1997, P ROY SOC B-BIOL SCI, V264, P1239, DOI 10.1098/rspb.1997.0171; PULLIAM HR, 1982, J THEOR BIOL, V95, P89, DOI 10.1016/0022-5193(82)90289-2; SMITH JM, 1991, ANIM BEHAV, V42, P1034, DOI 10.1016/S0003-3472(05)80161-7; Wright J, 1990, BEHAV ECOL, V1, P116, DOI 10.1093/beheco/1.2.116	17	300	302	0	95	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					368	371		10.1038/43869	http://dx.doi.org/10.1038/43869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517633				2022-12-28	WOS:000082822600049
J	Zhen, M; Jin, YS				Zhen, M; Jin, YS			The liprin protein SYD-2 regulates the differentiation of presynaptic termini in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SYNAPTIC VESICLES; TYROSINE-PHOSPHATASE; NERVE-TERMINALS; ACTIVE ZONE; SYNAPTOTAGMIN; ORGANIZATION; MUTANTS; SYSTEM	At synaptic junctions, specialized subcellular structures occur in both pre- and postsynaptic cells. Most presynaptic termini contain electron-dense membrane structures(1), often referred to as active zones, which function in vesicle docking and release(2). The components of those active zones and how they are formed are largely unknown. We report here that a mutation in the Caenorhabditis elegans syd-2 (for synapse-defective) gene causes a diffused localization of several presynaptic proteins and of a synaptic-vesicle membrane associated green fluorescent protein (GFP) marker(3,4). Ultrastructural analysis revealed that the active zones of syd-2 mutants were significantly lengthened, whereas the total number of vesicles per synapse and the number of vesicles at the prominent active zones were comparable to those in wild-type animals. Synaptic transmission is partially impaired in syn-2 mutants. syd-2 encodes a member of the liprin (for LAR-interacting protein) family of proteins which interact with LAR-type (for leukocyte common antigen related) receptor proteins with tyrosine phosphatase activity (RPTPs)(5,6). SYD-2 protein is localized at presynaptic termini independently of the presence of vesicles, and functions cell autonomously. We propose that SYD-2 regulates the differentiation of presynaptic termini in particular the formation of the active zone, by acting as an intracellular anchor for RPTP signalling at synaptic junctions.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Jin, YS (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.		Zhen, Mei/A-4967-2012	Zhen, Mei/0000-0003-0086-9622; Jin, Yishi/0000-0002-9371-9860	NINDS NIH HHS [NS35546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BRENNER S, 1974, GENETICS, V77, P71; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hallam SJ, 1998, NATURE, V395, P78, DOI 10.1038/25757; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Jin YS, 1999, J NEUROSCI, V19, P539; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1999, J NEUROSCI METH, V89, P33, DOI 10.1016/S0165-0270(99)00031-X; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; TRENT C, 1983, GENETICS, V104, P619; WANG YQ, 1993, J MATER RES, V8, P388, DOI 10.1557/JMR.1993.0388; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yochem J, 1998, GENETICS, V149, P1323	28	278	296	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					371	375		10.1038/43886	http://dx.doi.org/10.1038/43886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517634				2022-12-28	WOS:000082822600050
J	Rauschecker, JP				Rauschecker, JP			Neuroscience - Making brain circuits listen	SCIENCE			English	Editorial Material							CEREBRAL-CORTEX; NUCLEUS BASALIS; PLASTICITY; REORGANIZATION; ORGANIZATION; STIMULATION; CAT		Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA	Georgetown University	Rauschecker, JP (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA.	rauscheckerj@giccs.georgetown.edu	Rauschecker, Josef P/A-4120-2013	Rauschecker, Josef P./0000-0003-4353-9084				Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; Balkany T, 1996, OTOLARYNG HEAD NECK, V114, P748, DOI 10.1016/S0194-5998(96)70097-9; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Francis HW, 1999, ARCH OTOLARYNGOL, V125, P499, DOI 10.1001/archotol.125.5.499; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; HOCHMAIR ES, 1979, INT J ARTIF ORGANS, V2, P255; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Klinke R, 1999, SCIENCE, V285, P1729, DOI 10.1126/science.285.5434.1729; LOEB GE, 1990, ANNU REV NEUROSCI, V13, P357, DOI 10.1146/annurev.neuro.13.1.357; Loeb Gerald E., 1996, Seminars in Hearing, V17, P309, DOI 10.1055/s-0028-1083061; MELCHER JR, 1998, NEUROIMAGE, V6, pS385; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Rajan R, 1998, AUDIOL NEURO-OTOL, V3, P123, DOI 10.1159/000013786; Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Sanes JN, 1997, ADV NEUROL, V73, P277; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SNYDER RL, 1990, HEARING RES, V50, P7, DOI 10.1016/0378-5955(90)90030-S; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WURTH N, 1999, GOTTINGEN NEUROBIO R, V27, P318	26	13	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1686	1687		10.1126/science.285.5434.1686	http://dx.doi.org/10.1126/science.285.5434.1686			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523187				2022-12-28	WOS:000082472600023
J	Krasner, AS				Krasner, AS			Glucocorticoid-induced adrenal insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN-INDUCED HYPOGLYCEMIA; LOW-DOSE PREDNISONE; ADRENOCORTICOTROPIN TEST; CORTICOSTEROID-THERAPY; RHEUMATOID-ARTHRITIS; WITHDRAWAL SYNDROME; PITUITARY; RESPONSES; HORMONE; RECOVERY		Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD 21205 USA	Johns Hopkins University	Krasner, AS (corresponding author), Pfizer Inc, Eastern Point Rd,POB 8031, Groton, CT 06340 USA.	alan_s_krasner@groton.pfizer.com						Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; ACKERMAN GL, 1968, NEW ENGL J MED, V278, P405, DOI 10.1056/NEJM196802222780801; AMATRUDA TT, 1960, J CLIN ENDOCR METAB, V20, P339, DOI 10.1210/jcem-20-3-339; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BYYNY RL, 1976, NEW ENGL J MED, V295, P30; CARELLA MJ, 1993, J CLIN ENDOCR METAB, V76, P1188, DOI 10.1210/jc.76.5.1188; CARTER ME, 1970, ANN RHEUM DIS, V29, P409, DOI 10.1136/ard.29.4.409; CARTER ME, 1972, ANN RHEUM DIS, V31, P379, DOI 10.1136/ard.31.5.379; CHRISTY NP, 1992, NEW ENGL J MED, V326, P266, DOI 10.1056/NEJM199201233260410; Dickstein G, 1997, ENDOCRINOLOGIST, V7, P285, DOI 10.1097/00019616-199707050-00002; DIXON RB, 1980, AM J MED, V68, P224, DOI 10.1016/0002-9343(80)90358-7; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; FISH HR, 1986, METABOLISM, V35, P763, DOI 10.1016/0026-0495(86)90245-3; Glowniak JV, 1997, SURGERY, V121, P123, DOI 10.1016/S0039-6060(97)90280-4; GRABER AL, 1965, J CLIN ENDOCR METAB, V25, P11, DOI 10.1210/jcem-25-1-11; JASANI MK, 1967, Q J MED, V36, P261; JASANI MK, 1968, Q J MED, V37, P407; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Kountz DS, 1997, AM FAM PHYSICIAN, V55, P521; LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003-4819-119-10-199311150-00001; LAROCHELLE GE, 1993, AM J MED, V95, P258, DOI 10.1016/0002-9343(93)90277-V; MAY ME, 1985, AM J MED, V79, P679, DOI 10.1016/0002-9343(85)90517-0; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; NICHOLS T, 1965, J CLIN ENDOCR METAB, V25, P343, DOI 10.1210/jcem-25-3-343; ORTH DN, 1994, CURRENT THERAPY ENDO, P124; Papanicolaou DA, 1996, J CLIN ENDOCR METAB, V81, P2303, DOI 10.1210/jc.81.6.2303; SALEM M, 1994, ANN SURG, V219, P416, DOI 10.1097/00000658-199404000-00013; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; Streeten DHP, 1999, J CLIN ENDOCR METAB, V84, P835, DOI 10.1210/jc.84.3.835; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; THYGESON NM, 1984, ARCH INTERN MED, V144, P2288, DOI 10.1001/archinte.144.11.2288; Weintrob N, 1998, J CLIN ENDOCR METAB, V83, P88, DOI 10.1210/jc.83.1.88; YAFFE SJ, 1966, N Y STATE J MED, V66, P827; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	36	113	117	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					671	676		10.1001/jama.282.7.671	http://dx.doi.org/10.1001/jama.282.7.671			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517721				2022-12-28	WOS:000082033700027
J	Sachs, JP; Lehman, SJ				Sachs, JP; Lehman, SJ			Subtropical North Atlantic temperatures 60,000 to 30,000 years ago	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; ABRUPT CLIMATE-CHANGE; DEEP-WATER; HEINRICH EVENTS; SARGASSO SEA; ICE; OCEAN; GREENLAND; ISOTOPE; VARIABILITY	A reconstruction of sea surface temperature based on alkenone unsaturation ratios in sediments of the Bermuda Rise provides a detailed record of subtropical climate from 60,000 to 30,000 years ago. Northern Sargasso Sea temperatures changed repeatedly by 2 degrees to 5 degrees C, covarying with high-latitude temperatures that were previously inferred from Greenland ice cores. The largest temperature increases were comparable in magnitude to the full glacial-Holocene warming at the site. Abrupt cold reversals of 3 degrees to 5 degrees C, Lasting Less than 250 years, occurred during the onset of two such even ts (Greenland interstadials 8 and 12), suggesting that the largest, most rapid warmings were especially unstable.	Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Sachs, JP (corresponding author), Columbia Univ Barnard Coll, Dept Environm Sci, 3009 Broadway, New York, NY 10027 USA.							Adkins JF, 1997, NATURE, V390, P154, DOI 10.1038/36540; ADKINS JF, 1995, EOS T AM GEOPHYS U S, V76, pF282; Alley RB, 1997, J GEOPHYS RES-OCEANS, V102, P26367, DOI 10.1029/96JC03837; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; Boyle EA, 1997, P NATL ACAD SCI USA, V94, P8300, DOI 10.1073/pnas.94.16.8300; Broecker W.S., 1997, GSA TODAY, V7, P1; Chapman MR, 1998, EARTH PLANET SC LETT, V159, P57, DOI 10.1016/S0012-821X(98)00068-5; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; Curry WB, 1997, PALEOCEANOGRAPHY, V12, P1, DOI 10.1029/96PA02413; DANSGAARD W, 1964, TELLUS, V16, P436; DEUSER WG, 1986, DEEP-SEA RES, V33, P225, DOI 10.1016/0198-0149(86)90120-2; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hendy IL, 1999, GEOLOGY, V27, P291, DOI 10.1130/0091-7613(1999)027<0291:LQNPSW>2.3.CO;2; JOUZEL J, 1994, J GEOPHYS RES-ATMOS, V99, P25791, DOI 10.1029/94JD01819; KEIGWIN LD, 1994, J GEOPHYS RES-OCEANS, V99, P12397, DOI 10.1029/94JC00525; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; Keigwin LD, 1999, PALEOCEANOGRAPHY, V14, P164, DOI 10.1029/1998PA900026; LEHMAN SJ, 1992, EOS T AM GEOPHYS U S, V73, P259; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; LOWELL TV, 1995, SCIENCE, V269, P1541, DOI 10.1126/science.269.5230.1541; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; OPPO DW, 1995, PALEOCEANOGRAPHY, V10, P901, DOI 10.1029/95PA02089; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; PRAHL FG, 1988, GEOCHIM COSMOCHIM AC, V52, P2303, DOI 10.1016/0016-7037(88)90132-9; PRAHL FG, 1987, NATURE, V330, P367, DOI 10.1038/330367a0; SCHILLER A, 1996, 188 M PLANCK I MET; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; SHUMAN CA, 1995, J GEOPHYS RES-ATMOS, V100, P9165, DOI 10.1029/95JD00560; SUMAN DO, 1989, DEEP-SEA RES, V36, P869, DOI 10.1016/0198-0149(89)90033-2; Vidal L, 1997, EARTH PLANET SC LETT, V146, P13, DOI 10.1016/S0012-821X(96)00192-6; Weaver AJ, 1998, NATURE, V394, P847, DOI 10.1038/29695; Webb RS, 1997, NATURE, V385, P695, DOI 10.1038/385695a0; Zahn R, 1997, PALEOCEANOGRAPHY, V12, P696, DOI 10.1029/97PA00581	41	136	149	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					756	759		10.1126/science.286.5440.756	http://dx.doi.org/10.1126/science.286.5440.756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531057				2022-12-28	WOS:000083303200049
J	Ziesche, R; Hofbauer, E; Wittmann, K; Petkov, V; Block, LH				Ziesche, R; Hofbauer, E; Wittmann, K; Petkov, V; Block, LH			A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE-EXPRESSION; TGF-BETA; IFN-GAMMA; LUNG; INFLAMMATION	Background Patients with idiopathic pulmonary fibrosis have progressive scarring of the lung and usually die within four to five years after symptoms develop. Treatment with oral glucocorticoids is often ineffective. We conducted an open, randomized trial of treatment with a combination of interferon gamma-1b, which has antifibrotic properties, and an oral glucocorticoid. Methods We studied 18 patients with idiopathic pulmonary fibrosis who had not had responses to glucocorticoids or other immunosuppressive agents. Nine patients were treated for 12 months with oral prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily), and nine with a combination of 200 mu g of interferon gamma-1b (given three times per week subcutaneously) and 7.5 mg of prednisolone (given once a day). Results All the patients completed the study. Lung function deteriorated in all nine patients in the group given prednisolone alone: total lung capacity decreased from a mean (+/-SD) of 66+/-8 percent of the predicted value at base line to 62+/-6 percent at 12 months. In contrast, in the group receiving interferon gamma-1b plus prednisolone, total lung capacity increased (from 70+/-6 percent of the predicted value at base line to 79+/-12 percent at 12 months, P<0.001 for the difference between the groups). In the group that received interferon gamma-1b plus prednisolone, the partial pressure of arterial oxygen at rest increased from 65+/-9 mm Hg at base line to 76+/-8 mm Hg at 12 months, whereas in the group that received prednisolone alone it decreased from 65+/-6 to 62+/-4 mm Hg (P<0.001 for the difference in the change from baseline values between the two groups); on maximal exertion, the value increased from 55+/-6 to 65+/-8 mm Hg in the group that received combined treatment and decreased from 55+/-6 mm Hg to 52+/-5 mm Hg in the group given prednisolone alone (P<0.001). The side effects of interferon gamma-1b, such as fever, chills, and muscle pain, subsided within the first 9 to 12 weeks. Conclusions In a preliminary study, 12 months of treatment with interferon gamma-1b plus prednisolone was associated with substantial improvements in the condition of patients with idiopathic pulmonary fibrosis who had had no response to glucocorticoids alone. (N Engl J Med 1999;341:1264-9.) (C)1999, Massachusetts Medical Society.	Univ Vienna, Sch Med, Dept Internal Med 4, Div Pulm Med, A-1090 Vienna, Austria	University of Vienna	Block, LH (corresponding author), Univ Vienna, Sch Med, Dept Internal Med 4, Div Pulm Med, Wahringer Gurtel 18-10, A-1090 Vienna, Austria.							BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; Gilbert KM, 1997, IMMUNOL INVEST, V26, P459, DOI 10.3109/08820139709022702; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; HARNONCOURT K, 1982, OSTERREICH ARZTEZTG, V37, P1640; *IDV, 1998, 6008 IDV; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; Lee YJ, 1997, J IMMUNOL, V158, P2065; Naganuma Hirofumi, 1996, Neurologia Medico-Chirurgica, V36, P789, DOI 10.2176/nmc.36.789; PRIOR C, 1992, CLIN EXP IMMUNOL, V88, P280; Qin LH, 1996, HUM GENE THER, V7, P1981, DOI 10.1089/hum.1996.7.16-1981; Ryu JH, 1998, MAYO CLIN PROC, V73, P1085, DOI 10.4065/73.11.1085; Sempowski GD, 1996, J CELL PHYSIOL, V167, P290, DOI 10.1002/(SICI)1097-4652(199605)167:2<290::AID-JCP13>3.3.CO;2-A; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SPECKS U, 1995, AM J RESP CRIT CARE, V151, P1956, DOI 10.1164/ajrccm.151.6.7767545; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; TUKIAINEN P, 1983, THORAX, V38, P349, DOI 10.1136/thx.38.5.349; WATTERS LC, 1986, AM REV RESPIR DIS, V133, P97, DOI 10.1164/arrd.1986.133.1.97; ZIESCHE R, 1996, CHEST, V110, pS25	22	420	475	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1264	1269		10.1056/NEJM199910213411703	http://dx.doi.org/10.1056/NEJM199910213411703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528036				2022-12-28	WOS:000083226300003
J	Harris, ST; Watts, NB; Genant, HK; McKeever, CD; Hangartner, T; Keller, M; Chesnut, CH; Brown, J; Eriksen, EF; Hoseyni, MS; Axelrod, DW; Miller, PD				Harris, ST; Watts, NB; Genant, HK; McKeever, CD; Hangartner, T; Keller, M; Chesnut, CH; Brown, J; Eriksen, EF; Hoseyni, MS; Axelrod, DW; Miller, PD		VERT Study Grp	Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-D SUPPLEMENTATION; BONE-MINERAL DENSITY; ORAL RISEDRONATE; MULTIPLE-MYELOMA; ALENDRONATE; THERAPY; TOLERABILITY; PAMIDRONATE; ESTROGEN; OLDER	Context Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has not been evaluated in the treatment of established postmenopausal osteoporosis. Objective To test the efficacy and safety of daily treatment with risedronate to reduce the risk of vertebral and other fractures in postmenopausal women with established osteoporosis. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 2458 ambulatory postmenopausal women younger than 85 years with at least 1 vertebral fracture at baseline who were enrolled at 1 of 110 centers in North America conducted between December 1993 and January 1998. interventions Subjects were randomly assigned to receive oral treatment for 3 years with risedronate (2.5 or 5 mg/d) or placebo. All subjects received calcium, 1000 mg/d, Vitamin D (cholecalciferol, up to 500 IU/d) was provided if baseline levels of 25-hydroxyvitamin D were low. Main Outcome Measures Incidence of new vertebral fractures as detected by quantitative and semiquantitative assessments of radiographs; incidence of radiographically confirmed nonvertebral fractures and change from baseline in bone mineral density as determined by dual x-ray absorptiometry. Results The 2.5 mg/d of risedronate arm was discontinued after 1 year; in the placebo and 5 mg/d of risedronate arms, 450 and 489 subjects, respectively, completed all 3 years of the trial. Treatment with 5 mg/d of risedronate, compared with placebo, decreased the cumulative incidence of new vertebral fractures by 41% (95% confidence interval [CI], 18%-58%) over 3 years (11.3% vs 16.3%; P=.003). A fracture reduction of 65% (95% CI, 38%-81%) was observed after the first year (2.4% vs 6.4%; P<.001). The cumulative incidence of nonvertebral fractures over 3 years was reduced by 39% (95% CI, 6%-61%) (5.2% vs 8.4%; P=.02). Bone mineral density increased significantly compared with placebo at the lumbar spine (5.4% vs 1.1%), femoral neck (1.6% vs -1.2%), femoral trochanter (3.3% vs -0.7%), and midshaft of the radius (0.2% vs -1.4%). Bone formed during risedronate treatment was histologically normal. The overall safety profile of risedronate, including gastrointestinal safely, was similar to that of placebo, Conclusions These data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.	Univ San Francisco, San Francisco, CA 94117 USA; Emory Univ, Dept Med, Atlanta, GA 30322 USA; Res Hlth Hlth Adv, Houston, TX USA; Wright State Univ, Biomed Imaging Lab, Dayton, OH 45435 USA; San Diego Arthrit & Osteoporosis Med Clin, San Diego, CA USA; Univ Washington, Dept Nucl Med, Seattle, WA 98195 USA; Univ Laval, Ctr Hosp, Dept Rheumatol, St Foy, PQ G1K 7P4, Canada; Aarhus Kommune Hosp, Dept Endocrinol, DK-8000 Aarhus, Denmark; Procter & Gamble Co, Pharmaceut, Cincinnati, OH USA; Colorado Ctr Bone Res, Lakewood, CO USA	University of San Francisco; Emory University; University System of Ohio; Wright State University Dayton; University of Washington; University of Washington Seattle; Laval University; Aarhus University; Procter & Gamble; Colorado Center For Bone Research	Harris, ST (corresponding author), Univ San Francisco, 350 Parnassus Ave,Suite 706, San Francisco, CA 94117 USA.		Hangartner, Thomas/AAG-4479-2020; Eriksen, Erik Fink/AAF-5056-2020					Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHESNUT C, 1998, OSTEOPOROSIS INT S3, V8, P13; COHENSOLAL ME, 1993, BONE, V14, P505, DOI 10.1016/8756-3282(93)90187-F; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Ettinger B, 1998, AM J MANAG CARE, V4, P1377; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; ETTINGER B, 1998, OSTEOPOROSIS INT S3, V8, P11; GENANT HK, 1994, J BONE MINER RES, V9, P1503; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Genant HK, 1996, J BONE MINER RES, V11, P707; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Hosking DJ, 1998, BONE, V22, P51, DOI 10.1016/S8756-3282(97)00222-6; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay Robert, 1995, P133; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MACONI G, 1995, AM J GASTROENTEROL, V90, P1889; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; Miller PD, 1999, AM J MED, V106, P513, DOI 10.1016/S0002-9343(99)00062-5; Mortensen L, 1998, J CLIN ENDOCR METAB, V83, P396, DOI 10.1210/jc.83.2.396; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756-3282(94)90890-7; Spivacow FR, 1996, CURR THER RES CLIN E, V57, P123, DOI 10.1016/S0011-393X(96)80006-3; STEIGER P, 1995, BONE, V17, P435	31	1823	1888	0	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1344	1352		10.1001/jama.282.14.1344	http://dx.doi.org/10.1001/jama.282.14.1344			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527181	Bronze			2022-12-28	WOS:000083000800029
J	Berenson, GS; Srinivasan, SR				Berenson, GS; Srinivasan, SR			Prevention of atherosclerosis in childhood	LANCET			English	Editorial Material									Tulane Univ, Med Ctr, Tulane Sch Publ Hlth, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA; Tulane Univ, Med Ctr, Tulane Sch Publ Hlth, Dept Epidemiol, New Orleans, LA 70112 USA	Tulane University; Tulane University	Berenson, GS (corresponding author), Tulane Univ, Med Ctr, Tulane Sch Publ Hlth, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA.							BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; Downey A M, 1989, Health Values, V13, P31; Kannel WB, 1995, AM J MED SCI, V310, pS15, DOI 10.1097/00000441-199512000-00004; LAUER RM, 1995, JAMA-J AM MED ASSOC, V273, P1429, DOI 10.1001/jama.273.18.1429; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Niinikoski H, 1997, PEDIATRICS, V99, P687, DOI 10.1542/peds.99.5.687; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Stein EA, 1999, JAMA-J AM MED ASSOC, V281, P137, DOI 10.1001/jama.281.2.137	9	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1223	1224						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520626				2022-12-28	WOS:000083010400003
J	Kane, R; Choi, CY				Kane, R; Choi, CY			China's one child family policy	BRITISH MEDICAL JOURNAL			English	Article							BIRTH		Univ Melbourne, Dept Psychiat, Off Gender & Hlth, Carlton, Vic 2053, Australia; Australian Inst Hlth & Welf, Welf Div, Bruce, ACT 2617, Australia	University of Melbourne	Kane, R (corresponding author), Univ Melbourne, Dept Psychiat, Off Gender & Hlth, Carlton, Vic 2053, Australia.							Banister J., 1987, CHINAS CHANGING POPU; FEENEY G, 1993, POPUL DEV REV, V19, P61, DOI 10.2307/2938385; FENG G, 1992, POPULATION RES, V4, P28; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; GREENHALGH S, 1992, 38 POP COUNC; HAO Y, 1988, AUSTR J CHINESE AFFA, V19, P165; HULL T, 1991, 2 AUSTR INT DEV ASS; JOHNSON K, 1993, AUST J CHINESE A JUL, P61; KANE P, 1995, CHINA 1990S; KANE P, 1997, CHINA HDB REGIONAL H; Kane Penny, 1987, 2 BILLION POPULATION; Kaufman J, 1997, IDS BULL-I DEV STUD, V28, P61; Lee J, 1999, POPUL DEV REV, V25, P33, DOI 10.1111/j.1728-4457.1999.00033.x; LIU Z, 1980, POPULATION THEORY CH; Milwertz Cecilia Nathansen, 1997, ACCEPTING POPULATION; Ruzicka L T, 1998, Asia Pac Popul J, V13, P55; SCHARPING T, 1997, FLOATING POPULATION; *UN, 1998, ST ESA A, V169; ZENG Y, 1993, POPUL DEV REV, V19, P283; ZENG Y, 1996, POPULATION STUDIES, V50, P27	20	42	43	5	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					992	994		10.1136/bmj.319.7215.992	http://dx.doi.org/10.1136/bmj.319.7215.992			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10514169	Green Published			2022-12-28	WOS:000083111700038
J	Ackert, RP; Barclay, DJ; Borns, HW; Calkin, PE; Kurz, MD; Fastook, JL; Steig, EJ				Ackert, RP; Barclay, DJ; Borns, HW; Calkin, PE; Kurz, MD; Fastook, JL; Steig, EJ			Measurements of past ice sheet elevations in interior West Antarctica	SCIENCE			English	Article							COSMOGENIC CL-36; POLAR ICE; PRODUCTION-RATES; GLACIAL HISTORY; LATE WISCONSIN; EXPOSURE AGES; ROSS-SEA; BE-10; CHRONOLOGY; FLUCTUATIONS	A Lateral moraine band on Mount Waesche, a volcanic nunatak in Marie Byrd Land, provides estimates of past ice sheet surface elevations in West Antarctica. Helium-3 and chlorine-36 surface exposure ages indicate that the proximal part of the moraine, up to 45 meters above the present ice surface, was deposited about 10,000 years ago, substantially Later than the maximum ice extent in the Ross Embayment. The upper distal part of the moraine may record multiple earlier ice sheet high stands. A nonequilibrium ice sheet model predicts a delay of several thousand years in maximum ice levels at Mount Waesche relative to the maximum ice extent in the Ross Sea. The glacial geologic evidence, coupled with the ice sheet model, indicates that the contribution of the Ross Sea sector of the West Antarctic Ice Sheet to Holocene sea Level rise was only about 3 meters. These results eliminate West Antarctic ice as the principle source of the large meltwater pulse during the early Holocene.	Woods Hole Oceanog Inst, MIT Woods Hole Oceanog Inst Joint Program, Woods Hole, MA 02543 USA; Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; SUNY Coll Cortland, Dept Geol, Cortland, NY 13045 USA; Univ Maine, Inst Quaternary Studies, Orono, ME 04469 USA; Univ Maine, Dept Comp Sci, Orono, ME 04469 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Penn, Dept Earth & Environm Sci, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution; State University of New York (SUNY) System; SUNY Cortland; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; University of Colorado System; University of Colorado Boulder; University of Pennsylvania	Ackert, RP (corresponding author), Woods Hole Oceanog Inst, MIT Woods Hole Oceanog Inst Joint Program, MS 25,Clark 419, Woods Hole, MA 02543 USA.		Steig, Eric J/G-9088-2015	Steig, Eric J/0000-0002-8191-5549; Kurz, Mark/0000-0003-1745-2356; Fastook, James/0000-0003-3900-671X				Anderson J.B., 1992, ANTARCT RES SER, V57, P39, DOI DOI 10.1029/AR057P0039; BOCKHEIM JG, 1989, QUATERNARY RES, V31, P229, DOI 10.1016/0033-5894(89)90007-0; BORNS HW, 1995, ANTARCT J US, V30, P100; BROOK EJ, 1993, QUATERNARY RES, V39, P11, DOI 10.1006/qres.1993.1002; BROOK EJ, 1995, EARTH PLANET SC LETT, V131, P41, DOI 10.1016/0012-821X(95)00006-X; BROWN ET, 1991, GEOCHIM COSMOCHIM AC, V55, P2269, DOI 10.1016/0016-7037(91)90103-C; CERLING TE, 1994, GEOCHIM COSMOCHIM AC, V58, P349; DENTON GH, 1989, QUATERNARY RES, V31, P151, DOI 10.1016/0033-5894(89)90004-5; DENTON GH, 1991, GEOLOGY ANTARCTICA, P365; DENTON GH, 1989, QUATERNARY RES, V31, P189; DORNACK EW, IN PRESS GEOL SOC AM; DUNBAR NW, IN PRESS ANTARCT J U; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FASTOOK JL, 1994, J GLACIOL, V40, P167, DOI 10.3189/S0022143000003944; GOSSE JC, 1995, SCIENCE, V268, P1329, DOI 10.1126/science.268.5215.1329; GROOTES PM, 1986, QUATERNARY RES, V26, P49, DOI 10.1016/0033-5894(86)90083-9; HALL BL, IN PRESS GEOGR ANN; Huybrechts P., 1990, ANN GLACIOL, V14, P115; HUYBRECHTS P, 1990, CLIM DYNAM, V5, P79, DOI DOI 10.1007/BF00207423; JENSSEN D, 1983, CLIMATIC RECORD POLA, P138; KURZ MD, 1986, GEOCHIM COSMOCHIM AC, V50, P2855, DOI 10.1016/0016-7037(86)90232-2; LAL D, 1991, EARTH PLANET SC LETT, V104, P424, DOI 10.1016/0012-821X(91)90220-C; LEMASURIER WE, 1989, J GEOPHYS RES-SOLID, V94, P7223, DOI 10.1029/JB094iB06p07223; LEMASURIER WE, 1990, AM GEOPHYS UNION ANT, V48, P208; Licht KJ, 1996, GEOLOGY, V24, P223, DOI 10.1130/0091-7613(1996)024<0223:COLWIR>2.3.CO;2; Licht KJ, 1999, GEOL SOC AM BULL, V111, P91, DOI 10.1130/0016-7606(1999)111<0091:DSTAGM>2.3.CO;2; LIU BL, 1994, WATER RESOUR RES, V30, P3115, DOI 10.1029/94WR00761; MARTINERIE P, 1992, EARTH PLANET SC LETT, V112, P1, DOI 10.1016/0012-821X(92)90002-D; MERCER JH, 1968, GEOL SOC AM BULL, V79, P471, DOI 10.1130/0016-7606(1968)79[471:GGOTRG]2.0.CO;2; NISHIIZUMI K, 1991, EARTH PLANET SC LETT, V104, P440, DOI 10.1016/0012-821X(91)90221-3; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; Phillips F.M., 1996, RADIOCARBON, V38, P98; Phillips FM, 1997, GEOL SOC AM BULL, V109, P1453, DOI 10.1130/0016-7606(1997)109<1453:CCABAO>2.3.CO;2; Phillips FM, 1996, GEOPHYS RES LETT, V23, P949, DOI 10.1029/96GL00960; Phillips FM, 1996, SCIENCE, V274, P749, DOI 10.1126/science.274.5288.749; RAYNAUD D, 1979, NATURE, V281, P289, DOI 10.1038/281289a0; Raynaud D., 1982, ANN GLACIOL, V3, P269; SHIPP SS, IN PRESS GEOL SOC AM; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; Steig EJ, 1997, ANN GLACIOL, V25, P418, DOI 10.3189/S0260305500014385; STEIG EJ, UNPUB; STONE J, COMMUNICATION; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TUSHINGHAM AM, 1991, J GEOPHYS RES-SOLID, V96, P4497, DOI 10.1029/90JB01583	44	80	82	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					276	280		10.1126/science.286.5438.276	http://dx.doi.org/10.1126/science.286.5438.276			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514368				2022-12-28	WOS:000083024400040
J	Conway, H; Hall, BL; Denton, GH; Gades, AM; Waddington, ED				Conway, H; Hall, BL; Denton, GH; Gades, AM; Waddington, ED			Past and future grounding-line retreat of the West Antarctic Ice Sheet	SCIENCE			English	Article							SEA-LEVEL RECORD; LATE WISCONSIN; COLLAPSE; OCEAN; CONFIGURATION; DEGLACIATION; RADIOCARBON; CHRONOLOGY; HISTORY; SHELF	The history of deglaciation of the West Antarctic Ice Sheet (WAIS) gives clues about its future. Southward grounding-line migration was dated past three Locations in the Ross Sea Embayment. Results indicate that most recession occurred during the middle to Late Holocene in the absence of substantial sea Level or climate forcing. Current grounding-line retreat may reflect ongoing ice recession that has been under way since the early Holocene. If so, the WAIS could continue to retreat even in the absence of further external forcing.	Univ Washington, Geophys Program, Seattle, WA 98195 USA; Univ Maine, Inst Quaternary Studies, Orono, ME 04469 USA; Univ Maine, Dept Geol Sci, Orono, ME 04469 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA	University of Washington; University of Washington Seattle; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; Woods Hole Oceanographic Institution	Conway, H (corresponding author), Univ Washington, Geophys Program, Seattle, WA 98195 USA.							Anderson J.B., 1992, ANTARCT RES SER, V57, P39, DOI DOI 10.1029/AR057P0039; Andrews JT, 1999, QUATERNARY RES, V52, P206, DOI 10.1006/qres.1999.2047; Bard E, 1998, GEOCHIM COSMOCHIM AC, V62, P2025, DOI 10.1016/S0016-7037(98)00130-6; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; BARONI C, 1991, QUATERNARY RES, V36, P157, DOI 10.1016/0033-5894(91)90023-X; BARONI C, 1994, GEOLOGY, V22, P23, DOI 10.1130/0091-7613(1994)022<0023:APRAHP>2.3.CO;2; Bentley CR, 1998, J GLACIOL, V44, P157, DOI 10.3189/S0022143000002446; Berkman PA, 1996, GEOPHYS RES LETT, V23, P363, DOI 10.1029/96GL00151; Bindschadler R, 1998, SCIENCE, V282, P428, DOI 10.1126/science.282.5388.428; Bindschadler R, 1998, SCIENCE, V279, P689, DOI 10.1126/science.279.5351.689; BLANCHON P, 1995, GEOLOGY, V23, P4, DOI 10.1130/0091-7613(1995)023<0004:RDDTLD>2.3.CO;2; BOCKHEIM JG, 1989, QUATERNARY RES, V31, P229, DOI 10.1016/0033-5894(89)90007-0; CLAPP JL, 1965, 651 U WISC; CLAYTONGREENE JM, 1988, NEW ZEAL J GEOL GEOP, V31, P353, DOI 10.1080/00288306.1988.10417781; DAGEL MA, 1989, THESIS U MAINE ORONO; Dansgaard W., 1969, J GLACIOL, V8, P215, DOI [10.3189/S0022143000031208, DOI 10.3189/S0022143000031208, 10.3189/s0022143000031208]; DENTON GH, 1989, QUATERNARY RES, V31, P151, DOI 10.1016/0033-5894(89)90004-5; DOMACK EW, 1989, QUATERNARY RES, V31, P277, DOI 10.1016/0033-5894(89)90009-4; Doran PT, 1999, PALAEOGEOGR PALAEOCL, V147, P223, DOI 10.1016/S0031-0182(98)00159-X; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FILLON RH, 1981, GEOLOGICAL SURVEY B, V811, P105; HALL BL, IN PRESS GEOGRAF ANN; HALL BL, IN PRESS J QUAT SCI; HALL BL, 1996, ANTARCT J US, V31, P78; Harris P. T., 1996, Papers and Proceedings of the Royal Society of Tasmania, V130, P47; Jacobel RW, 1996, J GEOPHYS RES-SOL EA, V101, P5499, DOI 10.1029/95JB03735; James TS, 1998, J GEOPHYS RES-SOL EA, V103, P4993, DOI 10.1029/97JB03539; KELLOGG TB, 1990, CONTRIBUTIONS ANTA 1, V50, P25; Licht KJ, 1998, POLAR RES, V17, P203, DOI 10.1111/j.1751-8369.1998.tb00272.x; Licht KJ, 1996, GEOLOGY, V24, P223, DOI 10.1130/0091-7613(1996)024<0223:COLWIR>2.3.CO;2; Licht KJ, 1999, GEOL SOC AM BULL, V111, P91, DOI 10.1130/0016-7606(1999)111<0091:DSTAGM>2.3.CO;2; MACAYEAL DR, 1992, NATURE, V359, P29, DOI 10.1038/359029a0; MARCHANT DR, IN PRESS GEOGRAF ANN; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; Morse DL, 1998, GEOPHYS RES LETT, V25, P3383, DOI 10.1029/98GL52486; PELTIER WR, 1988, QUATERNARY RES, V29, P93, DOI 10.1016/0033-5894(88)90054-3; Peltier WR, 1998, REV GEOPHYS, V36, P603, DOI 10.1029/98RG02638; RASMUSSEN LA, 1985, J GLACIOL, V31, P115, DOI 10.3189/S0022143000006341; RAYMOND CF, 1983, J GLACIOL, V29, P357, DOI 10.3189/S0022143000030288; RETZLAFF R, 1993, J GLACIOL, V39, P495, DOI 10.3189/S0022143000016397; Scherer RP, 1998, SCIENCE, V281, P82, DOI 10.1126/science.281.5373.82; SHABTAIE S, 1987, J GEOPHYS RES-SOLID, V92, P1311, DOI 10.1029/JB092iB02p01311; SHIPP SS, IN PRESS GEOL SOC AM; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Stuiver M., 1981, LAST GREAT ICE SHEET, P319; THOMAS RH, 1988, ANN GLACIOL, V11, P8; TUSHINGHAM AM, 1991, J GEOPHYS RES-SOLID, V96, P4497, DOI 10.1029/90JB01583; Vaughan DG, 1999, NATURE, V398, P323, DOI 10.1038/18653; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]	49	332	340	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					280	283		10.1126/science.286.5438.280	http://dx.doi.org/10.1126/science.286.5438.280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514369				2022-12-28	WOS:000083024400041
J	Hensher, M; Edwards, N				Hensher, M; Edwards, N			The hospital of the future - Hospital provision, activity, and productivity in England since the 1980s	BRITISH MEDICAL JOURNAL			English	Article									NHS Confederat, London SW1P 4ND, England; Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, N (corresponding author), NHS Confederat, London SW1P 4ND, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827				APPLEBY J, 1997, HLTH SERV J, V107, P36; *DEP HLTH, 1998, OUTP WARD ATT ENGL; *DEP HLTH, 1998, BED AV ENGL; Department of Health and Social Security, 1983, NHS MAN ENQ; Edwards N, 1997, Health Serv J, V107, P26; EDWARDS N, 1996, HLTH SERV J, V106, P24; Kendrick S, 1995, Health Serv J, V105, P26; LAINGS, 1993, LAINGS REV PRIVATE H; VETTER N., 1995, HOSP CTR EXCELLENCE	9	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					911	914		10.1136/bmj.319.7214.911	http://dx.doi.org/10.1136/bmj.319.7214.911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506055	Green Published			2022-12-28	WOS:000082975600034
J	Morris, PJ; Johnson, RJ; Fuggle, SV; Belger, MA; Briggs, JD				Morris, PJ; Johnson, RJ; Fuggle, SV; Belger, MA; Briggs, JD		UKTSSA	Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK	LANCET			English	Article							KIDNEY-TRANSPLANTS; SURVIVAL; ALLOGRAFTS	Background In the UK, kidneys are exchanged between centres on the basis of matching for HLA, We analysed various factors that might affect graft outcome to establish whether exchange of kidneys on this basis remains valid. Methods 6363 primary cadaveric renal transplants carried out in 23 centres in the UK between 1986 and 1993 were used in the analysis. 6338 (99.6%) patients who underwent transplantation were followed up at 1 year. 5-year follow-up data were available for 2907 (97.8%) of the 2972 patients who survived to 5 years. We made random checks to validate the data. A multifactorial analysis with Cox's proportional hazards models was used to analyse factors that had a possible effect on graft outcome. To ensure that the analysis of matching was constant during the 8-year study, our analysis was based on the HLA antigens used for organ exchange (11 A locus antigens, 27 B locus antigens, and 12 DR locus antigens). We assessed overall outcome at 5 years and during three periods after transplantation at: 0-3 months, 3-36 months, and after 36 months. Findings The following factors were significantly associated with graft outcome in the multifactorial analysis: year of graft, age of donor, age of recipient, whether the recipient had diabetes, cause of donor's death, cold ischaemic time, transport of kidneys, transplant centre, and matching for HLA. The best outcome was achieved with kidneys that had no mismatches at HLA-A, HLA-B, and HLA-DR loci (000 mismatches). The next most favourable outcome was achieved with one mismatch at either A or B loci or one mismatch at both the A and B, but no mismatch at the DR locus (100, 010, or 110 mismatches). Age of the donor and recipient had a significant effect on transplant outcome: older age was associated with increased risk of graft failure. Interpretation Various factors affect the outcome of primary cadaveric renal transplantation, particularly the age of the donor and the recipient. However, the effect of matching for HLA remains a strong one and fully justifies the continuing policy in the UK of exchanging kidneys on the basis of HLA matching, especially to recipients when there is a 000 mismatch for HLA between donor and recipient. On the basis of this analysis, a new allocation scheme for kidneys was introduced in the UK in 1998, During the first 9 months of the scheme, there has been a doubling of the number of HLA-000 mismatched kidneys transplanted.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England; UK Transplant Support Serv Author, Bristol, Avon, England	University of Oxford	Morris, PJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.			Johnson, Rachel/0000-0001-9199-3455				Cecka J M, 1998, Clin Transpl, P1; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; CHERTOW G, 1995, KIDNEY INT S, V52, P548; CHO YW, 1995, CLIN TRANSPLANTS 199, P453; FISCHEL RJ, 1991, TRANSPLANTATION, V51, P118, DOI 10.1097/00007890-199101000-00018; GABER LW, 1995, TRANSPLANTATION, V60, P334, DOI 10.1097/00007890-199508270-00006; GILKS WR, 1986, TRANSPLANTATION, V42, P39, DOI 10.1097/00007890-198607000-00008; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; HELD PJ, 1994, NEW ENGL J MED, V331, P765, DOI 10.1056/NEJM199409223311203; Koo DDH, 1998, AM J PATHOL, V153, P557, DOI 10.1016/S0002-9440(10)65598-8; OPELZ G, 1993, TRANSPLANTATION, V55, P782; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; PETERS TG, 1995, TRANSPLANTATION, V59, P191, DOI 10.1097/00007890-199501270-00007; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TERASAKI PI, 1994, TRANSPLANTATION, V57, P1450, DOI 10.1097/00007890-199405270-00008; TESI RJ, 1994, LANCET, V343, P461, DOI 10.1016/S0140-6736(94)92698-0; THOROGOOD J, 1992, TRANSPLANTATION, V54, P152, DOI 10.1097/00007890-199207000-00027; THOROGOOD J, 1991, TRANSPLANTATION, V52, P831, DOI 10.1097/00007890-199111000-00015	18	196	200	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1147	1152		10.1016/S0140-6736(99)01104-6	http://dx.doi.org/10.1016/S0140-6736(99)01104-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513707				2022-12-28	WOS:000082954100009
J	Liljas, A				Liljas, A			Perspectives: Structure - Function is structure	SCIENCE			English	Editorial Material							ELONGATION-FACTOR-G; CRYSTAL-STRUCTURE; RESOLUTION		Univ Lund, Ctr Chem & Chem Engn, Dept Mol Biophys, SE-22100 Lund, Sweden	Lund University	Liljas, A (corresponding author), Univ Lund, Ctr Chem & Chem Engn, Dept Mol Biophys, POB 124,SE-221, SE-22100 Lund, Sweden.							AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GARRETT RA, RIBOSOME STRUCTURE F; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; YONATH A, COMMUNICATION; YONATH AE, 1980, BIOCHEM INT, V1, P428	14	13	15	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2077	2078		10.1126/science.285.5436.2077	http://dx.doi.org/10.1126/science.285.5436.2077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523206				2022-12-28	WOS:000082734300029
J	Ridley, BA; Nivi, B; Jacobson, JM				Ridley, BA; Nivi, B; Jacobson, JM			All-inorganic field effect transistors fabricated by printing	SCIENCE			English	Article							SEMICONDUCTOR NANOCRYSTALS; NANOCLUSTERS; TEMPERATURE	A solution of cadmium selenide nanocrystals was used to print inorganic thin-film transistors with field effect mobilities up to 1 square centimeter per volt second. This mobility is an order of magnitude larger than those reported for printed organic transistors. A field effect was achieved by developing a synthesis that yielded discretely sized nanocrystals less than 2 nanometers in size, which were free of intimately bound organic capping groups. The resulting nanocrystal solution exhibited low-temperature grain growth, which formed single crystal areas encompassing hundreds of nanocrystals, This process suggests a route to inexpensive, all-printed, high-quality inorganic logic on plastic substrates.	MIT, Media Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Jacobson, JM (corresponding author), MIT, Media Lab, 20 Ames St, Cambridge, MA 02139 USA.	jacobson@media.mit.edu		Jacobson, Joseph/0000-0002-1332-3197				Alivisatos AP, 1998, MRS BULL, V23, P18, DOI 10.1557/S0883769400031225; Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834; Behrens S, 1996, ANGEW CHEM INT EDIT, V35, P2215, DOI 10.1002/anie.199622151; BOWENKATARI JE, 1994, J PHYS CHEM-US, V98, P4109, DOI DOI 10.1021/J100066A034); BRODY TP, 1992, P SOC PHOTO-OPT INS, V1664, P2, DOI 10.1117/12.60344; BRODY TP, 1997, IEEE ELECTR DEVICE L, V18, P5; Brus L, 1998, J PHYS CHEM SOLIDS, V59, P459, DOI 10.1016/S0022-3697(97)00201-1; BUFFAT P, 1976, PHYS REV A, V13, P2287, DOI 10.1103/PhysRevA.13.2287; DODABALAPUR A, 1998, APPL PHYS LETT, V73, P2; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; Garnier F, 1998, APPL PHYS LETT, V73, P1721, DOI 10.1063/1.122257; Goldstein AN, 1996, APPL PHYS A-MATER, V62, P33, DOI 10.1007/BF01568084; GOLDSTEIN AN, 1992, SCIENCE, V256, P1425, DOI 10.1126/science.256.5062.1425; HERRON N, 1993, SCIENCE, V259, P1426, DOI 10.1126/science.259.5100.1426; JACOBSON JM, 1999, ANN M MAT RES SOC G; Kuno M, 1997, J CHEM PHYS, V106, P9869, DOI 10.1063/1.473875; Lin YY, 1997, IEEE ELECTR DEVICE L, V18, P606, DOI 10.1109/55.644085; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; REITA C, 1993, INFORM DISPLAY, V2, P10; SCHULTZ DL, 1997, AM I PHYS C P, V394, P683; SCILLA GJ, 1981, J VAC SCI TECHNOL, V18, P37, DOI 10.1116/1.570696; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; STEIGERWALD ML, 1988, J AM CHEM SOC, V110, P3046, DOI 10.1021/ja00218a008; VANCALSTER A, 1988, J CRYST GROWTH, V86, P924, DOI 10.1016/0022-0248(90)90826-7; VOSSMEYER T, 1994, J PHYS CHEM-US, V98, P7665, DOI 10.1021/j100082a044; 1992, MAT RES SOC S P, V272, P229; 1996, MAT RES SOC S P, V426, P349; 1991, MAT RES SOC S P, V206, P271; 1997, MAT RES SOC S P, V472, P439	29	401	494	3	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					746	749		10.1126/science.286.5440.746	http://dx.doi.org/10.1126/science.286.5440.746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531054				2022-12-28	WOS:000083303200046
J	Whitley, E; Gunnell, D; Dorling, D; Smith, GD				Whitley, E; Gunnell, D; Dorling, D; Smith, GD			Ecological study of social fragmentation, poverty, and suicide	BRITISH MEDICAL JOURNAL			English	Article							VOTING-PATTERNS; MORTALITY; ENGLAND; WALES; AREA; PARASUICIDE; DEPRIVATION; HEALTH; RISK	Objectives To investigate the association between suicide and area based measures of deprivation and social fragmentation. Design Ecological study. Setting 633 parliamentary constituencies of Great Britain as defined in 1991. Main outcome measures Age and sex specific mortality rates for suicide and all other causes for 1981-92, Results Mortality from suicide and all other causes increased with increasing Townsend deprivation score, social fragmentation score, and abstention from voting in all age and sex groups. Suicide mortality was most strongly related to social fragmentation, whereas deaths from other causes were more closely associated with Townsend score. Constituencies with absolute increases in social fragmentation and Townsend scores between 1981 and 1991 tended to have greater increases in suicide rates over the same period. The relation between change in social fragmentation and suicide was largely independent of Townsend score, whereas the association with Townsend score was generally reduced after adjustment for social fragmentation. Conclusions Suicide rates are more strongly associated with measures of social fragmentation than with poverty at a constituency level.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Sch Geog Sci, Bristol BS8 2PR, Avon, England	University of Bristol; University of Bristol	Whitley, E (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.		Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470				ASHFORD JR, 1976, INT J EPIDEMIOL, V5, P133, DOI 10.1093/ije/5.2.133; BUNTING J, 1998, POPULATION TRENDS, V93, P7; Carstairs V, 1995, J EPIDEMIOL COMMUN H, V49, pS3, DOI 10.1136/jech.49.Suppl_2.S3; Charlton J., 1992, Population Trends, P10; CHARLTON J, 1995, INT J EPIDEMIOL, V24, pS45, DOI 10.1093/ije/24.Supplement_1.S45; Congdon P, 1996, URBAN STUD, V33, P137, DOI 10.1080/00420989650012194; Durkheim E, 1952, SUICIDE STUDY SOCIOL; GUNNELL DJ, 1995, BRIT MED J, V311, P226, DOI 10.1136/bmj.311.6999.226; LESTER D, 1988, SOC PSYCH PSYCH EPID, V23, P202, DOI 10.1007/BF01794789; MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; Sainsbury P, 1955, SUICIDE LONDON; Saunderson T, 1998, J PUBLIC HEALTH MED, V20, P261, DOI 10.1093/oxfordjournals.pubmed.a024767; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; Smith GD, 1997, BRIT MED J, V315, P430, DOI 10.1136/bmj.315.7105.430; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; Smith GD, 1996, BRIT MED J, V313, P1573, DOI 10.1136/bmj.313.7072.1573; Townsend PP., 1988, HLTH DEPRIVATION INE	18	169	173	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1034	1037		10.1136/bmj.319.7216.1034	http://dx.doi.org/10.1136/bmj.319.7216.1034			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521194	Green Published, Bronze			2022-12-28	WOS:000083210100025
J	McInnes, BIA; McBride, JS; Evans, NJ; Lambert, DD; Andrew, AS				McInnes, BIA; McBride, JS; Evans, NJ; Lambert, DD; Andrew, AS			Osmium isotope constraints on ore metal recycling in subduction zones	SCIENCE			English	Article							PLATINUM-GROUP ELEMENTS; RE-OS; ABYSSAL PERIDOTITES; SULFIDE DEPOSITS; OCEANIC-CRUST; UPPER-MANTLE; SYSTEMATICS; COMPLEX; OXYGEN; GOLD	Veined peridotite xenoliths from the mantle beneath the giant Ladolam gold deposit on Lihir Island, Papua New Guinea, are 2 to 800 times more enriched in copper, gold, platinum, and palladium than surrounding depleted are mantle. Cold ores have osmium isotope compositions similar to those of the underlying subduction-modified mantle peridotite source region, indicating that the primary origin of the metals was the mantle. Because the mantle is relatively depleted in gold, copper, and palladium, tectonic processes that enhance the advective transport and concentration of these fluid soluble metals may be a prerequisite for generating porphyry-epithermal copper-gold deposits.	CSIRO, N Ryde, NSW 6170, Australia; Monash Univ, Dept Earth Sci, Clayton, Vic 3168, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Monash University	McInnes, BIA (corresponding author), CSIRO, POB 136, N Ryde, NSW 6170, Australia.		McInnes, Brent/B-7408-2013; MCINNES, BRENT/N-3049-2019; Andrew, Anita/R-5327-2019	MCINNES, BRENT/0000-0002-2776-0574; Andrew, Anita/0000-0002-3032-9187; Evans, Noreen/0000-0002-7615-8328				BALLHAUS C, 1994, GEOCHIM COSMOCHIM AC, V58, P811, DOI 10.1016/0016-7037(94)90507-X; BEZMEN NI, 1994, GEOCHIM COSMOCHIM AC, V58, P1251, DOI 10.1016/0016-7037(94)90379-4; BOUDREAU AE, 1986, J PETROL, V27, P967, DOI 10.1093/petrology/27.4.967; Brandon AD, 1996, SCIENCE, V272, P861, DOI 10.1126/science.272.5263.861; CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; COCKER JD, 1982, EARTH PLANET SC LETT, V61, P112, DOI 10.1016/0012-821X(82)90043-7; Eiler JM, 1998, NATURE, V393, P777, DOI 10.1038/31679; ELIOPOULOS DG, 1991, ECON GEOL BULL SOC, V86, P740, DOI 10.2113/gsecongeo.86.4.740; Exon N. F., 1986, BMR Journal of Australian Geology & Geophysics, V10, P39; Fleet ME, 1996, GEOCHIM COSMOCHIM AC, V60, P2397, DOI 10.1016/0016-7037(96)00100-7; Foster JG, 1996, NATURE, V382, P703, DOI 10.1038/382703a0; Freydier C, 1997, GEOLOGY, V25, P775, DOI 10.1130/0091-7613(1997)025<0775:ROISOS>2.3.CO;2; FUROMOTO AS, 1976, TECTONOPHYSICS, V34, P71; GREGORY RT, 1981, J GEOPHYS RES, V86, P2737, DOI 10.1029/JB086iB04p02737; HART SR, 1993, EOS, P120; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; HERZIG P, 1994, EOS, V75, P513; HERZIG PM, 1995, PACRIM C 1995, V9, P279; JAMES DE, 1981, ANNU REV EARTH PL SC, V9, P311, DOI 10.1146/annurev.ea.09.050181.001523; KYSER TK, 1986, REV MINERAL, V16, P141; Lambert DD, 1998, ECON GEOL BULL SOC, V93, P121, DOI 10.2113/gsecongeo.93.2.121; LAMBERT DD, 1994, J PETROL, V35, P1717, DOI 10.1093/petrology/35.6.1717; Lambert DD, 1998, AUST J EARTH SCI, V45, P265, DOI 10.1080/08120099808728386; Loucks RR, 1999, SCIENCE, V284, P2159, DOI 10.1126/science.284.5423.2159; MCCANDLESS TE, 1991, GEOLOGY, V19, P1225, DOI 10.1130/0091-7613(1991)019<1225:OIACSF>2.3.CO;2; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; McInnes B., 1994, EOS, V75, P747; MCINNES B, UNPUB; MCINNES BIA, 1999, RES REV, V1, P11; MCINNES BIA, 1996, COMPOSITION STRUCTUR; Mitchell A.H.G., 1972, I MINING METALLURG B, V81, pB10; MITCHELL RH, 1981, GEOCHIM COSMOCHIM AC, V45, P2425, DOI 10.1016/0016-7037(81)90096-X; MUEHLENBACHS K, 1986, REV MINERAL, V16, P425; Mutschler F.E., 1985, T GEOL SOC S AFR, V88, P355; PEACH CL, 1990, GEOCHIM COSMOCHIM AC, V54, P3379, DOI 10.1016/0016-7037(90)90292-S; PRICHARD HM, 1988, CAN MINERAL, V26, P979; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; SASSANI DC, 1990, GEOLOGY, V18, P925, DOI 10.1130/0091-7613(1990)018<0925:SASOPI>2.3.CO;2; SAWKINS FJ, 1972, J GEOL, V80, P377, DOI 10.1086/627762; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; Shirey SB, 1997, CAN J EARTH SCI, V34, P489, DOI 10.1139/e17-040; SHIREY SB, 1995, ANAL CHEM, V67, P235; SILLITOE RH, 1972, ECON GEOL, V67, P184, DOI 10.2113/gsecongeo.67.2.184; SILLITOE RH, 1983, UNCONVENTIONAL METAL, P207; Smoliar MI, 1996, SCIENCE, V271, P1099, DOI 10.1126/science.271.5252.1099; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; TARDUNO JA, 1991, SCIENCE, V254, P399, DOI 10.1126/science.254.5030.399; TARKIAN M, 1995, MINER DEPOSITA, V30, P39; WALKER RJ, 1994, GEOCHIM COSMOCHIM AC, V58, P4179, DOI 10.1016/0016-7037(94)90272-0; WALKER RJ, 1991, EARTH PLANET SC LETT, V105, P416, DOI 10.1016/0012-821X(91)90182-H; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WALKER RJ, 1989, SCIENCE, V243, P519, DOI 10.1126/science.243.4890.519; WIDOM E, 1999, EOS T, V80, P354	54	237	252	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					512	516		10.1126/science.286.5439.512	http://dx.doi.org/10.1126/science.286.5439.512			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521343				2022-12-28	WOS:000083121200055
J	Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD				Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD			Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS	Background For decades it has been assumed that postprimary tuberculosis is usually caused by reactivation of endogenous infection rather than by a new, exogenous infection. Methods We performed DNA fingerprinting with restriction-fragment-length polymorphism analysis on pairs of isolates of Mycobacterium tuberculosis from 16 compliant patients who had a relapse of pulmonary tuberculosis after curative treatment of post-primary tuberculosis. The patients lived in areas of South Africa where tuberculosis is endemic. Medical records were reviewed for clinical data. Results For 12 of the 16 patients, the restriction-fragment-length polymorphism banding patterns for the isolates obtained after the relapse were different from those for the isolates from the initial tuberculous disease. This finding indicates that reinfection was the cause of the recurrence of tuberculosis after curative treatment. Two patients had reinfections with a multidrug-resistant strain. All 15 patients who were tested for the human immunodeficiency virus were seronegative. Conclusions Exogenous reinfection appears to be a major cause of postprimary tuberculosis after a previous cure in an area with a high incidence of this disease. This finding emphasizes the importance of achieving cures and of preventing anyone with infectious tuberculosis from exposing others to the disease. (N Engl J Med 1999;341:1174-9.) (C)1999, Massachusetts Medical Society.	Univ Stellenbosch, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Katholieke Univ Leuven, Dept Pediat, Louvain, Belgium	Stellenbosch University; Stellenbosch University; Stellenbosch University; KU Leuven	van Helden, PD (corresponding author), Univ Stellenbosch, Dept Biochem Med, POB 19063, ZA-7505 Tygerberg, South Africa.		Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Warren, Robin/0000-0001-5741-7358				ALLAN WGL, 1982, TUBERCLE, V63, P89; ALLAN WGL, 1977, AM REV RESPIR DIS, V115, P727; Beyers N, 1996, S AFR MED J, V86, P40; BRITISH THORACIC ASSOCIATION, 1982, American Review of Respiratory Disease, V126, P460; CANETTI G, 1972, Bulletin of the International Union Against Tuberculosis, V47, P116; DAS S, 1993, TUBERCLE LUNG DIS, V74, P48; KATZ HL, 1958, VETERANS ADM ARMED F, P214; MCKINNEY JD, 1997, PERSISTING PROBLEMS, P69; MITCHISON DA, 1980, TUBERCLE, V61, P135, DOI 10.1016/0041-3879(80)90002-1; SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037, DOI 10.1128/JCM.33.11.3037-3039.1995; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1991, P TUBERC RES COUNC, V24, P62; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; Warren R, 1996, J CLIN MICROBIOL, V34, P2219, DOI 10.1128/JCM.34.9.2219-2224.1996	15	471	483	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1174	1179		10.1056/NEJM199910143411602	http://dx.doi.org/10.1056/NEJM199910143411602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519895				2022-12-28	WOS:000083087400002
J	Laffey, JG; Kavanagh, BP				Laffey, JG; Kavanagh, BP			Carbon dioxide and the critically ill - too little of a good thing?	LANCET			English	Article							RESPIRATORY-DISTRESS-SYNDROME; BRONCHOPULMONARY DYSPLASIA; PERMISSIVE HYPERCAPNIA; ACIDOSIS; RAT; VENTILATION; HYPOCAPNIA; MORTALITY; ADULT; BRAIN	Permissive hypercapnia (acceptance of raised concentrations of carbon dioxide in mechanically ventilated patients) may be associated with increased survival as a result of less ventilator-associated lung injury. Conversely, hypocapnia is associated with many acute illnesses (eg, asthma, systemic inflammatory response syndrome, pulmonary oedema), and is thought to reflect underlying hyperventilation. Accumulating clinical and basic scientific evidence points to an active role for carbon dioxide in organ injury, in which raised concentrations of carbon dioxide are protective, and low concentrations are injurious. We hypothesise that therapeutic hypercapnia might be tested in severely ill patients to see whether supplemental carbon dioxide could reduce the adverse effects of hypocapnia and promote the beneficial effects of hypercapnia. Such an approach could also expand our understanding of the pathogenesis of disorders in which hypocapnia is a constitutive element.	Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Dept Anaesthesia, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Med Surg Intens Care Unit, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Kavanagh, BP (corresponding author), Hosp Sick Children, Dept Crit Care, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bpk@sickkids.on.ca	Laffey, John/G-4204-2010	Laffey, John/0000-0002-1246-9573				ABUROMEH S, 1986, AM J PHYSIOL, V250, pF702, DOI 10.1152/ajprenal.1986.250.4.F702; Allen DB, 1997, ARCH SURG-CHICAGO, V132, P991; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Berkowitz BA, 1996, INVEST OPHTH VIS SCI, V37, P2089; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Cardenas VJ, 1996, CRIT CARE MED, V24, P827, DOI 10.1097/00003246-199605000-00017; CUTILLO A, 1974, AM REV RESPIR DIS, V110, P25; du Plessis AJ, 1997, J THORAC CARDIOV SUR, V114, P991, DOI 10.1016/S0022-5223(97)70013-8; GARLAND JS, 1995, ARCH PEDIAT ADOL MED, V149, P617, DOI 10.1001/archpedi.1995.02170190027005; Gewirtz AT, 1998, J LEUKOCYTE BIOL, V64, P98, DOI 10.1002/jlb.64.1.98; Graziani LJ, 1997, CLIN PERINATOL, V24, P655, DOI 10.1016/S0095-5108(18)30163-5; HASHIMOTO K, 1991, BRAIN DEV-JPN, V13, P155, DOI 10.1016/S0387-7604(12)80021-0; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1995, ACTA ANAESTH SCAND, V39, P201, DOI 10.1111/j.1399-6576.1995.tb04359.x; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HOLMES JM, 1994, CURR EYE RES, V13, P779, DOI 10.3109/02713689409047013; Hood VL, 1998, NEW ENGL J MED, V339, P819, DOI 10.1056/NEJM199809173391207; HORNBEIN TF, 1989, NEW ENGL J MED, V321, P1714, DOI 10.1056/NEJM198912213212505; KITAKAZE M, 1988, J CLIN INVEST, V82, P920, DOI 10.1172/JCI113699; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NOMURA F, 1994, CIRCULATION, V90, P321; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; OYARZUN MJ, 1986, RESPIRATION, V49, P187, DOI 10.1159/000194878; Parfenova H, 1996, AM J PHYSIOL-CELL PH, V270, pC1503, DOI 10.1152/ajpcell.1996.270.5.C1503; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; REYNOLDS AM, 1992, AM REV RESPIR DIS, V145, P80, DOI 10.1164/ajrccm/145.1.80; Saugstad OD, 1997, ACTA PAEDIATR, V86, P1277, DOI 10.1111/j.1651-2227.1997.tb14897.x; Serrano CV, 1996, AM J PHYSIOL-CELL PH, V271, pC962, DOI 10.1152/ajpcell.1996.271.3.C962; Shibata K, 1998, AM J RESP CRIT CARE, V158, P1578, DOI 10.1164/ajrccm.158.5.9804039; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Torbati D, 1998, CRIT CARE MED, V26, P1863, DOI 10.1097/00003246-199811000-00030; VANNUCCI RC, 1995, PEDIATRICS, V95, P868; Wang HC, 1996, FASEB J, V10, P1318, DOI 10.1096/fasebj.10.11.8836046; WUNG JT, 1985, PEDIATRICS, V76, P488; Xu LJ, 1998, NEUROREPORT, V9, P875, DOI 10.1097/00001756-199803300-00021; Yamaguchi K, 1996, AM J PHYSIOL-HEART C, V270, pH252, DOI 10.1152/ajpheart.1996.270.1.H252	39	171	177	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1283	1286		10.1016/S0140-6736(99)02388-0	http://dx.doi.org/10.1016/S0140-6736(99)02388-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520649				2022-12-28	WOS:000083010400044
J	Casalino, LP				Casalino, LP			The unintended consequences of measuring quality on the quality of medical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE; PHYSICIANS; MANAGEMENT; REFORM; SYSTEM; AGENT; WORK		Stanford Coastside Med Clin, Half Moon Bay, CA 94019 USA	Stanford University	Casalino, LP (corresponding author), Stanford Coastside Med Clin, Half Moon Bay, CA 94019 USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				Abbott A., 1988, SYSTEM PROFESSIONS E; Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; ARROW KJ, 1963, AM ECON REV, V53, P941; Belkin GS, 1997, J HEALTH POLIT POLIC, V22, P509, DOI 10.1215/03616878-22-2-509; Berwick D. M, 1990, CURING HLTH CARE NEW; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Blumenthal D, 1998, MILBANK Q, V76, P625, DOI 10.1111/1468-0009.00108; BLUMENTHAL D, 1994, HEALTH AFFAIR, V13, P252, DOI 10.1377/hlthaff.13.1.252; BLUMENTHAL D, 1994, NEW ENGL J MED, V331, P1017, DOI 10.1056/NEJM199410133311511; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; BLUMENTHAL D, 1995, IMPROVING CLIN PRACT; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; Brook RH, 1997, JAMA-J AM MED ASSOC, V278, P1612, DOI 10.1001/jama.278.19.1612; CASALINO LP, 1997, EVOLUTION MED GROUPS; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Coye MJ, 1998, MILBANK Q, V76, P759, DOI 10.1111/1468-0009.00117; DETSKY AS, 1995, NEW ENGL J MED, V333, P589, DOI 10.1056/NEJM199508313330911; Dudley RA, 1998, MILBANK Q, V76, P649, DOI 10.1111/1468-0009.00109; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Freidson E., 1994, PROFESSIONALISM REBO; FREY BS, 1993, ECON INQ, V31, P663, DOI 10.1111/j.1465-7295.1993.tb00897.x; HAFFERTY FW, 1995, J HEALTH SOC BEHAV, V35, P132, DOI 10.2307/2626961; Hansmann Henry B., 1996, OWNERSHIP ENTERPRISE; James E., 1986, NONPROFIT ENTERPRISE; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; McGlynn EA, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.3.7; MEIER B, 1996, NY TIMES        0402, pD8; MEYER MW, 1994, HDB EC SOCIOLOGY, P556; Milgrom P., 1992, EC ORG MANAGEMENT; Newcomer LN, 1998, HEALTH AFFAIR, V17, P32, DOI 10.1377/hlthaff.17.4.32; North D.C., 1990, I I CHANGE EC PERFOR; Parsons T., 1951, SOCIAL SYSTEM; Saks Mike, 1994, PROFESSIONS PUBLIC I; SAPPINGTON DEM, 1991, J ECON PERSPECT, V5, P45, DOI 10.1257/jep.5.2.45; Schlackman N, 1993, Am J Med Qual, V8, P103, DOI 10.1177/0885713X9300800214; Schlesinger M, 1996, J HEALTH POLIT POLIC, V21, P697, DOI 10.1215/03616878-21-4-697; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Sharma A, 1997, ACAD MANAGE REV, V22, P758, DOI 10.2307/259412; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Smith MA, 1997, JAMA-J AM MED ASSOC, V278, P1573, DOI 10.1001/jama.278.19.1573; Starr P, 1982, SOCIAL TRANSFORMATIO; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; Zbaracki MJ, 1998, ADMIN SCI QUART, V43, P602, DOI 10.2307/2393677	50	142	143	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1147	1150		10.1056/NEJM199910073411511	http://dx.doi.org/10.1056/NEJM199910073411511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245BW	10511617				2022-12-28	WOS:000083087200011
J	Wisner, KL; Gelenberg, AJ; Leonard, H; Zarin, D; Frank, E				Wisner, KL; Gelenberg, AJ; Leonard, H; Zarin, D; Frank, E			Pharmacologic treatment of depression during pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SEROTONIN REUPTAKE INHIBITORS; BIRTH OUTCOMES; PSYCHIATRIC-ILLNESS; STRESS; MANAGEMENT; FLUOXETINE; WITHDRAWAL; SYMPTOMS; AGE	Context Despite the frequency of depression in women of childbearing age, information to guide patients and physicians through a consideration of treatment during pregnancy is limited. Objective To identify risk factors associated with treatment of major depression during pregnancy to help physicians develop treatment plans that optimize clinical care. Data Sources Reports of prospective controlled trials in English were identified from MEDLINE and Health STAR using the search terms antidepressant during pregnancy and depression during pregnancy, by manually searching bibliographies of review articles, and through discussions with investigators for 1989-1999. Study Selection We selected studies in which maternal and infant health outcomes associated with antidepressant exposure were compared with those of non-teratogen-exposed controls. Four studies published since 1993 were identified and included in the analysis. Data Extraction We abstracted information about identification of subjects, comparison groups, pregnancy, and birth outcomes. We organized the data along 5 domains of reproductive toxicity: intrauterine fetal death, morphologic teratogenicity, growth impairment, behavioral teratogenicity, and neonatal toxicity. Data Synthesis Data were available for tricyclic antidepressants (collectively), fluoxetine, and newer selective serotonin reuptake inhibitors (collectively), Exposure to these agents did not increase risk for intrauterine death or major birth defects. Decreased birth weights of infants exposed to fluoxetine in the third trimester were identified in 1 study. The development of children whose mothers took tricyclics or fluoxetine during gestation did not differ from that of controls. Direct drug effects and withdrawal syndromes occurred in some neonates whose mothers were treated with antidepressants near term, Conclusions Although few in number, new information from prospective studies provides a welcome change from decision making based on nonprospective data. Monitoring and interventions for patients with identified risks leg, poor weight gain) are recommended.	Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Univ Arizona, Hlth Sci Ctr, Dept Psychiat, Tucson, AZ USA; Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USA; Amer Psychiat Assoc, Washington, DC USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA	Case Western Reserve University; University of Arizona; University of Arizona Health Sciences; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	Wisner, KL (corresponding author), Case Western Reserve Univ, Sch Med, Suite 280,11400 Euclid Ave, Cleveland, OH 44106 USA.			Wisner, Katherine/0000-0003-3458-5986	PHS HHS [R01 53735, R01 57102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altshuler LL, 1996, AM J PSYCHIAT, V153, P592; *AM MED ASS, 1983, AMA DRUG EV, P31; *AM PSYCH ASS, 1993, AM J PSYCHIAT S, V150, P4; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P1255; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1037, DOI 10.1001/jama.281.11.1037; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; BURKE KC, 1991, ARCH GEN PSYCHIAT, V48, P789; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Cohen LS, 1997, NEW ENGL J MED, V336, P872; COWE L, 1982, BRIT MED J, V284, P1837, DOI 10.1136/bmj.284.6332.1837-a; Eggermont E, 1972, Acta Paediatr Belg, V26, P197; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Gracious B L, 1997, Depress Anxiety, V6, P124, DOI 10.1002/(SICI)1520-6394(1997)6:3<124::AID-DA6>3.0.CO;2-D; Guy W., 1976, DHEW PUBL; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hutchings DE, 1983, TERATOGENESIS REPROD, P207; ISTVAN J, 1986, PSYCHOL BULL, V100, P331, DOI 10.1037/0033-2909.100.3.331; JONES KL, 1974, LANCET, V1, P1076; KENT LSW, 1995, BRIT J PSYCHIAT, V167, P412, DOI 10.1192/bjp.167.3.412b; KETTER TA, 1995, J CLIN PSYCHOPHARM, V15, P387, DOI 10.1097/00004714-199512000-00002; Kulin NA, 1998, JAMA-J AM MED ASSOC, V279, P609, DOI 10.1001/jama.279.8.609; Lane RM, 1996, INT CLIN PSYCHOPHARM, V11, P31, DOI 10.1097/00004850-199612005-00005; LEPPIG KA, 1987, J PEDIATR, V110, P530; LIVEZEY GT, 1992, DRUG THERAPY OBSTET, P3; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; OHARA MW, 1984, J ABNORM PSYCHOL, V93, P158, DOI 10.1037/0021-843X.93.2.158; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; PAVY TJG, 1995, CAN J ANAESTH, V42, P618, DOI 10.1007/BF03011881; PEINDL KS, 1996, PRIM PSYCHIAT, V3, P43; PEREZ V, 1971, AM J OBSTET GYNECOL, V110, P428, DOI 10.1016/0002-9378(71)90747-2; Robert E, 1996, NEW ENGL J MED, V335, P1056, DOI 10.1056/NEJM199610033351411; SANDMAN CA, 1994, ANN NY ACAD SCI, V739, P198, DOI 10.1111/j.1749-6632.1994.tb19822.x; STEER RA, 1992, J CLIN EPIDEMIOL, V45, P1093, DOI 10.1016/0895-4356(92)90149-H; Torchia, 1998, DEV HUMAN CLIN ORIEN; Wadelius M, 1997, CLIN PHARMACOL THER, V62, P400, DOI 10.1016/S0009-9236(97)90118-1; WADHWA PD, 1993, AM J OBSTET GYNECOL, V169, P858, DOI 10.1016/0002-9378(93)90016-C; WEBSTER PAC, 1973, LANCET, V2, P318; Wilson J. G., 1977, HDB TERATOLOGY, V1, P47; WISNER KL, 1993, J AFFECT DISORDERS, V28, P39, DOI 10.1016/0165-0327(93)90075-U; WISNER KL, 1993, AM J PSYCHIAT, V150, P1541; Wisner KL, 1997, PSYCHOPHARMACOL BULL, V33, P243; Wisner KL, 1997, SEMIN REPROD ENDOCR, V15, P77, DOI 10.1055/s-2008-1067970; Wisner KL, 1988, PSYCHIAT CONSULTATIO, P165; ZIMMERMAN M, 1986, ARCH GEN PSYCHIAT, V43, P1076; ZUCKERMAN B, 1990, J DEV BEHAV PEDIATR, V11, P190; 1997, FED REG, V97, P20247; 1995, US NEWS WORLD R 0327	48	142	146	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1264	1269		10.1001/jama.282.13.1264	http://dx.doi.org/10.1001/jama.282.13.1264			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517430				2022-12-28	WOS:000082901100035
J	Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP				Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP			Animal behaviour - Aquatic sex pheromone from a male tree frog	NATURE			English	Article							SKIN; PEPTIDE; LITORIA		Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Environm Biol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide; University of Adelaide	Wabnitz, PA (corresponding author), Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia.		Smith, Ben PC/GXZ-8778-2022; , John/AAP-5150-2020	Wabnitz, Paul/0000-0002-0820-9509; Smith, Benjamin/0000-0003-0651-9420				AGOSTA WC, 1994, J CHEM EDUC, V71, P242, DOI 10.1021/ed071p242; BIRCH MC, 1974, PHEROMONES, V32, P1; BUTENANDT A, 1984, TECHNIQUES PHEROMONE, P4; Erspamer V., 1993, AMPHIBIAN BIOL, P178; Houck LD, 1998, AM ZOOL, V38, P108; JOHNSTONE RE, 1983, PHEROMONES REPROD MA, P8; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; Steinborner ST, 1998, J PEPT RES, V51, P121; TYLER MJ, 1992, J PHARMACOL TOXICOL, V28, P199, DOI 10.1016/1056-8719(92)90004-K; Wabnitz PA, 1998, J PEPT RES, V52, P477; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x	12	106	111	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					444	445		10.1038/46724	http://dx.doi.org/10.1038/46724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519546				2022-12-28	WOS:000082981200043
J	Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C				Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C			Effect of second vaginal delivery on anorectal physiology and faecal continence: a prospective study	LANCET			English	Article							ANAL-SPHINCTER INJURY; FECAL INCONTINENCE; PELVIC FLOOR; CHILDBIRTH; DAMAGE; WOMEN	Background Because obstetric injury to the anal sphincters may be occult, and because the mechanism of injury differs between first and subsequent deliveries, we prospectively assessed the effects of first and second vaginal deliveries on anal physiology and continence. Methods We undertook a prospective observational study of 59 previously nulliparous women through two successive vaginal deliveries by means of a bower-function questionnaire, and an anorectal-physiology assessment, both antepartum and 6-12 weeks post parium. Findings 13 (22%) women reported altered faecal continence after their first vaginal delivery: eight had persistent symptoms during their second pregnancy, of whom seven deteriorated after the second delivery; five regained continence before their second pregnancy, but two became incontinent again after the second delivery. Five women developed incontinence for the first time after their second vaginal delivery, of whom three had occult primiparous sphincter injury. 20 (34%) women, seven of whom had no symptoms, had anal-sphincter injury as a result of their first delivery, but only two new injuries occurred after the second vaginal delivery (p=0.013). Although pudendal neuropathy was no more common after the second than after the first vaginal delivery (15 vs 19%, p=0.8), pudendal-nerve latency was longer after the second delivery (p=0.02). Interpretation Primiparous women with persistent symptoms of altered faecal continence experience deterioration after a second vaginal delivery. Women with transient faecal incontinence or occult anal-sphincter injury after their first vaginal delivery are at high risk of faecal incontinence after a second vaginal delivery. The risk of mechanical anal sphincter injury is greatest after the first delivery.	Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Dublin 2, Ireland; Mater Misericordiae Hosp, Dept Radiol, Dublin, Ireland; Mater Misericordiae Hosp, Dept Surg, Dublin, Ireland	National Maternity Hospital, Dublin; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin	O'Herlihy, C (corresponding author), Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Holles St, Dublin 2, Ireland.		O'Connell, Patrick Ronan/H-6583-2019	O'Connell, Patrick Ronan/0000-0002-1846-5629				ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BOYLAN P, ANN CLIN REPORTS 199; Campbell DM, 1996, CLIN RADIOL, V51, P559, DOI 10.1016/S0009-9260(96)80135-8; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; Donnelly V, 1998, OBSTET GYNECOL, V92, P955, DOI 10.1016/S0029-7844(98)00255-5; Donnelly V, 1997, BRIT J OBSTET GYNAEC, V104, P311, DOI 10.1111/j.1471-0528.1997.tb11459.x; Donnelly VS, 1998, DIS COLON RECTUM, V41, P586, DOI 10.1007/BF02235263; Fynes M, 1998, OBSTET GYNECOL, V92, P496, DOI 10.1016/S0029-7844(98)00256-7; Fynes MM, 1999, DIS COLON RECTUM, V42, P753, DOI 10.1007/BF02236930; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; ODRISCOLL MD, 1986, ACTIVE MANAGEMENT LA; PERRY RE, 1990, AM J SURG, V159, P112, DOI 10.1016/S0002-9610(05)80615-4; PESCATORI M, 1992, DIS COLON RECTUM, V35, P482, DOI 10.1007/BF02049407; SNOOKS JJ, 1985, COLOPROCTOLOGY PELVI, P112; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; Sultan AH, 1996, BRIT J OBSTET GYNAEC, V103, P731, DOI 10.1111/j.1471-0528.1996.tb09864.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636	23	149	151	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					983	986		10.1016/S0140-6736(98)11205-9	http://dx.doi.org/10.1016/S0140-6736(98)11205-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501360				2022-12-28	WOS:000082596000011
J	Krag, D; Moffat, F				Krag, D; Moffat, F			Nuclear medicine and the surgeon	LANCET			English	Article							SENTINEL LYMPH-NODE; BREAST-CANCER; GAMMA-PROBE; MELANOMA; SCINTIGRAPHY; LOCALIZATION; BIOPSY	Nuclear medicine provides the surgeon with important diagnostic acid functional information on specific organs and with therapy for a limited set of diseases. Clinical applications of nuclear medicine are beginning to guide surgeons to specific locations, notably to sentinel lymph nodes in patients with cancer. The role of radionuclide diagnosis in oncology has been covered earlier in this Lancet series,(1) so here is a surgeon's perspective on sentinel node and other oncological applications and on the surgical value of nuclear medicine in non-malignant diseases.	Univ Vermont, Dept Surg, Burlington, VT 05405 USA; Univ Miami, Sylvester Comprehens Canc Ctr, Div Surg Oncol, Miami, FL 33152 USA	University of Vermont; University of Miami	Krag, D (corresponding author), Univ Vermont, Dept Surg, Burlington, VT 05405 USA.							ALEX JC, 1993, SURG ONCOL, V2, P303, DOI 10.1016/S0960-7404(06)80006-X; Borgstein P, 1998, J AM COLL SURGEONS, V186, P275, DOI 10.1016/S1072-7515(98)00011-8; Braithwaite LR, 1923, BRIT J SURG, V11, P7, DOI 10.1002/bjs.1800114103; CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I; Corstens FHM, 1999, LANCET, V354, P765, DOI 10.1016/S0140-6736(99)06070-5; DUBOVSKY EV, 1995, SEMIN NUCL MED, V25, P49, DOI 10.1016/S0001-2998(05)80006-6; Eary JF, 1999, LANCET, V354, P853; FRILLING A, 1998, SURGERY, V124, P1037; GILEC SA, 1997, NUCL MED ANN 1997, P209; Gulec SA, 1997, NUCL MED A, P209; Hill ADK, 1999, ANN SURG, V229, P528, DOI 10.1097/00000658-199904000-00012; Hindie E, 1999, LANCET, V353, P2200, DOI 10.1016/S0140-6736(98)09089-8; Hoffman EJ, 1999, EUR J NUCL MED, V26, P913, DOI 10.1007/s002590050468; Hughes K, 1997, ANN SURG, V226, P621, DOI 10.1097/00000658-199711000-00007; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Krag D N, 1992, Surg Oncol, V1, P371, DOI 10.1016/0960-7404(92)90038-M; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; Martelli H, 1998, SURGERY, V123, P51, DOI 10.1016/S0039-6060(98)70228-4; Moffat FL, 1999, CANCER INVEST, V17, P322, DOI 10.3109/07357909909032874; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Mumtaz H, 1996, ANN ROY COLL SURG, V78, P420; NEGRIN JA, 1995, SEMIN NUCL MED, V25, P28, DOI 10.1016/S0001-2998(05)80004-2; Norman J, 1998, SURGERY, V124, P1088, DOI 10.1067/msy.1998.92007; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; Schwaiger M, 1999, LANCET, V354, P661, DOI 10.1016/S0140-6736(99)06057-2; SHAH AN, 1995, SEMIN NUCL MED, V25, P36, DOI 10.1016/S0001-2998(05)80005-4; Shi W, 1998, QJM-MON J ASSOC PHYS, V91, P295, DOI 10.1093/qjmed/91.4.295; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VENDRELLTORNE E, 1972, J NUCL MED, V13, P801; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0; Wioland M, 1996, EUR J NUCL MED, V23, P1003, DOI 10.1007/BF01084380; WOLTERING EA, 1995, PRINCIPLES PRACTICE, V9, P1; Yim JH, 1998, SURGERY, V124, P1037, DOI 10.1067/msy.1998.92553	34	6	6	2	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					1019	1022		10.1016/S0140-6736(99)06097-3	http://dx.doi.org/10.1016/S0140-6736(99)06097-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501381				2022-12-28	WOS:000082596000042
J	Carrell, RW				Carrell, RW			Biochemistry - How serpins are shaping up	SCIENCE			English	Editorial Material							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTITHROMBIN; ADHESION		Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Carrell, RW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.							Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BANDA M, 1998, J BIOL CHEM, V263, P4481; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Chang WSW, 1997, THROMB HAEMOSTASIS, V77, P323; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Preissner KT, 1997, THROMB HAEMOSTASIS, V78, P88; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; ZHOU A, IN PRESS BLOOD; 1999, P 2 INT S STRUCT BIO	12	23	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1861	+		10.1126/science.285.5435.1861	http://dx.doi.org/10.1126/science.285.5435.1861			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515791				2022-12-28	WOS:000082638300033
J	Druss, BG; Rosenheck, RA				Druss, BG; Rosenheck, RA			Association between use of unconventional therapies and conventional medical services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; ALTERNATIVE MEDICINE; UNITED-STATES; COSTS; DEPRESSION; CARE; PATTERNS	Context The terms alternative and complementary medicine suggest 2 contradictory possibilities. Whether individuals use unconventional therapies as a substitute for or as an "add on" to conventional medical treatments is uncertain. Objective To determine the association between use of unconventional therapies and conventional medical care in a national sample. Design, Setting, and Participants The 1996 Medical Expenditure Panel Survey was distributed to a probability sample of the noninstitutionalized civilian US population. Of 24 676 individuals responding (77.7% response rate), 16 068 adults 18 years or older were included in the analysis. Main Outcome Measures Visits to practitioners for unconventional therapies and conventional medical services, including number of inpatient, outpatient, and emergency department visits and use of 8 types of preventive medical services (blood pressure, cholesterol level, physical examination, influenza vaccination, prostate examination, breast examination, mammography, and Papanicolaou test). Results During 1996, an estimated 6.5% of the US population had visits for both unconventional therapies and conventional medical care; 1.8% used only unconventional services; 59.5% used only conventional care; and 32.2% used neither. Compared with those with only conventional visits, those who used both types of care had significantly more outpatient physician visits (7.9 vs 5.4; P<.001), and used more of all types of preventive services except mammography. These groups did not differ significantly in inpatient care, prescription drug use, or number of emergency department visits. Individuals in the top quartile of number of physician visits were more than twice as likely as those in the bottom quartile to have used unconventional therapies in the past year (14.5% vs 6.4%; P<.001). The association between unconventional treatments and physician visits remained after adjusting for potential confounders and across different types of unconventional treatment. Conclusions In this sample, use of unconventional therapies was substantially lower than has been reported in previous national surveys, but was associated with increased use of physician services. From a health services perspective, practitioner-based unconventional therapies appear to serve more as a complement than an alternative to conventional medicine.	Yale Univ, Dept Psychiat, West Haven, CT USA; Yale Univ, Dept Publ Hlth, West Haven, CT USA	Yale University; Yale University	Druss, BG (corresponding author), 950 Campbell Ave,116A, West Haven, CT 06516 USA.	benjamin.druss@yale.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; CAIRNS J, 1995, BRIT MED J, V311, P1520, DOI 10.1136/bmj.311.7019.1520; COHEN J, 1997, AHCPR PUBL; COHEN S, 1997, AHCPR PUBL; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P263; DADY PJ, 1987, NEW ZEAL MED J, V100, P110; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eskinazi DP, 1998, JAMA-J AM MED ASSOC, V280, P1621, DOI 10.1001/jama.280.18.1621; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Gundling KE, 1998, ARCH INTERN MED, V158, P2185, DOI 10.1001/archinte.158.20.2185; HASKELL W, 1998, STANF CTR RES DIS PR; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Jonas W, 1998, JAMA, V279, P708; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; KOLATA G, 1998, N Y TIMES       0604, P4; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P1553, DOI 10.1001/jama.280.18.1553; MCFARLAND BH, 1985, MED CARE, V23, P1221, DOI 10.1097/00005650-198511000-00001; *MED EXP PAN SURV, 1997, AHCPR PUBL; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; SPIGELBLATT L, 1994, PEDIATRICS, V94, P811; Von Korff M, 1998, PSYCHOSOM MED, V60, P143, DOI 10.1097/00006842-199803000-00005; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	25	292	292	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					651	656		10.1001/jama.282.7.651	http://dx.doi.org/10.1001/jama.282.7.651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517718	Bronze			2022-12-28	WOS:000082033700024
J	Josefson, D				Josefson, D			High PSA levels may show body is fighting cancer	BRITISH MEDICAL JOURNAL			English	News Item																		Fortier AH, 1999, J NATL CANCER I, V91, P1635, DOI 10.1093/jnci/91.19.1635	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1025	1025		10.1136/bmj.319.7216.1025	http://dx.doi.org/10.1136/bmj.319.7216.1025			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521187	Green Published			2022-12-28	WOS:000083210100016
J	Ives, AR; Gross, K; Klug, JL				Ives, AR; Gross, K; Klug, JL			Stability and variability in competitive communities	SCIENCE			English	Article							STATISTICAL INEVITABILITY; DIVERSITY; ECOLOGY; BIODIVERSITY; ECOSYSTEM	Long-term variability in the abundance of populations depends on the sensitivity of species to environmental fluctuations and the amplification of environmental fluctuations by interactions among species. Although competitive interactions and species number may have diverse effects on variability measured at the individual species level, a combination of theoretical analyses shows that these factors have no effect on variability measured at the community level. Therefore, biodiversity may increase community stability by promoting diversity among species in their responses to environmental fluctuations, but increasing the number and strength of competitive interactions has little effect.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ives, AR (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	arives@facstaff.wisc.edu	Ives, Anthony/A-5698-2008	Ives, Anthony/0000-0001-9375-9523				Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; ELTON CS, 1958, ECOLOGY INVASIONS PL; FROST TM, 1994, LINKING SPECIES ECOS, P224; Ives AR, 1998, ECOLOGY, V79, P1039, DOI 10.2307/176599; IVES AR, 1995, ECOL MONOGR, V65, P217, DOI 10.2307/2937138; LAWTON JH, 1993, BIODIVERSITY ECOSYST, V80, P255; MACARTHUR R, 1955, ECOLOGY, V36, P533, DOI 10.2307/1929601; MARGALEF R, 1969, BROOKHAVEN SYM BIOL, P25; May R.M., 1974, STABILITY COMPLEXITY; MAY RM, 1972, NATURE, V238, P413, DOI 10.1038/238413a0; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Pimm S.L., 1991, BALANCE NATURE; PIMM SL, 1984, NATURE, V307, P321, DOI 10.1038/307321a0; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0	18	225	242	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					542	544		10.1126/science.286.5439.542	http://dx.doi.org/10.1126/science.286.5439.542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	245RD	10521351				2022-12-28	WOS:000083121200063
J	Macdonald, J				Macdonald, J			An unusual treatment - Intractable hiccups	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					976	976		10.1136/bmj.319.7215.976	http://dx.doi.org/10.1136/bmj.319.7215.976			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514164	Green Published			2022-12-28	WOS:000083111700031
J	Fujita, W; Awaga, K				Fujita, W; Awaga, K			Room-temperature magnetic bistability in organic radical crystals	SCIENCE			English	Article							TRANSITION; SYSTEM	A Large first-order magnetic phase transition in an organic radical, 1,3,5-trithia-2,4,6-triazapentalenyl. is described. The transition occurs with a wide thermal hysteresis Loop over the temperature range 230 to 305 kelvin. The high-temperature phase is paramagnetic, and its structure consists of a uniform one-dimensional stacking of the radical. The Low-temperature phase is diamagnetic because of strong dimerization along the stacking direction. The results may have applications in thermal sensors, switching units, and information storage media based on organic radical crystals.	Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Meguro Ku, Tokyo 1538902, Japan; Japan Sci & Technol Corp, PRESTO, Chiyoda Ku, Tokyo 1020074, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Awaga, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Meguro Ku, Tokyo 1538902, Japan.							ANDRE JJ, 1968, CR ACAD SCI B PHYS, V266, P1057; BLEANEY B, 1952, PROC R SOC LON SER-A, V214, P451, DOI 10.1098/rspa.1952.0181; BRAY JW, 1975, PHYS REV LETT, V35, P744, DOI 10.1103/PhysRevLett.35.744; BRAY PJ, 1982, NUCL INSTRUM METHODS, V1, P1; ESTES WE, 1978, INORG CHEM, V17, P1415, DOI 10.1021/ic50184a005; Kahn O, 1998, SCIENCE, V279, P44, DOI 10.1126/science.279.5347.44; Kahn O, 1999, CHEM BRIT, V35, P24; KEPLER RG, 1963, J CHEM PHYS, V39, P3528, DOI 10.1063/1.1734225; KROBER J, 1993, J AM CHEM SOC, V115, P9810, DOI 10.1021/ja00074a062; MUKAI K, 1969, B CHEM SOC JPN, V42, P40, DOI 10.1246/bcsj.42.40; POTT GT, 1967, J CHEM PHYS, V47, P408, DOI 10.1063/1.1711909; SLICHTER CP, 1972, J CHEM PHYS, V56, P2142, DOI 10.1063/1.1677511; STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208; Vegter JG, 1969, CHEM PHYS LETT, V3, P427, DOI 10.1016/0009-2614(69)80157-0; WOLMERSHAUSER G, 1989, ANGEW CHEM INT EDIT, V28, P920, DOI 10.1002/anie.198909201	15	413	420	2	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					261	262		10.1126/science.286.5438.261	http://dx.doi.org/10.1126/science.286.5438.261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514363				2022-12-28	WOS:000083024400035
J	Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW				Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW			Anaerobic microbes: Oxygen detoxification without superoxide dismutase	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ALKYL HYDROPEROXIDE REDUCTASE; AMINO-ACID-SEQUENCE; RBO GENE-PRODUCT; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; DESULFOVIBRIO-GIGAS; REDOX PROTEINS; RESOLUTION	Superoxide reductase from the hyperthermophilic anaerobe Pyrococcus furiosus uses electrons from reduced nicotinamide adenine dinucleotide phosphate, by way of rubredoxin and an oxidoreductase, to reduce superoxide to hydrogen peroxide, which is then reduced to water by peroxidases. Unlike superoxide dismutase, the enzyme that protects aerobes from the toxic effects of oxygen, SOR does not catalyze the production of oxygen from superoxide and therefore confers a selective advantage on anaerobes. Superoxide reductase and associated proteins are catalytically active 80 degrees C below the optimum growth temperature (100 degrees C) of P. furiosus, conditions under which the organism is likely to be exposed to oxygen.	Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Adams, MWW (corresponding author), Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	adams@bmb.uga.edu						Adams MWW, 1996, ADV PROTEIN CHEM, V48, P101; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alban PS, 1998, J APPL MICROBIOL, V85, P875, DOI 10.1046/j.1365-2672.1998.00602.x; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Bau R, 1998, J BIOL INORG CHEM, V3, P484, DOI 10.1007/s007750050258; BEAUCHAMP C, 1970, J BIOL CHEM, V245, P4641; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; CYPIONKA H, 1985, FEMS MICROBIOL ECOL, V31, P39, DOI 10.1016/0378-1097(85)90045-X; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Flohe L, 1988, CRC HDB FREE RADICAL, V3, P287; FOUQUET Y, 1993, ECON GEOL BULL SOC, V88, P2018, DOI 10.2113/gsecongeo.88.8.2018; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Fridovich I, 1998, J EXP BIOL, V201, P1203; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JENNEY FE, UNPUB; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KITAMURA M, 1998, AB020341 GENBANK; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; LAI KN, 1992, M96560 GENBANK; LEE TH, 1998, AAD03716 GANBANK; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; Ma K, 1999, J BACTERIOL, V181, P5530, DOI 10.1128/JB.181.17.5530-5533.1999; Mallett TC, 1998, BIOCHEMISTRY-US, V37, P8790, DOI 10.1021/bi9803630; Marklund, 1985, HDB METHODS OXYGEN R, V243, P247; MARVINSIKKEMA FD, 1993, ARCH MICROBIOL, V160, P388; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P328; NAKAYAMA K, 1994, J BACTERIOL, V176, P1939, DOI 10.1128/jb.176.7.1939-1943.1994; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; PRIEUR D, 1999, GENOSCOPE; ROBERTON AM, 1970, J BACTERIOL, V102, P43, DOI 10.1128/JB.102.1.43-51.1970; Rocha ER, 1996, J BACTERIOL, V178, P6895, DOI 10.1128/jb.178.23.6895-6903.1996; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SEARCY DG, 1995, ARCH BIOCHEM BIOPHYS, V318, P251, DOI 10.1006/abbi.1995.1228; SHENVI NV, 1997, AF034841 GENBANK; SHENVI NV, 1997, AF034965 GENBANK; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; Summit M, 1998, DEEP-SEA RES PT II, V45, P2751, DOI 10.1016/S0967-0645(98)00092-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TIVEY MK, 1995, SEAFLOOR HYDROTHERMA, P158; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; van Niel EWJ, 1998, APPL ENVIRON MICROB, V64, P1034	67	317	324	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					306	309		10.1126/science.286.5438.306	http://dx.doi.org/10.1126/science.286.5438.306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514376				2022-12-28	WOS:000083024400048
J	Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC				Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC			The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; IDENTIFICATION; PRODUCT; CONJUGATION; DEGRADATION; ONCOGENE; COMPLEX; SYSTEM; YEAST	Ubiquitination of receptor protein-tyrosine kinases (RPTKs) terminates signaling by marking active receptors for degradation. c-Cbl, an adapter protein for RPTKs, positively regulates RPTK ubiquitination in a manner dependent on its variant SRC homology 2 (SH2) and RING finger domains. Ubiquitin-protein Ligases (or E3s) are the components of ubiquitination pathways that recognize target substrates and promote their Ligation to ubiquitin. The c-Cbl protein acted as an E3 that can recognize tyrosine-phosphorylated substrates, such as the activated platelet-derived growth factor receptor, through its SH2 domain and that recruits and allosterically activates an E2 ubiquitin-conjugating enzyme through its RING domain. These results reveal an SH2-containing protein that functions as a ubiquitin-protein Ligase and thus provide a distinct mechanism for substrate targeting in the ubiquitin system.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Salk Institute; McGill University; La Jolla Institute for Immunology	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA.	hunter@salk.edu		LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL CANCER INSTITUTE [R35CA039780, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, T32CA09523] Funding Source: Medline; NIDDK NIH HHS [R01 DK56558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Haas AL, 1997, FASEB J, V11, P1257; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; JOAZEIRO CAP, UNPUB; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; OU F, COMMUNICATION; Oughtred R, 1998, J BIOL CHEM, V273, P18435, DOI 10.1074/jbc.273.29.18435; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Rajapurohitam V, 1999, DEV BIOL, V212, P217, DOI 10.1006/dbio.1999.9342; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THILEN CB, 1998, IMMUNOL CELL BIOL, V76, P473; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	32	877	904	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					309	312		10.1126/science.286.5438.309	http://dx.doi.org/10.1126/science.286.5438.309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514377				2022-12-28	WOS:000083024400049
J	Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M				Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M			Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors	NATURE			English	Article							RECEPTOR-ALPHA-GENE; BONE-MARROW; REARRANGEMENT; MICE; IDENTIFICATION; EXPRESSION; CHAIN; DIFFERENTIATION; THYMOCYTES; THYMUS	The mechanisms controlling the commitment of haematopoietic progenitors to the B-lymphoid lineage are poorly understood. The observations that mice deficient in E2A(1,2) and EBF3 lack B-lineage cells have implicated these two transcription factors in the commitment process. Moreover, the expression of genes encoding components of the rearrangement machinery (RAG1, RAG2, TdT) or pre-B-cell receptor (lambda 5, VpreB, Ig alpha, Ig beta) has been considered to indicate B-lineage commitment(4). All these genes including E2A and EBF are expressed in pro-B cells lacking the transcription factor Pax5 (refs 5-7). Here we show that cloned Pax5-deficient pro-B cells transferred into RAG2-deficient mice provide longterm reconstitution of the thymus and give rise to mature T cells expressing alpha/beta-T-cell receptors. The bone marrow of these mice contains a population of cells of Pax5(-/-) origin with the same phenotype as the donor pro-B cells. When transferred into secondary recipients, these pro-B cells again home to the bone marrow and reconstitute the thymus. Hence, B-Lineage commitment is determined neither by immunoglobulin DJ rearrangement nor by the expression of E2A, EBF, lambda 5, VpreB, Ig alpha and Ig beta. Instead, our data implicate Pax5 in the control of B-lineage commitment.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Rolink, AG (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Busslinger, Meinrad J./J-1249-2016; Nutt, Stephen L/C-9256-2013	Busslinger, Meinrad J./0000-0002-9111-9351; Nutt, Stephen L/0000-0002-0020-6637				Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BORN W, 1988, J IMMUNOL, V140, P3228; BRUNO L, 1995, EUR J IMMUNOL, V25, P1877, DOI 10.1002/eji.1830250713; CEREDIG R, 1984, THYMUS, V6, P15; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Melchers F, 1999, FUNDAMENTAL IMMUNOLO, V4th, P183; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLLINK A, 1991, EMBO J, V10, P327; ROLLINK A, 1994, INT IMMUNOL, V6, P1257; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang H, 1998, P NATL ACAD SCI USA, V95, P6831, DOI 10.1073/pnas.95.12.6831; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	26	293	300	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					603	606		10.1038/44164	http://dx.doi.org/10.1038/44164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524629				2022-12-28	WOS:000083054900054
J	Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE				Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE			The relationship between cyclooxygenase-2 expression and colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN COLON-CANCER; NONSTEROIDAL ANTIINFLAMMATORY DRUG; SPONTANEOUS INTESTINAL ADENOMAS; MIN MOUSE MODEL; PLASMINOGEN-ACTIVATOR; DEPENDENT INCREASE; REDUCED RISK; ASPIRIN USE; SULINDAC	Context Epidemiological studies have implicated the inducible form of cyclooxygenase (COX-2) in the pathogenesis of colorectal cancer; however, its role is not fully understood. Objective To examine the relationship between the expression of COX-2 in human colorectal cancer and patient survival. Design Patients diagnosed as having colorectal cancer were evaluated and followed up for up to 9.4 years (median follow-up, 2.7 years). Tumor sections were stained for COX-2 using a rabbit polyclonal antibody raised against human COX-2, The extent of COX-2 staining was graded by 2 observers blinded to outcome, Preabsorption of the anti-COX-2 antibody with a COX-2 peptide abolished the staining, demonstrating the specificity of the assay. Setting Gastrointestinal unit of a large general teaching hospital in Dublin, Ireland. Participants Seventy-six patients (median age, 66.5 years) with colorectal cancer (Dukes tumor stage A, n = 9; Dukes B, n = 30; Dukes C, n = 25; Dukes D, n = 12) whose diagnosis was made between 1988 and 1991, Fourteen normal colon biopsies were stained for COX-2 as controls. Main Outcome Measures Survival in years following diagnosis compared by extent of COX-2 epithelial staining (grade 1, <1%; grade 2, 1%-19%; grade 3, 20%-49%; grade 4, greater than or equal to 50%), Dukes stage, tumor size, and lymph mode metastasis. Results COX-2 was found in tumor epithelial cells, inflammatory cells, vascular endothelium, and/or fibroblasts. The extent of epithelial staining was heterogeneous, varying markedly among different tumors. Normal tissue adjacent to the tumors also stained weakly for COX-2, No COX-2 was detected in control tissue samples, The Kaplan-Meier survival estimate was 68% in patients who had grade 1 tumor epithelial staining compared with 35% in those with higher grades combined (log-rank chi(2) = 5.7; P =.02). Greater expression of COX-2 correlated with more advanced Dukes stage (Kendall tau-b, 0.22; P=.03) and larger tumor size (Kendall tau-b, 0.21; P=.02) and was particularly evident in tumors with lymph node involvement (Kendall tau-b, 0.26; P=.02). Conclusions Our data indicate that COX-2 expression in colorectal cancer may be related to survival. These data add to the growing epidemiological and experimental evidence that COX-2 may play a role in colorectal tumorigenesis.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin 2, Ireland; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland; St Vincents Hosp, Dept Gastroenterol, Dublin 4, Ireland; Beaumont Hosp, Dept Gastroenterol, Dublin 9, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; University College Dublin; University College Dublin	Sheehan, KM (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, 123 St Stephens Green, Dublin 2, Ireland.	ksheehan@rcsi.ie	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Sheehan, Katherine/0000-0002-8969-3610				Barnes CJ, 1998, GASTROENTEROLOGY, V114, P873, DOI 10.1016/S0016-5085(98)70305-1; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fujita T, 1998, CANCER RES, V58, P4823; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRAHAM DM, 1990, MODERN PATHOL, V3, P332; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jacoby RF, 1996, CANCER RES, V56, P710; JASS JR, 1987, J CLIN PATHOL, V40, P1016, DOI 10.1136/jcp.40.9.1016; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; Mulcahy HE, 1997, DIS COLON RECTUM, V40, P326, DOI 10.1007/BF02050424; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8; SANO H, 1995, CANCER RES, V55, P3785; SHEPHERD NA, 1989, HISTOPATHOLOGY, V14, P613, DOI 10.1111/j.1365-2559.1989.tb02202.x; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Skelly MM, 1997, CLIN CANCER RES, V3, P1837; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Troisi RJ, 1999, CANCER, V85, P1670, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1670::AID-CNCR5>3.0.CO;2-M; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Yang VW, 1998, CANCER RES, V58, P1750	33	356	382	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1254	1257		10.1001/jama.282.13.1254	http://dx.doi.org/10.1001/jama.282.13.1254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517428	Bronze			2022-12-28	WOS:000082901100033
J	Hanna, FWF; Lazarus, JH; Scanlon, MF				Hanna, FWF; Lazarus, JH; Scanlon, MF			Fortnightly review - Controversial aspects of thyroid disease	BRITISH MEDICAL JOURNAL			English	Review							GRAVES-OPHTHALMOPATHY; L-THYROXINE; BONE MASS; HYPERTHYROIDISM; THERAPY; HYPOTHYROIDISM; LEVOTHYROXINE; METAANALYSIS; AMIODARONE		Prince Charles Hosp, Dept Med, Cardiff CF47 9DT, S Glam, Wales; Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Hanna, FWF (corresponding author), Prince Charles Hosp, Dept Med, Merthyr Tydfill, Cardiff CF47 9DT, S Glam, Wales.		Lazarus, John H/H-5108-2017	Lazarus, John H/0000-0001-8852-704X; hanna, fahmy/0000-0001-5800-1442				Ain KB, 1996, PHARMACOTHERAPY, V16, P1103; AIN KB, 1991, JAMA-J AM MED ASSOC, V266, P2118, DOI 10.1001/jama.266.15.2118; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; DAVIES PDO, 1986, WORLD J SURG, V10, P681, DOI 10.1007/BF01655556; DEGROOT LJ, 1995, J CLIN ENDOCR METAB, V80, P339, DOI 10.1210/jc.80.2.339; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; GOODWIN TM, 1992, J CLIN ENDOCR METAB, V75, P1333, DOI 10.1210/jc.75.5.1333; Harjai KJ, 1997, ANN INTERN MED, V126, P63, DOI 10.7326/0003-4819-126-1-199701010-00009; Hermus AR, 1998, NEW ENGL J MED, V338, P1438, DOI 10.1056/NEJM199805143382007; Hofbauer LC, 1997, J CLIN ENDOCR METAB, V82, P2244, DOI 10.1210/jc.82.7.2244; KAUFMAN DW, 1988, BRIT MED J, V297, P262; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; Marqusee E, 1998, ENDOCRIN METAB CLIN, V27, P37, DOI 10.1016/S0889-8529(05)70296-6; METCALFE RA, 1994, CLIN ENDOCRINOL, V40, P67, DOI 10.1111/j.1365-2265.1994.tb02445.x; NICHOLAS WC, 1995, SOUTH MED J, V88, P973, DOI 10.1097/00007611-199509000-00018; NORDYKE R A, 1990, Comprehensive Therapy, V16, P28; PARLE JV, 1993, BRIT J GEN PRACT, V43, P107; Prummel MF, 1997, CLIN EXP IMMUNOL, V110, P292; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P808, DOI 10.1210/jc.82.3.808; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SCHECTMAN JM, 1991, ARCH INTERN MED, V151, P2163, DOI 10.1001/archinte.151.11.2163; TAJIRI J, 1990, ARCH INTERN MED, V150, P621, DOI 10.1001/archinte.150.3.621; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TAN SY, 1992, POSTGRAD MED J, V68, P483, DOI 10.1136/pgmj.68.800.483-a; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VROBEL TR, 1989, PROG CARDIOVASC DIS, V31, P393, DOI 10.1016/0033-0620(89)90016-9; Weetman AP, 1997, BRIT MED J, V314, P1175, DOI 10.1136/bmj.314.7088.1175; Wiersinga WM, 1998, NEW ENGL J MED, V338, P121, DOI 10.1056/NEJM199801083380209; WIERSINGA WM, 1997, PHARMACOTHERAPEUTICS, P225; Wood LC, 1998, ENDOCRIN METAB CLIN, V27, P101, DOI 10.1016/S0889-8529(05)70301-7; 1997, DRUG THER B, V35, P49; 1999, CURR PROBL PHARMACOV, V25, P3	34	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					894	899		10.1136/bmj.319.7214.894	http://dx.doi.org/10.1136/bmj.319.7214.894			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506049	Green Published			2022-12-28	WOS:000082975600028
J	Frazier, OH; March, RJ; Horvath, KA				Frazier, OH; March, RJ; Horvath, KA		Transmyocardial Carbon Dioxide Laser Revascular	Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM; ISCHEMIA	Background The construction of subendocardial channels to perfuse ischemic areas of the myocardium has been investigated since the 1950s. We assessed the safety and efficacy of transmyocardial revascularization with a carbon dioxide laser in patients with refractory angina and left ventricular free-wall ischemia that was not amenable to direct coronary revascularization. Methods In a prospective, controlled, multicenter trial, we randomly assigned 91 patients to undergo transmyocardial revascularization and 101 patients to receive continued medical treatment. The severity of angina (according to the Canadian Cardiovascular Society [CCS] classification), quality of life, and cardiac perfusion (as assessed by thallium-201 scanning) were evaluated at base line and 3, 6, and 12 months after randomization. Results At 12 months, angina had improved by at least two CCS classes in 72 percent of the patients assigned to transmyocardial revascularization, as compared with 13 percent of the patients assigned to medical treatment who continued medical treatment (P<0.001). Patients in the transmyocardial-revascularization group also had a significantly improved quality of life as compared with the medical-treatment group. Myocardial perfusion improved by 20 percent in the transmyocardial-revascularization group and worsened by 27 percent in the medical-treatment group (P = 0.002). In the first year of follow-up, 2 percent of patients assigned to undergo transmyocardial revascularization were hospitalized because of unstable angina, as compared with 69 percent of patients assigned to medical treatment (P<0.001). The perioperative mortality rate associated with transmyocardial revascularization was 3 percent. The rate of survival at 12 months was 85 percent in the transmyocardial-revascularization group and 79 percent in the medical-treatment group (P = 0.50). Conclusions In patients with angina refractory to medical treatment and coronary artery disease that precluded coronary-artery bypass surgery or percutaneous transluminal coronary angioplasty, transmyocardial revascularization improved cardiac perfusion and clinical status over a 12-month period. (N Engl J Med 1999;341:1021-8.) (C)1999, Massachusetts Medical Society.	St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiovasc Surg & Res, Houston, TX 77225 USA; Rush Presbyterian St Lukes Med Ctr, Dept Cardiovasc Surg, Chicago, IL 60612 USA; Northwestern Univ, Sch Med, Div Cardiothorac Surg, Chicago, IL USA	Saint Lukes Episcopal Hospital; Texas Heart Institute; Rush University; Northwestern University	Frazier, OH (corresponding author), St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiovasc Surg & Res, POB 20345, Houston, TX 77225 USA.							Berwing K, 1997, CIRCULATION, V96, P3156; COOLEY DA, 1994, TEX HEART I J, V21, P220; GOLDMAN A, 1956, J THORAC SURG, V31, P364; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V268, P1860; Horvath KA, 1997, J THORAC CARDIOV SUR, V113, P645, DOI 10.1016/S0022-5223(97)70221-6; HORVATH KA, 1995, J AM COLL CARDIOL, V25, P258, DOI 10.1016/0735-1097(94)00410-R; Horvath KA, 1998, CIRCULATION, V98, P217; Kadipasaoglu KA, 1997, LASER SURG MED, V20, P6, DOI 10.1002/(SICI)1096-9101(1997)20:1<6::AID-LSM2>3.0.CO;2-U; MASSIMO C, 1957, J THORAC SURG, V34, P257; MIRHOSEINI M, 1981, Journal of Microsurgery, V2, P253; Mirhoseini M, 1993, J Clin Laser Med Surg, V11, P15; MIRHOSEINI M, 1988, ANN THORAC SURG, V45, P415, DOI 10.1016/S0003-4975(98)90015-7; OKADA M, 1986, Kobe Journal of Medical Sciences, V32, P151; PIRES LA, 1995, AM HEART J, V129, P799, DOI 10.1016/0002-8703(95)90332-1; Schofield PM, 1999, LANCET, V353, P519, DOI 10.1016/S0140-6736(98)11478-2; SEN PK, 1968, SURGERY, V64, P861; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; YANO OJ, 1993, ANN THORAC SURG, V56, P46, DOI 10.1016/0003-4975(93)90401-3	19	273	288	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1021	1028		10.1056/NEJM199909303411402	http://dx.doi.org/10.1056/NEJM199909303411402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502591				2022-12-28	WOS:000082880500002
J	Carvalho, AB; Clark, AG				Carvalho, AB; Clark, AG			Genetic recombination - Intron size and natural selection	NATURE			English	Article							SMALL DROSOPHILA INTRON; MELANOGASTER; SEQUENCES		Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; Penn State Univ, Inst Mol Evolutionary Genet, Mueller Lab 208, University Pk, PA 16802 USA	Universidade Federal do Rio de Janeiro; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Carvalho, AB (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.		Carvalho, Antonio/D-5402-2013	Carvalho, Antonio/0000-0001-8959-6469; Clark, Andrew/0000-0001-7159-8511				Comeron JM, 1999, GENETICS, V151, P239; GUO M, 1995, J MOL BIOL, V253, P426, DOI 10.1006/jmbi.1995.0564; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; Kennedy CF, 1997, MOL CELL BIOL, V17, P2774, DOI 10.1128/MCB.17.5.2774; KLIMAN RM, 1993, MOL BIOL EVOL, V10, P1239; Moriyama EN, 1998, MOL BIOL EVOL, V15, P770, DOI 10.1093/oxfordjournals.molbev.a025980; MORONI G, 1993, ATLAS DROSOPHILA GEN, P319; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEPHAN W, 1994, GENETICS, V138, P135, DOI 10.1093/genetics/138.1.135	13	105	107	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					344	344		10.1038/43827	http://dx.doi.org/10.1038/43827			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517631				2022-12-28	WOS:000082822600041
J	Peters, JM; McKay, RM; McKay, JP; Graff, JM				Peters, JM; McKay, RM; McKay, JP; Graff, JM			Casein kinase I transduces Wnt signals	NATURE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; EARLY XENOPUS-EMBRYOS; C-ELEGANS EMBRYOS; BETA-CATENIN; CAENORHABDITIS-ELEGANS; SPEMANN ORGANIZER; AXIS FORMATION; BUDDING YEAST; PROTEIN; TRANSCRIPTION	The Wnt signalling cascade is essential for the development of both invertebrates and vertebrates, and is altered during tumorigenesis. Although a general framework for Wnt signalling has been elucidated, not all of the components have been identified. Here we describe a serine kinase, casein kinase I (CKI), which was isolated by expression cloning in Xenopus embryos. CKI reproduces several properties of Wnt signals, including generation of complete dorsal axes, stabilization of beta-catenin and induction of genes that are direct targets of Wnt signals. Dominant-negative forms of CKI and a pharmacological blocker of CKI inhibited Wnt signals in Xenopus, Inhibiting CKI in Caenorhabditis elegans generated worms with a mom phenotype, indicative of a loss of Wnt signals. In addition, CKI bound to and increased the phosphorylation of dishevelled, a known component of the Wnt pathway. These data indicate that CKI may be a conserved component of the Wnt pathway.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, 5323 Harry Hines Blvd,NB 5-208, Dallas, TX 75235 USA.	graff02@utsw.swmed.edu						Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Camac G., 1996, DEVELOPMENT, V122, P3055; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; EPSTEIN HF, 1995, METHODS CELL BIOL; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LeSuer JA, 1999, DEVELOPMENT, V126, P137; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu QH, 1998, DEVELOPMENT, V125, P4767; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	50	374	390	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					345	350		10.1038/43830	http://dx.doi.org/10.1038/43830			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517632				2022-12-28	WOS:000082822600042
J	Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA				Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA			Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease	ANNALS OF INTERNAL MEDICINE			English	Article						dexamethasone; adrenocortical disorder, primary, pigmented; adrenocortical disorder, macronodular; Carney complex; Cushing syndrome	GASTRIC-INHIBITORY POLYPEPTIDE; FAMILIAL CUSHINGS-SYNDROME; CARNEY COMPLEX; ADRENAL-CELLS; FREE CORTISOL; RARE CAUSE; DYSPLASIA; MYXOMAS; SUBTYPE; CT	Background: Primary pigmented nodular adrenocortical disease causes the Cushing syndrome in children and young adults and is most frequently associated with the Carney complex. Objective: To evaluate diagnostic tests for primary pigmented nodular adrenocortical disease. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 21 patients with primary pigmented nodular adrenocortical disease. The control groups consisted of 9 patients with macronodular adrenocortical disease and 15 patients with primary unilateral adrenocortical disease (single adenomas). Measurements: Clinical characteristics, radiologic imaging, and a 6-day Liddle test with determination of urinary free cortisol and 17-hydroxycorticosteroid excretion. Results: Adrenal imaging and other tests were of limited value for the diagnosis of primary pigmented nodular adrenocortical disease. The Liddle test, however, distinguished patients with this disorder from those with other primary adrenocortical lesions. An increase of 50% or more in urinary free cortisol levels on day 6 of the Liddle test identified 9 of 13 patients (69.2% [95% Cl, 46.6% to 91.8%]) with primary pigmented nodular adrenocortical disease, excluded all patients with macronodular adrenocortical disease, and was present in only 3 of the 15 patients with single adrenocortical adenomas (20% [Cl, 0% to 40.2%]). An increase in urinary free cortisol excretion of 100% or more on day 6 of the Liddle test identified only patients with primary pigmented nodular adrenocortical disease. Conclusions: Patients with primary pigmented nodular adrenocortical disease responded to dexamethasone with a paradoxical increase in glucocorticoid excretion during the Liddle test. This feature distinguishes such patients from those who have the Cushing syndrome caused by other primary adrenal disorders and may lead to timely detection of the Carney complex (a potentially fatal disorder) in asymptomatic patients.	NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; Mayo Clinic	Stratakis, CA (corresponding author), NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	stratakc@cc1.nichd.nih.gov	Stratakis, Constantine/AAP-4745-2020; Sarlis, Nicholas/AAN-9444-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000638] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000638, ZIAHD000642, Z01HD000642, Z01HD000615] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCHAMBEAUDMOUV.F, 1996, 10 INT C END SAN FRA, P899; Basson CT, 1997, AM J CARDIOL, V79, P994, DOI 10.1016/S0002-9149(97)00033-7; BOHM N, 1983, ACTA ENDOCRINOL-COP, V102, P428, DOI 10.1530/acta.0.1020428; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BROOKS RV, 1966, J ENDOCRINOL, V36, P53, DOI 10.1677/joe.0.0360053; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; CATICHA O, 1993, J CLIN ENDOCR METAB, V77, P494, DOI 10.1210/jc.77.2.494; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; DEMOOR P, 1965, J CLIN ENDOCR METAB, V25, P612, DOI 10.1210/jcem-25-5-612; DOPPMAN JL, 1989, RADIOLOGY, V172, P415, DOI 10.1148/radiology.172.2.2748822; Doppman JL, 1997, ENDOCRIN METAB CLIN, V26, P973, DOI 10.1016/S0889-8529(05)70290-5; DOPPMAN JL, 1991, J COMPUT ASSIST TOMO, V15, P773, DOI 10.1097/00004728-199109000-00009; ELIAS LL, 1999, ENDOCINE SOC, P582; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P3517; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; KIRSCHNER MA, 1964, J CLIN ENDOCR METAB, V24, P947, DOI 10.1210/jcem-24-10-947; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V70, P192, DOI 10.1210/jcem-70-1-192; LARSEN JL, 1986, AM J MED, V80, P976, DOI 10.1016/0002-9343(86)90648-0; LEVIN ME, 1966, AM J MED, V40, P318, DOI 10.1016/0002-9343(66)90112-4; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LIEBERMAN SA, 1994, EUR J ENDOCRINOL, V131, P67, DOI 10.1530/eje.0.1310067; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; OELKERS W, 1986, ACTA ENDOCRINOL-COP, V113, P370, DOI 10.1530/acta.0.1130370; Papanicolaou DA, 1998, J CLIN ENDOCR METAB, V83, P1163, DOI 10.1210/jc.83.4.1163; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; RUDER HJ, 1974, J CLIN ENDOCR METAB, V39, P1138, DOI 10.1210/jcem-39-6-1138; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P1274, DOI 10.1210/jc.82.4.1274; SHENOY BV, 1984, AM J SURG PATHOL, V8, P335, DOI 10.1097/00000478-198405000-00002; SILVERMAN SR, 1963, J CLIN ENDOCR METAB, V23, P167, DOI 10.1210/jcem-23-2-167; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, J CLIN ENDOCR METAB, V84, P1122, DOI 10.1210/jc.84.3.1122; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; WULFFRAAT NM, 1988, J CLIN ENDOCR METAB, V66, P301, DOI 10.1210/jcem-66-2-301; YOTSUMOTO S, 1979, J CLIN ENDOCR METAB, V48, P660, DOI 10.1210/jcem-48-4-660; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407; ZEIGER MA, 1991, SURGERY, V110, P1106	41	155	166	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					585	+		10.7326/0003-4819-131-8-199910190-00006	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523219				2022-12-28	WOS:000083196600005
J	Cox, NJ; Subbarao, K				Cox, NJ; Subbarao, K			Influenza	LANCET			English	Article							VIRUS-INFECTIONS; A INFECTIONS; YOUNG-ADULTS; CHILDREN; EFFICACY; VACCINATION; IMPACT; PREVENTION; EPIDEMICS; ZANAMIVIR	Influenza is the most frequent cause of acute respiratory illness requiring medical intervention because it affects all age groups and because it can recur in any individual. During the past three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions that put them at risk for complications. However, the continuing impact of influenza in these and other population groups has motivated the development of novel approaches for prevention and control of influenza. Several important advances in the field of influenza have occurred in the last few years. An experimental live, attenuated, intranasally administered trivalent influenza vaccine was shown to be highly effective in protecting young children against influenza A H3N2 and influenza B. New antiviral drugs based on the structure of the neuraminidase molecule were assessed in clinical trials and found to be effective against influenza A and B viruses. The expected use of these new antiviral agents has accelerated the development of rapid point-of-care diagnostic tests. The availability of new diagnostic tests, new antiviral drugs, and new vaccines will undoubtedly alter our approaches to influenza control and have an impact on clinical practice.	Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Cox, NJ (corresponding author), Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.			Subbarao, Kanta/0000-0003-1713-3056				[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bennett N M, 1973, Med J Aust, V1, P19; BLUMENFELD HL, 1959, J CLIN INVEST, V38, P199, DOI 10.1172/JCI103789; CARILLI AD, 1964, NEW ENGL J MED, V270, P123, DOI 10.1056/NEJM196401162700303; DAGAN R, 1984, PEDIATR INFECT DIS J, V3, P218, DOI 10.1097/00006454-198405000-00007; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; FERSON MJ, 1991, J PAEDIATR CHILD H, V27, P308, DOI 10.1111/j.1440-1754.1991.tb02545.x; Fujimoto S, 1998, LANCET, V352, P873, DOI 10.1016/S0140-6736(98)12449-2; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HAYDEN FG, 1998, INF DIS SOC AM DENV; HAYDEN FG, 1998, ORAL GS4104 TREATMEN; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; KERR AA, 1975, LANCET, V1, P291; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V257, P1053, DOI 10.1001/jama.257.8.1053; McCullers JA, 1999, CLIN INFECT DIS, V28, P898, DOI 10.1086/515214; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; MURPHY BR, 1993, INFECT DIS CLIN PRAC, V2, P174, DOI 10.1097/00019048-199305000-00003; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1999, JAMA-J AM MED ASSOC, V282, P137, DOI 10.1001/jama.282.2.137; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nicholson KG, 1998, TXB INFLUENZA, P222; NOBLE GR, 1982, BASIC APPL INFLUENZA, P11; PAISLEY JW, 1978, AM J DIS CHILD, V132, P34, DOI 10.1001/archpedi.1978.02120260036007; PARROTT RH, 1962, J PEDIATR-US, V61, P205, DOI 10.1016/S0022-3476(62)80255-8; POIRIER KAR, 1995, ADV PEDIAT INFECT DI, V10, P125; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; PRICE DA, 1976, CLIN PEDIATR, V15, P362; SAENZ AC, 1969, LANCET, V1, P91; SANDERS DY, 1970, SO MED J, V63, P413; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Smith W, 1933, LANCET, V2, P66, DOI 10.1016/S0140-6736(00)78541-2; Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998; The International Committee on Taxonomy of Viruses, 7 INT COMM TAX VIR; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WOODALL J, 1958, BRIT MED J, V4, P1316; WRIGHT PF, 1980, J INFECT DIS, V141, P430, DOI 10.1093/infdis/141.4.430; WRIGHT PF, 1977, NEW ENGL J MED, V296, P829, DOI 10.1056/NEJM197704142961501; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	48	523	588	0	49	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1277	1282		10.1016/S0140-6736(99)01241-6	http://dx.doi.org/10.1016/S0140-6736(99)01241-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520648	Green Submitted			2022-12-28	WOS:000083010400043
J	McMichael, AJ; Powles, JW				McMichael, AJ; Powles, JW			Human numbers, environment, sustainability, and health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POPULATION		Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England	University of Cambridge; University of London; London School of Hygiene & Tropical Medicine	Powles, JW (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.	jwp11@cam.ac.uk		Powles, John/0000-0002-0766-7989				BONGAARTS J, 1992, POPUL DEV REV, V18, P299, DOI 10.2307/1973681; BROWN LR, VITAL SIGNS 1996 199; Caldwell L.K., 1990, 2 WORLDS SCI ENV MOV; *CARB DIOX INF AN, 1997, HIST CARB DIOX EM; CARTER T, 1999, INTERIM CHARACTERIZA; Cohen J. E., 1995, MANY PEOPLE CAN EART; COHEN MN, 1998, HUMAN BIOL SOCIAL IN; Daily G.C, 1997, NATURES SERVICE SOC; DAVIS K, 1951, POPULATION INDIA PAK, P62; Diamond Jared M., 1998, GUNS GERMS STEEL FAT; Dixon J., 1998, PROTECTING OUR PLANE; Engelman R., 1998, PROFILES CARBON UPDA; HENRY L, 1961, EUGEN QUART, V8, P81, DOI 10.1080/19485565.1961.9987465; HOLDREN JP, 1991, POPUL ENVIRON, V12, P231, DOI 10.1007/BF01357916; Howell N., 1979, DEMOGRAPHY DOBE KUNG; King M, 1996, BRIT MED J, V313, P995, DOI 10.1136/bmj.313.7063.995; LAST JM, 1992, ROSENAU LAST PUBLIC, P677; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; LOH J, 1998, LIVING PLANT REPORT; Lutz W, 1997, NATURE, V387, P803, DOI 10.1038/42935; McMichael A J, 1993, PLANETARY OVERLOAD G; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; REES W, IN PRESS ECOLOGICAL; Rees W.E., 1996, OUR ECOLOGICAL FOOTP; Rotberg Robert I., 1985, HUNGER HIST IMPACT C; RUKANG F, 1993, SOC SCI MED, V36, P1319; SERAGELDIN I, 1996, ENV SUSTAINABLE DEV, V5, P4; Short R V, 1980, J Reprod Fertil Suppl, VSuppl 28, P3; SHORT RV, 1994, ANN NY ACAD SCI, V709, P416, DOI 10.1111/j.1749-6632.1994.tb30427.x; SHORT RV, 1980, J REPROD FERTIL S, V28, P43; SHORT RV, 1980, J REPROD FERTIL S, V28, P59; SOUTHWICK CH, 1996, GLOBAL ECOLOGY HUMAN, P144; TAYLOR CE, 1967, SCIENCE, V157, P651, DOI 10.1126/science.157.3789.651; Todaro M.P., 1981, EC DEV 3 WORLD; Tuxill J, 1998, LOSING STRANDS WEB L; Wigley TML, 1996, NATURE, V379, P240, DOI 10.1038/379240a0; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; World Bank, 1997, STAT CHANG WORLD WOR; World Commission on Environment and Development, 1987, OUR COMMON FUTURE; *WORLD RES I UN EN, 1998, WORLD RES 1998 99; Wynne-Edwards V. C., 1962, pUnpaginated	41	21	21	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1999	319	7215					977	980		10.1136/bmj.319.7215.977	http://dx.doi.org/10.1136/bmj.319.7215.977			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514165	Green Published			2022-12-28	WOS:000083111700032
J	Zhou, XJ; Bogdanov, P; Kellar, SA; Noda, T; Eisaki, H; Uchida, S; Hussain, Z; Shen, ZX				Zhou, XJ; Bogdanov, P; Kellar, SA; Noda, T; Eisaki, H; Uchida, S; Hussain, Z; Shen, ZX			One-dimensional electronic structure and suppression of d-wave node state in (La1.28Nd0.6Sr0.12) CuO4	SCIENCE			English	Article							ANGLE-RESOLVED PHOTOEMISSION; T-C SUPERCONDUCTORS; DOMAIN-WALLS; SPIN FLUCTUATIONS; TEMPERATURE SUPERCONDUCTORS; DOPED ANTIFERROMAGNETS; TRANSITION TEMPERATURE; CHARGE; BI2SR2CACU2O8+DELTA; PROXIMITY	Angle-resolved photoemission spectroscopy was carried out on (La1.28Nd0.6 Sr-0.12)CuO4, a model system of the charge- and spin-ordered state, or stripe phase. The electronic structure contains characteristic features consistent with other cuprates, such as the flat band at Low energy near the Brillouin zone face. However, the low-energy excitation near the expected d-wave node region is strongly suppressed. The frequency-integrated spectral weight is confined inside one-dimensional segments in the momentum space (defined by horizontal momenta \k(x)\ = pi/4 and vertical momenta \k(y)\ = pi/4), deviating strongly from the more rounded Fermi surface expected from band calculations. This departure from the two-dimensional Fermi surface persists to a very high energy scale. These results provide important information for establishing a theory to understand the charge and spin ordering in cuprates and their relation with high-temperature superconductivity.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Univ Tokyo, Dept Superconduct, Bunkyo Ku, Tokyo 133, Japan	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Tokyo	Shen, ZX (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	zxshen@stanford.edu	Eisaki, Hiroshi/F-6317-2018	Eisaki, Hiroshi/0000-0002-8299-6416				Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; Balatsky AV, 1999, PHYS REV LETT, V82, P5337, DOI 10.1103/PhysRevLett.82.5337; Balatsky AV, 1999, SCIENCE, V284, P1137, DOI 10.1126/science.284.5417.1137; CASTELLANI C, 1995, PHYS REV LETT, V75, P4650, DOI 10.1103/PhysRevLett.75.4650; Castro Neto AH, 1996, PHYS REV LETT, V76, P2165, DOI 10.1103/PhysRevLett.76.2165; DAGOTTO E, 1994, REV MOD PHYS, V66, P763, DOI 10.1103/RevModPhys.66.763; DICKINSON PH, 1993, PHYS REV B, V47, P11447, DOI 10.1103/PhysRevB.47.11447; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; Eskes H, 1998, PHYS REV B, V58, P6963, DOI 10.1103/PhysRevB.58.6963; Eskes H, 1996, PHYS REV B, V54, pR724, DOI 10.1103/PhysRevB.54.R724; Hasselmann N, 1999, PHYS REV LETT, V82, P2135, DOI 10.1103/PhysRevLett.82.2135; Hunt AW, 1999, PHYS REV LETT, V82, P4300, DOI 10.1103/PhysRevLett.82.4300; Joynt R, 1999, SCIENCE, V284, P777, DOI 10.1126/science.284.5415.777; KIVELSON SA, 1994, STRONGLY CORRELATED ELECTRONIC MATERIALS - THE LOS ALAMOS SYMPOSIUM, 1993, P619; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Marshall DS, 1996, PHYS REV LETT, V76, P4841, DOI 10.1103/PhysRevLett.76.4841; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; NAKAMURA Y, 1992, PHYS REV B, V46, P5841, DOI 10.1103/PhysRevB.46.5841; Nayak C, 1997, PHYS REV LETT, V78, P2465, DOI 10.1103/PhysRevLett.78.2465; POILBLANC D, 1989, PHYS REV B, V39, P9749, DOI 10.1103/PhysRevB.39.9749; Salkola MI, 1996, PHYS REV LETT, V77, P155, DOI 10.1103/PhysRevLett.77.155; SCHULZ HJ, 1989, J PHYS-PARIS, V50, P2833, DOI 10.1051/jphys:0198900500180283300; Smith CM, 1998, PHYS REV B, V58, P453, DOI 10.1103/PhysRevB.58.453; Tohyama T, 1999, PHYS REV LETT, V82, P4910, DOI 10.1103/PhysRevLett.82.4910; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Tranquada JM, 1999, PHYS REV B, V59, P14712, DOI 10.1103/PhysRevB.59.14712; Wells BO, 1997, SCIENCE, V277, P1067, DOI 10.1126/science.277.5329.1067; White SR, 1998, PHYS REV LETT, V81, P3227, DOI 10.1103/PhysRevLett.81.3227; Yamada K, 1998, PHYS REV B, V57, P6165, DOI 10.1103/PhysRevB.57.6165; Zaanen J, 1996, PHYS REV B, V53, P8671, DOI 10.1103/PhysRevB.53.8671; Zaanen J, 1996, ANN PHYS-LEIPZIG, V5, P224; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; Zaanen J, 1998, PHYS REV B, V58, pR11868, DOI 10.1103/PhysRevB.58.R11868; Zimmermann M., 1998, EPL-EUROPHYS LETT, V41, P629	36	216	218	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					268	272		10.1126/science.286.5438.268	http://dx.doi.org/10.1126/science.286.5438.268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514366				2022-12-28	WOS:000083024400038
J	Chandra, B				Chandra, B			Islands I hardly knew	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1209	1210		10.1001/jama.282.13.1209	http://dx.doi.org/10.1001/jama.282.13.1209			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517405				2022-12-28	WOS:000082901100001
J	Robinson, JC				Robinson, JC			Blended payment methods in physician organizations under managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDEPENDENT PRACTICE ASSOCIATION; HEALTH-CARE; INCENTIVES; CALIFORNIA; SELECTION	Context Independent practice associations (IPAs) are developing new methods of physician reimbursement to balance the objectives of encouraging individual productivity and clinical cooperation, The economic literature on payment incentives, derived from nonhealth industries, predicts that methods blending elements of fee-for-service and capitation will outperform exclusive reliance on either form of payment. Objective To identify emerging payment methods within IPA physician groups that contract with managed care organizations. Design and Setting Case studies of 7 large IPAs in the San Francisco, Calif, metropolitan region that served 826 000 health maintenance organization (HMO) patients during the summer and fall of 1998, Main Outcome Measure Payment methods of IPAs for primary care physicians, specialists, and physicians grouped by specialty department within the overall IPA structure. Results All the IPAs contracted with multiple HMOs for the full range of primary and specialty care physicians' services but paid member physicians using methods that blended elements of fee-for-service and subcapitation. For primary care, most IPAs used monthly capitation adjusted for patient age, sex, and selected diagnoses, supplemented with fee-for-service payment for a wide range of visits and procedures, including patient visits in subacute, skilled nursing facility, emergency department, or home settings; for preventive care services; for office procedures requiring expensive supplies; and, most importantly, for borderline primary care procedures that either could be performed directly or referred to specialty care. All the IPAs paid specialty departments on a capitated basis and delegated to the departments responsibility for allocating the budget among individuals. Allocation mechanisms for individual specialists included adjusted fee-for-service, referral-based capitation, and blends of both. Conclusion Our results and case studies indicate that IPAs are developing payment methods that blend elements of fee-for-service and capitation in innovative ways for primary care and specialty physicians.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.							ALCHIAN AA, 1972, AM ECON REV, V62, P777; Alchian AA, 1950, J POLIT ECON, V58, P211, DOI 10.1086/256940; BAKER GP, 1988, J FINANC, V43, P593, DOI 10.2307/2328185; Bodenheimer T, 1999, NEW ENGL J MED, V340, P584, DOI 10.1056/NEJM199902183400725; CASALINO LP, 1992, JAMA-J AM MED ASSOC, V267, P403; ELLIS RP, 1993, J ECON PERSPECT, V7, P135, DOI 10.1257/jep.7.4.135; Fisher ES, 1999, JAMA-J AM MED ASSOC, V281, P446, DOI 10.1001/jama.281.5.446; GIACOMINI M, 1995, ANNU REV PUBL HEALTH, V16, P401; *GOV COMM, 1995, GREAT GOOD REC AM PH; Grumbach K, 1998, HEALTH AFFAIR, V17, P227, DOI 10.1377/hlthaff.17.3.227; *HOECHST MAR ROUSS, 1998, MAN CAR DIG SER 1998; HOLMSTROM BR, 1989, HDB IND ORG, P61; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LAFFONT JJ, 1986, J POLIT ECON, V94, P614, DOI 10.1086/261392; LUFT HS, 1988, HEALTH AFFAIR, V7, P97, DOI 10.1377/hlthaff.7.3.97; Newhouse JP, 1996, J ECON LIT, V34, P1236; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; PENNER MJ, 1997, CAPITATION CALIFORNI; Prendergast C, 1999, J ECON LIT, V37, P7, DOI 10.1257/jel.37.1.7; Reinhardt UE, 1999, JAMA-J AM MED ASSOC, V281, P462, DOI 10.1001/jama.281.5.462; ROBINSON JC, 1999, CORPORATE PRACTICE M; SAPPINGTON DEM, 1991, J ECON PERSPECT, V5, P45, DOI 10.1257/jep.5.2.45; SCHLEIFER A, 1985, RAND J ECON, V16, P319; SHENKIN BN, 1995, JAMA-J AM MED ASSOC, V273, P1937, DOI 10.1001/jama.273.24.1937; Thompson JW, 1998, HEALTH AFFAIR, V17, P152, DOI 10.1377/hlthaff.17.1.152; Wennberg J. E., 1996, DARTMOUTH ATLAS HLTH; Williamson O. E., 1985, EC I CAPITALISM; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; Yin R.K., 1994, CASE STUDY RES; Zeckhauser R., 1985, PRINCIPAL AGENTS STR	31	38	40	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1258	1263		10.1001/jama.282.13.1258	http://dx.doi.org/10.1001/jama.282.13.1258			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517429				2022-12-28	WOS:000082901100034
J	Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C				Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C			Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; LIPOPROTEINS; MENOPAUSE; MORTALITY; HEALTH	Objective To assess whether risk factor profiles for cardiovascular disease differed, before starting treatment, between women who would subsequently use hormone replacement therapy and those who would remain untreated. Design Prospective population study, initiated in 1968-9, with follow ups in 1974, 1980, and 1992. Setting Gothenburg, Sweden. Participants 1201 women born in 1918, 1922, and 1930, representative of women of the same age in the general population. Main outcome measures Hormone replacement therapy as a function of initial systolic and diastolic blood pressure, waist and hip circumference, waist to hip ratio, body mass index, serum concentrations of cholesterol and triglycerides, smoking status, education, leisure time activity, and socioeconomic group. Results 179 of the 1201 women (14.9%) used hormone replacement therapy sometime during the 24 year follow up period. Multivariate models indicated that these women had significantly lower blood pressure, had less obesity, and belonged to a higher social group before the start of treatment than women who would remain untreated. Conclusion Women who would subsequently use hormone replacement therapy were already at lower cardiovascular risk before the start of treatment than women who would remain untreated. Some of the claimed beneficial effects of treatment may thus be explained by women who would use hormone replacement therapy representing a healthier cohort than women who would remain untreated.	Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, SE-41345 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Rodstrom, K (corresponding author), Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden.	Kerstin.Rodstrom@allmed.gu.se						BarrettConnor E, 1996, MATURITAS, V23, P227, DOI 10.1016/0378-5122(95)00975-2; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; Bengtsson C, 1997, SCAND J PRIM HEALTH, V15, P214, DOI 10.3109/02813439709035031; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND S, V549; Carlsson G., 1958, SOCIAL MOBILITY CLAS; CHRISTIANSEN C, 1991, AM J MED, V90, P107; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HALLING A, 1984, SWED DENT J, V8, P183; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VANDERMAAREL SM, 1995, EUR J HUM GENET, V3, P207; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816	22	51	52	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	1999	319	7214					890	893		10.1136/bmj.319.7214.890	http://dx.doi.org/10.1136/bmj.319.7214.890			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506047	Green Published, Bronze			2022-12-28	WOS:000082975600026
J	Shale, DJ				Shale, DJ			New volumes for old?	LANCET			English	Editorial Material									Univ Wales, Coll Med, Dept Med, Llandough Hosp, Cardiff CF64 2XX, S Glam, Wales	Cardiff University	Shale, DJ (corresponding author), Univ Wales, Coll Med, Dept Med, Llandough Hosp, Cardiff CF64 2XX, S Glam, Wales.							Cliff IJ, 1999, THORAX, V54, P329, DOI 10.1136/thx.54.4.329; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; *EUR COMM COAL STE, 1983, B EUR PHYSIOPATHO S5, V19, P11; RODENSTEIN DO, 1982, AM REV RESPIR DIS, V126, P1040	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1050	1051		10.1016/S0140-6736(99)90133-2	http://dx.doi.org/10.1016/S0140-6736(99)90133-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509492				2022-12-28	WOS:000082777500006
J	Sawyer, SM; Bowes, G				Sawyer, SM; Bowes, G			Adolescence on the health agenda	LANCET			English	Article							CHRONIC ILLNESS; CHILDHOOD; CARE; TRANSITION; PREVALENCE; BEHAVIORS; MEDICINE; SETTINGS; PATTERNS; IMPACT		Royal Childrens Hosp, Ctr Adolescent Hlth, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne	Sawyer, SM (corresponding author), Ctr Adolescent Hlth, 2 Gatehouse St, Parkville, Vic 3052, Australia.							ANDERSON N, 1997, MON VITAL STAT RE S2, V45; BERGMAN FP, 1996, PEDIATRICS, V97, P791; BLUM RW, 1993, J ADOLESCENT HEALTH, V14, P570, DOI 10.1016/1054-139X(93)90143-D; Blum RW, 1996, AM J PUBLIC HEALTH, V86, P1767, DOI 10.2105/AJPH.86.12.1767; BLUM RW, 1992, TXB ADOLESCENT MED, P28; Borowsky IW, 1999, ARCH PEDIAT ADOL MED, V153, P573, DOI 10.1001/archpedi.153.6.573; DONOVAN JE, 1985, J CONSULT CLIN PSYCH, V53, P890, DOI 10.1037/0022-006X.53.6.890; FELNER RD, 1989, PRIMARY PREVENTION P; Ford CA, 1997, JAMA-J AM MED ASSOC, V278, P1029, DOI 10.1001/jama.278.12.1029; GLOVER S, 1998, FAMILY MATTERS, V49, P11; GROTEVANT HD, 1985, CHILD DEV, V56, P415, DOI 10.2307/1129730; Harrison J, 1997, YOUTH SUICIDE SELF I; INGERSOLL GM, 1989, ADOLESCENCE; JESSOR R, 1993, AM PSYCHOL, V48, P117, DOI 10.1037/0003-066X.48.2.117; Krohn MD, 1997, J HEALTH SOC BEHAV, V38, P87, DOI 10.2307/2955363; Krohne H. W., 1990, HLTH HAZARDS ADOLESC, P115; LAVIGNE JV, 1992, J PEDIATR PSYCHOL, V17, P133, DOI 10.1093/jpepsy/17.2.133; Losel F., 1990, HLTH HAZARDS ADOLESC, P299, DOI 10.1515/9783110847659-015; LUTHAR SS, 1991, AM J ORTHOPSYCHIAT, V6, P6; *NAT HLTH MED RES, 1997, DEPR YOUNG PEOPL CLI; NeumarkSztainer D, 1996, AM J PUBLIC HEALTH, V86, P1599, DOI 10.2105/AJPH.86.11.1599; Newacheck PW, 1998, AM J PUBLIC HEALTH, V88, P610, DOI 10.2105/AJPH.88.4.610; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Patton GC, 1997, PSYCHOL MED, V27, P715, DOI 10.1017/S003329179600462X; Patton GC, 1996, AM J PUBLIC HEALTH, V86, P225, DOI 10.2105/AJPH.86.2.225; Patton GC, 1999, BRIT MED J, V318, P765, DOI 10.1136/bmj.318.7186.765; Pless IB, 1996, CAN MED ASSOC J, V155, P1429; PLESS IB, 1989, DEV MED CHILD NEUROL, V31, P746; PLESS IB, 1991, J CHILD PSYCHOL PSYC, V32, P347, DOI 10.1111/j.1469-7610.1991.tb00312.x; Raphael D, 1996, J ADOLESCENT HEALTH, V19, P6, DOI 10.1016/1054-139X(95)00233-I; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; ROSEN D, 1995, J ADOLESCENT HEALTH, V17, P10, DOI 10.1016/1054-139X(95)00077-6; RUTTER M, 1993, J ADOLESCENT HEALTH, V14, P626, DOI 10.1016/1054-139X(93)90196-V; Sanci LA, 1999, J ADOLESCENT HEALTH, V24, P81; Sawyer SM, 1997, J PAEDIATR CHILD H, V33, P88, DOI 10.1111/j.1440-1754.1997.tb01005.x; Sawyer SM, 1998, J PAEDIATR CHILD H, V34, P414, DOI 10.1046/j.1440-1754.1998.00265.x; SAWYER SM, 1998, DIABETES ADOLESCENT, P255; SCHABAS R, 1992, OPPORTUNITIES HLTH; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; *US OFF TECHN ASS, 1991, AD HLTH; VINER R, 1998, EVIDENCE BASED BEST; WHO, 1993, HLTH YOUNG PEOPLE; WOLMAN C, 1994, J ADOLESCENT HEALTH, V15, P199, DOI 10.1016/1054-139X(94)90504-5; Zubrick S. R., 1997, W AUSTR CHILD HLTH S	44	12	12	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP	1999	354			2			S31	S34		10.1016/S0140-6736(99)90256-8	http://dx.doi.org/10.1016/S0140-6736(99)90256-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	239QH	10507258				2022-12-28	WOS:000082780700008
J	Ettinger, B; Black, DM; Mitlak, BH; Knickerbocker, RK; Nickelsen, T; Genant, HK; Christiansen, C; Delmas, PD; Zanchetta, JR; Stakkestad, J; Gluer, CC; Krueger, K; Cohen, FJ; Eckert, S; Ensrud, KE; Avioli, LV; Lips, P; Cummings, SR				Ettinger, B; Black, DM; Mitlak, BH; Knickerbocker, RK; Nickelsen, T; Genant, HK; Christiansen, C; Delmas, PD; Zanchetta, JR; Stakkestad, J; Gluer, CC; Krueger, K; Cohen, FJ; Eckert, S; Ensrud, KE; Avioli, LV; Lips, P; Cummings, SR		Multiple Outcomes Raloxifene Evaluation	Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN REPLACEMENT THERAPY; BONE-MINERAL DENSITY; VENOUS THROMBOEMBOLISM; ENDOMETRIAL FLUID; ELDERLY WOMEN; PREVENTION; CALCIUM; OLDER; USERS	Context Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. Objective To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures. Design The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial. Setting and Participants A total of 7705 women aged 31 to 80 years in 25 countries who had been postmenopausal for at least 2 years and who met World Health Organization criteria for having osteoporosis. The study began in 1994 and had up to 36 months of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 months of follow-up for serious adverse events. Interventions Participants were randomized to 60 mg/d or 120 mg/d of raloxifene or to identically appearing placebo pills; in addition, all women received supplemental calcium and cholecalciferol. Main Outcome Measures Incident vertebral fracture was determined radiographically at baseline and at scheduled 24- and 36-month visits. Nonvertebral fracture was ascertained by interview at 6-month-interim visits. Bone mineral density was determined annually by dual-energy x-ray absorptiometry, Results At 36 months of the evaluable radiographs in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving placebo, 6.6% of those receiving 60 mg/d of raloxifene, and 5.4% of those receiving 120 mg/d of raloxifene. Risk of vertebral fracture was reduced in both study groups receiving raloxifene (for 60-mg/d group: relative risk [RR], 0.7; 95% confidence interval [CI], 0.5-0.8; for 120-mg/d group: RR, 0.5; 95% CI, 0.4-0.7). Frequency of vertebral fracture was reduced both in women who did and did not have prevalent fracture. Risk of nonvertebral fracture for raloxifene vs placebo did not differ significantly (RR, 0.9; 95% CI, 0.8-1.1 for both raloxifene groups combined). Compared with placebo, raloxifene increased bone mineral density in the femoral neck by 2.1% (60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) and 2.7% (120 mg) P<0.001 for all comparisons). Women receiving raloxifene had increased risk of Venous th romboembolus vs placebo (RR, 3.1; 95% CI, 1.5-6.2). Raloxifene did not cause vaginal bleeding or breast pain and was associated with a lower incidence of breast cancer. Conclusions In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA; Ctr Clin & Basic Res, Ballerup, Denmark; INSERM, F-69008 Lyon, France; Inst Invest Metab, Buenos Aires, DF, Argentina; CECOR AS, Ctr Clin Osteoporosis Res, Haugesund, Norway; Univ Kiel, Dept Diagnost Radiol, D-24098 Kiel, Germany; Vet Affairs Med Ctr, Minneapolis, MN USA; Washington Univ, St Louis, MO USA; Vrije Univ Amsterdam, Amsterdam, Netherlands	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Eli Lilly; Center Clinical & Basic Research; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Kiel; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Washington University (WUSTL); Vrije Universiteit Amsterdam	Ettinger, B (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway,13th Floor, Oakland, CA 94611 USA.	bxe@dor.kaiser.org	Glüer, Claus-Christian/C-9752-2010	Glüer, Claus-Christian/0000-0003-3539-8955; Ensrud, Kristine/0000-0002-9069-3036; Cohen, Fredric/0000-0002-6874-5338				Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BONDE M, 1994, CLIN CHEM, V40, P2022; Brooks SE, 1996, GYNECOL ONCOL, V63, P19, DOI 10.1006/gyno.1996.0271; CAMPBELL S, 1997, BAILLIERE CLIN OB GY, V4, P31; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Garnero P, 1996, J BONE MINER RES, V11, P1531; Genant HK, 1996, J BONE MINER RES, V11, P984; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lu Y, 1996, J BONE MINER RES, V11, P626; Lu Y, 1997, STAT MED, V16, P1889, DOI 10.1002/(SICI)1097-0258(19970830)16:16<1889::AID-SIM607>3.0.CO;2-V; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; *USDA, 1907, NAT ADV DRUG REACT D; Vuento MH, 1996, ULTRASOUND OBST GYN, V8, P37, DOI 10.1046/j.1469-0705.1996.08010037.x	25	2388	2487	6	109	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					637	645		10.1001/jama.282.7.637	http://dx.doi.org/10.1001/jama.282.7.637			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517716				2022-12-28	WOS:000082033700022
J	Wolffe, AP; Matzke, MA				Wolffe, AP; Matzke, MA			Epigenetics: Regulation through repression	SCIENCE			English	Review							X-CHROMOSOME INACTIVATION; TRANSCRIPTION FACTOR ACCESS; BINDING-PROTEIN MECP2; DE-NOVO METHYLATION; DNA METHYLATION; HISTONE ACETYLATION; TRANSPOSABLE ELEMENT; CYTOSINE METHYLATION; CHROMATIN STRUCTURE; II TRANSCRIPTION	Epigenetics is the study of heritable changes in gene expression that occur without a change in DNA sequence. Epigenetic phenomena have major economic and medical relevance, and several, such as imprinting and paramutation, violate Mendelian principles. Recent discoveries Link the recognition of nucleic acid sequence homology to the targeting of DNA methylation, chromosome remodeling, and RNA turnover. Although epigenetic mechanisms help to protect cells from parasitic elements, this defense can complicate the genetic manipulation of plants and animals. Essential for normal development, epigenetic controls become misdirected in cancer cells and other human disease syndromes.	NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Austrian Academy of Sciences	Wolffe, AP (corresponding author), NICHHD, Mol Embryol Lab, NIH, Bldg 18T,Room 106, Bethesda, MD 20892 USA.	awlme@helix.nih.gov; amatzke@server1.imolbio.oeaw.ac.at	Ahuja, Nita/H-1064-2011					Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; AragonAlcaide L, 1997, CURR BIOL, V7, P905, DOI 10.1016/S0960-9822(06)00383-6; ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457; Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BOOM R, 1987, J GEN VIROL, V68, P2839, DOI 10.1099/0022-1317-68-11-2839; Brannan CI, 1999, CURR OPIN GENET DEV, V9, P164, DOI 10.1016/S0959-437X(99)80025-2; Bright S, 1999, NATURE, V400, P14, DOI 10.1038/21766; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; BRINK RA, 1960, Q REV BIOL, V35, P120, DOI 10.1086/403016; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CASSENS S, 1994, J GEN VIROL, V75, P3255, DOI 10.1099/0022-1317-75-11-3255; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; CONSTANZI C, 1998, NATURE, V393, P599; Crawford KM, 1999, CURR BIOL, V9, pR281, DOI 10.1016/S0960-9822(99)80179-1; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Dorer DR, 1997, GENETICS, V147, P1181; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; FLAVELL AJ, 1994, CURR OPIN GENET DEV, V4, P838, DOI 10.1016/0959-437X(94)90068-X; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Francke U, 1998, CIBA F SYMP, V214, P264; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Gasser SM, 1998, CIBA F SYMP, V214, P114; Gemkow MJ, 1998, DEVELOPMENT, V125, P4541; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; GRUENBAUM Y, 1983, P NATL ACAD SCI-BIOL, V80, P4919, DOI 10.1073/pnas.80.16.4919; HAUSEN RS, 1992, HUM MOL GENET, V1, P571; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; Henikoff S, 1998, CELL, V93, P329, DOI 10.1016/S0092-8674(00)81161-7; Henikoff S, 1998, GENETICS, V149, P307; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HORSTHEMKE B, 1995, GENOMIC IMPRINTING C, P295; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Jaenisch R, 1998, CIBA F SYMP, V214, P200; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; Jakowitsch J, 1999, PLANT J, V17, P131, DOI 10.1046/j.1365-313X.1999.00357.x; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jeppesen P, 1997, BIOESSAYS, V19, P67, DOI 10.1002/bies.950190111; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jong MTC, 1999, HUM MOL GENET, V8, P783, DOI 10.1093/hmg/8.5.783; Jorgensen RA, 1999, TRENDS GENET, V15, P11, DOI 10.1016/S0168-9525(98)01651-5; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; KONDO Y, 1990, CANCER RES, V50, P7852; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; Kuriyama S, 1998, GENE THER, V5, P1299, DOI 10.1038/sj.gt.3300738; Laker C, 1998, J VIROL, V72, P339, DOI 10.1128/JVI.72.1.339-348.1998; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li HW, 1999, EMBO J, V18, P2683, DOI 10.1093/emboj/18.10.2683; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Luff B, 1999, MOL CELL, V3, P505, DOI 10.1016/S1097-2765(00)80478-5; LYON MF, 1990, NATURE, V348, P585, DOI 10.1038/348585a0; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; Martienssen R, 1999, NAT GENET, V22, P6, DOI 10.1038/8708; Martienssen R, 1998, CURR OPIN GENET DEV, V8, P240, DOI 10.1016/S0959-437X(98)80147-0; Martienssen R, 1996, CURR BIOL, V6, P810, DOI 10.1016/S0960-9822(02)00601-2; Martinez-Perez E, 1999, J CELL SCI, V112, P1761; Matzke M. A., 1996, Epigenetic mechanisms of gene regulation., P377; Matzke MA, 1998, TRENDS ECOL EVOL, V13, P241, DOI 10.1016/S0169-5347(98)01390-1; Matzke MA, 1999, BIOESSAYS, V21, P761, DOI 10.1002/(SICI)1521-1878(199909)21:9&lt;761::AID-BIES7&gt;3.0.CO;2-C; Matzke MA, 1996, TRENDS PLANT SCI, V1, P382, DOI 10.1016/S1360-1385(96)80313-X; MESSING J, 1999, RESULTS PROBLEMS CEL, P23; Mette MF, 1999, EMBO J, V18, P241, DOI 10.1093/emboj/18.1.241; MEYER P, 1995, GENE SILENCING HIGHE, pR5; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Morris JR, 1999, GENE DEV, V13, P253, DOI 10.1101/gad.13.3.253; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Palauqui JC, 1999, CURR BIOL, V9, P59, DOI 10.1016/S0960-9822(99)80016-5; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Park YD, 1996, PLANT J, V9, P183, DOI 10.1046/j.1365-313X.1996.09020183.x; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; Pelissier T, 1999, NUCLEIC ACIDS RES, V27, P1625, DOI 10.1093/nar/27.7.1625; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PHILLIPS RL, 1994, P NATL ACAD SCI USA, V91, P5222, DOI 10.1073/pnas.91.12.5222; Pickard BG, 1999, CELL, V98, P5, DOI 10.1016/S0092-8674(00)80600-5; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Preuss D, 1999, PLANT CELL, V11, P765, DOI 10.1105/tpc.11.5.765; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Regev A, 1998, MOL BIOL EVOL, V15, P880, DOI 10.1093/oxfordjournals.molbev.a025992; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Riggs A. D., 1996, TORRENTS SPRING, P1; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Riggs AD, 1998, CIBA F SYMP, V214, P214; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; ROSSIGNOL JL, 1995, CURR TOP MICROBIOL, V197, P179; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Schaefer BC, 1997, MOL CELL BIOL, V17, P364, DOI 10.1128/MCB.17.1.364; Scheid OM, 1996, P NATL ACAD SCI USA, V93, P7114, DOI 10.1073/pnas.93.14.7114; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; Scowcroft W.R., 1985, GENETIC FLUX PLANTS, P217; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; SKIRVIN RM, 1994, HORTSCIENCE, V29, P1232, DOI 10.21273/HORTSCI.29.11.1232; STARN M, 1998, MOL CELL BIOL, V18, P6165; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walker EL, 1998, GENETICS, V148, P1973; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wassenegger M, 1999, TRENDS PLANT SCI, V4, P207, DOI 10.1016/S1360-1385(99)01416-8; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; Wilmut I, 1998, SCI AM, V279, P58, DOI 10.1038/scientificamerican1298-58; Wolffe AP, 1998, CIBA F SYMP, V214, P1; Wu CT, 1999, CURR OPIN GENET DEV, V9, P237, DOI 10.1016/S0959-437X(99)80035-5; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; YOUSSOUFIAN H, 1982, P NATL ACAD SCI-BIOL, V79, P2207, DOI 10.1073/pnas.79.7.2207	166	855	965	5	326	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					481	486		10.1126/science.286.5439.481	http://dx.doi.org/10.1126/science.286.5439.481			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521337				2022-12-28	WOS:000083121200049
J	Finucane, TE; Christmas, C; Travis, K				Finucane, TE; Christmas, C; Travis, K			Tube feeding in patients with advanced dementia - A review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; LONG-TERM-CARE; NURSING-HOME PATIENTS; ASPIRATION PNEUMONIA; ENTERAL NUTRITION; NASOGASTRIC TUBE; GASTROESOPHAGEAL REFLUX; PULMONARY ASPIRATION; MEGESTROL-ACETATE; ELDERLY PATIENTS	Patients with advanced dementia frequently develop eating difficulties and weight loss. Enteral feeding tubes are often used in this situation, yet benefits and risks of this therapy are unclear. We searched MEDLINE, 1966 through March 1999, to identify data about whether tube feeding in patients with advanced dementia can prevent aspiration pneumonia, prolong survival, reduce the risk of pressure sores or infections, improve function, or provide palliation. We found no published randomized trials that compare tube feeding with oral feeding. We found no data to suggest that tube feeding improves any of these clinically important outcomes and some data to suggest that it does not. Further, risks are substantial. The widespread practice of tube feeding should be carefully reconsidered, and we believe that for severely demented patients the practice should be discouraged on clinical grounds.	Johns Hopkins Bayview Med Ctr, Div Geriatr med & Gerontol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Finucane, TE (corresponding author), Johns Hopkins Geriatr Ctr, 5505 Hopkins Bayview Cir, Baltimore, MD 21224 USA.							ABBASI AA, 1994, NUTR REV, V52, P113, DOI 10.1111/j.1753-4887.1994.tb01403.x; ADAMS MB, 1986, ARCH SURG-CHICAGO, V121, P236; BAETEN C, 1992, SCAND J GASTROENTERO, V27, P95, DOI 10.3109/00365529209096035; BERGSTROM LR, 1995, MAYO CLIN PROC, V70, P829; Berlowitz DR, 1996, ANN INTERN MED, V124, P557, DOI 10.7326/0003-4819-124-6-199603150-00003; Berlowitz DR, 1997, J AM GERIATR SOC, V45, P30, DOI 10.1111/j.1532-5415.1997.tb00974.x; BourdelMarchasson I, 1997, INT J QUAL HEALTH C, V9, P297, DOI 10.1093/intqhc/9.4.297; Boylston Eula, 1996, Journal of Nutrition for the Elderly, V15, P43, DOI 10.1300/J052v15n03_04; CANEL D, 1987, J PEDIATR SURG, V22, P54; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; COGEN R, 1991, AM J GASTROENTEROL, V86, P1610; Cowen ME, 1997, J GEN INTERN MED, V12, P88, DOI 10.1046/j.1525-1497.1997.00012.x; CRAIG TJ, 1980, AM J PSYCHIAT, V137, P1366; CRAIG TJ, 1982, JAMA-J AM MED ASSOC, V248, P2114, DOI 10.1001/jama.1982.03330170022014; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; DEPASO WJ, 1991, CLIN CHEST MED, V12, P269; FAY DE, 1991, AM J GASTROENTEROL, V86, P1604; Feinberg MJ, 1996, DYSPHAGIA, V11, P104, DOI 10.1007/BF00417899; FERNANDEZCREHUE.NM, 1992, J HOSP INFECT, V21, P111; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; Finestone HM, 1996, ARCH PHYS MED REHAB, V77, P340, DOI 10.1016/S0003-9993(96)90081-7; Finocchiaro C, 1997, NUTRITION, V13, P520, DOI 10.1016/S0899-9007(97)00030-0; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Fisman DN, 1999, J AM GERIATR SOC, V47, P349, DOI 10.1111/j.1532-5415.1999.tb03000.x; FOX KA, 1995, AM J SURG, V170, P564, DOI 10.1016/S0002-9610(99)80016-6; Franzoni S, 1996, J AM GERIATR SOC, V44, P1366, DOI 10.1111/j.1532-5415.1996.tb01409.x; GHOSH S, 1993, GUT, V34, P859, DOI 10.1136/gut.34.6.859; GOLDEN A, 1997, NURS HOME MED, V5, P382; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; GRUNOW JE, 1989, J PEDIATR SURG, V24, P42, DOI 10.1016/S0022-3468(89)80298-2; GUTIERREZ ED, 1991, RADIOLOGY, V178, P759, DOI 10.1148/radiology.178.3.1899727; HASSETT JM, 1988, SURG GYNECOL OBSTET, V167, P383; HEIMBACH DM, 1970, ANN SURG, V172, P311, DOI 10.1097/00000658-197008000-00020; HENDERSON CT, 1992, J AM COLL NUTR, V11, P309; HORNER J, 1988, NEUROLOGY, V38, P1359; HULL MA, 1993, LANCET, V341, P869, DOI 10.1016/0140-6736(93)93072-9; KAW M, 1994, DIGEST DIS SCI, V39, P738, DOI 10.1007/BF02087416; KEYMLING M, 1994, GUT, V35, pS77, DOI 10.1136/gut.35.1_Suppl.S77; Klein S, 1997, AM J CLIN NUTR, V66, P683, DOI 10.1093/ajcn/66.3.683; KOHLI H, 1995, AM SURGEON, V61, P191; KORETZ RL, 1986, GUT, V27, P85, DOI 10.1136/gut.27.Suppl_1.85; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; LEVINE CD, 1995, AM J ROENTGENOL, V164, P347, DOI 10.2214/ajr.164.2.7839967; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; LIGHT VL, 1995, GASTROINTEST ENDOSC, V42, P330, DOI 10.1016/S0016-5107(95)70132-X; Loser C, 1998, DIGEST DIS SCI, V43, P2549, DOI 10.1023/A:1026615106348; MATINO JJ, 1981, ARCH SURG-CHICAGO, V116, P169; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MILLER KS, 1985, CHEST, V88, P230, DOI 10.1378/chest.88.2.230; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; MITCHELL SL, 1998, J GERONTOL A-BIOL, V53, pM1; Morley JE, 1996, J AM GERIATR SOC, V44, P1403, DOI 10.1111/j.1532-5415.1996.tb01419.x; Navalpotro MAB, 1998, REV CLIN ESP, V198, P487; NEVINS MA, 1989, N J MED, V10, P779; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; PARK RHR, 1992, BRIT MED J, V304, P1406, DOI 10.1136/bmj.304.6839.1406; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; Pick N, 1996, J AM GERIATR SOC, V44, P763, DOI 10.1111/j.1532-5415.1996.tb03731.x; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; ROUBENOFF R, 1989, ARCH INTERN MED, V149, P184, DOI 10.1001/archinte.149.1.184; Russell GN, 1996, ANESTH ANALG, V83, P228, DOI 10.1097/00000539-199608000-00005; Scott Amanda G., 1994, Palliative Medicine, V8, P45, DOI 10.1177/026921639400800108; STOLKE D, 1982, ANASTH INTENSIV NOTF, V17, P104, DOI 10.1055/s-2007-1003858; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TSAI CC, 1992, J AM GERIATR SOC, V40, P821, DOI 10.1111/j.1532-5415.1992.tb01856.x; VOLICER L, 1989, J GERIATR PSYCH NEUR, V2, P189; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; Vreugde S., 1994, Acta Oto-Rhino-Laryngologica Belgica, V48, P229; WASILJEW BK, 1982, AM J SURG, V143, P194; ZERN RT, 1985, OBSTET GYNECOL, V65, pS81	77	567	576	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1365	1370		10.1001/jama.282.14.1365	http://dx.doi.org/10.1001/jama.282.14.1365			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527184				2022-12-28	WOS:000083000800032
J	Farrar, JJ				Farrar, JJ			Nipah-virus encephalitis - investigation of a new infection	LANCET			English	Editorial Material									Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England	University of Oxford	Farrar, JJ (corresponding author), Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Dist 5, Ho Chi Minh City, Vietnam.		Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X				Cardosa MJ, 1999, LANCET, V354, P987, DOI 10.1016/S0140-6736(98)11032-2; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0	3	22	26	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1222	1223		10.1016/S0140-6736(99)90124-1	http://dx.doi.org/10.1016/S0140-6736(99)90124-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520625				2022-12-28	WOS:000083010400002
J	Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A				Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A			Arsenic poisoning in the Ganges delta	NATURE			English	Article							GROUNDWATER		Geol Survey India, Kolkata 700016, W Bengal, India; Indian Inst Technol, Dept Civil Engn, Kanpur 208016, Uttar Pradesh, India	Geological Survey India; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Acharyya, SK (corresponding author), Geol Survey India, Kolkata 700016, W Bengal, India.							Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; Bhattacharya P., 1997, INT J WATER RESOUR D, V13, P79, DOI DOI 10.1080/07900629749944; Hiller K., 1988, GEOL JB D, V90, P3; Joshi A, 1996, J ENVIRON ENG-ASCE, V122, P769, DOI 10.1061/(ASCE)0733-9372(1996)122:8(769); Mallick S, 1996, CURR SCI INDIA, V70, P956; MUKHERJEE A, 1997, INDIAN J GEOL, V69, P41; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; WONG PLN, 1995, CHIN I ENV ENG, V5, P241	8	316	342	7	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					545	545		10.1038/44052	http://dx.doi.org/10.1038/44052			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524619	Bronze			2022-12-28	WOS:000083054900036
J	O'Craven, KM; Downing, PE; Kanwisher, N				O'Craven, KM; Downing, PE; Kanwisher, N			fMRI evidence for objects as the units of attentional selection	NATURE			English	Article							VISUAL-ATTENTION; BRAIN POTENTIALS; NEURAL MECHANISMS; HUMAN MT; MODULATION; PERCEPTION; SPOTLIGHT; CORTEX; AREAS; COLOR	Contrasting theories of visual attention emphasize selection by spatial location(1), visual features (such as motion or colour)(2-4) or whole objects(5,6). Here we used functional magnetic resonance imaging (fMRI) to test key predictions of the object-based theory, which proposes that pre-attentive mechanisms segment the visual array into discrete objects, groups, or surfaces, which serve as targets for visual attention(5-9). Subjects viewed stimuli consisting of a face transparently superimposed on a house, with one moving and the other stationary. In different conditions, subjects attended to the face, the house or the motion. The magnetic resonance signal from each subject's fusiform face area(10), parahippocampal place area(11) and area MT/MST12 provided a measure of the processing of faces, houses and visual motion, respectively. Although all three attributes occupied the same location, attending to one attribute of an object (such as the motion of a moving face) enhanced the neural representation not only of that attribute but also of the other attribute of the same object (for example, the face), compared with attributes of the other object (for example, the house). These results cannot be explained by models in which attention selects locations or features, and provide physiological evidence that whole objects are selected even when only one visual attribute is relevant.	Massachusetts Gen Hosp, NMR Ctr, Charlestown, MA 02129 USA; Radcliffe Coll, Bunting Inst, Cambridge, MA 02138 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Kanwisher, N (corresponding author), Massachusetts Gen Hosp, NMR Ctr, Bldg 149 13th St, Charlestown, MA 02129 USA.			Downing, Paul/0000-0002-5046-2858				Beauchamp MS, 1997, J NEUROPHYSIOL, V78, P516, DOI 10.1152/jn.1997.78.1.516; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DRIVER J, 1994, NEUROPSYCHOLOGIA, V32, P1353, DOI 10.1016/0028-3932(94)00068-9; DRIVER J, 1989, J EXP PSYCHOL HUMAN, V15, P448, DOI 10.1037/0096-1523.15.3.448; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gandhi SP, 1999, P NATL ACAD SCI USA, V96, P3314, DOI 10.1073/pnas.96.6.3314; HE ZY, 1995, ACTA MECH SOLIDA SIN, V8, P1; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kastner S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5; MANGUN GR, 1990, PERCEPT PSYCHOPHYS, V47, P532, DOI 10.3758/BF03203106; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; QIAN N, 1994, J NEUROSCI, V14, P7357; Roelfsema PR, 1998, NATURE, V395, P376, DOI 10.1038/26475; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TREISMAN AM, 1969, PSYCHOL REV, V76, P282, DOI 10.1037/h0027242; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; Valdes-Sosa M, 1998, J COGNITIVE NEUROSCI, V10, P137, DOI 10.1162/089892998563743; Vandenberghe R, 1997, J NEUROSCI, V17, P3739; WOLFE JM, 1989, J EXP PSYCHOL HUMAN, V15, P419, DOI 10.1037/0096-1523.15.3.419	30	618	628	1	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					584	587		10.1038/44134	http://dx.doi.org/10.1038/44134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	244MG	10524624				2022-12-28	WOS:000083054900049
J	Simon, HU; Plotz, SG; Dummer, R; Blaser, K				Simon, HU; Plotz, SG; Dummer, R; Blaser, K			Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOMA STUDY-GROUP; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; SEZARY-SYNDROME; APOPTOSIS; FAS; IDENTIFICATION; CLASSIFICATION; NEOPLASMS; EXPANSION	Background The cause of persistent eosinophilia and the hypereosinophilic syndrome is unknown. Recent work suggests that in some patients with the hypereosinophilic syndrome, a clone of abnormal T cells produces large amounts of interleukin-5, a cytokine required for the growth and differentiation of eosinophils. We examined T-cell surface markers, rearranged T-cell-receptor genes, and in vitro production of cytokines by T cells from patients with idiopathic eosinophilia. Methods The expression of surface molecules on T cells was measured by flow cytometry. Cytokine expression was measured by enzyme-linked immunosorbent assay, flow cytometry, and immunohistochemical analysis. To identify dominant (clonal) rearrangements of the T-cell receptor within the lymphocyte population, Southern blot analysis (beta chain) and the polymerase chain reaction (gamma chain) were performed according to standard protocols. Results Among 60 patients with idiopathic eosinophilia, 16 had circulating T cells with an aberrant immunophenotype. In each of these patients, the abnormal immunophenotype was unique. Evidence of clonal rearrangements of the T-cell receptor was obtained in 8 of the 16 patients. In most instances, the abnormal T cells expressed large amounts of surface proteins associated with T-cell activation (the a chain of the interleukin-2 receptor and the HLA-DR antigen). Moreover, the aberrant T cells produced large amounts of interleukin-5 in vitro. Conclusions Clonal populations of abnormal T cells producing interleukin-5 occur in some patients with idiopathic eosinophilia. (N Engl J Med 1999;341:1112-20.) (C)1999, Massachusetts Medical Society.	Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Tech Univ Munich, Res Ctr Environm & Hlth, D-8000 Munich, Germany; Univ Zurich, Dept Dermatol, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Technical University of Munich; University of Zurich	Simon, HU (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	hus@siaf.unizh.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bogen SA, 1996, AM J CLIN PATHOL, V106, P739; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Dummer R, 1996, BLOOD, V88, P1383, DOI 10.1182/blood.V88.4.1383.bloodjournal8841383; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; HARRIS NL, 1994, BLOOD, V84, P1361; Kamarashev J, 1998, J CUTAN PATHOL, V25, P407, DOI 10.1111/j.1600-0560.1998.tb01766.x; Meyer JC, 1997, EXP DERMATOL, V6, P122, DOI 10.1111/j.1600-0625.1997.tb00158.x; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Willemze R, 1997, BLOOD, V90, P354; WOOD GS, 1991, AM J PATHOL, V138, P1503	22	381	396	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1112	1120		10.1056/NEJM199910073411503	http://dx.doi.org/10.1056/NEJM199910073411503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511609	Bronze			2022-12-28	WOS:000083087200003
J	Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF				Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF			Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues	LANCET			English	Article; Proceedings Paper	6th Conference on Retroviruses and Opportunistic Infections	JAN 31-FEB 04, 1999	CHICAGO, IL				IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; RESPIRATORY-CHAIN; HIV TRANSMISSION; PREVENTION; TOXICITY; DNA; AZT	Background Zidovudine is commonly administered during pregnancy to prevent mother-to-child HIV-transmission. We investigated mitochondrial toxic effects in children exposed to zidovudine in utero and after birth. Methods We analysed observations of a trial of tolerance of combined zidovudine and lamivudine and preliminary results of a continuing retrospective analysis of clinical and biological symptoms of mitochondrial dysfunction in children born to HIV-1-infected women in France. Mitochondrial dysfunction was studied by spectrophotometry and polarography of respiratory-chain complexes in various tissues. Findings Fight children had mitochondrial dysfunction. Five, of whom two died, presented with delayed neurological symptoms and three were symptom-free but had severe biological or neurological abnormalities. Four of these children had been exposed to combined zidovudine and lamivudine, and four to zidovudine alone. No child was infected with HIV-1. All children had abnormally low absolute or relative activities of respiratory-chain complexes I, IV, or both months or years after the end of antiretroviral treatment. No mutation currently associated with constitutional disease was detected in any patient. Interpretation Our findings support the hypothesis of a link between mitochondrial dysfunction and the perinatal administration of prophylactic nucleoside analogues. Current recommendations for zidovudine monotherapy should however be maintained. Further assessment of the toxic effects of these drugs is required.	Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U429 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U393 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, Virol Lab, F-75743 Paris, France; Hop Bicetre, Serv Neurol Pediat, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, U292 Lab, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, CRI 9612 Lab, Le Kremlin Bicetre, France; Hop Bicetre, Biochim Lab, Le Kremlin Bicetre, France; Hop Bicetre, Serv Neuropathol, Le Kremlin Bicetre, France; Hop Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Cochin Port Royal, Paris, France; Hop Lariboisiere, F-75475 Paris, France; Hop St Vincent de Paul, Serv Neurol, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Blanche, S (corresponding author), Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France.	stephane.blanche@nck.ap-hop-paris.fr	Rötig, Agnès/G-9592-2017; Mandelbrot, Laurent/AAD-3554-2019	Rötig, Agnès/0000-0003-0589-0703; Mandelbrot, Laurent/0000-0002-5883-7597				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; [Anonymous], 1994, LANCET, V344, P207; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; CHRETIEN D, BIOCH J, V329, P249; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695; GERSCHENSON M, 1998, AM J HUM GENET, V63, pA164; Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kreuzer KA, 1997, ANN HEMATOL, V75, P179, DOI 10.1007/s002770050340; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Morris K, 1998, LANCET, V351, P651, DOI 10.1016/S0140-6736(05)78436-1; NEWELL ML, 1995, DRUG SAFETY, V12, P274, DOI 10.2165/00002018-199512040-00007; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; PONCHAUT S, 1995, EUR J PEDIATR, V154, P79, DOI 10.1007/BF01972980; Poulton J, 1998, Eur J Paediatr Neurol, V2, P99, DOI 10.1016/S1090-3798(98)80049-4; *PUBL HLTH SERV, 1998, MMWR-MORBID MORTAL W, V47, P688; ROUSE DJ, 1995, J ACQ IMMUN DEF SYND, V9, P401; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V; Scalfaro P, 1998, INTENS CARE MED, V24, P247, DOI 10.1007/s001340050558; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012	28	479	495	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1084	1089		10.1016/S0140-6736(99)07219-0	http://dx.doi.org/10.1016/S0140-6736(99)07219-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	239PA	10509500				2022-12-28	WOS:000082777500014
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Protein interaction - Complex grabbing	SCIENCE			English	Editorial Material																		RIGAUT G, IN PRESS NATURE BIOT	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1868						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-28	WOS:000082638300036
J	Zeisel, SH				Zeisel, SH			Health - Regulation of "nutraceuticals"	SCIENCE			English	Editorial Material									Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA.							AARTS T, 1998, NUTR BUS J, V3, P1; Clydesdale FM, 1997, NUTR REV, V55, P413, DOI 10.1111/j.1753-4887.1997.tb01588.x; Klepser TB, 1999, AM J HEALTH-SYST PH, V56, P125, DOI 10.1093/ajhp/56.2.125; VOGEL MR, 1998, PHARM TODAY, V4, P14; Williamson BL, 1998, TOXICOL LETT, V99, P139, DOI 10.1016/S0378-4274(98)00223-9; 1997, FED REG         0604, V62, P30677; 1999, MORB MORTAL WKLY REP, V481, P37; 1997, FED REG         0206, V62, P5699	8	200	207	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1853	+		10.1126/science.285.5435.1853	http://dx.doi.org/10.1126/science.285.5435.1853			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515789				2022-12-28	WOS:000082638300027
J	Laurent, G				Laurent, G			A systems perspective on early olfactory coding	SCIENCE			English	Review							OSCILLATING NEURAL ASSEMBLIES; RECEPTOR NEURONS; ODOR MIXTURES; DENDRODENDRITIC INHIBITION; BULB; INFORMATION; RESPONSES; SALAMANDER; MECHANISMS; INSECTS	This review critically examines neuronal coding strategies and how they might apply to olfactory processing. Basic notions such as identity, spatial, temporal, and correlation codes are defined and different perspectives are brought to the study of neural codes. Odors as physical stimuli and their processing by the early olfactory system, one or two synapses away from the receptors, are discussed. Finally, the concept of Lateral inhibition, as usually understood and applied to odor coding by mitral (or equivalent) cells, is challenged and extended to a broader context, possibly more appropriate for olfactory processing.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Oka, Yoshitaka/C-9670-2010; Laurent, Gilles/A-4583-2012	Oka, Yoshitaka/0000-0002-3482-3051; Laurent, Gilles/0000-0002-2296-114X				ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Abbott LF, 1999, NEURAL COMPUT, V11, P91, DOI 10.1162/089976699300016827; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; Agosta WC., 1992, CHEM COMMUNICATION L; AKERS RP, 1992, CHEM SENSES, V17, P191, DOI 10.1093/chemse/17.2.191; ATTNEAVE F, 1954, PSYCHOL REV, V61, P183, DOI 10.1037/h0054663; BAYLIN F, 1979, J GEN PHYSIOL, V74, P17, DOI 10.1085/jgp.74.1.17; Blakemore C., 2010, VISION CODING EFFICI, P363, DOI 10.1017/cbo9780511626197.034; Bozza TC, 1998, J NEUROSCI, V18, P4560; Brunel N, 1998, NEURAL COMPUT, V10, P1731, DOI 10.1162/089976698300017115; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUONVISO N, 1990, J NEUROPHYSIOL, V63, P447, DOI 10.1152/jn.1990.63.3.447; CARIANI P, 1994, ORIGINS: BRAIN AND SELF ORGANIZATION, P208; Chandra S, 1998, J EXP BIOL, V201, P3113; Christensen TA, 1998, J NEUROSCI, V18, P5999; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2053, DOI 10.1152/jn.1995.73.5.2053; DORRIES K, IN PRESS J NEUROPHYS; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Faber T, 1999, NAT NEUROSCI, V2, P74, DOI 10.1038/4576; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FREEMAN WJ, 1972, J NEUROPHYSIOL, V35, P762, DOI 10.1152/jn.1972.35.6.762; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GETCHELL TV, 1986, PHYSIOL REV, V66, P772, DOI 10.1152/physrev.1986.66.3.772; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; HARTLINE HK, 1957, J GEN PHYSIOL, V40, P357, DOI 10.1085/jgp.40.3.357; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Hopfield JJ, 1996, P NATL ACAD SCI USA, V93, P15440, DOI 10.1073/pnas.93.26.15440; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KAUER JS, 1974, BRAIN RES, V188, P139; KONISHI M, 1990, COLD SPRING HARB SYM, V55, P575; LAING DG, 1989, PHYSIOL BEHAV, V45, P689, DOI 10.1016/0031-9384(89)90280-1; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Laurent G, 1997, CURR OPIN NEUROBIOL, V7, P547, DOI 10.1016/S0959-4388(97)80035-9; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; LEVETEAU J, 1966, SCIENCE, V153, P175, DOI 10.1126/science.153.3732.175; Linster C, 1997, BEHAV BRAIN RES, V87, P1, DOI 10.1016/S0166-4328(96)02271-1; Lu XCM, 1998, NEUROSCIENCE, V84, P849, DOI 10.1016/S0306-4522(97)00520-4; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; MACRIDES F, 1972, SCIENCE, V175, P85; MAFRANETO A, 1994, NATURE, V369, P142, DOI 10.1038/369142a0; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MASSON C, 1990, PHYSIOL REV, V70, P199, DOI 10.1152/physrev.1990.70.1.199; Meister M, 1999, NEURON, V22, P435, DOI 10.1016/S0896-6273(00)80700-X; MEREDITH M, 1986, J NEUROPHYSIOL, V56, P572, DOI 10.1152/jn.1986.56.3.572; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOZELL MM, 1964, NATURE, V203, P1181, DOI 10.1038/2031181a0; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; Pouget A, 1999, NEURAL COMPUT, V11, P85, DOI 10.1162/089976699300016818; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; RUDERMAN DL, 1994, NETWORK-COMP NEURAL, V5, P517, DOI 10.1088/0954-898X/5/4/006; Schoppa NE, 1998, J NEUROSCI, V18, P6790; SCOTT JW, 1987, NEUROBIOLOGY TASTE S, P151; Shannon E. E., 1963, MATH THEORY COMMUNIC; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; Shipley MT, 1996, J NEUROBIOL, V30, P123; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; Smith BH, 1998, PHYSIOL BEHAV, V65, P397, DOI 10.1016/S0031-9384(98)00142-5; SMITH BH, 1994, ANNU REV ENTOMOL, V39, P351, DOI 10.1146/annurev.en.39.010194.002031; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; STOPFER M, UNPUB; THEUNISSEN F, 1995, J COMPUT NEUROSCI, V2, P149, DOI 10.1007/BF00961885; Traub RD, 1999, FAST OSCILLATIONS CO; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; Wibe A, 1996, J COMP PHYSIOL A, V179, P331, DOI 10.1007/BF00194987; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371; Zeki S., 1993, VISION BRAIN; Zhang KC, 1999, NEURAL COMPUT, V11, P75, DOI 10.1162/089976699300016809; Zhang KC, 1998, J NEUROPHYSIOL, V79, P1017, DOI 10.1152/jn.1998.79.2.1017; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	79	240	246	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					723	728		10.1126/science.286.5440.723	http://dx.doi.org/10.1126/science.286.5440.723			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531051				2022-12-28	WOS:000083303200043
J	Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F				Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F			Clinical consequences of electrocardiographic artifact mimicking ventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-RISK		Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Knight, BP (corresponding author), Univ Michigan Hlth Syst, 1500 E Med Ctr Dr,B1F245, Ann Arbor, MI 48109 USA.							Dyke DBS, 1997, J CARDIOVASC ELECTR, V8, P1327, DOI 10.1111/j.1540-8167.1997.tb01025.x; FALK RH, 1987, AM J CARDIOL, V59, P924, DOI 10.1016/0002-9149(87)91124-6; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; KANTOR HI, 1966, AM J OBSTET GYNECOL, V94, P287, DOI 10.1016/0002-9378(66)90484-4; KLEINMAN B, 1990, J CLIN MONITOR, V6, P258; KRASNOW AZ, 1976, AM HEART J, V91, P349, DOI 10.1016/S0002-8703(76)80220-7; LAMPERT BA, 1988, ANESTH ANALG, V67, P1096, DOI 10.1213/00000539-198867110-00014; LIN SL, 1991, JPN HEART J, V32, P847; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MURDOCK DK, 1986, HEART LUNG, V15, P150; PAULSEN AW, 1988, ANESTHESIOLOGY, V69, P803, DOI 10.1097/00000542-198811000-00043; SCHILLER EC, 1988, ANESTHESIOLOGY, V68, P477, DOI 10.1097/00000542-198803000-00043	13	143	147	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1270	1274		10.1056/NEJM199910213411704	http://dx.doi.org/10.1056/NEJM199910213411704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528037				2022-12-28	WOS:000083226300004
J	Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S				Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S			Partial-liver transplantation to treat familial amyloid polyneuropathy: Follow-up of 11 patients	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSTHYRETIN AMYLOIDOSIS; CLINICAL IMPROVEMENT; SWEDISH PATIENTS; NERVE	Background: Recently, liver transplantation has been used to treat patients with familial amyloid polyneuropathy (FAP). Objective: To describe the clinical course of patients with FAP who received partial-liver transplantation from living donors. Design: Case series. Setting: University hospital in Matsumoto, Japan. Patients: 11 patients with FAP who underwent partial-liver transplantation. The transthyretin gene abnormality in all 11 patients was the substitution of methionine for valine at position 30. Intervention: Partial liver transplantation from living donors. Measurements: Preoperative and follow-up (3 to 64 months) clinical data, including routine laboratory data, nerve conduction velocity tests, and sural nerve histology. Results: All 7 patients who had severe gastrointestinal autonomic disorders or polyneuropathy localized to the lower limbs for less than 4 years showed improvement. Three of 4 patients with polyneuropathy involving both the upper and lower limbs had adverse outcomes, including two deaths. The preoperative duration of their illness was more than 6 years. These 3 patients also had marked decreases in creatinine clearance and nerve conduction velocities and severe loss of myelinated fibers in sural nerves. Conclusion: Preoperative clinical severity and duration of illness are associated with outcomes after liver transplantation for FAP.	Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University	Ikeda, S (corresponding author), Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan.	ikedasi@hsp.md.shinshu-u.ac.jp						Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; Coutinho P., 1980, AMYLOID AMYLOIDOSIS, P88; ERICZON BG, 1999, FAMILIAL AMYLOID POL; HANYU N, 1989, ANN NEUROL, V25, P340, DOI 10.1002/ana.410250405; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1991, CLIN GENET, V40, P242; Ikeda S, 1997, AMYLOID, V4, P18, DOI 10.3109/13506129708995264; IKEDA S, 1992, EUR NEUROL, V32, P308, DOI 10.1159/000116850; IKEDA SI, 1987, BRAIN, V110, P315, DOI 10.1093/brain/110.2.315; Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017; KYLE RA, 1993, PERIPHERAL NEUROPATH, P1294; MAKUUCHI M, 1993, SURGERY, V113, P395; PARRILLA P, 1995, BRIT J SURG, V82, P825, DOI 10.1002/bjs.1800820634; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; STEEN L, 1994, AMYLOID, V1, P138, DOI 10.3109/13506129409148636; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; THOMAS PK, 1974, BRAIN, V97, P395, DOI 10.1093/brain/97.1.395	19	44	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					592	595		10.7326/0003-4819-131-8-199910190-00008	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523220				2022-12-28	WOS:000083196600006
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Acupuncture	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									FILSHIE J, 1997, MED ACUPUNCTURE; KAPTCHUK T, 1983, CHINESE MED WEB HAS; Maciocia G., 1989, FDN CHINESE MED	3	89	92	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					973	976		10.1136/bmj.319.7215.973	http://dx.doi.org/10.1136/bmj.319.7215.973			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514163	Green Published			2022-12-28	WOS:000083111700030
J	Wolfson, M; Kaplan, G; Lynch, J; Ross, N; Backlund, E				Wolfson, M; Kaplan, G; Lynch, J; Ross, N; Backlund, E			Relation between income inequality and mortality: empirical demonstration	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES	Objective To assess the extent to which observed associations at population level between income inequality and mortality are statistical artefacts. Design Indirect "what if" simulation by using observed risks of mortality at individual level as a function of income to construct hypothetical state level mortality specific for age and sex as if the statistical artefact argument were 100% correct. Setting Data from the 1990 census for the 50 US states plus Washington, DC, were used for population distributions by age, sex, state, and income range; data disaggregated by age, sex, and state from the Centers for Disease Control and Prevention were used for mortality; and regressions from the national longitudinal mortality study were used for the individual level relation between income and risk of mortality. Results Hypothetical mortality while correlated with inequality (as amplied by the logic of the statistical artefact argument), showed a weaker association with states' levels of income inequality than the observed mortality Conclusions The observed associations in the United States at the state level between income inequality and mortality cannot be entirely or substantially explained as statistical artefacts of an underlying individual level relation between income and mortality There remains an important association between income inequality and mortality at state level over and above anything that could be accounted for by any statistical artefact. This result reinforces the need to consider a broad range of factors, including the social milieu, as fundamental determinants of health.	STAT Canada, Inst & Social Stat Branch, Ottawa, ON K1A 0T6, Canada; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; STAT Canada, Social & Econ Studies Div, Ottawa, ON K1A 0T6, Canada; US Bur Census, Washington, DC 20233 USA	Statistics Canada; University of Michigan System; University of Michigan; Statistics Canada	Wolfson, M (corresponding author), STAT Canada, Inst & Social Stat Branch, Ottawa, ON K1A 0T6, Canada.		Kaplan, George/AAJ-2398-2020					BACKLUND E, 1996, ANN EPIDEMIOL, V6, P1; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; DULEEP HO, 1995, SOC SECUR BULL, V58, P34; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; Kaplan GA, 1996, BRIT MED J, V312, P1253; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1998, BRIT MED J, V317, P917; Kennedy BP, 1996, BRIT MED J, V312, P1194; KENNEDY BP, 1996, BRIT MED J, V312, P1044; Lynch J W, 1997, J Health Psychol, V2, P297, DOI 10.1177/135910539700200303; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; PRESTON SH, 1975, POP STUD-J DEMOG, V29, P231, DOI 10.2307/2173509; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; Townsend P., 1988, INEQUALITIES HLTH BL; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WOLFSON M, 1993, J GERONTOL, V48, pS167, DOI 10.1093/geronj/48.4.S167; Wolfson MC, 1997, REV INCOME WEALTH, P401	18	132	135	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					953	955		10.1136/bmj.319.7215.953	http://dx.doi.org/10.1136/bmj.319.7215.953			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10514157	Green Published, Bronze			2022-12-28	WOS:000083111700022
J	Barton, MB; Harris, R; Fletcher, SW				Barton, MB; Harris, R; Fletcher, SW			Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIAL; CARCINOMA IN-SITU; DETECTION DEMONSTRATION PROJECT; PHYSICAL-EXAMINATION; SELF-EXAMINATION; OVARIAN-CANCER; DOM-PROJECT; LUMP DETECTION; DEATH RATES; MAMMOGRAPHY	Context The clinical breast examination (CBE) is widely recommended and practiced as a tool for breast cancer screening; however, its effectiveness is dependent on its precision and accuracy. Objective To collect evidence on the effectiveness of CBE in screening for breast cancer and information on the best technique to use. Data Sources We searched the English-language literature using the MEDLINE database (1966-1997) and manual review of all reference lists, as well as contacting investigators of several published studies for clarifications and unpublished data. Study Selection and Data Extraction To study CBE effectiveness, we included all controlled trials and case-control studies in which CBE was at least part of the screening modality; for technique, we included both clinical studies and those that used silicone breast models. All 3 authors reviewed and agreed on the studies selected for inclusion in the pooled analyses. Data Synthesis Randomized clinical trials demonstrated reduced breast cancer mortality rates among women screened by both CBE and mammography, Evidence of CBE's independent contribution was less direct; CBE alone detected between 3% and 45% of breast cancers found that screening mammography missed. The precision of CBE was difficult to determine because of the lack of consistent and standardized examination techniques. Studies on CBE precision reported fair agreement (kappa = 0.22-0.59). Pooling trial data, we estimated CBE sensitivity at 54% and specificity at 94%, The likelihood ratio of a positive CBE result is 10.6 (95% confidence interval [CI], 5.8-19.2), while the likelihood ratio of a negative test result is 0.47 (95 % CI, 0.40-0.56). Longer duration of CBE and a higher number of specific techniques used were associated with greater accuracy. The preferred technique for CBE includes proper positioning of the patient, thorough ness of search, use of a vertical-strip search pattern, proper position and movement of the fingers, and a CBE duration of at least 3 minutes per breast. The value of inspection is unproved. Professional and lay examiners improved their sensitivity on silicone breast models after being taught this technique, Conclusions Indirect evidence supports the effectiveness of CBE in screening for breast cancer. Although the screening clinical examination by itself does not rule out disease, the high specificity of certain abnormal findings greatly increases the probability of breast cancer.	Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Med Sch, Boston, MA USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Barton, MB (corresponding author), Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.	mary_barton@hms.harvard.edu						ADAMS CK, 1976, PERCEPT PSYCHOPHYS, V20, P163, DOI 10.3758/BF03198595; ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; Baines C J, 1997, J Natl Cancer Inst Monogr, P125; BAINES CJ, 1992, J GERONTOL, V47, P63; BAINES CJ, 1989, CANCER, V63, P1816; BAINES CJ, 1987, J CHRON DIS, V40, P361, DOI 10.1016/0021-9681(87)90052-X; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Barton M. B., 1999, JGIM, V14, P9; Barton MB, 1999, ANN INTERN MED, V130, P651, DOI 10.7326/0003-4819-130-8-199904200-00005; Basset AA, 1985, SCREENING CANC, P271; BATES B, 1998, GUIDE PHYSICAL EXAMI; BENDER HG, 1988, GYNECOL ONCOL, V31, P166, DOI 10.1016/0090-8258(88)90287-9; BLOOM HS, 1982, PERCEPT PSYCHOPHYS, V32, P251, DOI 10.3758/BF03206229; BOYD NF, 1981, AM J SURG, V142, P331, DOI 10.1016/0002-9610(81)90341-X; BURNS PE, 1978, J CAN ASSOC RADIOL, V29, P22; BUTLER JA, 1990, ARCH SURG-CHICAGO, V125, P893; CAMPBELL HS, 1994, ACAD MED, V69, P993, DOI 10.1097/00001888-199412000-00019; CAMPBELL HS, 1991, AM J PREV MED, V7, P1; CHAMBERLAIN J, 1979, CLIN ONCOL, V5, P135; CHAMBERLAIN J, 1975, LANCET, V2, P1026; CHAMBERLAIN J, 1992, BRIT MED J, V304, P346; CHAMBERLAIN J, 1988, LANCET, V2, P411; Chamberlain J., 1991, CANC SCREENING, P3; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; CLATTO S, 1987, TUMORI, V73, P457; COLLETTE HJA, 1984, LANCET, V1, P1224; COLLETTE HJA, 1992, J EPIDEMIOL COMMUN H, V46, P382, DOI 10.1136/jech.46.4.382; COLLETTE HJA, 1985, MATURITAS, V7, P43, DOI 10.1016/0378-5122(85)90033-7; DAY PJ, 1990, MED J AUSTRALIA, V152, P635, DOI 10.5694/j.1326-5377.1990.tb125419.x; deAndrade JM, 1996, TUMORI, V82, P596, DOI 10.1177/030089169608200617; DIPIETRO S, 1987, EUR J SURG ONCOL, V13, P335; DONEGAN WL, 1992, NEW ENGL J MED, V327, P937; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1994, NEW ENGL J MED, V331, P10, DOI 10.1056/NEJM199407073310103; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eddy DM., 1992, META ANAL CONFIDENCE; EDDY DM, 1992, FAST PRO V1 8 SOFTWA; EDEIKEN S, 1988, CANCER, V61, P263, DOI 10.1002/1097-0142(19880115)61:2<263::AID-CNCR2820610211>3.0.CO;2-Z; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FLETCHER SW, 1985, JAMA-J AM MED ASSOC, V253, P2224, DOI 10.1001/jama.253.15.2224; FLETCHER SW, 1990, ANN INTERN MED, V112, P772, DOI 10.7326/0003-4819-112-10-772; FLETCHER SW, 1989, J GEN INTERN MED, V4, P277, DOI 10.1007/BF02597396; FLETCHER SW, 1999, UP TO DATE MED; Fonseca R, 1997, ANN INTERN MED, V127, P1013, DOI 10.7326/0003-4819-127-11-199712010-00013; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GULAY H, 1994, J AM COLL SURGEONS, V178, P471; HALL DC, 1977, CANCER, V40, P364, DOI 10.1002/1097-0142(197707)40:1<364::AID-CNCR2820400151>3.0.CO;2-A; HALL DC, 1980, CANCER, V46, P408, DOI 10.1002/1097-0142(19800715)46:2<408::AID-CNCR2820460233>3.0.CO;2-P; HANSELL DM, 1988, CLIN RADIOL, V39, P150; Harvey BJ, 1997, CAN MED ASSOC J, V157, P1205; HENDRICK RE, 1997, NATL CANCER I MONOGR, V22, P87; HERMANSEN C, 1987, CANCER, V60, P1866, DOI 10.1002/1097-0142(19871015)60:8<1866::AID-CNCR2820600832>3.0.CO;2-Z; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; KAHN KL, 1984, CLIN RES, V32, pA649; Kendall M. G., 1961, KENDALLS ADV THEORY, V2; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; LAWRENCE HC, 1994, CLIN OBSTET GYNECOL, V37, P881, DOI 10.1097/00003081-199412000-00014; Lee K. C., 1997, JGIM, V12, P93; LEIBMAN AJ, 1992, AM J ROENTGENOL, V159, P493, DOI 10.2214/ajr.159.3.1503012; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; LOVE SM, 1982, NEW ENGL J MED, V307, P1010, DOI 10.1056/NEJM198210143071611; MADDEN MC, 1978, J BIOENG, V2, P427; MAHONEY L, 1982, CAN MED ASSOC J, V127, P729; McDermott MM, 1996, J GEN INTERN MED, V11, P112, DOI 10.1007/BF02599588; MEYER KK, 1975, AM SURGEON, V41, P774; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MITTRA I, 1994, LANCET, V343, P342, DOI 10.1016/S0140-6736(94)91170-3; MOSS SM, 1993, EUR J CANCER, V29A, P255, DOI 10.1016/0959-8049(93)90187-K; MUSHLIN AI, 1985, ANN INTERN MED, V103, P79, DOI 10.7326/0003-4819-103-1-79; Orel SG, 1998, RADIOGRAPHICS, V18, P903, DOI 10.1148/radiographics.18.4.9672975; PALLI D, 1986, INT J CANCER, V38, P501, DOI 10.1002/ijc.2910380408; Physician Insurers Association of America, 1995, BREAST CANC STUD JUN; PILGRIM C, 1993, J GEN INTERN MED, V8, P685, DOI 10.1007/BF02598289; Ries L, 1998, SEER CANC STAT REV 1; Ries L. A. G., 1999, SEER CANC STAT REV 1; ROBERTS MM, 1990, LANCET, V335, P241; ROWELL S, 1994, AM J HUM GENET, V55, P861; SAPIRA JD, 1990, ART SCI BEDISDE DIAG; SAUNDERS KJ, 1986, CANCER, V58, P2531, DOI 10.1002/1097-0142(19861201)58:11<2531::AID-CNCR2820581128>3.0.CO;2-J; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; Shapiro S, 1988, PERIODIC SCREENING B; Stephenson H S, 1979, J Behav Med, V2, P239, DOI 10.1007/BF00844921; Stomper PC, 1996, AM J ROENTGENOL, V167, P1261, DOI 10.2214/ajr.167.5.8911192; STRAX P, 1967, CANCER, V20, P2184, DOI 10.1002/1097-0142(196712)20:12<2184::AID-CNCR2820201217>3.0.CO;2-3; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, 1991, CANC SCREENING, P23; TALLEY NJ, 1992, CLIN EXAMINATION SYS; THOMAS DC, 1981, J CHRON DIS, V34, P617, DOI 10.1016/0021-9681(81)90061-8; THOMAS LB, 1977, PUBLICATION NIH; *UK TRIAL EARL DET, 1993, BREAST, V2, P1; VANDAM PA, 1988, RADIOLOGY, V166, P435, DOI 10.1148/radiology.166.2.3275983; VENET L, 1971, CANCER, V28, P1546, DOI 10.1002/1097-0142(197112)28:6<1546::AID-CNCR2820280630>3.0.CO;2-#; VERBEEK ALM, 1984, LANCET, V1, P1222; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Welch HG, 1998, J NATL CANCER I, V90, P1389, DOI 10.1093/jnci/90.18.1389; WHITE E, 1993, ANNU REV PUBL HEALTH, V14, P605; Whittemore AS, 1997, AM J HUM GENET, V60, P496; WILLMS JL, 1994, PHYSICAL DIAGNOSIS B; WINCHESTER DP, 1992, CANCER, V69, P1947, DOI 10.1002/1097-0142(19920401)69:7+<1947::AID-CNCR2820691713>3.0.CO;2-2; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Wood WC, 1996, SEMIN ONCOL, V23, P446; *YORKSH BREAST CAN, 1977, BMJ-BRIT MED J, V2, P1196; 1998, CMAJ, V158, pS3	110	245	253	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1270	1280		10.1001/jama.282.13.1270	http://dx.doi.org/10.1001/jama.282.13.1270			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517431				2022-12-28	WOS:000082901100036
J	Henney, JE				Henney, JE			Warning on dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-28	WOS:000082901100006
J	Arlt, W; Callies, F; van Vlijmen, JC; Koehler, I; Reincke, M; Bidlingmaier, M; Huebler, D; Oettel, M; Ernst, M; Schulte, HM; Allolio, B				Arlt, W; Callies, F; van Vlijmen, JC; Koehler, I; Reincke, M; Bidlingmaier, M; Huebler, D; Oettel, M; Ernst, M; Schulte, HM; Allolio, B			Dehydroepiandrosterone replacement in women with adrenal insufficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; ORAL DEHYDROEPIANDROSTERONE; ANDROGEN REPLACEMENT; SEX-DIFFERENCES; DHEA; MEN; SULFATE; DEPRESSION; ESTROGENS; STEROIDS	Background The physiologic role of dehydroepiandrosterone in humans is still unclear. Adrenal insufficiency leads to a deficiency of dehydroepiandrosterone; we therefore investigated the effects of dehydroepiandrosterone replacement in patients with adrenal insufficiency. Methods In a double-blind study, 24 women with adrenal insufficiency received in random order 50 mg of dehydroepiandrosterone orally each morning for four months and placebo daily for four months, with a one-month washout period. We measured serum steroid hormones, insulin-like growth factor I, lipids, and sex hormone-binding globulin, and we evaluated well-being and sexuality with the use of validated psychological questionnaires and visual-analogue scales, respectively. The women were assessed before treatment, after one and four months of treatment with dehydroepiandrosterone, after one and four months of placebo, and one month after the end of the second treatment period. Results Treatment with dehydroepiandrosterone raised the initially low serum concentrations of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and testosterone into the normal range; serum concentrations of sex hormone-binding globulin, total cholesterol, and high-density lipoprotein cholesterol decreased significantly. Dehydroepiandrosterone significantly improved overall well-being as well as scores for depression and anxiety. For the global severity index, the mean (+/-SD) change from base line was -0.18+/-0.29 after four months of dehydroepiandrosterone therapy, as compared with 0.03+/-0.29 after four months of placebo (P = 0.02). As compared with placebo, dehydroepiandrosterone significantly increased the frequency of sexual thoughts (P = 0.006), sexual interest (P = 0.002), and satisfaction with both mental and physical aspects of sexuality (P = 0.009 and P = 0.02, respectively). Conclusions Dehydroepiandrosterone improves well-being and sexuality in women with adrenal insufficiency. (N Engl J Med 1999;341:1013-20.) (C)1999, Massachusetts Medical Society.	Med Univ Hosp, Dept Endocrinol, D-97080 Wurzburg, Germany; Med Univ Hosp Innenstadt, Munich, Germany; Jenapharm, Jena, Germany; Inst Hormone & Fertil Res, D-2000 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Munich	Arlt, W (corresponding author), Med Univ Hosp, Dept Endocrinol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	w.arlt@medizin.uni-wuerzburg.de	Arlt, Wiebke/B-6310-2009	Arlt, Wiebke/0000-0001-5106-9719				ABADIE JM, 1993, DIABETES, V42, P662, DOI 10.2337/diabetes.42.5.662; ABRAMOVITCH RA, 1974, J ORG CHEM, V39, P340, DOI 10.1021/jo00917a013; Arlt W, 1998, J CLIN ENDOCR METAB, V83, P1928, DOI 10.1210/jc.83.6.1928; Baulieu EE, 1996, J CLIN ENDOCR METAB, V81, P3147, DOI 10.1210/jc.81.9.3147; BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; BRAHLER E, 1979, PSYCHOTHER MED PSYCH, V29, P14; Casson PR, 1998, FERTIL STERIL, V70, P107, DOI 10.1016/S0015-0282(98)00121-6; CASSON PR, 1995, FERTIL STERIL, V63, P1027, DOI 10.1016/S0015-0282(16)57542-6; Casson PR, 1996, INT J FERTIL MENOP S, V41, P412; CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002-9378(93)90431-H; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; CUTLER GB, 1978, ENDOCRINOLOGY, V103, P2112, DOI 10.1210/endo-103-6-2112; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; FRANKE GH, 1992, DIAGNOSTICA, V38, P160; Herrmann C, 1994, DIAGNOSTICA, V40, P143; Kudielka BM, 1998, J CLIN ENDOCR METAB, V83, P1756, DOI 10.1210/jc.83.5.1756; Labrie F, 1997, J CLIN ENDOCR METAB, V82, P2403, DOI 10.1210/jc.82.8.2403; Labrie F, 1997, J CLIN ENDOCR METAB, V82, P3498, DOI 10.1210/jc.82.10.3498; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; MARTEL C, 1994, MOL CELL ENDOCRINOL, V104, P103, DOI 10.1016/0303-7207(94)90056-6; MELCHIOR CL, 1994, PHARMACOL BIOCHEM BE, V47, P437, DOI 10.1016/0091-3057(94)90140-6; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; MORALES AJ, 1995, J CLIN ENDOCR METAB, V80, P2799; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; Prasad A, 1997, PHYSIOL BEHAV, V62, P1053, DOI 10.1016/S0031-9384(97)00239-4; Steyer R., 1994, DIAGNOSTICA, V40, P320; WALLENSTEIN S, 1977, BIOMETRICS, V33, P261, DOI 10.2307/2529321; Wolf OT, 1998, J GERONTOL A-BIOL, V53, pM385, DOI 10.1093/gerona/53A.5.M385; Wolf OT, 1997, J CLIN ENDOCR METAB, V82, P2363, DOI 10.1210/jc.82.7.2363; Wolkowitz OM, 1997, BIOL PSYCHIAT, V41, P311, DOI 10.1016/S0006-3223(96)00043-1; Yen SSC, 1995, ANN NY ACAD SCI, V774, P128, DOI 10.1111/j.1749-6632.1995.tb17377.x; Young J, 1997, J CLIN ENDOCR METAB, V82, P2578, DOI 10.1210/jc.82.8.2578; Zerssen D. V., 1976, BESCHWERDEN LISTE MA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	458	473	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1013	1020		10.1056/NEJM199909303411401	http://dx.doi.org/10.1056/NEJM199909303411401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502590				2022-12-28	WOS:000082880500001
J	Pilz, B; Mesner, C; Baetgen, S; Luft, FC				Pilz, B; Mesner, C; Baetgen, S; Luft, FC			Coma in a park	LANCET			English	Article							YEW		Humboldt Univ, Med Fac Charite, Elisabeth Diakonissen & Krankenhaus, D-13122 Berlin, Germany; Humboldt Univ, Med Fac Charite, Franz Volhard Clin, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Luft, FC (corresponding author), Humboldt Univ, Med Fac Charite, Elisabeth Diakonissen & Krankenhaus, D-13122 Berlin, Germany.	luft@fvk-berlin.de		Luft, Friedrich/0000-0002-8635-1199				Feldman R, 1988, Pol Arch Med Wewn, V79, P26; FIEDLER HH, 1994, BERL MUNCH TIERARZTL, V107, P50; HURT S, 1836, LANCET, V1, P394; Krenzelok EP, 1998, J TOXICOL-CLIN TOXIC, V36, P219, DOI 10.3109/15563659809028942; VONDACH B, 1988, SCHWEIZ MED WSCHR, V118, P1113	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1090	1090		10.1016/S0140-6736(99)08180-5	http://dx.doi.org/10.1016/S0140-6736(99)08180-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509501				2022-12-28	WOS:000082777500015
J	van Weel, C; van Grunsven, P				van Weel, C; van Grunsven, P			Resistance to prescribing and to antibiotics	LANCET			English	Editorial Material							DOXYCYCLINE; TRIAL		Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Graham A, 1999, BRIT MED J, V319, P173, DOI 10.1136/bmj.319.7203.173; HAYNES RB, COMPLIANCE HLTH CARE; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Spach DH, 1998, ANN ALLERG ASTHMA IM, V81, P293, DOI 10.1016/S1081-1206(10)63121-3; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; ZWART S, 1999, THESIS U UTRECHT UTR; 1990, LANCET, V335, P262	9	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1052	1052		10.1016/S0140-6736(99)90107-1	http://dx.doi.org/10.1016/S0140-6736(99)90107-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509494				2022-12-28	WOS:000082777500008
J	Rossi, JJ				Rossi, JJ			Molecular biology - Ribozymes in the nucleolus	SCIENCE			English	Editorial Material							VIRAL-RNA; LOCALIZATION		City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA.	jrossi@coh.org						Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Buonomo SBC, 1999, RNA, V5, P993, DOI 10.1017/S1355838299990064; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pyper JM, 1998, J VIROL, V72, P7697, DOI 10.1128/JVI.72.9.7697-7702.1998; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2	14	14	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1685	1685		10.1126/science.285.5434.1685	http://dx.doi.org/10.1126/science.285.5434.1685			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523186				2022-12-28	WOS:000082472600022
J	[Anonymous]				[Anonymous]			BMA establishes racial equality committee	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1999	319	7216					1076	1076						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521222				2022-12-28	WOS:000083210100077
J	Allen, C; Glasziou, P; Del Mar, C				Allen, C; Glasziou, P; Del Mar, C			Bed rest: a potentially harmful treatment needing more careful evaluation	LANCET			English	Article							LOW-BACK-PAIN; PROSPECTIVE RANDOMIZED TRIAL; LUMBAR-PUNCTURE HEADACHE; EARLY AMBULATION; MYOCARDIAL-INFARCTION; PATIENT COMFORT; CLINICAL-TRIAL; CATHETERIZATION; MOBILIZATION; ANGIOGRAPHY	Background Bed rest is not only used in the management of patients who are not able to mobilise, but is also prescribed as a treatment for a large number of medical conditions, a procedure that has been challenged. We searched the literature for evidence of benefit or harm of bed rest for any condition. Methods We systematically searched MEDLINE and the Cochrane library, and retrieved reports on randomised controlled trials of bed rest versus early mobilisation for any medical condition, including medical procedures. Findings 39 trials of bed rest for 15 different conditions (total patients 5777) were found. In 24 trials investigating bed rest following a medical procedure, no outcomes improved significantly and eight worsened significantly in some procedures (lumbar puncture, spinal anaesthesia, radiculography, and cardiac catheterisation). In 15 trials investigating bed rest as a primary treatment, no outcomes improved significantly and nine worsened significantly for some conditions (acute low back pain, labour, proteinuric hypertension during pregnancy, myocardial infarction, and acute infectious hepatitis). Interpretation We should not assume any efficacy for bed rest. Further studies need to be done to establish evidence for the benefit or harm of bed rest as a treatment.	Univ Queensland, Grad Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia	University of Queensland	Glasziou, P (corresponding author), Univ Queensland, Grad Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia.		Del Mar, Chris B/B-1136-2008; Glasziou, Paul/A-7832-2008	Del Mar, Chris B/0000-0003-3821-8163; Glasziou, Paul/0000-0001-7564-073X				ANDERSEN A P D, 1986, Regional-Anaesthesie, V9, P15; Antman EM, 1998, HARRISONS PRINCIPLES; BARKMAN A, 1994, HEART LUNG, V23, P112; Baum RA, 1996, CATHETER CARDIO DIAG, V39, P230, DOI 10.1002/(SICI)1097-0304(199611)39:3<230::AID-CCD4>3.0.CO;2-F; CARBAAT PAT, 1981, LANCET, V2, P1133; CHAKRAVARTY K, 1994, BRIT J RHEUMATOL, V33, P464; CHALMERS TC, 1955, J CLIN INVEST, V34, P1163, DOI 10.1172/JCI103164; COCHRANE AL, 1981, HERZ, V6, P112; COOK PT, 1989, ANAESTHESIA, V44, P389, DOI 10.1111/j.1365-2044.1989.tb11334.x; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Dock W, 1944, J AMER MED ASSOC, V125, P1083, DOI 10.1001/jama.1944.02850340009004; Elam Kenneth C., 1995, Journal of Emergency Medicine, V13, P143, DOI 10.1016/0736-4679(94)00134-0; EVANS C, 1987, Physiotherapy Canada, V39, P96; Fassoulaki A, 1991, Anaesthesiol Reanim, V16, P375; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; FOWLOW B, 1995, HEART LUNG, V24, P28, DOI 10.1016/S0147-9563(05)80092-5; Ghormley RK, 1944, J AMER MED ASSOC, V125, P1085, DOI 10.1001/jama.1944.02850340011005; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; Graham J, 1968, J Bone Joint Surg Br, V50, P562; HARRISON RF, 1993, INT J FERTIL, V38, P160; Harrison TR, 1944, J AMER MED ASSOC, V125, P1075, DOI 10.1001/jama.1944.02850340001001; Hilton J., 1863, INFLUENCE MECH PHYSL; Hippocrates, 1849, GENUINE WORKS HIPPOC; IRVIN CW, 1950, NEW ENGL J MED, V243, P486, DOI 10.1056/NEJM195009282431304; Isik FF, 1997, PLAST RECONSTR SURG, V100, P350, DOI 10.1097/00006534-199708000-00011; Juran N B, 1996, Am J Crit Care, V5, P442; Keeling A, 1996, Am J Crit Care, V5, P277; KEELING AW, 1994, APPL NURS RES, V7, P14, DOI 10.1016/0897-1897(94)90015-9; LAMERS HJ, 1973, BMJ-BRIT MED J, V1, P257, DOI 10.1136/bmj.1.5848.257; LAU KW, 1993, CATHETER CARDIO DIAG, V28, P34, DOI 10.1002/ccd.1810280107; Levine SA, 1944, J AMER MED ASSOC, V126, P80, DOI 10.1001/jama.1944.02850370018004; Lim R, 1997, AM J CARDIOL, V80, P222, DOI 10.1016/S0002-9149(97)00326-3; MACPHERSON P, 1983, CLIN RADIOL, V34, P325, DOI 10.1016/S0009-9260(83)80350-X; MACPHERSON P, 1985, NEURORADIOLOGY, V27, P214, DOI 10.1007/BF00344490; MACPHERSON P, 1984, CLIN RADIOL, V35, P287, DOI 10.1016/S0009-9260(84)80095-1; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MATHEWS DD, 1982, BRIT J OBSTET GYNAEC, V89, P128, DOI 10.1111/j.1471-0528.1982.tb04678.x; MATHEWS DD, 1980, BRIT J OBSTET GYNAEC, V87, P1095, DOI 10.1111/j.1471-0528.1980.tb04479.x; Menninger K, 1944, J AMER MED ASSOC, V125, P1087, DOI 10.1001/jama.1944.02850340013006; MILLER RR, 1976, ANN INTERN MED, V84, P700, DOI 10.7326/0003-4819-84-6-700; MILLS JA, 1971, NEW ENGL J MED, V284, P453, DOI 10.1056/NEJM197103042840901; MINUK GY, 1987, GASTROENTEROLOGY, V92, P290, DOI 10.1016/0016-5085(87)90119-3; PoolerLunse C, 1996, HEART LUNG, V25, P117, DOI 10.1016/S0147-9563(96)80113-0; PRATT JH, 1920, SOUTH MED J, V13, P481; Riegel B, 1996, Am J Crit Care, V5, P91; *ROYAL INF MED DIV, 1973, LANCET, V2, P346; SCHMITT M A, 1991, Journal of Burn Care and Rehabilitation, V12, P33, DOI 10.1097/00004630-199101000-00008; Serpell MG, 1998, BRIT MED J, V316, P1709, DOI 10.1136/bmj.316.7146.1709; SPRIGGS DA, 1992, POSTGRAD MED J, V68, P581, DOI 10.1136/pgmj.68.801.581; TEASDALE E, 1983, NEURORADIOLOGY, V25, P85, DOI 10.1007/BF00333297; THORNBERRY EA, 1988, BRIT J ANAESTH, V60, P195, DOI 10.1093/bja/60.2.195; VILMING ST, 1988, CEPHALALGIA, V8, P75, DOI 10.1046/j.1468-2982.1988.0802075.x; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; WALDHAUSEN JHT, 1990, ANN SURG, V212, P671, DOI 10.1097/00000658-199012000-00004; WEST RR, 1979, BRIT HEART J, V42, P381; WEST RR, 1985, BRIT HEART J, V53, P243; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; WILKINSON MJB, 1995, BRIT J GEN PRACT, V45, P481; Williams RH, 1938, AM HEART J, V15, P385, DOI 10.1016/S0002-8703(38)90292-3; Wood RA, 1997, CATHETER CARDIO DIAG, V42, P8, DOI 10.1002/(SICI)1097-0304(199709)42:1<8::AID-CCD3>3.0.CO;2-8; WYNN-WILLIAMS N, 1960, Tubercle, V41, P352, DOI 10.1016/S0041-3879(60)80037-2	61	297	306	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1229	1233		10.1016/S0140-6736(98)10063-6	http://dx.doi.org/10.1016/S0140-6736(98)10063-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520630				2022-12-28	WOS:000083010400007
J	Brewer, B				Brewer, B			Both sides	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					1013	1013		10.1136/bmj.319.7215.1013	http://dx.doi.org/10.1136/bmj.319.7215.1013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514189	Green Published			2022-12-28	WOS:000083111700067
J	Morpurgo, AF; Kong, J; Marcus, CM; Dai, H				Morpurgo, AF; Kong, J; Marcus, CM; Dai, H			Gate-controlled superconducting proximity effect in carbon nanotubes	SCIENCE			English	Article							CONSTRICTIONS	The superconducting proximity effect in single-walled carbon nanotubes connected to niobium electrodes was controlled with the use of nearby gates that tune the niobium-nanotube transparency. At 4.2 kelvin, when the transparency was tuned to be high, a dip in the Low-bias differential resistance was observed, indicating a proximity effect mediated by Andreev reflection. When the transparency was tuned to be Low, signatures of Andreev reflection disappeared and only tunneling conduction was observed. Below similar to 4 kelvin, a narrow peak in differential resistance around zero bias appeared superimposed on the Andreev dip, probably as a result of electron-electron interaction competing with the proximity effect.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Morpurgo, AF (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	morpurg1@leland.stanford.edu; cmarcus@stanford.edu	Marcus, Charles M./M-4526-2014	Marcus, Charles M./0000-0003-2420-4692				Andreev A. F., 1964, ZH EKSP TEOR FIZ, V46, P1823; Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; BLONDER GE, 1982, PHYS REV B, V25, P4515, DOI 10.1103/PhysRevB.25.4515; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; DENHARTOG SG, 1998, THESIS U GRONINGEN; Emery V. J., 1979, HIGHLY CONDUCTING 1, P247; Esteve D, 1997, NATO ADV SCI I E-APP, V345, P375; HEIDA JP, 1998, THESIS U GRONINGEN; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Kasumov AY, 1999, SCIENCE, V284, P1508, DOI 10.1126/science.284.5419.1508; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; OCTAVIO M, 1983, PHYS REV B, V27, P6739, DOI 10.1103/PhysRevB.27.6739; Oreg Y, 1999, PHYS REV LETT, V82, P1269, DOI 10.1103/PhysRevLett.82.1269; Soh HT, 1999, APPL PHYS LETT, V75, P627, DOI 10.1063/1.124462; Takayanagi H, 1998, PHYSICA B, V249, P462, DOI 10.1016/S0921-4526(98)00164-1; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; van Wees BJ, 1997, NATO ADV SCI I E-APP, V345, P469; VOIT J, 1995, REP PROG PHYS, V58, P977, DOI 10.1088/0034-4885/58/9/002	22	214	217	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					263	265		10.1126/science.286.5438.263	http://dx.doi.org/10.1126/science.286.5438.263			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514364				2022-12-28	WOS:000083024400036
J	Noda, T; Eisaki, H; Uchida, S				Noda, T; Eisaki, H; Uchida, S			Evidence for one-dimensional charge transport in La2-x-yNdySrxCuO4	SCIENCE			English	Article							STRIPE ORDER; NORMAL-STATE; LA2-XSRXCUO4; PHASE; TEMPERATURE; SUPERCONDUCTIVITY; TRANSITION; LA1.48ND0.4SR0.12CUO4; FLUCTUATIONS; INSULATOR	Doping dependences of the resistivity and the Hall coefficient are presented for neodymium-doped Lanthanum strontium cuprate (La1.4-xNd0.6SrxCuO4) in the static spin-charge stripe ordered phase. For doping concentration x less than or equal to 1/8, a rapid decrease in the magnitude of the Hall coefficient at Low temperatures provides evidence for one-dimensional charge transport, whereas for x > 1/8, the Hall coefficient remains relatively Large in the ordered phase. The results indicate a crossover from one- to two-dimensional charge transport taking place at x = 1/8.	Univ Tokyo, Dept Superconduct, Tokyo 1138656, Japan	University of Tokyo	Noda, T (corresponding author), Univ Tokyo, Dept Superconduct, Tokyo 1138656, Japan.		Eisaki, Hiroshi/F-6317-2018	Eisaki, Hiroshi/0000-0002-8299-6416				ANDO Y, 1995, PHYS REV LETT, V75, P4662, DOI 10.1103/PhysRevLett.75.4662; Boebinger GS, 1996, PHYS REV LETT, V77, P5417, DOI 10.1103/PhysRevLett.77.5417; BUCHNER B, 1994, PHYS REV LETT, V73, P1841, DOI 10.1103/PhysRevLett.73.1841; Castro Neto AH, 1997, PHYS REV LETT, V78, P3931, DOI 10.1103/PhysRevLett.78.3931; CHEONG SW, 1994, PHYS REV B, V49, P7088, DOI 10.1103/PhysRevB.49.7088; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; CRAWFORD MK, 1991, PHYS REV B, V44, P7749, DOI 10.1103/PhysRevB.44.7749; Eskes H, 1998, PHYS REV B, V58, P6963, DOI 10.1103/PhysRevB.58.6963; Hucker M, 1998, J PHYS CHEM SOLIDS, V59, P1821, DOI 10.1016/S0022-3697(98)00115-2; Hunt AW, 1999, PHYS REV LETT, V82, P4300, DOI 10.1103/PhysRevLett.82.4300; Kimura H, 1999, PHYS REV B, V59, P6517, DOI 10.1103/PhysRevB.59.6517; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Kuwahara H, 1996, SCIENCE, V272, P80, DOI 10.1126/science.272.5258.80; MACHIDA K, 1989, PHYSICA C, V158, P192, DOI 10.1016/0921-4534(89)90316-X; MASON TE, 1993, PHYS REV LETT, V71, P919, DOI 10.1103/PhysRevLett.71.919; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; NAKAMURA Y, 1992, PHYS REV B, V46, P5841, DOI 10.1103/PhysRevB.46.5841; SERA M, 1989, SOLID STATE COMMUN, V69, P851, DOI 10.1016/0038-1098(89)90278-0; Suzuki T, 1998, PHYS REV B, V57, pR3229, DOI 10.1103/PhysRevB.57.R3229; Tajima S, 1998, J PHYS CHEM SOLIDS, V59, P2015, DOI 10.1016/S0022-3697(98)00163-2; Tranquada JM, 1997, PHYS REV LETT, V78, P338, DOI 10.1103/PhysRevLett.78.338; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Tranquada JM, 1996, PHYS REV B, V54, P7489, DOI 10.1103/PhysRevB.54.7489; TRANQUADA JM, UNPUB; Von Zimmermann M, 1998, EUROPHYS LETT, V41, P629, DOI 10.1209/epl/i1998-00204-2; Yamada K, 1998, PHYS REV B, V57, P6165, DOI 10.1103/PhysRevB.57.6165; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	29	196	197	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					265	268		10.1126/science.286.5438.265	http://dx.doi.org/10.1126/science.286.5438.265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514365				2022-12-28	WOS:000083024400037
J	Defleur, A; White, T; Valensi, P; Slimak, L; Cregut-Bonnoure, E				Defleur, A; White, T; Valensi, P; Slimak, L; Cregut-Bonnoure, E			Neanderthal cannibalism at Moula-Guercy, Ardeche, France	SCIENCE			English	Article								The cave site of Moula-Guercy, 80 meters above the modern Rhone River, was occupied by Neanderthals approximately 100,000 years ago. Excavations since 1991 have yielded rich paleontological, paleobotanical, and archaeological assemblages, including parts of six Neanderthals. The Neanderthals are contemporary with stone tools and faunal remains in the same tightly controlled stratigraphic and spatial contexts. The inference of Neanderthal cannibalism at Moula-Guercy is based on comparative analysis of hominid and ungulate bone spatial distributions, modifications by stone tools, and skeletal part representations.	Fac Med Marseille, Secteur Nord, Lab Anthropol, CNRS,UMR 6569, F-13916 Marseille 20, France; Univ Calif Berkeley, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Lab Prehist Lazaret, F-06300 Nice, France; Univ Aix Marseille 1, CNRS, UMR 6636, F-13094 Aix En Provence 2, France; Musee Requien, F-84000 Avignon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Defleur, A (corresponding author), Fac Med Marseille, Secteur Nord, Lab Anthropol, CNRS,UMR 6569, Blvd Pierre Dramart, F-13916 Marseille 20, France.		Slimak, Ludovic/AAG-7890-2020					Bocquet-Appel JP, 1999, J ARCHAEOL SCI, V26, P327, DOI 10.1006/jasc.1998.0370; Bordes F., 1961, TYPOLOGIE PALEOLITHI; Defleur A, 1998, CR ACAD SCI II A, V326, P453, DOI 10.1016/S1251-8050(98)80070-0; DEFLEUR A, 1993, NATURE, V362, P214, DOI 10.1038/362214a0; Fernandez-Jalvo Y, 1996, SCIENCE, V271, P277, DOI 10.1126/science.271.5247.277; GORJANOVICKRAMB.D, 1906, DILUVIALE MENSCH KRA; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; HUGHES C, 1951, ANN PALEONTOL, V37, P155; LEMORT F, 1989, B SOC PREHISTORIQUE, V86, P79, DOI DOI 10.3406/BSPF.1989.9367; Malez M., 1982, PALAEONTOLOGIA JUGOS, V29, P1; RUSSELL M, 1986, AM J PHYS ANTHROPOL, V72, P373; RUSSELL M, 1986, AM J PHYS ANTHROPOL, V72, P381; SMITH F, 1976, REPORT INVESTIGATION, V15, P1; TRINKAUS E, 1985, J HUM EVOL, V14, P203, DOI 10.1016/S0047-2484(85)80007-5; Turner C.G., 1999, MAN CORN CANNIBALISM; Ulrich H., 1982, BRNO, V21, P253; VANDERMEERSCH B, 1980, GALLIA PREHISTOIRE, V23, P301; VILLA P, 1986, SCIENCE, V233, P431, DOI 10.1126/science.233.4762.431; White T.D., 1992, PREHISTORIC CANNIBAL	19	139	145	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					128	131		10.1126/science.286.5437.128	http://dx.doi.org/10.1126/science.286.5437.128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	241WT	10506562				2022-12-28	WOS:000082907400052
J	Rao, MP; Sanchez-Herencia, AJ; Beltz, GE; McMeeking, RM; Lange, FF				Rao, MP; Sanchez-Herencia, AJ; Beltz, GE; McMeeking, RM; Lange, FF			Laminar ceramics that exhibit a threshold strength	SCIENCE			English	Article							COMPOSITES; ALUMINA; STRESSES; MULLITE	Thin compressive layers within a Laminar ceramic arrest targe cracks (surface and internal) and produce a threshold strength. This phenomenon increases the damage tolerance of ceramics and will allow engineers to design reliable ceramic components for structural applications. The stress intensity factor derived for a crack sandwiched between two compressive Layers suggests that the threshold strength is proportional to the residual compressive stress and the thickness of the compressive layer and is inversely proportional to the distance between the compressive layers. Laminates composed of thick alumina layers (605 +/- 11 micrometers) and thin mullite/alumina compressive Layers (37 +/- 1.4 micrometers) fabricated for this study had a threshold strength of 482 +/- 20 megapascals, in fair agreement with the theory.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mech & Environm Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Lange, FF (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Sanchez-Herencia, Antonio Javier/I-2110-2015; Sanchez-Herencia, Antonio Javier/D-1518-2011; Sanchez-Herencia, Antonio Javier/P-3807-2019; Rao, Masaru P/H-3864-2011	Sanchez-Herencia, Antonio Javier/0000-0003-2874-6640; Sanchez-Herencia, Antonio Javier/0000-0002-9982-4127; Sanchez-Herencia, Antonio Javier/0000-0003-2874-6640; Rao, Masaru P/0000-0002-5939-6332; Sanchez-Herencia, Antonio Javier/0000-0002-2104-1691				FRANKS GV, 1995, J AM CERAM SOC, V78, P1324, DOI 10.1111/j.1151-2916.1995.tb08489.x; GREEN DJ, 1984, J MATER SCI, V19, P2165, DOI 10.1007/BF01058092; Green DJ, 1999, SCIENCE, V283, P1295, DOI 10.1126/science.283.5406.1295; Green DJ, 1998, INTRO MECH PROPERTIE, P218; Hillman C, 1996, J AM CERAM SOC, V79, P2127, DOI 10.1111/j.1151-2916.1996.tb08946.x; HoneymanColvin P, 1996, J AM CERAM SOC, V79, P1810, DOI 10.1111/j.1151-2916.1996.tb07999.x; Lakshminarayanan R, 1996, J AM CERAM SOC, V79, P79, DOI 10.1111/j.1151-2916.1996.tb07883.x; LANGE FF, 1979, J AM CERAM SOC, V62, P629, DOI 10.1111/j.1151-2916.1979.tb12749.x; LANGE FF, 1989, J AM CERAM SOC, V72, P3, DOI 10.1111/j.1151-2916.1989.tb05945.x; MA Q, 1994, J AM CERAM SOC, V77, P298, DOI 10.1111/j.1151-2916.1994.tb06996.x; MAZDIYASNI KS, 1972, J AM CERAM SOC, V55, P548, DOI 10.1111/j.1151-2916.1972.tb13434.x; MCMEEKING RM, UNPUB; MUSSLER BH, 1984, AM CERAM SOC BULL, V63, P705; Oechsner M, 1996, J AM CERAM SOC, V79, P1834, DOI 10.1111/j.1151-2916.1996.tb08003.x; PUJARI VK, 1995, AM CERAM SOC BULL, V74, P86; REQUENA J, 1989, J AM CERAM SOC, V72, P1511, DOI 10.1111/j.1151-2916.1989.tb07692.x; RINCONJM, 1986, J AM CERAM SOC, V69, pC29; Sanchez-Herencia AJ, 1999, J AM CERAM SOC, V82, P1512, DOI 10.1111/j.1151-2916.1999.tb01949.x; Tada H, 1985, STRESS ANAL CRACKS H; YU B, UNPUB	20	222	225	4	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					102	105		10.1126/science.286.5437.102	http://dx.doi.org/10.1126/science.286.5437.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506553				2022-12-28	WOS:000082907400043
J	Merrill, SA; McGeary, M				Merrill, SA; McGeary, M			Science priorities - Who's balancing the Federal research portfolio and how?	SCIENCE			English	Article									Natl Res Council, Board Sci Technol & Econ Policy, Washington, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	Merrill, SA (corresponding author), Natl Res Council, Board Sci Technol & Econ Policy, 2101 Constitut Ave NW,FO 2014, Washington, DC 20418 USA.							*COMM EC DEV, 1998, AM BAS RES PROSP DIS; *COMM SCI, 1993, ENG PUBL POL SCI TEC; LANE N, 1999, MEMORANDUM HEADS EXE; MCGEARY M, 1999, SECURING AM IND STRE; *NAT SCI FDN, 1999, NSF99325; *NAT SCI FDN, 1999, FED FUNDS SURV FIELD; *NAT SCI FDN, 1999, 99346 NSF; National Research Council, 1995, ALL FED FUNDS SCI TE; Smith PM, 1997, ISSUES SCI TECHNOL, V13, P33	9	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1679	1680		10.1126/science.285.5434.1679	http://dx.doi.org/10.1126/science.285.5434.1679			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523184				2022-12-28	WOS:000082472600019
J	McNagny, SE				McNagny, SE			Prescribing hormone replacement therapy for menopausal symptoms	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; FIBROCYSTIC BREAST DISEASE; POSTMENOPAUSAL ESTROGEN THERAPY; MYOCARDIAL-INFARCTION; HOT FLASHES; CARDIOVASCULAR-DISEASE; ANDROGEN REPLACEMENT; VENOUS THROMBOEMBOLISM; TRANSDERMAL ESTROGEN; ENDOMETRIAL CANCER	This paper addresses the clinical presentation of menopause, pretreatment assessment for hormone replacement therapy, benefits and risks of this treatment, common hormone replacement regimens and their side effects, and patient management. The case-based discussion focuses on the clinical management of a patient who is considering hormone replacement therapy for menopausal symptoms.	Emory Univ, Sch Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, 69 Butler St, Atlanta, GA 30303 USA.	bhudson@mail.acponline.org			WHI NIH HHS [N01-WH-3211] Funding Source: Medline	WHI NIH HHS		Abraham D, 1997, MAYO CLIN PROC, V72, P1051, DOI 10.4065/72.11.1051; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Barrett-Connor E, 1998, J WOMENS HEALTH, V7, P839, DOI 10.1089/jwh.1998.7.839; Barrett-Connor E, 1998, J AM GERIATR SOC, V46, P918, DOI 10.1111/j.1532-5415.1998.tb02732.x; Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BERKOWITZ GS, 1984, INT J CANCER, V34, P443, DOI 10.1002/ijc.2910340403; BERKOWITZ GS, 1985, AM J EPIDEMIOL, V121, P238, DOI 10.1093/oxfordjournals.aje.a113994; Berman RS, 1997, J WOMENS HEALTH, V6, P219, DOI 10.1089/jwh.1997.6.219; Calle EE, 1997, CANCER CAUSE CONTROL, V8, P127, DOI 10.1023/A:1018403826168; Casson PR, 1996, INT J FERTIL MENOP S, V41, P412; Chae CU, 1997, THROMB HAEMOSTASIS, V78, P770; Chung TKH, 1996, MATURITAS, V25, P115, DOI 10.1016/0378-5122(96)01050-X; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; CORSON SL, 1993, INT J FERTIL, V38, P79; CROOK D, 1992, AM J OBSTET GYNECOL, V166, P950, DOI 10.1016/0002-9378(92)91370-P; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; EDEN JA, 1995, MENOPAUSE, V2, P67; ETTINGER B, 1993, CLIN THER, V15, P950; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; EVANS MP, 1995, MAYO CLIN PROC, V70, P800, DOI 10.4065/70.8.800; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; Fanchin R, 1997, OBSTET GYNECOL, V90, P396, DOI 10.1016/S0029-7844(97)00270-6; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gelfand MM, 1997, CLIN THER, V19, P383, DOI 10.1016/S0149-2918(97)80125-7; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Greendale GA, 1997, ENDOCRIN METAB CLIN, V26, P261, DOI 10.1016/S0889-8529(05)70246-2; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAAS S, 1988, OBSTET GYNECOL, V71, P671; HARGROVE JT, 1995, MED CLIN N AM, V79, P1337, DOI 10.1016/S0025-7125(16)30005-0; Hasler CM, 1998, J WOMENS HEALTH, V7, P519, DOI 10.1089/jwh.1998.7.519; Hebert-Croteau N, 1998, CANCER EPIDEM BIOMAR, V7, P653; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; HEMMINKI E, 1993, J CLIN EPIDEMIOL, V46, P211, DOI 10.1016/0895-4356(93)90068-C; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HEMMINKI E, 1993, OBSTET GYNECOL, V82, P1021; Hendrix SL, 1997, ENDOCRIN METAB CLIN, V26, P379, DOI 10.1016/S0889-8529(05)70253-X; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JICK SS, 1986, AM J EPIDEMIOL, V124, P746, DOI 10.1093/oxfordjournals.aje.a114450; Johnson SR, 1998, MED CLIN N AM, V82, P297, DOI 10.1016/S0025-7125(05)70608-8; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; Kaunitz AM, 1997, ENDOCRIN METAB CLIN, V26, P391, DOI 10.1016/S0889-8529(05)70254-1; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; Lindsay R, 1998, ENDOCRIN METAB CLIN, V27, P399, DOI 10.1016/S0889-8529(05)70012-8; LIP GYH, 1994, J HUM HYPERTENS, V8, P491; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; LUFKIN EG, 1994, MAYO CLIN PROC, V69, P131, DOI 10.1016/S0025-6196(12)61038-6; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MacGregor EA, 1997, NEUROL CLIN, V15, P125, DOI 10.1016/S0733-8619(05)70299-1; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MARCHESONI D, 1991, Clinical and Experimental Obstetrics and Gynecology, V18, P281; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McBee WL, 1997, ENDOCRIN METAB CLIN, V26, P329, DOI 10.1016/S0889-8529(05)70250-4; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; MILLER VT, 1994, OBSTET GYNECOL, V83, P173; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; NACHTIGALL LE, 1990, OBSTET GYNECOL, V75, pS77; NAGAMANI M, 1987, AM J OBSTET GYNECOL, V156, P561, DOI 10.1016/0002-9378(87)90050-0; Nagata C, 1998, MATURITAS, V29, P105, DOI 10.1016/S0378-5122(98)00012-7; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Sarrel P, 1998, J REPROD MED, V43, P847; Seidl MM, 1998, CAN FAM PHYSICIAN, V44, P1271; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SILBERSTEIN SD, 1991, NEUROLOGY, V41, P786, DOI 10.1212/WNL.41.6.786; Sotelo MM, 1997, ENDOCRIN METAB CLIN, V26, P313, DOI 10.1016/S0889-8529(05)70249-8; Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; SPORRONG T, 1989, OBSTET GYNECOL, V73, P754; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Staropoli CA, 1998, J WOMENS HEALTH, V7, P1149, DOI 10.1089/jwh.1998.7.1149; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Stevenson J C, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P30; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; STUMPF PG, 1994, OBSTET GYN CLIN N AM, V21, P219; Sulak PJ, 1997, ENDOCRIN METAB CLIN, V26, P399, DOI 10.1016/S0889-8529(05)70255-3; TAITEL HF, 1995, INT J FERTIL MENOP S, V40, P207; THORNEYCROFT IH, 1995, PROG CARDIOVASC DIS, V38, P243, DOI 10.1016/S0033-0620(95)80015-8; Trabal JF, 1997, MENOPAUSE, V4, P130; TRAPIDO EJ, 1984, J NATL CANCER I, V73, P1101; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; WATTS NB, 1995, OBSTET GYNECOL, V85, P529, DOI 10.1016/0029-7844(94)00448-M; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; WEINSTEIN L, 1990, AM J OBSTET GYNECOL, V162, P1534, DOI 10.1016/0002-9378(90)90917-V; WHELAN EA, 1990, AM J EPIDEMIOL, V131, P625, DOI 10.1093/oxfordjournals.aje.a115546; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; Wild RA, 1996, OBSTET GYNECOL, V87, pS27, DOI 10.1016/0029-7844(95)00434-3; WREN BG, 1983, MATURITAS, V5, P135, DOI 10.1016/0378-5122(83)90009-9; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	110	51	53	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					605	616		10.7326/0003-4819-131-8-199910190-00010	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523222				2022-12-28	WOS:000083196600008
J	Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A				Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A			Stressful life events and difficulties and onset of breast cancer: case-control study	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the relation between stressful life events and difficulties and the onset of breast cancer. Design Case-control study. Setting 3 NHS breast clinics serving west Leeds. Participants 399 consecutive women, aged 40-79, attending the breast clinics who were Leeds residents. Main outcome measures Odds ratios of the risk of developing breast cancer after experiencing one or more severe life events, severe difficulties, severe 2 year non-personal health difficulties, or severe 2 year personal health difficulties in the 5 years before clinical presentation. Results 332 (83%) women participated. Women diagnosed with breast cancer were no more likely to have experienced one or more severe life events (adjusted odds ratio 0.91, 95% confidence interval 0.47 to 1.81; P = 0.79); one or more severe difficulties (0.86, 0.41 to 1.81; P = 0.69); a 2 year severe non-personal health difficulty (0.53, 0.12 to 2.31; P = 0.4); or a 2 year severe personal health difficulty (2.73, 0.68 to 10.93; P = 0.16) than women diagnosed with a benign breast lump. Conclusion These findings do not support the hypothesis that severe life events or difficulties are associated with onset of breast cancer.	Leeds Gen Infirm, Dept Liaison Psychiat, Leeds LS1 3EX, W Yorkshire, England; Univ Leeds, Nuffield Inst Hlth, Sub Unit Med Stat, Leeds LS2 9PL, W Yorkshire, England	Leeds General Infirmary; University of Leeds; University of Leeds	Protheroe, D (corresponding author), No Hosp, Epping, Vic 3076, Australia.		horgan, kieran/I-3892-2016	House, Allan/0000-0001-8721-8026				BAGHURST KI, 1992, J EPIDEMIOL COMMUN H, V46, P120, DOI 10.1136/jech.46.2.120; BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brown G., 1978, SOCIAL ORIGINS DEPRE; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1015, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1015::AID-CNCR1>3.0.CO;2-G; CHEN CC, 1995, BRIT MED J, V311, P1527, DOI 10.1136/bmj.311.7019.1527; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; GEYER S, 1991, J PSYCHOSOM RES, V35, P355, DOI 10.1016/0022-3999(91)90090-B; HOSMER DW, 1989, APPL LOGISTIC REGRES; LESHAN L, 1959, J NATL CANCER I, V22, P1; McGee R, 1996, PSYCHOL MED, V26, P441, DOI 10.1017/S0033291700035522; MECHANIC D, 1972, NEW ENGL J MED, V286, P1132, DOI 10.1056/NEJM197205252862105; Petticrew M, 1999, BRIT J HEALTH PSYCH, V4, P1, DOI 10.1348/135910799168434; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; Reed MJ, 1996, BRIT MED J, V312, P845	15	83	85	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1027	1030		10.1136/bmj.319.7216.1027	http://dx.doi.org/10.1136/bmj.319.7216.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521192	Bronze, Green Published			2022-12-28	WOS:000083210100022
J	Wardle, J; Taylor, T; Sutton, S; Atkin, W				Wardle, J; Taylor, T; Sutton, S; Atkin, W			Does publicity about cancer screening raise fear of cancer? Randomised trial of the psychological effect of information about cancer screening	BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Epidemiol & Publ Hlth, ICRF Hlth Behav Unit, London WC1E 6BT, England; St Marks Hosp, ICRF Colorectal Canc Unit, Harrow, Middx, England	University of London; University College London; Imperial College London	Wardle, J (corresponding author), UCL, Dept Epidemiol & Publ Hlth, ICRF Hlth Behav Unit, Mortimer St, London WC1E 6BT, England.	j.wardle@ucl.ac.uk		Sutton, Stephen/0000-0003-1610-0404				Atkin WS, 1998, GUT, V42, P560, DOI 10.1136/gut.42.4.560; SKRABANEK P, 1985, LANCET, V2, P316; SOGAARD AJ, 1992, SCAND J PSYCHOL, V33, P125, DOI 10.1111/j.1467-9450.1992.tb00892.x; WARDLE J, 1992, J PSYCHOSOM RES, V36, P609, DOI 10.1016/0022-3999(92)90051-3; WOODS SM, 1966, J MED EDUC, V41, P785	5	28	28	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1037	1038		10.1136/bmj.319.7216.1037	http://dx.doi.org/10.1136/bmj.319.7216.1037			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521195	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000083210100026
J	Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA				Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA			Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-DEATH; DRUGS; DISRUPTION; DELETION; PROTEIN; ENZYME	Covalent intermediates between topoisomerase I and DNA can become dead-end complexes that read to cell death. Here, the isolation of the gene for an enzyme that can hydrolyze the bond between this protein and DNA is described. Enzyme-defective mutants of yeast are hypersensitive to treatments that increase the amount of covalent complexes, indicative of enzyme involvement in repair. The gene is conserved in eukaryotes and identifies a family of enzymes that has not been previously recognized. The presence of this gene in humans may have implications for the effectiveness of topoisomerase I poisons, such as the camptothecins, in chemotherapy.	NIMH, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Nash, HA (corresponding author), NIMH, Mol Biol Lab, Bldg 36,Room 1B08, Bethesda, MD 20892 USA.	nash@codon.nih.gov						BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brachmann CB, 1998, YEAST, V14, P115; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pouliot J. J., UNPUB; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHERMAN F, 1993, EMBO J, V12, P3; TRECO DA, 1991, CURRENT PROTOCOLS MO, V2; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	20	304	313	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					552	555		10.1126/science.286.5439.552	http://dx.doi.org/10.1126/science.286.5439.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521354	Green Submitted			2022-12-28	WOS:000083121200066
J	Beecham, L				Beecham, L			England to have more walk-in clinics	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					940	940						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514149				2022-12-28	WOS:000083111700013
J	Peltzer, G; Crampe, F; King, G				Peltzer, G; Crampe, F; King, G			Evidence of nonlinear elasticity of the crust from the Mw7.6 Manyi (Tibet) earthquake	SCIENCE			English	Article							DIFFERENTIAL RADAR INTERFEROMETRY; PORE FLUID-FLOW; LANDERS EARTHQUAKE; SOUTHERN-CALIFORNIA; DEFORMATION; SEQUENCE; AFTERSHOCKS; DISPLACEMENTS; FAULTS	Satellite synthetic aperture radar (SAR) interferometry shows that the magnitude 7.6 Manyi earthquake of 8 November 1997 produced a 170-kilometer-long surface break with up to 7 meters of Left-Lateral slip, reactivating a N76 degrees E quaternary fault in western Tibet. The radar interferometric map reveals asymmetric, along-strike displacement profiles between the two sides of the surface rupture, a pattern that cannot be explained with linear elastic theory. This observation suggests that the elastic moduli of the crust in tension and in compression are different because of the presence of cracks in the crust at shallow depth. A model indicates that a ratio of 2 between compressive and tensile elastic moduli can account for the observed asymmetry, a ratio that is consistent with Laboratory and borehole measurements.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Inst Phys Globe, Paris, France	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); UDICE-French Research Universities; Universite Paris Cite	Peltzer, G (corresponding author), CALTECH, Jet Prop Lab, MS 300-233,4800 Oak Grove Dr, Pasadena, CA 91109 USA.		Peltzer, Gilles/V-8108-2019					ANDERSON DL, 1975, J GEOPHYS RES, V80, P1497, DOI 10.1029/JB080i011p01497; ARMIJO R, 1989, J GEOPHYS RES-SOLID, V94, P2787, DOI 10.1029/JB094iB03p02787; BROWN ET, 1989, ROCK MECH ROCK ENG, V22, P189, DOI 10.1007/BF01470986; CRIPPEN RE, 1992, EPISODES, V15, P56, DOI 10.18814/epiiugs/1992/v15i1/009; DELAMETER WR, 1975, J APPL MECH-T ASME, V42, P74, DOI 10.1115/1.3423557; DIETZ LD, 1990, GEOPHYS RES LETT, V17, P1417, DOI 10.1029/GL017i009p01417; Dorbath C, 1996, J GEOPHYS RES-SOL EA, V101, P27917, DOI 10.1029/96JB02092; *ESTEC, 1992, ESA PUBL DIV; FREYMUELLER J, 1994, B SEISMOL SOC AM, V84, P646; GABRIEL AK, 1989, J GEOPHYS RES-SOLID, V94, P9183, DOI 10.1029/JB094iB07p09183; HAIMSON BC, 1974, SOC PETROL ENG J, V14, P145, DOI 10.2118/4241-PA; HUDNUT KW, 1989, GEOPHYS RES LETT, V16, P199, DOI 10.1029/GL016i002p00199; HUDNUT KW, 1994, B SEISMOL SOC AM, V84, P625; IVINS ER, 1986, PHILOS T R SOC A, V318, P285, DOI 10.1098/rsta.1986.0077; Jaeger J. C., 1979, FUNDAMENTALS ROCK ME; KHAN FK, 1988, MECH MATER, V6, P271; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; MUIRWOOD R, 1993, J GEOPHYS RES-SOL EA, V98, P22035, DOI 10.1029/93JB02219; Murakami M, 1996, J GEOPHYS RES-SOL EA, V101, P8605, DOI 10.1029/95JB02912; NUR A, 1972, SCIENCE, V175, P885, DOI 10.1126/science.175.4024.885; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Peltzer G, 1996, SCIENCE, V273, P1202, DOI 10.1126/science.273.5279.1202; REASENBERG P, 1982, J GEOPHYS RES, V87, P637, DOI 10.1029/JB087iB13p10637; RUNDLE JB, 1980, B SEISMOL SOC AM, V70, P1869; SAUCIER F, 1991, THESIS U OREGON; Scholz CH, 1974, GEOLOGY, V2, P551; SHEN ZK, 1994, B SEISMOL SOC AM, V84, P780; STIMPSON B, 1993, CAN GEOTECH J, V30, P338, DOI 10.1139/t93-028; TAPPONNIER P, 1977, J GEOPHYS RES, V82, P2905, DOI 10.1029/JB082i020p02905; WALTER AW, 1982, B SEISMOL SOC AM, V72, P1567; WYATT FK, 1994, B SEISMOL SOC AM, V84, P768; ZEBKER HA, 1994, J GEOPHYS RES-SOL EA, V99, P19617, DOI 10.1029/94JB01179	32	201	237	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					272	276		10.1126/science.286.5438.272	http://dx.doi.org/10.1126/science.286.5438.272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514367				2022-12-28	WOS:000083024400039
J	Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T				Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T			Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase-alpha	NATURE			English	Article							DISULFIDE BOND; KINASE; DOMAIN; FORM; PHOSPHORYLATION; PP60(C-SRC); ACTIVATION	Protein-tyrosine phosphatases (PTPs) are vital for regulating tryosine phosphorylation in many processes, including growth and differentiation(1,2). The regulation of receptor-like PTP (RPTP) activity remains poorly understood, but based on the crystal structure of RPTP alpha domain 1 we have proposed that dimerization can negatively regulate activity, through the interaction of an inhibitory 'wedge' on one monomer with the catalytic cleft of domain 1 in the other monomer(3,4). Here we show that dimerization inhibits the activity of a full-length RPTP in vivo. We generated stable disulphide-bonded full-length RPTP alpha homodimers by expressing mutants with single cysteines at different positions in the ectodomain juxtamembrane region. Expression of wild-type RPTP alpha and Phe135Cys and Thr141Cys mutants in RPTP alpha-null mouse embryo cells increased dephosphorylation and activity of Tyr529 in the protein tyrosine kinase c-Src; in contrast, expression of a Pro137Cys mutant did not. Mutation of Pro 210/211 to leucine in the inhibitory wedge of the Pro137Cys mutant restored its ability to activate c-Src, indicating that dimerization may inhibit full-length RPTP alpha activity in a manner stereochemically consistent with RPTP alpha crystal structures(3). Our results suggest that RPTP alpha activity can in principle be negatively regulated by dimerization in vivo.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Salk Institute; Salk Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); New York University	Jiang, GL (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noel, Joseph P/A-9459-2009					Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	28	153	159	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					606	610		10.1038/44170	http://dx.doi.org/10.1038/44170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524630				2022-12-28	WOS:000083054900055
J	Hayden, FG; Treanor, JJ; Fritz, RS; Lobo, M; Betts, RF; Miller, M; Kinnersley, N; Mills, RG; Ward, P; Straus, SE				Hayden, FG; Treanor, JJ; Fritz, RS; Lobo, M; Betts, RF; Miller, M; Kinnersley, N; Mills, RG; Ward, P; Straus, SE			Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza - Randomized controlled trials for prevention and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GG167 4-GUANIDINO-2,4-DIDEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID; A VIRUS-INFECTION; SIALIC-ACID; EFFICACY; REPLICATION; AMANTADINE; SAFETY; MICE; HYDROCHLORIDE; PROPHYLAXIS	Context Influenza virus neuraminidase is thought to be essential for virus replication in humans; however, to date, available neuraminidase inhibitors are limited to zanamivir, which is topically administered. Objective To determine the safety, tolerability, and antiviral activity of oral neuraminidase inhibitor oseltamivir (GS4104/Ro64-0796) for prevention and the early treatment of influenza in experimentally infected humans. Design Two randomized, double-blind, placebo-controlled trials conducted between June and July 1997. Setting Individual hotel rooms; 2 large US university medical schools. Participants A total of 117 healthy adult volunteers (aged 18-40 years; median age, 21 years) who were susceptible (hemagglutination-inhibition antibody titer less than or equal to 1:8). Interventions All subjects were inoculated intranasally with influenza A/Texas/36/91 (H1N1) virus. For the prophylaxis study, oral oseltamivir (100 mg once daily [n = 12], 100 mg twice daily [n = 12], or matching placebo [n = 13], starting 26 hours before virus inoculation) was administered. For the treatment study, the same drug was given (20 mg, 100 mg, or 200 mg twice daily, 200 mg once daily, or matching placebo [n = 16], in each group starting 28 hours after inoculation). All regimens were continued for 5 days. Main Outcome Measures Comparing placebo groups with pooled treatment groups, for prophylaxis, outcomes included frequency of infection and viral shedding; for treatment, viral shedding in titers. Results In the prophylaxis study, 8 (67%) of 12 placebo and 8 (38%) of 21 oseltamivir recipients became infected (P = .16; efficacy, 61%); 6 (50%) placebo compared with 0 oseltamivir recipients shed virus (P<.001; efficacy, 100%), and 33% of placebo but no oseltamivir recipient had infection-related respiratory illness (P<.01). Among infected subjects in the treatment study (n = 69), the viral titer area under the curve of the combined oseltamivir groups (n = 56) was lower (median [interquartile range {IQR}], 80 [23-151] vs 273 [79-306] log(10) tissue culture-infective doses(50) per milliliter x hour; P = .02) than the placebo group (n = 13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131) to 58 (35-59) hours (P = .003). Oseltamivir treatment also reduced symptom scores (median [IQR] score-hours, 225 [97-349] vs 400 [189-645]; P = .05), and nasal proinflammatory cytokine levels. Transient mild to moderate nausea after dosing was observed in 15 (17%) of 88 oseltamivir and 2 (7%) of 29 placebo recipients (95% confidence interval for difference, -11% to 68%), which was largely prevented by ingestion with food. Conclusions In these trials, prophylaxis and early treatment with oral oseltamivir were both associated with significant antiviral and clinical effects in experimental human influenza.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Rochester, Sch Med, Rochester, NY USA; NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; Gilead Sci Inc, Foster City, CA 94404 USA; Roche Discovery Welwyn Hoffman LaRoche & Co, Welwyn Garden City, Herts, England; NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	University of Virginia; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Gilead Sciences; Roche Holding; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Roche Holding	Hayden, FG (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Internal Med, Box 473, Charlottesville, VA 22908 USA.			Ward, Penelope/0000-0002-7585-4313	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], ANTIMICROB AGENTS CH; AOKI FY, 1998, 38 ANN INT C ANT AG; BURNET FM, 1948, AUST J EXP BIOL MED, V26, P371, DOI 10.1038/icb.1948.38; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P21, DOI 10.2165/00003088-199936001-00003; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936001-00001; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; COLMAN PM, 1994, PROTEIN SCI, V3, P1687, DOI 10.1002/pro.5560031007; DAWKINS AT, 1968, J AMER MED ASSOC, V203, P1095, DOI 10.1001/jama.203.13.1095; DOUGLAS RG, 1990, NEW ENGL J MED, V322, P443, DOI 10.1056/NEJM199002153220706; Eisenberg EJ, 1997, ANTIMICROB AGENTS CH, V41, P1949, DOI 10.1128/AAC.41.9.1949; Hayden F. G., 1997, Antiviral Research, V34, pA86; HAYDEN FG, 1982, ANTIVIR RES, V2, P147, DOI 10.1016/0166-3542(82)90016-X; HAYDEN FG, 1991, ANTIMICROB AGENTS CH, V35, P1741, DOI 10.1128/AAC.35.9.1741; HAYDEN FG, 1994, ANTIMICROB AGENTS CH, V38, P1178, DOI 10.1128/AAC.38.5.1178; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HAYDEN FG, 1986, ANTIMICROB AGENTS CH, V29, P339, DOI 10.1128/AAC.29.2.339; HAYDEN FG, 1998, 38 ANN INT C ANT AG; Kim C. U., 1997, Antiviral Research, V34, pA74, DOI 10.1016/S0166-3542(97)83253-6; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Li WX, 1998, ANTIMICROB AGENTS CH, V42, P647, DOI 10.1128/AAC.42.3.647; LIU CG, 1995, J VIROL, V69, P1099, DOI 10.1128/JVI.69.2.1099-1106.1995; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; REUMAN PD, 1989, ANTIVIR RES, V11, P27, DOI 10.1016/0166-3542(89)90018-1; RYAN DM, 1994, ANTIMICROB AGENTS CH, V38, P2270, DOI 10.1128/AAC.38.10.2270; RYAN DM, 1995, ANTIMICROB AGENTS CH, V39, P2583, DOI 10.1128/AAC.39.11.2583; SANTNER TJ, 1980, J AM STAT ASSOC, V75, P386, DOI 10.2307/2287464; SEARS SD, 1987, ANTIMICROB AGENTS CH, V31, P1470, DOI 10.1128/AAC.31.10.1470; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; SMORODINTSEV AA, 1970, J AMER MED ASSOC, V213, P1448, DOI 10.1001/jama.213.9.1448; TOGO Y, 1970, J AMER MED ASSOC, V211, P1149, DOI 10.1001/jama.211.7.1149; TREANOR JJ, 1998, 38 ANN INT C ANT AG; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Walker JB, 1997, J INFECT DIS, V176, P1417, DOI 10.1086/514136; WOOD ND, 1997, 37 INT C ANT AG CHEM	39	425	453	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1240	1246		10.1001/jama.282.13.1240	http://dx.doi.org/10.1001/jama.282.13.1240			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517426				2022-12-28	WOS:000082901100031
J	Remafedi, G				Remafedi, G			Sexual orientation and youth suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BISEXUAL YOUTH; RISK-FACTORS; GAY; ADOLESCENTS; BEHAVIOR; HOMOSEXUALITY; SAMPLE; MALES		Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Remafedi, G (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.				PHS HHS [5-T71-MC-00006-22] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bagley C, 1997, Crisis, V18, P24, DOI 10.1027/0227-5910.18.1.24; DAUGELLI AR, 1993, AM J COMMUN PSYCHOL, V21, P421, DOI 10.1007/BF00942151; DuRant RH, 1998, J PEDIATR-US, V133, P113, DOI 10.1016/S0022-3476(98)70189-1; Faulkner AH, 1998, AM J PUBLIC HEALTH, V88, P262, DOI 10.2105/AJPH.88.2.262; Garofalo R, 1999, ARCH PEDIAT ADOL MED, V153, P487; Garofalo R, 1998, PEDIATRICS, V101, P895, DOI 10.1542/peds.101.5.895; GIBSON P, 1989, US DEP HLTH HUM SERV, V3; HAMMELMAN TL, 1993, J GAY LESBIAN PSYCHO, V2, P77, DOI DOI 10.1300/J236V02N01_; HARRY J, 1983, J HEALTH SOC BEHAV, V24, P350, DOI 10.2307/2136401; Hershberger SL, 1997, J ADOLESCENT RES, V12, P477, DOI 10.1177/0743554897124004; HUNTER J, 1990, J INTERPERS VIOLENCE, V5, P295, DOI DOI 10.1177/088626090005003004; MUEHRER P, 1995, SUICIDE LIFE-THREAT, V25, P72, DOI 10.1111/j.1943-278X.1995.tb00492.x; Nicholas J., 1998, YOUTH STUDIES AUSTR, V17, P28; PROCTOR CD, 1994, SOC WORK, V39, P504, DOI 10.1093/sw/39.5.504; REMAFEDI G, 1991, PEDIATRICS, V87, P869; REMAFEDI G, 1987, PEDIATRICS, V79, P331; Remafedi G, 1998, AM J PUBLIC HEALTH, V88, P57, DOI 10.2105/AJPH.88.1.57; RICH CL, 1986, SUICIDE LIFE-THREAT, V16, P448; ROESLER T, 1972, J AMER MED ASSOC, V219, P1018, DOI 10.1001/jama.219.8.1018; ROTHERAMBORUS MJ, 1994, J ADOLESCENT RES, V9, P498, DOI 10.1177/074355489494007; SCHNEIDER SG, 1989, SUICIDE LIFE-THREAT, V19, P381; SHAFFER D, 1995, SUICIDE LIFE-THREAT, V25, P64, DOI 10.1111/j.1943-278X.1995.tb00491.x	22	54	55	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1291	1292		10.1001/jama.282.13.1291	http://dx.doi.org/10.1001/jama.282.13.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517437	hybrid			2022-12-28	WOS:000082901100043
J	Yom, SS				Yom, SS			Gay men and lesbians in medicine has discrimination left the room?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Yom, SS (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.			Yom, Sue/0000-0002-0779-7476				MATHEWS WC, 1986, WESTERN J MED, V144, P106; MOORE K, 1999, ANTILESBIAN GAY BISE, P1; Schatz B, 1994, ANTIGAY DISCRIMINATI	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1286	1286		10.1001/jama.282.13.1286-JMS1006-2-1	http://dx.doi.org/10.1001/jama.282.13.1286-JMS1006-2-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517434	Bronze			2022-12-28	WOS:000082901100039
J	Kirkland, KB; Weinstein, JM				Kirkland, KB; Weinstein, JM			Adverse effects of contact isolation	LANCET			English	Article								Healthcare workers are half as likely to enter the rooms of patients in contact isolation, but are more likely to wash their hands after caring for them than after caring for patients not in isolation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Kirkland, KB (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							[Anonymous], 1995, INFECT CONT HOSP EP, V16, P105; Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123; Knowles H E, 1993, Nurs Times, V89, P53; Peel RK, 1997, BRIT MED J, V315, P58; Teare EL, 1997, BRIT MED J, V314, P665, DOI 10.1136/bmj.314.7081.665	5	170	170	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1177	1178		10.1016/S0140-6736(99)04196-3	http://dx.doi.org/10.1016/S0140-6736(99)04196-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513715				2022-12-28	WOS:000082954100017
J	Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS				Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS			The gravity field of Mars: Results from Mars global surveyor	SCIENCE			English	Article							ORBITER LASER ALTIMETER; IMPACT BASINS; GIANT IMPACT; TOPOGRAPHY; DICHOTOMY; MISSION; MODEL; MOON	Observations of the gravity field of Mars reveal a planet that has responded differently in its northern and southern hemispheres to major impacts and volcanic processes. The rough, elevated southern hemisphere has a relatively featureless gravitational signature indicating a state of near-isostatic compensation, whereas the smooth, Low northern plains display a wider range of gravitational anomalies that indicates a thinner but stronger surface Layer than in the south. The northern hemisphere shows evidence for buried impact basins, although none large enough to explain the hemispheric elevation difference. The gravitational potential signature of Tharsis is approximately axisymmetric and contains the Tharsis Montes but not the Olympus Mons or Alba Patera volcanoes. The gravity signature of Valles Marineris extends into Chryse and provides an estimate of material removed by early fluvial activity.	NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Stanford Univ, Ctr Radio Astron, Stanford, CA 94305 USA; Grp Rech Geodesie Spatiales, Toulouse, France	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Stanford University	Smith, DE (corresponding author), NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Lemoine, Frank/D-1215-2013	Lemoine, Frank G./0000-0002-3051-1456				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; Anderson S, 1998, J GEOPHYS RES-PLANET, V103, P11113, DOI 10.1029/98JE00740; BALMINO G, 1982, J GEOPHYS RES, V87, P9735, DOI 10.1029/JB087iB12p09735; BRATT SR, 1985, J GEOPHYS RES-SOLID, V90, P2415, DOI 10.1029/JB090iB14p12415; Carr M., 1981, SURFACE MARS; COMER RP, 1985, REV GEOPHYS, V23, P61, DOI 10.1029/RG023i001p00061; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Heiskanen W.A., 1967, PHYS GEODESY; Johnson C., UNPUB; Kaula W.M., 1966, THEORY SATELLITE GEO; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; KONOPLIV AS, 1995, JPL PUBL, V955; Lemoine F., 1998, DEV JOINT NASA GSFC; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; NEUMANN GA, 1997, LUNAR PLANET SCI C, V28, P1713; SCHULTZ RA, 1990, J GEOPHYS RES-SOLID, V95, P14175, DOI 10.1029/JB095iB09p14175; SENGOR AMC, 1978, GEOPHYS RES LETT, V5, P419, DOI 10.1029/GL005i006p00419; SJOGREN WL, 1999, EOS, V80, P204; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SMITH DE, 1999, EOS, V80, P204; SOLOMON SC, 1998, LUNAR PLANET SCI, V29, P1389; Turcotte D. L., 1982, GEODYNAMICS APPL CON, DOI 10.1017/CBO9780511843877; TURCOTTE DL, 1981, J GEOPHYS RES, V86, P3951, DOI 10.1029/JB086iB05p03951; TYLER GL, 1992, J GEOPHYS RES-PLANET, V97, P7759, DOI 10.1029/92JE00513; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zuber MT, 1998, GEOPHYS RES LETT, V25, P4393, DOI 10.1029/1998GL900129; [No title captured]	37	112	116	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					94	97		10.1126/science.286.5437.94	http://dx.doi.org/10.1126/science.286.5437.94			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506567				2022-12-28	WOS:000082907400040
J	Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS				Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS			Ascaris haemoglobin is a nitric oxide-activated 'deoxygenase'	NATURE			English	Article							S-NITROSOHEMOGLOBIN; OXYGEN AVIDITY; HEMOGLOBIN; SUUM; FLAVOHEMOGLOBIN; SUPEROXIDE; BIOSYNTHESIS; EXPRESSION; GLOBIN; GENE	The parasitic nematode Ascaris lumbricoides infects one billion people worldwide. Its perienteric fluid contains an octameric haemoglobin(1-3) that binds oxygen nearly 25,000 times more tightly than does human haemoglobin(4,5). Despite numerous investigations, the biological function of this molecule has remained elusive. The distal haem pocket contains a metal, oxygen and thiol(6), all of which are known to be reactive with nitric oxide. Here we show that Ascaris haemoglobin enzymatically consumes oxygen in a reaction driven by nitric oxide, thus keeping the perienteric fluid hypoxic. The mechanism of this reaction involves unprecedented chemistry of a haem group, a thiol and nitric oxide. We propose that Ascaris haemoglobin functions as a 'deoxygenase', using nitric oxide to detoxify oxygen. The structural and functional adaptations of Ascaris haemoglobin suggest that the molecular evolution of haemoglobin can be rationalized by its nitric oxide related functions.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dep Mol Microbiol & Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Duke Marine Biomed Ctr, Nicholas Sch Environm, Pivers Isl, NC 28516 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.		Gow, Andrew/N-8566-2013; Dewhirst, Mark/Q-1302-2019; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Dewhirst, Mark/0000-0003-3459-6546; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; Balagopalakrishna C, 1998, BIOCHEMISTRY-US, V37, P13194, DOI 10.1021/bi980941c; BASCAL ZA, 1995, J NEUROPHYSIOL, V74, P1880; BLAXTER ML, 1993, PARASITOL TODAY, V9, P353, DOI 10.1016/0169-4758(93)90082-Q; BOWMAN JW, 1995, J NEUROPHYSIOL, V74, P1880, DOI 10.1152/jn.1995.74.5.1880; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hardison R, 1998, J EXP BIOL, V201, P1099; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHERMAN DR, 1992, SCIENCE, V258, P1930, DOI 10.1126/science.1470914; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Young WK, 1996, BRIT J CANCER, V74, pS256	30	182	192	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					497	502		10.1038/46822	http://dx.doi.org/10.1038/46822			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519555				2022-12-28	WOS:000082981200061
J	Costa, DC; Pilowsky, LS; Ell, PJ				Costa, DC; Pilowsky, LS; Ell, PJ			Nuclear medicine in neurology and psychiatry	LANCET			English	Article							D2-DOPAMINE RECEPTOR OCCUPANCY; EMISSION COMPUTED-TOMOGRAPHY; ACUTE ISCHEMIC STROKE; IN-VIVO; SCHIZOPHRENIC-PATIENTS; TEMPORAL-LOBE; BRAIN-DEATH; BLOOD-FLOW; SPECT; CLOZAPINE	Progress in nuclear medicine has always been a function of technological advances, and applications in neurology and psychiatry illustrate the point. Improvements in radiation detectors now allow for three-dimensional and quantitative mapping of the distribution of a labelled compound in the human brain. New ligands permit the study of specific functioning signals of the blood/brain barrier, blood Row, metabolism (oxygen, glucose, aminoacids), and neurotransmission (dopamine, benzodiazepine, serotonin receptors). The picomolar sensitivity of nuclear medicine can now be coupled to a wide group of ligands which offer specific information that can be obtained in no other way in the living patient.	UCL, Inst Nucl Med, London W1N 8AA, England; Inst Psychiat, London, England	University of London; University College London; University of London; King's College London	Ell, PJ (corresponding author), UCL, Inst Nucl Med, Mortimer St, London W1N 8AA, England.	p.ell@nucmed.ucl.ac.uk	Costa, Durval C C./F-1744-2018	Costa, Durval C C./0000-0001-8039-4924				Bader JB, 1999, EUR J NUCL MED, V26, P144, DOI 10.1007/s002590050370; Barber PA, 1998, STROKE, V29, P2522, DOI 10.1161/01.STR.29.12.2522; BROOKS DJ, 1991, J NEUROL NEUROSUR PS, V54, P1, DOI 10.1136/jnnp.54.1.1; BURT RW, 1992, RADIOLOGY, V182, P461, DOI 10.1148/radiology.182.2.1732965; BUTLER CRE, 1998, NUCL MED CLIN DIAGNO, P713; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; COSTA DC, 1991, EUR J NUCL MED, V18, P503; COSTA DC, 1990, EUR J NUCL MED, V16, P813, DOI 10.1007/BF00833017; COSTA DC, 1999, NUCL MED COMMUN, V20, P467; Dewey SL, 1998, SYNAPSE, V30, P119, DOI 10.1002/(SICI)1098-2396(199810)30:2<119::AID-SYN1>3.0.CO;2-F; Erkinjuntti T, 1997, NEW ENGL J MED, V337, P1667, DOI 10.1056/NEJM199712043372306; Facco E, 1998, INTENS CARE MED, V24, P911, DOI 10.1007/s001340050689; FARDE L, 1989, PSYCHOPHARMACOLOGY, V99, pS28, DOI 10.1007/BF00442555; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; Garada, 1997, Semin Clin Neuropsychiatry, V2, P188; GILMAN S, 1992, NEW ENGL J MED, V326, P1671, DOI 10.1056/NEJM199206183262506; GIUBILEI F, 1990, STROKE, V21, P895, DOI 10.1161/01.STR.21.6.895; Goodwin GM, 1996, BRIT MED BULL, V52, P495; JOBST KA, 1992, J NEUROL NEUROSUR PS, V55, P190, DOI 10.1136/jnnp.55.3.190; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; MASDEU JC, 1994, NEUROLOGY, V44, P1970, DOI 10.1212/WNL.44.10.1970; Miller RF, 1998, SEX TRANSM INFECT, V74, P258, DOI 10.1136/sti.74.4.258; MOUNTZ JM, 1990, J NUCL MED, V31, P61; NORDSTROM AL, 1993, BIOL PSYCHIAT, V33, P227, DOI 10.1016/0006-3223(93)90288-O; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Owens J, 1997, NUCL MED COMMUN, V18, P149, DOI 10.1097/00006231-199702000-00010; PEROUTKA SJ, 1980, AM J PSYCHIAT, V137, P1518; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; Pilowsky LS, 1997, LANCET, V350, P490, DOI 10.1016/S0140-6736(05)63079-6; Raichle ME, 1998, SEMIN NUCL MED, V28, P278, DOI 10.1016/S0001-2998(98)80033-0; ROWE CC, 1991, NEUROLOGY, V41, P1096, DOI 10.1212/WNL.41.7.1096; RUOTTINEN H, 1993, J CEREB BLOOD FLOW M, V13, pS359; Schapira AHV, 1999, BRIT MED J, V318, P311, DOI 10.1136/bmj.318.7179.311; SCHWARZ J, 1992, NEUROLOGY, V42, P556, DOI 10.1212/WNL.42.3.556; Seibyl JP, 1998, J NUCL MED, V39, P1500; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; SHORVON SD, 1988, TXB EPILEPSY, P611; Skoog I, 1998, LANCET, V352, P4; Travis MJ, 1997, BRIT J PSYCHIAT, V171, P290, DOI 10.1192/bjp.171.3.290c; Trichard C, 1998, AM J PSYCHIAT, V155, P505, DOI 10.1176/ajp.155.4.505; Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0; Volkow ND, 1999, J PHARMACOL EXP THER, V288, P14; Walker Z, 1997, EUR J NUCL MED, V24, P609; WARD AA, 1983, ARNMD, V61, P371	44	25	27	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1107	1111		10.1016/S0140-6736(99)06095-X	http://dx.doi.org/10.1016/S0140-6736(99)06095-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509515				2022-12-28	WOS:000082777500042
J	Johnson, RD; Liu, N; Jasin, M				Johnson, RD; Liu, N; Jasin, M			Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination	NATURE			English	Article							EMBRYONIC STEM-CELLS; IONIZING-RADIATION; RAD57 PROTEINS; GENE; RESISTANCE; ENDONUCLEASE; DISRUPTION; EXPRESSION; MEMBER; FAMILY	The repair of DNA double-strand breaks is essential for cells to maintain their genomic integrity. Two major mechanisms are responsible for repairing these breaks in mammalian cells, nonhomologous end-joining (NHEJ) and homologous recombination (HR)(1,2): the importance of the former in mammalian cells is well established(3), whereas the role of the latter is just emerging, Homologous recombination is presumably promoted by an evolutionarily conserved group of genes termed the Rad52 epistasis (4-11). An essential component of the HR pathway is the group strand-exchange protein, known as RecA in bacteria(8) or Rad51 in yeast(6). Several mammalian genes have been implicated in repair by homologous recombination on the basis of their sequence homology to yeast Rad51 (ref. 11): one of these is human XRCC2 (refs 12, 13). Here we show that XRCC2 is essential for the efficient repair of DNA double-strand breaks by homologous recombination between sister chromatids, We find that hamster cells deficient in XRCC2 show more than a 100-fold decrease in HR induced by double-strand breaks compared with the parental cell line. This defect is corrected to almost wild-type levels by transient transfection with a plasmid expressing XRCC2. The repair defect in XRCC2 mutant cells appears to be restricted to recombinational repair because NHEJ is normal. We conclude that XRCC2 is involved in the repair of DNA double-strand breaks by homologous recombination.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	Memorial Sloan Kettering Cancer Center; Cornell University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org						Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JASIN M, DNA DAMAGE REPAIR, V3; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIU BL, 1983, PUBL PURPLE MOUNTAIN, V2, P1; Nickoloff JA, 1998, CONT CANC RES, P335; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Smih F, 1995, NUCLEIC ACIDS RES, V23, P5012, DOI 10.1093/nar/23.24.5012; Smith GR, 1998, CONT CANC RES, P135; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vogelstein B., 1998, GENETIC BASIS HUMAN; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	29	277	295	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					397	399		10.1038/43935	http://dx.doi.org/10.1038/43935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517641	Bronze			2022-12-28	WOS:000082822600057
J	O'Brien, SJ; Menotti-Raymond, M; Murphy, WJ; Nash, WG; Wienberg, J; Stanyon, R; Copeland, NG; Jenkins, NA; Womack, JE; Graves, JAM				O'Brien, SJ; Menotti-Raymond, M; Murphy, WJ; Nash, WG; Wienberg, J; Stanyon, R; Copeland, NG; Jenkins, NA; Womack, JE; Graves, JAM			The promise of comparative genomics in mammals	SCIENCE			English	Review							GENETIC-LINKAGE MAP; QUANTITATIVE-TRAIT LOCI; SPONTANEOUSLY HYPERTENSIVE RAT; CHEMOKINE RECEPTOR CXCR4; IN-SITU HYBRIDIZATION; ZOO-FISH; CHROMOSOMAL EVOLUTION; BLOOD-PRESSURE; Y-CHROMOSOME; CARNIVORE KARYOTYPE	Dense genetic maps of human, mouse, and rat genomes that are based on coding genes and on microsatellite and single-nucleotide polymorphism markers have been complemented by precise gene homolog alignment with moderate-resolution maps of Livestock, companion animals, and additional mammal species. Comparative genetic assessment expands the utility of these maps in gene discovery, in functional genomics, and in tracking the evolutionary forces that sculpted the genome organization of modern mammalian species.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Mammalian Genet Lab, Adv Biosci Labs, Frederick, MD 21702 USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathol, College Stn, TX 77843 USA; La Trobe Univ, Dept Genet & Evolut, Melbourne, Vic 3083, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Texas A&M University System; Texas A&M University College Station; La Trobe University	O'Brien, SJ (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.		Graves, Jennifer A.M./A-1387-2008; OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757; Graves, Jennifer/0000-0001-6480-7856; Stanyon, Roscoe/0000-0002-7229-1092				ADAMS MD, 1995, NATURE, V377, P3; Al-Bayati HK, 1999, MAMM GENOME, V10, P569, DOI 10.1007/s003359901046; Alvarez V, 1998, HUM GENET, V102, P483, DOI 10.1007/s004390050726; Amemiya CT, 1999, METHOD CELL BIOL, V60, P235; Andersson L, 1997, J HERED, V88, P380, DOI 10.1093/oxfordjournals.jhered.a023122; ANDERSSON L, 1994, SCIENCE, V263, P1771, DOI 10.1126/science.8134840; Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; [Anonymous], 1999, WALKERS MAMMALS WORL; Bailey Ernest, 1998, ILAR J, V39, P171; BARENDSE W, 1994, NAT GENET, V6, P227, DOI 10.1038/ng0394-227; Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; Bennetzen JL, 1998, P NATL ACAD SCI USA, V95, P1975, DOI 10.1073/pnas.95.5.1975; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BISHOP MD, 1994, GENETICS, V136, P619; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Broad Thomas E., 1998, ILAR J, V39, P160; Bromham L, 1999, TRENDS ECOL EVOL, V14, P113, DOI 10.1016/S0169-5347(98)01507-9; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Burt David W., 1998, ILAR J, V39, P229; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CHAPMAN VM, 1978, ORIGINS INBRED MICE, P555; CHARLIER C, 1995, MAMM GENOME, V6, P788, DOI 10.1007/BF00539005; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chowdhary BP, 1996, MAMM GENOME, V7, P297, DOI 10.1007/s003359900086; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cockett NE, 1999, MAMM GENOME, V10, P35, DOI 10.1007/s003359900938; Cohen OJ, 1998, J VIROL, V72, P6215, DOI 10.1128/JVI.72.7.6215-6217.1998; COLLINS FC, 1999, SCIENCE, V278, P1580; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; CONSIGLIERE S, 1996, CHROMOSOME RES, V3, P1; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CRAWFORD AM, 1995, GENETICS, V140, P703; DAVIS SJM, 1983, FOUILLES RECENTES KH, P189; Davisson Muriel T., 1998, ILAR J, V39, P96; de Gortari MJ, 1998, MAMM GENOME, V9, P204, DOI 10.1007/s003359900726; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUTRILLAUX B, 1979, HUM GENET, V48, P251, DOI 10.1007/BF00272830; Ehrlich J, 1997, GENETICS, V147, P289; ELLEGREN H, 1993, GENOMICS, V17, P599, DOI 10.1006/geno.1993.1378; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Ferguson-Smith Malcolm A., 1998, ILAR J, V39, P68; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; Fronicke L, 1997, CHROMOSOMA, V106, P108; Fronicke L, 1996, MAMM GENOME, V7, P285, DOI 10.1007/s003359900084; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Galloway SM, 1996, GENOME RES, V6, P667, DOI 10.1101/gr.6.8.667; Gates MA, 1999, GENOME RES, V9, P334; Gatesy J, 1999, SYST BIOL, V48, P6, DOI 10.1080/106351599260409; Geldermann H, 1996, J ANIM BREED GENET, V113, P381, DOI 10.1111/j.1439-0388.1996.tb00629.x; GEORGES M, 1993, NAT GENET, V4, P206, DOI 10.1038/ng0693-206; GEORGES M, 1993, P NATL ACAD SCI USA, V90, P1058, DOI 10.1073/pnas.90.3.1058; GEORGES M, 1995, GENETICS, V139, P907; Gibbons A, 1998, SCIENCE, V281, P1432, DOI 10.1126/science.281.5382.1432; GLAS R, 1998, ILAR J, V39; GOLDMAN D, 1989, EVOLUTION, V43, P282, DOI 10.1111/j.1558-5646.1989.tb04228.x; Goureau A, 1996, GENOMICS, V36, P252, DOI 10.1006/geno.1996.0460; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; GRAVES JAM, 1999, ILAR J COMP GENE MAP, V39, P47; Graves Jennifer A. Marshall, 1998, ILAR J, V39, P48; GREEN CE, 1998, INFECT DIS DOG CAT; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hameister H, 1997, CHROMOSOME RES, V5, P5, DOI 10.1023/A:1018433200553; Hardy WD, 1980, FELINE LEUKEMIA VIRU; HAYES H, 1995, CYTOGENET CELL GENET, V71, P168, DOI 10.1159/000134100; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOCHHAUS A, 1999, EUR J MED RES, V3, P216; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; James MR, 1997, TRENDS GENET, V13, P171, DOI 10.1016/S0168-9525(97)01130-X; JAUCH A, 1992, P NATL ACAD SCI USA, V89, P8611, DOI 10.1073/pnas.89.18.8611; Ji Q, 1999, NATURE, V398, P326; JOHANSSON M, 1995, GENOMICS, V25, P682, DOI 10.1016/0888-7543(95)80011-A; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; KOEHLER U, 1995, GENOMICS, V30, P287, DOI 10.1006/geno.1995.9875; KOEHLER U, 1995, AM J PHYS ANTHROPOL, V97, P37, DOI 10.1002/ajpa.1330970104; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li R, 1999, GENOMICS, V58, P9, DOI 10.1006/geno.1999.5772; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lindgren G, 1998, GENOME RES, V8, P951, DOI 10.1101/gr.8.9.951; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu FGR, 1999, SYST BIOL, V48, P54, DOI 10.1080/106351599260436; LYON MF, 1990, GENETIC VARIANTS STR; Marklund L, 1996, ANIM GENET, V27, P255, DOI 10.1111/j.1365-2052.1996.tb00487.x; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Marshall E, 1999, SCIENCE, V284, P1439, DOI 10.1126/science.284.5419.1439; Martin MP, 1998, J ACQ IMMUN DEF SYND, V19, P430, DOI 10.1097/00042560-199812010-00017; Masood E, 1999, NATURE, V398, P545, DOI 10.1038/19126; Mazeyrat S, 1998, HUM MOL GENET, V7, P1713, DOI 10.1093/hmg/7.11.1713; McConkey EH, 1997, TRENDS GENET, V13, P350, DOI 10.1016/S0168-9525(97)01226-2; McKenna MC, 1997, CLASSIFICATION MAMMA; Menotti-Raymond M, 1999, GENOMICS, V57, P9, DOI 10.1006/geno.1999.5743; Miyamoto MM, 1996, MOL PHYLOGENET EVOL, V6, P373, DOI 10.1006/mpev.1996.0087; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morescalchi MA, 1997, CHROMOSOME RES, V5, P527, DOI 10.1023/A:1018489602312; Morin PA, 1998, GENOMICS, V53, P12, DOI 10.1006/geno.1998.5460; Muir PD, 1997, J HERED, V88, P366, DOI 10.1093/oxfordjournals.jhered.a023120; Muller S, 1997, CYTOGENET CELL GENET, V78, P260, DOI 10.1159/000134669; MULLER S, IN PRESS CHROMOSOMA; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; Murphy KC, 1996, J MOL NEUROSCI, V7, P147, DOI 10.1007/BF02736794; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY WG, UNPUB; Murphy WJ, 1999, GENOMICS, V57, P1, DOI 10.1006/geno.1998.5695; MURPHY WJ, IN PRESS GENOME RES; Musser G G, 1993, MAMMAL SPECIES WORLD; Nadeau JH, 1998, TRENDS GENET, V14, P495, DOI 10.1016/S0168-9525(98)01607-2; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nagle DL, 1999, NATURE, V398, P148, DOI 10.1038/18210; Nash WG, 1998, CYTOGENET CELL GENET, V83, P182, DOI 10.1159/000015176; NASH WG, 1987, CYTOGENET CELL GENET, V45, P206, DOI 10.1159/000132455; Neff MW, 1999, GENETICS, V151, P803; NGUYEN GT, IN PRESS J INFECT DI; Nicholas F., 1987, VET GENETICS; Nicholas FW, ONLINE MENDELIAN INH; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; O'Brien S, 1993, GENETIC MAPS LOCUS M; O'Brien SJ, 1991, CURR OPIN GENET DEV, V1, P104; OBRIEN SJ, 1985, NATURE, V317, P140, DOI 10.1038/317140a0; OBrien SJ, 1997, SCI AM, V277, P44, DOI 10.1038/scientificamerican0997-44; OBRIEN SJ, 1988, ANNU REV GENET, V22, P323, DOI 10.1146/annurev.ge.22.120188.001543; OBRIEN SJ, 1995, NAT MED, V1, P742, DOI 10.1038/nm0895-742; OBrien SJ, 1997, J HERED, V88, P408, DOI 10.1093/oxfordjournals.jhered.a023127; OBrien SJ, 1997, TRENDS GENET, V13, P393, DOI 10.1016/S0168-9525(97)01297-3; OBRIEN SJ, 1991, CYTOGENET CELL GENET, V58, P1124, DOI 10.1159/000133725; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; OSTRANDER EA, IN PRESS TRENDS GENE; Pask A, 1999, CELL MOL LIFE SCI, V55, P864, DOI 10.1007/s000180050340; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; PATTERSON DF, 1999, CANINE GENETIC DIS I; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; RETTENBERGER G, 1995, CHROMOSOME RES, V3, P479, DOI 10.1007/BF00713962; RETTENBERGER G, 1995, GENOMICS, V26, P372, DOI 10.1016/0888-7543(95)80222-8; Riggs PK, 1997, J HERED, V88, P373, DOI 10.1093/oxfordjournals.jhered.a023121; Robinson R, 1991, GENETICS CAT BREEDER; Rohrer GA, 1996, GENOME RES, V6, P371, DOI 10.1101/gr.6.5.371; ROHRER GA, 1994, GENETICS, V136, P231; Rosenbaum M, 1999, NEW ENGL J MED, V341, P913, DOI 10.1056/NEJM199909163411211; Schibler L, 1998, GENOME RES, V8, P901, DOI 10.1101/gr.8.9.901; Serov O.L., 1998, ILAR J, V39, P189; Serov O.L., 1998, ILAR J, V39, P195; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Shoshani J, 1998, MOL PHYLOGENET EVOL, V9, P572, DOI 10.1006/mpev.1998.0520; SINCLAIR AH, 1988, NATURE, V336, P780, DOI 10.1038/336780a0; Slattery JP, 1995, J HERED, V86, P413, DOI 10.1093/oxfordjournals.jhered.a111615; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Springer MS, 1999, SYST BIOL, V48, P65, DOI 10.1080/106351599260445; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Steen RG, 1999, GENOME RES, V9, pAP1; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tate ML, 1997, J HERED, V88, P361, DOI 10.1093/oxfordjournals.jhered.a023119; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Waddell PJ, 1999, SYST BIOL, V48, P31, DOI 10.1080/106351599260427; Wakefield M. J., 1998, ILAR J, V39; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; WAYNE RK, 1987, CYTOGENET CELL GENET, V44, P134, DOI 10.1159/000132357; Wayne RK, 1999, BIOESSAYS, V21, P247, DOI 10.1002/(SICI)1521-1878(199903)21:3&lt;247::AID-BIES9&gt;3.0.CO;2-Z; WAYNE RK, 1987, CYTOGENET CELL GENET, V44, P123, DOI 10.1159/000132356; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weissenbach J, 1998, CLIN CHEM LAB MED, V36, P511, DOI 10.1515/CCLM.1998.086; Werner P, 1999, MAMM GENOME, V10, P814, DOI 10.1007/s003359901096; Wienberg J, 1997, CYTOGENET CELL GENET, V77, P211, DOI 10.1159/000134579; Wienberg J, 1997, CURR OPIN GENET DEV, V7, P784, DOI 10.1016/S0959-437X(97)80041-X; Wienberg Johannes, 1998, ILAR J, V39, P77; Womack JE, 1997, MAMM GENOME, V8, P854, DOI 10.1007/s003359900593; WOMACK JE, 1995, CURR OPIN GENET DEV, V5, P725, DOI 10.1016/0959-437X(95)80004-O; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YH, 1998, J IMMUNOL, V160, P4018; Zhu BL, 1999, MAMM GENOME, V10, P706, DOI 10.1007/s003359901075; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	203	394	403	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					458	+		10.1126/science.286.5439.458	http://dx.doi.org/10.1126/science.286.5439.458			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577209				2022-12-28	WOS:000083121200047
J	Murphy, BS; Prull, TA				Murphy, BS; Prull, TA			Early Lung Cancer Action Project	LANCET			English	Letter									St Vincents Hosp & Med Ctr, Clin Strategies Program, New York, NY 10011 USA; St Vincents Hosp & Med Ctr, Dept Med, New York, NY 10011 USA	Saint Vincents Hospital Manhattan; Saint Vincents Hospital Manhattan	Murphy, BS (corresponding author), St Vincents Hosp & Med Ctr, Clin Strategies Program, New York, NY 10011 USA.							ELWOOD M, 1998, CRITICAL APPRAISAL E, P107; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6	2	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1205	1205		10.1016/S0140-6736(99)00175-0	http://dx.doi.org/10.1016/S0140-6736(99)00175-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513729				2022-12-28	WOS:000082954100047
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1965: Andre Lwoff (1902-94), Francois Jacob (b 1920), and Jacques Monod (1910-76)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	9	10	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					434	434		10.1016/S0140-6736(05)75863-3	http://dx.doi.org/10.1016/S0140-6736(05)75863-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10501404				2022-12-28	WOS:000081764900071
